[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fZ5KkNE1pN_EV3ljo1wC3S0KTpGqIB_6dY33n3c8g0p4":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"Janssen Research & Development, LLC",[4],922,false,169,209,4902379,188,47,[14,17,20,23,26,29,31,34],{"name":15,"count":16},"Healthy",231,{"name":18,"count":19},"Multiple Myeloma",52,{"name":21,"count":22},"Depressive Disorder, Major",30,{"name":24,"count":25},"Diabetes Mellitus, Type 2",26,{"name":27,"count":28},"Colitis, Ulcerative",19,{"name":30,"count":28},"Prostatic Neoplasms",{"name":32,"count":33},"Schizophrenia",17,{"name":35,"count":33},"Carcinoma, Non-Small-Cell Lung",[37,42,47,52,57,61,66,71,76,80],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03523442","A Study of Androgen Receptor (AR) Antagonist Apalutamide in Chinese Participants With Metastatic Castration-Resistant Prostate Cancer","2019-07-09","Apalutamide",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT03462719","A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)\u002FSmall Lymphocytic Lymphoma (SLL)","2021-02-26","Ibrutinib",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03431350","A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer","2021-08-31","Niraparib 200 mg",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03748641","A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer","2021-10-08","Niraparib",{"nctId":58,"briefTitle":59,"date":60,"intervention":56},"NCT04577833","A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer","2021-10-15",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT04557098","A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma","2021-11-09","Teclistamab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT03399799","Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","2022-07-07","Talquetamab",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT02365597","An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer","2022-09-15","Erdafitinib",{"nctId":77,"briefTitle":78,"date":79,"intervention":75},"NCT03473743","A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer","2022-09-30",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04538664","A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions","2023-05-03","Amivantamab",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,478,639,722,744,972,1131,1402,1653,1760,1894,1952,2162,2256,2338,2395,2471,2689,2727,2833,2879,2947,3004,3050,3091,3121,3164,3219,3256,3299,3434,3585,3796,3881,3950,3988,4027,4061,4091,4121,4147,4173,4282,4384,4496,4562,4588,4620,4642,4664,4686,4717,4739,4761,4783,4805,4827,4866,4903,4925,4947,4977,5005,5027,5045,5063,5081,5099,5117,5135,5153,5180,5198,5216,5234,5252,5270,5288,5306,5331,5357,5375,5393,5411,5429,5447,5465,5483,5729,5758,5780,5808,5917,5944,5985,6021,6049,6078,6111,6133,6151,6169,6187,6205,6223,6241,6259,6277,6295,6313,6337,6355,6373,6391,6409,6427,6445,6463,6481,6499,6521,6546,6572,6590,6608,6626,6644,6665,6683,6701,6719,6737,6755,6773,6848,6880,6912,6941,6998,7044,7078,7108,7130,7152,7218,7244,7270,7302,7339,7378,7404,7434,7461,7486,7510,7535,7559,7577,7595,7613,7631,7658,7676,7694,7712,7737,7755,7773,7791,7816,7834,7852,7870,7888,7906,7924,7942,7960,7978,7996,8014,8040,8058,8076,8094,8112,8130,8155,8180,8245,8327,8376,8436,8476,8534,8560,8582,8614,8645,8679,8697,8728,8746,8764,8782,8800,8818,8836,8854,8872,8954,8996,9046,9121,9159,9197,9235,9273,9311,9349,9404,9438,9472,9520,9570,9603,9644,9697,9727,9769,9813,9844,9870,9896,9940,9987,10013,10039,10085,10130,10156,10195,10217,10239,10274,10296,10318,10340,10362,10384,10406,10428,10462,10484,10518,10540,10562,10584,10606,10628,10646,10671,10689,10707,10725,10749,10767,10790,10812,10830,10855,10879,10906,10924,10949,10967,10996,11014,11032,11056,11074,11092,11110,11128,11146,11164,11188,11206,11224,11242,11265,11292,11310,11328,11346,11364,11382,11400,11418,11440,11458,11476,11494,11512,11530,11548,11570,11595,11613,11631,11649,11667,11685,11703,11721,11739,11757,11775,11793,11811,11829,11852,11876,11894,11919,11943,11961,11988,12006,12024,12042,12060,12078,12096,12122,12140,12158,12252,12327,12369,12443,12509,12547,12597,12656,12720,12772,12817,12855,12896,12935,12975,13022,13071,13107,13133,13170,13196,13237,13277,13308,13341,13367,13401,13445,13471,13503,13529,13568,13594,13616,13638,13660,13692,13714,13736,13768,13796,13824,13858,13892,13929,13965,13987,14009,14031,14053,14082,14115,14141,14174,14196,14221,14239,14257,14275,14293,14311,14329,14347,14365,14383,14401,14430,14448,14466,14484,14502,14520,14538,14556,14580,14598,14616,14634,14652,14670,14688,14706,14724,14742,14760,14778,14796,14814,14838,14856,14874,14892,14910,14935,14962,14980,14998,15016,15034,15057,15083,15101,15119,15137,15155,15173,15197,15218,15239,15257,15283,15301,15319,15341,15364,15382,15400,15423,15441,15465,15483,15505,15533,15551,15569,15587,15605,15629,15654,15672,15690,15718,15736,15754,15772,15790,15813,15838,15856,15878,15907,15925,15943,15961,15979,15997,16019,16041,16059,16077,16095,16113,16135,16158,16180,16205,16223,16241,16259,16277,16295,16313,16331,16349,16374,16392,16410,16428,16446,16464,16482,16504,16522,16540,16558,16580,16598,16616,16634,16713,16767,16818,16867,16901,16931,16979,17009,17046,17076,17119,17156,17201,17243,17269,17304,17330,17352,17374,17396,17427,17451,17473,17502,17528,17557,17579,17612,17634,17663,17685,17707,17729,17754,17781,17803,17830,17863,17890,17922,17944,17978,18016,18041,18063,18085,18107,18136,18158,18180,18211,18233,18255,18277,18310,18332,18354,18376,18398,18425,18443,18461,18479,18497,18515,18533,18551,18569,18587,18605,18623,18641,18659,18682,18700,18718,18736,18754,18772,18790,18811,18829,18847,18865,18887,18905,18928,18946,18964,18982,19000,19018,19036,19054,19078,19096,19114,19136,19159,19177,19195,19213,19231,19249,19267,19289,19312,19330,19348,19371,19393,19411,19433,19451,19469,19493,19511,19529,19547,19565,19583,19601,19619,19641,19659,19686,19704,19722,19747,19765,19783,19806,19824,19846,19871,19889,19911,19929,19947,19965,19983,20005,20023,20046,20070,20088,20112,20130,20155,20173,20191,20209,20227,20245,20267,20285,20303,20321,20339,20357,20375,20393,20411,20429,20447,20465,20483,20501,20525,20543,20567,20585,20603,20630,20648,20666,20684,20702,20725,20743,20761,20785,20803,20826,20850,20868,20886,20908,20932,20950,20968,20986,21004,21022,21040,21062,21080,21101,21119,21137,21155,21173,21196,21214,21236,21257,21275,21297,21315,21340,21358,21376,21401,21419,21447,21465,21483,21501,21519,21537,21555,21578,21596,21618,21636,21654,21676,21694,21712,21730,21748,21766,21784,21802,21820,21838,21870,21888,21906,21924,21942,21960,21978,21996,22014,22032,22050,22068,22092,22114,22132,22159,22177,22195,22213,22231,22249,22267,22288,22312,22330,22352,22374,22392,22418,22436,22454,22472,22493,22511,22529,22547,22565,22583,22601,22619,22637,22655,22673,22691,22709,22727,22750,22777,22795,22813,22831,22856,22874,22892,22915,22933,22951,22973,22991,23012,23030,23060,23078,23096,23114,23132,23150,23168,23186,23204,23229,23247,23265,23283,23301,23319,23343,23361,23379,23401,23419,23441,23459,23477,23500,23518,23536,23554,23572,23595,23613,23631,23649,23667,23685,23703,23721,23739,23757,23783,23801,23819,23837,23861,23879,23897,23915,23933,23951,23969,23987,24012,24030,24048,24066,24084,24102,24127,24145,24168,24186,24204,24227,24250,24268,24293,24311,24334,24360,24378,24396,24414,24432,24454,24472,24496,24514,24532,24556,24574,24595,24616,24642,24660,24678,24696,24720,24741,24769,24787,24805,24823,24841,24859,24882,24900,24918,24936,24954,24972,24990,25012,25030,25048,25066,25084,25105,25126,25154,25172,25190,25208,25226,25251,25269,25287,25309,25327,25345,25367,25385,25406,25429,25455,25473,25491,25509,25527,25545,25563,25581,25599,25617,25635,25653,25671,25689,25711,25729,25753,25771,25794,25812,25833,25856,25874,25892,25910,25932,25950,25972,26090,26155,26189,26226,26264,26286,26308,26330,26352,26374,26401,26419,26437,26462,26480,26498,26516,26534,26552,26570,26597,26615,26637,26655,26673,26694,26712,26730,26748,26766,26784,26802,26820,26845,26863,26885,26907,26925,26948,26966,26988,27006,27024,27048,27066],{"intervention":94,"totalTrials":95,"cells":96},"Guselkumab",35,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":187,"PHASE3":246,"PHASE4":447,"NA":469},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[102,112,122,134,144,154,163,178],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":111},"NCT02570373","A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants","COMPLETED",[87],"2016-01-12","2015-09-25",8,[15],[94],{"nctId":113,"briefTitle":114,"status":105,"phases":115,"primaryCompletion":116,"completion":117,"start":118,"enrollment":119,"conditions":120,"interventions":121},"NCT01866007","A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants",[87],"2013-09-20","2013-10-09","2013-05-09",141,[15],[94,94,94,94],{"nctId":123,"briefTitle":124,"status":125,"phases":126,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":130,"interventions":132},"NCT05083078","A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis","TERMINATED",[87],"2022-07-01","2021-11-04",11,[131,15],"Arthritis, Psoriatic",[94,133],"Risankizumab",{"nctId":135,"briefTitle":136,"status":137,"phases":138,"primaryCompletion":139,"completion":139,"start":140,"enrollment":99,"conditions":141,"interventions":143},"NCT04704843","A Study of Guselkumab in Adult Participants With Celiac Disease","WITHDRAWN",[87],"2021-09-13","2021-06-17",[142],"Celiac Disease",[94],{"nctId":145,"briefTitle":146,"status":105,"phases":147,"primaryCompletion":139,"completion":148,"start":149,"enrollment":150,"conditions":151,"interventions":153},"NCT03649971","A Study of Guselkumab in Participants With Familial Adenomatous Polyposis",[87],"2022-03-23","2018-11-19",77,[152],"Adenomatous Polyposis Coli",[94],{"nctId":155,"briefTitle":156,"status":105,"phases":157,"primaryCompletion":158,"completion":158,"start":159,"enrollment":160,"conditions":161,"interventions":162},"NCT04617691","A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants",[87],"2021-07-20","2020-11-30",140,[15],[94],{"nctId":164,"briefTitle":165,"status":105,"phases":166,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":170,"interventions":172},"NCT02397382","Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis",[87],"2016-08-31","2015-06-18",16,[171],"Psoriasis",[94,173,174,175,176,177],"Midazolam","Warfarin","Omeprazole","Dextromethorphan","Caffeine",{"nctId":179,"briefTitle":180,"status":105,"phases":181,"primaryCompletion":139,"completion":182,"start":183,"enrollment":184,"conditions":185,"interventions":186},"NCT04147338","A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants",[87],"2021-12-07","2019-10-30",440,[15],[94],{"trials":188,"activeCount":245,"soonestReadout":239},[189,203,215,225,235],{"nctId":190,"briefTitle":191,"status":192,"phases":193,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":198,"interventions":200},"NCT05242471","A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease","ACTIVE_NOT_RECRUITING",[88],"2025-05-23","2029-11-05","2022-07-22",703,[199],"Crohn's Disease",[94,201,202],"Golimumab","JNJ-78934804",{"nctId":204,"briefTitle":205,"status":105,"phases":206,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":211,"interventions":213},"NCT02319759","Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)",[88],"2016-05-31","2017-01-17","2015-03-27",149,[212],"Psoriatic Arthritis",[94,214],"Ustekinumab",{"nctId":216,"briefTitle":217,"status":105,"phases":218,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":223,"interventions":224},"NCT05071664","A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoriatic Arthritis",[88],"2024-05-14","2024-08-06","2021-10-25",91,[131],[94,201],{"nctId":226,"briefTitle":227,"status":125,"phases":228,"primaryCompletion":229,"completion":229,"start":230,"enrollment":231,"conditions":232,"interventions":234},"NCT04633447","A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis",[88],"2024-05-22","2020-12-10",53,[233],"Giant Cell Arteritis",[94],{"nctId":236,"briefTitle":237,"status":192,"phases":238,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":243,"interventions":244},"NCT05242484","A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis",[88],"2025-05-15","2029-03-27","2022-09-19",577,[27],[94,201,202],2,{"trials":247,"activeCount":129,"soonestReadout":441},[248,259,269,280,290,301,313,324,335,345,355,364,374,384,393,402,417,427,437],{"nctId":249,"briefTitle":250,"status":105,"phases":251,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":256,"interventions":257},"NCT03090100","A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis",[89],"2018-08-02","2018-09-20","2017-04-27",1048,[171],[94,258],"Secukinumab",{"nctId":260,"briefTitle":261,"status":105,"phases":262,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":268},"NCT02203032","A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab",[89],"2015-12-25","2016-05-24","2014-10-07",872,[171],[214,94],{"nctId":270,"briefTitle":271,"status":272,"phases":273,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":279},"NCT07577856","A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis","NOT_YET_RECRUITING",[89],"2028-08-11","2030-10-30","2026-05-29",644,[27],[202,94],{"nctId":281,"briefTitle":282,"status":192,"phases":283,"primaryCompletion":284,"completion":285,"start":286,"enrollment":287,"conditions":288,"interventions":289},"NCT04936308","Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response\u002FIntolerance to One Prior Anti-TNF Alpha Agent",[89],"2024-10-28","2026-07-16","2021-09-28",453,[131],[94],{"nctId":291,"briefTitle":292,"status":192,"phases":293,"primaryCompletion":294,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":300},"NCT04033445","A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis",[88,89],"2023-09-19","2027-09-29","2019-09-26",1064,[299],"Ulcerative Colitis",[94],{"nctId":302,"briefTitle":303,"status":304,"phases":305,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":310,"interventions":312},"NCT07499232","A Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease","RECRUITING",[89],"2028-11-15","2030-12-11","2026-04-21",530,[311],"Crohn Disease",[94,133],{"nctId":314,"briefTitle":315,"status":192,"phases":316,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":321,"interventions":323},"NCT05083182","A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis",[89],"2026-01-12","2026-12-05","2022-08-30",50,[322],"Arthritis, Juvenile",[214,94],{"nctId":325,"briefTitle":326,"status":105,"phases":327,"primaryCompletion":328,"completion":328,"start":329,"enrollment":330,"conditions":331,"interventions":334},"NCT05272150","Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and\u002For Scalp Psoriasis",[89],"2025-05-30","2022-07-13",213,[332,333],"Plaque Psoriasis","Scalp Psoriasis",[94],{"nctId":336,"briefTitle":337,"status":105,"phases":338,"primaryCompletion":339,"completion":340,"start":341,"enrollment":342,"conditions":343,"interventions":344},"NCT03158285","A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis",[89],"2019-02-25","2020-11-10","2017-07-12",741,[131],[94],{"nctId":346,"briefTitle":347,"status":125,"phases":348,"primaryCompletion":349,"completion":350,"start":351,"enrollment":352,"conditions":353,"interventions":354},"NCT05784129","A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection",[89],"2023-09-29","2023-10-10","2023-02-21",4,[199],[94],{"nctId":356,"briefTitle":357,"status":272,"phases":358,"primaryCompletion":359,"completion":360,"start":276,"enrollment":361,"conditions":362,"interventions":363},"NCT07577843","A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease",[89],"2028-06-12","2030-07-12",460,[311],[202,94],{"nctId":365,"briefTitle":366,"status":304,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT05923073","A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease",[89],"2027-10-27","2028-07-12","2024-03-13",120,[199],[94,94],{"nctId":375,"briefTitle":376,"status":105,"phases":377,"primaryCompletion":378,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":383},"NCT03162796","A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti -Tumor Necrosis Factor (TNF) Alpha Agent(s)",[89],"2019-03-14","2019-11-18","2017-08-24",383,[131],[94],{"nctId":385,"briefTitle":386,"status":192,"phases":387,"primaryCompletion":388,"completion":389,"start":140,"enrollment":390,"conditions":391,"interventions":392},"NCT04882098","A Study of Guselkumab in Participants With Active Psoriatic Arthritis",[89],"2024-12-30","2027-10-05",1054,[131],[94],{"nctId":394,"briefTitle":395,"status":105,"phases":396,"primaryCompletion":397,"completion":397,"start":398,"enrollment":399,"conditions":400,"interventions":401},"NCT02905331","Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis",[89],"2018-02-06","2017-02-28",78,[171],[94],{"nctId":403,"briefTitle":404,"status":192,"phases":405,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":410,"interventions":411},"NCT03466411","A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease",[88,89],"2023-10-20","2028-01-28","2018-04-13",1409,[199],[412,413,414,415,416,94,214],"Guselkumab Dose 1","Guselkumab Dose 2","Guselkumab Dose 3","Guselkumab Dose 4","Guselkumab Dose 5",{"nctId":418,"briefTitle":419,"status":304,"phases":420,"primaryCompletion":421,"completion":421,"start":422,"enrollment":423,"conditions":424,"interventions":426},"NCT06663332","A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants",[89],"2031-12-12","2024-10-29",196,[425,27,131,322],"Crohns Disease",[94],{"nctId":428,"briefTitle":429,"status":105,"phases":430,"primaryCompletion":431,"completion":431,"start":432,"enrollment":433,"conditions":434,"interventions":436},"NCT06039189","Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis",[89],"2025-04-14","2023-08-24",338,[435],"Moderate Plaque Psoriasis",[94],{"nctId":438,"briefTitle":439,"status":192,"phases":440,"primaryCompletion":441,"completion":442,"start":443,"enrollment":371,"conditions":444,"interventions":445},"NCT03451851","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants",[89],"2023-07-19","2026-12-18","2018-07-11",[171],[94,446],"Etanercept",{"trials":448,"activeCount":468,"soonestReadout":462},[449,458],{"nctId":450,"briefTitle":451,"status":105,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT04914429","A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis",[90],"2023-09-26","2021-08-25",327,[171],[94],{"nctId":459,"briefTitle":460,"status":192,"phases":461,"primaryCompletion":462,"completion":463,"start":464,"enrollment":465,"conditions":466,"interventions":467},"NCT04929210","A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease",[90],"2026-08-04","2027-04-13","2021-08-30",411,[131],[94],1,{"trials":470,"activeCount":99},[471],{"nctId":472,"briefTitle":473,"status":474,"phases":475,"conditions":476,"interventions":477},"NCT04948398","Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis","NO_LONGER_AVAILABLE",[],[152],[94],{"intervention":41,"totalTrials":479,"cells":480},13,{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":576,"PHASE3":600,"PHASE4":625,"NA":637},{"trials":482,"activeCount":99},[],{"trials":484,"activeCount":352,"soonestReadout":40},[485,497,507,519,533,538,547,567],{"nctId":486,"briefTitle":487,"status":105,"phases":488,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":493,"interventions":494},"NCT02924766","A Safety and Pharmacokinetics Study of Niraparib Plus an Androgen Receptor-Targeted Therapy in Men With Metastatic Castration-Resistant Prostate Cancer (BEDIVERE)",[87],"2019-07-18","2019-07-19","2016-10-03",34,[30],[56,41,495,496],"Abiraterone Acetate","Prednisone",{"nctId":498,"briefTitle":499,"status":105,"phases":500,"primaryCompletion":501,"completion":501,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT04154774","A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function",[87],"2025-02-10","2019-11-07",18,[505],"Hepatic Impairment",[41],{"nctId":508,"briefTitle":509,"status":192,"phases":510,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":514,"interventions":516},"NCT04662580","ARX517\u002FJNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer",[87],"2026-12-31","2021-05-03",183,[515],"Metastatic Prostate Cancer",[517,41,518,496],"ARX517","Abiraterone acetate",{"nctId":520,"briefTitle":521,"status":304,"phases":522,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":527,"interventions":528},"NCT06095089","A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer",[87],"2027-06-21","2028-06-28","2023-11-01",355,[30],[529,530,41,531,532],"JNJ-78278343","JNJ-87189401","Lutetium Lu-177 Vipivotide Tetraxetan","JNJ-101556143",{"nctId":38,"briefTitle":39,"status":192,"phases":534,"primaryCompletion":40,"completion":511,"start":535,"enrollment":28,"conditions":536,"interventions":537},[87],"2018-08-31",[30],[41],{"nctId":539,"briefTitle":540,"status":105,"phases":541,"primaryCompletion":542,"completion":542,"start":543,"enrollment":544,"conditions":545,"interventions":546},"NCT03802682","A Study of Apalutamide Administered Orally as Whole Tablets and as a Mixture in Applesauce in Healthy Participants",[87],"2019-04-11","2019-01-11",12,[15],[41],{"nctId":548,"briefTitle":549,"status":304,"phases":550,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":555,"interventions":558},"NCT05818683","A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer",[87],"2027-08-31","2028-05-23","2023-04-26",300,[556,557],"Metastatic Castration-resistant Prostate Neoplasms","Metastatic Hormone-sensitive Prostate Cancer",[559,560,561,562,41,563,564,565,566,532],"Pasritamig","Cetrelimab","Cabazitaxel","Docetaxel","Enzalutamide","Darolutamide","Abiraterone acetate plus prednisone","Lutetium Lu-177 vipivotide tetraxetan",{"nctId":568,"briefTitle":569,"status":125,"phases":570,"primaryCompletion":79,"completion":79,"start":148,"enrollment":571,"conditions":572,"interventions":573},"NCT05295927","A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)",[87],3,[30],[574,495,575,41],"EPI-7386","Prednisone or Prednisolone",{"trials":577,"activeCount":99},[578,588],{"nctId":579,"briefTitle":580,"status":137,"phases":581,"primaryCompletion":582,"completion":582,"start":583,"enrollment":99,"conditions":584,"interventions":586},"NCT02906605","A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer",[88],"2018-09","2016-10",[585],"Prostatic Neoplasms, Castration-Resistant",[587,41],"JNJ-809",{"nctId":589,"briefTitle":590,"status":105,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":597},"NCT04523207","A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases",[88],"2023-10-23","2023-10-25","2020-08-19",108,[30],[41,598,599],"ADT","Relugolix",{"trials":601,"activeCount":245,"soonestReadout":617},[602,613],{"nctId":603,"briefTitle":604,"status":192,"phases":605,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":610,"interventions":611},"NCT03767244","A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",[89],"2026-12-01","2028-10-13","2019-06-11",2517,[30],[41,612],"Androgen Deprivation Therapy",{"nctId":614,"briefTitle":615,"status":192,"phases":616,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":621,"interventions":623},"NCT05884398","A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC",[89],"2026-10-12","2028-10-12","2023-08-31",420,[622],"Metastatic Castrate-sensitive Prostate Cancer",[41,624],"Androgen-deprivation Therapy",{"trials":626,"activeCount":468,"soonestReadout":631},[627],{"nctId":628,"briefTitle":629,"status":192,"phases":630,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":635,"interventions":636},"NCT04108208","A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)",[90],"2023-06-01","2026-06-05","2019-12-17",75,[30],[41,624],{"trials":638,"activeCount":99},[],{"intervention":640,"totalTrials":641,"cells":642},"Cilta-cel",6,{"EARLY_PHASE1":643,"PHASE1":645,"PHASE2":647,"PHASE3":685,"PHASE4":708,"NA":720},{"trials":644,"activeCount":99},[],{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":571,"soonestReadout":666},[649,662,671],{"nctId":650,"briefTitle":651,"status":304,"phases":652,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":657,"interventions":658},"NCT07149857","A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel",[88],"2028-04-12","2029-04-06","2025-10-03",60,[18],[640,659,660,661],"Cyclophosphamide","Induction therapy","Fludarabine",{"nctId":663,"briefTitle":664,"status":192,"phases":665,"primaryCompletion":666,"completion":667,"start":668,"enrollment":129,"conditions":669,"interventions":670},"NCT06550895","A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma",[88],"2026-08-31","2027-08-26","2024-09-16",[18],[640,70],{"nctId":672,"briefTitle":673,"status":192,"phases":674,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":679,"interventions":680},"NCT06577025","A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma",[88],"2030-09-02","2030-09-30","2024-08-20",43,[18],[640,70,681,65,682,683,684,659,661],"Daratumumab","Bortezomib","Lenalidomide","Dexamethasone",{"trials":686,"activeCount":245,"soonestReadout":701},[687,697],{"nctId":688,"briefTitle":689,"status":192,"phases":690,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":695,"interventions":696},"NCT04923893","A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy",[89],"2029-02-14","2036-09-22","2021-08-19",743,[18],[682,684,683,640,659,661],{"nctId":698,"briefTitle":699,"status":192,"phases":700,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":705,"interventions":706},"NCT04181827","A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma",[89],"2024-05-01","2029-04-09","2020-06-12",419,[18],[640,707,682,684,681],"Pomalidomide",{"trials":709,"activeCount":468,"soonestReadout":714},[710],{"nctId":711,"briefTitle":712,"status":304,"phases":713,"primaryCompletion":714,"completion":715,"start":716,"enrollment":717,"conditions":718,"interventions":719},"NCT05201781","A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel",[90],"2037-07-29","2042-06-01","2022-03-09",295,[18],[640],{"trials":721,"activeCount":99},[],{"intervention":624,"totalTrials":245,"cells":723},{"EARLY_PHASE1":724,"PHASE1":726,"PHASE2":728,"PHASE3":730,"PHASE4":736,"NA":742},{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"trials":729,"activeCount":99},[],{"trials":731,"activeCount":468,"soonestReadout":617},[732],{"nctId":614,"briefTitle":615,"status":192,"phases":733,"primaryCompletion":617,"completion":618,"start":619,"enrollment":620,"conditions":734,"interventions":735},[89],[622],[41,624],{"trials":737,"activeCount":468,"soonestReadout":631},[738],{"nctId":628,"briefTitle":629,"status":192,"phases":739,"primaryCompletion":631,"completion":632,"start":633,"enrollment":634,"conditions":740,"interventions":741},[90],[30],[41,624],{"trials":743,"activeCount":99},[],{"intervention":84,"totalTrials":745,"cells":746},20,{"EARLY_PHASE1":747,"PHASE1":749,"PHASE2":772,"PHASE3":894,"PHASE4":960,"NA":962},{"trials":748,"activeCount":99},[],{"trials":750,"activeCount":245,"soonestReadout":766},[751,762],{"nctId":752,"briefTitle":753,"status":192,"phases":754,"primaryCompletion":511,"completion":511,"start":264,"enrollment":755,"conditions":756,"interventions":758},"NCT02609776","Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer",[87],751,[757],"Non-Small-Cell Lung Cancer",[84,84,759,760,761],"Lazertinib","Carboplatin","Pemetrexed",{"nctId":763,"briefTitle":764,"status":192,"phases":765,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":770,"interventions":771},"NCT04077463","A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer",[87],"2026-06-03","2028-03-27","2019-09-04",701,[35],[759,84,760,761],{"trials":773,"activeCount":893,"soonestReadout":875},[774,790,802,812,825,835,843,853,864,871,880],{"nctId":775,"briefTitle":776,"status":304,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":784},"NCT05379595","A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer",[87,88],"2027-04-27","2030-10-31","2022-07-29",225,[783],"Advanced or Metastatic Colorectal Cancer",[785,786,787,788,789,84],"Amivantamab IV","Fluorouracil","Leucovorin","Oxaliplatin","Irinotecan",{"nctId":791,"briefTitle":792,"status":304,"phases":793,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":798,"interventions":799},"NCT06667076","A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",[88],"2029-05-23","2030-12-26","2024-12-16",480,[35],[84,759,800,801],"Chemotherapy: Pemetrexed","Chemotherapy: Carboplatin",{"nctId":803,"briefTitle":804,"status":272,"phases":805,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":810,"interventions":811},"NCT07586202","A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC",[88],"2028-03-02","2028-04-01","2026-07-28",68,[35],[84,759,760,761],{"nctId":813,"briefTitle":814,"status":304,"phases":815,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":820,"interventions":822},"NCT06385080","A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer",[87,88],"2027-12-27","2032-12-27","2024-04-22",287,[821],"Squamous Cell Carcinoma of Head and Neck",[84,823,824,760],"Pembrolizumab","Paclitaxel",{"nctId":826,"briefTitle":827,"status":192,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":834},"NCT05908734","A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer",[87,88],"2027-01-31","2027-03-31","2023-05-18",71,[35],[560,84],{"nctId":836,"briefTitle":837,"status":125,"phases":838,"primaryCompletion":350,"completion":350,"start":839,"enrollment":503,"conditions":840,"interventions":842},"NCT05653427","A Study of Amivantamab Monotherapy in Participants With Previously Treated Advanced Hepatocellular Carcinoma",[88],"2022-12-08",[841],"Carcinoma, Hepatocellular",[84],{"nctId":844,"briefTitle":845,"status":304,"phases":846,"primaryCompletion":847,"completion":848,"start":849,"enrollment":656,"conditions":850,"interventions":851},"NCT07227025","A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer",[87,88],"2028-11-30","2029-04-30","2026-03-03",[35],[84,852],"Olomorasib",{"nctId":854,"briefTitle":855,"status":192,"phases":856,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":861,"interventions":862},"NCT05488314","A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer",[87,88],"2026-06-09","2027-04-28","2022-12-13",57,[35],[863,84],"Capmatinib",{"nctId":865,"briefTitle":866,"status":192,"phases":867,"primaryCompletion":276,"completion":857,"start":868,"enrollment":544,"conditions":869,"interventions":870},"NCT06532032","A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer",[87,88],"2024-07-23",[35],[84,562],{"nctId":872,"briefTitle":873,"status":192,"phases":874,"primaryCompletion":875,"completion":830,"start":831,"enrollment":809,"conditions":876,"interventions":877},"NCT05663866","Premedication to Reduce Amivantamab Associated Infusion Related Reactions",[88],"2024-03-29",[35],[684,878,879,84,759],"Montelukast","Methotrexate",{"nctId":881,"briefTitle":882,"status":304,"phases":883,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":888,"interventions":890},"NCT05498428","A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer",[88],"2027-08-17","2028-08-18","2022-11-11",520,[889],"Carcinoma, Non-small-Cell Lung",[84,759,760,761,891,892],"Direct Oral Anticoagulant","Low Molecular Weight Heparin",10,{"trials":895,"activeCount":641,"soonestReadout":83},[896,911,922,932,942,953],{"nctId":897,"briefTitle":898,"status":304,"phases":899,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":904,"interventions":906},"NCT06750094","A Study of Amivantamab and FOLFIRI Versus Cetuximab\u002FBevacizumab and FOLFIRI in Participants With KRAS\u002FNRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy",[89],"2027-12-15","2029-04-13","2024-12-12",700,[905],"Colorectal Neoplasms",[84,907,908,909,910,789],"Cetuximab","Bevacizumab","5-fluorouracil","Leucovorin calcium\u002FLevoleucovorin",{"nctId":912,"briefTitle":913,"status":304,"phases":914,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":919,"interventions":920},"NCT06662786","A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS\u002FNRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer",[89],"2028-12-15","2032-01-20","2024-10-18",1000,[905],[84,907,909,910,788,921],"Irinotecan Hydrochloride",{"nctId":923,"briefTitle":924,"status":192,"phases":925,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":930,"interventions":931},"NCT04988295","A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure",[89],"2023-07-10","2027-11-30","2021-11-17",776,[35],[759,84,761,760],{"nctId":933,"briefTitle":934,"status":192,"phases":935,"primaryCompletion":936,"completion":927,"start":937,"enrollment":938,"conditions":939,"interventions":940},"NCT04487080","A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[89],"2023-08-11","2020-09-30",1074,[35],[84,941,759],"Osimertinib",{"nctId":943,"briefTitle":944,"status":304,"phases":945,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":949,"interventions":950},"NCT07276399","A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent\u002FMetastatic Head and Neck Cancer",[89],"2029-06-18","2025-12-03",500,[821],[84,823,760,951,952],"5-Flurouracil","Cisplatin",{"nctId":81,"briefTitle":82,"status":192,"phases":954,"primaryCompletion":83,"completion":955,"start":956,"enrollment":957,"conditions":958,"interventions":959},[89],"2027-08-02","2020-10-13",308,[35],[84,761,760,761],{"trials":961,"activeCount":99},[],{"trials":963,"activeCount":99},[964],{"nctId":965,"briefTitle":966,"status":967,"phases":968,"conditions":969,"interventions":971},"NCT04599712","Pre-Approval Access With Amivantamab (JNJ-61186372) in Participants With Metastatic Non-Small Cell Lung Cancer","APPROVED_FOR_MARKETING",[],[970],"Metastatic Non-Small Cell Lung Cancer",[84],{"intervention":65,"totalTrials":169,"cells":973},{"EARLY_PHASE1":974,"PHASE1":976,"PHASE2":1030,"PHASE3":1052,"PHASE4":1115,"NA":1117},{"trials":975,"activeCount":99},[],{"trials":977,"activeCount":1029,"soonestReadout":1012},[978,987,998,1008,1020],{"nctId":979,"briefTitle":980,"status":192,"phases":981,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":985,"interventions":986},"NCT04108195","A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma",[87],"2027-04-07","2020-02-21",290,[18],[681,70,65,707],{"nctId":988,"briefTitle":989,"status":192,"phases":990,"primaryCompletion":991,"completion":992,"start":993,"enrollment":994,"conditions":995,"interventions":997},"NCT03145181","Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",[87],"2025-09-25","2027-05-28","2017-05-16",302,[996],"Hematological Malignancies",[65,65],{"nctId":999,"briefTitle":1000,"status":192,"phases":1001,"primaryCompletion":1002,"completion":1003,"start":1004,"enrollment":595,"conditions":1005,"interventions":1007},"NCT06425991","A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",[87],"2027-02-28","2027-03-03","2024-06-07",[1006],"Relapsed or Refractory Multiple Myeloma",[65],{"nctId":1009,"briefTitle":1010,"status":192,"phases":1011,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1016,"interventions":1018},"NCT05338775","A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma",[87],"2025-05-22","2027-05-03","2022-05-25",74,[1017],"Relapsed\u002F Refractory Multiple Myeloma",[70,65,1019],"PD-1 Inhibitor",{"nctId":1021,"briefTitle":1022,"status":192,"phases":1023,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":1026,"interventions":1027},"NCT04722146","A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",[87],"2027-10-13","2021-03-12",[18],[65,681,707,683,682,1028],"Nirogacestat",5,{"trials":1031,"activeCount":571,"soonestReadout":64},[1032,1038,1048],{"nctId":62,"briefTitle":63,"status":192,"phases":1033,"primaryCompletion":64,"completion":992,"start":1034,"enrollment":1035,"conditions":1036,"interventions":1037},[88],"2020-09-17",194,[996],[65],{"nctId":1039,"briefTitle":1040,"status":192,"phases":1041,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":1046,"interventions":1047},"NCT04586426","A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",[87,88],"2025-03-18","2026-10-27","2020-12-15",228,[18],[70,65],{"nctId":672,"briefTitle":673,"status":192,"phases":1049,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":1050,"interventions":1051},[88],[18],[640,70,681,65,682,683,684,659,661],{"trials":1053,"activeCount":641,"soonestReadout":1090},[1054,1065,1075,1086,1097,1106],{"nctId":1055,"briefTitle":1056,"status":304,"phases":1057,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1063},"NCT06208150","A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide",[89],"2026-04-23","2028-03-31","2024-01-22",795,[18],[70,707,65,1064,684,682],"Elotuzumab",{"nctId":1066,"briefTitle":1067,"status":304,"phases":1068,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1073,"interventions":1074},"NCT05552222","A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma",[89],"2031-04-30","2033-10-28","2022-10-25",1590,[18],[65,681,683,684,70],{"nctId":1076,"briefTitle":1077,"status":304,"phases":1078,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":1083,"interventions":1084},"NCT07258511","A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2028-12-12","2031-09-30","2026-02-04",400,[18],[1085,65],"JNJ-79635322",{"nctId":1087,"briefTitle":1088,"status":192,"phases":1089,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1094,"interventions":1095},"NCT05572515","A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2025-10-13","2031-08-31","2023-03-29",614,[1006],[65,707,682,684,1096],"Carfilzomib",{"nctId":1098,"briefTitle":1099,"status":192,"phases":1100,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1104,"interventions":1105},"NCT05083169","A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2028-12-08","2021-10-14",587,[18],[681,707,684,682,65],{"nctId":1107,"briefTitle":1108,"status":272,"phases":1109,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":903,"conditions":1113,"interventions":1114},"NCT07518186","A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2029-04-29","2032-12-08","2026-06-08",[18],[1085,65],{"trials":1116,"activeCount":99},[],{"trials":1118,"activeCount":99},[1119,1125],{"nctId":1120,"briefTitle":1121,"status":967,"phases":1122,"conditions":1123,"interventions":1124},"NCT05463939","Teclistamab Expanded Access Treatment Protocol for Relapsed or Refractory Multiple Myeloma Patients",[],[1006],[65],{"nctId":1126,"briefTitle":1127,"status":474,"phases":1128,"conditions":1129,"interventions":1130},"NCT05161598","Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)",[],[18],[65],{"intervention":684,"totalTrials":1132,"cells":1133},28,{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1183,"PHASE3":1255,"PHASE4":1398,"NA":1400},{"trials":1135,"activeCount":99},[],{"trials":1137,"activeCount":99},[1138,1156,1171],{"nctId":1139,"briefTitle":1140,"status":137,"phases":1141,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":1145,"interventions":1150},"NCT05521087","A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed\u002FRefractory Acute Leukemias",[87],"2026-09-11","2030-01-29","2025-12-26",[1146,1147,1148,1149],"Acute Leukemias","Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Acute Leukemia of Ambiguous Lineage",[1151,661,1152,1153,684,1154,1155],"JNJ-75276617","Cytarabine","Intrathecal Chemotherapy","Vincristine","Pegaspargase",{"nctId":1157,"briefTitle":1158,"status":105,"phases":1159,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT01998971","A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma",[87],"2019-01-31","2024-01-11","2014-02-18",240,[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],"Velcade","Melphalan","Thalidomide","Diphenhydramine","Acetaminophen",{"nctId":1172,"briefTitle":1173,"status":105,"phases":1174,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":1178,"interventions":1181},"NCT01273493","A Pharmacokinetic Study of Trabectedin in Patients With Advanced Malignancies and Hepatic Dysfunction",[87],"2014-04","2010-12",15,[1179,1180],"Neoplasm Metastases","Hepatic Insufficiency",[1182,684],"Trabectedin",{"trials":1184,"activeCount":352,"soonestReadout":875},[1185,1197,1207,1217,1227,1236,1247,1251],{"nctId":1186,"briefTitle":1187,"status":105,"phases":1188,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":1193,"interventions":1194},"NCT01615029","Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma",[87,88],"2015-10-02","2024-10-23","2012-06-26",45,[18],[1195,1196,683,684],"Part 1 (Dose Escalation): Daratumumab","Part 2 (Dose Expansion): Daratumumab",{"nctId":1198,"briefTitle":1199,"status":105,"phases":1200,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1205,"interventions":1206},"NCT02874742","Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma",[88],"2019-01-25","2022-04-08","2016-08-29",224,[18],[683,682,684,681],{"nctId":1208,"briefTitle":1209,"status":192,"phases":1210,"primaryCompletion":328,"completion":1211,"start":1212,"enrollment":1213,"conditions":1214,"interventions":1216},"NCT05250973","A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis",[88],"2026-10-22","2022-03-01",151,[1215],"Amyloidosis",[681,659,682,684],{"nctId":1218,"briefTitle":1219,"status":105,"phases":1220,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":1225,"interventions":1226},"NCT03412565","A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens",[88],"2020-08-12","2024-04-18","2018-04-26",265,[18],[681,682,683,684,1167,496,1096],{"nctId":1228,"briefTitle":1229,"status":192,"phases":1230,"primaryCompletion":462,"completion":1231,"start":502,"enrollment":1232,"conditions":1233,"interventions":1234},"NCT04133636","A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma",[88],"2029-09-03",210,[18],[1235,683,681,682,684],"JNJ-68284528",{"nctId":1237,"briefTitle":1238,"status":105,"phases":1239,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":1244,"interventions":1245},"NCT00401843","A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma",[88],"2011-08-16","2019-09-24","2006-11-28",307,[18],[1246,682,684],"Siltuximab",{"nctId":672,"briefTitle":673,"status":192,"phases":1248,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":1249,"interventions":1250},[88],[18],[640,70,681,65,682,683,684,659,661],{"nctId":872,"briefTitle":873,"status":192,"phases":1252,"primaryCompletion":875,"completion":830,"start":831,"enrollment":809,"conditions":1253,"interventions":1254},[88],[35],[684,878,879,84,759],{"trials":1256,"activeCount":109,"soonestReadout":701},[1257,1267,1277,1286,1290,1302,1306,1315,1329,1333,1343,1351,1355,1359,1370,1374,1388],{"nctId":1258,"briefTitle":1259,"status":105,"phases":1260,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":1265,"interventions":1266},"NCT02811978","Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma",[89],"2018-05-07","2018-11-10","2016-09-27",81,[18],[682,684],{"nctId":1268,"briefTitle":1269,"status":192,"phases":1270,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1275,"interventions":1276},"NCT05455320","A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment",[89],"2027-07-30","2028-05-25","2022-10-13",864,[1006],[70,681,707,684],{"nctId":1278,"briefTitle":1279,"status":105,"phases":1280,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":330,"conditions":1284,"interventions":1285},"NCT03234972","A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma",[89],"2019-10-07","2024-02-27","2017-11-30",[18],[681,1166,684],{"nctId":1055,"briefTitle":1056,"status":304,"phases":1287,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1288,"interventions":1289},[89],[18],[70,707,65,1064,684,682],{"nctId":1291,"briefTitle":1292,"status":105,"phases":1293,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":1298,"interventions":1299},"NCT02195479","A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma",[89],"2017-11-21","2024-08-07","2014-12-09",706,[18],[1166,1167,496,1300,684,1301],"Daratumumab IV","Daratumumab SC",{"nctId":1066,"briefTitle":1067,"status":304,"phases":1303,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1304,"interventions":1305},[89],[18],[65,681,683,684,70],{"nctId":1307,"briefTitle":1308,"status":105,"phases":1309,"primaryCompletion":1310,"completion":308,"start":1311,"enrollment":1312,"conditions":1313,"interventions":1314},"NCT03652064","A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy",[89],"2024-05-07","2018-11-06",395,[18],[681,682,683,684],{"nctId":1316,"briefTitle":1317,"status":105,"phases":1318,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1327},"NCT01846611","A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL\u002FCAELYX With DOXIL\u002FCAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",[89],"2018-01-18","2018-11-16","2013-10-16",581,[1324,1325,1326],"Ovarian Neoplasms","Peritoneal Neoplasms","Fallopian Tube Neoplasms",[1182,1328,684,1328],"DOXIL",{"nctId":1087,"briefTitle":1088,"status":192,"phases":1330,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1331,"interventions":1332},[89],[1006],[65,707,682,684,1096],{"nctId":1334,"briefTitle":1335,"status":105,"phases":1336,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":1341,"interventions":1342},"NCT02252172","Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma",[89],"2018-09-24","2024-10-02","2015-02-16",737,[18],[1300,683,684,1301],{"nctId":1344,"briefTitle":1345,"status":304,"phases":1346,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":948,"conditions":1349,"interventions":1350},"NCT05438043","A Study of Daratumumab",[89],"2029-01-31","2022-12-15",[18],[681,1096,684,683,707],{"nctId":1098,"briefTitle":1099,"status":192,"phases":1352,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1353,"interventions":1354},[89],[18],[681,707,684,682,65],{"nctId":688,"briefTitle":689,"status":192,"phases":1356,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":1357,"interventions":1358},[89],[18],[682,684,683,640,659,661],{"nctId":1360,"briefTitle":1361,"status":105,"phases":1362,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1367,"interventions":1368},"NCT02136134","Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2016-01-11","2024-01-10","2014-08-15",498,[18],[681,1369,684],"VELCADE",{"nctId":698,"briefTitle":699,"status":192,"phases":1371,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":1372,"interventions":1373},[89],[18],[640,707,682,684,681],{"nctId":1375,"briefTitle":1376,"status":125,"phases":1377,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":1381,"interventions":1383},"NCT02703272","A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma",[89],"2021-06-11","2016-07-01",72,[1382],"Lymphoma, Non-Hodgkin",[46,1384,1385,760,1386,1154,1387,684],"Rituximab","Ifosfamide","Etoposide","Idarubicin",{"nctId":1389,"briefTitle":1390,"status":105,"phases":1391,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1396,"interventions":1397},"NCT02076009","A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma",[89],"2016-03-07","2024-11-21","2014-07-23",569,[18],[681,683,684],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"intervention":681,"totalTrials":492,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1457,"PHASE3":1559,"PHASE4":1637,"NA":1639},{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":571,"soonestReadout":982},[1408,1412,1422,1430,1440,1444,1453],{"nctId":979,"briefTitle":980,"status":192,"phases":1409,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1410,"interventions":1411},[87],[18],[681,70,65,707],{"nctId":1413,"briefTitle":1414,"status":105,"phases":1415,"primaryCompletion":1416,"completion":1417,"start":1418,"enrollment":1419,"conditions":1420,"interventions":1421},"NCT04121260","A Study of Subcutaneous Delivery of JNJ-54767414 in Chinese Participants With Multiple Myeloma",[87],"2021-04-27","2023-10-13","2019-12-25",21,[18],[681],{"nctId":1423,"briefTitle":1424,"status":105,"phases":1425,"primaryCompletion":1426,"completion":1426,"start":1427,"enrollment":320,"conditions":1428,"interventions":1429},"NCT02852837","Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy",[87],"2019-12-13","2016-09-26",[18],[681],{"nctId":1431,"briefTitle":1432,"status":105,"phases":1433,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":1437,"interventions":1438},"NCT03320707","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-54767414 (Daratumumab) in Healthy Participants",[87],"2019-08-27","2017-10-16",66,[15],[681,1439],"rHuPH20",{"nctId":1157,"briefTitle":1158,"status":105,"phases":1441,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1442,"interventions":1443},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"nctId":1445,"briefTitle":1446,"status":304,"phases":1447,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":160,"conditions":1451,"interventions":1452},"NCT06768489","A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma",[87],"2027-11-19","2028-11-23","2024-12-04",[18],[1085,681,707,683],{"nctId":1021,"briefTitle":1022,"status":192,"phases":1454,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":1455,"interventions":1456},[87],[18],[65,681,707,683,682,1028],{"trials":1458,"activeCount":571,"soonestReadout":328},[1459,1470,1474,1484,1497,1501,1511,1515,1526,1538,1542,1546],{"nctId":1460,"briefTitle":1461,"status":105,"phases":1462,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":492,"conditions":1466,"interventions":1468},"NCT03011034","Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment",[88],"2019-01-23","2021-10-05","2017-02-14",[1467],"Myelodysplastic Syndromes",[1469,681],"Talacotuzumab",{"nctId":1198,"briefTitle":1199,"status":105,"phases":1471,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":1472,"interventions":1473},[88],[18],[683,682,684,681],{"nctId":1475,"briefTitle":1476,"status":105,"phases":1477,"primaryCompletion":1478,"completion":296,"start":1479,"enrollment":1480,"conditions":1481,"interventions":1482},"NCT03023423","A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer",[87,88],"2018-05-17","2016-12-23",100,[35],[1483,681],"Atezolizumab",{"nctId":1485,"briefTitle":1486,"status":105,"phases":1487,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":1492,"interventions":1493},"NCT01985126","An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD",[88],"2015-01-09","2017-05-30","2013-09-27",124,[18],[1494,1495,1496,1170,1169,681],"Daratumumab 16 mg\u002Fkg","Daratumumab 8 mg\u002Fkg","Methylprednisolone",{"nctId":1208,"briefTitle":1209,"status":192,"phases":1498,"primaryCompletion":328,"completion":1211,"start":1212,"enrollment":1213,"conditions":1499,"interventions":1500},[88],[1215],[681,659,682,684],{"nctId":1502,"briefTitle":1503,"status":105,"phases":1504,"primaryCompletion":1505,"completion":1506,"start":1465,"enrollment":1507,"conditions":1508,"interventions":1510},"NCT02927925","A Study to Assess the Clinical Efficacy and Safety of Daratumumab in Participants With Relapsed or Refractory Natural Killer\u002FT-Cell Lymphoma (NKTCL), Nasal Type",[88],"2020-01-02","2020-01-07",32,[1509],"Lymphoma",[681],{"nctId":1218,"briefTitle":1219,"status":105,"phases":1512,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":1513,"interventions":1514},[88],[18],[681,682,683,684,1167,496,1096],{"nctId":1516,"briefTitle":1517,"status":105,"phases":1518,"primaryCompletion":1519,"completion":1520,"start":1521,"enrollment":1522,"conditions":1523,"interventions":1524},"NCT02316106","A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma",[88],"2023-06-02","2024-06-03","2015-05-20",123,[18],[1525,1525,1525],"daratumumab",{"nctId":1527,"briefTitle":1528,"status":125,"phases":1529,"primaryCompletion":1530,"completion":1530,"start":1531,"enrollment":1532,"conditions":1533,"interventions":1537},"NCT02413489","An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed\u002FRefractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma",[88],"2017-06-01","2015-09-02",36,[1534,1535,1536],"Lymphoma, Mantle-Cell","Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular",[681],{"nctId":1228,"briefTitle":1229,"status":192,"phases":1539,"primaryCompletion":462,"completion":1231,"start":502,"enrollment":1232,"conditions":1540,"interventions":1541},[88],[18],[1235,683,681,682,684],{"nctId":672,"briefTitle":673,"status":192,"phases":1543,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":1544,"interventions":1545},[88],[18],[640,70,681,65,682,683,684,659,661],{"nctId":1547,"briefTitle":1548,"status":105,"phases":1549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":1553,"interventions":1555},"NCT03384654","A Study to Evaluate the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Participants Greater Than or Equal to (>=)1 and Less Than or Equal to (\u003C=) 30 Years of Age With Relapsed\u002FRefractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",[88],"2022-09-22","2022-09-27","2018-05-14",[1554],"Precursor Cell Lymphoblastic Leukemia-Lymphoma",[681,1154,496,1556,1557,659,1152,1558,879],"Doxorubicin","Peg-asparaginase","6-mercaptopurine",{"trials":1560,"activeCount":641,"soonestReadout":1573},[1561,1565,1569,1578,1588,1592,1596,1607,1611,1615,1619,1623,1633],{"nctId":1268,"briefTitle":1269,"status":192,"phases":1562,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1563,"interventions":1564},[89],[1006],[70,681,707,684],{"nctId":1278,"briefTitle":1279,"status":105,"phases":1566,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":330,"conditions":1567,"interventions":1568},[89],[18],[681,1166,684],{"nctId":1570,"briefTitle":1571,"status":192,"phases":1572,"primaryCompletion":1573,"completion":276,"start":1574,"enrollment":1575,"conditions":1576,"interventions":1577},"NCT03901963","A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant",[89],"2024-04-04","2019-04-26",200,[18],[681,683],{"nctId":1579,"briefTitle":1580,"status":105,"phases":1581,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":893,"conditions":1585,"interventions":1586},"NCT03357952","A Study of JNJ-63723283, an Anti-programmed Death-1 Monoclonal Antibody, Administered in Combination With Daratumumab, Compared With Daratumumab Alone in Participants With Relapsed or Refractory Multiple Myeloma",[88,89],"2018-10-24","2021-11-19","2017-11-16",[18],[681,1587],"JNJ-63723283",{"nctId":1066,"briefTitle":1067,"status":304,"phases":1589,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1590,"interventions":1591},[89],[18],[65,681,683,684,70],{"nctId":1307,"briefTitle":1308,"status":105,"phases":1593,"primaryCompletion":1310,"completion":308,"start":1311,"enrollment":1312,"conditions":1594,"interventions":1595},[89],[18],[681,682,683,684],{"nctId":1597,"briefTitle":1598,"status":105,"phases":1599,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":1604,"interventions":1605},"NCT03201965","A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis",[89],"2020-02-14","2024-11-19","2017-10-05",416,[1215],[659,682,1606,681],"Dexamethasone, 40 mg",{"nctId":1344,"briefTitle":1345,"status":304,"phases":1608,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":948,"conditions":1609,"interventions":1610},[89],[18],[681,1096,684,683,707],{"nctId":1098,"briefTitle":1099,"status":192,"phases":1612,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1613,"interventions":1614},[89],[18],[681,707,684,682,65],{"nctId":1360,"briefTitle":1361,"status":105,"phases":1616,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":1617,"interventions":1618},[89],[18],[681,1369,684],{"nctId":698,"briefTitle":699,"status":192,"phases":1620,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":1621,"interventions":1622},[89],[18],[640,707,682,684,681],{"nctId":1624,"briefTitle":1625,"status":105,"phases":1626,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":1631,"interventions":1632},"NCT03217812","A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)",[89],"2020-07-02","2024-03-08","2017-11-23",220,[18],[1166,1167,496,681],{"nctId":1389,"briefTitle":1390,"status":105,"phases":1634,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":1635,"interventions":1636},[89],[18],[681,683,684],{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[1641,1647],{"nctId":1642,"briefTitle":1643,"status":967,"phases":1644,"conditions":1645,"interventions":1646},"NCT02477891","Early Access Treatment With Daratumumab for (Relapsed or Refractory) Multiple Myeloma",[],[18],[681],{"nctId":1648,"briefTitle":1649,"status":967,"phases":1650,"conditions":1651,"interventions":1652},"NCT04264884","Pre-Approval Access for Administration of Daratumumab Subcutaneously (SC) in Participants Who Are Unable to Receive Intravenous (IV) Daratumumab",[],[],[681],{"intervention":70,"totalTrials":1177,"cells":1654},{"EARLY_PHASE1":1655,"PHASE1":1657,"PHASE2":1683,"PHASE3":1720,"PHASE4":1744,"NA":1746},{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":352,"soonestReadout":69},[1659,1666,1670,1679],{"nctId":67,"briefTitle":68,"status":192,"phases":1660,"primaryCompletion":69,"completion":1661,"start":1662,"enrollment":1663,"conditions":1664,"interventions":1665},[87],"2027-10-20","2017-12-16",279,[996],[70],{"nctId":979,"briefTitle":980,"status":192,"phases":1667,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1668,"interventions":1669},[87],[18],[681,70,65,707],{"nctId":1671,"briefTitle":1672,"status":192,"phases":1673,"primaryCompletion":1674,"completion":1024,"start":1675,"enrollment":1676,"conditions":1677,"interventions":1678},"NCT05050097","A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma",[87],"2025-03-31","2021-09-22",166,[18],[70,1096,1301,683,707],{"nctId":1009,"briefTitle":1010,"status":192,"phases":1680,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":1681,"interventions":1682},[87],[1017],[70,65,1019],{"trials":1684,"activeCount":1029,"soonestReadout":1042},[1685,1695,1708,1712,1716],{"nctId":1686,"briefTitle":1687,"status":304,"phases":1688,"primaryCompletion":1689,"completion":1690,"start":1691,"enrollment":1692,"conditions":1693,"interventions":1694},"NCT04634552","A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",[88],"2027-06-30","2029-03-30","2021-02-01",510,[996],[70],{"nctId":1696,"briefTitle":1697,"status":304,"phases":1698,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":1701,"interventions":1702},"NCT06500884","A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events",[88],"2030-05-30","2024-08-26",[18],[70,1703,1704,1705,1706,1707],"Prophylaxis A","Prophylaxis B","Prophylaxis C","Prophylaxis D","Ramantamig",{"nctId":663,"briefTitle":664,"status":192,"phases":1709,"primaryCompletion":666,"completion":667,"start":668,"enrollment":129,"conditions":1710,"interventions":1711},[88],[18],[640,70],{"nctId":1039,"briefTitle":1040,"status":192,"phases":1713,"primaryCompletion":1042,"completion":1043,"start":1044,"enrollment":1045,"conditions":1714,"interventions":1715},[87,88],[18],[70,65],{"nctId":672,"briefTitle":673,"status":192,"phases":1717,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":1718,"interventions":1719},[88],[18],[640,70,681,65,682,683,684,659,661],{"trials":1721,"activeCount":571,"soonestReadout":1058},[1722,1726,1736,1740],{"nctId":1268,"briefTitle":1269,"status":192,"phases":1723,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1724,"interventions":1725},[89],[1006],[70,681,707,684],{"nctId":1727,"briefTitle":1728,"status":137,"phases":1729,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":99,"conditions":1733,"interventions":1734},"NCT05461209","A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed\u002FRefractory Multiple Myeloma",[89],"2022-11-15","2024-10-31","2022-10-20",[1017],[70,1735],"Belantamab Mafodotin",{"nctId":1055,"briefTitle":1056,"status":304,"phases":1737,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1738,"interventions":1739},[89],[18],[70,707,65,1064,684,682],{"nctId":1066,"briefTitle":1067,"status":304,"phases":1741,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":1742,"interventions":1743},[89],[18],[65,681,683,684,70],{"trials":1745,"activeCount":99},[],{"trials":1747,"activeCount":99},[1748,1754],{"nctId":1749,"briefTitle":1750,"status":967,"phases":1751,"conditions":1752,"interventions":1753},"NCT05757973","Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma",[],[1006],[70],{"nctId":1755,"briefTitle":1756,"status":474,"phases":1757,"conditions":1758,"interventions":1759},"NCT05503550","Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma",[],[1006],[70],{"intervention":759,"totalTrials":169,"cells":1761},{"EARLY_PHASE1":1762,"PHASE1":1764,"PHASE2":1821,"PHASE3":1868,"PHASE4":1890,"NA":1892},{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":245,"soonestReadout":766},[1766,1770,1780,1790,1801,1809,1813],{"nctId":752,"briefTitle":753,"status":192,"phases":1767,"primaryCompletion":511,"completion":511,"start":264,"enrollment":755,"conditions":1768,"interventions":1769},[87],[757],[84,84,759,760,761],{"nctId":1771,"briefTitle":1772,"status":105,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":745,"conditions":1776,"interventions":1777},"NCT05076877","A Study of Lazertinib (JNJ-73841937) in Healthy Participants",[87],"2022-02-10","2021-09-17",[15],[759,173,1778,1779],"Rosuvastatin","Metformin",{"nctId":1781,"briefTitle":1782,"status":105,"phases":1783,"primaryCompletion":1784,"completion":1785,"start":1786,"enrollment":1787,"conditions":1788,"interventions":1789},"NCT05742594","A Study of Four Different Oral Tablet Formulations of Lazertinib (JNJ-73841937) in Healthy Adult Participants",[87],"2023-03-31","2023-04-03","2023-01-03",64,[15],[759],{"nctId":1791,"briefTitle":1792,"status":105,"phases":1793,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1507,"conditions":1797,"interventions":1798},"NCT04410094","A Study to Assess the Effects of Itraconazole and Rifampin on Lazertinib in Healthy Adult Participants",[87],"2020-12-30","2021-02-02","2020-09-14",[15],[759,1799,1800],"Itraconazole","Rifampin",{"nctId":1802,"briefTitle":1803,"status":105,"phases":1804,"primaryCompletion":1805,"completion":1805,"start":1806,"enrollment":1380,"conditions":1807,"interventions":1808},"NCT05896683","A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants",[87],"2023-09-01","2023-05-30",[15],[759],{"nctId":763,"briefTitle":764,"status":192,"phases":1810,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":1811,"interventions":1812},[87],[35],[759,84,760,761],{"nctId":1814,"briefTitle":1815,"status":105,"phases":1816,"primaryCompletion":1817,"completion":1817,"start":1818,"enrollment":169,"conditions":1819,"interventions":1820},"NCT05112952","A Study to Evaluate the Effect of Hepatic Impairment on Lazertinib (JNJ-73841937)",[87],"2022-07-11","2021-11-30",[505,15],[759],{"trials":1822,"activeCount":1029,"soonestReadout":875},[1823,1827,1831,1850,1860,1864],{"nctId":791,"briefTitle":792,"status":304,"phases":1824,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":1825,"interventions":1826},[88],[35],[84,759,800,801],{"nctId":803,"briefTitle":804,"status":272,"phases":1828,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":1829,"interventions":1830},[88],[35],[84,759,760,761],{"nctId":1832,"briefTitle":1833,"status":192,"phases":1834,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1840},"NCT06120140","Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib",[88],"2027-05-31","2032-01-31","2024-02-16",305,[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],"Amivantamab SC","Doxycycline","Minocycline","Clindamycin","Chlorhexidine","Zinc gluconate","Propranolol","Timolol","Clobetasol",{"nctId":1851,"briefTitle":1852,"status":105,"phases":1853,"primaryCompletion":1854,"completion":1855,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1859},"NCT04075396","A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)",[87,88],"2021-01-08","2022-11-14","2019-10-16",29,[35],[759],{"nctId":872,"briefTitle":873,"status":192,"phases":1861,"primaryCompletion":875,"completion":830,"start":831,"enrollment":809,"conditions":1862,"interventions":1863},[88],[35],[684,878,879,84,759],{"nctId":881,"briefTitle":882,"status":304,"phases":1865,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":1866,"interventions":1867},[88],[889],[84,759,760,761,891,892],{"trials":1869,"activeCount":571,"soonestReadout":926},[1870,1874,1878],{"nctId":923,"briefTitle":924,"status":192,"phases":1871,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":1872,"interventions":1873},[89],[35],[759,84,761,760],{"nctId":933,"briefTitle":934,"status":192,"phases":1875,"primaryCompletion":936,"completion":927,"start":937,"enrollment":938,"conditions":1876,"interventions":1877},[89],[35],[84,941,759],{"nctId":1879,"briefTitle":1880,"status":192,"phases":1881,"primaryCompletion":1882,"completion":1689,"start":1883,"enrollment":1884,"conditions":1885,"interventions":1887},"NCT05388669","A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer",[89],"2024-01-03","2022-08-05",418,[1886],"Advanced or Metastatic Non-small Cell Lung Cancer",[759,1888,1889],"Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase","Amivantamab Intravenous",{"trials":1891,"activeCount":99},[],{"trials":1893,"activeCount":99},[],{"intervention":707,"totalTrials":129,"cells":1895},{"EARLY_PHASE1":1896,"PHASE1":1898,"PHASE2":1920,"PHASE3":1922,"PHASE4":1948,"NA":1950},{"trials":1897,"activeCount":99},[],{"trials":1899,"activeCount":352,"soonestReadout":1674},[1900,1904,1908,1912,1916],{"nctId":979,"briefTitle":980,"status":192,"phases":1901,"primaryCompletion":982,"completion":982,"start":983,"enrollment":984,"conditions":1902,"interventions":1903},[87],[18],[681,70,65,707],{"nctId":1671,"briefTitle":1672,"status":192,"phases":1905,"primaryCompletion":1674,"completion":1024,"start":1675,"enrollment":1676,"conditions":1906,"interventions":1907},[87],[18],[70,1096,1301,683,707],{"nctId":1157,"briefTitle":1158,"status":105,"phases":1909,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":1910,"interventions":1911},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"nctId":1445,"briefTitle":1446,"status":304,"phases":1913,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":160,"conditions":1914,"interventions":1915},[87],[18],[1085,681,707,683],{"nctId":1021,"briefTitle":1022,"status":192,"phases":1917,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":1918,"interventions":1919},[87],[18],[65,681,707,683,682,1028],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":641,"soonestReadout":701},[1924,1928,1932,1936,1940,1944],{"nctId":1268,"briefTitle":1269,"status":192,"phases":1925,"primaryCompletion":1271,"completion":1272,"start":1273,"enrollment":1274,"conditions":1926,"interventions":1927},[89],[1006],[70,681,707,684],{"nctId":1055,"briefTitle":1056,"status":304,"phases":1929,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1930,"interventions":1931},[89],[18],[70,707,65,1064,684,682],{"nctId":1087,"briefTitle":1088,"status":192,"phases":1933,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":1934,"interventions":1935},[89],[1006],[65,707,682,684,1096],{"nctId":1344,"briefTitle":1345,"status":304,"phases":1937,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":948,"conditions":1938,"interventions":1939},[89],[18],[681,1096,684,683,707],{"nctId":1098,"briefTitle":1099,"status":192,"phases":1941,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":1942,"interventions":1943},[89],[18],[681,707,684,682,65],{"nctId":698,"briefTitle":699,"status":192,"phases":1945,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":1946,"interventions":1947},[89],[18],[640,707,682,684,681],{"trials":1949,"activeCount":99},[],{"trials":1951,"activeCount":99},[],{"intervention":1953,"totalTrials":745,"cells":1954},"Nipocalimab",{"EARLY_PHASE1":1955,"PHASE1":1957,"PHASE2":1995,"PHASE3":2057,"PHASE4":2150,"NA":2152},{"trials":1956,"activeCount":99},[],{"trials":1958,"activeCount":99},[1959,1967,1976,1985],{"nctId":1960,"briefTitle":1961,"status":105,"phases":1962,"primaryCompletion":1963,"completion":1963,"start":1964,"enrollment":22,"conditions":1965,"interventions":1966},"NCT05151692","A Study of JNJ-80202135 in Healthy Chinese Adult Participants",[87],"2022-09-09","2022-05-30",[15],[1953],{"nctId":1968,"briefTitle":1969,"status":105,"phases":1970,"primaryCompletion":1971,"completion":1971,"start":50,"enrollment":1972,"conditions":1973,"interventions":1974},"NCT04973566","A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants",[87],"2022-05-27",48,[15],[1953,446,1975],"Hydroxychloroquine",{"nctId":1977,"briefTitle":1978,"status":105,"phases":1979,"primaryCompletion":1980,"completion":1980,"start":1981,"enrollment":1982,"conditions":1983,"interventions":1984},"NCT04848558","A Study of Nipocalimab in Healthy Male and Female Participants",[87],"2022-05-26","2021-05-25",89,[15],[1953],{"nctId":1986,"briefTitle":1987,"status":105,"phases":1988,"primaryCompletion":1989,"completion":1989,"start":1990,"enrollment":1507,"conditions":1991,"interventions":1992},"NCT05827874","A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy Participants",[87],"2023-10-04","2023-04-12",[15],[1953,1993,1994],"Tdap","PPSV23",{"trials":1996,"activeCount":468,"soonestReadout":2050},[1997,2005,2016,2026,2037,2046],{"nctId":1998,"briefTitle":1999,"status":105,"phases":2000,"primaryCompletion":2001,"completion":2001,"start":1102,"enrollment":231,"conditions":2002,"interventions":2004},"NCT04991753","A Proof-of-concept Study of the Efficacy and Safety of Nipocalimab in Participants With Active Rheumatoid Arthritis",[88],"2022-08-10",[2003],"Arthritis, Rheumatoid",[1953],{"nctId":2006,"briefTitle":2007,"status":105,"phases":2008,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":1045,"conditions":2012,"interventions":2014},"NCT04882878","A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus",[88],"2024-04-30","2024-12-26","2021-08-20",[2013],"Systemic Lupus Erythematosus",[1953,2015],"Standard-of-care treatment",{"nctId":2017,"briefTitle":2018,"status":105,"phases":2019,"primaryCompletion":2020,"completion":422,"start":2021,"enrollment":2022,"conditions":2023,"interventions":2024},"NCT06028438","A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis",[88],"2024-08-29","2023-08-15",103,[2003],[1953,2025],"Certolizumab",{"nctId":2027,"briefTitle":2028,"status":105,"phases":2029,"primaryCompletion":592,"completion":2030,"start":2031,"enrollment":2032,"conditions":2033,"interventions":2035},"NCT04968912","A Study of Nipocalimab in Adults With Primary Sjogren's Syndrome (pSS)",[88],"2023-11-30","2021-09-21",163,[2034],"Sjogren's Syndrome",[1953,2036],"Standard of Care Treatment",{"nctId":2038,"briefTitle":2039,"status":137,"phases":2040,"primaryCompletion":2041,"completion":2041,"start":2042,"enrollment":99,"conditions":2043,"interventions":2045},"NCT04883619","A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis",[88],"2028-02-28","2026-01-15",[2044],"Lupus Nephritis",[1953,2015],{"nctId":2047,"briefTitle":2048,"status":192,"phases":2049,"primaryCompletion":2050,"completion":2051,"start":2052,"enrollment":1532,"conditions":2053,"interventions":2055},"NCT05379634","A Study of Nipocalimab in Participants With Active Idiopathic Inflammatory Myopathies",[88],"2025-09-04","2026-09-16","2022-07-05",[2054],"Myositis",[1953,2056],"Glucocorticoids",{"trials":2058,"activeCount":2149,"soonestReadout":2063},[2059,2070,2081,2092,2102,2112,2123,2132,2142],{"nctId":2060,"briefTitle":2061,"status":304,"phases":2062,"primaryCompletion":2063,"completion":1690,"start":2064,"enrollment":2065,"conditions":2066,"interventions":2068},"NCT04951622","A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis",[89],"2023-11-17","2021-07-15",199,[2067],"Myasthenia Gravis",[1953,2069],"Nipocalimab SC-LIV",{"nctId":2071,"briefTitle":2072,"status":304,"phases":2073,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":2077,"conditions":2078,"interventions":2079},"NCT07217587","Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis",[89],"2027-09-28","2028-12-11","2026-01-05",115,[2067],[1953,2080],"Efgartigimod",{"nctId":2082,"briefTitle":2083,"status":192,"phases":2084,"primaryCompletion":2085,"completion":2086,"start":1450,"enrollment":2087,"conditions":2088,"interventions":2090},"NCT06741969","Nipocalimab in Moderate to Severe Sjogren's Disease",[89],"2028-01-01","2029-05-18",655,[2089],"Sjogrens Syndrome",[1953,2091],"Standard of care treatment",{"nctId":2093,"briefTitle":2094,"status":304,"phases":2095,"primaryCompletion":2096,"completion":946,"start":2097,"enrollment":2098,"conditions":2099,"interventions":2101},"NCT05327114","Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[88,89],"2027-05-14","2022-09-23",201,[2100],"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[1953],{"nctId":2103,"briefTitle":2104,"status":304,"phases":2105,"primaryCompletion":2106,"completion":2106,"start":2107,"enrollment":2108,"conditions":2109,"interventions":2111},"NCT06449651","A Study of Nipocalimab in Reducing the Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)",[89],"2029-12-05","2024-11-11",39,[2110],"Thrombocytopenia, Neonatal Alloimmune",[1953],{"nctId":2113,"briefTitle":2114,"status":304,"phases":2115,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":2120,"interventions":2122},"NCT07438496","A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus",[89],"2028-12-06","2031-11-07","2026-03-05",600,[2121],"Lupus Erythematosus, Systemic",[1953,2091],{"nctId":2124,"briefTitle":2125,"status":304,"phases":2126,"primaryCompletion":2127,"completion":2128,"start":2129,"enrollment":544,"conditions":2130,"interventions":2131},"NCT05265273","A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis",[88,89],"2026-06-26","2029-07-02","2022-07-20",[2067],[1953],{"nctId":2133,"briefTitle":2134,"status":304,"phases":2135,"primaryCompletion":2136,"completion":2137,"start":2138,"enrollment":371,"conditions":2139,"interventions":2141},"NCT05912517","A Study of Nipocalimab in Pregnancies at Risk for Severe Hemolytic Disease of the Fetus and Newborn (HDFN)",[89],"2027-08-05","2029-10-08","2023-12-20",[2140],"Hemolytic Disease of the Fetus and Newborn",[1953],{"nctId":2143,"briefTitle":2144,"status":304,"phases":2145,"primaryCompletion":900,"completion":2106,"start":501,"enrollment":320,"conditions":2146,"interventions":2147},"NCT06533098","A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)",[89],[2110],[1953,2148,496],"Intravenous immunoglobulins",9,{"trials":2151,"activeCount":99},[],{"trials":2153,"activeCount":99},[2154],{"nctId":2155,"briefTitle":2156,"status":2157,"phases":2158,"conditions":2159,"interventions":2161},"NCT05221619","Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)","TEMPORARILY_NOT_AVAILABLE",[],[2160],"Warm Autoimmune Hemolytic Anemia",[1953],{"intervention":682,"totalTrials":33,"cells":2163},{"EARLY_PHASE1":2164,"PHASE1":2166,"PHASE2":2172,"PHASE3":2207,"PHASE4":2252,"NA":2254},{"trials":2165,"activeCount":99},[],{"trials":2167,"activeCount":468,"soonestReadout":982},[2168],{"nctId":1021,"briefTitle":1022,"status":192,"phases":2169,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":2170,"interventions":2171},[87],[18],[65,681,707,683,682,1028],{"trials":2173,"activeCount":571,"soonestReadout":328},[2174,2178,2182,2186,2190,2194,2198],{"nctId":1198,"briefTitle":1199,"status":105,"phases":2175,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":2176,"interventions":2177},[88],[18],[683,682,684,681],{"nctId":1208,"briefTitle":1209,"status":192,"phases":2179,"primaryCompletion":328,"completion":1211,"start":1212,"enrollment":1213,"conditions":2180,"interventions":2181},[88],[1215],[681,659,682,684],{"nctId":1218,"briefTitle":1219,"status":105,"phases":2183,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":2184,"interventions":2185},[88],[18],[681,682,683,684,1167,496,1096],{"nctId":1228,"briefTitle":1229,"status":192,"phases":2187,"primaryCompletion":462,"completion":1231,"start":502,"enrollment":1232,"conditions":2188,"interventions":2189},[88],[18],[1235,683,681,682,684],{"nctId":1237,"briefTitle":1238,"status":105,"phases":2191,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":2192,"interventions":2193},[88],[18],[1246,682,684],{"nctId":672,"briefTitle":673,"status":192,"phases":2195,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":2196,"interventions":2197},[88],[18],[640,70,681,65,682,683,684,659,661],{"nctId":2199,"briefTitle":2200,"status":105,"phases":2201,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":1532,"conditions":2205,"interventions":2206},"NCT05564052","A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma",[88],"2023-12-06","2024-09-26","2022-12-06",[1534],[46,683,1384,682],{"trials":2208,"activeCount":1029,"soonestReadout":701},[2209,2213,2224,2228,2232,2236,2240,2244,2248],{"nctId":1258,"briefTitle":1259,"status":105,"phases":2210,"primaryCompletion":1261,"completion":1262,"start":1263,"enrollment":1264,"conditions":2211,"interventions":2212},[89],[18],[682,684],{"nctId":2214,"briefTitle":2215,"status":105,"phases":2216,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":2220,"conditions":2221,"interventions":2222},"NCT00103506","Study of DOXIL\u002FCAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma",[89],"2014-05","2014-06","2004-12",646,[18],[682,682,2223],"Doxorubicin hydrochloride",{"nctId":1055,"briefTitle":1056,"status":304,"phases":2225,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":2226,"interventions":2227},[89],[18],[70,707,65,1064,684,682],{"nctId":1307,"briefTitle":1308,"status":105,"phases":2229,"primaryCompletion":1310,"completion":308,"start":1311,"enrollment":1312,"conditions":2230,"interventions":2231},[89],[18],[681,682,683,684],{"nctId":1087,"briefTitle":1088,"status":192,"phases":2233,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":2234,"interventions":2235},[89],[1006],[65,707,682,684,1096],{"nctId":1597,"briefTitle":1598,"status":105,"phases":2237,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":2238,"interventions":2239},[89],[1215],[659,682,1606,681],{"nctId":1098,"briefTitle":1099,"status":192,"phases":2241,"primaryCompletion":1101,"completion":1101,"start":1102,"enrollment":1103,"conditions":2242,"interventions":2243},[89],[18],[681,707,684,682,65],{"nctId":688,"briefTitle":689,"status":192,"phases":2245,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":2246,"interventions":2247},[89],[18],[682,684,683,640,659,661],{"nctId":698,"briefTitle":699,"status":192,"phases":2249,"primaryCompletion":701,"completion":702,"start":703,"enrollment":704,"conditions":2250,"interventions":2251},[89],[18],[640,707,682,684,681],{"trials":2253,"activeCount":99},[],{"trials":2255,"activeCount":99},[],{"intervention":683,"totalTrials":33,"cells":2257},{"EARLY_PHASE1":2258,"PHASE1":2260,"PHASE2":2278,"PHASE3":2304,"PHASE4":2334,"NA":2336},{"trials":2259,"activeCount":99},[],{"trials":2261,"activeCount":571,"soonestReadout":1674},[2262,2266,2270,2274],{"nctId":1671,"briefTitle":1672,"status":192,"phases":2263,"primaryCompletion":1674,"completion":1024,"start":1675,"enrollment":1676,"conditions":2264,"interventions":2265},[87],[18],[70,1096,1301,683,707],{"nctId":1157,"briefTitle":1158,"status":105,"phases":2267,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":2268,"interventions":2269},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"nctId":1445,"briefTitle":1446,"status":304,"phases":2271,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":160,"conditions":2272,"interventions":2273},[87],[18],[1085,681,707,683],{"nctId":1021,"briefTitle":1022,"status":192,"phases":2275,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":2276,"interventions":2277},[87],[18],[65,681,707,683,682,1028],{"trials":2279,"activeCount":245,"soonestReadout":462},[2280,2284,2288,2292,2296,2300],{"nctId":1186,"briefTitle":1187,"status":105,"phases":2281,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":2282,"interventions":2283},[87,88],[18],[1195,1196,683,684],{"nctId":1198,"briefTitle":1199,"status":105,"phases":2285,"primaryCompletion":1201,"completion":1202,"start":1203,"enrollment":1204,"conditions":2286,"interventions":2287},[88],[18],[683,682,684,681],{"nctId":1218,"briefTitle":1219,"status":105,"phases":2289,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":2290,"interventions":2291},[88],[18],[681,682,683,684,1167,496,1096],{"nctId":1228,"briefTitle":1229,"status":192,"phases":2293,"primaryCompletion":462,"completion":1231,"start":502,"enrollment":1232,"conditions":2294,"interventions":2295},[88],[18],[1235,683,681,682,684],{"nctId":672,"briefTitle":673,"status":192,"phases":2297,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":2298,"interventions":2299},[88],[18],[640,70,681,65,682,683,684,659,661],{"nctId":2199,"briefTitle":2200,"status":105,"phases":2301,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":1532,"conditions":2302,"interventions":2303},[88],[1534],[46,683,1384,682],{"trials":2305,"activeCount":352,"soonestReadout":1573},[2306,2310,2314,2318,2322,2326,2330],{"nctId":1570,"briefTitle":1571,"status":192,"phases":2307,"primaryCompletion":1573,"completion":276,"start":1574,"enrollment":1575,"conditions":2308,"interventions":2309},[89],[18],[681,683],{"nctId":1066,"briefTitle":1067,"status":304,"phases":2311,"primaryCompletion":1069,"completion":1070,"start":1071,"enrollment":1072,"conditions":2312,"interventions":2313},[89],[18],[65,681,683,684,70],{"nctId":1307,"briefTitle":1308,"status":105,"phases":2315,"primaryCompletion":1310,"completion":308,"start":1311,"enrollment":1312,"conditions":2316,"interventions":2317},[89],[18],[681,682,683,684],{"nctId":1334,"briefTitle":1335,"status":105,"phases":2319,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":2320,"interventions":2321},[89],[18],[1300,683,684,1301],{"nctId":1344,"briefTitle":1345,"status":304,"phases":2323,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":948,"conditions":2324,"interventions":2325},[89],[18],[681,1096,684,683,707],{"nctId":688,"briefTitle":689,"status":192,"phases":2327,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":2328,"interventions":2329},[89],[18],[682,684,683,640,659,661],{"nctId":1389,"briefTitle":1390,"status":105,"phases":2331,"primaryCompletion":1392,"completion":1393,"start":1394,"enrollment":1395,"conditions":2332,"interventions":2333},[89],[18],[681,683,684],{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[],{"intervention":760,"totalTrials":893,"cells":2339},{"EARLY_PHASE1":2340,"PHASE1":2342,"PHASE2":2352,"PHASE3":2373,"PHASE4":2391,"NA":2393},{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":245,"soonestReadout":766},[2344,2348],{"nctId":752,"briefTitle":753,"status":192,"phases":2345,"primaryCompletion":511,"completion":511,"start":264,"enrollment":755,"conditions":2346,"interventions":2347},[87],[757],[84,84,759,760,761],{"nctId":763,"briefTitle":764,"status":192,"phases":2349,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":2350,"interventions":2351},[87],[35],[759,84,760,761],{"trials":2353,"activeCount":352,"soonestReadout":79},[2354,2358,2362,2369],{"nctId":803,"briefTitle":804,"status":272,"phases":2355,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":2356,"interventions":2357},[88],[35],[84,759,760,761],{"nctId":813,"briefTitle":814,"status":304,"phases":2359,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":2360,"interventions":2361},[87,88],[821],[84,823,824,760],{"nctId":77,"briefTitle":78,"status":192,"phases":2363,"primaryCompletion":79,"completion":511,"start":2364,"enrollment":2365,"conditions":2366,"interventions":2368},[87,88],"2018-04-05",125,[2367],"Urothelial Carcinoma",[75,560,952,760],{"nctId":881,"briefTitle":882,"status":304,"phases":2370,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":2371,"interventions":2372},[88],[889],[84,759,760,761,891,892],{"trials":2374,"activeCount":571,"soonestReadout":83},[2375,2379,2383,2387],{"nctId":923,"briefTitle":924,"status":192,"phases":2376,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":2377,"interventions":2378},[89],[35],[759,84,761,760],{"nctId":943,"briefTitle":944,"status":304,"phases":2380,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":2381,"interventions":2382},[89],[821],[84,823,760,951,952],{"nctId":81,"briefTitle":82,"status":192,"phases":2384,"primaryCompletion":83,"completion":955,"start":956,"enrollment":957,"conditions":2385,"interventions":2386},[89],[35],[84,761,760,761],{"nctId":1375,"briefTitle":1376,"status":125,"phases":2388,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":2389,"interventions":2390},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"intervention":560,"totalTrials":109,"cells":2396},{"EARLY_PHASE1":2397,"PHASE1":2399,"PHASE2":2414,"PHASE3":2443,"PHASE4":2467,"NA":2469},{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":468,"soonestReadout":551},[2401,2405],{"nctId":548,"briefTitle":549,"status":304,"phases":2402,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":2403,"interventions":2404},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"nctId":2406,"briefTitle":2407,"status":105,"phases":2408,"primaryCompletion":2409,"completion":2409,"start":2410,"enrollment":129,"conditions":2411,"interventions":2413},"NCT05242445","A Study of Cetrelimab in Participants With Chronic Hepatitis B Virus Infection",[87],"2023-05-09","2022-04-19",[2412],"Hepatitis B, Chronic",[560],{"trials":2415,"activeCount":352,"soonestReadout":79},[2416,2427,2431,2435],{"nctId":2417,"briefTitle":2418,"status":192,"phases":2419,"primaryCompletion":2420,"completion":2421,"start":2422,"enrollment":1630,"conditions":2423,"interventions":2425},"NCT04640623","A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",[88],"2025-07-03","2027-09-30","2020-12-18",[2424],"Urinary Bladder Neoplasms",[2426,560],"TAR-200",{"nctId":826,"briefTitle":827,"status":192,"phases":2428,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":2429,"interventions":2430},[87,88],[35],[560,84],{"nctId":77,"briefTitle":78,"status":192,"phases":2432,"primaryCompletion":79,"completion":511,"start":2364,"enrollment":2365,"conditions":2433,"interventions":2434},[87,88],[2367],[75,560,952,760],{"nctId":2436,"briefTitle":2437,"status":192,"phases":2438,"primaryCompletion":2439,"completion":2440,"start":69,"enrollment":2032,"conditions":2441,"interventions":2442},"NCT04919512","A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder",[88],"2025-02-04","2026-03-31",[2424],[2426,560],{"trials":2444,"activeCount":245,"soonestReadout":2460},[2445,2456],{"nctId":2446,"briefTitle":2447,"status":192,"phases":2448,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":2451,"conditions":2452,"interventions":2454},"NCT05714202","A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)",[89],"2029-09-18","2023-03-23",1135,[2453],"Bladder Cancer",[2426,560,2455],"BCG Vesiculture",{"nctId":2457,"briefTitle":2458,"status":192,"phases":2459,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2464,"interventions":2465},"NCT04658862","A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder",[89],"2026-12-30","2028-12-31","2020-12-07",518,[2424],[560,2426,952,2466],"Gemcitabine",{"trials":2468,"activeCount":99},[],{"trials":2470,"activeCount":99},[],{"intervention":496,"totalTrials":2472,"cells":2473},25,{"EARLY_PHASE1":2474,"PHASE1":2476,"PHASE2":2518,"PHASE3":2580,"PHASE4":2685,"NA":2687},{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":245,"soonestReadout":60},[2478,2482,2494,2498,2504,2508],{"nctId":486,"briefTitle":487,"status":105,"phases":2479,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":2480,"interventions":2481},[87],[30],[56,41,495,496],{"nctId":2483,"briefTitle":2484,"status":105,"phases":2485,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":492,"conditions":2489,"interventions":2491},"NCT01017939","A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer",[87],"2010-06","2012-04","2010-01",[2490],"Prostate Neoplasms",[518,496,2492,2493],"Dextromethorphan hydrobromide","Theophylline",{"nctId":508,"briefTitle":509,"status":192,"phases":2495,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":2496,"interventions":2497},[87],[515],[517,41,518,496],{"nctId":58,"briefTitle":59,"status":192,"phases":2499,"primaryCompletion":60,"completion":511,"start":2500,"enrollment":2501,"conditions":2502,"interventions":2503},[87],"2020-11-13",136,[30],[56,495,496],{"nctId":1157,"briefTitle":1158,"status":105,"phases":2505,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":2506,"interventions":2507},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"nctId":2509,"briefTitle":2510,"status":105,"phases":2511,"primaryCompletion":2512,"completion":2513,"start":2514,"enrollment":2515,"conditions":2516,"interventions":2517},"NCT00910754","A QT\u002FQTc and Multi-Dose Pharmacokinetic Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer",[87],"2009-11","2012-05","2009-05",33,[2490],[518,496],{"trials":2519,"activeCount":99},[2520,2531,2539,2549,2560,2572,2576],{"nctId":2521,"briefTitle":2522,"status":105,"phases":2523,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":2526,"conditions":2527,"interventions":2528},"NCT00911859","A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients",[88],"2013-04","2009-06",118,[18],[2529,2530,1166,1166,1167,1167,496,496,1166,1167,496],"Siltuximab11 mg\u002Fkg","Siltuximab 8.3 mg\u002Fkg or 11 mg\u002Fkg",{"nctId":2532,"briefTitle":2533,"status":105,"phases":2534,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":860,"conditions":2537,"interventions":2538},"NCT00544440","An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma",[88],"2012-08","2007-10",[2490],[518,496],{"nctId":2540,"briefTitle":2541,"status":105,"phases":2542,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":2546,"interventions":2547},"NCT02217566","Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy",[88],"2018-10-26","2014-09-23",46,[30],[518,496,2548],"Androgen deprivation therapy",{"nctId":2550,"briefTitle":2551,"status":105,"phases":2552,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":1838,"conditions":2555,"interventions":2557},"NCT05811351","A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)",[88],"2026-02-23","2023-03-06",[2556],"Geographic Atrophy",[2558,496,2559],"JNJ-81201887","Triamcinolone",{"nctId":2561,"briefTitle":2562,"status":105,"phases":2563,"primaryCompletion":2564,"completion":2565,"start":2512,"enrollment":2566,"conditions":2567,"interventions":2569},"NCT00924469","A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone Acetate in Male Participants With Prostate Cancer",[88],"2012-02","2012-03",58,[2568],"Prostate Cancer",[2570,2571,496],"Abiraterone","Leuprolide",{"nctId":1218,"briefTitle":1219,"status":105,"phases":2573,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":2574,"interventions":2575},[88],[18],[681,682,683,684,1167,496,1096],{"nctId":1547,"briefTitle":1548,"status":105,"phases":2577,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":2578,"interventions":2579},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":2581,"activeCount":352,"soonestReadout":55},[2582,2593,2601,2611,2623,2633,2642,2646,2656,2666,2677,2681],{"nctId":2583,"briefTitle":2584,"status":192,"phases":2585,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":2590,"interventions":2592},"NCT04497844","A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",[89],"2025-01-07","2027-11-01","2020-09-23",696,[2591],"Metastatic Castration-sensitive Prostate Cancer",[56,518,496],{"nctId":53,"briefTitle":54,"status":192,"phases":2594,"primaryCompletion":55,"completion":2595,"start":1201,"enrollment":2596,"conditions":2597,"interventions":2599},[89],"2027-02-27",765,[2598],"Castration-Resistant Prostatic Cancer",[56,495,496,2600],"New Formulation of Niraparib and Abiraterone Acetate",{"nctId":2602,"briefTitle":2603,"status":105,"phases":2604,"primaryCompletion":2605,"completion":2606,"start":2607,"enrollment":2608,"conditions":2609,"interventions":2610},"NCT00887198","Abiraterone Acetate in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",[89],"2014-03-31","2017-05-25","2009-04-28",1088,[2568],[518,496],{"nctId":2612,"briefTitle":2613,"status":105,"phases":2614,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":2619,"interventions":2620},"NCT01715285","A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)",[89],"2016-10-31","2022-02-13","2013-02-12",1209,[2490],[518,496,2621,2622],"Abiraterone acetate Placebo","Prednisone Placebo",{"nctId":2624,"briefTitle":2625,"status":105,"phases":2626,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":2631,"interventions":2632},"NCT01855750","A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma",[89],"2018-02-26","2019-04-05","2013-09-03",838,[1509],[46,1384,659,1556,1154,496],{"nctId":2634,"briefTitle":2635,"status":304,"phases":2636,"primaryCompletion":1448,"completion":2637,"start":2638,"enrollment":2639,"conditions":2640,"interventions":2641},"NCT07225946","A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer",[89],"2029-07-20","2025-12-19",800,[585],[559,562,496],{"nctId":1291,"briefTitle":1292,"status":105,"phases":2643,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":2644,"interventions":2645},[89],[18],[1166,1167,496,1300,684,1301],{"nctId":2647,"briefTitle":2648,"status":105,"phases":2649,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":2654,"interventions":2655},"NCT01695135","A Study of Abiraterone Acetate Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Docetaxel-Based Chemotherapy",[89],"2014-06-20","2018-05-08","2012-08-09",214,[2490],[518,496],{"nctId":2657,"briefTitle":2658,"status":105,"phases":2659,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":1507,"conditions":2662,"interventions":2665},"NCT01517802","A Study That Provides Long-term Safety Follow-up and Examines Long-term Exposure to Abiraterone Acetate",[89],"2021-04-22","2012-03-28",[2663,2664],"Metastatic Castration-resistant Prostate Cancer","Metastatic Breast Cancer",[518,496],{"nctId":2667,"briefTitle":2668,"status":105,"phases":2669,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":2673,"interventions":2674},"NCT01974440","A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma",[89],"2023-06-21","2014-01-31",403,[1509],[2675,1384,659,1556,1154,496,2676],"Bendamustine","PCI-32765",{"nctId":1624,"briefTitle":1625,"status":105,"phases":2678,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":2679,"interventions":2680},[89],[18],[1166,1167,496,681],{"nctId":2143,"briefTitle":2144,"status":304,"phases":2682,"primaryCompletion":900,"completion":2106,"start":501,"enrollment":320,"conditions":2683,"interventions":2684},[89],[2110],[1953,2148,496],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"intervention":761,"totalTrials":641,"cells":2690},{"EARLY_PHASE1":2691,"PHASE1":2693,"PHASE2":2703,"PHASE3":2713,"PHASE4":2723,"NA":2725},{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":245,"soonestReadout":766},[2695,2699],{"nctId":752,"briefTitle":753,"status":192,"phases":2696,"primaryCompletion":511,"completion":511,"start":264,"enrollment":755,"conditions":2697,"interventions":2698},[87],[757],[84,84,759,760,761],{"nctId":763,"briefTitle":764,"status":192,"phases":2700,"primaryCompletion":766,"completion":767,"start":768,"enrollment":769,"conditions":2701,"interventions":2702},[87],[35],[759,84,760,761],{"trials":2704,"activeCount":245,"soonestReadout":884},[2705,2709],{"nctId":803,"briefTitle":804,"status":272,"phases":2706,"primaryCompletion":806,"completion":807,"start":808,"enrollment":809,"conditions":2707,"interventions":2708},[88],[35],[84,759,760,761],{"nctId":881,"briefTitle":882,"status":304,"phases":2710,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":2711,"interventions":2712},[88],[889],[84,759,760,761,891,892],{"trials":2714,"activeCount":245,"soonestReadout":83},[2715,2719],{"nctId":923,"briefTitle":924,"status":192,"phases":2716,"primaryCompletion":926,"completion":927,"start":928,"enrollment":929,"conditions":2717,"interventions":2718},[89],[35],[759,84,761,760],{"nctId":81,"briefTitle":82,"status":192,"phases":2720,"primaryCompletion":83,"completion":955,"start":956,"enrollment":957,"conditions":2721,"interventions":2722},[89],[35],[84,761,760,761],{"trials":2724,"activeCount":99},[],{"trials":2726,"activeCount":99},[],{"intervention":2728,"totalTrials":893,"cells":2729},"JNJ-77242113",{"EARLY_PHASE1":2730,"PHASE1":2732,"PHASE2":2742,"PHASE3":2777,"PHASE4":2829,"NA":2831},{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[2734],{"nctId":2735,"briefTitle":2736,"status":105,"phases":2737,"primaryCompletion":2738,"completion":1990,"start":2739,"enrollment":22,"conditions":2740,"interventions":2741},"NCT05703841","A Study of JNJ-77242113 Following Oral Administration in Healthy Chinese Adult Participants",[87],"2023-04-07","2023-02-14",[15],[2728],{"trials":2743,"activeCount":99},[2744,2752,2760,2769],{"nctId":2745,"briefTitle":2746,"status":105,"phases":2747,"primaryCompletion":349,"completion":349,"start":2748,"enrollment":2749,"conditions":2750,"interventions":2751},"NCT05364554","A Long-term Extension Study of JNJ-77242113 in Participants With Moderate-to-Severe Plaque Psoriasis",[88],"2022-06-10",227,[332],[2728],{"nctId":2753,"briefTitle":2754,"status":105,"phases":2755,"primaryCompletion":1348,"completion":1348,"start":2756,"enrollment":2757,"conditions":2758,"interventions":2759},"NCT05223868","A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis",[88],"2022-02-03",255,[332],[2728],{"nctId":2761,"briefTitle":2762,"status":105,"phases":2763,"primaryCompletion":2450,"completion":2764,"start":2765,"enrollment":2766,"conditions":2767,"interventions":2768},"NCT05357755","A Study of JNJ-77242113 for the Treatment of Moderate-to-Severe Plaque Psoriasis",[88],"2023-04-10","2022-06-13",90,[332],[2728],{"nctId":2770,"briefTitle":2771,"status":105,"phases":2772,"primaryCompletion":2203,"completion":2076,"start":2773,"enrollment":2774,"conditions":2775,"interventions":2776},"NCT06049017","A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis",[88],"2023-10-09",252,[27],[2728],{"trials":2778,"activeCount":1029,"soonestReadout":2824},[2779,2790,2800,2810,2820],{"nctId":2780,"briefTitle":2781,"status":192,"phases":2782,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":2786,"conditions":2787,"interventions":2788},"NCT06143878","A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis",[89],"2024-09-17","2027-06-01","2024-02-01",774,[332],[2728,2789],"Deucravacitinib",{"nctId":2791,"briefTitle":2792,"status":192,"phases":2793,"primaryCompletion":2794,"completion":2795,"start":2796,"enrollment":2797,"conditions":2798,"interventions":2799},"NCT06934226","A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis",[89],"2025-11-17","2027-08-20","2025-04-15",752,[332],[2728,214],{"nctId":2801,"briefTitle":2802,"status":192,"phases":2803,"primaryCompletion":2804,"completion":2805,"start":2806,"enrollment":2807,"conditions":2808,"interventions":2809},"NCT06220604","A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)",[89],"2024-11-15","2027-09-20","2024-03-09",731,[332],[2728,2789],{"nctId":2811,"briefTitle":2812,"status":192,"phases":2813,"primaryCompletion":2814,"completion":2815,"start":2816,"enrollment":2817,"conditions":2818,"interventions":2819},"NCT06095115","A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis",[89],"2024-07-29","2027-04-06","2023-10-12",684,[332],[2728],{"nctId":2821,"briefTitle":2822,"status":192,"phases":2823,"primaryCompletion":2824,"completion":2825,"start":2816,"enrollment":2826,"conditions":2827,"interventions":2828},"NCT06095102","A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and\u002For Palms of the Hands and the Soles of the Feet)",[89],"2024-06-19","2027-02-17",311,[332],[2728],{"trials":2830,"activeCount":99},[],{"trials":2832,"activeCount":99},[],{"intervention":1085,"totalTrials":1029,"cells":2834},{"EARLY_PHASE1":2835,"PHASE1":2837,"PHASE2":2854,"PHASE3":2865,"PHASE4":2875,"NA":2877},{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":245,"soonestReadout":2843},[2839,2850],{"nctId":2840,"briefTitle":2841,"status":304,"phases":2842,"primaryCompletion":2843,"completion":2844,"start":2845,"enrollment":2846,"conditions":2847,"interventions":2849},"NCT05652335","A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis",[87],"2027-04-19","2028-08-28","2022-11-22",180,[1006,2848],"Previously Treated Amyloid Light-chain (AL) Amyloidosis",[1085],{"nctId":1445,"briefTitle":1446,"status":304,"phases":2851,"primaryCompletion":1448,"completion":1449,"start":1450,"enrollment":160,"conditions":2852,"interventions":2853},[87],[18],[1085,681,707,683],{"trials":2855,"activeCount":468,"soonestReadout":2860},[2856],{"nctId":2857,"briefTitle":2858,"status":304,"phases":2859,"primaryCompletion":2860,"completion":1079,"start":2861,"enrollment":2862,"conditions":2863,"interventions":2864},"NCT07266441","A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma",[88],"2027-06-14","2026-02-08",157,[18],[1085],{"trials":2866,"activeCount":245,"soonestReadout":1079},[2867,2871],{"nctId":1076,"briefTitle":1077,"status":304,"phases":2868,"primaryCompletion":1079,"completion":1080,"start":1081,"enrollment":1082,"conditions":2869,"interventions":2870},[89],[18],[1085,65],{"nctId":1107,"briefTitle":1108,"status":272,"phases":2872,"primaryCompletion":1110,"completion":1111,"start":1112,"enrollment":903,"conditions":2873,"interventions":2874},[89],[18],[1085,65],{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"intervention":2880,"totalTrials":1029,"cells":2881},"Venetoclax",{"EARLY_PHASE1":2882,"PHASE1":2884,"PHASE2":2910,"PHASE3":2923,"PHASE4":2943,"NA":2945},{"trials":2883,"activeCount":99},[],{"trials":2885,"activeCount":245,"soonestReadout":2903},[2886,2899],{"nctId":2887,"briefTitle":2888,"status":304,"phases":2889,"primaryCompletion":2136,"completion":2890,"start":2891,"enrollment":2892,"conditions":2893,"interventions":2896},"NCT06651229","A Study of JNJ-90189892 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms",[87],"2028-11-21","2025-03-21",155,[2894,2895],"Leukemia, Myeloid, Acute","Myelodysplastic Neoplasms",[2897,2898,2880],"JNJ-90189892","Azacitadine",{"nctId":2900,"briefTitle":2901,"status":192,"phases":2902,"primaryCompletion":2903,"completion":1003,"start":2904,"enrollment":423,"conditions":2905,"interventions":2906},"NCT05453903","A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies",[87],"2026-10-30","2022-10-04",[2894],[2907,2880,2908,1152,2909],"Bleximenib","Azacitidine","Daunorubicin or Idarubicin",{"trials":2911,"activeCount":468,"soonestReadout":900},[2912],{"nctId":2913,"briefTitle":2914,"status":304,"phases":2915,"primaryCompletion":900,"completion":2916,"start":2917,"enrollment":2918,"conditions":2919,"interventions":2922},"NCT05963074","A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia",[88],"2029-03-19","2024-05-30",320,[2920,2921],"Leukemia, Lymphocytic, Chronic, B-Cell","Small Lymphocytic Lymphoma",[46,2880],{"trials":2924,"activeCount":245,"soonestReadout":45},[2925,2934],{"nctId":2926,"briefTitle":2927,"status":304,"phases":2928,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2119,"conditions":2932,"interventions":2933},"NCT06852222","A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)",[89],"2029-06-22","2029-08-15","2025-06-04",[2894],[2907,2880,2908],{"nctId":43,"briefTitle":44,"status":192,"phases":2935,"primaryCompletion":45,"completion":2936,"start":2937,"enrollment":2938,"conditions":2939,"interventions":2940},[89],"2029-04-05","2018-04-17",211,[2920],[46,2880,2941,2942,46],"Chlorambucil","Obinutuzumab",{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"intervention":2426,"totalTrials":2948,"cells":2949},7,{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2962,"PHASE3":2972,"PHASE4":2994,"NA":2996},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[2954],{"nctId":2955,"briefTitle":2956,"status":105,"phases":2957,"primaryCompletion":2958,"completion":74,"start":2959,"enrollment":95,"conditions":2960,"interventions":2961},"NCT03404791","A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy",[87],"2019-12-23","2017-11-20",[2424],[2426],{"trials":2963,"activeCount":245,"soonestReadout":2439},[2964,2968],{"nctId":2417,"briefTitle":2418,"status":192,"phases":2965,"primaryCompletion":2420,"completion":2421,"start":2422,"enrollment":1630,"conditions":2966,"interventions":2967},[88],[2424],[2426,560],{"nctId":2436,"briefTitle":2437,"status":192,"phases":2969,"primaryCompletion":2439,"completion":2440,"start":69,"enrollment":2032,"conditions":2970,"interventions":2971},[88],[2424],[2426,560],{"trials":2973,"activeCount":571,"soonestReadout":2460},[2974,2978,2990],{"nctId":2446,"briefTitle":2447,"status":192,"phases":2975,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":2451,"conditions":2976,"interventions":2977},[89],[2453],[2426,560,2455],{"nctId":2979,"briefTitle":2980,"status":192,"phases":2981,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":2986,"interventions":2988},"NCT06211764","A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)",[89],"2030-11-27","2031-04-14","2024-04-09",272,[2987],"Non-Muscle Invasive Bladder Neoplasms",[2426,2989,2466],"Mitomycin C",{"nctId":2457,"briefTitle":2458,"status":192,"phases":2991,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":2992,"interventions":2993},[89],[2424],[560,2426,952,2466],{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[2998],{"nctId":2999,"briefTitle":3000,"status":967,"phases":3001,"conditions":3002,"interventions":3003},"NCT06877676","Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use",[],[2987],[2426],{"intervention":659,"totalTrials":109,"cells":3005},{"EARLY_PHASE1":3006,"PHASE1":3008,"PHASE2":3010,"PHASE3":3028,"PHASE4":3046,"NA":3048},{"trials":3007,"activeCount":99},[],{"trials":3009,"activeCount":99},[],{"trials":3011,"activeCount":571,"soonestReadout":328},[3012,3016,3020,3024],{"nctId":650,"briefTitle":651,"status":304,"phases":3013,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":3014,"interventions":3015},[88],[18],[640,659,660,661],{"nctId":1208,"briefTitle":1209,"status":192,"phases":3017,"primaryCompletion":328,"completion":1211,"start":1212,"enrollment":1213,"conditions":3018,"interventions":3019},[88],[1215],[681,659,682,684],{"nctId":672,"briefTitle":673,"status":192,"phases":3021,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":3022,"interventions":3023},[88],[18],[640,70,681,65,682,683,684,659,661],{"nctId":1547,"briefTitle":1548,"status":105,"phases":3025,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":3026,"interventions":3027},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":3029,"activeCount":468,"soonestReadout":691},[3030,3034,3038,3042],{"nctId":2624,"briefTitle":2625,"status":105,"phases":3031,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":3032,"interventions":3033},[89],[1509],[46,1384,659,1556,1154,496],{"nctId":1597,"briefTitle":1598,"status":105,"phases":3035,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":3036,"interventions":3037},[89],[1215],[659,682,1606,681],{"nctId":688,"briefTitle":689,"status":192,"phases":3039,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":3040,"interventions":3041},[89],[18],[682,684,683,640,659,661],{"nctId":2667,"briefTitle":2668,"status":105,"phases":3043,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":3044,"interventions":3045},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"trials":3047,"activeCount":99},[],{"trials":3049,"activeCount":99},[],{"intervention":2466,"totalTrials":352,"cells":3051},{"EARLY_PHASE1":3052,"PHASE1":3054,"PHASE2":3056,"PHASE3":3058,"PHASE4":3087,"NA":3089},{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[],{"trials":3059,"activeCount":352,"soonestReadout":2460},[3060,3070,3074,3083],{"nctId":3061,"briefTitle":3062,"status":304,"phases":3063,"primaryCompletion":524,"completion":3064,"start":1222,"enrollment":3065,"conditions":3066,"interventions":3067},"NCT06319820","A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer",[89],"2032-12-31",641,[2987],[3068,2466,3069],"TAR-210","MMC",{"nctId":2979,"briefTitle":2980,"status":192,"phases":3071,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":3072,"interventions":3073},[89],[2987],[2426,2989,2466],{"nctId":3075,"briefTitle":3076,"status":304,"phases":3077,"primaryCompletion":3078,"completion":3079,"start":3080,"enrollment":1630,"conditions":3081,"interventions":3082},"NCT06919965","A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer",[89],"2028-04-06","2032-03-16","2025-09-10",[2987],[3068,2989,2466],{"nctId":2457,"briefTitle":2458,"status":192,"phases":3084,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":3085,"interventions":3086},[89],[2424],[560,2426,952,2466],{"trials":3088,"activeCount":99},[],{"trials":3090,"activeCount":99},[],{"intervention":202,"totalTrials":352,"cells":3092},{"EARLY_PHASE1":3093,"PHASE1":3095,"PHASE2":3097,"PHASE3":3107,"PHASE4":3117,"NA":3119},{"trials":3094,"activeCount":99},[],{"trials":3096,"activeCount":99},[],{"trials":3098,"activeCount":245,"soonestReadout":239},[3099,3103],{"nctId":190,"briefTitle":191,"status":192,"phases":3100,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":3101,"interventions":3102},[88],[199],[94,201,202],{"nctId":236,"briefTitle":237,"status":192,"phases":3104,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":3105,"interventions":3106},[88],[27],[94,201,202],{"trials":3108,"activeCount":245,"soonestReadout":359},[3109,3113],{"nctId":270,"briefTitle":271,"status":272,"phases":3110,"primaryCompletion":274,"completion":275,"start":276,"enrollment":277,"conditions":3111,"interventions":3112},[89],[27],[202,94],{"nctId":356,"briefTitle":357,"status":272,"phases":3114,"primaryCompletion":359,"completion":360,"start":276,"enrollment":361,"conditions":3115,"interventions":3116},[89],[311],[202,94],{"trials":3118,"activeCount":99},[],{"trials":3120,"activeCount":99},[],{"intervention":559,"totalTrials":352,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3142,"PHASE3":3144,"PHASE4":3160,"NA":3162},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":245,"soonestReadout":3135},[3127,3131],{"nctId":548,"briefTitle":549,"status":304,"phases":3128,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":3129,"interventions":3130},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"nctId":3132,"briefTitle":3133,"status":304,"phases":3134,"primaryCompletion":3135,"completion":3136,"start":3137,"enrollment":3138,"conditions":3139,"interventions":3140},"NCT07319871","A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer",[87],"2027-01-07","2027-04-30","2026-01-14",40,[30],[559,3141],"JNJ-86974680",{"trials":3143,"activeCount":99},[],{"trials":3145,"activeCount":245,"soonestReadout":1448},[3146,3156],{"nctId":3147,"briefTitle":3148,"status":304,"phases":3149,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":3152,"conditions":3153,"interventions":3154},"NCT07164443","A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)",[89],"2028-05-30","2025-09-02",663,[556],[559,3155],"Best Supportive Care",{"nctId":2634,"briefTitle":2635,"status":304,"phases":3157,"primaryCompletion":1448,"completion":2637,"start":2638,"enrollment":2639,"conditions":3158,"interventions":3159},[89],[585],[559,562,496],{"trials":3161,"activeCount":99},[],{"trials":3163,"activeCount":99},[],{"intervention":3165,"totalTrials":352,"cells":3166},"Icotrokinra",{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3171,"PHASE3":3173,"PHASE4":3215,"NA":3217},{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":352,"soonestReadout":3198},[3175,3185,3194,3205],{"nctId":3176,"briefTitle":3177,"status":304,"phases":3178,"primaryCompletion":3179,"completion":3180,"start":3181,"enrollment":3182,"conditions":3183,"interventions":3184},"NCT07196748","A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis",[89],"2028-01-14","2032-01-13","2025-10-01",882,[27],[3165],{"nctId":3186,"briefTitle":3187,"status":304,"phases":3188,"primaryCompletion":3189,"completion":3190,"start":655,"enrollment":3191,"conditions":3192,"interventions":3193},"NCT07196722","A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease",[88,89],"2028-09-19","2032-10-06",1092,[311],[3165],{"nctId":3195,"briefTitle":3196,"status":192,"phases":3197,"primaryCompletion":3198,"completion":3199,"start":3200,"enrollment":3201,"conditions":3202,"interventions":3203},"NCT06878404","A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis",[89],"2026-05-27","2028-02-04","2025-02-21",552,[131],[3165,3204],"Active reference comparator",{"nctId":3206,"briefTitle":3207,"status":304,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3211,"enrollment":3212,"conditions":3213,"interventions":3214},"NCT06807424","A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis",[89],"2027-02-10","2028-10-18","2025-01-09",750,[131],[3165],{"trials":3216,"activeCount":99},[],{"trials":3218,"activeCount":99},[],{"intervention":562,"totalTrials":352,"cells":3220},{"EARLY_PHASE1":3221,"PHASE1":3223,"PHASE2":3229,"PHASE3":3235,"PHASE4":3252,"NA":3254},{"trials":3222,"activeCount":99},[],{"trials":3224,"activeCount":468,"soonestReadout":551},[3225],{"nctId":548,"briefTitle":549,"status":304,"phases":3226,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":3227,"interventions":3228},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":3230,"activeCount":468,"soonestReadout":276},[3231],{"nctId":865,"briefTitle":866,"status":192,"phases":3232,"primaryCompletion":276,"completion":857,"start":868,"enrollment":544,"conditions":3233,"interventions":3234},[87,88],[35],[84,562],{"trials":3236,"activeCount":245,"soonestReadout":3245},[3237,3241],{"nctId":2634,"briefTitle":2635,"status":304,"phases":3238,"primaryCompletion":1448,"completion":2637,"start":2638,"enrollment":2639,"conditions":3239,"interventions":3240},[89],[585],[559,562,496],{"nctId":3242,"briefTitle":3243,"status":192,"phases":3244,"primaryCompletion":3245,"completion":511,"start":3246,"enrollment":3247,"conditions":3248,"interventions":3250},"NCT03390504","A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations",[89],"2024-04-15","2018-03-23",629,[3249],"Urothelial Cancer",[75,3251,562,823],"Vinflunine",{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[],{"intervention":2907,"totalTrials":352,"cells":3257},{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3277,"PHASE3":3289,"PHASE4":3295,"NA":3297},{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":245,"soonestReadout":3266},[3262,3273],{"nctId":3263,"briefTitle":3264,"status":304,"phases":3265,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":893,"conditions":3269,"interventions":3270},"NCT07295951","A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia",[87],"2026-06-14","2026-07-13","2025-11-18",[1148,1146,1147],[3271,3272],"14C-bleximenib","bleximenib",{"nctId":2900,"briefTitle":2901,"status":192,"phases":3274,"primaryCompletion":2903,"completion":1003,"start":2904,"enrollment":423,"conditions":3275,"interventions":3276},[87],[2894],[2907,2880,2908,1152,2909],{"trials":3278,"activeCount":468,"soonestReadout":3283},[3279],{"nctId":3280,"briefTitle":3281,"status":304,"phases":3282,"primaryCompletion":3283,"completion":3284,"start":3285,"enrollment":620,"conditions":3286,"interventions":3288},"NCT04811560","A Phase 1\u002F2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",[87,88],"2027-02-26","2030-09-22","2021-05-19",[3287],"Acute Leukemia",[2907],{"trials":3290,"activeCount":468,"soonestReadout":2929},[3291],{"nctId":2926,"briefTitle":2927,"status":304,"phases":3292,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2119,"conditions":3293,"interventions":3294},[89],[2894],[2907,2880,2908],{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[],{"intervention":518,"totalTrials":1419,"cells":3300},{"EARLY_PHASE1":3301,"PHASE1":3303,"PHASE2":3367,"PHASE3":3397,"PHASE4":3423,"NA":3425},{"trials":3302,"activeCount":99},[],{"trials":3304,"activeCount":245,"soonestReadout":60},[3305,3316,3320,3324,3334,3338,3346,3350,3354,3363],{"nctId":3306,"briefTitle":3307,"status":105,"phases":3308,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":3312,"conditions":3313,"interventions":3314},"NCT01664728","An Expanded Access Study of Abiraterone Acetate in Patients With Advanced Prostate Cancer Who Have Completed Clinical Study COU-AA-001",[87],"2009-02","2012-09","2007-04",54,[2490],[518,3315],"Glucocorticoid",{"nctId":486,"briefTitle":487,"status":105,"phases":3317,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":3318,"interventions":3319},[87],[30],[56,41,495,496],{"nctId":2483,"briefTitle":2484,"status":105,"phases":3321,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":492,"conditions":3322,"interventions":3323},[87],[2490],[518,496,2492,2493],{"nctId":3325,"briefTitle":3326,"status":105,"phases":3327,"primaryCompletion":3328,"completion":3328,"start":3329,"enrollment":169,"conditions":3330,"interventions":3332},"NCT01873001","A Study to Assess the Effect of Abiraterone (JNJ-589485) on the Pharmacokinetics of Pioglitazone Following Administration of Abiraterone Acetate (JNJ-212082) and Pioglitazone HCl Tablets in Healthy Male Participants",[87],"2013-07","2013-05",[3331],"Healthy Volunteers",[3333,518],"Pioglitazone HCl",{"nctId":508,"briefTitle":509,"status":192,"phases":3335,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":3336,"interventions":3337},[87],[515],[517,41,518,496],{"nctId":3339,"briefTitle":3340,"status":105,"phases":3341,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":28,"conditions":3343,"interventions":3344},"NCT01655147","A Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of Abiraterone in Healthy Male Participants",[87],"2012-01",[15],[518,3345],"Rifampicin",{"nctId":58,"briefTitle":59,"status":192,"phases":3347,"primaryCompletion":60,"completion":511,"start":2500,"enrollment":2501,"conditions":3348,"interventions":3349},[87],[30],[56,495,496],{"nctId":568,"briefTitle":569,"status":125,"phases":3351,"primaryCompletion":79,"completion":79,"start":148,"enrollment":571,"conditions":3352,"interventions":3353},[87],[30],[574,495,575,41],{"nctId":3355,"briefTitle":3356,"status":105,"phases":3357,"primaryCompletion":3358,"completion":3358,"start":3359,"enrollment":3360,"conditions":3361,"interventions":3362},"NCT02230046","Bioequivalence Study of Abiraterone Acetate Coated and Uncoated Tablet Formulations in Healthy Male Participants",[87],"2014-11","2014-10",102,[15],[518,518,518],{"nctId":2509,"briefTitle":2510,"status":105,"phases":3364,"primaryCompletion":2512,"completion":2513,"start":2514,"enrollment":2515,"conditions":3365,"interventions":3366},[87],[2490],[518,496],{"trials":3368,"activeCount":99},[3369,3373,3384,3388],{"nctId":2532,"briefTitle":2533,"status":105,"phases":3370,"primaryCompletion":2535,"completion":2535,"start":2536,"enrollment":860,"conditions":3371,"interventions":3372},[88],[2490],[518,496],{"nctId":3374,"briefTitle":3375,"status":105,"phases":3376,"primaryCompletion":3377,"completion":3378,"start":3379,"enrollment":3380,"conditions":3381,"interventions":3382},"NCT01685983","A Study of Abiraterone Acetate (JNJ-212082) and Prednisolone in Patients With Advanced Prostate Cancer",[88],"2013-01-24","2018-03-06","2011-08-30",82,[2568],[518,3383],"Prednisolone",{"nctId":2540,"briefTitle":2541,"status":105,"phases":3385,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":3386,"interventions":3387},[88],[30],[518,496,2548],{"nctId":3389,"briefTitle":3390,"status":105,"phases":3391,"primaryCompletion":3392,"completion":3392,"start":3393,"enrollment":1436,"conditions":3394,"interventions":3395},"NCT00473746","Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer",[87,88],"2012-12","2006-06",[2490],[518,518,3396],"prednisone\u002Fprednisolone or dexamethasone",{"trials":3398,"activeCount":245,"soonestReadout":55},[3399,3403,3407,3411,3415,3419],{"nctId":2583,"briefTitle":2584,"status":192,"phases":3400,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":3401,"interventions":3402},[89],[2591],[56,518,496],{"nctId":53,"briefTitle":54,"status":192,"phases":3404,"primaryCompletion":55,"completion":2595,"start":1201,"enrollment":2596,"conditions":3405,"interventions":3406},[89],[2598],[56,495,496,2600],{"nctId":2602,"briefTitle":2603,"status":105,"phases":3408,"primaryCompletion":2605,"completion":2606,"start":2607,"enrollment":2608,"conditions":3409,"interventions":3410},[89],[2568],[518,496],{"nctId":2612,"briefTitle":2613,"status":105,"phases":3412,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":3413,"interventions":3414},[89],[2490],[518,496,2621,2622],{"nctId":2647,"briefTitle":2648,"status":105,"phases":3416,"primaryCompletion":2650,"completion":2651,"start":2652,"enrollment":2653,"conditions":3417,"interventions":3418},[89],[2490],[518,496],{"nctId":2657,"briefTitle":2658,"status":105,"phases":3420,"primaryCompletion":2660,"completion":2660,"start":2661,"enrollment":1507,"conditions":3421,"interventions":3422},[89],[2663,2664],[518,496],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[3427],{"nctId":3428,"briefTitle":3429,"status":474,"phases":3430,"conditions":3431,"interventions":3432},"NCT01834209","A Study of Abiraterone Acetate Plus Prednisone in Asymptomatic or Mildly Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer",[],[2490],[518,3433],"Prednisone or prednisolone",{"intervention":214,"totalTrials":503,"cells":3435},{"EARLY_PHASE1":3436,"PHASE1":3438,"PHASE2":3475,"PHASE3":3501,"PHASE4":3557,"NA":3568},{"trials":3437,"activeCount":99},[],{"trials":3439,"activeCount":99},[3440,3447,3456,3465],{"nctId":3441,"briefTitle":3442,"status":105,"phases":3443,"primaryCompletion":3444,"completion":3444,"start":2217,"enrollment":160,"conditions":3445,"interventions":3446},"NCT02156375","A Pharmacokinetic Study of Single-Dose Intravenous Ustekinumab Delivered in 2 Different Liquid in Vial Formulations",[87],"2014-12",[15],[214,214],{"nctId":3448,"briefTitle":3449,"status":105,"phases":3450,"primaryCompletion":3451,"completion":3452,"start":3453,"enrollment":554,"conditions":3454,"interventions":3455},"NCT04816513","A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants",[87],"2022-01-07","2022-01-26","2021-04-14",[15],[214],{"nctId":3457,"briefTitle":3458,"status":105,"phases":3459,"primaryCompletion":3460,"completion":3461,"start":3462,"enrollment":1192,"conditions":3463,"interventions":3464},"NCT02968108","A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease",[87],"2018-09-19","2022-03-18","2017-01-18",[311],[214],{"nctId":3466,"briefTitle":3467,"status":105,"phases":3468,"primaryCompletion":3469,"completion":3469,"start":3470,"enrollment":3471,"conditions":3472,"interventions":3474},"NCT05252533","A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis",[87],"2024-01-26","2022-05-24",31,[3473,171,322],"Juvenile Psoriatic Arthritis",[214],{"trials":3476,"activeCount":99},[3477,3481,3492],{"nctId":204,"briefTitle":205,"status":105,"phases":3478,"primaryCompletion":207,"completion":208,"start":209,"enrollment":210,"conditions":3479,"interventions":3480},[88],[212],[94,214],{"nctId":3482,"briefTitle":3483,"status":137,"phases":3484,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":99,"conditions":3488,"interventions":3489},"NCT04655807","A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease",[88],"2023-05-24","2023-09-04","2021-03-03",[311],[3490,3491,214],"JNJ-64304500","Adalimumab",{"nctId":3493,"briefTitle":3494,"status":105,"phases":3495,"primaryCompletion":230,"completion":3496,"start":3497,"enrollment":3498,"conditions":3499,"interventions":3500},"NCT02877134","Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease",[88],"2022-01-24","2016-08-25",388,[311],[3490,214],{"trials":3502,"activeCount":352,"soonestReadout":406},[3503,3507,3517,3521,3530,3534,3543,3547],{"nctId":260,"briefTitle":261,"status":105,"phases":3504,"primaryCompletion":263,"completion":264,"start":265,"enrollment":266,"conditions":3505,"interventions":3506},[89],[171],[214,94],{"nctId":3508,"briefTitle":3509,"status":125,"phases":3510,"primaryCompletion":3511,"completion":3511,"start":3512,"enrollment":3513,"conditions":3514,"interventions":3515},"NCT03517722","A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus",[89],"2020-11-05","2018-04-16",516,[2121],[214,3516],"Ustekinumab 90 mg",{"nctId":314,"briefTitle":315,"status":192,"phases":3518,"primaryCompletion":317,"completion":318,"start":319,"enrollment":320,"conditions":3519,"interventions":3520},[89],[322],[214,94],{"nctId":3522,"briefTitle":3523,"status":137,"phases":3524,"primaryCompletion":3525,"completion":2440,"start":3526,"enrollment":99,"conditions":3527,"interventions":3528},"NCT04060888","A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus",[89],"2022-01-31","2020-07-14",[2121],[214,3529],"Ustekinumab 90 milligram",{"nctId":2791,"briefTitle":2792,"status":192,"phases":3531,"primaryCompletion":2794,"completion":2795,"start":2796,"enrollment":2797,"conditions":3532,"interventions":3533},[89],[332],[2728,214],{"nctId":3535,"briefTitle":3536,"status":192,"phases":3537,"primaryCompletion":295,"completion":3538,"start":3539,"enrollment":3540,"conditions":3541,"interventions":3542},"NCT05092269","A Long-term Extension Study of Ustekinumab in Pediatric Participants",[89],"2028-03-15","2021-10-18",159,[311,27,131],[214],{"nctId":403,"briefTitle":404,"status":192,"phases":3544,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":3545,"interventions":3546},[88,89],[199],[412,413,414,415,416,94,214],{"nctId":3548,"briefTitle":3549,"status":105,"phases":3550,"primaryCompletion":3551,"completion":3552,"start":3553,"enrollment":3554,"conditions":3555,"interventions":3556},"NCT04673357","A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease",[89],"2024-11-28","2025-03-03","2021-04-06",101,[311],[214],{"trials":3558,"activeCount":99},[3559],{"nctId":3560,"briefTitle":3561,"status":105,"phases":3562,"primaryCompletion":3563,"completion":3563,"start":3564,"enrollment":3565,"conditions":3566,"interventions":3567},"NCT05029921","A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease",[90],"2025-05-18","2021-12-10",182,[311],[214],{"trials":3569,"activeCount":99},[3570,3576],{"nctId":3571,"briefTitle":3572,"status":474,"phases":3573,"conditions":3574,"interventions":3575},"NCT03362736","An Early Access Program For Ustekinumab In Participants With Moderately To Severely Active Crohn's Disease",[],[311],[214],{"nctId":3577,"briefTitle":3578,"status":105,"phases":3579,"primaryCompletion":3580,"completion":3580,"start":3581,"enrollment":3582,"conditions":3583,"interventions":3584},"NCT05242458","A Study of Ustekinumab Treatment in Children With Crohn's Disease",[],"2023-05-22","2022-03-21",545,[199],[214],{"intervention":46,"totalTrials":3586,"cells":3587},24,{"EARLY_PHASE1":3588,"PHASE1":3590,"PHASE2":3690,"PHASE3":3718,"PHASE4":3784,"NA":3794},{"trials":3589,"activeCount":99},[],{"trials":3591,"activeCount":99},[3592,3601,3608,3617,3628,3636,3644,3653,3662,3669,3680],{"nctId":3593,"briefTitle":3594,"status":105,"phases":3595,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":3360,"conditions":3598,"interventions":3599},"NCT02841150","Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules",[87],"2016-08","2016-06",[15],[3600,46],"IMBRUVICA",{"nctId":3602,"briefTitle":3603,"status":105,"phases":3604,"primaryCompletion":3605,"completion":3605,"start":1203,"enrollment":2022,"conditions":3606,"interventions":3607},"NCT02877225","Study to Assess the Bioequivalence of Ibrutinib 140 Milligram (mg) Tablet to 140 mg IMBRUVICA Capsule",[87],"2016-11-11",[15],[46,3600],{"nctId":3609,"briefTitle":3610,"status":105,"phases":3611,"primaryCompletion":3612,"completion":3613,"start":3359,"enrollment":1132,"conditions":3614,"interventions":3615},"NCT02271438","A Study to Evaluate the Effects of Ibrutinib on Cardiac Repolarization in Healthy Participants",[87],"2015-04","2015-05",[15],[46,3616],"Moxifloxacin",{"nctId":3618,"briefTitle":3619,"status":105,"phases":3620,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":25,"conditions":3623,"interventions":3625},"NCT02381080","Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancy",[87],"2016-06-24","2015-05-19",[3624],"B-Cell Chronic Lymphocytic Leukemia",[46,3626,3627],"Erythromycin","Voriconazole",{"nctId":3629,"briefTitle":3630,"status":105,"phases":3631,"primaryCompletion":3632,"completion":3632,"start":3633,"enrollment":745,"conditions":3634,"interventions":3635},"NCT02638116","A Drug Interaction Study to Assess the Effect of Omeprazole on the Pharmacokinetics of Ibrutinib in Healthy Adults",[87],"2016-03","2016-01",[15],[46,175],{"nctId":3637,"briefTitle":3638,"status":105,"phases":3639,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1419,"conditions":3641,"interventions":3642},"NCT01626651","A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Ibrutinib in Healthy Participants",[87],"2012-06",[15],[46,3643],"Ketoconazole",{"nctId":3645,"briefTitle":3646,"status":105,"phases":3647,"primaryCompletion":3648,"completion":3648,"start":3649,"enrollment":1192,"conditions":3650,"interventions":3651},"NCT04876092","A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL",[87],"2025-02-13","2021-07-28",[2920,1382],[3652,46],"JNJ-67856633",{"nctId":3654,"briefTitle":3655,"status":105,"phases":3656,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":3138,"conditions":3659,"interventions":3660},"NCT02390609","A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults",[87],"2015-11","2015-03",[15],[3661,46,46,46,46,46],"Ibrutinib (Treatment A) [Reference]",{"nctId":3663,"briefTitle":3664,"status":105,"phases":3665,"primaryCompletion":3310,"completion":3310,"start":2535,"enrollment":641,"conditions":3666,"interventions":3668},"NCT01674322","A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants",[87],[3667],"Healthy Participants",[46],{"nctId":3670,"briefTitle":3671,"status":105,"phases":3672,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":2472,"conditions":3676,"interventions":3677},"NCT03301207","A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy",[87],"2018-07-17","2018-12-04","2017-10-20",[2920],[46,3678,3679,173],"OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg","Bupropion",{"nctId":3681,"briefTitle":3682,"status":137,"phases":3683,"primaryCompletion":3684,"completion":3685,"start":3686,"enrollment":99,"conditions":3687,"interventions":3688},"NCT02743546","Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma",[87],"2018-09-30","2020-03-31","2016-07-20",[2920,1535,1536,1534],[3689,46],"Duvortuxizumab",{"trials":3691,"activeCount":468,"soonestReadout":900},[3692,3703,3710,3714],{"nctId":3693,"briefTitle":3694,"status":105,"phases":3695,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3698,"conditions":3699,"interventions":3701},"NCT02329847","A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of the Combination of Ibrutinib With Nivolumab in Participants With Hematologic Malignancies",[87,88],"2022-02-09","2015-03-11",144,[3700],"Hematologic Neoplasms",[46,3702],"Nivolumab",{"nctId":3704,"briefTitle":3705,"status":105,"phases":3706,"primaryCompletion":3613,"completion":3613,"start":2535,"enrollment":371,"conditions":3707,"interventions":3709},"NCT01599949","A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy",[88],[3708],"Mantle Cell Lymphoma",[46],{"nctId":2913,"briefTitle":2914,"status":304,"phases":3711,"primaryCompletion":900,"completion":2916,"start":2917,"enrollment":2918,"conditions":3712,"interventions":3713},[88],[2920,2921],[46,2880],{"nctId":2199,"briefTitle":2200,"status":105,"phases":3715,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":1532,"conditions":3716,"interventions":3717},[88],[1534],[46,683,1384,682],{"trials":3719,"activeCount":245,"soonestReadout":45},[3720,3731,3735,3745,3754,3765,3776,3780],{"nctId":3721,"briefTitle":3722,"status":105,"phases":3723,"primaryCompletion":3724,"completion":3725,"start":3726,"enrollment":3727,"conditions":3728,"interventions":3730},"NCT01973387","A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia\u002FLymphoma",[89],"2015-12-01","2017-08-11","2013-10-28",160,[3729,2921],"Chronic Lymphocytic Leukemia",[1384,46],{"nctId":2624,"briefTitle":2625,"status":105,"phases":3732,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":3733,"interventions":3734},[89],[1509],[46,1384,659,1556,1154,496],{"nctId":3736,"briefTitle":3737,"status":105,"phases":3738,"primaryCompletion":3739,"completion":3740,"start":3741,"enrollment":3742,"conditions":3743,"interventions":3744},"NCT01776840","A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma",[89],"2021-06-30","2024-06-24","2013-05-16",523,[3708],[2675,1384,46],{"nctId":3746,"briefTitle":3747,"status":105,"phases":3748,"primaryCompletion":1463,"completion":1463,"start":3749,"enrollment":3750,"conditions":3751,"interventions":3752},"NCT01611090","A Study of Ibrutinib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",[89],"2012-09-19",578,[3729,2921],[46,3753,1384],"Bendamustine hydrochloride",{"nctId":3755,"briefTitle":3756,"status":105,"phases":3757,"primaryCompletion":3758,"completion":3759,"start":3760,"enrollment":3761,"conditions":3762,"interventions":3763},"NCT01646021","Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy",[89],"2015-06-05","2016-12-15","2012-12-10",280,[3708],[46,3764],"Temsirolimus",{"nctId":3766,"briefTitle":3767,"status":304,"phases":3768,"primaryCompletion":511,"completion":551,"start":3769,"enrollment":903,"conditions":3770,"interventions":3775},"NCT01804686","A Long-term Extension Study of PCI-32765 (Ibrutinib)",[89],"2013-09-09",[3729,2921,3708,3771,3772,3773,3774],"Follicular Lymphoma","Diffuse Large B-cell Lymphoma","Waldenstrom Macroglobulinemia","Chronic Graft Versus Host Disease",[46],{"nctId":43,"briefTitle":44,"status":192,"phases":3777,"primaryCompletion":45,"completion":2936,"start":2937,"enrollment":2938,"conditions":3778,"interventions":3779},[89],[2920],[46,2880,2941,2942,46],{"nctId":1375,"briefTitle":1376,"status":125,"phases":3781,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":3782,"interventions":3783},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":3785,"activeCount":99},[3786],{"nctId":3787,"briefTitle":3788,"status":105,"phases":3789,"primaryCompletion":3790,"completion":3790,"start":3791,"enrollment":33,"conditions":3792,"interventions":3793},"NCT04042376","A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)",[90],"2024-03-19","2019-12-18",[3773],[46],{"trials":3795,"activeCount":99},[],{"intervention":75,"totalTrials":2149,"cells":3797},{"EARLY_PHASE1":3798,"PHASE1":3800,"PHASE2":3827,"PHASE3":3871,"PHASE4":3877,"NA":3879},{"trials":3799,"activeCount":99},[],{"trials":3801,"activeCount":99},[3802,3811,3819],{"nctId":3803,"briefTitle":3804,"status":105,"phases":3805,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":3312,"conditions":3808,"interventions":3809},"NCT03135106","A Study to Evaluate the Effect of Fluconazole and Itraconazole on Erdafitinib Pharmacokinetics in Healthy Adult Participants",[87],"2017-09-01","2017-04-14",[15],[75,3810,1799],"Fluconazole",{"nctId":3812,"briefTitle":3813,"status":105,"phases":3814,"primaryCompletion":3815,"completion":3815,"start":3816,"enrollment":169,"conditions":3817,"interventions":3818},"NCT03066687","A Study to Determine the Effect of Food on the Pharmacokinetics of Erdafitinib in Healthy Participants",[87],"2017-05-12","2017-03-14",[15],[75],{"nctId":3820,"briefTitle":3821,"status":125,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":25,"conditions":3825,"interventions":3826},"NCT03587363","A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib",[87],"2020-12-22","2018-12-06",[505],[75],{"trials":3828,"activeCount":245,"soonestReadout":74},[3829,3840,3846,3857,3861],{"nctId":3830,"briefTitle":3831,"status":105,"phases":3832,"primaryCompletion":3833,"completion":3834,"start":3835,"enrollment":3836,"conditions":3837,"interventions":3839},"NCT04083976","A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations",[88],"2023-12-04","2026-02-28","2019-11-20",316,[3838],"Advanced Solid Tumor",[75],{"nctId":72,"briefTitle":73,"status":192,"phases":3841,"primaryCompletion":74,"completion":830,"start":3842,"enrollment":3843,"conditions":3844,"interventions":3845},[88],"2015-04-22",239,[3249],[75,173,1779],{"nctId":3847,"briefTitle":3848,"status":105,"phases":3849,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3853,"conditions":3854,"interventions":3855},"NCT04172675","A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",[88],"2024-07-12","2025-02-27","2020-02-28",107,[2424],[75,3856,3856],"Investigator Choice",{"nctId":77,"briefTitle":78,"status":192,"phases":3858,"primaryCompletion":79,"completion":511,"start":2364,"enrollment":2365,"conditions":3859,"interventions":3860},[87,88],[2367],[75,560,952,760],{"nctId":3862,"briefTitle":3863,"status":105,"phases":3864,"primaryCompletion":3865,"completion":3866,"start":3867,"enrollment":95,"conditions":3868,"interventions":3870},"NCT02699606","A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma",[88],"2021-10-12","2024-03-15","2016-07-08",[3869],"Neoplasm",[75],{"trials":3872,"activeCount":468,"soonestReadout":3245},[3873],{"nctId":3242,"briefTitle":3243,"status":192,"phases":3874,"primaryCompletion":3245,"completion":511,"start":3246,"enrollment":3247,"conditions":3875,"interventions":3876},[89],[3249],[75,3251,562,823],{"trials":3878,"activeCount":99},[],{"trials":3880,"activeCount":99},[],{"intervention":412,"totalTrials":641,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3921,"PHASE4":3946,"NA":3948},{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":99},[],{"trials":3888,"activeCount":99},[3889,3897,3908],{"nctId":3890,"briefTitle":3891,"status":125,"phases":3892,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":2515,"conditions":3895,"interventions":3896},"NCT04376827","A Study of Guselkumab in Participants With Active Lupus Nephritis",[88],"2023-02-01","2020-09-15",[2044],[412,413,2015],{"nctId":3898,"briefTitle":3899,"status":105,"phases":3900,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":2653,"conditions":3904,"interventions":3905},"NCT03662542","A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis",[88],"2020-12-01","2021-11-15","2018-11-20",[27],[412,413,3906,3907],"Golimumab Dose 1","Golimumab Dose 2",{"nctId":3909,"briefTitle":3910,"status":105,"phases":3911,"primaryCompletion":3912,"completion":3912,"start":3913,"enrollment":3914,"conditions":3915,"interventions":3917},"NCT03628924","A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)",[88],"2020-05-22","2018-09-04",184,[3916],"Hidradenitis Suppurativa",[3918,3919,3920],"Guselkumab dose 1","Guselkumab dose 2","Guselkumab dose 3",{"trials":3922,"activeCount":571,"soonestReadout":3927},[3923,3933,3942],{"nctId":3924,"briefTitle":3925,"status":192,"phases":3926,"primaryCompletion":3927,"completion":3928,"start":3929,"enrollment":3930,"conditions":3931,"interventions":3932},"NCT05197049","A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease",[89],"2023-07-04","2028-10-30","2022-01-19",350,[311],[412,413,414],{"nctId":3934,"briefTitle":3935,"status":192,"phases":3936,"primaryCompletion":3937,"completion":3938,"start":3939,"enrollment":1884,"conditions":3940,"interventions":3941},"NCT05528510","A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",[89],"2024-04-02","2028-10-06","2022-09-13",[27],[412,413,414],{"nctId":403,"briefTitle":404,"status":192,"phases":3943,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":3944,"interventions":3945},[88,89],[199],[412,413,414,415,416,94,214],{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"intervention":413,"totalTrials":641,"cells":3951},{"EARLY_PHASE1":3952,"PHASE1":3954,"PHASE2":3956,"PHASE3":3970,"PHASE4":3984,"NA":3986},{"trials":3953,"activeCount":99},[],{"trials":3955,"activeCount":99},[],{"trials":3957,"activeCount":99},[3958,3962,3966],{"nctId":3890,"briefTitle":3891,"status":125,"phases":3959,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":2515,"conditions":3960,"interventions":3961},[88],[2044],[412,413,2015],{"nctId":3898,"briefTitle":3899,"status":105,"phases":3963,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":2653,"conditions":3964,"interventions":3965},[88],[27],[412,413,3906,3907],{"nctId":3909,"briefTitle":3910,"status":105,"phases":3967,"primaryCompletion":3912,"completion":3912,"start":3913,"enrollment":3914,"conditions":3968,"interventions":3969},[88],[3916],[3918,3919,3920],{"trials":3971,"activeCount":571,"soonestReadout":3927},[3972,3976,3980],{"nctId":3924,"briefTitle":3925,"status":192,"phases":3973,"primaryCompletion":3927,"completion":3928,"start":3929,"enrollment":3930,"conditions":3974,"interventions":3975},[89],[311],[412,413,414],{"nctId":3934,"briefTitle":3935,"status":192,"phases":3977,"primaryCompletion":3937,"completion":3938,"start":3939,"enrollment":1884,"conditions":3978,"interventions":3979},[89],[27],[412,413,414],{"nctId":403,"briefTitle":404,"status":192,"phases":3981,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":3982,"interventions":3983},[88,89],[199],[412,413,414,415,416,94,214],{"trials":3985,"activeCount":99},[],{"trials":3987,"activeCount":99},[],{"intervention":56,"totalTrials":1029,"cells":3989},{"EARLY_PHASE1":3990,"PHASE1":3992,"PHASE2":4002,"PHASE3":4013,"PHASE4":4023,"NA":4025},{"trials":3991,"activeCount":99},[],{"trials":3993,"activeCount":468,"soonestReadout":60},[3994,3998],{"nctId":486,"briefTitle":487,"status":105,"phases":3995,"primaryCompletion":489,"completion":490,"start":491,"enrollment":492,"conditions":3996,"interventions":3997},[87],[30],[56,41,495,496],{"nctId":58,"briefTitle":59,"status":192,"phases":3999,"primaryCompletion":60,"completion":511,"start":2500,"enrollment":2501,"conditions":4000,"interventions":4001},[87],[30],[56,495,496],{"trials":4003,"activeCount":99},[4004],{"nctId":4005,"briefTitle":4006,"status":105,"phases":4007,"primaryCompletion":4008,"completion":4009,"start":167,"enrollment":4010,"conditions":4011,"interventions":4012},"NCT02854436","An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies",[88],"2021-01-26","2023-08-16",289,[30],[56],{"trials":4014,"activeCount":245,"soonestReadout":55},[4015,4019],{"nctId":2583,"briefTitle":2584,"status":192,"phases":4016,"primaryCompletion":2586,"completion":2587,"start":2588,"enrollment":2589,"conditions":4017,"interventions":4018},[89],[2591],[56,518,496],{"nctId":53,"briefTitle":54,"status":192,"phases":4020,"primaryCompletion":55,"completion":2595,"start":1201,"enrollment":2596,"conditions":4021,"interventions":4022},[89],[2598],[56,495,496,2600],{"trials":4024,"activeCount":99},[],{"trials":4026,"activeCount":99},[],{"intervention":1096,"totalTrials":1029,"cells":4028},{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4041,"PHASE3":4047,"PHASE4":4057,"NA":4059},{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":468,"soonestReadout":1674},[4033,4037],{"nctId":1671,"briefTitle":1672,"status":192,"phases":4034,"primaryCompletion":1674,"completion":1024,"start":1675,"enrollment":1676,"conditions":4035,"interventions":4036},[87],[18],[70,1096,1301,683,707],{"nctId":1157,"briefTitle":1158,"status":105,"phases":4038,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":4039,"interventions":4040},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":4042,"activeCount":99},[4043],{"nctId":1218,"briefTitle":1219,"status":105,"phases":4044,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":4045,"interventions":4046},[88],[18],[681,682,683,684,1167,496,1096],{"trials":4048,"activeCount":245,"soonestReadout":1090},[4049,4053],{"nctId":1087,"briefTitle":1088,"status":192,"phases":4050,"primaryCompletion":1090,"completion":1091,"start":1092,"enrollment":1093,"conditions":4051,"interventions":4052},[89],[1006],[65,707,682,684,1096],{"nctId":1344,"briefTitle":1345,"status":304,"phases":4054,"primaryCompletion":1347,"completion":1347,"start":1348,"enrollment":948,"conditions":4055,"interventions":4056},[89],[18],[681,1096,684,683,707],{"trials":4058,"activeCount":99},[],{"trials":4060,"activeCount":99},[],{"intervention":661,"totalTrials":352,"cells":4062},{"EARLY_PHASE1":4063,"PHASE1":4065,"PHASE2":4071,"PHASE3":4081,"PHASE4":4087,"NA":4089},{"trials":4064,"activeCount":99},[],{"trials":4066,"activeCount":99},[4067],{"nctId":1139,"briefTitle":1140,"status":137,"phases":4068,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":4069,"interventions":4070},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"trials":4072,"activeCount":245,"soonestReadout":653},[4073,4077],{"nctId":650,"briefTitle":651,"status":304,"phases":4074,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":4075,"interventions":4076},[88],[18],[640,659,660,661],{"nctId":672,"briefTitle":673,"status":192,"phases":4078,"primaryCompletion":675,"completion":676,"start":677,"enrollment":678,"conditions":4079,"interventions":4080},[88],[18],[640,70,681,65,682,683,684,659,661],{"trials":4082,"activeCount":468,"soonestReadout":691},[4083],{"nctId":688,"briefTitle":689,"status":192,"phases":4084,"primaryCompletion":691,"completion":692,"start":693,"enrollment":694,"conditions":4085,"interventions":4086},[89],[18],[682,684,683,640,659,661],{"trials":4088,"activeCount":99},[],{"trials":4090,"activeCount":99},[],{"intervention":414,"totalTrials":352,"cells":4092},{"EARLY_PHASE1":4093,"PHASE1":4095,"PHASE2":4097,"PHASE3":4103,"PHASE4":4117,"NA":4119},{"trials":4094,"activeCount":99},[],{"trials":4096,"activeCount":99},[],{"trials":4098,"activeCount":99},[4099],{"nctId":3909,"briefTitle":3910,"status":105,"phases":4100,"primaryCompletion":3912,"completion":3912,"start":3913,"enrollment":3914,"conditions":4101,"interventions":4102},[88],[3916],[3918,3919,3920],{"trials":4104,"activeCount":571,"soonestReadout":3927},[4105,4109,4113],{"nctId":3924,"briefTitle":3925,"status":192,"phases":4106,"primaryCompletion":3927,"completion":3928,"start":3929,"enrollment":3930,"conditions":4107,"interventions":4108},[89],[311],[412,413,414],{"nctId":3934,"briefTitle":3935,"status":192,"phases":4110,"primaryCompletion":3937,"completion":3938,"start":3939,"enrollment":1884,"conditions":4111,"interventions":4112},[89],[27],[412,413,414],{"nctId":403,"briefTitle":404,"status":192,"phases":4114,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":4115,"interventions":4116},[88,89],[199],[412,413,414,415,416,94,214],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[],{"intervention":823,"totalTrials":571,"cells":4122},{"EARLY_PHASE1":4123,"PHASE1":4125,"PHASE2":4127,"PHASE3":4133,"PHASE4":4143,"NA":4145},{"trials":4124,"activeCount":99},[],{"trials":4126,"activeCount":99},[],{"trials":4128,"activeCount":468,"soonestReadout":816},[4129],{"nctId":813,"briefTitle":814,"status":304,"phases":4130,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":4131,"interventions":4132},[87,88],[821],[84,823,824,760],{"trials":4134,"activeCount":245,"soonestReadout":3245},[4135,4139],{"nctId":943,"briefTitle":944,"status":304,"phases":4136,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":4137,"interventions":4138},[89],[821],[84,823,760,951,952],{"nctId":3242,"briefTitle":3243,"status":192,"phases":4140,"primaryCompletion":3245,"completion":511,"start":3246,"enrollment":3247,"conditions":4141,"interventions":4142},[89],[3249],[75,3251,562,823],{"trials":4144,"activeCount":99},[],{"trials":4146,"activeCount":99},[],{"intervention":952,"totalTrials":571,"cells":4148},{"EARLY_PHASE1":4149,"PHASE1":4151,"PHASE2":4153,"PHASE3":4159,"PHASE4":4169,"NA":4171},{"trials":4150,"activeCount":99},[],{"trials":4152,"activeCount":99},[],{"trials":4154,"activeCount":468,"soonestReadout":79},[4155],{"nctId":77,"briefTitle":78,"status":192,"phases":4156,"primaryCompletion":79,"completion":511,"start":2364,"enrollment":2365,"conditions":4157,"interventions":4158},[87,88],[2367],[75,560,952,760],{"trials":4160,"activeCount":245,"soonestReadout":2460},[4161,4165],{"nctId":943,"briefTitle":944,"status":304,"phases":4162,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":4163,"interventions":4164},[89],[821],[84,823,760,951,952],{"nctId":2457,"briefTitle":2458,"status":192,"phases":4166,"primaryCompletion":2460,"completion":2461,"start":2462,"enrollment":2463,"conditions":4167,"interventions":4168},[89],[2424],[560,2426,952,2466],{"trials":4170,"activeCount":99},[],{"trials":4172,"activeCount":99},[],{"intervention":201,"totalTrials":544,"cells":4174},{"EARLY_PHASE1":4175,"PHASE1":4177,"PHASE2":4197,"PHASE3":4230,"PHASE4":4272,"NA":4274},{"trials":4176,"activeCount":99},[],{"trials":4178,"activeCount":99},[4179,4188],{"nctId":4180,"briefTitle":4181,"status":105,"phases":4182,"primaryCompletion":4183,"completion":4184,"start":4185,"enrollment":95,"conditions":4186,"interventions":4187},"NCT01900574","A Study to Assess the Safety and Pharmacokinetics of Subcutaneously Administered Golimumab, a Human Anti-TNFα Antibody, in Pediatric Patients With Moderate to Severe Active Ulcerative Colitis",[87],"2015-02-18","2022-09-01","2013-08-09",[27],[201],{"nctId":4189,"briefTitle":4190,"status":105,"phases":4191,"primaryCompletion":4192,"completion":4193,"start":1435,"enrollment":109,"conditions":4194,"interventions":4196},"NCT03298542","A Study to Evaluate SIMPONI (Golimumab) Therapy in Children, Adolescents and Young Adults With Pre-Symptomatic Type 1 Diabetes",[87],"2020-12-21","2021-06-01",[4195],"Pre-Symptomatic Type 1 Diabetes",[201],{"trials":4198,"activeCount":245,"soonestReadout":239},[4199,4203,4207,4218,4226],{"nctId":190,"briefTitle":191,"status":192,"phases":4200,"primaryCompletion":194,"completion":195,"start":196,"enrollment":197,"conditions":4201,"interventions":4202},[88],[199],[94,201,202],{"nctId":216,"briefTitle":217,"status":105,"phases":4204,"primaryCompletion":219,"completion":220,"start":221,"enrollment":222,"conditions":4205,"interventions":4206},[88],[131],[94,201],{"nctId":4208,"briefTitle":4209,"status":105,"phases":4210,"primaryCompletion":4211,"completion":4212,"start":4213,"enrollment":4214,"conditions":4215,"interventions":4217},"NCT02846545","A Study of SIMPONI® to Arrest Beta-cell Loss in Type 1 Diabetes",[88],"2019-05-21","2021-01-05","2016-08-26",84,[4216],"Diabetes Mellitus, Type 1",[201],{"nctId":4219,"briefTitle":4220,"status":105,"phases":4221,"primaryCompletion":4222,"completion":3633,"start":4223,"enrollment":2022,"conditions":4224,"interventions":4225},"NCT01988961","A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis",[88],"2015-02","2013-12",[27],[201],{"nctId":236,"briefTitle":237,"status":192,"phases":4227,"primaryCompletion":239,"completion":240,"start":241,"enrollment":242,"conditions":4228,"interventions":4229},[88],[27],[94,201,202],{"trials":4231,"activeCount":468,"soonestReadout":4236},[4232,4242,4253,4263],{"nctId":4233,"briefTitle":4234,"status":192,"phases":4235,"primaryCompletion":4236,"completion":4237,"start":4238,"enrollment":4214,"conditions":4239,"interventions":4240},"NCT03596645","A Study to Assess the Efficacy and Safety of Golimumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis",[89],"2023-11-21","2027-02-01","2018-10-29",[27],[201,4241],"Infliximab",{"nctId":4243,"briefTitle":4244,"status":105,"phases":4245,"primaryCompletion":4246,"completion":4247,"start":4248,"enrollment":4249,"conditions":4250,"interventions":4252},"NCT02186873","A Study of Golimumab in Participants With Active Ankylosing Spondylitis",[89],"2015-12-15","2016-10-11","2014-09-03",208,[4251],"Ankylosing Spondylitis",[201],{"nctId":4254,"briefTitle":4255,"status":105,"phases":4256,"primaryCompletion":4257,"completion":4258,"start":4259,"enrollment":4260,"conditions":4261,"interventions":4262},"NCT02277444","A Study to Evaluate the Pharmacokinetics, Efficacy and Safety of Intravenous Golimumab in Pediatric Participants With Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy",[89],"2018-07-09","2024-09-27","2014-12-22",130,[322],[201,879],{"nctId":4264,"briefTitle":4265,"status":105,"phases":4266,"primaryCompletion":4267,"completion":4268,"start":4269,"enrollment":797,"conditions":4270,"interventions":4271},"NCT02181673","A Study of Golimumab in Participants With Active Psoriatic Arthritis",[89],"2016-05-05","2017-03-22","2014-09-08",[131],[201],{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[4276],{"nctId":4277,"briefTitle":4278,"status":474,"phases":4279,"conditions":4280,"interventions":4281},"NCT03945903","Pre-Approval Access to Golimumab Subcutaneous for the Treatment of Stage 3 Type-1 Diabetes Mellitus in Children and Young Adults",[],[4216],[201],{"intervention":173,"totalTrials":544,"cells":4283},{"EARLY_PHASE1":4284,"PHASE1":4286,"PHASE2":4353,"PHASE3":4368,"PHASE4":4380,"NA":4382},{"trials":4285,"activeCount":99},[],{"trials":4287,"activeCount":99},[4288,4296,4306,4310,4319,4326,4336,4340,4344],{"nctId":4289,"briefTitle":4290,"status":125,"phases":4291,"primaryCompletion":2364,"completion":2364,"start":4292,"enrollment":12,"conditions":4293,"interventions":4294},"NCT03139500","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-61803534 and to Evaluate the Effect of JNJ-61803534 on the Pharmacokinetics of Midazolam in Healthy Participants",[87],"2017-05-17",[15],[4295,173],"JNJ-61803534",{"nctId":4297,"briefTitle":4298,"status":137,"phases":4299,"primaryCompletion":4300,"completion":4301,"start":4193,"enrollment":99,"conditions":4302,"interventions":4303},"NCT03890341","Study in Women on the Effect of JNJ-64530440 on Oral Contraceptive and Midazolam, and the Effect of a High-fat Meal on JNJ-64530440",[87],"2021-08-01","2021-11-01",[15],[4304,173,4305],"Drospirenone\u002FEthinylestradiol","JNJ-64530440",{"nctId":1771,"briefTitle":1772,"status":105,"phases":4307,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":745,"conditions":4308,"interventions":4309},[87],[15],[759,173,1778,1779],{"nctId":4311,"briefTitle":4312,"status":105,"phases":4313,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":832,"conditions":4316,"interventions":4317},"NCT02568176","Pharmacokinetic Study of Intranasal Esketamine and Its Effects on the Pharmacokinetics of Orally-Administered Midazolam and Bupropion in Healthy Participants",[87],"2016-02","2015-10",[15],[173,4318,3679],"Esketamine",{"nctId":4320,"briefTitle":4321,"status":105,"phases":4322,"primaryCompletion":4314,"completion":4314,"start":3657,"enrollment":503,"conditions":4323,"interventions":4324},"NCT02617810","A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants",[87],[15],[4325,173,174],"JNJ-42847922",{"nctId":4327,"briefTitle":4328,"status":105,"phases":4329,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":4332,"interventions":4333},"NCT01636557","A Study to Evaluate the Effect of a Single Dose of CNTO 136 (Sirukumab) on CYP450 Enzyme Activities After Subcutaneous Administration in Patients With Rheumatoid Arthritis",[87],"2013-10-19","2012-10-11",[2003],[4334,173,174,4335,175,177],"Sirukumab","Vitamin K",{"nctId":164,"briefTitle":165,"status":105,"phases":4337,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":4338,"interventions":4339},[87],[171],[94,173,174,175,176,177],{"nctId":3670,"briefTitle":3671,"status":105,"phases":4341,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":2472,"conditions":4342,"interventions":4343},[87],[2920],[46,3678,3679,173],{"nctId":4345,"briefTitle":4346,"status":105,"phases":4347,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":169,"conditions":4349,"interventions":4350},"NCT02211079","A Study to Assess Effect of JNJ-54861911 on Pharmacokinetics of Cocktail Representatives for Cytochrome P450 (CYP) 3A4, CYP2B6, CYP2C9, and CYP1A2 Substrates",[87],"2014-09",[15],[4351,177,173,4352],"JNJ-54861911","Tolbutamide",{"trials":4354,"activeCount":468,"soonestReadout":74},[4355,4359],{"nctId":72,"briefTitle":73,"status":192,"phases":4356,"primaryCompletion":74,"completion":830,"start":3842,"enrollment":3843,"conditions":4357,"interventions":4358},[88],[3249],[75,173,1779],{"nctId":4360,"briefTitle":4361,"status":105,"phases":4362,"primaryCompletion":1784,"completion":1784,"start":1602,"enrollment":4363,"conditions":4364,"interventions":4365},"NCT03185819","Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide",[88],147,[21],[4366,4367,173,4318,4318,4318],"Intranasal Placebo","Midazolam Placebo Solution",{"trials":4369,"activeCount":468,"soonestReadout":4374},[4370],{"nctId":4371,"briefTitle":4372,"status":304,"phases":4373,"primaryCompletion":4374,"completion":4375,"start":4376,"enrollment":4377,"conditions":4378,"interventions":4379},"NCT07227454","A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder",[89],"2031-04-09","2031-09-15","2026-01-08",258,[21],[4318,173],{"trials":4381,"activeCount":99},[],{"trials":4383,"activeCount":99},[],{"intervention":4385,"totalTrials":129,"cells":4386},"Seltorexant",{"EARLY_PHASE1":4387,"PHASE1":4389,"PHASE2":4435,"PHASE3":4447,"PHASE4":4492,"NA":4494},{"trials":4388,"activeCount":99},[],{"trials":4390,"activeCount":99},[4391,4404,4410,4419,4427],{"nctId":4392,"briefTitle":4393,"status":105,"phases":4394,"primaryCompletion":4395,"completion":4395,"start":4396,"enrollment":4397,"conditions":4398,"interventions":4401},"NCT05106153","A Study to Determine the Abuse Potential of Seltorexant Compared to Suvorexant and Zolpidem",[87],"2023-05-12","2021-12-17",127,[4399,4400],"Healthy Non-dependent, Recreational Sedative Users","Abuse Potential",[4402,4403,4385],"Suvorexant","Zolpidem",{"nctId":4405,"briefTitle":4406,"status":105,"phases":4407,"primaryCompletion":1212,"completion":1212,"start":2756,"enrollment":893,"conditions":4408,"interventions":4409},"NCT05236868","A Study of JNJ-42847922 (Seltorexant) in Healthy Participants",[87],[15],[4385],{"nctId":4411,"briefTitle":4412,"status":105,"phases":4413,"primaryCompletion":4414,"completion":4414,"start":4415,"enrollment":19,"conditions":4416,"interventions":4417},"NCT03494907","A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants",[87],"2018-08-13","2018-04-09",[15],[4385,4418],"Moxifloxacin Dose 1",{"nctId":4420,"briefTitle":4421,"status":125,"phases":4422,"primaryCompletion":4423,"completion":4423,"start":4424,"enrollment":3471,"conditions":4425,"interventions":4426},"NCT04951609","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy",[87],"2024-04-08","2021-09-02",[21],[4385],{"nctId":4428,"briefTitle":4429,"status":105,"phases":4430,"primaryCompletion":4431,"completion":1794,"start":1796,"enrollment":4432,"conditions":4433,"interventions":4434},"NCT04553042","A Study of Seltorexant in Healthy Participants",[87],"2020-12-20",69,[15],[4385],{"trials":4436,"activeCount":99},[4437],{"nctId":4438,"briefTitle":4439,"status":105,"phases":4440,"primaryCompletion":4441,"completion":4441,"start":4442,"enrollment":4443,"conditions":4444,"interventions":4446},"NCT05307692","A Study of Seltorexant in Participants With Probable Alzheimer's Disease",[88],"2023-11-10","2022-05-19",88,[4445],"Alzheimer Disease",[4385],{"trials":4448,"activeCount":245,"soonestReadout":2460},[4449,4458,4467,4475,4483],{"nctId":4450,"briefTitle":4451,"status":105,"phases":4452,"primaryCompletion":4453,"completion":4453,"start":3894,"enrollment":4454,"conditions":4455,"interventions":4456},"NCT04513912","A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy",[89],"2023-10-03",757,[21],[4385,4457],"Quetiapine XR",{"nctId":4459,"briefTitle":4460,"status":105,"phases":4461,"primaryCompletion":4462,"completion":2009,"start":4463,"enrollment":4464,"conditions":4465,"interventions":4466},"NCT04533529","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant",[89],"2023-04-25","2020-09-16",588,[21],[4385],{"nctId":4468,"briefTitle":4469,"status":125,"phases":4470,"primaryCompletion":3470,"completion":4471,"start":3894,"enrollment":4472,"conditions":4473,"interventions":4474},"NCT04532749","A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy",[89],"2022-07-14",212,[21],[4385],{"nctId":4476,"briefTitle":4477,"status":304,"phases":4478,"primaryCompletion":2460,"completion":2460,"start":4479,"enrollment":2797,"conditions":4480,"interventions":4481},"NCT06559306","Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms",[89],"2024-07-25",[21],[4385,4482],"Selective Serotonin Reuptake Inhibitor",{"nctId":4484,"briefTitle":4485,"status":304,"phases":4486,"primaryCompletion":4487,"completion":4488,"start":4489,"enrollment":2119,"conditions":4490,"interventions":4491},"NCT07573176","A Study of Seltorexant as Monotherapy in Adults and Elderly Participants With Major Depressive Disorder",[89],"2028-08-24","2029-05-03","2026-04-30",[21],[4385],{"trials":4493,"activeCount":99},[],{"trials":4495,"activeCount":99},[],{"intervention":4497,"totalTrials":1029,"cells":4498},"Milvexian",{"EARLY_PHASE1":4499,"PHASE1":4501,"PHASE2":4522,"PHASE3":4524,"PHASE4":4558,"NA":4560},{"trials":4500,"activeCount":99},[],{"trials":4502,"activeCount":99},[4503,4514],{"nctId":4504,"briefTitle":4505,"status":105,"phases":4506,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":19,"conditions":4510,"interventions":4511},"NCT04543383","A Study to Assess the Reversal of the Anticoagulant Effects of Milvexian by 4-Factor Prothrombin Complex Concentrate (4F-PCC) (Part 1) and Recombinant Human Factor VIIa (rFVIIa) (Part 2) in Healthy Participants",[87],"2023-06-07","2023-06-09","2020-07-27",[15],[4497,4512,4513],"4-Factor Prothrombin Complex Concentrate","Recombinant Human Factor VIIa",{"nctId":4515,"briefTitle":4516,"status":105,"phases":4517,"primaryCompletion":4518,"completion":4519,"start":3453,"enrollment":2077,"conditions":4520,"interventions":4521},"NCT04844424","A Study of JNJ-70033093 (Milvexian) in Healthy Adult Participants",[87],"2022-05-06","2022-07-12",[15],[4497],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":245,"soonestReadout":4530},[4526,4538,4547],{"nctId":4527,"briefTitle":4528,"status":192,"phases":4529,"primaryCompletion":4530,"completion":4530,"start":4531,"enrollment":4532,"conditions":4533,"interventions":4535},"NCT05757869","A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation",[89],"2026-10-31","2023-04-11",20284,[4534],"Atrial Fibrillation",[4497,4536,4537],"Apixaban","Apixaban Placebo",{"nctId":4539,"briefTitle":4540,"status":105,"phases":4541,"primaryCompletion":4542,"completion":4542,"start":2738,"enrollment":4543,"conditions":4544,"interventions":4546},"NCT05754957","A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome",[89],"2026-02-06",14194,[4545],"Acute Coronary Syndrome",[4497],{"nctId":4548,"briefTitle":4549,"status":192,"phases":4550,"primaryCompletion":4551,"completion":4552,"start":4553,"enrollment":4554,"conditions":4555,"interventions":4557},"NCT05702034","A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE",[89],"2026-11-11","2026-12-09","2023-02-15",12532,[4556],"Ischemic Stroke; Ischemic Attack, Transient",[4497],{"trials":4559,"activeCount":99},[],{"trials":4561,"activeCount":99},[],{"intervention":2091,"totalTrials":571,"cells":4563},{"EARLY_PHASE1":4564,"PHASE1":4566,"PHASE2":4568,"PHASE3":4574,"PHASE4":4584,"NA":4586},{"trials":4565,"activeCount":99},[],{"trials":4567,"activeCount":99},[],{"trials":4569,"activeCount":99},[4570],{"nctId":2027,"briefTitle":2028,"status":105,"phases":4571,"primaryCompletion":592,"completion":2030,"start":2031,"enrollment":2032,"conditions":4572,"interventions":4573},[88],[2034],[1953,2036],{"trials":4575,"activeCount":245,"soonestReadout":2085},[4576,4580],{"nctId":2082,"briefTitle":2083,"status":192,"phases":4577,"primaryCompletion":2085,"completion":2086,"start":1450,"enrollment":2087,"conditions":4578,"interventions":4579},[89],[2089],[1953,2091],{"nctId":2113,"briefTitle":2114,"status":304,"phases":4581,"primaryCompletion":2116,"completion":2117,"start":2118,"enrollment":2119,"conditions":4582,"interventions":4583},[89],[2121],[1953,2091],{"trials":4585,"activeCount":99},[],{"trials":4587,"activeCount":99},[],{"intervention":2908,"totalTrials":571,"cells":4589},{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4598,"PHASE3":4610,"PHASE4":4616,"NA":4618},{"trials":4591,"activeCount":99},[],{"trials":4593,"activeCount":468,"soonestReadout":2903},[4594],{"nctId":2900,"briefTitle":2901,"status":192,"phases":4595,"primaryCompletion":2903,"completion":1003,"start":2904,"enrollment":423,"conditions":4596,"interventions":4597},[87],[2894],[2907,2880,2908,1152,2909],{"trials":4599,"activeCount":99},[4600],{"nctId":4601,"briefTitle":4602,"status":137,"phases":4603,"primaryCompletion":2410,"completion":4604,"start":4605,"enrollment":99,"conditions":4606,"interventions":4608},"NCT04264806","A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)",[88],"2025-01-28","2021-05-06",[1467,4607],"Leukemia, Myelomonocytic, Chronic",[2908,4609],"Cusatuzumab",{"trials":4611,"activeCount":468,"soonestReadout":2929},[4612],{"nctId":2926,"briefTitle":2927,"status":304,"phases":4613,"primaryCompletion":2929,"completion":2930,"start":2931,"enrollment":2119,"conditions":4614,"interventions":4615},[89],[2894],[2907,2880,2908],{"trials":4617,"activeCount":99},[],{"trials":4619,"activeCount":99},[],{"intervention":788,"totalTrials":245,"cells":4621},{"EARLY_PHASE1":4622,"PHASE1":4624,"PHASE2":4626,"PHASE3":4632,"PHASE4":4638,"NA":4640},{"trials":4623,"activeCount":99},[],{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":468,"soonestReadout":778},[4628],{"nctId":775,"briefTitle":776,"status":304,"phases":4629,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":4630,"interventions":4631},[87,88],[783],[785,786,787,788,789,84],{"trials":4633,"activeCount":468,"soonestReadout":915},[4634],{"nctId":912,"briefTitle":913,"status":304,"phases":4635,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":4636,"interventions":4637},[89],[905],[84,907,909,910,788,921],{"trials":4639,"activeCount":99},[],{"trials":4641,"activeCount":99},[],{"intervention":789,"totalTrials":245,"cells":4643},{"EARLY_PHASE1":4644,"PHASE1":4646,"PHASE2":4648,"PHASE3":4654,"PHASE4":4660,"NA":4662},{"trials":4645,"activeCount":99},[],{"trials":4647,"activeCount":99},[],{"trials":4649,"activeCount":468,"soonestReadout":778},[4650],{"nctId":775,"briefTitle":776,"status":304,"phases":4651,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":4652,"interventions":4653},[87,88],[783],[785,786,787,788,789,84],{"trials":4655,"activeCount":468,"soonestReadout":900},[4656],{"nctId":897,"briefTitle":898,"status":304,"phases":4657,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":4658,"interventions":4659},[89],[905],[84,907,908,909,910,789],{"trials":4661,"activeCount":99},[],{"trials":4663,"activeCount":99},[],{"intervention":907,"totalTrials":245,"cells":4665},{"EARLY_PHASE1":4666,"PHASE1":4668,"PHASE2":4670,"PHASE3":4672,"PHASE4":4682,"NA":4684},{"trials":4667,"activeCount":99},[],{"trials":4669,"activeCount":99},[],{"trials":4671,"activeCount":99},[],{"trials":4673,"activeCount":245,"soonestReadout":900},[4674,4678],{"nctId":897,"briefTitle":898,"status":304,"phases":4675,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":4676,"interventions":4677},[89],[905],[84,907,908,909,910,789],{"nctId":912,"briefTitle":913,"status":304,"phases":4679,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":4680,"interventions":4681},[89],[905],[84,907,909,910,788,921],{"trials":4683,"activeCount":99},[],{"trials":4685,"activeCount":99},[],{"intervention":908,"totalTrials":245,"cells":4687},{"EARLY_PHASE1":4688,"PHASE1":4690,"PHASE2":4705,"PHASE3":4707,"PHASE4":4713,"NA":4715},{"trials":4689,"activeCount":99},[],{"trials":4691,"activeCount":468,"soonestReadout":4696},[4692],{"nctId":4693,"briefTitle":4694,"status":304,"phases":4695,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":1630,"conditions":4699,"interventions":4701},"NCT06663319","A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers",[87],"2028-02-25","2028-07-19","2024-10-15",[905,4700],"Gastrointestinal Neoplasms",[4702,908,4703,4704],"JNJ-89402638","FOLFOX","FOLFIRI",{"trials":4706,"activeCount":99},[],{"trials":4708,"activeCount":468,"soonestReadout":900},[4709],{"nctId":897,"briefTitle":898,"status":304,"phases":4710,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":4711,"interventions":4712},[89],[905],[84,907,908,909,910,789],{"trials":4714,"activeCount":99},[],{"trials":4716,"activeCount":99},[],{"intervention":909,"totalTrials":245,"cells":4718},{"EARLY_PHASE1":4719,"PHASE1":4721,"PHASE2":4723,"PHASE3":4725,"PHASE4":4735,"NA":4737},{"trials":4720,"activeCount":99},[],{"trials":4722,"activeCount":99},[],{"trials":4724,"activeCount":99},[],{"trials":4726,"activeCount":245,"soonestReadout":900},[4727,4731],{"nctId":897,"briefTitle":898,"status":304,"phases":4728,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":4729,"interventions":4730},[89],[905],[84,907,908,909,910,789],{"nctId":912,"briefTitle":913,"status":304,"phases":4732,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":4733,"interventions":4734},[89],[905],[84,907,909,910,788,921],{"trials":4736,"activeCount":99},[],{"trials":4738,"activeCount":99},[],{"intervention":910,"totalTrials":245,"cells":4740},{"EARLY_PHASE1":4741,"PHASE1":4743,"PHASE2":4745,"PHASE3":4747,"PHASE4":4757,"NA":4759},{"trials":4742,"activeCount":99},[],{"trials":4744,"activeCount":99},[],{"trials":4746,"activeCount":99},[],{"trials":4748,"activeCount":245,"soonestReadout":900},[4749,4753],{"nctId":897,"briefTitle":898,"status":304,"phases":4750,"primaryCompletion":900,"completion":901,"start":902,"enrollment":903,"conditions":4751,"interventions":4752},[89],[905],[84,907,908,909,910,789],{"nctId":912,"briefTitle":913,"status":304,"phases":4754,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":4755,"interventions":4756},[89],[905],[84,907,909,910,788,921],{"trials":4758,"activeCount":99},[],{"trials":4760,"activeCount":99},[],{"intervention":3068,"totalTrials":245,"cells":4762},{"EARLY_PHASE1":4763,"PHASE1":4765,"PHASE2":4767,"PHASE3":4769,"PHASE4":4779,"NA":4781},{"trials":4764,"activeCount":99},[],{"trials":4766,"activeCount":99},[],{"trials":4768,"activeCount":99},[],{"trials":4770,"activeCount":245,"soonestReadout":3078},[4771,4775],{"nctId":3061,"briefTitle":3062,"status":304,"phases":4772,"primaryCompletion":524,"completion":3064,"start":1222,"enrollment":3065,"conditions":4773,"interventions":4774},[89],[2987],[3068,2466,3069],{"nctId":3075,"briefTitle":3076,"status":304,"phases":4776,"primaryCompletion":3078,"completion":3079,"start":3080,"enrollment":1630,"conditions":4777,"interventions":4778},[89],[2987],[3068,2989,2466],{"trials":4780,"activeCount":99},[],{"trials":4782,"activeCount":99},[],{"intervention":2789,"totalTrials":245,"cells":4784},{"EARLY_PHASE1":4785,"PHASE1":4787,"PHASE2":4789,"PHASE3":4791,"PHASE4":4801,"NA":4803},{"trials":4786,"activeCount":99},[],{"trials":4788,"activeCount":99},[],{"trials":4790,"activeCount":99},[],{"trials":4792,"activeCount":245,"soonestReadout":2783},[4793,4797],{"nctId":2780,"briefTitle":2781,"status":192,"phases":4794,"primaryCompletion":2783,"completion":2784,"start":2785,"enrollment":2786,"conditions":4795,"interventions":4796},[89],[332],[2728,2789],{"nctId":2801,"briefTitle":2802,"status":192,"phases":4798,"primaryCompletion":2804,"completion":2805,"start":2806,"enrollment":2807,"conditions":4799,"interventions":4800},[89],[332],[2728,2789],{"trials":4802,"activeCount":99},[],{"trials":4804,"activeCount":99},[],{"intervention":2989,"totalTrials":245,"cells":4806},{"EARLY_PHASE1":4807,"PHASE1":4809,"PHASE2":4811,"PHASE3":4813,"PHASE4":4823,"NA":4825},{"trials":4808,"activeCount":99},[],{"trials":4810,"activeCount":99},[],{"trials":4812,"activeCount":99},[],{"trials":4814,"activeCount":245,"soonestReadout":3078},[4815,4819],{"nctId":2979,"briefTitle":2980,"status":192,"phases":4816,"primaryCompletion":2982,"completion":2983,"start":2984,"enrollment":2985,"conditions":4817,"interventions":4818},[89],[2987],[2426,2989,2466],{"nctId":3075,"briefTitle":3076,"status":304,"phases":4820,"primaryCompletion":3078,"completion":3079,"start":3080,"enrollment":1630,"conditions":4821,"interventions":4822},[89],[2987],[3068,2989,2466],{"trials":4824,"activeCount":99},[],{"trials":4826,"activeCount":99},[],{"intervention":3155,"totalTrials":571,"cells":4828},{"EARLY_PHASE1":4829,"PHASE1":4831,"PHASE2":4833,"PHASE3":4856,"PHASE4":4862,"NA":4864},{"trials":4830,"activeCount":99},[],{"trials":4832,"activeCount":99},[],{"trials":4834,"activeCount":99},[4835,4846],{"nctId":4836,"briefTitle":4837,"status":105,"phases":4838,"primaryCompletion":4839,"completion":4840,"start":4841,"enrollment":4842,"conditions":4843,"interventions":4845},"NCT01024036","A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease",[88],"2013-03-25","2017-02-24","2010-03-18",79,[4844],"Multicentric Castleman's Disease",[1246,3155],{"nctId":4847,"briefTitle":4848,"status":125,"phases":4849,"primaryCompletion":3310,"completion":3310,"start":4850,"enrollment":4851,"conditions":4852,"interventions":4854},"NCT01513317","A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome",[88],"2011-11",76,[4853],"Myelodysplastic Syndrome",[1246,4855],"Best supportive care",{"trials":4857,"activeCount":468,"soonestReadout":3150},[4858],{"nctId":3147,"briefTitle":3148,"status":304,"phases":4859,"primaryCompletion":3150,"completion":3150,"start":3151,"enrollment":3152,"conditions":4860,"interventions":4861},[89],[556],[559,3155],{"trials":4863,"activeCount":99},[],{"trials":4865,"activeCount":99},[],{"intervention":4867,"totalTrials":245,"cells":4868},"Apixaban placebo",{"EARLY_PHASE1":4869,"PHASE1":4871,"PHASE2":4873,"PHASE3":4893,"PHASE4":4899,"NA":4901},{"trials":4870,"activeCount":99},[],{"trials":4872,"activeCount":99},[],{"trials":4874,"activeCount":99},[4875],{"nctId":4876,"briefTitle":4877,"status":105,"phases":4878,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":4881,"interventions":4883},"NCT03251482","A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery",[88],"2018-11-05","2017-11-13",[4882],"VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery",[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],"JNJ-64179375 0.3 mg\u002Fkg","JNJ-64179375 0.6 mg\u002Fkg","JNJ-64179375 1.2 mg\u002Fkg","JNJ-64179375","JNJ-64179375 A mg\u002Fkg","JNJ-64179375 B mg\u002Fkg","JNJ-64179375 C mg\u002Fkg","JNJ-64179375 D mg\u002Fkg","Apixaban 2.5 mg",{"trials":4894,"activeCount":468,"soonestReadout":4530},[4895],{"nctId":4527,"briefTitle":4528,"status":192,"phases":4896,"primaryCompletion":4530,"completion":4530,"start":4531,"enrollment":4532,"conditions":4897,"interventions":4898},[89],[4534],[4497,4536,4537],{"trials":4900,"activeCount":99},[],{"trials":4902,"activeCount":99},[],{"intervention":133,"totalTrials":245,"cells":4904},{"EARLY_PHASE1":4905,"PHASE1":4907,"PHASE2":4913,"PHASE3":4915,"PHASE4":4921,"NA":4923},{"trials":4906,"activeCount":99},[],{"trials":4908,"activeCount":99},[4909],{"nctId":123,"briefTitle":124,"status":125,"phases":4910,"primaryCompletion":127,"completion":127,"start":128,"enrollment":129,"conditions":4911,"interventions":4912},[87],[131,15],[94,133],{"trials":4914,"activeCount":99},[],{"trials":4916,"activeCount":468,"soonestReadout":306},[4917],{"nctId":302,"briefTitle":303,"status":304,"phases":4918,"primaryCompletion":306,"completion":307,"start":308,"enrollment":309,"conditions":4919,"interventions":4920},[89],[311],[94,133],{"trials":4922,"activeCount":99},[],{"trials":4924,"activeCount":99},[],{"intervention":612,"totalTrials":245,"cells":4926},{"EARLY_PHASE1":4927,"PHASE1":4929,"PHASE2":4931,"PHASE3":4937,"PHASE4":4943,"NA":4945},{"trials":4928,"activeCount":99},[],{"trials":4930,"activeCount":99},[],{"trials":4932,"activeCount":99},[4933],{"nctId":2540,"briefTitle":2541,"status":105,"phases":4934,"primaryCompletion":2543,"completion":2543,"start":2544,"enrollment":2545,"conditions":4935,"interventions":4936},[88],[30],[518,496,2548],{"trials":4938,"activeCount":468,"soonestReadout":606},[4939],{"nctId":603,"briefTitle":604,"status":192,"phases":4940,"primaryCompletion":606,"completion":607,"start":608,"enrollment":609,"conditions":4941,"interventions":4942},[89],[30],[41,612],{"trials":4944,"activeCount":99},[],{"trials":4946,"activeCount":99},[],{"intervention":4948,"totalTrials":245,"cells":4949},"M281",{"EARLY_PHASE1":4950,"PHASE1":4952,"PHASE2":4954,"PHASE3":4963,"PHASE4":4973,"NA":4975},{"trials":4951,"activeCount":99},[],{"trials":4953,"activeCount":99},[],{"trials":4955,"activeCount":99},[4956],{"nctId":4957,"briefTitle":4958,"status":105,"phases":4959,"primaryCompletion":4960,"completion":4960,"start":2364,"enrollment":2472,"conditions":4961,"interventions":4962},"NCT03842189","A Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN)",[88],"2024-08-05",[2140],[4948],{"trials":4964,"activeCount":468,"soonestReadout":4969},[4965],{"nctId":4966,"briefTitle":4967,"status":192,"phases":4968,"primaryCompletion":4969,"completion":807,"start":4970,"enrollment":2526,"conditions":4971,"interventions":4972},"NCT04119050","Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia",[88,89],"2025-02-02","2019-08-15",[2160],[4948],{"trials":4974,"activeCount":99},[],{"trials":4976,"activeCount":99},[],{"intervention":4482,"totalTrials":245,"cells":4978},{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4983,"PHASE3":4995,"PHASE4":5001,"NA":5003},{"trials":4980,"activeCount":99},[],{"trials":4982,"activeCount":99},[],{"trials":4984,"activeCount":99},[4985],{"nctId":4986,"briefTitle":4987,"status":105,"phases":4988,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":3853,"conditions":4992,"interventions":4993},"NCT03321526","A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy",[88],"2019-06-13","2019-06-27","2017-12-12",[21],[4325,4457,4482,4994],"Serotonin-Norepinephrine Reuptake Inhibitor",{"trials":4996,"activeCount":468,"soonestReadout":2460},[4997],{"nctId":4476,"briefTitle":4477,"status":304,"phases":4998,"primaryCompletion":2460,"completion":2460,"start":4479,"enrollment":2797,"conditions":4999,"interventions":5000},[89],[21],[4385,4482],{"trials":5002,"activeCount":99},[],{"trials":5004,"activeCount":99},[],{"intervention":446,"totalTrials":245,"cells":5006},{"EARLY_PHASE1":5007,"PHASE1":5009,"PHASE2":5015,"PHASE3":5017,"PHASE4":5023,"NA":5025},{"trials":5008,"activeCount":99},[],{"trials":5010,"activeCount":99},[5011],{"nctId":1968,"briefTitle":1969,"status":105,"phases":5012,"primaryCompletion":1971,"completion":1971,"start":50,"enrollment":1972,"conditions":5013,"interventions":5014},[87],[15],[1953,446,1975],{"trials":5016,"activeCount":99},[],{"trials":5018,"activeCount":468,"soonestReadout":441},[5019],{"nctId":438,"briefTitle":439,"status":192,"phases":5020,"primaryCompletion":441,"completion":442,"start":443,"enrollment":371,"conditions":5021,"interventions":5022},[89],[171],[94,446],{"trials":5024,"activeCount":99},[],{"trials":5026,"activeCount":99},[],{"intervention":3069,"totalTrials":468,"cells":5028},{"EARLY_PHASE1":5029,"PHASE1":5031,"PHASE2":5033,"PHASE3":5035,"PHASE4":5041,"NA":5043},{"trials":5030,"activeCount":99},[],{"trials":5032,"activeCount":99},[],{"trials":5034,"activeCount":99},[],{"trials":5036,"activeCount":468,"soonestReadout":524},[5037],{"nctId":3061,"briefTitle":3062,"status":304,"phases":5038,"primaryCompletion":524,"completion":3064,"start":1222,"enrollment":3065,"conditions":5039,"interventions":5040},[89],[2987],[3068,2466,3069],{"trials":5042,"activeCount":99},[],{"trials":5044,"activeCount":99},[],{"intervention":921,"totalTrials":468,"cells":5046},{"EARLY_PHASE1":5047,"PHASE1":5049,"PHASE2":5051,"PHASE3":5053,"PHASE4":5059,"NA":5061},{"trials":5048,"activeCount":99},[],{"trials":5050,"activeCount":99},[],{"trials":5052,"activeCount":99},[],{"trials":5054,"activeCount":468,"soonestReadout":915},[5055],{"nctId":912,"briefTitle":913,"status":304,"phases":5056,"primaryCompletion":915,"completion":916,"start":917,"enrollment":918,"conditions":5057,"interventions":5058},[89],[905],[84,907,909,910,788,921],{"trials":5060,"activeCount":99},[],{"trials":5062,"activeCount":99},[],{"intervention":2069,"totalTrials":468,"cells":5064},{"EARLY_PHASE1":5065,"PHASE1":5067,"PHASE2":5069,"PHASE3":5071,"PHASE4":5077,"NA":5079},{"trials":5066,"activeCount":99},[],{"trials":5068,"activeCount":99},[],{"trials":5070,"activeCount":99},[],{"trials":5072,"activeCount":468,"soonestReadout":2063},[5073],{"nctId":2060,"briefTitle":2061,"status":304,"phases":5074,"primaryCompletion":2063,"completion":1690,"start":2064,"enrollment":2065,"conditions":5075,"interventions":5076},[89],[2067],[1953,2069],{"trials":5078,"activeCount":99},[],{"trials":5080,"activeCount":99},[],{"intervention":2080,"totalTrials":468,"cells":5082},{"EARLY_PHASE1":5083,"PHASE1":5085,"PHASE2":5087,"PHASE3":5089,"PHASE4":5095,"NA":5097},{"trials":5084,"activeCount":99},[],{"trials":5086,"activeCount":99},[],{"trials":5088,"activeCount":99},[],{"trials":5090,"activeCount":468,"soonestReadout":2074},[5091],{"nctId":2071,"briefTitle":2072,"status":304,"phases":5092,"primaryCompletion":2074,"completion":2075,"start":2076,"enrollment":2077,"conditions":5093,"interventions":5094},[89],[2067],[1953,2080],{"trials":5096,"activeCount":99},[],{"trials":5098,"activeCount":99},[],{"intervention":2600,"totalTrials":468,"cells":5100},{"EARLY_PHASE1":5101,"PHASE1":5103,"PHASE2":5105,"PHASE3":5107,"PHASE4":5113,"NA":5115},{"trials":5102,"activeCount":99},[],{"trials":5104,"activeCount":99},[],{"trials":5106,"activeCount":99},[],{"trials":5108,"activeCount":468,"soonestReadout":55},[5109],{"nctId":53,"briefTitle":54,"status":192,"phases":5110,"primaryCompletion":55,"completion":2595,"start":1201,"enrollment":2596,"conditions":5111,"interventions":5112},[89],[2598],[56,495,496,2600],{"trials":5114,"activeCount":99},[],{"trials":5116,"activeCount":99},[],{"intervention":2455,"totalTrials":468,"cells":5118},{"EARLY_PHASE1":5119,"PHASE1":5121,"PHASE2":5123,"PHASE3":5125,"PHASE4":5131,"NA":5133},{"trials":5120,"activeCount":99},[],{"trials":5122,"activeCount":99},[],{"trials":5124,"activeCount":99},[],{"trials":5126,"activeCount":468,"soonestReadout":2449},[5127],{"nctId":2446,"briefTitle":2447,"status":192,"phases":5128,"primaryCompletion":2449,"completion":2449,"start":2450,"enrollment":2451,"conditions":5129,"interventions":5130},[89],[2453],[2426,560,2455],{"trials":5132,"activeCount":99},[],{"trials":5134,"activeCount":99},[],{"intervention":1064,"totalTrials":468,"cells":5136},{"EARLY_PHASE1":5137,"PHASE1":5139,"PHASE2":5141,"PHASE3":5143,"PHASE4":5149,"NA":5151},{"trials":5138,"activeCount":99},[],{"trials":5140,"activeCount":99},[],{"trials":5142,"activeCount":99},[],{"trials":5144,"activeCount":468,"soonestReadout":1058},[5145],{"nctId":1055,"briefTitle":1056,"status":304,"phases":5146,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":5147,"interventions":5148},[89],[18],[70,707,65,1064,684,682],{"trials":5150,"activeCount":99},[],{"trials":5152,"activeCount":99},[],{"intervention":5154,"totalTrials":468,"cells":5155},"Genetic: AAV5-hRKp.RPGR Intermediate Dose",{"EARLY_PHASE1":5156,"PHASE1":5158,"PHASE2":5160,"PHASE3":5162,"PHASE4":5176,"NA":5178},{"trials":5157,"activeCount":99},[],{"trials":5159,"activeCount":99},[],{"trials":5161,"activeCount":99},[],{"trials":5163,"activeCount":468,"soonestReadout":5168},[5164],{"nctId":5165,"briefTitle":5166,"status":192,"phases":5167,"primaryCompletion":5168,"completion":5169,"start":5170,"enrollment":5171,"conditions":5172,"interventions":5174},"NCT04794101","Follow-up Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene",[89],"2029-09-20","2029-12-07","2020-12-04",97,[5173],"X-Linked Retinitis Pigmentosa",[5154,5175],"Genetic: AAV5-hRKp.RPGR Low Dose",{"trials":5177,"activeCount":99},[],{"trials":5179,"activeCount":99},[],{"intervention":5175,"totalTrials":468,"cells":5181},{"EARLY_PHASE1":5182,"PHASE1":5184,"PHASE2":5186,"PHASE3":5188,"PHASE4":5194,"NA":5196},{"trials":5183,"activeCount":99},[],{"trials":5185,"activeCount":99},[],{"trials":5187,"activeCount":99},[],{"trials":5189,"activeCount":468,"soonestReadout":5168},[5190],{"nctId":5165,"briefTitle":5166,"status":192,"phases":5191,"primaryCompletion":5168,"completion":5169,"start":5170,"enrollment":5171,"conditions":5192,"interventions":5193},[89],[5173],[5154,5175],{"trials":5195,"activeCount":99},[],{"trials":5197,"activeCount":99},[],{"intervention":4536,"totalTrials":468,"cells":5199},{"EARLY_PHASE1":5200,"PHASE1":5202,"PHASE2":5204,"PHASE3":5206,"PHASE4":5212,"NA":5214},{"trials":5201,"activeCount":99},[],{"trials":5203,"activeCount":99},[],{"trials":5205,"activeCount":99},[],{"trials":5207,"activeCount":468,"soonestReadout":4530},[5208],{"nctId":4527,"briefTitle":4528,"status":192,"phases":5209,"primaryCompletion":4530,"completion":4530,"start":4531,"enrollment":4532,"conditions":5210,"interventions":5211},[89],[4534],[4497,4536,4537],{"trials":5213,"activeCount":99},[],{"trials":5215,"activeCount":99},[],{"intervention":941,"totalTrials":468,"cells":5217},{"EARLY_PHASE1":5218,"PHASE1":5220,"PHASE2":5222,"PHASE3":5224,"PHASE4":5230,"NA":5232},{"trials":5219,"activeCount":99},[],{"trials":5221,"activeCount":99},[],{"trials":5223,"activeCount":99},[],{"trials":5225,"activeCount":468,"soonestReadout":936},[5226],{"nctId":933,"briefTitle":934,"status":192,"phases":5227,"primaryCompletion":936,"completion":927,"start":937,"enrollment":938,"conditions":5228,"interventions":5229},[89],[35],[84,941,759],{"trials":5231,"activeCount":99},[],{"trials":5233,"activeCount":99},[],{"intervention":1888,"totalTrials":468,"cells":5235},{"EARLY_PHASE1":5236,"PHASE1":5238,"PHASE2":5240,"PHASE3":5242,"PHASE4":5248,"NA":5250},{"trials":5237,"activeCount":99},[],{"trials":5239,"activeCount":99},[],{"trials":5241,"activeCount":99},[],{"trials":5243,"activeCount":468,"soonestReadout":1882},[5244],{"nctId":1879,"briefTitle":1880,"status":192,"phases":5245,"primaryCompletion":1882,"completion":1689,"start":1883,"enrollment":1884,"conditions":5246,"interventions":5247},[89],[1886],[759,1888,1889],{"trials":5249,"activeCount":99},[],{"trials":5251,"activeCount":99},[],{"intervention":1889,"totalTrials":468,"cells":5253},{"EARLY_PHASE1":5254,"PHASE1":5256,"PHASE2":5258,"PHASE3":5260,"PHASE4":5266,"NA":5268},{"trials":5255,"activeCount":99},[],{"trials":5257,"activeCount":99},[],{"trials":5259,"activeCount":99},[],{"trials":5261,"activeCount":468,"soonestReadout":1882},[5262],{"nctId":1879,"briefTitle":1880,"status":192,"phases":5263,"primaryCompletion":1882,"completion":1689,"start":1883,"enrollment":1884,"conditions":5264,"interventions":5265},[89],[1886],[759,1888,1889],{"trials":5267,"activeCount":99},[],{"trials":5269,"activeCount":99},[],{"intervention":3204,"totalTrials":468,"cells":5271},{"EARLY_PHASE1":5272,"PHASE1":5274,"PHASE2":5276,"PHASE3":5278,"PHASE4":5284,"NA":5286},{"trials":5273,"activeCount":99},[],{"trials":5275,"activeCount":99},[],{"trials":5277,"activeCount":99},[],{"trials":5279,"activeCount":468,"soonestReadout":3198},[5280],{"nctId":3195,"briefTitle":3196,"status":192,"phases":5281,"primaryCompletion":3198,"completion":3199,"start":3200,"enrollment":3201,"conditions":5282,"interventions":5283},[89],[131],[3165,3204],{"trials":5285,"activeCount":99},[],{"trials":5287,"activeCount":99},[],{"intervention":951,"totalTrials":468,"cells":5289},{"EARLY_PHASE1":5290,"PHASE1":5292,"PHASE2":5294,"PHASE3":5296,"PHASE4":5302,"NA":5304},{"trials":5291,"activeCount":99},[],{"trials":5293,"activeCount":99},[],{"trials":5295,"activeCount":99},[],{"trials":5297,"activeCount":468,"soonestReadout":946},[5298],{"nctId":943,"briefTitle":944,"status":304,"phases":5299,"primaryCompletion":946,"completion":946,"start":947,"enrollment":948,"conditions":5300,"interventions":5301},[89],[821],[84,823,760,951,952],{"trials":5303,"activeCount":99},[],{"trials":5305,"activeCount":99},[],{"intervention":5307,"totalTrials":468,"cells":5308},"Daratumumab SC: daratumumab + rHuPH20",{"EARLY_PHASE1":5309,"PHASE1":5311,"PHASE2":5313,"PHASE3":5315,"PHASE4":5327,"NA":5329},{"trials":5310,"activeCount":99},[],{"trials":5312,"activeCount":99},[],{"trials":5314,"activeCount":99},[],{"trials":5316,"activeCount":468,"soonestReadout":701},[5317],{"nctId":5318,"briefTitle":5319,"status":192,"phases":5320,"primaryCompletion":701,"completion":5321,"start":5322,"enrollment":5323,"conditions":5324,"interventions":5326},"NCT03301220","A Study of Subcutaneous Daratumumab Versus Active Monitoring in Participants With High-Risk Smoldering Multiple Myeloma",[89],"2026-06-30","2017-11-07",390,[5325],"Smoldering Multiple Myeloma",[5307],{"trials":5328,"activeCount":99},[],{"trials":5330,"activeCount":99},[],{"intervention":5332,"totalTrials":468,"cells":5333},"Guselkumab Subcutaneous",{"EARLY_PHASE1":5334,"PHASE1":5336,"PHASE2":5338,"PHASE3":5340,"PHASE4":5353,"NA":5355},{"trials":5335,"activeCount":99},[],{"trials":5337,"activeCount":99},[],{"trials":5339,"activeCount":99},[],{"trials":5341,"activeCount":468,"soonestReadout":5346},[5342],{"nctId":5343,"briefTitle":5344,"status":192,"phases":5345,"primaryCompletion":5346,"completion":5347,"start":5348,"enrollment":5349,"conditions":5350,"interventions":5351},"NCT06260163","A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis",[89],"2028-05-22","2028-08-14","2024-01-19",112,[27],[5332,5352],"Guselkumab Intravenous",{"trials":5354,"activeCount":99},[],{"trials":5356,"activeCount":99},[],{"intervention":5352,"totalTrials":468,"cells":5358},{"EARLY_PHASE1":5359,"PHASE1":5361,"PHASE2":5363,"PHASE3":5365,"PHASE4":5371,"NA":5373},{"trials":5360,"activeCount":99},[],{"trials":5362,"activeCount":99},[],{"trials":5364,"activeCount":99},[],{"trials":5366,"activeCount":468,"soonestReadout":5346},[5367],{"nctId":5343,"briefTitle":5344,"status":192,"phases":5368,"primaryCompletion":5346,"completion":5347,"start":5348,"enrollment":5349,"conditions":5369,"interventions":5370},[89],[27],[5332,5352],{"trials":5372,"activeCount":99},[],{"trials":5374,"activeCount":99},[],{"intervention":415,"totalTrials":468,"cells":5376},{"EARLY_PHASE1":5377,"PHASE1":5379,"PHASE2":5381,"PHASE3":5383,"PHASE4":5389,"NA":5391},{"trials":5378,"activeCount":99},[],{"trials":5380,"activeCount":99},[],{"trials":5382,"activeCount":99},[],{"trials":5384,"activeCount":468,"soonestReadout":406},[5385],{"nctId":403,"briefTitle":404,"status":192,"phases":5386,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":5387,"interventions":5388},[88,89],[199],[412,413,414,415,416,94,214],{"trials":5390,"activeCount":99},[],{"trials":5392,"activeCount":99},[],{"intervention":416,"totalTrials":468,"cells":5394},{"EARLY_PHASE1":5395,"PHASE1":5397,"PHASE2":5399,"PHASE3":5401,"PHASE4":5407,"NA":5409},{"trials":5396,"activeCount":99},[],{"trials":5398,"activeCount":99},[],{"trials":5400,"activeCount":99},[],{"trials":5402,"activeCount":468,"soonestReadout":406},[5403],{"nctId":403,"briefTitle":404,"status":192,"phases":5404,"primaryCompletion":406,"completion":407,"start":408,"enrollment":409,"conditions":5405,"interventions":5406},[88,89],[199],[412,413,414,415,416,94,214],{"trials":5408,"activeCount":99},[],{"trials":5410,"activeCount":99},[],{"intervention":3251,"totalTrials":468,"cells":5412},{"EARLY_PHASE1":5413,"PHASE1":5415,"PHASE2":5417,"PHASE3":5419,"PHASE4":5425,"NA":5427},{"trials":5414,"activeCount":99},[],{"trials":5416,"activeCount":99},[],{"trials":5418,"activeCount":99},[],{"trials":5420,"activeCount":468,"soonestReadout":3245},[5421],{"nctId":3242,"briefTitle":3243,"status":192,"phases":5422,"primaryCompletion":3245,"completion":511,"start":3246,"enrollment":3247,"conditions":5423,"interventions":5424},[89],[3249],[75,3251,562,823],{"trials":5426,"activeCount":99},[],{"trials":5428,"activeCount":99},[],{"intervention":2941,"totalTrials":468,"cells":5430},{"EARLY_PHASE1":5431,"PHASE1":5433,"PHASE2":5435,"PHASE3":5437,"PHASE4":5443,"NA":5445},{"trials":5432,"activeCount":99},[],{"trials":5434,"activeCount":99},[],{"trials":5436,"activeCount":99},[],{"trials":5438,"activeCount":468,"soonestReadout":45},[5439],{"nctId":43,"briefTitle":44,"status":192,"phases":5440,"primaryCompletion":45,"completion":2936,"start":2937,"enrollment":2938,"conditions":5441,"interventions":5442},[89],[2920],[46,2880,2941,2942,46],{"trials":5444,"activeCount":99},[],{"trials":5446,"activeCount":99},[],{"intervention":2942,"totalTrials":468,"cells":5448},{"EARLY_PHASE1":5449,"PHASE1":5451,"PHASE2":5453,"PHASE3":5455,"PHASE4":5461,"NA":5463},{"trials":5450,"activeCount":99},[],{"trials":5452,"activeCount":99},[],{"trials":5454,"activeCount":99},[],{"trials":5456,"activeCount":468,"soonestReadout":45},[5457],{"nctId":43,"briefTitle":44,"status":192,"phases":5458,"primaryCompletion":45,"completion":2936,"start":2937,"enrollment":2938,"conditions":5459,"interventions":5460},[89],[2920],[46,2880,2941,2942,46],{"trials":5462,"activeCount":99},[],{"trials":5464,"activeCount":99},[],{"intervention":2148,"totalTrials":468,"cells":5466},{"EARLY_PHASE1":5467,"PHASE1":5469,"PHASE2":5471,"PHASE3":5473,"PHASE4":5479,"NA":5481},{"trials":5468,"activeCount":99},[],{"trials":5470,"activeCount":99},[],{"trials":5472,"activeCount":99},[],{"trials":5474,"activeCount":468,"soonestReadout":900},[5475],{"nctId":2143,"briefTitle":2144,"status":304,"phases":5476,"primaryCompletion":900,"completion":2106,"start":501,"enrollment":320,"conditions":5477,"interventions":5478},[89],[2110],[1953,2148,496],{"trials":5480,"activeCount":99},[],{"trials":5482,"activeCount":99},[],{"intervention":4318,"totalTrials":1857,"cells":5484},{"EARLY_PHASE1":5485,"PHASE1":5487,"PHASE2":5621,"PHASE3":5644,"PHASE4":5719,"NA":5721},{"trials":5486,"activeCount":99},[],{"trials":5488,"activeCount":99},[5489,5497,5506,5510,5517,5526,5533,5542,5551,5560,5568,5575,5582,5591,5600,5608,5614],{"nctId":5490,"briefTitle":5491,"status":105,"phases":5492,"primaryCompletion":3612,"completion":3612,"start":5493,"enrollment":503,"conditions":5494,"interventions":5495},"NCT02343289","A Study to Evaluate the Absolute Bioavailability of Intranasal and Oral Esketamine and the Effects of Clarithromycin on the Pharmacokinetics of Intranasal Esketamine in Healthy Participants",[87],"2015-01",[15],[4318,5496],"Clarithromycin",{"nctId":5498,"briefTitle":5499,"status":105,"phases":5500,"primaryCompletion":3359,"completion":3359,"start":2218,"enrollment":12,"conditions":5501,"interventions":5503},"NCT02154334","Study to Assess the Effects of Allergic Rhinitis and Co-administration of Mometasone or Oxymetazoline on the Pharmacokinetics, Safety, and Tolerability of Intranasal Esketamine",[87],[5502],"Allergic Rhinitis",[4318,5504,5505],"Mometasone","Oxymetazoline",{"nctId":4311,"briefTitle":4312,"status":105,"phases":5507,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":832,"conditions":5508,"interventions":5509},[87],[15],[173,4318,3679],{"nctId":5511,"briefTitle":5512,"status":105,"phases":5513,"primaryCompletion":3329,"completion":3329,"start":3392,"enrollment":2566,"conditions":5514,"interventions":5515},"NCT01780259","A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants",[87],[15],[4318,5516],"Triazolam",{"nctId":5518,"briefTitle":5519,"status":105,"phases":5520,"primaryCompletion":5521,"completion":5521,"start":5522,"enrollment":3586,"conditions":5523,"interventions":5525},"NCT02611505","A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine",[87],"2017-02-27","2015-11-30",[505,5524],"Normal Hepatic Function",[4318],{"nctId":5527,"briefTitle":5528,"status":105,"phases":5529,"primaryCompletion":5530,"completion":5530,"start":2218,"enrollment":3586,"conditions":5531,"interventions":5532},"NCT02094378","A Study to Evaluate the Effect of Intranasal Esketamine on Cognitive Functioning in Healthy Subjects",[87],"2014-08",[15],[4318],{"nctId":5534,"briefTitle":5535,"status":105,"phases":5536,"primaryCompletion":5537,"completion":5537,"start":5538,"enrollment":5539,"conditions":5540,"interventions":5541},"NCT02857777","Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly Japanese, and Healthy Younger Adult Japanese Subjects",[87],"2017-01-27","2016-08-09",37,[15],[4318],{"nctId":5543,"briefTitle":5544,"status":105,"phases":5545,"primaryCompletion":5546,"completion":5546,"start":5547,"enrollment":169,"conditions":5548,"interventions":5549},"NCT03298906","A Study to Assess the Effect of Ticlopidine on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine in Healthy Participants",[87],"2017-11-27","2017-09-26",[15],[4318,5550],"Ticlopidine",{"nctId":5552,"briefTitle":5553,"status":105,"phases":5554,"primaryCompletion":5555,"completion":5555,"start":5556,"enrollment":5557,"conditions":5558,"interventions":5559},"NCT02060929","A Study to Evaluate the Pharmacokinetics of Intranasal Esketamine Administered With and Without a Nasal Guide on the Intranasal Device",[87],"2014-01","2013-10",14,[15],[4318],{"nctId":5561,"briefTitle":5562,"status":137,"phases":5563,"primaryCompletion":4507,"completion":4507,"start":4184,"enrollment":99,"conditions":5564,"interventions":5566},"NCT05268497","A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant Depression",[87],[5565],"Depression",[4318,5567],"Antidepressant",{"nctId":5569,"briefTitle":5570,"status":105,"phases":5571,"primaryCompletion":2217,"completion":2217,"start":5572,"enrollment":492,"conditions":5573,"interventions":5574},"NCT02129088","A Pharmacokinetic, Safety and Tolerability Study of Esketamine in Healthy Elderly and Adult Participants",[87],"2014-03",[15],[4318],{"nctId":5576,"briefTitle":5577,"status":105,"phases":5578,"primaryCompletion":3444,"completion":3444,"start":4348,"enrollment":25,"conditions":5579,"interventions":5580},"NCT02228239","Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants",[87],[15],[4318,5581],"Mirtazapine",{"nctId":5583,"briefTitle":5584,"status":105,"phases":5585,"primaryCompletion":5586,"completion":5586,"start":5587,"enrollment":1507,"conditions":5588,"interventions":5590},"NCT02606084","A Study to Assess the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine",[87],"2018-02-02","2015-12-04",[5589,15],"Renal Impairment",[4318],{"nctId":5592,"briefTitle":5593,"status":105,"phases":5594,"primaryCompletion":5595,"completion":5595,"start":5596,"enrollment":5597,"conditions":5598,"interventions":5599},"NCT02919579","A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive Disorder",[87],"2018-06-29","2016-10-07",27,[21],[4318],{"nctId":5601,"briefTitle":5602,"status":105,"phases":5603,"primaryCompletion":5604,"completion":5604,"start":5605,"enrollment":1436,"conditions":5606,"interventions":5607},"NCT02846519","Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Healthy Han Chinese, Korean, Japanese, and Caucasian Participants and the Effects of Rifampin on the Pharmacokinetics of Intranasally Administered Esketamine",[87],"2016-05-28","2016-02-26",[15],[4318,1800],{"nctId":5609,"briefTitle":5610,"status":105,"phases":5611,"primaryCompletion":5493,"completion":5493,"start":3444,"enrollment":169,"conditions":5612,"interventions":5613},"NCT02345148","Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants",[87],[15],[4318],{"nctId":5615,"briefTitle":5616,"status":105,"phases":5617,"primaryCompletion":5555,"completion":5555,"start":5618,"enrollment":1857,"conditions":5619,"interventions":5620},"NCT01980303","A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers",[87],"2013-11",[3331],[4318],{"trials":5622,"activeCount":99},[5623,5632,5640],{"nctId":5624,"briefTitle":5625,"status":105,"phases":5626,"primaryCompletion":5627,"completion":5627,"start":5628,"enrollment":809,"conditions":5629,"interventions":5631},"NCT02133001","A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for Suicide",[88],"2016-02-01","2014-05-23",[5630],"Major Depressive Disorder",[4318],{"nctId":5633,"briefTitle":5634,"status":105,"phases":5635,"primaryCompletion":5636,"completion":5636,"start":5637,"enrollment":22,"conditions":5638,"interventions":5639},"NCT01640080","A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression",[88],"2013-06-03","2012-06-27",[5630],[4318,4318],{"nctId":4360,"briefTitle":4361,"status":105,"phases":5641,"primaryCompletion":1784,"completion":1784,"start":1602,"enrollment":4363,"conditions":5642,"interventions":5643},[88],[21],[4366,4367,173,4318,4318,4318],{"trials":5645,"activeCount":468,"soonestReadout":4374},[5646,5654,5668,5672,5683,5692,5701,5710],{"nctId":5647,"briefTitle":5648,"status":105,"phases":5649,"primaryCompletion":542,"completion":542,"start":5650,"enrollment":5651,"conditions":5652,"interventions":5653},"NCT03097133","54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide",[89],"2017-06-15",230,[21],[4318],{"nctId":5655,"briefTitle":5656,"status":105,"phases":5657,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":5661,"interventions":5663},"NCT02417064","A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",[89],"2018-02-20","2015-08-10",346,[5662],"Treatment-resistant Depression",[4318,5664,5665,5666,5667],"Duloxetine","Escitalopram","Sertraline","Venlafaxine Extended Release",{"nctId":4371,"briefTitle":4372,"status":304,"phases":5669,"primaryCompletion":4374,"completion":4375,"start":4376,"enrollment":4377,"conditions":5670,"interventions":5671},[89],[21],[4318,173],{"nctId":5673,"briefTitle":5674,"status":105,"phases":5675,"primaryCompletion":5676,"completion":5677,"start":5678,"enrollment":5679,"conditions":5680,"interventions":5682},"NCT02493868","A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression",[89],"2018-02-15","2018-02-16","2015-10-01",719,[5681],"Depressive Disorder, Treatment-Resistant",[4318,5664,5665,5666,5667],{"nctId":5684,"briefTitle":5685,"status":105,"phases":5686,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":5690,"interventions":5691},"NCT02497287","A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression",[89],"2017-10-28","2015-09-30",802,[5662],[4318,5664,5665,5666,5667],{"nctId":5693,"briefTitle":5694,"status":105,"phases":5695,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":5698,"conditions":5699,"interventions":5700},"NCT02422186","A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression",[89],"2017-08-10","2015-08-20",139,[5681],[4318,5664,5665,5666,5667],{"nctId":5702,"briefTitle":5703,"status":105,"phases":5704,"primaryCompletion":5705,"completion":5705,"start":5706,"enrollment":5707,"conditions":5708,"interventions":5709},"NCT03039192","54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for Suicide",[89],"2018-12-18","2017-06-09",226,[21],[4318],{"nctId":5711,"briefTitle":5712,"status":105,"phases":5713,"primaryCompletion":1530,"completion":5714,"start":5715,"enrollment":5716,"conditions":5717,"interventions":5718},"NCT02418585","A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",[89],"2017-11-06","2015-08-07",236,[5662],[4318,5664,5665,5666,5667],{"trials":5720,"activeCount":99},[],{"trials":5722,"activeCount":99},[5723],{"nctId":5724,"briefTitle":5725,"status":967,"phases":5726,"conditions":5727,"interventions":5728},"NCT03829579","Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)",[],[5681],[4318],{"intervention":4241,"totalTrials":245,"cells":5730},{"EARLY_PHASE1":5731,"PHASE1":5733,"PHASE2":5735,"PHASE3":5737,"PHASE4":5743,"NA":5745},{"trials":5732,"activeCount":99},[],{"trials":5734,"activeCount":99},[],{"trials":5736,"activeCount":99},[],{"trials":5738,"activeCount":468,"soonestReadout":4236},[5739],{"nctId":4233,"briefTitle":4234,"status":192,"phases":5740,"primaryCompletion":4236,"completion":4237,"start":4238,"enrollment":4214,"conditions":5741,"interventions":5742},[89],[27],[201,4241],{"trials":5744,"activeCount":99},[],{"trials":5746,"activeCount":99},[5747],{"nctId":5748,"briefTitle":5749,"status":125,"phases":5750,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":4851,"conditions":5753,"interventions":5755},"NCT02293681","An Observational Study of Infliximab in Participants Suffering From Ankylosing Spondylitis With Hip Involvement",[],"2017-05-31","2015-04-10",[5754],"Spondylitis, Ankylosing",[4241,5756,5757],"NSAIDs","DMARDs",{"intervention":785,"totalTrials":245,"cells":5759},{"EARLY_PHASE1":5760,"PHASE1":5762,"PHASE2":5764,"PHASE3":5774,"PHASE4":5776,"NA":5778},{"trials":5761,"activeCount":99},[],{"trials":5763,"activeCount":99},[],{"trials":5765,"activeCount":245,"soonestReadout":778},[5766,5770],{"nctId":775,"briefTitle":776,"status":304,"phases":5767,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":5768,"interventions":5769},[87,88],[783],[785,786,787,788,789,84],{"nctId":1832,"briefTitle":1833,"status":192,"phases":5771,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":5772,"interventions":5773},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":5775,"activeCount":99},[],{"trials":5777,"activeCount":99},[],{"trials":5779,"activeCount":99},[],{"intervention":1707,"totalTrials":245,"cells":5781},{"EARLY_PHASE1":5782,"PHASE1":5784,"PHASE2":5786,"PHASE3":5802,"PHASE4":5804,"NA":5806},{"trials":5783,"activeCount":99},[],{"trials":5785,"activeCount":99},[],{"trials":5787,"activeCount":245,"soonestReadout":5796},[5788,5792],{"nctId":1696,"briefTitle":1697,"status":304,"phases":5789,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":5790,"interventions":5791},[88],[18],[70,1703,1704,1705,1706,1707],{"nctId":5793,"briefTitle":5794,"status":272,"phases":5795,"primaryCompletion":5796,"completion":5797,"start":5798,"enrollment":5651,"conditions":5799,"interventions":5800},"NCT07589634","A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed\u002FRefractory Multiple Myeloma",[88],"2027-12-31","2030-11-08","2026-07-20",[18],[1707,5801],"Tocilizumab",{"trials":5803,"activeCount":99},[],{"trials":5805,"activeCount":99},[],{"trials":5807,"activeCount":99},[],{"intervention":1779,"totalTrials":129,"cells":5809},{"EARLY_PHASE1":5810,"PHASE1":5812,"PHASE2":5835,"PHASE3":5850,"PHASE4":5905,"NA":5915},{"trials":5811,"activeCount":99},[],{"trials":5813,"activeCount":99},[5814,5818,5827],{"nctId":1771,"briefTitle":1772,"status":105,"phases":5815,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":745,"conditions":5816,"interventions":5817},[87],[15],[759,173,1778,1779],{"nctId":5819,"briefTitle":5820,"status":105,"phases":5821,"primaryCompletion":3358,"completion":3358,"start":5530,"enrollment":245,"conditions":5822,"interventions":5824},"NCT02221180","Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants",[87],[5823],"Bioequivalence",[5825,5826,1779],"Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]","Canagliflozin",{"nctId":5828,"briefTitle":5829,"status":105,"phases":5830,"primaryCompletion":5831,"completion":5831,"start":5832,"enrollment":1507,"conditions":5833,"interventions":5834},"NCT02611518","A Pharmacokinetic Interaction Study Between JNJ-54861911 and Transporter Substrates Rosuvastatin and Metformin in Healthy Participants",[87],"2016-06-14","2016-04-05",[15],[1778,4351,1779],{"trials":5836,"activeCount":468,"soonestReadout":74},[5837,5841],{"nctId":72,"briefTitle":73,"status":192,"phases":5838,"primaryCompletion":74,"completion":830,"start":3842,"enrollment":3843,"conditions":5839,"interventions":5840},[88],[3249],[75,173,1779],{"nctId":5842,"briefTitle":5843,"status":105,"phases":5844,"primaryCompletion":2487,"completion":2487,"start":5845,"enrollment":1663,"conditions":5846,"interventions":5847},"NCT01340664","An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy",[88],"2011-07",[24],[5848,5849,1779],"Canagliflozin 50 mg","Canagliflozin 150 mg",{"trials":5851,"activeCount":99},[5852,5863,5874,5884,5895],{"nctId":5853,"briefTitle":5854,"status":105,"phases":5855,"primaryCompletion":2565,"completion":2565,"start":5856,"enrollment":5857,"conditions":5858,"interventions":5859},"NCT01137812","The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)",[89],"2010-07",756,[24],[5860,5861,1779,5862],"Sitagliptin 100 mg","Canagliflozin 300 mg","Sulphonylurea",{"nctId":5864,"briefTitle":5865,"status":105,"phases":5866,"primaryCompletion":5867,"completion":5868,"start":5869,"enrollment":5870,"conditions":5871,"interventions":5872},"NCT00968812","CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride",[89],"2011-12","2013-01","2009-09",1452,[24],[5873,5826,1779],"Glimepiride",{"nctId":5875,"briefTitle":5876,"status":105,"phases":5877,"primaryCompletion":5878,"completion":2487,"start":5879,"enrollment":5880,"conditions":5881,"interventions":5882},"NCT01106625","The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)",[89],"2011-09","2010-05",469,[24],[5826,1779,5883],"Sulphonylruea",{"nctId":5885,"briefTitle":5886,"status":105,"phases":5887,"primaryCompletion":5888,"completion":5888,"start":5889,"enrollment":5890,"conditions":5891,"interventions":5892},"NCT01381900","A Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Alone or in Combination With a Sulphonylurea",[89],"2012-11","2011-08",678,[24],[5893,5894,1779,5862],"Canagliflozin 100mg","Canagliflozin 300mg",{"nctId":5896,"briefTitle":5897,"status":105,"phases":5898,"primaryCompletion":4850,"completion":5899,"start":2486,"enrollment":5900,"conditions":5901,"interventions":5902},"NCT01106690","The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)",[89],"2012-07",344,[24],[5826,5903,1779,5904],"Sitagliptin","Pioglitazone",{"trials":5906,"activeCount":99},[5907],{"nctId":5908,"briefTitle":5909,"status":105,"phases":5910,"primaryCompletion":5911,"completion":5911,"start":5912,"enrollment":1787,"conditions":5913,"interventions":5914},"NCT03267576","An Efficacy Study of Canagliflozin or Sitagliptin to Determine Glucose Variability in Mexican Participants With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin",[90],"2018-10-01","2017-10-27",[24],[5861,5860,1779],{"trials":5916,"activeCount":99},[],{"intervention":1587,"totalTrials":245,"cells":5918},{"EARLY_PHASE1":5919,"PHASE1":5921,"PHASE2":5923,"PHASE3":5934,"PHASE4":5940,"NA":5942},{"trials":5920,"activeCount":99},[],{"trials":5922,"activeCount":99},[],{"trials":5924,"activeCount":468,"soonestReadout":2063},[5925],{"nctId":5926,"briefTitle":5927,"status":192,"phases":5928,"primaryCompletion":2063,"completion":511,"start":5929,"enrollment":5930,"conditions":5931,"interventions":5933},"NCT02908906","A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers",[87,88],"2016-11-21",413,[5932],"Neoplasms",[1587],{"trials":5935,"activeCount":99},[5936],{"nctId":1579,"briefTitle":1580,"status":105,"phases":5937,"primaryCompletion":1582,"completion":1583,"start":1584,"enrollment":893,"conditions":5938,"interventions":5939},[88,89],[18],[681,1587],{"trials":5941,"activeCount":99},[],{"trials":5943,"activeCount":99},[],{"intervention":5945,"totalTrials":571,"cells":5946},"Bedaquiline",{"EARLY_PHASE1":5947,"PHASE1":5949,"PHASE2":5966,"PHASE3":5979,"PHASE4":5981,"NA":5983},{"trials":5948,"activeCount":99},[],{"trials":5950,"activeCount":99},[5951,5959],{"nctId":5952,"briefTitle":5953,"status":105,"phases":5954,"primaryCompletion":5955,"completion":5955,"start":5956,"enrollment":169,"conditions":5957,"interventions":5958},"NCT03800550","A Study to Assess the Drug-Drug Interaction Between Bedaquiline and Clarithromycin in Healthy Adult Participants",[87],"2019-06-04","2019-02-13",[15],[5945,5496],{"nctId":5960,"briefTitle":5961,"status":105,"phases":5962,"primaryCompletion":1506,"completion":1506,"start":5963,"enrollment":1532,"conditions":5964,"interventions":5965},"NCT04087759","A Study of Bedaquiline 100 Milligram (mg) Tablets Administered as Different Test Formulations Compared to the Commercial Tablet Formulation (F001) in Healthy Adult Participants",[87],"2019-09-16",[15],[5945,5945],{"trials":5967,"activeCount":468,"soonestReadout":5972},[5968],{"nctId":5969,"briefTitle":5970,"status":304,"phases":5971,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":656,"conditions":5975,"interventions":5977},"NCT02354014","Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children\u002FAdolescents With Pulmonary MDR-TB",[88],"2027-02-11","2028-11-02","2016-05-03",[5976],"Tuberculosis, Multidrug-Resistant",[5945,5978],"Background Regimen",{"trials":5980,"activeCount":99},[],{"trials":5982,"activeCount":99},[],{"trials":5984,"activeCount":99},[],{"intervention":5986,"totalTrials":245,"cells":5987},"Dupilumab",{"EARLY_PHASE1":5988,"PHASE1":5990,"PHASE2":5992,"PHASE3":6015,"PHASE4":6017,"NA":6019},{"trials":5989,"activeCount":99},[],{"trials":5991,"activeCount":99},[],{"trials":5993,"activeCount":468,"soonestReadout":6008},[5994,6004],{"nctId":5995,"briefTitle":5996,"status":125,"phases":5997,"primaryCompletion":5998,"completion":5999,"start":512,"enrollment":2065,"conditions":6000,"interventions":6002},"NCT04791319","A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis",[88],"2022-02-02","2022-03-31",[6001],"Dermatitis, Atopic",[6003,5986],"Bermekimab",{"nctId":6005,"briefTitle":6006,"status":192,"phases":6007,"primaryCompletion":6008,"completion":6009,"start":6010,"enrollment":6011,"conditions":6012,"interventions":6013},"NCT06881251","A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)",[88],"2026-03-09","2026-03-26","2025-02-26",256,[6001],[5986,6014],"JNJ-95475939",{"trials":6016,"activeCount":99},[],{"trials":6018,"activeCount":99},[],{"trials":6020,"activeCount":99},[],{"intervention":1843,"totalTrials":245,"cells":6022},{"EARLY_PHASE1":6023,"PHASE1":6025,"PHASE2":6027,"PHASE3":6043,"PHASE4":6045,"NA":6047},{"trials":6024,"activeCount":99},[],{"trials":6026,"activeCount":99},[],{"trials":6028,"activeCount":468,"soonestReadout":1835},[6029,6039],{"nctId":6030,"briefTitle":6031,"status":125,"phases":6032,"primaryCompletion":6033,"completion":6033,"start":6034,"enrollment":1857,"conditions":6035,"interventions":6037},"NCT01809340","The Effect of Minocycline on Relapse After Successful Intravenous Ketamine\u002FMinocycline-induced Symptoms Response in Subjects With Depression",[88],"2014-07","2013-06",[6036],"Depressive Disorder",[1843,6038],"Ketamine",{"nctId":1832,"briefTitle":1833,"status":192,"phases":6040,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6041,"interventions":6042},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6044,"activeCount":99},[],{"trials":6046,"activeCount":99},[],{"trials":6048,"activeCount":99},[],{"intervention":2558,"totalTrials":245,"cells":6050},{"EARLY_PHASE1":6051,"PHASE1":6053,"PHASE2":6055,"PHASE3":6072,"PHASE4":6074,"NA":6076},{"trials":6052,"activeCount":99},[],{"trials":6054,"activeCount":99},[],{"trials":6056,"activeCount":468,"soonestReadout":6061},[6057,6068],{"nctId":6058,"briefTitle":6059,"status":304,"phases":6060,"primaryCompletion":6061,"completion":6062,"start":6063,"enrollment":6064,"conditions":6065,"interventions":6067},"NCT06635148","A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)",[88],"2029-08-24","2030-07-16","2024-09-19",274,[2556,6066],"Macular Degeneration",[2558],{"nctId":2550,"briefTitle":2551,"status":105,"phases":6069,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":1838,"conditions":6070,"interventions":6071},[88],[2556],[2558,496,2559],{"trials":6073,"activeCount":99},[],{"trials":6075,"activeCount":99},[],{"trials":6077,"activeCount":99},[],{"intervention":6079,"totalTrials":245,"cells":6080},"Cetrelimab 480 mg",{"EARLY_PHASE1":6081,"PHASE1":6083,"PHASE2":6095,"PHASE3":6105,"PHASE4":6107,"NA":6109},{"trials":6082,"activeCount":99},[],{"trials":6084,"activeCount":99},[6085],{"nctId":6086,"briefTitle":6087,"status":105,"phases":6088,"primaryCompletion":6089,"completion":6089,"start":6090,"enrollment":2515,"conditions":6091,"interventions":6093},"NCT03551782","A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer",[87],"2021-11-11","2018-06-28",[6092],"Castration-Resistant Prostatic Neoplasms",[6079,6094],"Apalutamide 240 mg",{"trials":6096,"activeCount":468,"soonestReadout":50},[6097],{"nctId":48,"briefTitle":49,"status":192,"phases":6098,"primaryCompletion":50,"completion":511,"start":6099,"enrollment":2501,"conditions":6100,"interventions":6101},[88],"2018-03-02",[585],[51,6102,6079,6103,6104],"Cetrelimab 240 mg","Abiraterone acetate 1000 mg","Prednisone 5 mg",{"trials":6106,"activeCount":99},[],{"trials":6108,"activeCount":99},[],{"trials":6110,"activeCount":99},[],{"intervention":878,"totalTrials":245,"cells":6112},{"EARLY_PHASE1":6113,"PHASE1":6115,"PHASE2":6121,"PHASE3":6127,"PHASE4":6129,"NA":6131},{"trials":6114,"activeCount":99},[],{"trials":6116,"activeCount":99},[6117],{"nctId":1157,"briefTitle":1158,"status":105,"phases":6118,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":6119,"interventions":6120},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":6122,"activeCount":468,"soonestReadout":875},[6123],{"nctId":872,"briefTitle":873,"status":192,"phases":6124,"primaryCompletion":875,"completion":830,"start":831,"enrollment":809,"conditions":6125,"interventions":6126},[88],[35],[684,878,879,84,759],{"trials":6128,"activeCount":99},[],{"trials":6130,"activeCount":99},[],{"trials":6132,"activeCount":99},[],{"intervention":660,"totalTrials":468,"cells":6134},{"EARLY_PHASE1":6135,"PHASE1":6137,"PHASE2":6139,"PHASE3":6145,"PHASE4":6147,"NA":6149},{"trials":6136,"activeCount":99},[],{"trials":6138,"activeCount":99},[],{"trials":6140,"activeCount":468,"soonestReadout":653},[6141],{"nctId":650,"briefTitle":651,"status":304,"phases":6142,"primaryCompletion":653,"completion":654,"start":655,"enrollment":656,"conditions":6143,"interventions":6144},[88],[18],[640,659,660,661],{"trials":6146,"activeCount":99},[],{"trials":6148,"activeCount":99},[],{"trials":6150,"activeCount":99},[],{"intervention":786,"totalTrials":468,"cells":6152},{"EARLY_PHASE1":6153,"PHASE1":6155,"PHASE2":6157,"PHASE3":6163,"PHASE4":6165,"NA":6167},{"trials":6154,"activeCount":99},[],{"trials":6156,"activeCount":99},[],{"trials":6158,"activeCount":468,"soonestReadout":778},[6159],{"nctId":775,"briefTitle":776,"status":304,"phases":6160,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":6161,"interventions":6162},[87,88],[783],[785,786,787,788,789,84],{"trials":6164,"activeCount":99},[],{"trials":6166,"activeCount":99},[],{"trials":6168,"activeCount":99},[],{"intervention":787,"totalTrials":468,"cells":6170},{"EARLY_PHASE1":6171,"PHASE1":6173,"PHASE2":6175,"PHASE3":6181,"PHASE4":6183,"NA":6185},{"trials":6172,"activeCount":99},[],{"trials":6174,"activeCount":99},[],{"trials":6176,"activeCount":468,"soonestReadout":778},[6177],{"nctId":775,"briefTitle":776,"status":304,"phases":6178,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":6179,"interventions":6180},[87,88],[783],[785,786,787,788,789,84],{"trials":6182,"activeCount":99},[],{"trials":6184,"activeCount":99},[],{"trials":6186,"activeCount":99},[],{"intervention":800,"totalTrials":468,"cells":6188},{"EARLY_PHASE1":6189,"PHASE1":6191,"PHASE2":6193,"PHASE3":6199,"PHASE4":6201,"NA":6203},{"trials":6190,"activeCount":99},[],{"trials":6192,"activeCount":99},[],{"trials":6194,"activeCount":468,"soonestReadout":794},[6195],{"nctId":791,"briefTitle":792,"status":304,"phases":6196,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":6197,"interventions":6198},[88],[35],[84,759,800,801],{"trials":6200,"activeCount":99},[],{"trials":6202,"activeCount":99},[],{"trials":6204,"activeCount":99},[],{"intervention":801,"totalTrials":468,"cells":6206},{"EARLY_PHASE1":6207,"PHASE1":6209,"PHASE2":6211,"PHASE3":6217,"PHASE4":6219,"NA":6221},{"trials":6208,"activeCount":99},[],{"trials":6210,"activeCount":99},[],{"trials":6212,"activeCount":468,"soonestReadout":794},[6213],{"nctId":791,"briefTitle":792,"status":304,"phases":6214,"primaryCompletion":794,"completion":795,"start":796,"enrollment":797,"conditions":6215,"interventions":6216},[88],[35],[84,759,800,801],{"trials":6218,"activeCount":99},[],{"trials":6220,"activeCount":99},[],{"trials":6222,"activeCount":99},[],{"intervention":824,"totalTrials":468,"cells":6224},{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6229,"PHASE3":6235,"PHASE4":6237,"NA":6239},{"trials":6226,"activeCount":99},[],{"trials":6228,"activeCount":99},[],{"trials":6230,"activeCount":468,"soonestReadout":816},[6231],{"nctId":813,"briefTitle":814,"status":304,"phases":6232,"primaryCompletion":816,"completion":817,"start":818,"enrollment":819,"conditions":6233,"interventions":6234},[87,88],[821],[84,823,824,760],{"trials":6236,"activeCount":99},[],{"trials":6238,"activeCount":99},[],{"trials":6240,"activeCount":99},[],{"intervention":1703,"totalTrials":468,"cells":6242},{"EARLY_PHASE1":6243,"PHASE1":6245,"PHASE2":6247,"PHASE3":6253,"PHASE4":6255,"NA":6257},{"trials":6244,"activeCount":99},[],{"trials":6246,"activeCount":99},[],{"trials":6248,"activeCount":468,"soonestReadout":1699},[6249],{"nctId":1696,"briefTitle":1697,"status":304,"phases":6250,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":6251,"interventions":6252},[88],[18],[70,1703,1704,1705,1706,1707],{"trials":6254,"activeCount":99},[],{"trials":6256,"activeCount":99},[],{"trials":6258,"activeCount":99},[],{"intervention":1704,"totalTrials":468,"cells":6260},{"EARLY_PHASE1":6261,"PHASE1":6263,"PHASE2":6265,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6262,"activeCount":99},[],{"trials":6264,"activeCount":99},[],{"trials":6266,"activeCount":468,"soonestReadout":1699},[6267],{"nctId":1696,"briefTitle":1697,"status":304,"phases":6268,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":6269,"interventions":6270},[88],[18],[70,1703,1704,1705,1706,1707],{"trials":6272,"activeCount":99},[],{"trials":6274,"activeCount":99},[],{"trials":6276,"activeCount":99},[],{"intervention":1705,"totalTrials":468,"cells":6278},{"EARLY_PHASE1":6279,"PHASE1":6281,"PHASE2":6283,"PHASE3":6289,"PHASE4":6291,"NA":6293},{"trials":6280,"activeCount":99},[],{"trials":6282,"activeCount":99},[],{"trials":6284,"activeCount":468,"soonestReadout":1699},[6285],{"nctId":1696,"briefTitle":1697,"status":304,"phases":6286,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":6287,"interventions":6288},[88],[18],[70,1703,1704,1705,1706,1707],{"trials":6290,"activeCount":99},[],{"trials":6292,"activeCount":99},[],{"trials":6294,"activeCount":99},[],{"intervention":1706,"totalTrials":468,"cells":6296},{"EARLY_PHASE1":6297,"PHASE1":6299,"PHASE2":6301,"PHASE3":6307,"PHASE4":6309,"NA":6311},{"trials":6298,"activeCount":99},[],{"trials":6300,"activeCount":99},[],{"trials":6302,"activeCount":468,"soonestReadout":1699},[6303],{"nctId":1696,"briefTitle":1697,"status":304,"phases":6304,"primaryCompletion":1699,"completion":1699,"start":1700,"enrollment":1232,"conditions":6305,"interventions":6306},[88],[18],[70,1703,1704,1705,1706,1707],{"trials":6308,"activeCount":99},[],{"trials":6310,"activeCount":99},[],{"trials":6312,"activeCount":99},[],{"intervention":6314,"totalTrials":468,"cells":6315},"JNJ-95597528",{"EARLY_PHASE1":6316,"PHASE1":6318,"PHASE2":6320,"PHASE3":6331,"PHASE4":6333,"NA":6335},{"trials":6317,"activeCount":99},[],{"trials":6319,"activeCount":99},[],{"trials":6321,"activeCount":468,"soonestReadout":6326},[6322],{"nctId":6323,"briefTitle":6324,"status":304,"phases":6325,"primaryCompletion":6326,"completion":6327,"start":6328,"enrollment":2846,"conditions":6329,"interventions":6330},"NCT07230860","A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis",[88],"2026-11-19","2028-02-10","2026-01-20",[6001],[6314],{"trials":6332,"activeCount":99},[],{"trials":6334,"activeCount":99},[],{"trials":6336,"activeCount":99},[],{"intervention":852,"totalTrials":468,"cells":6338},{"EARLY_PHASE1":6339,"PHASE1":6341,"PHASE2":6343,"PHASE3":6349,"PHASE4":6351,"NA":6353},{"trials":6340,"activeCount":99},[],{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":468,"soonestReadout":847},[6345],{"nctId":844,"briefTitle":845,"status":304,"phases":6346,"primaryCompletion":847,"completion":848,"start":849,"enrollment":656,"conditions":6347,"interventions":6348},[87,88],[35],[84,852],{"trials":6350,"activeCount":99},[],{"trials":6352,"activeCount":99},[],{"trials":6354,"activeCount":99},[],{"intervention":1841,"totalTrials":468,"cells":6356},{"EARLY_PHASE1":6357,"PHASE1":6359,"PHASE2":6361,"PHASE3":6367,"PHASE4":6369,"NA":6371},{"trials":6358,"activeCount":99},[],{"trials":6360,"activeCount":99},[],{"trials":6362,"activeCount":468,"soonestReadout":1835},[6363],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6364,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6365,"interventions":6366},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6368,"activeCount":99},[],{"trials":6370,"activeCount":99},[],{"trials":6372,"activeCount":99},[],{"intervention":1842,"totalTrials":468,"cells":6374},{"EARLY_PHASE1":6375,"PHASE1":6377,"PHASE2":6379,"PHASE3":6385,"PHASE4":6387,"NA":6389},{"trials":6376,"activeCount":99},[],{"trials":6378,"activeCount":99},[],{"trials":6380,"activeCount":468,"soonestReadout":1835},[6381],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6382,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6383,"interventions":6384},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6386,"activeCount":99},[],{"trials":6388,"activeCount":99},[],{"trials":6390,"activeCount":99},[],{"intervention":1844,"totalTrials":468,"cells":6392},{"EARLY_PHASE1":6393,"PHASE1":6395,"PHASE2":6397,"PHASE3":6403,"PHASE4":6405,"NA":6407},{"trials":6394,"activeCount":99},[],{"trials":6396,"activeCount":99},[],{"trials":6398,"activeCount":468,"soonestReadout":1835},[6399],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6400,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6401,"interventions":6402},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6404,"activeCount":99},[],{"trials":6406,"activeCount":99},[],{"trials":6408,"activeCount":99},[],{"intervention":1845,"totalTrials":468,"cells":6410},{"EARLY_PHASE1":6411,"PHASE1":6413,"PHASE2":6415,"PHASE3":6421,"PHASE4":6423,"NA":6425},{"trials":6412,"activeCount":99},[],{"trials":6414,"activeCount":99},[],{"trials":6416,"activeCount":468,"soonestReadout":1835},[6417],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6418,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6419,"interventions":6420},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6422,"activeCount":99},[],{"trials":6424,"activeCount":99},[],{"trials":6426,"activeCount":99},[],{"intervention":1846,"totalTrials":468,"cells":6428},{"EARLY_PHASE1":6429,"PHASE1":6431,"PHASE2":6433,"PHASE3":6439,"PHASE4":6441,"NA":6443},{"trials":6430,"activeCount":99},[],{"trials":6432,"activeCount":99},[],{"trials":6434,"activeCount":468,"soonestReadout":1835},[6435],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6436,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6437,"interventions":6438},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6440,"activeCount":99},[],{"trials":6442,"activeCount":99},[],{"trials":6444,"activeCount":99},[],{"intervention":1847,"totalTrials":468,"cells":6446},{"EARLY_PHASE1":6447,"PHASE1":6449,"PHASE2":6451,"PHASE3":6457,"PHASE4":6459,"NA":6461},{"trials":6448,"activeCount":99},[],{"trials":6450,"activeCount":99},[],{"trials":6452,"activeCount":468,"soonestReadout":1835},[6453],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6454,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6455,"interventions":6456},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6458,"activeCount":99},[],{"trials":6460,"activeCount":99},[],{"trials":6462,"activeCount":99},[],{"intervention":1848,"totalTrials":468,"cells":6464},{"EARLY_PHASE1":6465,"PHASE1":6467,"PHASE2":6469,"PHASE3":6475,"PHASE4":6477,"NA":6479},{"trials":6466,"activeCount":99},[],{"trials":6468,"activeCount":99},[],{"trials":6470,"activeCount":468,"soonestReadout":1835},[6471],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6472,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6473,"interventions":6474},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6476,"activeCount":99},[],{"trials":6478,"activeCount":99},[],{"trials":6480,"activeCount":99},[],{"intervention":1849,"totalTrials":468,"cells":6482},{"EARLY_PHASE1":6483,"PHASE1":6485,"PHASE2":6487,"PHASE3":6493,"PHASE4":6495,"NA":6497},{"trials":6484,"activeCount":99},[],{"trials":6486,"activeCount":99},[],{"trials":6488,"activeCount":468,"soonestReadout":1835},[6489],{"nctId":1832,"briefTitle":1833,"status":192,"phases":6490,"primaryCompletion":1835,"completion":1836,"start":1837,"enrollment":1838,"conditions":6491,"interventions":6492},[88],[35],[785,1841,759,1842,1843,1844,1845,1846,1847,1848,1849],{"trials":6494,"activeCount":99},[],{"trials":6496,"activeCount":99},[],{"trials":6498,"activeCount":99},[],{"intervention":6500,"totalTrials":468,"cells":6501},"JNJ-88545223",{"EARLY_PHASE1":6502,"PHASE1":6504,"PHASE2":6506,"PHASE3":6515,"PHASE4":6517,"NA":6519},{"trials":6503,"activeCount":99},[],{"trials":6505,"activeCount":99},[],{"trials":6507,"activeCount":468,"soonestReadout":6512},[6508],{"nctId":6509,"briefTitle":6510,"status":304,"phases":6511,"primaryCompletion":6512,"completion":955,"start":2042,"enrollment":1163,"conditions":6513,"interventions":6514},"NCT07321873","A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis",[88],"2027-06-28",[131],[6500],{"trials":6516,"activeCount":99},[],{"trials":6518,"activeCount":99},[],{"trials":6520,"activeCount":99},[],{"intervention":6522,"totalTrials":468,"cells":6523},"Erdafitinib Intravesical Delivery System",{"EARLY_PHASE1":6524,"PHASE1":6526,"PHASE2":6528,"PHASE3":6540,"PHASE4":6542,"NA":6544},{"trials":6525,"activeCount":99},[],{"trials":6527,"activeCount":99},[],{"trials":6529,"activeCount":468,"soonestReadout":6534},[6530],{"nctId":6531,"briefTitle":6532,"status":304,"phases":6533,"primaryCompletion":6534,"completion":6535,"start":6536,"enrollment":6537,"conditions":6538,"interventions":6539},"NCT05316155","Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer",[87,88],"2028-03-30","2029-07-24","2022-04-11",235,[2987],[6522],{"trials":6541,"activeCount":99},[],{"trials":6543,"activeCount":99},[],{"trials":6545,"activeCount":99},[],{"intervention":6547,"totalTrials":468,"cells":6548},"Prizloncabtagene autoleucel",{"EARLY_PHASE1":6549,"PHASE1":6551,"PHASE2":6553,"PHASE3":6566,"PHASE4":6568,"NA":6570},{"trials":6550,"activeCount":99},[],{"trials":6552,"activeCount":99},[],{"trials":6554,"activeCount":468,"soonestReadout":6559},[6555],{"nctId":6556,"briefTitle":6557,"status":304,"phases":6558,"primaryCompletion":6559,"completion":6560,"start":6561,"enrollment":6562,"conditions":6563,"interventions":6565},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[87,88],"2028-12-29","2029-03-12","2022-08-12",439,[1382,6564,1535],"Lymphoma, B-Cell",[6547],{"trials":6567,"activeCount":99},[],{"trials":6569,"activeCount":99},[],{"trials":6571,"activeCount":99},[],{"intervention":6014,"totalTrials":468,"cells":6573},{"EARLY_PHASE1":6574,"PHASE1":6576,"PHASE2":6578,"PHASE3":6584,"PHASE4":6586,"NA":6588},{"trials":6575,"activeCount":99},[],{"trials":6577,"activeCount":99},[],{"trials":6579,"activeCount":468,"soonestReadout":6008},[6580],{"nctId":6005,"briefTitle":6006,"status":192,"phases":6581,"primaryCompletion":6008,"completion":6009,"start":6010,"enrollment":6011,"conditions":6582,"interventions":6583},[88],[6001],[5986,6014],{"trials":6585,"activeCount":99},[],{"trials":6587,"activeCount":99},[],{"trials":6589,"activeCount":99},[],{"intervention":5801,"totalTrials":468,"cells":6591},{"EARLY_PHASE1":6592,"PHASE1":6594,"PHASE2":6596,"PHASE3":6602,"PHASE4":6604,"NA":6606},{"trials":6593,"activeCount":99},[],{"trials":6595,"activeCount":99},[],{"trials":6597,"activeCount":468,"soonestReadout":5796},[6598],{"nctId":5793,"briefTitle":5794,"status":272,"phases":6599,"primaryCompletion":5796,"completion":5797,"start":5798,"enrollment":5651,"conditions":6600,"interventions":6601},[88],[18],[1707,5801],{"trials":6603,"activeCount":99},[],{"trials":6605,"activeCount":99},[],{"trials":6607,"activeCount":99},[],{"intervention":863,"totalTrials":468,"cells":6609},{"EARLY_PHASE1":6610,"PHASE1":6612,"PHASE2":6614,"PHASE3":6620,"PHASE4":6622,"NA":6624},{"trials":6611,"activeCount":99},[],{"trials":6613,"activeCount":99},[],{"trials":6615,"activeCount":468,"soonestReadout":857},[6616],{"nctId":854,"briefTitle":855,"status":192,"phases":6617,"primaryCompletion":857,"completion":858,"start":859,"enrollment":860,"conditions":6618,"interventions":6619},[87,88],[35],[863,84],{"trials":6621,"activeCount":99},[],{"trials":6623,"activeCount":99},[],{"trials":6625,"activeCount":99},[],{"intervention":2056,"totalTrials":468,"cells":6627},{"EARLY_PHASE1":6628,"PHASE1":6630,"PHASE2":6632,"PHASE3":6638,"PHASE4":6640,"NA":6642},{"trials":6629,"activeCount":99},[],{"trials":6631,"activeCount":99},[],{"trials":6633,"activeCount":468,"soonestReadout":2050},[6634],{"nctId":2047,"briefTitle":2048,"status":192,"phases":6635,"primaryCompletion":2050,"completion":2051,"start":2052,"enrollment":1532,"conditions":6636,"interventions":6637},[88],[2054],[1953,2056],{"trials":6639,"activeCount":99},[],{"trials":6641,"activeCount":99},[],{"trials":6643,"activeCount":99},[],{"intervention":6645,"totalTrials":468,"cells":6646},"JNJ-89495120",{"EARLY_PHASE1":6647,"PHASE1":6649,"PHASE2":6651,"PHASE3":6659,"PHASE4":6661,"NA":6663},{"trials":6648,"activeCount":99},[],{"trials":6650,"activeCount":99},[],{"trials":6652,"activeCount":468,"soonestReadout":2127},[6653],{"nctId":6654,"briefTitle":6655,"status":304,"phases":6656,"primaryCompletion":2127,"completion":2127,"start":2010,"enrollment":1480,"conditions":6657,"interventions":6658},"NCT06785012","A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder",[88],[21],[6645],{"trials":6660,"activeCount":99},[],{"trials":6662,"activeCount":99},[],{"trials":6664,"activeCount":99},[],{"intervention":51,"totalTrials":468,"cells":6666},{"EARLY_PHASE1":6667,"PHASE1":6669,"PHASE2":6671,"PHASE3":6677,"PHASE4":6679,"NA":6681},{"trials":6668,"activeCount":99},[],{"trials":6670,"activeCount":99},[],{"trials":6672,"activeCount":468,"soonestReadout":50},[6673],{"nctId":48,"briefTitle":49,"status":192,"phases":6674,"primaryCompletion":50,"completion":511,"start":6099,"enrollment":2501,"conditions":6675,"interventions":6676},[88],[585],[51,6102,6079,6103,6104],{"trials":6678,"activeCount":99},[],{"trials":6680,"activeCount":99},[],{"trials":6682,"activeCount":99},[],{"intervention":6102,"totalTrials":468,"cells":6684},{"EARLY_PHASE1":6685,"PHASE1":6687,"PHASE2":6689,"PHASE3":6695,"PHASE4":6697,"NA":6699},{"trials":6686,"activeCount":99},[],{"trials":6688,"activeCount":99},[],{"trials":6690,"activeCount":468,"soonestReadout":50},[6691],{"nctId":48,"briefTitle":49,"status":192,"phases":6692,"primaryCompletion":50,"completion":511,"start":6099,"enrollment":2501,"conditions":6693,"interventions":6694},[88],[585],[51,6102,6079,6103,6104],{"trials":6696,"activeCount":99},[],{"trials":6698,"activeCount":99},[],{"trials":6700,"activeCount":99},[],{"intervention":6103,"totalTrials":468,"cells":6702},{"EARLY_PHASE1":6703,"PHASE1":6705,"PHASE2":6707,"PHASE3":6713,"PHASE4":6715,"NA":6717},{"trials":6704,"activeCount":99},[],{"trials":6706,"activeCount":99},[],{"trials":6708,"activeCount":468,"soonestReadout":50},[6709],{"nctId":48,"briefTitle":49,"status":192,"phases":6710,"primaryCompletion":50,"completion":511,"start":6099,"enrollment":2501,"conditions":6711,"interventions":6712},[88],[585],[51,6102,6079,6103,6104],{"trials":6714,"activeCount":99},[],{"trials":6716,"activeCount":99},[],{"trials":6718,"activeCount":99},[],{"intervention":6104,"totalTrials":468,"cells":6720},{"EARLY_PHASE1":6721,"PHASE1":6723,"PHASE2":6725,"PHASE3":6731,"PHASE4":6733,"NA":6735},{"trials":6722,"activeCount":99},[],{"trials":6724,"activeCount":99},[],{"trials":6726,"activeCount":468,"soonestReadout":50},[6727],{"nctId":48,"briefTitle":49,"status":192,"phases":6728,"primaryCompletion":50,"completion":511,"start":6099,"enrollment":2501,"conditions":6729,"interventions":6730},[88],[585],[51,6102,6079,6103,6104],{"trials":6732,"activeCount":99},[],{"trials":6734,"activeCount":99},[],{"trials":6736,"activeCount":99},[],{"intervention":892,"totalTrials":468,"cells":6738},{"EARLY_PHASE1":6739,"PHASE1":6741,"PHASE2":6743,"PHASE3":6749,"PHASE4":6751,"NA":6753},{"trials":6740,"activeCount":99},[],{"trials":6742,"activeCount":99},[],{"trials":6744,"activeCount":468,"soonestReadout":884},[6745],{"nctId":881,"briefTitle":882,"status":304,"phases":6746,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":6747,"interventions":6748},[88],[889],[84,759,760,761,891,892],{"trials":6750,"activeCount":99},[],{"trials":6752,"activeCount":99},[],{"trials":6754,"activeCount":99},[],{"intervention":5978,"totalTrials":468,"cells":6756},{"EARLY_PHASE1":6757,"PHASE1":6759,"PHASE2":6761,"PHASE3":6767,"PHASE4":6769,"NA":6771},{"trials":6758,"activeCount":99},[],{"trials":6760,"activeCount":99},[],{"trials":6762,"activeCount":468,"soonestReadout":5972},[6763],{"nctId":5969,"briefTitle":5970,"status":304,"phases":6764,"primaryCompletion":5972,"completion":5973,"start":5974,"enrollment":656,"conditions":6765,"interventions":6766},[88],[5976],[5945,5978],{"trials":6768,"activeCount":99},[],{"trials":6770,"activeCount":99},[],{"trials":6772,"activeCount":99},[],{"intervention":879,"totalTrials":109,"cells":6774},{"EARLY_PHASE1":6775,"PHASE1":6777,"PHASE2":6779,"PHASE3":6817,"PHASE4":6833,"NA":6835},{"trials":6776,"activeCount":99},[],{"trials":6778,"activeCount":99},[],{"trials":6780,"activeCount":468,"soonestReadout":875},[6781,6789,6800,6809,6813],{"nctId":6782,"briefTitle":6783,"status":125,"phases":6784,"primaryCompletion":6033,"completion":6033,"start":3328,"enrollment":1419,"conditions":6785,"interventions":6787},"NCT01862224","A Synovial Biopsy Study of JNJ-38518168 in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[88],[6786],"Rheumatoid Arthritis",[6788,879],"JNJ-38518168",{"nctId":6790,"briefTitle":6791,"status":105,"phases":6792,"primaryCompletion":3444,"completion":3613,"start":6034,"enrollment":6793,"conditions":6794,"interventions":6795},"NCT01909427","An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy",[88],257,[6786],[6796,6796,6797,6798,6799,879],"CNTO 6785 200 mg","CNTO 6785 100 mg","CNTO 6785 50 mg","CNTO 6785 15 mg",{"nctId":6801,"briefTitle":6802,"status":125,"phases":6803,"primaryCompletion":6804,"completion":6805,"start":6806,"enrollment":2985,"conditions":6807,"interventions":6808},"NCT01679951","A Dose Range Finding Study of JNJ-38518168 in Patients With Active Rheumatoid Arthritis in Spite of Treatment With Methotrexate",[88],"2014-04-17","2014-07-03","2012-10-31",[6786],[6788,6788,6788,879],{"nctId":872,"briefTitle":873,"status":192,"phases":6810,"primaryCompletion":875,"completion":830,"start":831,"enrollment":809,"conditions":6811,"interventions":6812},[88],[35],[684,878,879,84,759],{"nctId":1547,"briefTitle":1548,"status":105,"phases":6814,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":6815,"interventions":6816},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":6818,"activeCount":99},[6819,6829],{"nctId":6820,"briefTitle":6821,"status":125,"phases":6822,"primaryCompletion":6823,"completion":2217,"start":1176,"enrollment":6824,"conditions":6825,"interventions":6827},"NCT01230827","A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)",[89],"2013-09",173,[6826],"Juvenile Idiopathic Arthritis",[6828,879],"CNTO 148",{"nctId":4254,"briefTitle":4255,"status":105,"phases":6830,"primaryCompletion":4257,"completion":4258,"start":4259,"enrollment":4260,"conditions":6831,"interventions":6832},[89],[322],[201,879],{"trials":6834,"activeCount":99},[],{"trials":6836,"activeCount":99},[6837],{"nctId":6838,"briefTitle":6839,"status":105,"phases":6840,"primaryCompletion":6841,"completion":6841,"start":6842,"enrollment":6843,"conditions":6844,"interventions":6846},"NCT04571697","A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy",[],"2020-10-27","2020-09-28",34647,[6845,4445],"Dementia",[879,6847],"Anti-TNF",{"intervention":1235,"totalTrials":571,"cells":6849},{"EARLY_PHASE1":6850,"PHASE1":6852,"PHASE2":6854,"PHASE3":6868,"PHASE4":6870,"NA":6872},{"trials":6851,"activeCount":99},[],{"trials":6853,"activeCount":99},[],{"trials":6855,"activeCount":468,"soonestReadout":462},[6856,6860],{"nctId":1228,"briefTitle":1229,"status":192,"phases":6857,"primaryCompletion":462,"completion":1231,"start":502,"enrollment":1232,"conditions":6858,"interventions":6859},[88],[18],[1235,683,681,682,684],{"nctId":6861,"briefTitle":6862,"status":105,"phases":6863,"primaryCompletion":6864,"completion":6864,"start":5595,"enrollment":6865,"conditions":6866,"interventions":6867},"NCT03548207","A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-Cell Maturation Antigen (BCMA) in Participants With Relapsed or Refractory Multiple Myeloma",[87,88],"2022-08-23",126,[18],[1235],{"trials":6869,"activeCount":99},[],{"trials":6871,"activeCount":99},[],{"trials":6873,"activeCount":99},[6874],{"nctId":6875,"briefTitle":6876,"status":474,"phases":6877,"conditions":6878,"interventions":6879},"NCT04452994","Individual Patient Investigational New Drug (IND) Expanded Access Program of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Participant With Multiple Myeloma",[],[18],[1235],{"intervention":6881,"totalTrials":245,"cells":6882},"AAV5-hRKp.RPGR",{"EARLY_PHASE1":6883,"PHASE1":6885,"PHASE2":6887,"PHASE3":6897,"PHASE4":6899,"NA":6901},{"trials":6884,"activeCount":99},[],{"trials":6886,"activeCount":99},[],{"trials":6888,"activeCount":468,"soonestReadout":6893},[6889],{"nctId":6890,"briefTitle":6891,"status":192,"phases":6892,"primaryCompletion":6893,"completion":6893,"start":6894,"enrollment":3586,"conditions":6895,"interventions":6896},"NCT06646289","A Follow-on Study for Second-Eye Treatment for Participants Previously Treated With Gene Therapy for X-Linked Retinitis Pigmentosa (XLRP)",[88],"2030-10-24","2024-10-10",[5173],[6881],{"trials":6898,"activeCount":99},[],{"trials":6900,"activeCount":99},[],{"trials":6902,"activeCount":99},[6903],{"nctId":6904,"briefTitle":6905,"status":105,"phases":6906,"primaryCompletion":6907,"completion":6907,"start":6908,"enrollment":6909,"conditions":6910,"interventions":6911},"NCT04312672","Long-term Follow-up Gene Therapy Study for RPGR- XLRP",[],"2025-09-17","2017-07-31",42,[5173],[6881],{"intervention":6913,"totalTrials":245,"cells":6914},"Direct oral anticoagulant",{"EARLY_PHASE1":6915,"PHASE1":6917,"PHASE2":6919,"PHASE3":6925,"PHASE4":6927,"NA":6929},{"trials":6916,"activeCount":99},[],{"trials":6918,"activeCount":99},[],{"trials":6920,"activeCount":468,"soonestReadout":884},[6921],{"nctId":881,"briefTitle":882,"status":304,"phases":6922,"primaryCompletion":884,"completion":885,"start":886,"enrollment":887,"conditions":6923,"interventions":6924},[88],[889],[84,759,760,761,891,892],{"trials":6926,"activeCount":99},[],{"trials":6928,"activeCount":99},[],{"trials":6930,"activeCount":99},[6931],{"nctId":6932,"briefTitle":6933,"status":105,"phases":6934,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":6937,"conditions":6938,"interventions":6940},"NCT04394234","A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants",[],"2020-06-01","2020-05-15",961985,[6939],"Uterine Hemorrhage",[6913,174],{"intervention":6942,"totalTrials":352,"cells":6943},"JNJ-80948543",{"EARLY_PHASE1":6944,"PHASE1":6946,"PHASE2":6990,"PHASE3":6992,"PHASE4":6994,"NA":6996},{"trials":6945,"activeCount":99},[],{"trials":6947,"activeCount":352,"soonestReadout":6968},[6948,6964,6973,6982],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":6952,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":6954,"interventions":6956},"NCT06788509","A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring","ENROLLING_BY_INVITATION",[87],"2028-01-19",[2894,2920,1382,1467,5932,6955,585],"Solid Tumor, Adult",[6957,3652,6958,6959,6960,6961,6962,6942,6963],"JNJ-75348780","JNJ-54179060","JNJ-64264681","JNJ-74856665","JNJ-70218902","JNJ-64619178","JNJ-87801493",{"nctId":6965,"briefTitle":6966,"status":192,"phases":6967,"primaryCompletion":6968,"completion":1271,"start":6969,"enrollment":6970,"conditions":6971,"interventions":6972},"NCT05424822","A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",[87],"2025-10-31","2022-08-18",167,[1382,2920],[6942],{"nctId":6974,"briefTitle":6975,"status":192,"phases":6976,"primaryCompletion":6977,"completion":6978,"start":6979,"enrollment":28,"conditions":6980,"interventions":6981},"NCT06660563","A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed\u002FRefractory B-Cell Non-Hodgkin Lymphoma (R\u002FR B-Cell NHL)",[87],"2026-09-07","2026-09-21","2024-10-22",[1382],[6942,6957],{"nctId":6983,"briefTitle":6984,"status":192,"phases":6985,"primaryCompletion":6986,"completion":666,"start":2202,"enrollment":6987,"conditions":6988,"interventions":6989},"NCT06139406","A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer",[87],"2026-01-30",70,[1382],[6963,6942,6957],{"trials":6991,"activeCount":99},[],{"trials":6993,"activeCount":99},[],{"trials":6995,"activeCount":99},[],{"trials":6997,"activeCount":99},[],{"intervention":529,"totalTrials":352,"cells":6999},{"EARLY_PHASE1":7000,"PHASE1":7002,"PHASE2":7036,"PHASE3":7038,"PHASE4":7040,"NA":7042},{"trials":7001,"activeCount":99},[],{"trials":7003,"activeCount":352,"soonestReadout":7030},[7004,7012,7022,7026],{"nctId":7005,"briefTitle":7006,"status":192,"phases":7007,"primaryCompletion":3209,"completion":3209,"start":7008,"enrollment":7009,"conditions":7010,"interventions":7011},"NCT04898634","A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",[87],"2021-07-13",216,[30],[529],{"nctId":7013,"briefTitle":7014,"status":304,"phases":7015,"primaryCompletion":7016,"completion":7017,"start":7018,"enrollment":160,"conditions":7019,"interventions":7020},"NCT07082920","A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer",[87],"2027-01-28","2027-03-01","2025-07-07",[30],[529,7021],"JNJ-95298177",{"nctId":520,"briefTitle":521,"status":304,"phases":7023,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":7024,"interventions":7025},[87],[30],[529,530,41,531,532],{"nctId":7027,"briefTitle":7028,"status":192,"phases":7029,"primaryCompletion":7030,"completion":7030,"start":7031,"enrollment":3698,"conditions":7032,"interventions":7034},"NCT04644770","A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer",[87],"2026-12-08","2020-11-12",[30,7033],"Adenocarcinoma",[7035,529],"JNJ-69086420",{"trials":7037,"activeCount":99},[],{"trials":7039,"activeCount":99},[],{"trials":7041,"activeCount":99},[],{"trials":7043,"activeCount":99},[],{"intervention":6957,"totalTrials":352,"cells":7045},{"EARLY_PHASE1":7046,"PHASE1":7048,"PHASE2":7070,"PHASE3":7072,"PHASE4":7074,"NA":7076},{"trials":7047,"activeCount":99},[],{"trials":7049,"activeCount":571,"soonestReadout":6986},[7050,7054,7062,7066],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7051,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7052,"interventions":7053},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7055,"briefTitle":7056,"status":105,"phases":7057,"primaryCompletion":7058,"completion":7058,"start":7059,"enrollment":4363,"conditions":7060,"interventions":7061},"NCT04540796","A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",[87],"2025-09-09","2020-11-20",[1382,2920],[6957],{"nctId":6974,"briefTitle":6975,"status":192,"phases":7063,"primaryCompletion":6977,"completion":6978,"start":6979,"enrollment":28,"conditions":7064,"interventions":7065},[87],[1382],[6942,6957],{"nctId":6983,"briefTitle":6984,"status":192,"phases":7067,"primaryCompletion":6986,"completion":666,"start":2202,"enrollment":6987,"conditions":7068,"interventions":7069},[87],[1382],[6963,6942,6957],{"trials":7071,"activeCount":99},[],{"trials":7073,"activeCount":99},[],{"trials":7075,"activeCount":99},[],{"trials":7077,"activeCount":99},[],{"intervention":6963,"totalTrials":571,"cells":7079},{"EARLY_PHASE1":7080,"PHASE1":7082,"PHASE2":7100,"PHASE3":7102,"PHASE4":7104,"NA":7106},{"trials":7081,"activeCount":99},[],{"trials":7083,"activeCount":571,"soonestReadout":6986},[7084,7088,7096],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7085,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7086,"interventions":7087},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7089,"briefTitle":7090,"status":304,"phases":7091,"primaryCompletion":7092,"completion":7092,"start":6328,"enrollment":4260,"conditions":7093,"interventions":7094},"NCT07308132","A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies",[87],"2028-08-31",[1382],[7095,6963],"JNJ-95566692",{"nctId":6983,"briefTitle":6984,"status":192,"phases":7097,"primaryCompletion":6986,"completion":666,"start":2202,"enrollment":6987,"conditions":7098,"interventions":7099},[87],[1382],[6963,6942,6957],{"trials":7101,"activeCount":99},[],{"trials":7103,"activeCount":99},[],{"trials":7105,"activeCount":99},[],{"trials":7107,"activeCount":99},[],{"intervention":531,"totalTrials":245,"cells":7109},{"EARLY_PHASE1":7110,"PHASE1":7112,"PHASE2":7122,"PHASE3":7124,"PHASE4":7126,"NA":7128},{"trials":7111,"activeCount":99},[],{"trials":7113,"activeCount":245,"soonestReadout":523},[7114,7118],{"nctId":520,"briefTitle":521,"status":304,"phases":7115,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":7116,"interventions":7117},[87],[30],[529,530,41,531,532],{"nctId":548,"briefTitle":549,"status":304,"phases":7119,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7120,"interventions":7121},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7123,"activeCount":99},[],{"trials":7125,"activeCount":99},[],{"trials":7127,"activeCount":99},[],{"trials":7129,"activeCount":99},[],{"intervention":532,"totalTrials":245,"cells":7131},{"EARLY_PHASE1":7132,"PHASE1":7134,"PHASE2":7144,"PHASE3":7146,"PHASE4":7148,"NA":7150},{"trials":7133,"activeCount":99},[],{"trials":7135,"activeCount":245,"soonestReadout":523},[7136,7140],{"nctId":520,"briefTitle":521,"status":304,"phases":7137,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":7138,"interventions":7139},[87],[30],[529,530,41,531,532],{"nctId":548,"briefTitle":549,"status":304,"phases":7141,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7142,"interventions":7143},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7145,"activeCount":99},[],{"trials":7147,"activeCount":99},[],{"trials":7149,"activeCount":99},[],{"trials":7151,"activeCount":99},[],{"intervention":7153,"totalTrials":641,"cells":7154},"Aticaprant",{"EARLY_PHASE1":7155,"PHASE1":7157,"PHASE2":7166,"PHASE3":7168,"PHASE4":7214,"NA":7216},{"trials":7156,"activeCount":99},[],{"trials":7158,"activeCount":468,"soonestReadout":523},[7159],{"nctId":7160,"briefTitle":7161,"status":304,"phases":7162,"primaryCompletion":523,"completion":523,"start":7163,"enrollment":1787,"conditions":7164,"interventions":7165},"NCT07615426","A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia",[87],"2026-03-02",[32],[7153],{"trials":7167,"activeCount":99},[],{"trials":7169,"activeCount":99},[7170,7180,7189,7198,7207],{"nctId":7171,"briefTitle":7172,"status":125,"phases":7173,"primaryCompletion":7174,"completion":7175,"start":7176,"enrollment":3554,"conditions":7177,"interventions":7179},"NCT06514742","A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant",[89],"2025-04-08","2025-04-24","2024-06-26",[21,7178],"Anhedonia",[7153],{"nctId":7181,"briefTitle":7182,"status":125,"phases":7183,"primaryCompletion":7184,"completion":7185,"start":1550,"enrollment":7186,"conditions":7187,"interventions":7188},"NCT05518149","A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)",[89],"2025-04-25","2025-05-08",871,[21],[7153],{"nctId":7190,"briefTitle":7191,"status":105,"phases":7192,"primaryCompletion":7193,"completion":7194,"start":2204,"enrollment":7195,"conditions":7196,"interventions":7197},"NCT05550532","A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy",[89],"2024-11-08","2024-11-13",444,[21,7178],[7153],{"nctId":7199,"briefTitle":7200,"status":105,"phases":7201,"primaryCompletion":7202,"completion":7202,"start":7203,"enrollment":7204,"conditions":7205,"interventions":7206},"NCT05455684","A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy",[89],"2024-09-18","2022-06-22",513,[21,7178],[7153],{"nctId":7208,"briefTitle":7209,"status":125,"phases":7210,"primaryCompletion":7211,"completion":7184,"start":6063,"enrollment":12,"conditions":7212,"interventions":7213},"NCT06635135","A Study of Aticaprant Plus an Antidepressant to Prevent Return of Depression Symptoms in Participants With Major Depressive Disorder Who Experience a Loss of Interest and Pleasure",[89],"2025-04-09",[21,7178],[7153],{"trials":7215,"activeCount":99},[],{"trials":7217,"activeCount":99},[],{"intervention":1301,"totalTrials":571,"cells":7219},{"EARLY_PHASE1":7220,"PHASE1":7222,"PHASE2":7228,"PHASE3":7230,"PHASE4":7240,"NA":7242},{"trials":7221,"activeCount":99},[],{"trials":7223,"activeCount":468,"soonestReadout":1674},[7224],{"nctId":1671,"briefTitle":1672,"status":192,"phases":7225,"primaryCompletion":1674,"completion":1024,"start":1675,"enrollment":1676,"conditions":7226,"interventions":7227},[87],[18],[70,1096,1301,683,707],{"trials":7229,"activeCount":99},[],{"trials":7231,"activeCount":99},[7232,7236],{"nctId":1291,"briefTitle":1292,"status":105,"phases":7233,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":7234,"interventions":7235},[89],[18],[1166,1167,496,1300,684,1301],{"nctId":1334,"briefTitle":1335,"status":105,"phases":7237,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":7238,"interventions":7239},[89],[18],[1300,683,684,1301],{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[],{"intervention":1152,"totalTrials":571,"cells":7245},{"EARLY_PHASE1":7246,"PHASE1":7248,"PHASE2":7258,"PHASE3":7264,"PHASE4":7266,"NA":7268},{"trials":7247,"activeCount":99},[],{"trials":7249,"activeCount":468,"soonestReadout":2903},[7250,7254],{"nctId":1139,"briefTitle":1140,"status":137,"phases":7251,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":7252,"interventions":7253},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"nctId":2900,"briefTitle":2901,"status":192,"phases":7255,"primaryCompletion":2903,"completion":1003,"start":2904,"enrollment":423,"conditions":7256,"interventions":7257},[87],[2894],[2907,2880,2908,1152,2909],{"trials":7259,"activeCount":99},[7260],{"nctId":1547,"briefTitle":1548,"status":105,"phases":7261,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":7262,"interventions":7263},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":7265,"activeCount":99},[],{"trials":7267,"activeCount":99},[],{"trials":7269,"activeCount":99},[],{"intervention":7271,"totalTrials":245,"cells":7272},"PD-1 inhibitor",{"EARLY_PHASE1":7273,"PHASE1":7275,"PHASE2":7281,"PHASE3":7296,"PHASE4":7298,"NA":7300},{"trials":7274,"activeCount":99},[],{"trials":7276,"activeCount":468,"soonestReadout":1012},[7277],{"nctId":1009,"briefTitle":1010,"status":192,"phases":7278,"primaryCompletion":1012,"completion":1013,"start":1014,"enrollment":1015,"conditions":7279,"interventions":7280},[87],[1017],[70,65,1019],{"trials":7282,"activeCount":99},[7283],{"nctId":7284,"briefTitle":7285,"status":105,"phases":7286,"primaryCompletion":7287,"completion":7288,"start":7289,"enrollment":5539,"conditions":7290,"interventions":7291},"NCT05275023","An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants",[88],"2023-12-12","2024-05-31","2022-06-30",[2412],[7292,7271,7293,7294,7295],"JNJ-73763989","Tenofovir Disoproxil","Tenofovir Alafenamide","Entecavir",{"trials":7297,"activeCount":99},[],{"trials":7299,"activeCount":99},[],{"trials":7301,"activeCount":99},[],{"intervention":3652,"totalTrials":352,"cells":7303},{"EARLY_PHASE1":7304,"PHASE1":7306,"PHASE2":7331,"PHASE3":7333,"PHASE4":7335,"NA":7337},{"trials":7305,"activeCount":99},[],{"trials":7307,"activeCount":468,"soonestReadout":6953},[7308,7315,7319,7327],{"nctId":7309,"briefTitle":7310,"status":105,"phases":7311,"primaryCompletion":1012,"completion":1012,"start":7312,"enrollment":5707,"conditions":7313,"interventions":7314},"NCT03900598","A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",[87],"2019-04-03",[2920,1382],[3652],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7316,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7317,"interventions":7318},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7320,"briefTitle":7321,"status":105,"phases":7322,"primaryCompletion":7323,"completion":7323,"start":7324,"enrollment":634,"conditions":7325,"interventions":7326},"NCT04657224","A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia",[87],"2025-01-16","2021-02-25",[1382,3729],[6959,3652],{"nctId":3645,"briefTitle":3646,"status":105,"phases":7328,"primaryCompletion":3648,"completion":3648,"start":3649,"enrollment":1192,"conditions":7329,"interventions":7330},[87],[2920,1382],[3652,46],{"trials":7332,"activeCount":99},[],{"trials":7334,"activeCount":99},[],{"trials":7336,"activeCount":99},[],{"trials":7338,"activeCount":99},[],{"intervention":6959,"totalTrials":352,"cells":7340},{"EARLY_PHASE1":7341,"PHASE1":7343,"PHASE2":7370,"PHASE3":7372,"PHASE4":7374,"NA":7376},{"trials":7342,"activeCount":99},[],{"trials":7344,"activeCount":468,"soonestReadout":6953},[7345,7354,7358,7362],{"nctId":7346,"briefTitle":7347,"status":105,"phases":7348,"primaryCompletion":7349,"completion":7349,"start":7350,"enrollment":7351,"conditions":7352,"interventions":7353},"NCT03607513","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-64264681 in Healthy Male and Female Participants",[87],"2019-08-09","2018-07-31",105,[15],[6959],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7355,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7356,"interventions":7357},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7320,"briefTitle":7321,"status":105,"phases":7359,"primaryCompletion":7323,"completion":7323,"start":7324,"enrollment":634,"conditions":7360,"interventions":7361},[87],[1382,3729],[6959,3652],{"nctId":7363,"briefTitle":7364,"status":105,"phases":7365,"primaryCompletion":7366,"completion":7366,"start":1627,"enrollment":7367,"conditions":7368,"interventions":7369},"NCT04210219","A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia",[87],"2025-05-28",85,[1382,2920],[6959],{"trials":7371,"activeCount":99},[],{"trials":7373,"activeCount":99},[],{"trials":7375,"activeCount":99},[],{"trials":7377,"activeCount":99},[],{"intervention":6961,"totalTrials":245,"cells":7379},{"EARLY_PHASE1":7380,"PHASE1":7382,"PHASE2":7396,"PHASE3":7398,"PHASE4":7400,"NA":7402},{"trials":7381,"activeCount":99},[],{"trials":7383,"activeCount":468,"soonestReadout":6953},[7384,7392],{"nctId":7385,"briefTitle":7386,"status":105,"phases":7387,"primaryCompletion":7388,"completion":7388,"start":7389,"enrollment":3380,"conditions":7390,"interventions":7391},"NCT04397276","A Study of JNJ-70218902 in Participants With Advanced Stage Solid Tumors",[87],"2025-09-16","2020-07-10",[5932],[6961],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7393,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7394,"interventions":7395},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"trials":7397,"activeCount":99},[],{"trials":7399,"activeCount":99},[],{"trials":7401,"activeCount":99},[],{"trials":7403,"activeCount":99},[],{"intervention":6960,"totalTrials":245,"cells":7405},{"EARLY_PHASE1":7406,"PHASE1":7408,"PHASE2":7426,"PHASE3":7428,"PHASE4":7430,"NA":7432},{"trials":7407,"activeCount":99},[],{"trials":7409,"activeCount":468,"soonestReadout":6953},[7410,7414],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7411,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7412,"interventions":7413},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7415,"briefTitle":7416,"status":105,"phases":7417,"primaryCompletion":7418,"completion":7418,"start":7419,"enrollment":7420,"conditions":7421,"interventions":7423},"NCT04609826","A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[87],"2025-08-25","2020-11-26",153,[1147,1467,7422],"Chronic Myelomonocytic Leukemia",[6960,7424,7425],"AZA","VEN",{"trials":7427,"activeCount":99},[],{"trials":7429,"activeCount":99},[],{"trials":7431,"activeCount":99},[],{"trials":7433,"activeCount":99},[],{"intervention":6962,"totalTrials":245,"cells":7435},{"EARLY_PHASE1":7436,"PHASE1":7438,"PHASE2":7453,"PHASE3":7455,"PHASE4":7457,"NA":7459},{"trials":7437,"activeCount":99},[],{"trials":7439,"activeCount":468,"soonestReadout":6953},[7440,7444],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7441,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7442,"interventions":7443},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"nctId":7445,"briefTitle":7446,"status":105,"phases":7447,"primaryCompletion":991,"completion":991,"start":7448,"enrollment":7449,"conditions":7450,"interventions":7452},"NCT03573310","A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS",[87],"2018-07-13",114,[5932,6955,7451,1467],"Non-Hodgkin Lymphoma",[6962],{"trials":7454,"activeCount":99},[],{"trials":7456,"activeCount":99},[],{"trials":7458,"activeCount":99},[],{"trials":7460,"activeCount":99},[],{"intervention":7462,"totalTrials":468,"cells":7463},"JNJ-87890387",{"EARLY_PHASE1":7464,"PHASE1":7466,"PHASE2":7478,"PHASE3":7480,"PHASE4":7482,"NA":7484},{"trials":7465,"activeCount":99},[],{"trials":7467,"activeCount":468,"soonestReadout":7472},[7468],{"nctId":7469,"briefTitle":7470,"status":304,"phases":7471,"primaryCompletion":7472,"completion":7473,"start":7474,"enrollment":1575,"conditions":7475,"interventions":7477},"NCT06178614","A Study of JNJ-87890387 for Advanced Solid Tumors",[87],"2027-03-16","2029-02-07","2023-12-14",[5932,7476],"Advanced Solid Tumors",[7462],{"trials":7479,"activeCount":99},[],{"trials":7481,"activeCount":99},[],{"trials":7483,"activeCount":99},[],{"trials":7485,"activeCount":99},[],{"intervention":7487,"totalTrials":468,"cells":7488},"JNJ-89853413",{"EARLY_PHASE1":7489,"PHASE1":7491,"PHASE2":7502,"PHASE3":7504,"PHASE4":7506,"NA":7508},{"trials":7490,"activeCount":99},[],{"trials":7492,"activeCount":468,"soonestReadout":7497},[7493],{"nctId":7494,"briefTitle":7495,"status":192,"phases":7496,"primaryCompletion":7497,"completion":7498,"start":7499,"enrollment":1787,"conditions":7500,"interventions":7501},"NCT06618001","A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms",[87],"2027-07-15","2028-01-12","2025-01-14",[2894,2895],[7487],{"trials":7503,"activeCount":99},[],{"trials":7505,"activeCount":99},[],{"trials":7507,"activeCount":99},[],{"trials":7509,"activeCount":99},[],{"intervention":7511,"totalTrials":468,"cells":7512},"JNJ-90009530",{"EARLY_PHASE1":7513,"PHASE1":7515,"PHASE2":7527,"PHASE3":7529,"PHASE4":7531,"NA":7533},{"trials":7514,"activeCount":99},[],{"trials":7516,"activeCount":468,"soonestReadout":7521},[7517],{"nctId":7518,"briefTitle":7519,"status":192,"phases":7520,"primaryCompletion":7521,"completion":7522,"start":7523,"enrollment":1419,"conditions":7524,"interventions":7526},"NCT05784441","A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r\u002Fr B-NHL)",[87],"2027-01-06","2040-01-03","2023-11-06",[7525],"Relapsed or Refractory B Cell Non-Hodgkin Lymphoma",[7511],{"trials":7528,"activeCount":99},[],{"trials":7530,"activeCount":99},[],{"trials":7532,"activeCount":99},[],{"trials":7534,"activeCount":99},[],{"intervention":7536,"totalTrials":468,"cells":7537},"JNJ-88549968",{"EARLY_PHASE1":7538,"PHASE1":7540,"PHASE2":7551,"PHASE3":7553,"PHASE4":7555,"NA":7557},{"trials":7539,"activeCount":99},[],{"trials":7541,"activeCount":468,"soonestReadout":7546},[7542],{"nctId":7543,"briefTitle":7544,"status":304,"phases":7545,"primaryCompletion":7546,"completion":653,"start":2138,"enrollment":1630,"conditions":7547,"interventions":7548},"NCT06150157","A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms",[87],"2026-12-04",[5932],[7536,7549,7550],"Ruxolitinib","Momelotinib",{"trials":7552,"activeCount":99},[],{"trials":7554,"activeCount":99},[],{"trials":7556,"activeCount":99},[],{"trials":7558,"activeCount":99},[],{"intervention":7549,"totalTrials":468,"cells":7560},{"EARLY_PHASE1":7561,"PHASE1":7563,"PHASE2":7569,"PHASE3":7571,"PHASE4":7573,"NA":7575},{"trials":7562,"activeCount":99},[],{"trials":7564,"activeCount":468,"soonestReadout":7546},[7565],{"nctId":7543,"briefTitle":7544,"status":304,"phases":7566,"primaryCompletion":7546,"completion":653,"start":2138,"enrollment":1630,"conditions":7567,"interventions":7568},[87],[5932],[7536,7549,7550],{"trials":7570,"activeCount":99},[],{"trials":7572,"activeCount":99},[],{"trials":7574,"activeCount":99},[],{"trials":7576,"activeCount":99},[],{"intervention":7550,"totalTrials":468,"cells":7578},{"EARLY_PHASE1":7579,"PHASE1":7581,"PHASE2":7587,"PHASE3":7589,"PHASE4":7591,"NA":7593},{"trials":7580,"activeCount":99},[],{"trials":7582,"activeCount":468,"soonestReadout":7546},[7583],{"nctId":7543,"briefTitle":7544,"status":304,"phases":7584,"primaryCompletion":7546,"completion":653,"start":2138,"enrollment":1630,"conditions":7585,"interventions":7586},[87],[5932],[7536,7549,7550],{"trials":7588,"activeCount":99},[],{"trials":7590,"activeCount":99},[],{"trials":7592,"activeCount":99},[],{"trials":7594,"activeCount":99},[],{"intervention":6958,"totalTrials":468,"cells":7596},{"EARLY_PHASE1":7597,"PHASE1":7599,"PHASE2":7605,"PHASE3":7607,"PHASE4":7609,"NA":7611},{"trials":7598,"activeCount":99},[],{"trials":7600,"activeCount":468,"soonestReadout":6953},[7601],{"nctId":6949,"briefTitle":6950,"status":6951,"phases":7602,"primaryCompletion":6953,"completion":3928,"start":388,"enrollment":371,"conditions":7603,"interventions":7604},[87],[2894,2920,1382,1467,5932,6955,585],[6957,3652,6958,6959,6960,6961,6962,6942,6963],{"trials":7606,"activeCount":99},[],{"trials":7608,"activeCount":99},[],{"trials":7610,"activeCount":99},[],{"trials":7612,"activeCount":99},[],{"intervention":517,"totalTrials":468,"cells":7614},{"EARLY_PHASE1":7615,"PHASE1":7617,"PHASE2":7623,"PHASE3":7625,"PHASE4":7627,"NA":7629},{"trials":7616,"activeCount":99},[],{"trials":7618,"activeCount":468,"soonestReadout":511},[7619],{"nctId":508,"briefTitle":509,"status":192,"phases":7620,"primaryCompletion":511,"completion":511,"start":512,"enrollment":513,"conditions":7621,"interventions":7622},[87],[515],[517,41,518,496],{"trials":7624,"activeCount":99},[],{"trials":7626,"activeCount":99},[],{"trials":7628,"activeCount":99},[],{"trials":7630,"activeCount":99},[],{"intervention":7632,"totalTrials":468,"cells":7633},"Ami-LC-MD",{"EARLY_PHASE1":7634,"PHASE1":7636,"PHASE2":7650,"PHASE3":7652,"PHASE4":7654,"NA":7656},{"trials":7635,"activeCount":99},[],{"trials":7637,"activeCount":468,"soonestReadout":7642},[7638],{"nctId":7639,"briefTitle":7640,"status":192,"phases":7641,"primaryCompletion":7642,"completion":7643,"start":340,"enrollment":7644,"conditions":7645,"interventions":7646},"NCT04606381","A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies",[87],"2024-07-11","2027-04-01",158,[5932],[7632,7647,7648,7649],"Ami-LC","Ami-HC","Ami-HC-CF",{"trials":7651,"activeCount":99},[],{"trials":7653,"activeCount":99},[],{"trials":7655,"activeCount":99},[],{"trials":7657,"activeCount":99},[],{"intervention":7647,"totalTrials":468,"cells":7659},{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7668,"PHASE3":7670,"PHASE4":7672,"NA":7674},{"trials":7661,"activeCount":99},[],{"trials":7663,"activeCount":468,"soonestReadout":7642},[7664],{"nctId":7639,"briefTitle":7640,"status":192,"phases":7665,"primaryCompletion":7642,"completion":7643,"start":340,"enrollment":7644,"conditions":7666,"interventions":7667},[87],[5932],[7632,7647,7648,7649],{"trials":7669,"activeCount":99},[],{"trials":7671,"activeCount":99},[],{"trials":7673,"activeCount":99},[],{"trials":7675,"activeCount":99},[],{"intervention":7648,"totalTrials":468,"cells":7677},{"EARLY_PHASE1":7678,"PHASE1":7680,"PHASE2":7686,"PHASE3":7688,"PHASE4":7690,"NA":7692},{"trials":7679,"activeCount":99},[],{"trials":7681,"activeCount":468,"soonestReadout":7642},[7682],{"nctId":7639,"briefTitle":7640,"status":192,"phases":7683,"primaryCompletion":7642,"completion":7643,"start":340,"enrollment":7644,"conditions":7684,"interventions":7685},[87],[5932],[7632,7647,7648,7649],{"trials":7687,"activeCount":99},[],{"trials":7689,"activeCount":99},[],{"trials":7691,"activeCount":99},[],{"trials":7693,"activeCount":99},[],{"intervention":7649,"totalTrials":468,"cells":7695},{"EARLY_PHASE1":7696,"PHASE1":7698,"PHASE2":7704,"PHASE3":7706,"PHASE4":7708,"NA":7710},{"trials":7697,"activeCount":99},[],{"trials":7699,"activeCount":468,"soonestReadout":7642},[7700],{"nctId":7639,"briefTitle":7640,"status":192,"phases":7701,"primaryCompletion":7642,"completion":7643,"start":340,"enrollment":7644,"conditions":7702,"interventions":7703},[87],[5932],[7632,7647,7648,7649],{"trials":7705,"activeCount":99},[],{"trials":7707,"activeCount":99},[],{"trials":7709,"activeCount":99},[],{"trials":7711,"activeCount":99},[],{"intervention":7713,"totalTrials":468,"cells":7714},"JNJ-95437446",{"EARLY_PHASE1":7715,"PHASE1":7717,"PHASE2":7729,"PHASE3":7731,"PHASE4":7733,"NA":7735},{"trials":7716,"activeCount":99},[],{"trials":7718,"activeCount":468,"soonestReadout":7723},[7719],{"nctId":7720,"briefTitle":7721,"status":304,"phases":7722,"primaryCompletion":7723,"completion":7724,"start":7725,"enrollment":7726,"conditions":7727,"interventions":7728},"NCT07107230","A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors",[87],"2027-11-18","2028-04-24","2025-07-15",380,[905],[7713],{"trials":7730,"activeCount":99},[],{"trials":7732,"activeCount":99},[],{"trials":7734,"activeCount":99},[],{"trials":7736,"activeCount":99},[],{"intervention":7021,"totalTrials":468,"cells":7738},{"EARLY_PHASE1":7739,"PHASE1":7741,"PHASE2":7747,"PHASE3":7749,"PHASE4":7751,"NA":7753},{"trials":7740,"activeCount":99},[],{"trials":7742,"activeCount":468,"soonestReadout":7016},[7743],{"nctId":7013,"briefTitle":7014,"status":304,"phases":7744,"primaryCompletion":7016,"completion":7017,"start":7018,"enrollment":160,"conditions":7745,"interventions":7746},[87],[30],[529,7021],{"trials":7748,"activeCount":99},[],{"trials":7750,"activeCount":99},[],{"trials":7752,"activeCount":99},[],{"trials":7754,"activeCount":99},[],{"intervention":3271,"totalTrials":468,"cells":7756},{"EARLY_PHASE1":7757,"PHASE1":7759,"PHASE2":7765,"PHASE3":7767,"PHASE4":7769,"NA":7771},{"trials":7758,"activeCount":99},[],{"trials":7760,"activeCount":468,"soonestReadout":3266},[7761],{"nctId":3263,"briefTitle":3264,"status":304,"phases":7762,"primaryCompletion":3266,"completion":3267,"start":3268,"enrollment":893,"conditions":7763,"interventions":7764},[87],[1148,1146,1147],[3271,3272],{"trials":7766,"activeCount":99},[],{"trials":7768,"activeCount":99},[],{"trials":7770,"activeCount":99},[],{"trials":7772,"activeCount":99},[],{"intervention":530,"totalTrials":468,"cells":7774},{"EARLY_PHASE1":7775,"PHASE1":7777,"PHASE2":7783,"PHASE3":7785,"PHASE4":7787,"NA":7789},{"trials":7776,"activeCount":99},[],{"trials":7778,"activeCount":468,"soonestReadout":523},[7779],{"nctId":520,"briefTitle":521,"status":304,"phases":7780,"primaryCompletion":523,"completion":524,"start":525,"enrollment":526,"conditions":7781,"interventions":7782},[87],[30],[529,530,41,531,532],{"trials":7784,"activeCount":99},[],{"trials":7786,"activeCount":99},[],{"trials":7788,"activeCount":99},[],{"trials":7790,"activeCount":99},[],{"intervention":7792,"totalTrials":468,"cells":7793},"JNJ-95804306",{"EARLY_PHASE1":7794,"PHASE1":7796,"PHASE2":7808,"PHASE3":7810,"PHASE4":7812,"NA":7814},{"trials":7795,"activeCount":99},[],{"trials":7797,"activeCount":468,"soonestReadout":2086},[7798],{"nctId":7799,"briefTitle":7800,"status":304,"phases":7801,"primaryCompletion":2086,"completion":7802,"start":7803,"enrollment":3761,"conditions":7804,"interventions":7805},"NCT07572006","A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies",[87],"2032-09-24","2026-05-13",[3700],[7792,7806,7807],"AML SoC","CLL\u002FSLL SoC",{"trials":7809,"activeCount":99},[],{"trials":7811,"activeCount":99},[],{"trials":7813,"activeCount":99},[],{"trials":7815,"activeCount":99},[],{"intervention":7806,"totalTrials":468,"cells":7817},{"EARLY_PHASE1":7818,"PHASE1":7820,"PHASE2":7826,"PHASE3":7828,"PHASE4":7830,"NA":7832},{"trials":7819,"activeCount":99},[],{"trials":7821,"activeCount":468,"soonestReadout":2086},[7822],{"nctId":7799,"briefTitle":7800,"status":304,"phases":7823,"primaryCompletion":2086,"completion":7802,"start":7803,"enrollment":3761,"conditions":7824,"interventions":7825},[87],[3700],[7792,7806,7807],{"trials":7827,"activeCount":99},[],{"trials":7829,"activeCount":99},[],{"trials":7831,"activeCount":99},[],{"trials":7833,"activeCount":99},[],{"intervention":7807,"totalTrials":468,"cells":7835},{"EARLY_PHASE1":7836,"PHASE1":7838,"PHASE2":7844,"PHASE3":7846,"PHASE4":7848,"NA":7850},{"trials":7837,"activeCount":99},[],{"trials":7839,"activeCount":468,"soonestReadout":2086},[7840],{"nctId":7799,"briefTitle":7800,"status":304,"phases":7841,"primaryCompletion":2086,"completion":7802,"start":7803,"enrollment":3761,"conditions":7842,"interventions":7843},[87],[3700],[7792,7806,7807],{"trials":7845,"activeCount":99},[],{"trials":7847,"activeCount":99},[],{"trials":7849,"activeCount":99},[],{"trials":7851,"activeCount":99},[],{"intervention":2897,"totalTrials":468,"cells":7853},{"EARLY_PHASE1":7854,"PHASE1":7856,"PHASE2":7862,"PHASE3":7864,"PHASE4":7866,"NA":7868},{"trials":7855,"activeCount":99},[],{"trials":7857,"activeCount":468,"soonestReadout":2136},[7858],{"nctId":2887,"briefTitle":2888,"status":304,"phases":7859,"primaryCompletion":2136,"completion":2890,"start":2891,"enrollment":2892,"conditions":7860,"interventions":7861},[87],[2894,2895],[2897,2898,2880],{"trials":7863,"activeCount":99},[],{"trials":7865,"activeCount":99},[],{"trials":7867,"activeCount":99},[],{"trials":7869,"activeCount":99},[],{"intervention":2898,"totalTrials":468,"cells":7871},{"EARLY_PHASE1":7872,"PHASE1":7874,"PHASE2":7880,"PHASE3":7882,"PHASE4":7884,"NA":7886},{"trials":7873,"activeCount":99},[],{"trials":7875,"activeCount":468,"soonestReadout":2136},[7876],{"nctId":2887,"briefTitle":2888,"status":304,"phases":7877,"primaryCompletion":2136,"completion":2890,"start":2891,"enrollment":2892,"conditions":7878,"interventions":7879},[87],[2894,2895],[2897,2898,2880],{"trials":7881,"activeCount":99},[],{"trials":7883,"activeCount":99},[],{"trials":7885,"activeCount":99},[],{"trials":7887,"activeCount":99},[],{"intervention":7035,"totalTrials":468,"cells":7889},{"EARLY_PHASE1":7890,"PHASE1":7892,"PHASE2":7898,"PHASE3":7900,"PHASE4":7902,"NA":7904},{"trials":7891,"activeCount":99},[],{"trials":7893,"activeCount":468,"soonestReadout":7030},[7894],{"nctId":7027,"briefTitle":7028,"status":192,"phases":7895,"primaryCompletion":7030,"completion":7030,"start":7031,"enrollment":3698,"conditions":7896,"interventions":7897},[87],[30,7033],[7035,529],{"trials":7899,"activeCount":99},[],{"trials":7901,"activeCount":99},[],{"trials":7903,"activeCount":99},[],{"trials":7905,"activeCount":99},[],{"intervention":561,"totalTrials":468,"cells":7907},{"EARLY_PHASE1":7908,"PHASE1":7910,"PHASE2":7916,"PHASE3":7918,"PHASE4":7920,"NA":7922},{"trials":7909,"activeCount":99},[],{"trials":7911,"activeCount":468,"soonestReadout":551},[7912],{"nctId":548,"briefTitle":549,"status":304,"phases":7913,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7914,"interventions":7915},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7917,"activeCount":99},[],{"trials":7919,"activeCount":99},[],{"trials":7921,"activeCount":99},[],{"trials":7923,"activeCount":99},[],{"intervention":563,"totalTrials":468,"cells":7925},{"EARLY_PHASE1":7926,"PHASE1":7928,"PHASE2":7934,"PHASE3":7936,"PHASE4":7938,"NA":7940},{"trials":7927,"activeCount":99},[],{"trials":7929,"activeCount":468,"soonestReadout":551},[7930],{"nctId":548,"briefTitle":549,"status":304,"phases":7931,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7932,"interventions":7933},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7935,"activeCount":99},[],{"trials":7937,"activeCount":99},[],{"trials":7939,"activeCount":99},[],{"trials":7941,"activeCount":99},[],{"intervention":564,"totalTrials":468,"cells":7943},{"EARLY_PHASE1":7944,"PHASE1":7946,"PHASE2":7952,"PHASE3":7954,"PHASE4":7956,"NA":7958},{"trials":7945,"activeCount":99},[],{"trials":7947,"activeCount":468,"soonestReadout":551},[7948],{"nctId":548,"briefTitle":549,"status":304,"phases":7949,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7950,"interventions":7951},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7953,"activeCount":99},[],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"trials":7959,"activeCount":99},[],{"intervention":565,"totalTrials":468,"cells":7961},{"EARLY_PHASE1":7962,"PHASE1":7964,"PHASE2":7970,"PHASE3":7972,"PHASE4":7974,"NA":7976},{"trials":7963,"activeCount":99},[],{"trials":7965,"activeCount":468,"soonestReadout":551},[7966],{"nctId":548,"briefTitle":549,"status":304,"phases":7967,"primaryCompletion":551,"completion":552,"start":553,"enrollment":554,"conditions":7968,"interventions":7969},[87],[556,557],[559,560,561,562,41,563,564,565,566,532],{"trials":7971,"activeCount":99},[],{"trials":7973,"activeCount":99},[],{"trials":7975,"activeCount":99},[],{"trials":7977,"activeCount":99},[],{"intervention":3141,"totalTrials":468,"cells":7979},{"EARLY_PHASE1":7980,"PHASE1":7982,"PHASE2":7988,"PHASE3":7990,"PHASE4":7992,"NA":7994},{"trials":7981,"activeCount":99},[],{"trials":7983,"activeCount":468,"soonestReadout":3135},[7984],{"nctId":3132,"briefTitle":3133,"status":304,"phases":7985,"primaryCompletion":3135,"completion":3136,"start":3137,"enrollment":3138,"conditions":7986,"interventions":7987},[87],[30],[559,3141],{"trials":7989,"activeCount":99},[],{"trials":7991,"activeCount":99},[],{"trials":7993,"activeCount":99},[],{"trials":7995,"activeCount":99},[],{"intervention":7095,"totalTrials":468,"cells":7997},{"EARLY_PHASE1":7998,"PHASE1":8000,"PHASE2":8006,"PHASE3":8008,"PHASE4":8010,"NA":8012},{"trials":7999,"activeCount":99},[],{"trials":8001,"activeCount":468,"soonestReadout":7092},[8002],{"nctId":7089,"briefTitle":7090,"status":304,"phases":8003,"primaryCompletion":7092,"completion":7092,"start":6328,"enrollment":4260,"conditions":8004,"interventions":8005},[87],[1382],[7095,6963],{"trials":8007,"activeCount":99},[],{"trials":8009,"activeCount":99},[],{"trials":8011,"activeCount":99},[],{"trials":8013,"activeCount":99},[],{"intervention":8015,"totalTrials":468,"cells":8016},"JNJ-89862175",{"EARLY_PHASE1":8017,"PHASE1":8019,"PHASE2":8032,"PHASE3":8034,"PHASE4":8036,"NA":8038},{"trials":8018,"activeCount":99},[],{"trials":8020,"activeCount":468,"soonestReadout":8025},[8021],{"nctId":8022,"briefTitle":8023,"status":304,"phases":8024,"primaryCompletion":8025,"completion":8026,"start":8027,"enrollment":8028,"conditions":8029,"interventions":8031},"NCT07223125","A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors",[87],"2026-12-15","2028-08-15","2025-10-10",360,[8030],"Advanced-stage Solid Tumors",[8015],{"trials":8033,"activeCount":99},[],{"trials":8035,"activeCount":99},[],{"trials":8037,"activeCount":99},[],{"trials":8039,"activeCount":99},[],{"intervention":2909,"totalTrials":468,"cells":8041},{"EARLY_PHASE1":8042,"PHASE1":8044,"PHASE2":8050,"PHASE3":8052,"PHASE4":8054,"NA":8056},{"trials":8043,"activeCount":99},[],{"trials":8045,"activeCount":468,"soonestReadout":2903},[8046],{"nctId":2900,"briefTitle":2901,"status":192,"phases":8047,"primaryCompletion":2903,"completion":1003,"start":2904,"enrollment":423,"conditions":8048,"interventions":8049},[87],[2894],[2907,2880,2908,1152,2909],{"trials":8051,"activeCount":99},[],{"trials":8053,"activeCount":99},[],{"trials":8055,"activeCount":99},[],{"trials":8057,"activeCount":99},[],{"intervention":1028,"totalTrials":468,"cells":8059},{"EARLY_PHASE1":8060,"PHASE1":8062,"PHASE2":8068,"PHASE3":8070,"PHASE4":8072,"NA":8074},{"trials":8061,"activeCount":99},[],{"trials":8063,"activeCount":468,"soonestReadout":982},[8064],{"nctId":1021,"briefTitle":1022,"status":192,"phases":8065,"primaryCompletion":982,"completion":1024,"start":1025,"enrollment":160,"conditions":8066,"interventions":8067},[87],[18],[65,681,707,683,682,1028],{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[],{"trials":8073,"activeCount":99},[],{"trials":8075,"activeCount":99},[],{"intervention":4702,"totalTrials":468,"cells":8077},{"EARLY_PHASE1":8078,"PHASE1":8080,"PHASE2":8086,"PHASE3":8088,"PHASE4":8090,"NA":8092},{"trials":8079,"activeCount":99},[],{"trials":8081,"activeCount":468,"soonestReadout":4696},[8082],{"nctId":4693,"briefTitle":4694,"status":304,"phases":8083,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":1630,"conditions":8084,"interventions":8085},[87],[905,4700],[4702,908,4703,4704],{"trials":8087,"activeCount":99},[],{"trials":8089,"activeCount":99},[],{"trials":8091,"activeCount":99},[],{"trials":8093,"activeCount":99},[],{"intervention":4703,"totalTrials":468,"cells":8095},{"EARLY_PHASE1":8096,"PHASE1":8098,"PHASE2":8104,"PHASE3":8106,"PHASE4":8108,"NA":8110},{"trials":8097,"activeCount":99},[],{"trials":8099,"activeCount":468,"soonestReadout":4696},[8100],{"nctId":4693,"briefTitle":4694,"status":304,"phases":8101,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":1630,"conditions":8102,"interventions":8103},[87],[905,4700],[4702,908,4703,4704],{"trials":8105,"activeCount":99},[],{"trials":8107,"activeCount":99},[],{"trials":8109,"activeCount":99},[],{"trials":8111,"activeCount":99},[],{"intervention":4704,"totalTrials":468,"cells":8113},{"EARLY_PHASE1":8114,"PHASE1":8116,"PHASE2":8122,"PHASE3":8124,"PHASE4":8126,"NA":8128},{"trials":8115,"activeCount":99},[],{"trials":8117,"activeCount":468,"soonestReadout":4696},[8118],{"nctId":4693,"briefTitle":4694,"status":304,"phases":8119,"primaryCompletion":4696,"completion":4697,"start":4698,"enrollment":1630,"conditions":8120,"interventions":8121},[87],[905,4700],[4702,908,4703,4704],{"trials":8123,"activeCount":99},[],{"trials":8125,"activeCount":99},[],{"trials":8127,"activeCount":99},[],{"trials":8129,"activeCount":99},[],{"intervention":8131,"totalTrials":468,"cells":8132},"JNJ-87562761",{"EARLY_PHASE1":8133,"PHASE1":8135,"PHASE2":8147,"PHASE3":8149,"PHASE4":8151,"NA":8153},{"trials":8134,"activeCount":99},[],{"trials":8136,"activeCount":468,"soonestReadout":8141},[8137],{"nctId":8138,"briefTitle":8139,"status":304,"phases":8140,"primaryCompletion":8141,"completion":8142,"start":8143,"enrollment":8144,"conditions":8145,"interventions":8146},"NCT06604715","A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma",[87],"2027-11-03","2027-11-15","2024-12-19",80,[1006],[8131],{"trials":8148,"activeCount":99},[],{"trials":8150,"activeCount":99},[],{"trials":8152,"activeCount":99},[],{"trials":8154,"activeCount":99},[],{"intervention":8156,"totalTrials":468,"cells":8157},"JNJ-88998377",{"EARLY_PHASE1":8158,"PHASE1":8160,"PHASE2":8172,"PHASE3":8174,"PHASE4":8176,"NA":8178},{"trials":8159,"activeCount":99},[],{"trials":8161,"activeCount":468,"soonestReadout":8166},[8162],{"nctId":8163,"briefTitle":8164,"status":192,"phases":8165,"primaryCompletion":8166,"completion":6559,"start":8167,"enrollment":2566,"conditions":8168,"interventions":8171},"NCT06470438","A Study of JNJ-88998377 for Relapsed\u002FRefractory B-cell Non-Hodgkin's Lymphoma",[87],"2027-10-29","2024-05-28",[1382,8169,8170],"Refractory B-Cell NHL","Relapsed B-cell NHL",[8156],{"trials":8173,"activeCount":99},[],{"trials":8175,"activeCount":99},[],{"trials":8177,"activeCount":99},[],{"trials":8179,"activeCount":99},[],{"intervention":5861,"totalTrials":2948,"cells":8181},{"EARLY_PHASE1":8182,"PHASE1":8184,"PHASE2":8194,"PHASE3":8204,"PHASE4":8237,"NA":8243},{"trials":8183,"activeCount":99},[],{"trials":8185,"activeCount":99},[8186],{"nctId":8187,"briefTitle":8188,"status":105,"phases":8189,"primaryCompletion":8190,"completion":8190,"start":5572,"enrollment":33,"conditions":8191,"interventions":8192},"NCT02000700","A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of Canagliflozin in Older Children and Adolescents With Type 2 Diabetes Mellitus",[87],"2016-04",[24],[8193,5848,5861],"Canagliflozin 100 mg",{"trials":8195,"activeCount":99},[8196],{"nctId":8197,"briefTitle":8198,"status":105,"phases":8199,"primaryCompletion":8200,"completion":8200,"start":2217,"enrollment":8201,"conditions":8202,"interventions":8203},"NCT02139943","A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)",[88],"2015-06",352,[4216],[8193,5861],{"trials":8205,"activeCount":99},[8206,8210,8220,8229],{"nctId":5853,"briefTitle":5854,"status":105,"phases":8207,"primaryCompletion":2565,"completion":2565,"start":5856,"enrollment":5857,"conditions":8208,"interventions":8209},[89],[24],[5860,5861,1779,5862],{"nctId":8211,"briefTitle":8212,"status":105,"phases":8213,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":8216,"conditions":8217,"interventions":8218},"NCT01809327","A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise",[89],"2014-12-02","2013-06-04",1186,[24],[8193,5861,8219],"Metformin XR",{"nctId":8221,"briefTitle":8222,"status":105,"phases":8223,"primaryCompletion":8224,"completion":8224,"start":8225,"enrollment":8226,"conditions":8227,"interventions":8228},"NCT03170518","A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to \u003C18 Years) With Type 2 Diabetes Mellitus",[89],"2023-09-20","2017-07-21",171,[24],[8193,5861],{"nctId":8230,"briefTitle":8231,"status":105,"phases":8232,"primaryCompletion":4850,"completion":3329,"start":2486,"enrollment":8233,"conditions":8234,"interventions":8235},"NCT01106651","A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus",[89],716,[24],[8193,5861,8236],"Antihyperglycemic agent",{"trials":8238,"activeCount":99},[8239],{"nctId":5908,"briefTitle":5909,"status":105,"phases":8240,"primaryCompletion":5911,"completion":5911,"start":5912,"enrollment":1787,"conditions":8241,"interventions":8242},[90],[24],[5861,5860,1779],{"trials":8244,"activeCount":99},[],{"intervention":8246,"totalTrials":641,"cells":8247},"Doripenem",{"EARLY_PHASE1":8248,"PHASE1":8250,"PHASE2":8267,"PHASE3":8269,"PHASE4":8311,"NA":8325},{"trials":8249,"activeCount":99},[],{"trials":8251,"activeCount":99},[8252,8259],{"nctId":8253,"briefTitle":8254,"status":125,"phases":8255,"primaryCompletion":2513,"completion":3640,"start":2565,"enrollment":468,"conditions":8256,"interventions":8258},"NCT01366651","A Study of Doripenem in CerebrospinalFluid After Doripenem Administration in Pediatric Patients Less Than 1 Year of Age",[87],[8257],"Meningitis",[8246,8246],{"nctId":8260,"briefTitle":8261,"status":105,"phases":8262,"primaryCompletion":2487,"completion":2487,"start":8263,"enrollment":19,"conditions":8264,"interventions":8266},"NCT01381848","A Study of Doripenem in Infants Less Than 12 Weeks of Age",[87],"2009-10",[8265],"Bacterial Infections",[8246,8246],{"trials":8268,"activeCount":99},[],{"trials":8270,"activeCount":99},[8271,8283,8301],{"nctId":8272,"briefTitle":8273,"status":125,"phases":8274,"primaryCompletion":6034,"completion":6034,"start":1176,"enrollment":8275,"conditions":8276,"interventions":8278},"NCT01110408","A Safety and Tolerability Study of Doripenem Compared With Cefepime in Children Hospitalized With Complicated Urinary Tract Infections",[89],41,[8277],"Complicated Urinary Tract Infections or Pyelonephritis",[8246,8279,8280,8281,8282],"Doripenem placebo","Cefepime","Cefepime placebo","Amoxicillin\u002Fclavulanate potassium",{"nctId":8284,"briefTitle":8285,"status":125,"phases":8286,"primaryCompletion":6823,"completion":6823,"start":1176,"enrollment":8275,"conditions":8287,"interventions":8298},"NCT01110382","A Safety and Tolerability Study of Doripenem Compared With Meropenem in Children Hospitalized With Complicated Intra-abdominal Infections",[89],[8288,8289,8290,8291,8292,8293,8294,8295,8296,8297],"Abscess, Intra-Abdominal","Abdominal Abscess","Abdomen, Acute","Abdominal Pain","Appendicitis","Rupture","Infection","Intestinal Perforation","Peritonitis","Ileus",[8246,8299,8300,8279,8282],"Meropenem placebo","Meropenem",{"nctId":8302,"briefTitle":8303,"status":125,"phases":8304,"primaryCompletion":2565,"completion":2565,"start":1176,"enrollment":2948,"conditions":8305,"interventions":8310},"NCT01110421","A Safety and Tolerability Study of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia",[89],[8306,8307,8308,8309],"Pneumonia, Bacterial","Community-Acquired Infections","Nosocomial Infection","Pneumonia, Ventilator-Associated",[8281,8280,8246,8279,8282],{"trials":8312,"activeCount":99},[8313],{"nctId":8314,"briefTitle":8315,"status":105,"phases":8316,"primaryCompletion":8317,"completion":8318,"start":8319,"enrollment":7009,"conditions":8320,"interventions":8323},"NCT00986102","PROUD Study: A Prospective Study on the Usage Patterns of Doripenem in the Asia Pacific Region",[90],"2011-09-05","2011-09-09","2009-07-17",[8321,8309,8322],"Pneumonia","Urinary Tract Infections",[8324],"doripenem",{"trials":8326,"activeCount":99},[],{"intervention":1799,"totalTrials":1029,"cells":8328},{"EARLY_PHASE1":8329,"PHASE1":8331,"PHASE2":8358,"PHASE3":8360,"PHASE4":8362,"NA":8374},{"trials":8330,"activeCount":99},[],{"trials":8332,"activeCount":99},[8333,8337,8341,8351],{"nctId":3803,"briefTitle":3804,"status":105,"phases":8334,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":3312,"conditions":8335,"interventions":8336},[87],[15],[75,3810,1799],{"nctId":1791,"briefTitle":1792,"status":105,"phases":8338,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1507,"conditions":8339,"interventions":8340},[87],[15],[759,1799,1800],{"nctId":8342,"briefTitle":8343,"status":105,"phases":8344,"primaryCompletion":8345,"completion":8345,"start":8346,"enrollment":1507,"conditions":8347,"interventions":8348},"NCT04208373","A Study to Assess the Effects of Itraconazole and Etravirine on JNJ-64417184 in Healthy Adult Participants",[87],"2020-03-10","2019-12-20",[15],[8349,1799,8350],"JNJ-64417184","Etravirine",{"nctId":8352,"briefTitle":8353,"status":105,"phases":8354,"primaryCompletion":3597,"completion":3597,"start":3632,"enrollment":2515,"conditions":8355,"interventions":8356},"NCT02729467","A Study to Assess the Effects of Itraconazole and Rifampicin on the Single-Dose Pharmacokinetics of JNJ-53718678 in Healthy Adults",[87],[15],[8357,1799,3345],"JNJ-53718678",{"trials":8359,"activeCount":99},[],{"trials":8361,"activeCount":99},[],{"trials":8363,"activeCount":99},[8364],{"nctId":8365,"briefTitle":8366,"status":125,"phases":8367,"primaryCompletion":8368,"completion":8369,"start":8370,"enrollment":3138,"conditions":8371,"interventions":8373},"NCT03923010","A Study of Itraconazole in the Management of Superficial Fungal Infections in India",[90],"2020-03-25","2020-03-27","2019-08-06",[8372],"Mycoses",[1799],{"trials":8375,"activeCount":99},[],{"intervention":8377,"totalTrials":1029,"cells":8378},"Canagliflozin, 100 mg",{"EARLY_PHASE1":8379,"PHASE1":8381,"PHASE2":8410,"PHASE3":8412,"PHASE4":8414,"NA":8434},{"trials":8380,"activeCount":99},[],{"trials":8382,"activeCount":99},[8383,8392,8402],{"nctId":8384,"briefTitle":8385,"status":105,"phases":8386,"primaryCompletion":8387,"completion":8387,"start":4269,"enrollment":8388,"conditions":8389,"interventions":8390},"NCT02009488","Treatment Differences Between Canagliflozin and Placebo in Insulin Secretion in Subjects With Type 2 Diabetes Mellitus (T2DM)",[87],"2017-01-03",59,[24],[8377,8391],"Canagliflozin, 300 mg",{"nctId":8393,"briefTitle":8394,"status":105,"phases":8395,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":245,"conditions":8397,"interventions":8398},"NCT02065752","A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components",[87],"2014-02",[3331],[8377,8399,8400,8401],"Metformin XR, 500 mg","CANA\u002FMET XR FDC, Formulation 1, 50 mg\u002F500 mg","CANA\u002FMET XR FDC, Formulation 2, 50 mg\u002F500 mg",{"nctId":8403,"briefTitle":8404,"status":105,"phases":8405,"primaryCompletion":6033,"completion":6033,"start":5572,"enrollment":12,"conditions":8406,"interventions":8407},"NCT02077803","A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants",[87],[15],[8377,8399,8408,8409],"CANA\u002FMET XR FDC, Formulation 1, 50 mg\u002F1000 mg","CANA\u002FMET XR FDC, Formulation 2, 50 mg\u002F1000 mg",{"trials":8411,"activeCount":99},[],{"trials":8413,"activeCount":99},[],{"trials":8415,"activeCount":99},[8416,8424],{"nctId":8417,"briefTitle":8418,"status":105,"phases":8419,"primaryCompletion":8420,"completion":8420,"start":8396,"enrollment":8421,"conditions":8422,"interventions":8423},"NCT02025907","A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin",[90],"2015-09",218,[24],[8377,8391],{"nctId":8425,"briefTitle":8426,"status":105,"phases":8427,"primaryCompletion":8428,"completion":8428,"start":8429,"enrollment":8430,"conditions":8431,"interventions":8433},"NCT01989754","A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus",[90],"2017-02-23","2014-01-16",5813,[24,8432],"Albuminuria",[8377,8391],{"trials":8435,"activeCount":99},[],{"intervention":8391,"totalTrials":1029,"cells":8437},{"EARLY_PHASE1":8438,"PHASE1":8440,"PHASE2":8460,"PHASE3":8462,"PHASE4":8464,"NA":8474},{"trials":8439,"activeCount":99},[],{"trials":8441,"activeCount":99},[8442,8446,8453],{"nctId":8384,"briefTitle":8385,"status":105,"phases":8443,"primaryCompletion":8387,"completion":8387,"start":4269,"enrollment":8388,"conditions":8444,"interventions":8445},[87],[24],[8377,8391],{"nctId":8447,"briefTitle":8394,"status":105,"phases":8448,"primaryCompletion":2218,"completion":2218,"start":8396,"enrollment":19,"conditions":8449,"interventions":8450},"NCT02073227",[87],[3331],[8391,8399,8451,8452],"CANA\u002FMET XR FDC, Formulation 1, 150 mg\u002F1,000 mg","CANA\u002FMET XR FDC, Formulation 2, 150 mg\u002F1,000 mg",{"nctId":8454,"briefTitle":8404,"status":105,"phases":8455,"primaryCompletion":2217,"completion":2217,"start":8396,"enrollment":571,"conditions":8456,"interventions":8457},"NCT02071368",[87],[15],[8391,8399,8458,8459],"CANA\u002FMET XR FDC, Formulation 1, 150 mg\u002F500","CANA\u002FMET XR FDC, Formulation 2, 150 mg\u002F500 mg",{"trials":8461,"activeCount":99},[],{"trials":8463,"activeCount":99},[],{"trials":8465,"activeCount":99},[8466,8470],{"nctId":8417,"briefTitle":8418,"status":105,"phases":8467,"primaryCompletion":8420,"completion":8420,"start":8396,"enrollment":8421,"conditions":8468,"interventions":8469},[90],[24],[8377,8391],{"nctId":8425,"briefTitle":8426,"status":105,"phases":8471,"primaryCompletion":8428,"completion":8428,"start":8429,"enrollment":8430,"conditions":8472,"interventions":8473},[90],[24,8432],[8377,8391],{"trials":8475,"activeCount":99},[],{"intervention":8477,"totalTrials":352,"cells":8478},"Esketamine 84 mg",{"EARLY_PHASE1":8479,"PHASE1":8481,"PHASE2":8497,"PHASE3":8511,"PHASE4":8521,"NA":8532},{"trials":8480,"activeCount":99},[],{"trials":8482,"activeCount":99},[8483],{"nctId":8484,"briefTitle":8485,"status":105,"phases":8486,"primaryCompletion":8487,"completion":8487,"start":8488,"enrollment":8489,"conditions":8490,"interventions":8492},"NCT02682225","Crossover Study to Evaluate the Abuse Potential of Intranasal Esketamine Compared to Racemic Intravenous Ketamine in Nondependent, Recreational Drug Users",[87],"2017-01-09","2016-03-25",55,[8491],"Drug Abuse",[8493,8494,8495,8496,8477],"Intravenous placebo","Intranasal placebo","Intravenous racemic ketamine","Esketamine 112 mg",{"trials":8498,"activeCount":99},[8499],{"nctId":8500,"briefTitle":8501,"status":105,"phases":8502,"primaryCompletion":8503,"completion":108,"start":8504,"enrollment":595,"conditions":8505,"interventions":8507},"NCT01998958","A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression",[88],"2015-07-21","2014-01-27",[8506],"Treatment Resistant Depressive Disorder",[8508,8509,8510,8477],"Esketamine 14 mg","Esketamine 28 mg","Esketamine 56 mg",{"trials":8512,"activeCount":99},[8513],{"nctId":8514,"briefTitle":8515,"status":105,"phases":8516,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":8519,"interventions":8520},"NCT03434041","A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression",[89],"2021-04-13","2018-05-25",[5681],[8510,8477,5664,5665,5666,5667],{"trials":8522,"activeCount":99},[8523],{"nctId":8524,"briefTitle":8525,"status":105,"phases":8526,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":8530,"interventions":8531},"NCT04599855","A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression",[90],"2024-01-31","2020-11-04",477,[5681],[8510,8477],{"trials":8533,"activeCount":99},[],{"intervention":8510,"totalTrials":571,"cells":8535},{"EARLY_PHASE1":8536,"PHASE1":8538,"PHASE2":8540,"PHASE3":8546,"PHASE4":8552,"NA":8558},{"trials":8537,"activeCount":99},[],{"trials":8539,"activeCount":99},[],{"trials":8541,"activeCount":99},[8542],{"nctId":8500,"briefTitle":8501,"status":105,"phases":8543,"primaryCompletion":8503,"completion":108,"start":8504,"enrollment":595,"conditions":8544,"interventions":8545},[88],[8506],[8508,8509,8510,8477],{"trials":8547,"activeCount":99},[8548],{"nctId":8514,"briefTitle":8515,"status":105,"phases":8549,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":8550,"interventions":8551},[89],[5681],[8510,8477,5664,5665,5666,5667],{"trials":8553,"activeCount":99},[8554],{"nctId":8524,"briefTitle":8525,"status":105,"phases":8555,"primaryCompletion":8527,"completion":8527,"start":8528,"enrollment":8529,"conditions":8556,"interventions":8557},[90],[5681],[8510,8477],{"trials":8559,"activeCount":99},[],{"intervention":5860,"totalTrials":245,"cells":8561},{"EARLY_PHASE1":8562,"PHASE1":8564,"PHASE2":8566,"PHASE3":8568,"PHASE4":8574,"NA":8580},{"trials":8563,"activeCount":99},[],{"trials":8565,"activeCount":99},[],{"trials":8567,"activeCount":99},[],{"trials":8569,"activeCount":99},[8570],{"nctId":5853,"briefTitle":5854,"status":105,"phases":8571,"primaryCompletion":2565,"completion":2565,"start":5856,"enrollment":5857,"conditions":8572,"interventions":8573},[89],[24],[5860,5861,1779,5862],{"trials":8575,"activeCount":99},[8576],{"nctId":5908,"briefTitle":5909,"status":105,"phases":8577,"primaryCompletion":5911,"completion":5911,"start":5912,"enrollment":1787,"conditions":8578,"interventions":8579},[90],[24],[5861,5860,1779],{"trials":8581,"activeCount":99},[],{"intervention":8583,"totalTrials":245,"cells":8584},"Paliperidone palmitate",{"EARLY_PHASE1":8585,"PHASE1":8587,"PHASE2":8589,"PHASE3":8591,"PHASE4":8602,"NA":8612},{"trials":8586,"activeCount":99},[],{"trials":8588,"activeCount":99},[],{"trials":8590,"activeCount":99},[],{"trials":8592,"activeCount":99},[8593],{"nctId":8594,"briefTitle":8595,"status":105,"phases":8596,"primaryCompletion":8597,"completion":8597,"start":8598,"enrollment":8599,"conditions":8600,"interventions":8601},"NCT01051531","A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia",[89],"2013-05-17","2010-04-22",546,[32],[8583],{"trials":8603,"activeCount":99},[8604],{"nctId":8605,"briefTitle":8606,"status":105,"phases":8607,"primaryCompletion":8608,"completion":8608,"start":8609,"enrollment":4472,"conditions":8610,"interventions":8611},"NCT01527305","A Study to Evaluate the Effectiveness and Safety of Paliperidone Palmitate in Subjects With Acute Schizophrenia",[90],"2013-12-31","2012-06-22",[32],[8583],{"trials":8613,"activeCount":99},[],{"intervention":8615,"totalTrials":245,"cells":8616},"EVRA patch",{"EARLY_PHASE1":8617,"PHASE1":8619,"PHASE2":8629,"PHASE3":8631,"PHASE4":8633,"NA":8643},{"trials":8618,"activeCount":99},[],{"trials":8620,"activeCount":99},[8621],{"nctId":8622,"briefTitle":8623,"status":105,"phases":8624,"primaryCompletion":1426,"completion":1426,"start":8625,"enrollment":809,"conditions":8626,"interventions":8627},"NCT04017195","A Study of New Transdermal Contraceptive Patch at End of Shelf Life and Currently Marketed EVRA at the Beginning of Shelf Life in Healthy Women",[87],"2019-07-12",[15],[8615,8628],"High molecular weight polyisobutylene",{"trials":8630,"activeCount":99},[],{"trials":8632,"activeCount":99},[],{"trials":8634,"activeCount":99},[8635],{"nctId":8636,"briefTitle":8637,"status":105,"phases":8638,"primaryCompletion":1261,"completion":1261,"start":8639,"enrollment":6987,"conditions":8640,"interventions":8641},"NCT03274297","A Study to Evaluate Bioequivalence and Adhesion of a Transdermal Contraceptive Patch Manufactured With Newly Sourced Adhesive Components and Currently Marketed EVRA in Healthy Adult Women",[90],"2017-09-20",[15],[8615,8642],"HMW PIB patch",{"trials":8644,"activeCount":99},[],{"intervention":8646,"totalTrials":245,"cells":8647},"Topiramate",{"EARLY_PHASE1":8648,"PHASE1":8650,"PHASE2":8652,"PHASE3":8654,"PHASE4":8667,"NA":8677},{"trials":8649,"activeCount":99},[],{"trials":8651,"activeCount":99},[],{"trials":8653,"activeCount":99},[],{"trials":8655,"activeCount":99},[8656],{"nctId":8657,"briefTitle":8658,"status":105,"phases":8659,"primaryCompletion":8660,"completion":8660,"start":8661,"enrollment":8662,"conditions":8663,"interventions":8665},"NCT02201251","A Study to Investigate the Safety of the Drugs Topiramate and Levetiracetam in Treating Children Recently Diagnosed With Epilepsy",[89],"2020-04-30","2014-10-06",63,[8664],"Epilepsy",[8646,8666],"Levetiracetam",{"trials":8668,"activeCount":99},[8669],{"nctId":8670,"briefTitle":8671,"status":105,"phases":8672,"primaryCompletion":8673,"completion":8673,"start":8674,"enrollment":5698,"conditions":8675,"interventions":8676},"NCT01689649","A Study to Assess Tolerability and Efficacy of Topiramate Monotherapy in Recently Diagnosed Patients With Epilepsy",[90],"2010-01-19","2008-05-02",[8664],[8646],{"trials":8678,"activeCount":99},[],{"intervention":8642,"totalTrials":468,"cells":8680},{"EARLY_PHASE1":8681,"PHASE1":8683,"PHASE2":8685,"PHASE3":8687,"PHASE4":8689,"NA":8695},{"trials":8682,"activeCount":99},[],{"trials":8684,"activeCount":99},[],{"trials":8686,"activeCount":99},[],{"trials":8688,"activeCount":99},[],{"trials":8690,"activeCount":99},[8691],{"nctId":8636,"briefTitle":8637,"status":105,"phases":8692,"primaryCompletion":1261,"completion":1261,"start":8639,"enrollment":6987,"conditions":8693,"interventions":8694},[90],[15],[8615,8642],{"trials":8696,"activeCount":99},[],{"intervention":8698,"totalTrials":468,"cells":8699},"Risperidone 3 mg",{"EARLY_PHASE1":8700,"PHASE1":8702,"PHASE2":8704,"PHASE3":8706,"PHASE4":8708,"NA":8726},{"trials":8701,"activeCount":99},[],{"trials":8703,"activeCount":99},[],{"trials":8705,"activeCount":99},[],{"trials":8707,"activeCount":99},[],{"trials":8709,"activeCount":99},[8710],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8713,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8716,"interventions":8717},"NCT03713658","A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities",[90],"2019-12-02","2018-10-18",[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],"Paliperidone Palmitate 50 mg eq.","Paliperidone Palmitate 75 mg eq.","Paliperidone Palmitate 100 mg eq.","Paliperidone Palmitate 150 mg eq.","Paliperidone Palmitate 175 mg eq.","Paliperidone Palmitate 263 mg eq.","Paliperidone Palmitate 350 mg eq.","Paliperidone Palmitate 525 mg eq.",{"trials":8727,"activeCount":99},[],{"intervention":8718,"totalTrials":468,"cells":8729},{"EARLY_PHASE1":8730,"PHASE1":8732,"PHASE2":8734,"PHASE3":8736,"PHASE4":8738,"NA":8744},{"trials":8731,"activeCount":99},[],{"trials":8733,"activeCount":99},[],{"trials":8735,"activeCount":99},[],{"trials":8737,"activeCount":99},[],{"trials":8739,"activeCount":99},[8740],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8741,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8742,"interventions":8743},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8745,"activeCount":99},[],{"intervention":8719,"totalTrials":468,"cells":8747},{"EARLY_PHASE1":8748,"PHASE1":8750,"PHASE2":8752,"PHASE3":8754,"PHASE4":8756,"NA":8762},{"trials":8749,"activeCount":99},[],{"trials":8751,"activeCount":99},[],{"trials":8753,"activeCount":99},[],{"trials":8755,"activeCount":99},[],{"trials":8757,"activeCount":99},[8758],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8759,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8760,"interventions":8761},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8763,"activeCount":99},[],{"intervention":8720,"totalTrials":468,"cells":8765},{"EARLY_PHASE1":8766,"PHASE1":8768,"PHASE2":8770,"PHASE3":8772,"PHASE4":8774,"NA":8780},{"trials":8767,"activeCount":99},[],{"trials":8769,"activeCount":99},[],{"trials":8771,"activeCount":99},[],{"trials":8773,"activeCount":99},[],{"trials":8775,"activeCount":99},[8776],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8777,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8778,"interventions":8779},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8781,"activeCount":99},[],{"intervention":8721,"totalTrials":468,"cells":8783},{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8788,"PHASE3":8790,"PHASE4":8792,"NA":8798},{"trials":8785,"activeCount":99},[],{"trials":8787,"activeCount":99},[],{"trials":8789,"activeCount":99},[],{"trials":8791,"activeCount":99},[],{"trials":8793,"activeCount":99},[8794],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8795,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8796,"interventions":8797},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8799,"activeCount":99},[],{"intervention":8722,"totalTrials":468,"cells":8801},{"EARLY_PHASE1":8802,"PHASE1":8804,"PHASE2":8806,"PHASE3":8808,"PHASE4":8810,"NA":8816},{"trials":8803,"activeCount":99},[],{"trials":8805,"activeCount":99},[],{"trials":8807,"activeCount":99},[],{"trials":8809,"activeCount":99},[],{"trials":8811,"activeCount":99},[8812],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8813,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8814,"interventions":8815},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8817,"activeCount":99},[],{"intervention":8723,"totalTrials":468,"cells":8819},{"EARLY_PHASE1":8820,"PHASE1":8822,"PHASE2":8824,"PHASE3":8826,"PHASE4":8828,"NA":8834},{"trials":8821,"activeCount":99},[],{"trials":8823,"activeCount":99},[],{"trials":8825,"activeCount":99},[],{"trials":8827,"activeCount":99},[],{"trials":8829,"activeCount":99},[8830],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8831,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8832,"interventions":8833},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8835,"activeCount":99},[],{"intervention":8724,"totalTrials":468,"cells":8837},{"EARLY_PHASE1":8838,"PHASE1":8840,"PHASE2":8842,"PHASE3":8844,"PHASE4":8846,"NA":8852},{"trials":8839,"activeCount":99},[],{"trials":8841,"activeCount":99},[],{"trials":8843,"activeCount":99},[],{"trials":8845,"activeCount":99},[],{"trials":8847,"activeCount":99},[8848],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8849,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8850,"interventions":8851},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8853,"activeCount":99},[],{"intervention":8725,"totalTrials":468,"cells":8855},{"EARLY_PHASE1":8856,"PHASE1":8858,"PHASE2":8860,"PHASE3":8862,"PHASE4":8864,"NA":8870},{"trials":8857,"activeCount":99},[],{"trials":8859,"activeCount":99},[],{"trials":8861,"activeCount":99},[],{"trials":8863,"activeCount":99},[],{"trials":8865,"activeCount":99},[8866],{"nctId":8711,"briefTitle":8712,"status":105,"phases":8867,"primaryCompletion":8714,"completion":8714,"start":8715,"enrollment":492,"conditions":8868,"interventions":8869},[90],[32],[8698,8718,8719,8720,8721,8722,8723,8724,8725],{"trials":8871,"activeCount":99},[],{"intervention":8873,"totalTrials":2948,"cells":8874},"Rivaroxaban",{"EARLY_PHASE1":8875,"PHASE1":8877,"PHASE2":8894,"PHASE3":8908,"PHASE4":8950,"NA":8952},{"trials":8876,"activeCount":99},[],{"trials":8878,"activeCount":99},[8879,8887],{"nctId":8880,"briefTitle":8881,"status":105,"phases":8882,"primaryCompletion":2565,"completion":2565,"start":8883,"enrollment":1857,"conditions":8884,"interventions":8886},"NCT01309438","A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function",[87],"2011-02",[15,8885],"Renal Insufficiency",[8873,8873,3626,3626],{"nctId":8888,"briefTitle":8889,"status":105,"phases":8890,"primaryCompletion":2513,"completion":2513,"start":8891,"enrollment":2545,"conditions":8892,"interventions":8893},"NCT01400646","A Study to Explore the Pharmacodynamic Changes When Transitioning From Rivaroxaban to Warfarin in Healthy Volunteers",[87],"2011-10",[15],[8873,174,4335,4335,174,174,174],{"trials":8895,"activeCount":99},[8896],{"nctId":8897,"briefTitle":8898,"status":105,"phases":8899,"primaryCompletion":8900,"completion":8900,"start":8901,"enrollment":8902,"conditions":8903,"interventions":8904},"NCT02293395","A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome",[88],"2016-10-14","2015-04-20",3037,[4545],[8905,8873,8906,8907],"Acetylsalicylic acid","Clopidogrel","Ticagrelor",{"trials":8909,"activeCount":99},[8910,8920,8930,8939],{"nctId":8911,"briefTitle":8912,"status":105,"phases":8913,"primaryCompletion":8914,"completion":8914,"start":8915,"enrollment":5349,"conditions":8916,"interventions":8918},"NCT02846532","Pharmacokinetic, Pharmacodynamic, Safety, and Efficacy Study of Rivaroxaban for Thromboprophylaxis in Pediatric Participants 2 to 8 Years of Age After the Fontan Procedure",[89],"2020-07-16","2016-11-16",[8917],"Thrombosis",[8873,8919],"Acetylsalicylic Acid",{"nctId":8921,"briefTitle":8922,"status":125,"phases":8923,"primaryCompletion":8924,"completion":8924,"start":8925,"enrollment":8926,"conditions":8927,"interventions":8929},"NCT04508023","A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",[89],"2022-06-01","2020-08-13",1284,[8928],"Coronavirus Disease 2019 (COVID-19)",[8873],{"nctId":8931,"briefTitle":8932,"status":105,"phases":8933,"primaryCompletion":8934,"completion":8934,"start":8935,"enrollment":8936,"conditions":8937,"interventions":8938},"NCT02555878","A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants",[89],"2018-08-24","2015-09-11",841,[5932],[8873],{"nctId":8940,"briefTitle":8941,"status":105,"phases":8942,"primaryCompletion":8943,"completion":8943,"start":8944,"enrollment":8945,"conditions":8946,"interventions":8949},"NCT01877915","A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure",[89],"2018-04-19","2013-09-10",5081,[8947,8948],"Heart Failure","Coronary Artery Disease",[8873],{"trials":8951,"activeCount":99},[],{"trials":8953,"activeCount":99},[],{"intervention":1384,"totalTrials":2948,"cells":8955},{"EARLY_PHASE1":8956,"PHASE1":8958,"PHASE2":8960,"PHASE3":8966,"PHASE4":8992,"NA":8994},{"trials":8957,"activeCount":99},[],{"trials":8959,"activeCount":99},[],{"trials":8961,"activeCount":99},[8962],{"nctId":2199,"briefTitle":2200,"status":105,"phases":8963,"primaryCompletion":2202,"completion":2203,"start":2204,"enrollment":1532,"conditions":8964,"interventions":8965},[88],[1534],[46,683,1384,682],{"trials":8967,"activeCount":99},[8968,8972,8976,8980,8984,8988],{"nctId":3721,"briefTitle":3722,"status":105,"phases":8969,"primaryCompletion":3724,"completion":3725,"start":3726,"enrollment":3727,"conditions":8970,"interventions":8971},[89],[3729,2921],[1384,46],{"nctId":2624,"briefTitle":2625,"status":105,"phases":8973,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":8974,"interventions":8975},[89],[1509],[46,1384,659,1556,1154,496],{"nctId":3736,"briefTitle":3737,"status":105,"phases":8977,"primaryCompletion":3739,"completion":3740,"start":3741,"enrollment":3742,"conditions":8978,"interventions":8979},[89],[3708],[2675,1384,46],{"nctId":3746,"briefTitle":3747,"status":105,"phases":8981,"primaryCompletion":1463,"completion":1463,"start":3749,"enrollment":3750,"conditions":8982,"interventions":8983},[89],[3729,2921],[46,3753,1384],{"nctId":2667,"briefTitle":2668,"status":105,"phases":8985,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":8986,"interventions":8987},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"nctId":1375,"briefTitle":1376,"status":125,"phases":8989,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":8990,"interventions":8991},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":8993,"activeCount":99},[],{"trials":8995,"activeCount":99},[],{"intervention":8193,"totalTrials":2948,"cells":8997},{"EARLY_PHASE1":8998,"PHASE1":9000,"PHASE2":9015,"PHASE3":9021,"PHASE4":9042,"NA":9044},{"trials":8999,"activeCount":99},[],{"trials":9001,"activeCount":99},[9002,9006],{"nctId":8187,"briefTitle":8188,"status":105,"phases":9003,"primaryCompletion":8190,"completion":8190,"start":5572,"enrollment":33,"conditions":9004,"interventions":9005},[87],[24],[8193,5848,5861],{"nctId":9007,"briefTitle":9008,"status":105,"phases":9009,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":9011,"interventions":9012},"NCT02846506","A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants",[87],44,[15],[9013,5848,8193,9014],"Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]","Metformin Extended Release",{"trials":9016,"activeCount":99},[9017],{"nctId":8197,"briefTitle":8198,"status":105,"phases":9018,"primaryCompletion":8200,"completion":8200,"start":2217,"enrollment":8201,"conditions":9019,"interventions":9020},[88],[4216],[8193,5861],{"trials":9022,"activeCount":99},[9023,9027,9034,9038],{"nctId":8211,"briefTitle":8212,"status":105,"phases":9024,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":8216,"conditions":9025,"interventions":9026},[89],[24],[8193,5861,8219],{"nctId":9028,"briefTitle":9029,"status":105,"phases":9030,"primaryCompletion":64,"completion":64,"start":8345,"enrollment":9031,"conditions":9032,"interventions":9033},"NCT04252287","A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure",[89],476,[8947],[8193],{"nctId":8221,"briefTitle":8222,"status":105,"phases":9035,"primaryCompletion":8224,"completion":8224,"start":8225,"enrollment":8226,"conditions":9036,"interventions":9037},[89],[24],[8193,5861],{"nctId":8230,"briefTitle":8231,"status":105,"phases":9039,"primaryCompletion":4850,"completion":3329,"start":2486,"enrollment":8233,"conditions":9040,"interventions":9041},[89],[24],[8193,5861,8236],{"trials":9043,"activeCount":99},[],{"trials":9045,"activeCount":99},[],{"intervention":3516,"totalTrials":2948,"cells":9047},{"EARLY_PHASE1":9048,"PHASE1":9050,"PHASE2":9052,"PHASE3":9064,"PHASE4":9117,"NA":9119},{"trials":9049,"activeCount":99},[],{"trials":9051,"activeCount":99},[],{"trials":9053,"activeCount":99},[9054],{"nctId":9055,"briefTitle":9056,"status":105,"phases":9057,"primaryCompletion":6034,"completion":6034,"start":5878,"enrollment":745,"conditions":9058,"interventions":9060},"NCT01389973","A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid",[88],[9059],"Primary Biliary Cirrhosis",[9061,9062,9063],"ustekinumab 90 mg","ustekinumab 45 mg","ustekinumab 180 mg",{"trials":9065,"activeCount":99},[9066,9070,9078,9090,9100,9108],{"nctId":3508,"briefTitle":3509,"status":125,"phases":9067,"primaryCompletion":3511,"completion":3511,"start":3512,"enrollment":3513,"conditions":9068,"interventions":9069},[89],[2121],[214,3516],{"nctId":9071,"briefTitle":9072,"status":105,"phases":9073,"primaryCompletion":2565,"completion":5888,"start":9074,"enrollment":9075,"conditions":9076,"interventions":9077},"NCT01077362","A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents",[89],"2010-03",312,[131],[9062,9061],{"nctId":9079,"briefTitle":9080,"status":125,"phases":9081,"primaryCompletion":4268,"completion":9082,"start":9083,"enrollment":9084,"conditions":9085,"interventions":9087},"NCT02437162","A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis",[89],"2017-09-06","2015-09-03",347,[9086],"Axial Spondyloarthritis",[9088,3516,9089],"Ustekinumab 45 mg","Golimumab 50 mg",{"nctId":9091,"briefTitle":9092,"status":105,"phases":9093,"primaryCompletion":9094,"completion":9095,"start":9096,"enrollment":9010,"conditions":9097,"interventions":9098},"NCT02698475","An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age",[89],"2017-12","2020-10","2016-05",[171],[9099,9088,3516],"Ustekinumab 0.75 mg\u002Fkg",{"nctId":9101,"briefTitle":9102,"status":105,"phases":9103,"primaryCompletion":8891,"completion":3329,"start":9104,"enrollment":9105,"conditions":9106,"interventions":9107},"NCT01009086","A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis",[89],"2009-12",615,[131],[9088,3516],{"nctId":9109,"briefTitle":9110,"status":125,"phases":9111,"primaryCompletion":9112,"completion":9112,"start":9113,"enrollment":9114,"conditions":9115,"interventions":9116},"NCT02438787","A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis",[89],"2017-08-31","2015-07-31",315,[9086],[9088,3516,9089],{"trials":9118,"activeCount":99},[],{"trials":9120,"activeCount":99},[],{"intervention":5664,"totalTrials":641,"cells":9122},{"EARLY_PHASE1":9123,"PHASE1":9125,"PHASE2":9127,"PHASE3":9129,"PHASE4":9155,"NA":9157},{"trials":9124,"activeCount":99},[],{"trials":9126,"activeCount":99},[],{"trials":9128,"activeCount":99},[],{"trials":9130,"activeCount":99},[9131,9135,9139,9143,9147,9151],{"nctId":8514,"briefTitle":8515,"status":105,"phases":9132,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":9133,"interventions":9134},[89],[5681],[8510,8477,5664,5665,5666,5667],{"nctId":5655,"briefTitle":5656,"status":105,"phases":9136,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":9137,"interventions":9138},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5673,"briefTitle":5674,"status":105,"phases":9140,"primaryCompletion":5676,"completion":5677,"start":5678,"enrollment":5679,"conditions":9141,"interventions":9142},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5684,"briefTitle":5685,"status":105,"phases":9144,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":9145,"interventions":9146},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5693,"briefTitle":5694,"status":105,"phases":9148,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":5698,"conditions":9149,"interventions":9150},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5711,"briefTitle":5712,"status":105,"phases":9152,"primaryCompletion":1530,"completion":5714,"start":5715,"enrollment":5716,"conditions":9153,"interventions":9154},[89],[5662],[4318,5664,5665,5666,5667],{"trials":9156,"activeCount":99},[],{"trials":9158,"activeCount":99},[],{"intervention":5665,"totalTrials":641,"cells":9160},{"EARLY_PHASE1":9161,"PHASE1":9163,"PHASE2":9165,"PHASE3":9167,"PHASE4":9193,"NA":9195},{"trials":9162,"activeCount":99},[],{"trials":9164,"activeCount":99},[],{"trials":9166,"activeCount":99},[],{"trials":9168,"activeCount":99},[9169,9173,9177,9181,9185,9189],{"nctId":8514,"briefTitle":8515,"status":105,"phases":9170,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":9171,"interventions":9172},[89],[5681],[8510,8477,5664,5665,5666,5667],{"nctId":5655,"briefTitle":5656,"status":105,"phases":9174,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":9175,"interventions":9176},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5673,"briefTitle":5674,"status":105,"phases":9178,"primaryCompletion":5676,"completion":5677,"start":5678,"enrollment":5679,"conditions":9179,"interventions":9180},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5684,"briefTitle":5685,"status":105,"phases":9182,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":9183,"interventions":9184},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5693,"briefTitle":5694,"status":105,"phases":9186,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":5698,"conditions":9187,"interventions":9188},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5711,"briefTitle":5712,"status":105,"phases":9190,"primaryCompletion":1530,"completion":5714,"start":5715,"enrollment":5716,"conditions":9191,"interventions":9192},[89],[5662],[4318,5664,5665,5666,5667],{"trials":9194,"activeCount":99},[],{"trials":9196,"activeCount":99},[],{"intervention":5666,"totalTrials":641,"cells":9198},{"EARLY_PHASE1":9199,"PHASE1":9201,"PHASE2":9203,"PHASE3":9205,"PHASE4":9231,"NA":9233},{"trials":9200,"activeCount":99},[],{"trials":9202,"activeCount":99},[],{"trials":9204,"activeCount":99},[],{"trials":9206,"activeCount":99},[9207,9211,9215,9219,9223,9227],{"nctId":8514,"briefTitle":8515,"status":105,"phases":9208,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":9209,"interventions":9210},[89],[5681],[8510,8477,5664,5665,5666,5667],{"nctId":5655,"briefTitle":5656,"status":105,"phases":9212,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":9213,"interventions":9214},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5673,"briefTitle":5674,"status":105,"phases":9216,"primaryCompletion":5676,"completion":5677,"start":5678,"enrollment":5679,"conditions":9217,"interventions":9218},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5684,"briefTitle":5685,"status":105,"phases":9220,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":9221,"interventions":9222},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5693,"briefTitle":5694,"status":105,"phases":9224,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":5698,"conditions":9225,"interventions":9226},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5711,"briefTitle":5712,"status":105,"phases":9228,"primaryCompletion":1530,"completion":5714,"start":5715,"enrollment":5716,"conditions":9229,"interventions":9230},[89],[5662],[4318,5664,5665,5666,5667],{"trials":9232,"activeCount":99},[],{"trials":9234,"activeCount":99},[],{"intervention":5667,"totalTrials":641,"cells":9236},{"EARLY_PHASE1":9237,"PHASE1":9239,"PHASE2":9241,"PHASE3":9243,"PHASE4":9269,"NA":9271},{"trials":9238,"activeCount":99},[],{"trials":9240,"activeCount":99},[],{"trials":9242,"activeCount":99},[],{"trials":9244,"activeCount":99},[9245,9249,9253,9257,9261,9265],{"nctId":8514,"briefTitle":8515,"status":105,"phases":9246,"primaryCompletion":8517,"completion":8517,"start":8518,"enrollment":2774,"conditions":9247,"interventions":9248},[89],[5681],[8510,8477,5664,5665,5666,5667],{"nctId":5655,"briefTitle":5656,"status":105,"phases":9250,"primaryCompletion":5658,"completion":5658,"start":5659,"enrollment":5660,"conditions":9251,"interventions":9252},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5673,"briefTitle":5674,"status":105,"phases":9254,"primaryCompletion":5676,"completion":5677,"start":5678,"enrollment":5679,"conditions":9255,"interventions":9256},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5684,"briefTitle":5685,"status":105,"phases":9258,"primaryCompletion":5687,"completion":5687,"start":5688,"enrollment":5689,"conditions":9259,"interventions":9260},[89],[5662],[4318,5664,5665,5666,5667],{"nctId":5693,"briefTitle":5694,"status":105,"phases":9262,"primaryCompletion":5696,"completion":5696,"start":5697,"enrollment":5698,"conditions":9263,"interventions":9264},[89],[5681],[4318,5664,5665,5666,5667],{"nctId":5711,"briefTitle":5712,"status":105,"phases":9266,"primaryCompletion":1530,"completion":5714,"start":5715,"enrollment":5716,"conditions":9267,"interventions":9268},[89],[5662],[4318,5664,5665,5666,5667],{"trials":9270,"activeCount":99},[],{"trials":9272,"activeCount":99},[],{"intervention":9088,"totalTrials":641,"cells":9274},{"EARLY_PHASE1":9275,"PHASE1":9277,"PHASE2":9279,"PHASE3":9285,"PHASE4":9307,"NA":9309},{"trials":9276,"activeCount":99},[],{"trials":9278,"activeCount":99},[],{"trials":9280,"activeCount":99},[9281],{"nctId":9055,"briefTitle":9056,"status":105,"phases":9282,"primaryCompletion":6034,"completion":6034,"start":5878,"enrollment":745,"conditions":9283,"interventions":9284},[88],[9059],[9061,9062,9063],{"trials":9286,"activeCount":99},[9287,9291,9295,9299,9303],{"nctId":9071,"briefTitle":9072,"status":105,"phases":9288,"primaryCompletion":2565,"completion":5888,"start":9074,"enrollment":9075,"conditions":9289,"interventions":9290},[89],[131],[9062,9061],{"nctId":9079,"briefTitle":9080,"status":125,"phases":9292,"primaryCompletion":4268,"completion":9082,"start":9083,"enrollment":9084,"conditions":9293,"interventions":9294},[89],[9086],[9088,3516,9089],{"nctId":9091,"briefTitle":9092,"status":105,"phases":9296,"primaryCompletion":9094,"completion":9095,"start":9096,"enrollment":9010,"conditions":9297,"interventions":9298},[89],[171],[9099,9088,3516],{"nctId":9101,"briefTitle":9102,"status":105,"phases":9300,"primaryCompletion":8891,"completion":3329,"start":9104,"enrollment":9105,"conditions":9301,"interventions":9302},[89],[131],[9088,3516],{"nctId":9109,"briefTitle":9110,"status":125,"phases":9304,"primaryCompletion":9112,"completion":9112,"start":9113,"enrollment":9114,"conditions":9305,"interventions":9306},[89],[9086],[9088,3516,9089],{"trials":9308,"activeCount":99},[],{"trials":9310,"activeCount":99},[],{"intervention":1166,"totalTrials":641,"cells":9312},{"EARLY_PHASE1":9313,"PHASE1":9315,"PHASE2":9321,"PHASE3":9327,"PHASE4":9345,"NA":9347},{"trials":9314,"activeCount":99},[],{"trials":9316,"activeCount":99},[9317],{"nctId":1157,"briefTitle":1158,"status":105,"phases":9318,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":9319,"interventions":9320},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":9322,"activeCount":99},[9323],{"nctId":2521,"briefTitle":2522,"status":105,"phases":9324,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":2526,"conditions":9325,"interventions":9326},[88],[18],[2529,2530,1166,1166,1167,1167,496,496,1166,1167,496],{"trials":9328,"activeCount":99},[9329,9333,9337,9341],{"nctId":1278,"briefTitle":1279,"status":105,"phases":9330,"primaryCompletion":1281,"completion":1282,"start":1283,"enrollment":330,"conditions":9331,"interventions":9332},[89],[18],[681,1166,684],{"nctId":1291,"briefTitle":1292,"status":105,"phases":9334,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":9335,"interventions":9336},[89],[18],[1166,1167,496,1300,684,1301],{"nctId":1360,"briefTitle":1361,"status":105,"phases":9338,"primaryCompletion":1363,"completion":1364,"start":1365,"enrollment":1366,"conditions":9339,"interventions":9340},[89],[18],[681,1369,684],{"nctId":1624,"briefTitle":1625,"status":105,"phases":9342,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":9343,"interventions":9344},[89],[18],[1166,1167,496,681],{"trials":9346,"activeCount":99},[],{"trials":9348,"activeCount":99},[],{"intervention":3491,"totalTrials":1029,"cells":9350},{"EARLY_PHASE1":9351,"PHASE1":9353,"PHASE2":9364,"PHASE3":9378,"PHASE4":9400,"NA":9402},{"trials":9352,"activeCount":99},[],{"trials":9354,"activeCount":99},[9355],{"nctId":9356,"briefTitle":9357,"status":105,"phases":9358,"primaryCompletion":9359,"completion":9360,"start":3580,"enrollment":745,"conditions":9361,"interventions":9362},"NCT05884242","A Study of Adalimumab on Inflammatory Mediators Following a Systemic Endotoxin Challenge",[87],"2023-08-01","2023-08-07",[15],[3491,9363],"Lipopolysaccharide",{"trials":9365,"activeCount":99},[9366,9370],{"nctId":3482,"briefTitle":3483,"status":137,"phases":9367,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":99,"conditions":9368,"interventions":9369},[88],[311],[3490,3491,214],{"nctId":9371,"briefTitle":9372,"status":125,"phases":9373,"primaryCompletion":9374,"completion":9375,"start":3865,"enrollment":1213,"conditions":9376,"interventions":9377},"NCT04988308","A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa",[88],"2022-10-14","2022-11-23",[3916],[6003,3491],{"trials":9379,"activeCount":99},[9380,9391],{"nctId":9381,"briefTitle":9382,"status":105,"phases":9383,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":9388,"interventions":9389},"NCT02207231","A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis",[89],"2015-09-29","2020-06-17","2014-11-26",837,[171],[9390,3491],"Guselkumab 100 mg",{"nctId":9392,"briefTitle":9393,"status":105,"phases":9394,"primaryCompletion":5678,"completion":9395,"start":9396,"enrollment":9397,"conditions":9398,"interventions":9399},"NCT02207244","A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment",[89],"2020-07-01","2014-11-03",992,[171],[9390,3491],{"trials":9401,"activeCount":99},[],{"trials":9403,"activeCount":99},[],{"intervention":1167,"totalTrials":1029,"cells":9405},{"EARLY_PHASE1":9406,"PHASE1":9408,"PHASE2":9414,"PHASE3":9424,"PHASE4":9434,"NA":9436},{"trials":9407,"activeCount":99},[],{"trials":9409,"activeCount":99},[9410],{"nctId":1157,"briefTitle":1158,"status":105,"phases":9411,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":9412,"interventions":9413},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":9415,"activeCount":99},[9416,9420],{"nctId":2521,"briefTitle":2522,"status":105,"phases":9417,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":2526,"conditions":9418,"interventions":9419},[88],[18],[2529,2530,1166,1166,1167,1167,496,496,1166,1167,496],{"nctId":1218,"briefTitle":1219,"status":105,"phases":9421,"primaryCompletion":1221,"completion":1222,"start":1223,"enrollment":1224,"conditions":9422,"interventions":9423},[88],[18],[681,682,683,684,1167,496,1096],{"trials":9425,"activeCount":99},[9426,9430],{"nctId":1291,"briefTitle":1292,"status":105,"phases":9427,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":9428,"interventions":9429},[89],[18],[1166,1167,496,1300,684,1301],{"nctId":1624,"briefTitle":1625,"status":105,"phases":9431,"primaryCompletion":1627,"completion":1628,"start":1629,"enrollment":1630,"conditions":9432,"interventions":9433},[89],[18],[1166,1167,496,681],{"trials":9435,"activeCount":99},[],{"trials":9437,"activeCount":99},[],{"intervention":1154,"totalTrials":1029,"cells":9439},{"EARLY_PHASE1":9440,"PHASE1":9442,"PHASE2":9448,"PHASE3":9454,"PHASE4":9468,"NA":9470},{"trials":9441,"activeCount":99},[],{"trials":9443,"activeCount":99},[9444],{"nctId":1139,"briefTitle":1140,"status":137,"phases":9445,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":9446,"interventions":9447},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"trials":9449,"activeCount":99},[9450],{"nctId":1547,"briefTitle":1548,"status":105,"phases":9451,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":9452,"interventions":9453},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":9455,"activeCount":99},[9456,9460,9464],{"nctId":2624,"briefTitle":2625,"status":105,"phases":9457,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":9458,"interventions":9459},[89],[1509],[46,1384,659,1556,1154,496],{"nctId":2667,"briefTitle":2668,"status":105,"phases":9461,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":9462,"interventions":9463},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"nctId":1375,"briefTitle":1376,"status":125,"phases":9465,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":9466,"interventions":9467},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":9469,"activeCount":99},[],{"trials":9471,"activeCount":99},[],{"intervention":2676,"totalTrials":1029,"cells":9473},{"EARLY_PHASE1":9474,"PHASE1":9476,"PHASE2":9499,"PHASE3":9510,"PHASE4":9516,"NA":9518},{"trials":9475,"activeCount":99},[],{"trials":9477,"activeCount":99},[9478,9484,9493],{"nctId":9479,"briefTitle":9480,"status":105,"phases":9481,"primaryCompletion":5618,"completion":5618,"start":3392,"enrollment":22,"conditions":9482,"interventions":9483},"NCT01767948","A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment",[87],[505],[2676],{"nctId":9485,"briefTitle":9486,"status":105,"phases":9487,"primaryCompletion":9488,"completion":9488,"start":6034,"enrollment":109,"conditions":9489,"interventions":9491},"NCT01866033","A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants",[87],"2013-08",[9490],"Healthy Volunteer",[2676,2676,2676,9492],"13C6 PCI-32765",{"nctId":9494,"briefTitle":9495,"status":105,"phases":9496,"primaryCompletion":5868,"completion":5868,"start":3392,"enrollment":503,"conditions":9497,"interventions":9498},"NCT01763021","A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants",[87],[3667],[2676,1800],{"trials":9500,"activeCount":99},[9501],{"nctId":9502,"briefTitle":9503,"status":105,"phases":9504,"primaryCompletion":9505,"completion":9505,"start":9506,"enrollment":9507,"conditions":9508,"interventions":9509},"NCT01779791","A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma",[88],"2016-05-18","2013-04-17",110,[1509],[2676],{"trials":9511,"activeCount":99},[9512],{"nctId":2667,"briefTitle":2668,"status":105,"phases":9513,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":9514,"interventions":9515},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"trials":9517,"activeCount":99},[],{"trials":9519,"activeCount":99},[],{"intervention":9521,"totalTrials":352,"cells":9522},"Aripiprazole",{"EARLY_PHASE1":9523,"PHASE1":9525,"PHASE2":9548,"PHASE3":9557,"PHASE4":9566,"NA":9568},{"trials":9524,"activeCount":99},[],{"trials":9526,"activeCount":99},[9527,9539],{"nctId":9528,"briefTitle":9529,"status":105,"phases":9530,"primaryCompletion":9531,"completion":9531,"start":9532,"enrollment":1264,"conditions":9533,"interventions":9536},"NCT02634463","Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone",[87],"2016-11-09","2015-11-09",[9534,9535],"Immunoassay","Antipsychotic",[9521,9537,9538],"Paliperidone","Risperidone",{"nctId":9540,"briefTitle":9541,"status":105,"phases":9542,"primaryCompletion":2487,"completion":9543,"start":2564,"enrollment":3471,"conditions":9544,"interventions":9545},"NCT01607762","A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics",[87],"2012-10",[15],[9521,9546,9547,9538,9537],"Quetiapine","Olanzapine",{"trials":9549,"activeCount":99},[9550],{"nctId":9551,"briefTitle":9552,"status":125,"phases":9553,"primaryCompletion":3633,"completion":3633,"start":3613,"enrollment":2149,"conditions":9554,"interventions":9556},"NCT02462473","A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry",[88],[32,9555],"Schizoaffective Disorder",[9521,9547,9537,9546,9538],{"trials":9558,"activeCount":99},[9559],{"nctId":9560,"briefTitle":9561,"status":105,"phases":9562,"primaryCompletion":3640,"completion":3640,"start":9104,"enrollment":1045,"conditions":9563,"interventions":9564},"NCT01009047","An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia",[89],[32],[9565,9521],"Paliperidone extended release",{"trials":9567,"activeCount":99},[],{"trials":9569,"activeCount":99},[],{"intervention":9537,"totalTrials":352,"cells":9571},{"EARLY_PHASE1":9572,"PHASE1":9574,"PHASE2":9584,"PHASE3":9590,"PHASE4":9599,"NA":9601},{"trials":9573,"activeCount":99},[],{"trials":9575,"activeCount":99},[9576,9580],{"nctId":9528,"briefTitle":9529,"status":105,"phases":9577,"primaryCompletion":9531,"completion":9531,"start":9532,"enrollment":1264,"conditions":9578,"interventions":9579},[87],[9534,9535],[9521,9537,9538],{"nctId":9540,"briefTitle":9541,"status":105,"phases":9581,"primaryCompletion":2487,"completion":9543,"start":2564,"enrollment":3471,"conditions":9582,"interventions":9583},[87],[15],[9521,9546,9547,9538,9537],{"trials":9585,"activeCount":99},[9586],{"nctId":9551,"briefTitle":9552,"status":125,"phases":9587,"primaryCompletion":3633,"completion":3633,"start":3613,"enrollment":2149,"conditions":9588,"interventions":9589},[88],[32,9555],[9521,9547,9537,9546,9538],{"trials":9591,"activeCount":99},[9592],{"nctId":9593,"briefTitle":9594,"status":105,"phases":9595,"primaryCompletion":2524,"completion":2524,"start":9596,"enrollment":2098,"conditions":9597,"interventions":9598},"NCT01662310","An Efficacy Study of Paliperidone for the Prevention of Relapse in Participants With Schizophrenia",[89],"2011-06",[32],[9537],{"trials":9600,"activeCount":99},[],{"trials":9602,"activeCount":99},[],{"intervention":9089,"totalTrials":352,"cells":9604},{"EARLY_PHASE1":9605,"PHASE1":9607,"PHASE2":9609,"PHASE3":9611,"PHASE4":9640,"NA":9642},{"trials":9606,"activeCount":99},[],{"trials":9608,"activeCount":99},[],{"trials":9610,"activeCount":99},[],{"trials":9612,"activeCount":99},[9613,9625,9629,9636],{"nctId":9614,"briefTitle":9615,"status":105,"phases":9616,"primaryCompletion":9617,"completion":9617,"start":9618,"enrollment":9619,"conditions":9620,"interventions":9621},"NCT00487539","An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis",[88,89],"2010-10","2007-08",1065,[27],[9622,9623,9624,9089],"Golimumab 100 mg","Golimumab 200 mg","Golimumab 400 mg",{"nctId":9079,"briefTitle":9080,"status":125,"phases":9626,"primaryCompletion":4268,"completion":9082,"start":9083,"enrollment":9084,"conditions":9627,"interventions":9628},[89],[9086],[9088,3516,9089],{"nctId":9630,"briefTitle":9615,"status":105,"phases":9631,"primaryCompletion":8891,"completion":4222,"start":9632,"enrollment":9633,"conditions":9634,"interventions":9635},"NCT00488631",[89],"2007-09",1228,[27],[9089,9622,9623],{"nctId":9109,"briefTitle":9110,"status":125,"phases":9637,"primaryCompletion":9112,"completion":9112,"start":9113,"enrollment":9114,"conditions":9638,"interventions":9639},[89],[9086],[9088,3516,9089],{"trials":9641,"activeCount":99},[],{"trials":9643,"activeCount":99},[],{"intervention":9645,"totalTrials":352,"cells":9646},"Fulranumab 1 mg",{"EARLY_PHASE1":9647,"PHASE1":9649,"PHASE2":9651,"PHASE3":9653,"PHASE4":9693,"NA":9695},{"trials":9648,"activeCount":99},[],{"trials":9650,"activeCount":99},[],{"trials":9652,"activeCount":99},[],{"trials":9654,"activeCount":99},[9655,9667,9675,9683],{"nctId":9656,"briefTitle":9657,"status":105,"phases":9658,"primaryCompletion":9659,"completion":9659,"start":9660,"enrollment":4842,"conditions":9661,"interventions":9664},"NCT02336685","Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001",[89],"2016-09-16","2015-07-07",[9662,9663],"Osteoarthritis","Pain",[9645,9665,9666],"Fulranumab 3 mg","Opioid",{"nctId":9668,"briefTitle":9669,"status":105,"phases":9670,"primaryCompletion":9671,"completion":9671,"start":9672,"enrollment":8275,"conditions":9673,"interventions":9674},"NCT02289716","Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003",[89],"2016-10-10","2015-07-10",[9662,9663],[9645,9665],{"nctId":9676,"briefTitle":9677,"status":105,"phases":9678,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":503,"conditions":9681,"interventions":9682},"NCT02336698","Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002",[89],"2016-09-15","2015-07-13",[9662,9663],[9645,9665],{"nctId":9684,"briefTitle":9685,"status":105,"phases":9686,"primaryCompletion":9687,"completion":9687,"start":9688,"enrollment":9689,"conditions":9690,"interventions":9691},"NCT02301234","Study of Safety, Efficacy of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3007",[89],"2016-09-19","2015-03-25",111,[9662,9663],[9645,9665,9692],"Celecoxib 100 mg",{"trials":9694,"activeCount":99},[],{"trials":9696,"activeCount":99},[],{"intervention":9665,"totalTrials":352,"cells":9698},{"EARLY_PHASE1":9699,"PHASE1":9701,"PHASE2":9703,"PHASE3":9705,"PHASE4":9723,"NA":9725},{"trials":9700,"activeCount":99},[],{"trials":9702,"activeCount":99},[],{"trials":9704,"activeCount":99},[],{"trials":9706,"activeCount":99},[9707,9711,9715,9719],{"nctId":9656,"briefTitle":9657,"status":105,"phases":9708,"primaryCompletion":9659,"completion":9659,"start":9660,"enrollment":4842,"conditions":9709,"interventions":9710},[89],[9662,9663],[9645,9665,9666],{"nctId":9668,"briefTitle":9669,"status":105,"phases":9712,"primaryCompletion":9671,"completion":9671,"start":9672,"enrollment":8275,"conditions":9713,"interventions":9714},[89],[9662,9663],[9645,9665],{"nctId":9676,"briefTitle":9677,"status":105,"phases":9716,"primaryCompletion":9679,"completion":9679,"start":9680,"enrollment":503,"conditions":9717,"interventions":9718},[89],[9662,9663],[9645,9665],{"nctId":9684,"briefTitle":9685,"status":105,"phases":9720,"primaryCompletion":9687,"completion":9687,"start":9688,"enrollment":9689,"conditions":9721,"interventions":9722},[89],[9662,9663],[9645,9665,9692],{"trials":9724,"activeCount":99},[],{"trials":9726,"activeCount":99},[],{"intervention":4334,"totalTrials":352,"cells":9728},{"EARLY_PHASE1":9729,"PHASE1":9731,"PHASE2":9743,"PHASE3":9745,"PHASE4":9765,"NA":9767},{"trials":9730,"activeCount":99},[],{"trials":9732,"activeCount":99},[9733,9737],{"nctId":4327,"briefTitle":4328,"status":105,"phases":9734,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":9735,"interventions":9736},[87],[2003],[4334,173,174,4335,175,177],{"nctId":9738,"briefTitle":9739,"status":105,"phases":9740,"primaryCompletion":5493,"completion":5493,"start":5572,"enrollment":3698,"conditions":9741,"interventions":9742},"NCT02079545","Bioavailability and Pharmacokinetics Study of Sirukumab in Healthy Male Participants",[87],[15],[4334,4334,4334,4334,4334],{"trials":9744,"activeCount":99},[],{"trials":9746,"activeCount":99},[9747,9756],{"nctId":9748,"briefTitle":9749,"status":105,"phases":9750,"primaryCompletion":9751,"completion":107,"start":9752,"enrollment":9753,"conditions":9754,"interventions":9755},"NCT01606761","A Study of CNTO 136 (Sirukumab), a Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T)",[89],"2015-03-17","2012-08-06",878,[2003],[4334,4334,4334],{"nctId":9757,"briefTitle":9758,"status":105,"phases":9759,"primaryCompletion":1531,"completion":9760,"start":9761,"enrollment":9762,"conditions":9763,"interventions":9764},"NCT01604343","A Study of CNTO 136 (Sirukumab), Administered Subcutaneously, in Patients With Active Rheumatoid Arthritis Despite Disease-Modifying Antirheumatic Drug (DMARD) Therapy (SIRROUND-D)",[89],"2016-12-06","2012-08-15",1670,[2003],[4334,4334,4334],{"trials":9766,"activeCount":99},[],{"trials":9768,"activeCount":99},[],{"intervention":9770,"totalTrials":571,"cells":9771},"Xilonix",{"EARLY_PHASE1":9772,"PHASE1":9774,"PHASE2":9776,"PHASE3":9786,"PHASE4":9809,"NA":9811},{"trials":9773,"activeCount":99},[],{"trials":9775,"activeCount":99},[],{"trials":9777,"activeCount":99},[9778],{"nctId":9779,"briefTitle":9780,"status":105,"phases":9781,"primaryCompletion":9782,"completion":9782,"start":2671,"enrollment":893,"conditions":9783,"interventions":9785},"NCT01965613","A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum",[88],"2016-12-31",[9784],"Pyoderma Gangrenosum",[9770],{"trials":9787,"activeCount":99},[9788,9799],{"nctId":9789,"briefTitle":9790,"status":105,"phases":9791,"primaryCompletion":5522,"completion":5522,"start":9792,"enrollment":9793,"conditions":9794,"interventions":9798},"NCT02138422","A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer",[89],"2014-07-31",276,[9795,9796,9797],"Symptomatic Colorectal Cancer","Advanced Colorectal Cancer","Colorectal Cancer With Cachexia",[9770],{"nctId":9800,"briefTitle":9801,"status":125,"phases":9802,"primaryCompletion":9803,"completion":9803,"start":9804,"enrollment":9805,"conditions":9806,"interventions":9808},"NCT01767857","A Phase III Study of Xilonix in Patients With Advanced Colorectal Cancer",[89],"2017-06-30","2013-03-31",643,[9807],"Metastatic Colorectal Cancer",[9770],{"trials":9810,"activeCount":99},[],{"trials":9812,"activeCount":99},[],{"intervention":5903,"totalTrials":571,"cells":9814},{"EARLY_PHASE1":9815,"PHASE1":9817,"PHASE2":9819,"PHASE3":9821,"PHASE4":9840,"NA":9842},{"trials":9816,"activeCount":99},[],{"trials":9818,"activeCount":99},[],{"trials":9820,"activeCount":99},[],{"trials":9822,"activeCount":99},[9823,9829,9836],{"nctId":9824,"briefTitle":9825,"status":105,"phases":9826,"primaryCompletion":5889,"completion":2565,"start":9074,"enrollment":5890,"conditions":9827,"interventions":9828},"NCT01081834","The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial",[89],[24],[5826,5903],{"nctId":9830,"briefTitle":9831,"status":105,"phases":9832,"primaryCompletion":8891,"completion":2513,"start":5879,"enrollment":8926,"conditions":9833,"interventions":9834},"NCT01106677","The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)",[89],[24],[5826,5903,9835],"Metformin immediate release",{"nctId":5896,"briefTitle":5897,"status":105,"phases":9837,"primaryCompletion":4850,"completion":5899,"start":2486,"enrollment":5900,"conditions":9838,"interventions":9839},[89],[24],[5826,5903,1779,5904],{"trials":9841,"activeCount":99},[],{"trials":9843,"activeCount":99},[],{"intervention":8279,"totalTrials":571,"cells":9845},{"EARLY_PHASE1":9846,"PHASE1":9848,"PHASE2":9850,"PHASE3":9852,"PHASE4":9866,"NA":9868},{"trials":9847,"activeCount":99},[],{"trials":9849,"activeCount":99},[],{"trials":9851,"activeCount":99},[],{"trials":9853,"activeCount":99},[9854,9858,9862],{"nctId":8272,"briefTitle":8273,"status":125,"phases":9855,"primaryCompletion":6034,"completion":6034,"start":1176,"enrollment":8275,"conditions":9856,"interventions":9857},[89],[8277],[8246,8279,8280,8281,8282],{"nctId":8284,"briefTitle":8285,"status":125,"phases":9859,"primaryCompletion":6823,"completion":6823,"start":1176,"enrollment":8275,"conditions":9860,"interventions":9861},[89],[8288,8289,8290,8291,8292,8293,8294,8295,8296,8297],[8246,8299,8300,8279,8282],{"nctId":8302,"briefTitle":8303,"status":125,"phases":9863,"primaryCompletion":2565,"completion":2565,"start":1176,"enrollment":2948,"conditions":9864,"interventions":9865},[89],[8306,8307,8308,8309],[8281,8280,8246,8279,8282],{"trials":9867,"activeCount":99},[],{"trials":9869,"activeCount":99},[],{"intervention":8282,"totalTrials":571,"cells":9871},{"EARLY_PHASE1":9872,"PHASE1":9874,"PHASE2":9876,"PHASE3":9878,"PHASE4":9892,"NA":9894},{"trials":9873,"activeCount":99},[],{"trials":9875,"activeCount":99},[],{"trials":9877,"activeCount":99},[],{"trials":9879,"activeCount":99},[9880,9884,9888],{"nctId":8272,"briefTitle":8273,"status":125,"phases":9881,"primaryCompletion":6034,"completion":6034,"start":1176,"enrollment":8275,"conditions":9882,"interventions":9883},[89],[8277],[8246,8279,8280,8281,8282],{"nctId":8284,"briefTitle":8285,"status":125,"phases":9885,"primaryCompletion":6823,"completion":6823,"start":1176,"enrollment":8275,"conditions":9886,"interventions":9887},[89],[8288,8289,8290,8291,8292,8293,8294,8295,8296,8297],[8246,8299,8300,8279,8282],{"nctId":8302,"briefTitle":8303,"status":125,"phases":9889,"primaryCompletion":2565,"completion":2565,"start":1176,"enrollment":2948,"conditions":9890,"interventions":9891},[89],[8306,8307,8308,8309],[8281,8280,8246,8279,8282],{"trials":9893,"activeCount":99},[],{"trials":9895,"activeCount":99},[],{"intervention":9897,"totalTrials":571,"cells":9898},"Group 1: Placebo",{"EARLY_PHASE1":9899,"PHASE1":9901,"PHASE2":9903,"PHASE3":9905,"PHASE4":9936,"NA":9938},{"trials":9900,"activeCount":99},[],{"trials":9902,"activeCount":99},[],{"trials":9904,"activeCount":99},[],{"trials":9906,"activeCount":99},[9907,9919,9926],{"nctId":9908,"briefTitle":9909,"status":105,"phases":9910,"primaryCompletion":6034,"completion":3328,"start":5845,"enrollment":9911,"conditions":9912,"interventions":9916},"NCT01369329","A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)",[89],769,[199,9913,9914,9915],"IBD","Colitis","Inflammatory Bowel Disease",[9917,9918,9897],"Group 2 ustekinumab 130 mg","Group 3: ustekinumab approximately 6 mg\u002Fkg",{"nctId":9920,"briefTitle":9921,"status":105,"phases":9922,"primaryCompletion":5530,"completion":3359,"start":5845,"enrollment":9923,"conditions":9924,"interventions":9925},"NCT01369342","A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)",[89],640,[199,9915,9913,9914],[9897,9917,9918],{"nctId":9927,"briefTitle":9928,"status":125,"phases":9929,"primaryCompletion":5547,"completion":5547,"start":9680,"enrollment":9930,"conditions":9931,"interventions":9933},"NCT02407223","An Efficacy and Safety Study of Ustekinumab in Participants With Active Nonradiographic Axial Spondyloarthritis",[89],356,[9932],"Nonradiographic Axial Spondylitis, Ankylosing",[9897,9934,9935],"Group 2: Ustekinumab 45 mg","Group 3: Ustekinumab 90 mg",{"trials":9937,"activeCount":99},[],{"trials":9939,"activeCount":99},[],{"intervention":9941,"totalTrials":571,"cells":9942},"Ustekinumab IV",{"EARLY_PHASE1":9943,"PHASE1":9945,"PHASE2":9961,"PHASE3":9972,"PHASE4":9983,"NA":9985},{"trials":9944,"activeCount":99},[],{"trials":9946,"activeCount":99},[9947],{"nctId":9948,"briefTitle":9949,"status":125,"phases":9950,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":9952,"interventions":9953},"NCT03358706","A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis",[87],"2021-11-22",[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],"Ustekinumab SC","Midazolam 2 mg","Warfarin 10 mg","Vitamin K 10 mg","Omeprazole 20 mg","Dextromethorphan 30 mg","Caffeine 100 mg",{"trials":9962,"activeCount":99},[9963],{"nctId":9964,"briefTitle":9965,"status":105,"phases":9966,"primaryCompletion":9967,"completion":9968,"start":9969,"enrollment":3360,"conditions":9970,"interventions":9971},"NCT02349061","A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus",[88],"2017-05-15","2019-03-13","2015-10-15",[2121],[9941,9954],{"trials":9973,"activeCount":99},[9974],{"nctId":9975,"briefTitle":9976,"status":105,"phases":9977,"primaryCompletion":9978,"completion":1818,"start":9672,"enrollment":9979,"conditions":9980,"interventions":9982},"NCT02407236","A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis",[89],"2018-08-10",961,[27,9981],"Inflammatory Bowel Diseases",[9941,9954],{"trials":9984,"activeCount":99},[],{"trials":9986,"activeCount":99},[],{"intervention":9954,"totalTrials":571,"cells":9988},{"EARLY_PHASE1":9989,"PHASE1":9991,"PHASE2":9997,"PHASE3":10003,"PHASE4":10009,"NA":10011},{"trials":9990,"activeCount":99},[],{"trials":9992,"activeCount":99},[9993],{"nctId":9948,"briefTitle":9949,"status":125,"phases":9994,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":9995,"interventions":9996},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"trials":9998,"activeCount":99},[9999],{"nctId":9964,"briefTitle":9965,"status":105,"phases":10000,"primaryCompletion":9967,"completion":9968,"start":9969,"enrollment":3360,"conditions":10001,"interventions":10002},[88],[2121],[9941,9954],{"trials":10004,"activeCount":99},[10005],{"nctId":9975,"briefTitle":9976,"status":105,"phases":10006,"primaryCompletion":9978,"completion":1818,"start":9672,"enrollment":9979,"conditions":10007,"interventions":10008},[89],[27,9981],[9941,9954],{"trials":10010,"activeCount":99},[],{"trials":10012,"activeCount":99},[],{"intervention":1556,"totalTrials":571,"cells":10014},{"EARLY_PHASE1":10015,"PHASE1":10017,"PHASE2":10019,"PHASE3":10025,"PHASE4":10035,"NA":10037},{"trials":10016,"activeCount":99},[],{"trials":10018,"activeCount":99},[],{"trials":10020,"activeCount":99},[10021],{"nctId":1547,"briefTitle":1548,"status":105,"phases":10022,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":10023,"interventions":10024},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":10026,"activeCount":99},[10027,10031],{"nctId":2624,"briefTitle":2625,"status":105,"phases":10028,"primaryCompletion":2627,"completion":2628,"start":2629,"enrollment":2630,"conditions":10029,"interventions":10030},[89],[1509],[46,1384,659,1556,1154,496],{"nctId":2667,"briefTitle":2668,"status":105,"phases":10032,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":10033,"interventions":10034},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"trials":10036,"activeCount":99},[],{"trials":10038,"activeCount":99},[],{"intervention":10040,"totalTrials":571,"cells":10041},"Sirukumab 50 mg",{"EARLY_PHASE1":10042,"PHASE1":10044,"PHASE2":10046,"PHASE3":10057,"PHASE4":10081,"NA":10083},{"trials":10043,"activeCount":99},[],{"trials":10045,"activeCount":99},[],{"trials":10047,"activeCount":99},[10048],{"nctId":10049,"briefTitle":10050,"status":105,"phases":10051,"primaryCompletion":10052,"completion":10052,"start":10053,"enrollment":10054,"conditions":10055,"interventions":10056},"NCT02473289","An Efficacy and Safety Study of Sirukumab in Participants With Major Depressive Disorder",[88],"2018-05-22","2015-07-23",193,[21],[10040],{"trials":10058,"activeCount":99},[10059,10069],{"nctId":10060,"briefTitle":10061,"status":105,"phases":10062,"primaryCompletion":10063,"completion":10063,"start":10064,"enrollment":10065,"conditions":10066,"interventions":10067},"NCT01856309","Long-term Safety and Efficacy of Sirukumab in Participants With RA Completing Studies CNTO136ARA3002 or CNTO136ARA3003",[89],"2018-04-30","2013-08-07",1820,[2003],[10068,10040],"Sirukumab 100 mg",{"nctId":10070,"briefTitle":10071,"status":105,"phases":10072,"primaryCompletion":10073,"completion":10073,"start":10074,"enrollment":10075,"conditions":10076,"interventions":10077},"NCT02019472","A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis",[89],"2016-08-17","2014-04-04",559,[2003],[10078,10079,10080],"adalimumab 40 mg","sirukumab 100 mg","sirukumab 50 mg",{"trials":10082,"activeCount":99},[],{"trials":10084,"activeCount":99},[],{"intervention":10086,"totalTrials":571,"cells":10087},"PP3M 350 mg eq.",{"EARLY_PHASE1":10088,"PHASE1":10090,"PHASE2":10092,"PHASE3":10094,"PHASE4":10126,"NA":10128},{"trials":10089,"activeCount":99},[],{"trials":10091,"activeCount":99},[],{"trials":10093,"activeCount":99},[],{"trials":10095,"activeCount":99},[10096,10106,10117],{"nctId":10097,"briefTitle":10098,"status":105,"phases":10099,"primaryCompletion":1175,"completion":1175,"start":2513,"enrollment":10100,"conditions":10101,"interventions":10102},"NCT01529515","A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia",[89],509,[32],[10103,10104,10086,10105],"PP3M 175 mg eq.","PP3M 263 mg eq.","PP3M 525 mg eq.",{"nctId":10107,"briefTitle":10108,"status":105,"phases":10109,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":10111,"interventions":10112},"NCT01515423","Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia",[89],1429,[32],[10103,10104,10086,10105,10113,10114,10115,10116],"PP1M 50 mg eq.","PP1M 75 mg eq.","PP1M 100 mg eq.","PP1M 150 mg eq.",{"nctId":10118,"briefTitle":10119,"status":105,"phases":10120,"primaryCompletion":10121,"completion":10121,"start":2959,"enrollment":8936,"conditions":10122,"interventions":10123},"NCT03345342","A Study of Paliperidone Palmitate 6-Month Formulation",[89],"2020-05-08",[32],[10124,10086,10105,10125],"PP6M","PP1M",{"trials":10127,"activeCount":99},[],{"trials":10129,"activeCount":99},[],{"intervention":10105,"totalTrials":571,"cells":10131},{"EARLY_PHASE1":10132,"PHASE1":10134,"PHASE2":10136,"PHASE3":10138,"PHASE4":10152,"NA":10154},{"trials":10133,"activeCount":99},[],{"trials":10135,"activeCount":99},[],{"trials":10137,"activeCount":99},[],{"trials":10139,"activeCount":99},[10140,10144,10148],{"nctId":10097,"briefTitle":10098,"status":105,"phases":10141,"primaryCompletion":1175,"completion":1175,"start":2513,"enrollment":10100,"conditions":10142,"interventions":10143},[89],[32],[10103,10104,10086,10105],{"nctId":10107,"briefTitle":10108,"status":105,"phases":10145,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":10146,"interventions":10147},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"nctId":10118,"briefTitle":10119,"status":105,"phases":10149,"primaryCompletion":10121,"completion":10121,"start":2959,"enrollment":8936,"conditions":10150,"interventions":10151},[89],[32],[10124,10086,10105,10125],{"trials":10153,"activeCount":99},[],{"trials":10155,"activeCount":99},[],{"intervention":10157,"totalTrials":571,"cells":10158},"Rilematovir",{"EARLY_PHASE1":10159,"PHASE1":10161,"PHASE2":10171,"PHASE3":10180,"PHASE4":10191,"NA":10193},{"trials":10160,"activeCount":99},[],{"trials":10162,"activeCount":99},[10163],{"nctId":10164,"briefTitle":10165,"status":105,"phases":10166,"primaryCompletion":10167,"completion":10167,"start":3564,"enrollment":503,"conditions":10168,"interventions":10169},"NCT05155007","A Study in Healthy Adult Participants to Assess the Effects of Ciclosporin Administration on Rilematovir",[87],"2022-02-04",[15],[10157,10170],"Ciclosporin",{"trials":10172,"activeCount":99},[10173],{"nctId":10174,"briefTitle":10175,"status":125,"phases":10176,"primaryCompletion":5999,"completion":5999,"start":928,"enrollment":1029,"conditions":10177,"interventions":10179},"NCT04978337","A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection",[88],[10178],"Respiratory Syncytial Virus",[10157],{"trials":10181,"activeCount":99},[10182],{"nctId":10183,"briefTitle":10184,"status":125,"phases":10185,"primaryCompletion":3461,"completion":3461,"start":10186,"enrollment":1132,"conditions":10187,"interventions":10189},"NCT04583280","A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)",[89],"2021-09-06",[10188],"Respiratory Tract Infections",[10157,10190],"Rilematovir X mg\u002Fkg",{"trials":10192,"activeCount":99},[],{"trials":10194,"activeCount":99},[],{"intervention":8919,"totalTrials":245,"cells":10196},{"EARLY_PHASE1":10197,"PHASE1":10199,"PHASE2":10201,"PHASE3":10207,"PHASE4":10213,"NA":10215},{"trials":10198,"activeCount":99},[],{"trials":10200,"activeCount":99},[],{"trials":10202,"activeCount":99},[10203],{"nctId":8897,"briefTitle":8898,"status":105,"phases":10204,"primaryCompletion":8900,"completion":8900,"start":8901,"enrollment":8902,"conditions":10205,"interventions":10206},[88],[4545],[8905,8873,8906,8907],{"trials":10208,"activeCount":99},[10209],{"nctId":8911,"briefTitle":8912,"status":105,"phases":10210,"primaryCompletion":8914,"completion":8914,"start":8915,"enrollment":5349,"conditions":10211,"interventions":10212},[89],[8917],[8873,8919],{"trials":10214,"activeCount":99},[],{"trials":10216,"activeCount":99},[],{"intervention":5862,"totalTrials":245,"cells":10218},{"EARLY_PHASE1":10219,"PHASE1":10221,"PHASE2":10223,"PHASE3":10225,"PHASE4":10235,"NA":10237},{"trials":10220,"activeCount":99},[],{"trials":10222,"activeCount":99},[],{"trials":10224,"activeCount":99},[],{"trials":10226,"activeCount":99},[10227,10231],{"nctId":5853,"briefTitle":5854,"status":105,"phases":10228,"primaryCompletion":2565,"completion":2565,"start":5856,"enrollment":5857,"conditions":10229,"interventions":10230},[89],[24],[5860,5861,1779,5862],{"nctId":5885,"briefTitle":5886,"status":105,"phases":10232,"primaryCompletion":5888,"completion":5888,"start":5889,"enrollment":5890,"conditions":10233,"interventions":10234},[89],[24],[5893,5894,1779,5862],{"trials":10236,"activeCount":99},[],{"trials":10238,"activeCount":99},[],{"intervention":10240,"totalTrials":245,"cells":10241},"ExPEC9V",{"EARLY_PHASE1":10242,"PHASE1":10244,"PHASE2":10246,"PHASE3":10248,"PHASE4":10270,"NA":10272},{"trials":10243,"activeCount":99},[],{"trials":10245,"activeCount":99},[],{"trials":10247,"activeCount":99},[],{"trials":10249,"activeCount":99},[10250,10259],{"nctId":10251,"briefTitle":10252,"status":105,"phases":10253,"primaryCompletion":10254,"completion":10254,"start":3739,"enrollment":10255,"conditions":10256,"interventions":10258},"NCT04899336","A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years",[89],"2025-08-27",17935,[10257],"Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention",[10240],{"nctId":10260,"briefTitle":10261,"status":105,"phases":10262,"primaryCompletion":10263,"completion":10264,"start":10265,"enrollment":10266,"conditions":10267,"interventions":10268},"NCT06134804","A Study of 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) and High-dose Quadrivalent Influenza Vaccine, With and Without Co-administration, in Adults Aged 65 Years or Older",[89],"2024-02-19","2024-07-26","2023-10-24",959,[10257],[10240,10269],"HD quadrivalent influenza vaccine",{"trials":10271,"activeCount":99},[],{"trials":10273,"activeCount":99},[],{"intervention":9622,"totalTrials":245,"cells":10275},{"EARLY_PHASE1":10276,"PHASE1":10278,"PHASE2":10280,"PHASE3":10282,"PHASE4":10292,"NA":10294},{"trials":10277,"activeCount":99},[],{"trials":10279,"activeCount":99},[],{"trials":10281,"activeCount":99},[],{"trials":10283,"activeCount":99},[10284,10288],{"nctId":9614,"briefTitle":9615,"status":105,"phases":10285,"primaryCompletion":9617,"completion":9617,"start":9618,"enrollment":9619,"conditions":10286,"interventions":10287},[88,89],[27],[9622,9623,9624,9089],{"nctId":9630,"briefTitle":9615,"status":105,"phases":10289,"primaryCompletion":8891,"completion":4222,"start":9632,"enrollment":9633,"conditions":10290,"interventions":10291},[89],[27],[9089,9622,9623],{"trials":10293,"activeCount":99},[],{"trials":10295,"activeCount":99},[],{"intervention":9623,"totalTrials":245,"cells":10297},{"EARLY_PHASE1":10298,"PHASE1":10300,"PHASE2":10302,"PHASE3":10304,"PHASE4":10314,"NA":10316},{"trials":10299,"activeCount":99},[],{"trials":10301,"activeCount":99},[],{"trials":10303,"activeCount":99},[],{"trials":10305,"activeCount":99},[10306,10310],{"nctId":9614,"briefTitle":9615,"status":105,"phases":10307,"primaryCompletion":9617,"completion":9617,"start":9618,"enrollment":9619,"conditions":10308,"interventions":10309},[88,89],[27],[9622,9623,9624,9089],{"nctId":9630,"briefTitle":9615,"status":105,"phases":10311,"primaryCompletion":8891,"completion":4222,"start":9632,"enrollment":9633,"conditions":10312,"interventions":10313},[89],[27],[9089,9622,9623],{"trials":10315,"activeCount":99},[],{"trials":10317,"activeCount":99},[],{"intervention":9390,"totalTrials":245,"cells":10319},{"EARLY_PHASE1":10320,"PHASE1":10322,"PHASE2":10324,"PHASE3":10326,"PHASE4":10336,"NA":10338},{"trials":10321,"activeCount":99},[],{"trials":10323,"activeCount":99},[],{"trials":10325,"activeCount":99},[],{"trials":10327,"activeCount":99},[10328,10332],{"nctId":9381,"briefTitle":9382,"status":105,"phases":10329,"primaryCompletion":9384,"completion":9385,"start":9386,"enrollment":9387,"conditions":10330,"interventions":10331},[89],[171],[9390,3491],{"nctId":9392,"briefTitle":9393,"status":105,"phases":10333,"primaryCompletion":5678,"completion":9395,"start":9396,"enrollment":9397,"conditions":10334,"interventions":10335},[89],[171],[9390,3491],{"trials":10337,"activeCount":99},[],{"trials":10339,"activeCount":99},[],{"intervention":8280,"totalTrials":245,"cells":10341},{"EARLY_PHASE1":10342,"PHASE1":10344,"PHASE2":10346,"PHASE3":10348,"PHASE4":10358,"NA":10360},{"trials":10343,"activeCount":99},[],{"trials":10345,"activeCount":99},[],{"trials":10347,"activeCount":99},[],{"trials":10349,"activeCount":99},[10350,10354],{"nctId":8272,"briefTitle":8273,"status":125,"phases":10351,"primaryCompletion":6034,"completion":6034,"start":1176,"enrollment":8275,"conditions":10352,"interventions":10353},[89],[8277],[8246,8279,8280,8281,8282],{"nctId":8302,"briefTitle":8303,"status":125,"phases":10355,"primaryCompletion":2565,"completion":2565,"start":1176,"enrollment":2948,"conditions":10356,"interventions":10357},[89],[8306,8307,8308,8309],[8281,8280,8246,8279,8282],{"trials":10359,"activeCount":99},[],{"trials":10361,"activeCount":99},[],{"intervention":8281,"totalTrials":245,"cells":10363},{"EARLY_PHASE1":10364,"PHASE1":10366,"PHASE2":10368,"PHASE3":10370,"PHASE4":10380,"NA":10382},{"trials":10365,"activeCount":99},[],{"trials":10367,"activeCount":99},[],{"trials":10369,"activeCount":99},[],{"trials":10371,"activeCount":99},[10372,10376],{"nctId":8272,"briefTitle":8273,"status":125,"phases":10373,"primaryCompletion":6034,"completion":6034,"start":1176,"enrollment":8275,"conditions":10374,"interventions":10375},[89],[8277],[8246,8279,8280,8281,8282],{"nctId":8302,"briefTitle":8303,"status":125,"phases":10377,"primaryCompletion":2565,"completion":2565,"start":1176,"enrollment":2948,"conditions":10378,"interventions":10379},[89],[8306,8307,8308,8309],[8281,8280,8246,8279,8282],{"trials":10381,"activeCount":99},[],{"trials":10383,"activeCount":99},[],{"intervention":9917,"totalTrials":245,"cells":10385},{"EARLY_PHASE1":10386,"PHASE1":10388,"PHASE2":10390,"PHASE3":10392,"PHASE4":10402,"NA":10404},{"trials":10387,"activeCount":99},[],{"trials":10389,"activeCount":99},[],{"trials":10391,"activeCount":99},[],{"trials":10393,"activeCount":99},[10394,10398],{"nctId":9908,"briefTitle":9909,"status":105,"phases":10395,"primaryCompletion":6034,"completion":3328,"start":5845,"enrollment":9911,"conditions":10396,"interventions":10397},[89],[199,9913,9914,9915],[9917,9918,9897],{"nctId":9920,"briefTitle":9921,"status":105,"phases":10399,"primaryCompletion":5530,"completion":3359,"start":5845,"enrollment":9923,"conditions":10400,"interventions":10401},[89],[199,9915,9913,9914],[9897,9917,9918],{"trials":10403,"activeCount":99},[],{"trials":10405,"activeCount":99},[],{"intervention":9918,"totalTrials":245,"cells":10407},{"EARLY_PHASE1":10408,"PHASE1":10410,"PHASE2":10412,"PHASE3":10414,"PHASE4":10424,"NA":10426},{"trials":10409,"activeCount":99},[],{"trials":10411,"activeCount":99},[],{"trials":10413,"activeCount":99},[],{"trials":10415,"activeCount":99},[10416,10420],{"nctId":9908,"briefTitle":9909,"status":105,"phases":10417,"primaryCompletion":6034,"completion":3328,"start":5845,"enrollment":9911,"conditions":10418,"interventions":10419},[89],[199,9913,9914,9915],[9917,9918,9897],{"nctId":9920,"briefTitle":9921,"status":105,"phases":10421,"primaryCompletion":5530,"completion":3359,"start":5845,"enrollment":9923,"conditions":10422,"interventions":10423},[89],[199,9915,9913,9914],[9897,9917,9918],{"trials":10425,"activeCount":99},[],{"trials":10427,"activeCount":99},[],{"intervention":10429,"totalTrials":245,"cells":10430},"Tenofovir Disoproxil Fumarate",{"EARLY_PHASE1":10431,"PHASE1":10433,"PHASE2":10445,"PHASE3":10447,"PHASE4":10458,"NA":10460},{"trials":10432,"activeCount":99},[],{"trials":10434,"activeCount":99},[10435],{"nctId":10436,"briefTitle":10437,"status":125,"phases":10438,"primaryCompletion":10439,"completion":10440,"start":10441,"enrollment":656,"conditions":10442,"interventions":10443},"NCT05423106","A Single and Multiple Ascending Dose Study of JNJ-64457744",[87],"2023-03-14","2023-03-20","2022-07-04",[15,2412],[10444,10429,7294,7295,10444],"JNJ-64457744",{"trials":10446,"activeCount":99},[],{"trials":10448,"activeCount":99},[10449],{"nctId":10450,"briefTitle":10451,"status":125,"phases":10452,"primaryCompletion":10453,"completion":10453,"start":1337,"enrollment":2566,"conditions":10454,"interventions":10456},"NCT03563742","A Study to Determine the Safety and Efficacy of Rilpivirine in Treatment-naive Indian Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection",[89],"2021-06-28",[10455],"Human Immunodeficiency Virus Infections",[10457,10429],"Rilpivirine 25 mg",{"trials":10459,"activeCount":99},[],{"trials":10461,"activeCount":99},[],{"intervention":4457,"totalTrials":245,"cells":10463},{"EARLY_PHASE1":10464,"PHASE1":10466,"PHASE2":10468,"PHASE3":10474,"PHASE4":10480,"NA":10482},{"trials":10465,"activeCount":99},[],{"trials":10467,"activeCount":99},[],{"trials":10469,"activeCount":99},[10470],{"nctId":4986,"briefTitle":4987,"status":105,"phases":10471,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":3853,"conditions":10472,"interventions":10473},[88],[21],[4325,4457,4482,4994],{"trials":10475,"activeCount":99},[10476],{"nctId":4450,"briefTitle":4451,"status":105,"phases":10477,"primaryCompletion":4453,"completion":4453,"start":3894,"enrollment":4454,"conditions":10478,"interventions":10479},[89],[21],[4385,4457],{"trials":10481,"activeCount":99},[],{"trials":10483,"activeCount":99},[],{"intervention":10485,"totalTrials":245,"cells":10486},"Pimodivir 600 mg",{"EARLY_PHASE1":10487,"PHASE1":10489,"PHASE2":10491,"PHASE3":10493,"PHASE4":10514,"NA":10516},{"trials":10488,"activeCount":99},[],{"trials":10490,"activeCount":99},[],{"trials":10492,"activeCount":99},[],{"trials":10494,"activeCount":99},[10495,10504],{"nctId":10496,"briefTitle":10497,"status":125,"phases":10498,"primaryCompletion":3685,"completion":8660,"start":10499,"enrollment":10500,"conditions":10501,"interventions":10503},"NCT03376321","A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A Infection",[89],"2018-01-03",334,[10502],"Influenza A",[10485],{"nctId":10505,"briefTitle":10506,"status":125,"phases":10507,"primaryCompletion":10508,"completion":10509,"start":10510,"enrollment":10511,"conditions":10512,"interventions":10513},"NCT03381196","A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications",[89],"2020-05-28","2020-08-24","2018-01-21",553,[10502],[10485],{"trials":10515,"activeCount":99},[],{"trials":10517,"activeCount":99},[],{"intervention":1300,"totalTrials":245,"cells":10519},{"EARLY_PHASE1":10520,"PHASE1":10522,"PHASE2":10524,"PHASE3":10526,"PHASE4":10536,"NA":10538},{"trials":10521,"activeCount":99},[],{"trials":10523,"activeCount":99},[],{"trials":10525,"activeCount":99},[],{"trials":10527,"activeCount":99},[10528,10532],{"nctId":1291,"briefTitle":1292,"status":105,"phases":10529,"primaryCompletion":1294,"completion":1295,"start":1296,"enrollment":1297,"conditions":10530,"interventions":10531},[89],[18],[1166,1167,496,1300,684,1301],{"nctId":1334,"briefTitle":1335,"status":105,"phases":10533,"primaryCompletion":1337,"completion":1338,"start":1339,"enrollment":1340,"conditions":10534,"interventions":10535},[89],[18],[1300,683,684,1301],{"trials":10537,"activeCount":99},[],{"trials":10539,"activeCount":99},[],{"intervention":2675,"totalTrials":245,"cells":10541},{"EARLY_PHASE1":10542,"PHASE1":10544,"PHASE2":10546,"PHASE3":10548,"PHASE4":10558,"NA":10560},{"trials":10543,"activeCount":99},[],{"trials":10545,"activeCount":99},[],{"trials":10547,"activeCount":99},[],{"trials":10549,"activeCount":99},[10550,10554],{"nctId":3736,"briefTitle":3737,"status":105,"phases":10551,"primaryCompletion":3739,"completion":3740,"start":3741,"enrollment":3742,"conditions":10552,"interventions":10553},[89],[3708],[2675,1384,46],{"nctId":2667,"briefTitle":2668,"status":105,"phases":10555,"primaryCompletion":1964,"completion":2670,"start":2671,"enrollment":2672,"conditions":10556,"interventions":10557},[89],[1509],[2675,1384,659,1556,1154,496,2676],{"trials":10559,"activeCount":99},[],{"trials":10561,"activeCount":99},[],{"intervention":10103,"totalTrials":245,"cells":10563},{"EARLY_PHASE1":10564,"PHASE1":10566,"PHASE2":10568,"PHASE3":10570,"PHASE4":10580,"NA":10582},{"trials":10565,"activeCount":99},[],{"trials":10567,"activeCount":99},[],{"trials":10569,"activeCount":99},[],{"trials":10571,"activeCount":99},[10572,10576],{"nctId":10097,"briefTitle":10098,"status":105,"phases":10573,"primaryCompletion":1175,"completion":1175,"start":2513,"enrollment":10100,"conditions":10574,"interventions":10575},[89],[32],[10103,10104,10086,10105],{"nctId":10107,"briefTitle":10108,"status":105,"phases":10577,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":10578,"interventions":10579},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":10581,"activeCount":99},[],{"trials":10583,"activeCount":99},[],{"intervention":10104,"totalTrials":245,"cells":10585},{"EARLY_PHASE1":10586,"PHASE1":10588,"PHASE2":10590,"PHASE3":10592,"PHASE4":10602,"NA":10604},{"trials":10587,"activeCount":99},[],{"trials":10589,"activeCount":99},[],{"trials":10591,"activeCount":99},[],{"trials":10593,"activeCount":99},[10594,10598],{"nctId":10097,"briefTitle":10098,"status":105,"phases":10595,"primaryCompletion":1175,"completion":1175,"start":2513,"enrollment":10100,"conditions":10596,"interventions":10597},[89],[32],[10103,10104,10086,10105],{"nctId":10107,"briefTitle":10108,"status":105,"phases":10599,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":10600,"interventions":10601},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":10603,"activeCount":99},[],{"trials":10605,"activeCount":99},[],{"intervention":10068,"totalTrials":245,"cells":10607},{"EARLY_PHASE1":10608,"PHASE1":10610,"PHASE2":10612,"PHASE3":10614,"PHASE4":10624,"NA":10626},{"trials":10609,"activeCount":99},[],{"trials":10611,"activeCount":99},[],{"trials":10613,"activeCount":99},[],{"trials":10615,"activeCount":99},[10616,10620],{"nctId":10060,"briefTitle":10061,"status":105,"phases":10617,"primaryCompletion":10063,"completion":10063,"start":10064,"enrollment":10065,"conditions":10618,"interventions":10619},[89],[2003],[10068,10040],{"nctId":10070,"briefTitle":10071,"status":105,"phases":10621,"primaryCompletion":10073,"completion":10073,"start":10074,"enrollment":10075,"conditions":10622,"interventions":10623},[89],[2003],[10078,10079,10080],{"trials":10625,"activeCount":99},[],{"trials":10627,"activeCount":99},[],{"intervention":258,"totalTrials":468,"cells":10629},{"EARLY_PHASE1":10630,"PHASE1":10632,"PHASE2":10634,"PHASE3":10636,"PHASE4":10642,"NA":10644},{"trials":10631,"activeCount":99},[],{"trials":10633,"activeCount":99},[],{"trials":10635,"activeCount":99},[],{"trials":10637,"activeCount":99},[10638],{"nctId":249,"briefTitle":250,"status":105,"phases":10639,"primaryCompletion":252,"completion":253,"start":254,"enrollment":255,"conditions":10640,"interventions":10641},[89],[171],[94,258],{"trials":10643,"activeCount":99},[],{"trials":10645,"activeCount":99},[],{"intervention":10647,"totalTrials":468,"cells":10648},"Decitabine 20 mg\u002Fm^2",{"EARLY_PHASE1":10649,"PHASE1":10651,"PHASE2":10653,"PHASE3":10655,"PHASE4":10667,"NA":10669},{"trials":10650,"activeCount":99},[],{"trials":10652,"activeCount":99},[],{"trials":10654,"activeCount":99},[],{"trials":10656,"activeCount":99},[10657],{"nctId":10658,"briefTitle":10659,"status":105,"phases":10660,"primaryCompletion":10661,"completion":10661,"start":10662,"enrollment":10663,"conditions":10664,"interventions":10665},"NCT02472145","An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy",[88,89],"2018-01-25","2015-08-04",326,[2894],[10647,10666],"Talacotuzumab 9 mg\u002Fkg",{"trials":10668,"activeCount":99},[],{"trials":10670,"activeCount":99},[],{"intervention":10666,"totalTrials":468,"cells":10672},{"EARLY_PHASE1":10673,"PHASE1":10675,"PHASE2":10677,"PHASE3":10679,"PHASE4":10685,"NA":10687},{"trials":10674,"activeCount":99},[],{"trials":10676,"activeCount":99},[],{"trials":10678,"activeCount":99},[],{"trials":10680,"activeCount":99},[10681],{"nctId":10658,"briefTitle":10659,"status":105,"phases":10682,"primaryCompletion":10661,"completion":10661,"start":10662,"enrollment":10663,"conditions":10683,"interventions":10684},[88,89],[2894],[10647,10666],{"trials":10686,"activeCount":99},[],{"trials":10688,"activeCount":99},[],{"intervention":9624,"totalTrials":468,"cells":10690},{"EARLY_PHASE1":10691,"PHASE1":10693,"PHASE2":10695,"PHASE3":10697,"PHASE4":10703,"NA":10705},{"trials":10692,"activeCount":99},[],{"trials":10694,"activeCount":99},[],{"trials":10696,"activeCount":99},[],{"trials":10698,"activeCount":99},[10699],{"nctId":9614,"briefTitle":9615,"status":105,"phases":10700,"primaryCompletion":9617,"completion":9617,"start":9618,"enrollment":9619,"conditions":10701,"interventions":10702},[88,89],[27],[9622,9623,9624,9089],{"trials":10704,"activeCount":99},[],{"trials":10706,"activeCount":99},[],{"intervention":8219,"totalTrials":468,"cells":10708},{"EARLY_PHASE1":10709,"PHASE1":10711,"PHASE2":10713,"PHASE3":10715,"PHASE4":10721,"NA":10723},{"trials":10710,"activeCount":99},[],{"trials":10712,"activeCount":99},[],{"trials":10714,"activeCount":99},[],{"trials":10716,"activeCount":99},[10717],{"nctId":8211,"briefTitle":8212,"status":105,"phases":10718,"primaryCompletion":8214,"completion":8214,"start":8215,"enrollment":8216,"conditions":10719,"interventions":10720},[89],[24],[8193,5861,8219],{"trials":10722,"activeCount":99},[],{"trials":10724,"activeCount":99},[],{"intervention":10726,"totalTrials":468,"cells":10727},"PP6M injection Dose 1",{"EARLY_PHASE1":10728,"PHASE1":10730,"PHASE2":10732,"PHASE3":10734,"PHASE4":10745,"NA":10747},{"trials":10729,"activeCount":99},[],{"trials":10731,"activeCount":99},[],{"trials":10733,"activeCount":99},[],{"trials":10735,"activeCount":99},[10736],{"nctId":10737,"briefTitle":10119,"status":105,"phases":10738,"primaryCompletion":10739,"completion":10739,"start":10740,"enrollment":10741,"conditions":10742,"interventions":10743},"NCT04072575",[89],"2022-05-03","2019-09-19",178,[32],[10726,10744],"PP6M injection Dose 2",{"trials":10746,"activeCount":99},[],{"trials":10748,"activeCount":99},[],{"intervention":10744,"totalTrials":468,"cells":10750},{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10755,"PHASE3":10757,"PHASE4":10763,"NA":10765},{"trials":10752,"activeCount":99},[],{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[10759],{"nctId":10737,"briefTitle":10119,"status":105,"phases":10760,"primaryCompletion":10739,"completion":10739,"start":10740,"enrollment":10741,"conditions":10761,"interventions":10762},[89],[32],[10726,10744],{"trials":10764,"activeCount":99},[],{"trials":10766,"activeCount":99},[],{"intervention":10768,"totalTrials":468,"cells":10769},"Dacarbazine",{"EARLY_PHASE1":10770,"PHASE1":10772,"PHASE2":10774,"PHASE3":10776,"PHASE4":10786,"NA":10788},{"trials":10771,"activeCount":99},[],{"trials":10773,"activeCount":99},[],{"trials":10775,"activeCount":99},[],{"trials":10777,"activeCount":99},[10778],{"nctId":10779,"briefTitle":10780,"status":105,"phases":10781,"primaryCompletion":5493,"completion":8190,"start":9596,"enrollment":10782,"conditions":10783,"interventions":10785},"NCT01343277","A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma",[89],579,[10784],"Advanced Liposarcoma or Leiomyosarcoma",[1182,10768],{"trials":10787,"activeCount":99},[],{"trials":10789,"activeCount":99},[],{"intervention":10791,"totalTrials":468,"cells":10792},"Ustekinumab - Half-Standard Dosage",{"EARLY_PHASE1":10793,"PHASE1":10795,"PHASE2":10797,"PHASE3":10799,"PHASE4":10808,"NA":10810},{"trials":10794,"activeCount":99},[],{"trials":10796,"activeCount":99},[],{"trials":10798,"activeCount":99},[],{"trials":10800,"activeCount":99},[10801],{"nctId":10802,"briefTitle":10803,"status":105,"phases":10804,"primaryCompletion":5868,"completion":5555,"start":5879,"enrollment":9507,"conditions":10805,"interventions":10806},"NCT01090427","A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)",[89],[171],[10791,10807],"Ustekinumab - Standard Dosage",{"trials":10809,"activeCount":99},[],{"trials":10811,"activeCount":99},[],{"intervention":10807,"totalTrials":468,"cells":10813},{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10818,"PHASE3":10820,"PHASE4":10826,"NA":10828},{"trials":10815,"activeCount":99},[],{"trials":10817,"activeCount":99},[],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[10822],{"nctId":10802,"briefTitle":10803,"status":105,"phases":10823,"primaryCompletion":5868,"completion":5555,"start":5879,"enrollment":9507,"conditions":10824,"interventions":10825},[89],[171],[10791,10807],{"trials":10827,"activeCount":99},[],{"trials":10829,"activeCount":99},[],{"intervention":10831,"totalTrials":468,"cells":10832},"Dapoxetine",{"EARLY_PHASE1":10833,"PHASE1":10835,"PHASE2":10837,"PHASE3":10839,"PHASE4":10851,"NA":10853},{"trials":10834,"activeCount":99},[],{"trials":10836,"activeCount":99},[],{"trials":10838,"activeCount":99},[],{"trials":10840,"activeCount":99},[10841],{"nctId":10842,"briefTitle":10843,"status":105,"phases":10844,"primaryCompletion":10845,"completion":10845,"start":10846,"enrollment":10847,"conditions":10848,"interventions":10850},"NCT01063881","The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy",[89],"2011-06-14","2010-05-22",285,[10849],"Sexual Dysfunction, Physiological",[10831],{"trials":10852,"activeCount":99},[],{"trials":10854,"activeCount":99},[],{"intervention":10856,"totalTrials":468,"cells":10857},"Galantamine",{"EARLY_PHASE1":10858,"PHASE1":10860,"PHASE2":10862,"PHASE3":10864,"PHASE4":10875,"NA":10877},{"trials":10859,"activeCount":99},[],{"trials":10861,"activeCount":99},[],{"trials":10863,"activeCount":99},[],{"trials":10865,"activeCount":99},[10866],{"nctId":10867,"briefTitle":10868,"status":125,"phases":10869,"primaryCompletion":2487,"completion":2513,"start":10870,"enrollment":10871,"conditions":10872,"interventions":10874},"NCT00679627","A Study of Galantamine Used to Treat Patients With Mild to Moderate Alzheimer's Disease",[89],"2008-06",2051,[10873],"Alzheimer's Disease",[10856],{"trials":10876,"activeCount":99},[],{"trials":10878,"activeCount":99},[],{"intervention":10880,"totalTrials":468,"cells":10881},"epoetin alfa + packed RBC transfusion",{"EARLY_PHASE1":10882,"PHASE1":10884,"PHASE2":10886,"PHASE3":10888,"PHASE4":10902,"NA":10904},{"trials":10883,"activeCount":99},[],{"trials":10885,"activeCount":99},[],{"trials":10887,"activeCount":99},[],{"trials":10889,"activeCount":99},[10890],{"nctId":10891,"briefTitle":10892,"status":105,"phases":10893,"primaryCompletion":10894,"completion":10895,"start":10896,"enrollment":10897,"conditions":10898,"interventions":10901},"NCT00338286","A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy",[89],"2014-07-07","2017-01-31","2006-03-02",2098,[10899,10900],"Breast Cancer","Neoplasm Metastasis",[10880],{"trials":10903,"activeCount":99},[],{"trials":10905,"activeCount":99},[],{"intervention":1735,"totalTrials":468,"cells":10907},{"EARLY_PHASE1":10908,"PHASE1":10910,"PHASE2":10912,"PHASE3":10914,"PHASE4":10920,"NA":10922},{"trials":10909,"activeCount":99},[],{"trials":10911,"activeCount":99},[],{"trials":10913,"activeCount":99},[],{"trials":10915,"activeCount":99},[10916],{"nctId":1727,"briefTitle":1728,"status":137,"phases":10917,"primaryCompletion":1730,"completion":1731,"start":1732,"enrollment":99,"conditions":10918,"interventions":10919},[89],[1017],[70,1735],{"trials":10921,"activeCount":99},[],{"trials":10923,"activeCount":99},[],{"intervention":10925,"totalTrials":468,"cells":10926},"No Treatment",{"EARLY_PHASE1":10927,"PHASE1":10929,"PHASE2":10931,"PHASE3":10933,"PHASE4":10945,"NA":10947},{"trials":10928,"activeCount":99},[],{"trials":10930,"activeCount":99},[],{"trials":10932,"activeCount":99},[],{"trials":10934,"activeCount":99},[10935],{"nctId":10936,"briefTitle":10937,"status":125,"phases":10938,"primaryCompletion":10939,"completion":10940,"start":10941,"enrollment":3586,"conditions":10942,"interventions":10944},"NCT03099135","A Long Term Follow-up Study in Participants Treated in a Preceding Phase 2 or 3 Study With a Regimen Containing Odalasvir and AL-335 With or Without Simeprevir for the Treatment of Hepatitis C Virus (HCV) Infection",[89],"2018-02-01","2018-02-13","2017-04-10",[10943],"Hepatitis C",[10925],{"trials":10946,"activeCount":99},[],{"trials":10948,"activeCount":99},[],{"intervention":5873,"totalTrials":468,"cells":10950},{"EARLY_PHASE1":10951,"PHASE1":10953,"PHASE2":10955,"PHASE3":10957,"PHASE4":10963,"NA":10965},{"trials":10952,"activeCount":99},[],{"trials":10954,"activeCount":99},[],{"trials":10956,"activeCount":99},[],{"trials":10958,"activeCount":99},[10959],{"nctId":5864,"briefTitle":5865,"status":105,"phases":10960,"primaryCompletion":5867,"completion":5868,"start":5869,"enrollment":5870,"conditions":10961,"interventions":10962},[89],[24],[5873,5826,1779],{"trials":10964,"activeCount":99},[],{"trials":10966,"activeCount":99},[],{"intervention":10968,"totalTrials":468,"cells":10969},"Rivaroxaban, 10 mg",{"EARLY_PHASE1":10970,"PHASE1":10972,"PHASE2":10974,"PHASE3":10976,"PHASE4":10992,"NA":10994},{"trials":10971,"activeCount":99},[],{"trials":10973,"activeCount":99},[],{"trials":10975,"activeCount":99},[],{"trials":10977,"activeCount":99},[10978],{"nctId":10979,"briefTitle":10980,"status":105,"phases":10981,"primaryCompletion":3378,"completion":10982,"start":10983,"enrollment":10984,"conditions":10985,"interventions":10990},"NCT02111564","A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge Patients",[89],"2018-05-03","2014-01-07",12024,[8947,10986,10987,10988,10989],"Respiratory Insufficiency","Stroke Acute","Infectious Diseases","Rheumatic Diseases",[10968,10991],"Rivaroxaban, 7.5 mg",{"trials":10993,"activeCount":99},[],{"trials":10995,"activeCount":99},[],{"intervention":10991,"totalTrials":468,"cells":10997},{"EARLY_PHASE1":10998,"PHASE1":11000,"PHASE2":11002,"PHASE3":11004,"PHASE4":11010,"NA":11012},{"trials":10999,"activeCount":99},[],{"trials":11001,"activeCount":99},[],{"trials":11003,"activeCount":99},[],{"trials":11005,"activeCount":99},[11006],{"nctId":10979,"briefTitle":10980,"status":105,"phases":11007,"primaryCompletion":3378,"completion":10982,"start":10983,"enrollment":10984,"conditions":11008,"interventions":11009},[89],[8947,10986,10987,10988,10989],[10968,10991],{"trials":11011,"activeCount":99},[],{"trials":11013,"activeCount":99},[],{"intervention":2223,"totalTrials":468,"cells":11015},{"EARLY_PHASE1":11016,"PHASE1":11018,"PHASE2":11020,"PHASE3":11022,"PHASE4":11028,"NA":11030},{"trials":11017,"activeCount":99},[],{"trials":11019,"activeCount":99},[],{"trials":11021,"activeCount":99},[],{"trials":11023,"activeCount":99},[11024],{"nctId":2214,"briefTitle":2215,"status":105,"phases":11025,"primaryCompletion":2217,"completion":2218,"start":2219,"enrollment":2220,"conditions":11026,"interventions":11027},[89],[18],[682,682,2223],{"trials":11029,"activeCount":99},[],{"trials":11031,"activeCount":99},[],{"intervention":11033,"totalTrials":468,"cells":11034},"Golimumab 1 mg per kg",{"EARLY_PHASE1":11035,"PHASE1":11037,"PHASE2":11039,"PHASE3":11041,"PHASE4":11052,"NA":11054},{"trials":11036,"activeCount":99},[],{"trials":11038,"activeCount":99},[],{"trials":11040,"activeCount":99},[],{"trials":11042,"activeCount":99},[11043],{"nctId":11044,"briefTitle":11045,"status":125,"phases":11046,"primaryCompletion":2514,"completion":2514,"start":9618,"enrollment":11047,"conditions":11048,"interventions":11049},"NCT00488774","An Efficacy and Safety Study of Golimumab in Participants With Ulcerative Colitis",[88,89],291,[27],[11033,11050,11051],"Golimumab 2 mg per kg","Golimumab 4 mg per kg",{"trials":11053,"activeCount":99},[],{"trials":11055,"activeCount":99},[],{"intervention":11050,"totalTrials":468,"cells":11057},{"EARLY_PHASE1":11058,"PHASE1":11060,"PHASE2":11062,"PHASE3":11064,"PHASE4":11070,"NA":11072},{"trials":11059,"activeCount":99},[],{"trials":11061,"activeCount":99},[],{"trials":11063,"activeCount":99},[],{"trials":11065,"activeCount":99},[11066],{"nctId":11044,"briefTitle":11045,"status":125,"phases":11067,"primaryCompletion":2514,"completion":2514,"start":9618,"enrollment":11047,"conditions":11068,"interventions":11069},[88,89],[27],[11033,11050,11051],{"trials":11071,"activeCount":99},[],{"trials":11073,"activeCount":99},[],{"intervention":11051,"totalTrials":468,"cells":11075},{"EARLY_PHASE1":11076,"PHASE1":11078,"PHASE2":11080,"PHASE3":11082,"PHASE4":11088,"NA":11090},{"trials":11077,"activeCount":99},[],{"trials":11079,"activeCount":99},[],{"trials":11081,"activeCount":99},[],{"trials":11083,"activeCount":99},[11084],{"nctId":11044,"briefTitle":11045,"status":125,"phases":11085,"primaryCompletion":2514,"completion":2514,"start":9618,"enrollment":11047,"conditions":11086,"interventions":11087},[88,89],[27],[11033,11050,11051],{"trials":11089,"activeCount":99},[],{"trials":11091,"activeCount":99},[],{"intervention":9666,"totalTrials":468,"cells":11093},{"EARLY_PHASE1":11094,"PHASE1":11096,"PHASE2":11098,"PHASE3":11100,"PHASE4":11106,"NA":11108},{"trials":11095,"activeCount":99},[],{"trials":11097,"activeCount":99},[],{"trials":11099,"activeCount":99},[],{"trials":11101,"activeCount":99},[11102],{"nctId":9656,"briefTitle":9657,"status":105,"phases":11103,"primaryCompletion":9659,"completion":9659,"start":9660,"enrollment":4842,"conditions":11104,"interventions":11105},[89],[9662,9663],[9645,9665,9666],{"trials":11107,"activeCount":99},[],{"trials":11109,"activeCount":99},[],{"intervention":10457,"totalTrials":468,"cells":11111},{"EARLY_PHASE1":11112,"PHASE1":11114,"PHASE2":11116,"PHASE3":11118,"PHASE4":11124,"NA":11126},{"trials":11113,"activeCount":99},[],{"trials":11115,"activeCount":99},[],{"trials":11117,"activeCount":99},[],{"trials":11119,"activeCount":99},[11120],{"nctId":10450,"briefTitle":10451,"status":125,"phases":11121,"primaryCompletion":10453,"completion":10453,"start":1337,"enrollment":2566,"conditions":11122,"interventions":11123},[89],[10455],[10457,10429],{"trials":11125,"activeCount":99},[],{"trials":11127,"activeCount":99},[],{"intervention":2621,"totalTrials":468,"cells":11129},{"EARLY_PHASE1":11130,"PHASE1":11132,"PHASE2":11134,"PHASE3":11136,"PHASE4":11142,"NA":11144},{"trials":11131,"activeCount":99},[],{"trials":11133,"activeCount":99},[],{"trials":11135,"activeCount":99},[],{"trials":11137,"activeCount":99},[11138],{"nctId":2612,"briefTitle":2613,"status":105,"phases":11139,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":11140,"interventions":11141},[89],[2490],[518,496,2621,2622],{"trials":11143,"activeCount":99},[],{"trials":11145,"activeCount":99},[],{"intervention":2622,"totalTrials":468,"cells":11147},{"EARLY_PHASE1":11148,"PHASE1":11150,"PHASE2":11152,"PHASE3":11154,"PHASE4":11160,"NA":11162},{"trials":11149,"activeCount":99},[],{"trials":11151,"activeCount":99},[],{"trials":11153,"activeCount":99},[],{"trials":11155,"activeCount":99},[11156],{"nctId":2612,"briefTitle":2613,"status":105,"phases":11157,"primaryCompletion":2615,"completion":2616,"start":2617,"enrollment":2618,"conditions":11158,"interventions":11159},[89],[2490],[518,496,2621,2622],{"trials":11161,"activeCount":99},[],{"trials":11163,"activeCount":99},[],{"intervention":11165,"totalTrials":468,"cells":11166},"Dara SC",{"EARLY_PHASE1":11167,"PHASE1":11169,"PHASE2":11171,"PHASE3":11173,"PHASE4":11184,"NA":11186},{"trials":11168,"activeCount":99},[],{"trials":11170,"activeCount":99},[],{"trials":11172,"activeCount":99},[],{"trials":11174,"activeCount":99},[11175],{"nctId":11176,"briefTitle":11177,"status":105,"phases":11178,"primaryCompletion":4990,"completion":11179,"start":5912,"enrollment":11180,"conditions":11181,"interventions":11182},"NCT03277105","A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma",[89],"2024-01-12",522,[18],[11165,11183],"Dara IV",{"trials":11185,"activeCount":99},[],{"trials":11187,"activeCount":99},[],{"intervention":11183,"totalTrials":468,"cells":11189},{"EARLY_PHASE1":11190,"PHASE1":11192,"PHASE2":11194,"PHASE3":11196,"PHASE4":11202,"NA":11204},{"trials":11191,"activeCount":99},[],{"trials":11193,"activeCount":99},[],{"trials":11195,"activeCount":99},[],{"trials":11197,"activeCount":99},[11198],{"nctId":11176,"briefTitle":11177,"status":105,"phases":11199,"primaryCompletion":4990,"completion":11179,"start":5912,"enrollment":11180,"conditions":11200,"interventions":11201},[89],[18],[11165,11183],{"trials":11203,"activeCount":99},[],{"trials":11205,"activeCount":99},[],{"intervention":8299,"totalTrials":468,"cells":11207},{"EARLY_PHASE1":11208,"PHASE1":11210,"PHASE2":11212,"PHASE3":11214,"PHASE4":11220,"NA":11222},{"trials":11209,"activeCount":99},[],{"trials":11211,"activeCount":99},[],{"trials":11213,"activeCount":99},[],{"trials":11215,"activeCount":99},[11216],{"nctId":8284,"briefTitle":8285,"status":125,"phases":11217,"primaryCompletion":6823,"completion":6823,"start":1176,"enrollment":8275,"conditions":11218,"interventions":11219},[89],[8288,8289,8290,8291,8292,8293,8294,8295,8296,8297],[8246,8299,8300,8279,8282],{"trials":11221,"activeCount":99},[],{"trials":11223,"activeCount":99},[],{"intervention":8300,"totalTrials":468,"cells":11225},{"EARLY_PHASE1":11226,"PHASE1":11228,"PHASE2":11230,"PHASE3":11232,"PHASE4":11238,"NA":11240},{"trials":11227,"activeCount":99},[],{"trials":11229,"activeCount":99},[],{"trials":11231,"activeCount":99},[],{"trials":11233,"activeCount":99},[11234],{"nctId":8284,"briefTitle":8285,"status":125,"phases":11235,"primaryCompletion":6823,"completion":6823,"start":1176,"enrollment":8275,"conditions":11236,"interventions":11237},[89],[8288,8289,8290,8291,8292,8293,8294,8295,8296,8297],[8246,8299,8300,8279,8282],{"trials":11239,"activeCount":99},[],{"trials":11241,"activeCount":99},[],{"intervention":11243,"totalTrials":468,"cells":11244},"Abiraterone acetate and prednisone",{"EARLY_PHASE1":11245,"PHASE1":11247,"PHASE2":11249,"PHASE3":11251,"PHASE4":11261,"NA":11263},{"trials":11246,"activeCount":99},[],{"trials":11248,"activeCount":99},[],{"trials":11250,"activeCount":99},[],{"trials":11252,"activeCount":99},[11253],{"nctId":11254,"briefTitle":11255,"status":105,"phases":11256,"primaryCompletion":9782,"completion":1160,"start":11257,"enrollment":11258,"conditions":11259,"interventions":11260},"NCT01591122","Study of Abiraterone Acetate Plus Prednisone in Patients With Chemo-naive Metastatic Castration-Resistant Prostate Cancer",[89],"2012-03-27",313,[2568],[11243],{"trials":11262,"activeCount":99},[],{"trials":11264,"activeCount":99},[],{"intervention":11266,"totalTrials":468,"cells":11267},"Ustekinumab 90 mg SC q8w",{"EARLY_PHASE1":11268,"PHASE1":11270,"PHASE2":11272,"PHASE3":11274,"PHASE4":11288,"NA":11290},{"trials":11269,"activeCount":99},[],{"trials":11271,"activeCount":99},[],{"trials":11273,"activeCount":99},[],{"trials":11275,"activeCount":99},[11276],{"nctId":11277,"briefTitle":11278,"status":105,"phases":11279,"primaryCompletion":11280,"completion":11281,"start":11282,"enrollment":11283,"conditions":11284,"interventions":11285},"NCT01369355","A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)",[89],"2015-06-10","2019-10-01","2011-09-13",1282,[199,9914,9913,9915],[11266,11286,11287],"Ustekinumab 130 mg IV","Ustekinumab 90 mg SC q12w",{"trials":11289,"activeCount":99},[],{"trials":11291,"activeCount":99},[],{"intervention":11286,"totalTrials":468,"cells":11293},{"EARLY_PHASE1":11294,"PHASE1":11296,"PHASE2":11298,"PHASE3":11300,"PHASE4":11306,"NA":11308},{"trials":11295,"activeCount":99},[],{"trials":11297,"activeCount":99},[],{"trials":11299,"activeCount":99},[],{"trials":11301,"activeCount":99},[11302],{"nctId":11277,"briefTitle":11278,"status":105,"phases":11303,"primaryCompletion":11280,"completion":11281,"start":11282,"enrollment":11283,"conditions":11304,"interventions":11305},[89],[199,9914,9913,9915],[11266,11286,11287],{"trials":11307,"activeCount":99},[],{"trials":11309,"activeCount":99},[],{"intervention":11287,"totalTrials":468,"cells":11311},{"EARLY_PHASE1":11312,"PHASE1":11314,"PHASE2":11316,"PHASE3":11318,"PHASE4":11324,"NA":11326},{"trials":11313,"activeCount":99},[],{"trials":11315,"activeCount":99},[],{"trials":11317,"activeCount":99},[],{"trials":11319,"activeCount":99},[11320],{"nctId":11277,"briefTitle":11278,"status":105,"phases":11321,"primaryCompletion":11280,"completion":11281,"start":11282,"enrollment":11283,"conditions":11322,"interventions":11323},[89],[199,9914,9913,9915],[11266,11286,11287],{"trials":11325,"activeCount":99},[],{"trials":11327,"activeCount":99},[],{"intervention":8666,"totalTrials":468,"cells":11329},{"EARLY_PHASE1":11330,"PHASE1":11332,"PHASE2":11334,"PHASE3":11336,"PHASE4":11342,"NA":11344},{"trials":11331,"activeCount":99},[],{"trials":11333,"activeCount":99},[],{"trials":11335,"activeCount":99},[],{"trials":11337,"activeCount":99},[11338],{"nctId":8657,"briefTitle":8658,"status":105,"phases":11339,"primaryCompletion":8660,"completion":8660,"start":8661,"enrollment":8662,"conditions":11340,"interventions":11341},[89],[8664],[8646,8666],{"trials":11343,"activeCount":99},[],{"trials":11345,"activeCount":99},[],{"intervention":3529,"totalTrials":468,"cells":11347},{"EARLY_PHASE1":11348,"PHASE1":11350,"PHASE2":11352,"PHASE3":11354,"PHASE4":11360,"NA":11362},{"trials":11349,"activeCount":99},[],{"trials":11351,"activeCount":99},[],{"trials":11353,"activeCount":99},[],{"trials":11355,"activeCount":99},[11356],{"nctId":3522,"briefTitle":3523,"status":137,"phases":11357,"primaryCompletion":3525,"completion":2440,"start":3526,"enrollment":99,"conditions":11358,"interventions":11359},[89],[2121],[214,3529],{"trials":11361,"activeCount":99},[],{"trials":11363,"activeCount":99},[],{"intervention":9835,"totalTrials":468,"cells":11365},{"EARLY_PHASE1":11366,"PHASE1":11368,"PHASE2":11370,"PHASE3":11372,"PHASE4":11378,"NA":11380},{"trials":11367,"activeCount":99},[],{"trials":11369,"activeCount":99},[],{"trials":11371,"activeCount":99},[],{"trials":11373,"activeCount":99},[11374],{"nctId":9830,"briefTitle":9831,"status":105,"phases":11375,"primaryCompletion":8891,"completion":2513,"start":5879,"enrollment":8926,"conditions":11376,"interventions":11377},[89],[24],[5826,5903,9835],{"trials":11379,"activeCount":99},[],{"trials":11381,"activeCount":99},[],{"intervention":8236,"totalTrials":468,"cells":11383},{"EARLY_PHASE1":11384,"PHASE1":11386,"PHASE2":11388,"PHASE3":11390,"PHASE4":11396,"NA":11398},{"trials":11385,"activeCount":99},[],{"trials":11387,"activeCount":99},[],{"trials":11389,"activeCount":99},[],{"trials":11391,"activeCount":99},[11392],{"nctId":8230,"briefTitle":8231,"status":105,"phases":11393,"primaryCompletion":4850,"completion":3329,"start":2486,"enrollment":8233,"conditions":11394,"interventions":11395},[89],[24],[8193,5861,8236],{"trials":11397,"activeCount":99},[],{"trials":11399,"activeCount":99},[],{"intervention":1328,"totalTrials":468,"cells":11401},{"EARLY_PHASE1":11402,"PHASE1":11404,"PHASE2":11406,"PHASE3":11408,"PHASE4":11414,"NA":11416},{"trials":11403,"activeCount":99},[],{"trials":11405,"activeCount":99},[],{"trials":11407,"activeCount":99},[],{"trials":11409,"activeCount":99},[11410],{"nctId":1316,"briefTitle":1317,"status":105,"phases":11411,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":11412,"interventions":11413},[89],[1324,1325,1326],[1182,1328,684,1328],{"trials":11415,"activeCount":99},[],{"trials":11417,"activeCount":99},[],{"intervention":11419,"totalTrials":468,"cells":11420},"Genetic: AAV5-hRKp.RPGR",{"EARLY_PHASE1":11421,"PHASE1":11423,"PHASE2":11425,"PHASE3":11427,"PHASE4":11436,"NA":11438},{"trials":11422,"activeCount":99},[],{"trials":11424,"activeCount":99},[],{"trials":11426,"activeCount":99},[],{"trials":11428,"activeCount":99},[11429],{"nctId":11430,"briefTitle":11431,"status":105,"phases":11432,"primaryCompletion":11433,"completion":11433,"start":5170,"enrollment":7351,"conditions":11434,"interventions":11435},"NCT04671433","Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene",[89],"2024-09-30",[5173],[11419,11419],{"trials":11437,"activeCount":99},[],{"trials":11439,"activeCount":99},[],{"intervention":9934,"totalTrials":468,"cells":11441},{"EARLY_PHASE1":11442,"PHASE1":11444,"PHASE2":11446,"PHASE3":11448,"PHASE4":11454,"NA":11456},{"trials":11443,"activeCount":99},[],{"trials":11445,"activeCount":99},[],{"trials":11447,"activeCount":99},[],{"trials":11449,"activeCount":99},[11450],{"nctId":9927,"briefTitle":9928,"status":125,"phases":11451,"primaryCompletion":5547,"completion":5547,"start":9680,"enrollment":9930,"conditions":11452,"interventions":11453},[89],[9932],[9897,9934,9935],{"trials":11455,"activeCount":99},[],{"trials":11457,"activeCount":99},[],{"intervention":9935,"totalTrials":468,"cells":11459},{"EARLY_PHASE1":11460,"PHASE1":11462,"PHASE2":11464,"PHASE3":11466,"PHASE4":11472,"NA":11474},{"trials":11461,"activeCount":99},[],{"trials":11463,"activeCount":99},[],{"trials":11465,"activeCount":99},[],{"trials":11467,"activeCount":99},[11468],{"nctId":9927,"briefTitle":9928,"status":125,"phases":11469,"primaryCompletion":5547,"completion":5547,"start":9680,"enrollment":9930,"conditions":11470,"interventions":11471},[89],[9932],[9897,9934,9935],{"trials":11473,"activeCount":99},[],{"trials":11475,"activeCount":99},[],{"intervention":6828,"totalTrials":468,"cells":11477},{"EARLY_PHASE1":11478,"PHASE1":11480,"PHASE2":11482,"PHASE3":11484,"PHASE4":11490,"NA":11492},{"trials":11479,"activeCount":99},[],{"trials":11481,"activeCount":99},[],{"trials":11483,"activeCount":99},[],{"trials":11485,"activeCount":99},[11486],{"nctId":6820,"briefTitle":6821,"status":125,"phases":11487,"primaryCompletion":6823,"completion":2217,"start":1176,"enrollment":6824,"conditions":11488,"interventions":11489},[89],[6826],[6828,879],{"trials":11491,"activeCount":99},[],{"trials":11493,"activeCount":99},[],{"intervention":9099,"totalTrials":468,"cells":11495},{"EARLY_PHASE1":11496,"PHASE1":11498,"PHASE2":11500,"PHASE3":11502,"PHASE4":11508,"NA":11510},{"trials":11497,"activeCount":99},[],{"trials":11499,"activeCount":99},[],{"trials":11501,"activeCount":99},[],{"trials":11503,"activeCount":99},[11504],{"nctId":9091,"briefTitle":9092,"status":105,"phases":11505,"primaryCompletion":9094,"completion":9095,"start":9096,"enrollment":9010,"conditions":11506,"interventions":11507},[89],[171],[9099,9088,3516],{"trials":11509,"activeCount":99},[],{"trials":11511,"activeCount":99},[],{"intervention":1606,"totalTrials":468,"cells":11513},{"EARLY_PHASE1":11514,"PHASE1":11516,"PHASE2":11518,"PHASE3":11520,"PHASE4":11526,"NA":11528},{"trials":11515,"activeCount":99},[],{"trials":11517,"activeCount":99},[],{"trials":11519,"activeCount":99},[],{"trials":11521,"activeCount":99},[11522],{"nctId":1597,"briefTitle":1598,"status":105,"phases":11523,"primaryCompletion":1600,"completion":1601,"start":1602,"enrollment":1603,"conditions":11524,"interventions":11525},[89],[1215],[659,682,1606,681],{"trials":11527,"activeCount":99},[],{"trials":11529,"activeCount":99},[],{"intervention":3753,"totalTrials":468,"cells":11531},{"EARLY_PHASE1":11532,"PHASE1":11534,"PHASE2":11536,"PHASE3":11538,"PHASE4":11544,"NA":11546},{"trials":11533,"activeCount":99},[],{"trials":11535,"activeCount":99},[],{"trials":11537,"activeCount":99},[],{"trials":11539,"activeCount":99},[11540],{"nctId":3746,"briefTitle":3747,"status":105,"phases":11541,"primaryCompletion":1463,"completion":1463,"start":3749,"enrollment":3750,"conditions":11542,"interventions":11543},[89],[3729,2921],[46,3753,1384],{"trials":11545,"activeCount":99},[],{"trials":11547,"activeCount":99},[],{"intervention":11549,"totalTrials":468,"cells":11550},"Mebendazole",{"EARLY_PHASE1":11551,"PHASE1":11553,"PHASE2":11555,"PHASE3":11557,"PHASE4":11566,"NA":11568},{"trials":11552,"activeCount":99},[],{"trials":11554,"activeCount":99},[],{"trials":11556,"activeCount":99},[],{"trials":11558,"activeCount":99},[11559],{"nctId":11560,"briefTitle":11561,"status":105,"phases":11562,"primaryCompletion":8420,"completion":8420,"start":3444,"enrollment":717,"conditions":11563,"interventions":11565},"NCT02034162","A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants",[89],[11564],"Helminth Infections",[11549],{"trials":11567,"activeCount":99},[],{"trials":11569,"activeCount":99},[],{"intervention":11571,"totalTrials":468,"cells":11572},"Tapentadol IR 50 mg",{"EARLY_PHASE1":11573,"PHASE1":11575,"PHASE2":11577,"PHASE3":11579,"PHASE4":11591,"NA":11593},{"trials":11574,"activeCount":99},[],{"trials":11576,"activeCount":99},[],{"trials":11578,"activeCount":99},[],{"trials":11580,"activeCount":99},[11581],{"nctId":11582,"briefTitle":11583,"status":105,"phases":11584,"primaryCompletion":11585,"completion":11585,"start":3342,"enrollment":11586,"conditions":11587,"interventions":11589},"NCT01516008","A Study of Tapentadol Immediate-Release in the Treatment of Patients With Acute Pain From Bunionectomy",[89],"2013-02",353,[11588],"Hallux Valgus",[11571,11590],"Tapentadol IR 75 mg",{"trials":11592,"activeCount":99},[],{"trials":11594,"activeCount":99},[],{"intervention":11590,"totalTrials":468,"cells":11596},{"EARLY_PHASE1":11597,"PHASE1":11599,"PHASE2":11601,"PHASE3":11603,"PHASE4":11609,"NA":11611},{"trials":11598,"activeCount":99},[],{"trials":11600,"activeCount":99},[],{"trials":11602,"activeCount":99},[],{"trials":11604,"activeCount":99},[11605],{"nctId":11582,"briefTitle":11583,"status":105,"phases":11606,"primaryCompletion":11585,"completion":11585,"start":3342,"enrollment":11586,"conditions":11607,"interventions":11608},[89],[11588],[11571,11590],{"trials":11610,"activeCount":99},[],{"trials":11612,"activeCount":99},[],{"intervention":5883,"totalTrials":468,"cells":11614},{"EARLY_PHASE1":11615,"PHASE1":11617,"PHASE2":11619,"PHASE3":11621,"PHASE4":11627,"NA":11629},{"trials":11616,"activeCount":99},[],{"trials":11618,"activeCount":99},[],{"trials":11620,"activeCount":99},[],{"trials":11622,"activeCount":99},[11623],{"nctId":5875,"briefTitle":5876,"status":105,"phases":11624,"primaryCompletion":5878,"completion":2487,"start":5879,"enrollment":5880,"conditions":11625,"interventions":11626},[89],[24],[5826,1779,5883],{"trials":11628,"activeCount":99},[],{"trials":11630,"activeCount":99},[],{"intervention":9692,"totalTrials":468,"cells":11632},{"EARLY_PHASE1":11633,"PHASE1":11635,"PHASE2":11637,"PHASE3":11639,"PHASE4":11645,"NA":11647},{"trials":11634,"activeCount":99},[],{"trials":11636,"activeCount":99},[],{"trials":11638,"activeCount":99},[],{"trials":11640,"activeCount":99},[11641],{"nctId":9684,"briefTitle":9685,"status":105,"phases":11642,"primaryCompletion":9687,"completion":9687,"start":9688,"enrollment":9689,"conditions":11643,"interventions":11644},[89],[9662,9663],[9645,9665,9692],{"trials":11646,"activeCount":99},[],{"trials":11648,"activeCount":99},[],{"intervention":5893,"totalTrials":468,"cells":11650},{"EARLY_PHASE1":11651,"PHASE1":11653,"PHASE2":11655,"PHASE3":11657,"PHASE4":11663,"NA":11665},{"trials":11652,"activeCount":99},[],{"trials":11654,"activeCount":99},[],{"trials":11656,"activeCount":99},[],{"trials":11658,"activeCount":99},[11659],{"nctId":5885,"briefTitle":5886,"status":105,"phases":11660,"primaryCompletion":5888,"completion":5888,"start":5889,"enrollment":5890,"conditions":11661,"interventions":11662},[89],[24],[5893,5894,1779,5862],{"trials":11664,"activeCount":99},[],{"trials":11666,"activeCount":99},[],{"intervention":5894,"totalTrials":468,"cells":11668},{"EARLY_PHASE1":11669,"PHASE1":11671,"PHASE2":11673,"PHASE3":11675,"PHASE4":11681,"NA":11683},{"trials":11670,"activeCount":99},[],{"trials":11672,"activeCount":99},[],{"trials":11674,"activeCount":99},[],{"trials":11676,"activeCount":99},[11677],{"nctId":5885,"briefTitle":5886,"status":105,"phases":11678,"primaryCompletion":5888,"completion":5888,"start":5889,"enrollment":5890,"conditions":11679,"interventions":11680},[89],[24],[5893,5894,1779,5862],{"trials":11682,"activeCount":99},[],{"trials":11684,"activeCount":99},[],{"intervention":3764,"totalTrials":468,"cells":11686},{"EARLY_PHASE1":11687,"PHASE1":11689,"PHASE2":11691,"PHASE3":11693,"PHASE4":11699,"NA":11701},{"trials":11688,"activeCount":99},[],{"trials":11690,"activeCount":99},[],{"trials":11692,"activeCount":99},[],{"trials":11694,"activeCount":99},[11695],{"nctId":3755,"briefTitle":3756,"status":105,"phases":11696,"primaryCompletion":3758,"completion":3759,"start":3760,"enrollment":3761,"conditions":11697,"interventions":11698},[89],[3708],[46,3764],{"trials":11700,"activeCount":99},[],{"trials":11702,"activeCount":99},[],{"intervention":5904,"totalTrials":468,"cells":11704},{"EARLY_PHASE1":11705,"PHASE1":11707,"PHASE2":11709,"PHASE3":11711,"PHASE4":11717,"NA":11719},{"trials":11706,"activeCount":99},[],{"trials":11708,"activeCount":99},[],{"trials":11710,"activeCount":99},[],{"trials":11712,"activeCount":99},[11713],{"nctId":5896,"briefTitle":5897,"status":105,"phases":11714,"primaryCompletion":4850,"completion":5899,"start":2486,"enrollment":5900,"conditions":11715,"interventions":11716},[89],[24],[5826,5903,1779,5904],{"trials":11718,"activeCount":99},[],{"trials":11720,"activeCount":99},[],{"intervention":10113,"totalTrials":468,"cells":11722},{"EARLY_PHASE1":11723,"PHASE1":11725,"PHASE2":11727,"PHASE3":11729,"PHASE4":11735,"NA":11737},{"trials":11724,"activeCount":99},[],{"trials":11726,"activeCount":99},[],{"trials":11728,"activeCount":99},[],{"trials":11730,"activeCount":99},[11731],{"nctId":10107,"briefTitle":10108,"status":105,"phases":11732,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":11733,"interventions":11734},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":11736,"activeCount":99},[],{"trials":11738,"activeCount":99},[],{"intervention":10114,"totalTrials":468,"cells":11740},{"EARLY_PHASE1":11741,"PHASE1":11743,"PHASE2":11745,"PHASE3":11747,"PHASE4":11753,"NA":11755},{"trials":11742,"activeCount":99},[],{"trials":11744,"activeCount":99},[],{"trials":11746,"activeCount":99},[],{"trials":11748,"activeCount":99},[11749],{"nctId":10107,"briefTitle":10108,"status":105,"phases":11750,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":11751,"interventions":11752},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":11754,"activeCount":99},[],{"trials":11756,"activeCount":99},[],{"intervention":10115,"totalTrials":468,"cells":11758},{"EARLY_PHASE1":11759,"PHASE1":11761,"PHASE2":11763,"PHASE3":11765,"PHASE4":11771,"NA":11773},{"trials":11760,"activeCount":99},[],{"trials":11762,"activeCount":99},[],{"trials":11764,"activeCount":99},[],{"trials":11766,"activeCount":99},[11767],{"nctId":10107,"briefTitle":10108,"status":105,"phases":11768,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":11769,"interventions":11770},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":11772,"activeCount":99},[],{"trials":11774,"activeCount":99},[],{"intervention":10116,"totalTrials":468,"cells":11776},{"EARLY_PHASE1":11777,"PHASE1":11779,"PHASE2":11781,"PHASE3":11783,"PHASE4":11789,"NA":11791},{"trials":11778,"activeCount":99},[],{"trials":11780,"activeCount":99},[],{"trials":11782,"activeCount":99},[],{"trials":11784,"activeCount":99},[11785],{"nctId":10107,"briefTitle":10108,"status":105,"phases":11786,"primaryCompletion":4222,"completion":3658,"start":2513,"enrollment":10110,"conditions":11787,"interventions":11788},[89],[32],[10103,10104,10086,10105,10113,10114,10115,10116],{"trials":11790,"activeCount":99},[],{"trials":11792,"activeCount":99},[],{"intervention":10124,"totalTrials":468,"cells":11794},{"EARLY_PHASE1":11795,"PHASE1":11797,"PHASE2":11799,"PHASE3":11801,"PHASE4":11807,"NA":11809},{"trials":11796,"activeCount":99},[],{"trials":11798,"activeCount":99},[],{"trials":11800,"activeCount":99},[],{"trials":11802,"activeCount":99},[11803],{"nctId":10118,"briefTitle":10119,"status":105,"phases":11804,"primaryCompletion":10121,"completion":10121,"start":2959,"enrollment":8936,"conditions":11805,"interventions":11806},[89],[32],[10124,10086,10105,10125],{"trials":11808,"activeCount":99},[],{"trials":11810,"activeCount":99},[],{"intervention":10125,"totalTrials":468,"cells":11812},{"EARLY_PHASE1":11813,"PHASE1":11815,"PHASE2":11817,"PHASE3":11819,"PHASE4":11825,"NA":11827},{"trials":11814,"activeCount":99},[],{"trials":11816,"activeCount":99},[],{"trials":11818,"activeCount":99},[],{"trials":11820,"activeCount":99},[11821],{"nctId":10118,"briefTitle":10119,"status":105,"phases":11822,"primaryCompletion":10121,"completion":10121,"start":2959,"enrollment":8936,"conditions":11823,"interventions":11824},[89],[32],[10124,10086,10105,10125],{"trials":11826,"activeCount":99},[],{"trials":11828,"activeCount":99},[],{"intervention":11830,"totalTrials":468,"cells":11831},"Ustekinumab Dose Based on BSA and Body Weight",{"EARLY_PHASE1":11832,"PHASE1":11834,"PHASE2":11836,"PHASE3":11838,"PHASE4":11848,"NA":11850},{"trials":11833,"activeCount":99},[],{"trials":11835,"activeCount":99},[],{"trials":11837,"activeCount":99},[],{"trials":11839,"activeCount":99},[11840],{"nctId":11841,"briefTitle":11842,"status":105,"phases":11843,"primaryCompletion":7185,"completion":11844,"start":11845,"enrollment":5349,"conditions":11846,"interventions":11847},"NCT04630028","A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)",[89],"2025-06-05","2021-03-17",[27],[11830],{"trials":11849,"activeCount":99},[],{"trials":11851,"activeCount":99},[],{"intervention":11853,"totalTrials":468,"cells":11854},"Esketamine Nasal Spray",{"EARLY_PHASE1":11855,"PHASE1":11857,"PHASE2":11859,"PHASE3":11861,"PHASE4":11872,"NA":11874},{"trials":11856,"activeCount":99},[],{"trials":11858,"activeCount":99},[],{"trials":11860,"activeCount":99},[],{"trials":11862,"activeCount":99},[11863],{"nctId":11864,"briefTitle":11865,"status":105,"phases":11866,"primaryCompletion":11867,"completion":11867,"start":11868,"enrollment":11869,"conditions":11870,"interventions":11871},"NCT02782104","A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression",[89],"2022-12-30","2016-06-09",1148,[5681],[11853],{"trials":11873,"activeCount":99},[],{"trials":11875,"activeCount":99},[],{"intervention":10269,"totalTrials":468,"cells":11877},{"EARLY_PHASE1":11878,"PHASE1":11880,"PHASE2":11882,"PHASE3":11884,"PHASE4":11890,"NA":11892},{"trials":11879,"activeCount":99},[],{"trials":11881,"activeCount":99},[],{"trials":11883,"activeCount":99},[],{"trials":11885,"activeCount":99},[11886],{"nctId":10260,"briefTitle":10261,"status":105,"phases":11887,"primaryCompletion":10263,"completion":10264,"start":10265,"enrollment":10266,"conditions":11888,"interventions":11889},[89],[10257],[10240,10269],{"trials":11891,"activeCount":99},[],{"trials":11893,"activeCount":99},[],{"intervention":11895,"totalTrials":468,"cells":11896},"Paliperidone ER",{"EARLY_PHASE1":11897,"PHASE1":11899,"PHASE2":11901,"PHASE3":11903,"PHASE4":11915,"NA":11917},{"trials":11898,"activeCount":99},[],{"trials":11900,"activeCount":99},[],{"trials":11902,"activeCount":99},[],{"trials":11904,"activeCount":99},[11905],{"nctId":11906,"briefTitle":11907,"status":105,"phases":11908,"primaryCompletion":5899,"completion":5899,"start":11909,"enrollment":1082,"conditions":11910,"interventions":11914},"NCT00488319","Open-label Study of Flexible-dose Paliperidone ER (Extended Release) to Treat Adolescent Schizophrenia.",[89],"2007-06",[32,11911,11912,11913],"Schizophrenic Disorders","Psychotic Disorders","Dementia Praecox",[11895],{"trials":11916,"activeCount":99},[],{"trials":11918,"activeCount":99},[],{"intervention":11920,"totalTrials":468,"cells":11921},"Oxycodone CR",{"EARLY_PHASE1":11922,"PHASE1":11924,"PHASE2":11926,"PHASE3":11928,"PHASE4":11939,"NA":11941},{"trials":11923,"activeCount":99},[],{"trials":11925,"activeCount":99},[],{"trials":11927,"activeCount":99},[],{"trials":11929,"activeCount":99},[11930],{"nctId":11931,"briefTitle":11932,"status":105,"phases":11933,"primaryCompletion":2535,"completion":2535,"start":11934,"enrollment":11935,"conditions":11936,"interventions":11937},"NCT01165281","A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain",[89],"2010-08",343,[9663],[11920,11938],"R331333",{"trials":11940,"activeCount":99},[],{"trials":11942,"activeCount":99},[],{"intervention":11938,"totalTrials":468,"cells":11944},{"EARLY_PHASE1":11945,"PHASE1":11947,"PHASE2":11949,"PHASE3":11951,"PHASE4":11957,"NA":11959},{"trials":11946,"activeCount":99},[],{"trials":11948,"activeCount":99},[],{"trials":11950,"activeCount":99},[],{"trials":11952,"activeCount":99},[11953],{"nctId":11931,"briefTitle":11932,"status":105,"phases":11954,"primaryCompletion":2535,"completion":2535,"start":11934,"enrollment":11935,"conditions":11955,"interventions":11956},[89],[9663],[11920,11938],{"trials":11958,"activeCount":99},[],{"trials":11960,"activeCount":99},[],{"intervention":11962,"totalTrials":468,"cells":11963},"Canagliflozin (JNJ-28431754) 100 mg",{"EARLY_PHASE1":11964,"PHASE1":11966,"PHASE2":11968,"PHASE3":11970,"PHASE4":11984,"NA":11986},{"trials":11965,"activeCount":99},[],{"trials":11967,"activeCount":99},[],{"trials":11969,"activeCount":99},[],{"trials":11971,"activeCount":99},[11972],{"nctId":11973,"briefTitle":11974,"status":105,"phases":11975,"primaryCompletion":11976,"completion":11976,"start":11977,"enrollment":11978,"conditions":11979,"interventions":11982},"NCT01032629","CANVAS - CANagliflozin cardioVascular Assessment Study",[89],"2017-02-22","2009-12-09",4330,[24,11980,11981],"Cardiovascular Diseases","Risk Factors",[11962,11983],"Canagliflozin (JNJ-28431754) 300 mg",{"trials":11985,"activeCount":99},[],{"trials":11987,"activeCount":99},[],{"intervention":11983,"totalTrials":468,"cells":11989},{"EARLY_PHASE1":11990,"PHASE1":11992,"PHASE2":11994,"PHASE3":11996,"PHASE4":12002,"NA":12004},{"trials":11991,"activeCount":99},[],{"trials":11993,"activeCount":99},[],{"trials":11995,"activeCount":99},[],{"trials":11997,"activeCount":99},[11998],{"nctId":11973,"briefTitle":11974,"status":105,"phases":11999,"primaryCompletion":11976,"completion":11976,"start":11977,"enrollment":11978,"conditions":12000,"interventions":12001},[89],[24,11980,11981],[11962,11983],{"trials":12003,"activeCount":99},[],{"trials":12005,"activeCount":99},[],{"intervention":10190,"totalTrials":468,"cells":12007},{"EARLY_PHASE1":12008,"PHASE1":12010,"PHASE2":12012,"PHASE3":12014,"PHASE4":12020,"NA":12022},{"trials":12009,"activeCount":99},[],{"trials":12011,"activeCount":99},[],{"trials":12013,"activeCount":99},[],{"trials":12015,"activeCount":99},[12016],{"nctId":10183,"briefTitle":10184,"status":125,"phases":12017,"primaryCompletion":3461,"completion":3461,"start":10186,"enrollment":1132,"conditions":12018,"interventions":12019},[89],[10188],[10157,10190],{"trials":12021,"activeCount":99},[],{"trials":12023,"activeCount":99},[],{"intervention":9565,"totalTrials":468,"cells":12025},{"EARLY_PHASE1":12026,"PHASE1":12028,"PHASE2":12030,"PHASE3":12032,"PHASE4":12038,"NA":12040},{"trials":12027,"activeCount":99},[],{"trials":12029,"activeCount":99},[],{"trials":12031,"activeCount":99},[],{"trials":12033,"activeCount":99},[12034],{"nctId":9560,"briefTitle":9561,"status":105,"phases":12035,"primaryCompletion":3640,"completion":3640,"start":9104,"enrollment":1045,"conditions":12036,"interventions":12037},[89],[32],[9565,9521],{"trials":12039,"activeCount":99},[],{"trials":12041,"activeCount":99},[],{"intervention":1385,"totalTrials":468,"cells":12043},{"EARLY_PHASE1":12044,"PHASE1":12046,"PHASE2":12048,"PHASE3":12050,"PHASE4":12056,"NA":12058},{"trials":12045,"activeCount":99},[],{"trials":12047,"activeCount":99},[],{"trials":12049,"activeCount":99},[],{"trials":12051,"activeCount":99},[12052],{"nctId":1375,"briefTitle":1376,"status":125,"phases":12053,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":12054,"interventions":12055},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":12057,"activeCount":99},[],{"trials":12059,"activeCount":99},[],{"intervention":1386,"totalTrials":468,"cells":12061},{"EARLY_PHASE1":12062,"PHASE1":12064,"PHASE2":12066,"PHASE3":12068,"PHASE4":12074,"NA":12076},{"trials":12063,"activeCount":99},[],{"trials":12065,"activeCount":99},[],{"trials":12067,"activeCount":99},[],{"trials":12069,"activeCount":99},[12070],{"nctId":1375,"briefTitle":1376,"status":125,"phases":12071,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":12072,"interventions":12073},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":12075,"activeCount":99},[],{"trials":12077,"activeCount":99},[],{"intervention":1387,"totalTrials":468,"cells":12079},{"EARLY_PHASE1":12080,"PHASE1":12082,"PHASE2":12084,"PHASE3":12086,"PHASE4":12092,"NA":12094},{"trials":12081,"activeCount":99},[],{"trials":12083,"activeCount":99},[],{"trials":12085,"activeCount":99},[],{"trials":12087,"activeCount":99},[12088],{"nctId":1375,"briefTitle":1376,"status":125,"phases":12089,"primaryCompletion":1378,"completion":1378,"start":1379,"enrollment":1380,"conditions":12090,"interventions":12091},[89],[1382],[46,1384,1385,760,1386,1154,1387,684],{"trials":12093,"activeCount":99},[],{"trials":12095,"activeCount":99},[],{"intervention":12097,"totalTrials":468,"cells":12098},"Atabecestat, 5 mg",{"EARLY_PHASE1":12099,"PHASE1":12101,"PHASE2":12103,"PHASE3":12105,"PHASE4":12118,"NA":12120},{"trials":12100,"activeCount":99},[],{"trials":12102,"activeCount":99},[],{"trials":12104,"activeCount":99},[],{"trials":12106,"activeCount":99},[12107],{"nctId":12108,"briefTitle":12109,"status":125,"phases":12110,"primaryCompletion":12111,"completion":12111,"start":12112,"enrollment":12113,"conditions":12114,"interventions":12116},"NCT02569398","An Efficacy and Safety Study of Atabecestat in Participants Who Are Asymptomatic at Risk for Developing Alzheimer's Dementia",[88,89],"2018-12-20","2015-10-29",557,[12115],"Asymptomatic Amyloid-positive",[12097,12117],"Atabecestat, 25 mg",{"trials":12119,"activeCount":99},[],{"trials":12121,"activeCount":99},[],{"intervention":12117,"totalTrials":468,"cells":12123},{"EARLY_PHASE1":12124,"PHASE1":12126,"PHASE2":12128,"PHASE3":12130,"PHASE4":12136,"NA":12138},{"trials":12125,"activeCount":99},[],{"trials":12127,"activeCount":99},[],{"trials":12129,"activeCount":99},[],{"trials":12131,"activeCount":99},[12132],{"nctId":12108,"briefTitle":12109,"status":125,"phases":12133,"primaryCompletion":12111,"completion":12111,"start":12112,"enrollment":12113,"conditions":12134,"interventions":12135},[88,89],[12115],[12097,12117],{"trials":12137,"activeCount":99},[],{"trials":12139,"activeCount":99},[],{"intervention":10078,"totalTrials":468,"cells":12141},{"EARLY_PHASE1":12142,"PHASE1":12144,"PHASE2":12146,"PHASE3":12148,"PHASE4":12154,"NA":12156},{"trials":12143,"activeCount":99},[],{"trials":12145,"activeCount":99},[],{"trials":12147,"activeCount":99},[],{"trials":12149,"activeCount":99},[12150],{"nctId":10070,"briefTitle":10071,"status":105,"phases":12151,"primaryCompletion":10073,"completion":10073,"start":10074,"enrollment":10075,"conditions":12152,"interventions":12153},[89],[2003],[10078,10079,10080],{"trials":12155,"activeCount":99},[],{"trials":12157,"activeCount":99},[],{"intervention":7292,"totalTrials":2149,"cells":12159},{"EARLY_PHASE1":12160,"PHASE1":12162,"PHASE2":12191,"PHASE3":12246,"PHASE4":12248,"NA":12250},{"trials":12161,"activeCount":99},[],{"trials":12163,"activeCount":99},[12164,12176,12184],{"nctId":12165,"briefTitle":12166,"status":105,"phases":12167,"primaryCompletion":12168,"completion":7176,"start":12169,"enrollment":3586,"conditions":12170,"interventions":12171},"NCT05123599","A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection",[87],"2023-07-31","2021-12-06",[2412],[7292,12172,12173,12174,12175],"JNJ-64300535","ETV monohydrate","Tenofovir disoproxil","TAF",{"nctId":12177,"briefTitle":12178,"status":105,"phases":12179,"primaryCompletion":12180,"completion":12180,"start":12181,"enrollment":503,"conditions":12182,"interventions":12183},"NCT04586439","A Study of JNJ-73763989 in Healthy Chinese Adult Participants",[87],"2021-02-18","2020-11-24",[15],[7292],{"nctId":12185,"briefTitle":12186,"status":105,"phases":12187,"primaryCompletion":12188,"completion":12188,"start":1675,"enrollment":1857,"conditions":12189,"interventions":12190},"NCT04963738","A Study of JNJ-73763989 in Adult Participants With Renal Impairment",[87],"2022-10-17",[5589],[7292],{"trials":12192,"activeCount":99},[12193,12203,12214,12225,12229,12238],{"nctId":12194,"briefTitle":12195,"status":125,"phases":12196,"primaryCompletion":12197,"completion":12197,"start":12198,"enrollment":468,"conditions":12199,"interventions":12200},"NCT05005507","A Study of JNJ-73763989, Pegylated Interferon Alpha-2a and Nucleos(t)Ide Analogs in Participants With Chronic Hepatitis B Virus Infection",[88],"2021-12-29","2021-11-03",[2412],[7292,12201,12174,12175,12202],"PegIFN-alpha-2a","ETV",{"nctId":12204,"briefTitle":12205,"status":105,"phases":12206,"primaryCompletion":12207,"completion":12208,"start":1034,"enrollment":19,"conditions":12209,"interventions":12211},"NCT04535544","A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus",[88],"2023-10-19","2025-03-05",[12210],"Hepatitis D, Chronic",[7292,12212,12174,12213],"Entecavir (ETV) monohydrate","Tenofovir alafenamide",{"nctId":12215,"briefTitle":12216,"status":105,"phases":12217,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":12221,"interventions":12223},"NCT04585789","A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection",[88],"2023-02-08","2024-01-09","2021-03-11",[12222],"Hepatitis B",[7292,12224,7295,12174,12213,12201],"JNJ-56136379",{"nctId":7284,"briefTitle":7285,"status":105,"phases":12226,"primaryCompletion":7287,"completion":7288,"start":7289,"enrollment":5539,"conditions":12227,"interventions":12228},[88],[2412],[7292,7271,7293,7294,7295],{"nctId":12230,"briefTitle":12231,"status":105,"phases":12232,"primaryCompletion":12233,"completion":12234,"start":1691,"enrollment":1972,"conditions":12235,"interventions":12236},"NCT04667104","A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection",[88],"2022-05-16","2023-04-17",[2412],[7292,12174,12213,12212,12237],"PegIFN-alpha2a",{"nctId":12239,"briefTitle":12240,"status":105,"phases":12241,"primaryCompletion":12242,"completion":12243,"start":1796,"enrollment":3312,"conditions":12244,"interventions":12245},"NCT04439539","A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection",[88],"2023-08-29","2024-02-13",[2412],[7292,12201,12174,12213,12224],{"trials":12247,"activeCount":99},[],{"trials":12249,"activeCount":99},[],{"trials":12251,"activeCount":99},[],{"intervention":4325,"totalTrials":2149,"cells":12253},{"EARLY_PHASE1":12254,"PHASE1":12256,"PHASE2":12297,"PHASE3":12321,"PHASE4":12323,"NA":12325},{"trials":12255,"activeCount":99},[],{"trials":12257,"activeCount":99},[12258,12265,12271,12277,12285,12289],{"nctId":12259,"briefTitle":12260,"status":105,"phases":12261,"primaryCompletion":1583,"completion":1583,"start":12262,"enrollment":3586,"conditions":12263,"interventions":12264},"NCT04960124","A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants",[87],"2021-08-05",[15,505],[4325],{"nctId":12266,"briefTitle":12267,"status":105,"phases":12268,"primaryCompletion":3444,"completion":3444,"start":8396,"enrollment":745,"conditions":12269,"interventions":12270},"NCT02067299","A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants",[87],[21],[4325],{"nctId":12272,"briefTitle":12273,"status":105,"phases":12274,"primaryCompletion":4314,"completion":4314,"start":3633,"enrollment":5557,"conditions":12275,"interventions":12276},"NCT02661893","A Drug Interaction Study in Healthy Participants to Assess the Effect of Rifampin on the Pharmacokinetics of JNJ-42847922",[87],[15],[4325,1800],{"nctId":12278,"briefTitle":12279,"status":105,"phases":12280,"primaryCompletion":12281,"completion":12281,"start":8200,"enrollment":169,"conditions":12282,"interventions":12283},"NCT02475161","A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants",[87],"2015-07",[15],[4325,12284],"Rabeprazole",{"nctId":4320,"briefTitle":4321,"status":105,"phases":12286,"primaryCompletion":4314,"completion":4314,"start":3657,"enrollment":503,"conditions":12287,"interventions":12288},[87],[15],[4325,173,174],{"nctId":12290,"briefTitle":12291,"status":105,"phases":12292,"primaryCompletion":12293,"completion":12293,"start":12294,"enrollment":3586,"conditions":12295,"interventions":12296},"NCT04616677","A Study to Evaluate the Effect of Renal Impairment on JNJ-42847922 in Adult Participants",[87],"2022-10-18","2021-03-31",[5589],[4325],{"trials":12298,"activeCount":99},[12299,12308,12312],{"nctId":12300,"briefTitle":12301,"status":105,"phases":12302,"primaryCompletion":12303,"completion":12304,"start":12305,"enrollment":819,"conditions":12306,"interventions":12307},"NCT03227224","A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy",[88],"2019-01-12","2019-01-19","2017-08-16",[21],[4325],{"nctId":4986,"briefTitle":4987,"status":105,"phases":12309,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":3853,"conditions":12310,"interventions":12311},[88],[21],[4325,4457,4482,4994],{"nctId":12313,"briefTitle":12314,"status":105,"phases":12315,"primaryCompletion":12316,"completion":12316,"start":12317,"enrollment":1132,"conditions":12318,"interventions":12320},"NCT02464046","Study to Evaluate Efficacy, Safety and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder Without Psychiatric Comorbidity",[88],"2015-12-02","2015-07-27",[12319],"Insomnia",[4325],{"trials":12322,"activeCount":99},[],{"trials":12324,"activeCount":99},[],{"trials":12326,"activeCount":99},[],{"intervention":12174,"totalTrials":2948,"cells":12328},{"EARLY_PHASE1":12329,"PHASE1":12331,"PHASE2":12337,"PHASE3":12363,"PHASE4":12365,"NA":12367},{"trials":12330,"activeCount":99},[],{"trials":12332,"activeCount":99},[12333],{"nctId":12165,"briefTitle":12166,"status":105,"phases":12334,"primaryCompletion":12168,"completion":7176,"start":12169,"enrollment":3586,"conditions":12335,"interventions":12336},[87],[2412],[7292,12172,12173,12174,12175],{"trials":12338,"activeCount":99},[12339,12343,12347,12351,12355,12359],{"nctId":12194,"briefTitle":12195,"status":125,"phases":12340,"primaryCompletion":12197,"completion":12197,"start":12198,"enrollment":468,"conditions":12341,"interventions":12342},[88],[2412],[7292,12201,12174,12175,12202],{"nctId":12204,"briefTitle":12205,"status":105,"phases":12344,"primaryCompletion":12207,"completion":12208,"start":1034,"enrollment":19,"conditions":12345,"interventions":12346},[88],[12210],[7292,12212,12174,12213],{"nctId":12215,"briefTitle":12216,"status":105,"phases":12348,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":12349,"interventions":12350},[88],[12222],[7292,12224,7295,12174,12213,12201],{"nctId":7284,"briefTitle":7285,"status":105,"phases":12352,"primaryCompletion":7287,"completion":7288,"start":7289,"enrollment":5539,"conditions":12353,"interventions":12354},[88],[2412],[7292,7271,7293,7294,7295],{"nctId":12230,"briefTitle":12231,"status":105,"phases":12356,"primaryCompletion":12233,"completion":12234,"start":1691,"enrollment":1972,"conditions":12357,"interventions":12358},[88],[2412],[7292,12174,12213,12212,12237],{"nctId":12239,"briefTitle":12240,"status":105,"phases":12360,"primaryCompletion":12242,"completion":12243,"start":1796,"enrollment":3312,"conditions":12361,"interventions":12362},[88],[2412],[7292,12201,12174,12213,12224],{"trials":12364,"activeCount":99},[],{"trials":12366,"activeCount":99},[],{"trials":12368,"activeCount":99},[],{"intervention":12370,"totalTrials":2948,"cells":12371},"Odalasvir",{"EARLY_PHASE1":12372,"PHASE1":12374,"PHASE2":12426,"PHASE3":12437,"PHASE4":12439,"NA":12441},{"trials":12373,"activeCount":99},[],{"trials":12375,"activeCount":99},[12376,12382,12391,12400,12408,12416],{"nctId":12377,"briefTitle":12378,"status":105,"phases":12379,"primaryCompletion":4415,"completion":4415,"start":9531,"enrollment":169,"conditions":12380,"interventions":12381},"NCT02961660","A Study to Evaluate the Effect of Severe Renal Impairment on the Single-dose Pharmacokinetics of Odalasvir",[87],[8885],[12370],{"nctId":12383,"briefTitle":12384,"status":105,"phases":12385,"primaryCompletion":583,"completion":583,"start":9096,"enrollment":12386,"conditions":12387,"interventions":12388},"NCT02824315","Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants",[87],22,[15],[12389,12370,12390],"AL-335","Simeprevir",{"nctId":12392,"briefTitle":12393,"status":105,"phases":12394,"primaryCompletion":8487,"completion":12395,"start":12396,"enrollment":1177,"conditions":12397,"interventions":12398},"NCT02945020","A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants",[87],"2017-01-20","2016-11-10",[15],[12399,12370,12390],"Dabigatran etexilate mesylate",{"nctId":12401,"briefTitle":12402,"status":105,"phases":12403,"primaryCompletion":12404,"completion":12405,"start":5831,"enrollment":3138,"conditions":12406,"interventions":12407},"NCT02821858","Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants",[87],"2016-09-09","2016-09-30",[15],[12370,12389],{"nctId":12409,"briefTitle":12410,"status":105,"phases":12411,"primaryCompletion":12412,"completion":12412,"start":3596,"enrollment":3586,"conditions":12413,"interventions":12414},"NCT02885454","To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants",[87],"2016-12",[15],[12415,12389,12370,12390],"Drospirenone\u002Fethinylestradiol",{"nctId":12417,"briefTitle":12418,"status":105,"phases":12419,"primaryCompletion":12420,"completion":12420,"start":12421,"enrollment":656,"conditions":12422,"interventions":12423},"NCT02889367","A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants",[87],"2017-03-04","2016-09-12",[15],[12424,12425,12370],"Odalasvir 100 mg","Odalasvir 500 mg",{"trials":12427,"activeCount":99},[12428],{"nctId":12429,"briefTitle":12430,"status":105,"phases":12431,"primaryCompletion":12432,"completion":1584,"start":9531,"enrollment":12433,"conditions":12434,"interventions":12436},"NCT02765490","Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection",[88],"2017-08-09",365,[12435],"Hepatitis C, Chronic",[12389,12370,12390],{"trials":12438,"activeCount":99},[],{"trials":12440,"activeCount":99},[],{"trials":12442,"activeCount":99},[],{"intervention":12444,"totalTrials":641,"cells":12445},"Lumicitabine",{"EARLY_PHASE1":12446,"PHASE1":12448,"PHASE2":12466,"PHASE3":12503,"PHASE4":12505,"NA":12507},{"trials":12447,"activeCount":99},[],{"trials":12449,"activeCount":99},[12450,12458],{"nctId":12451,"briefTitle":12452,"status":125,"phases":12453,"primaryCompletion":4257,"completion":4257,"start":3378,"enrollment":503,"conditions":12454,"interventions":12455},"NCT03468777","A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants",[87],[15],[12444,12456,12457],"Lansoprazole","Ranitidine",{"nctId":12459,"briefTitle":12460,"status":105,"phases":12461,"primaryCompletion":10982,"completion":10982,"start":12462,"enrollment":503,"conditions":12463,"interventions":12464},"NCT03441529","A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin\u002FTazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants",[87],"2018-02-09",[15],[12444,12465],"Piperacillin\u002FTazobactam",{"trials":12467,"activeCount":99},[12468,12477,12487,12496],{"nctId":12469,"briefTitle":12470,"status":105,"phases":12471,"primaryCompletion":12472,"completion":12472,"start":12473,"enrollment":2948,"conditions":12474,"interventions":12476},"NCT03332459","A Long-term Follow-up Study to Evaluate the Impact of Lumicitabine on the Incidence of Asthma and\u002For Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection",[88],"2020-04-13","2018-01-05",[12475],"Respiratory Syncytial Virus Infections",[12444],{"nctId":12478,"briefTitle":12479,"status":125,"phases":12480,"primaryCompletion":3673,"completion":3673,"start":12481,"enrollment":12482,"conditions":12483,"interventions":12485},"NCT02935673","Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine Regimens in Adult Participants Hospitalized With Respiratory Syncytial Virus",[88],"2016-10-25",49,[12484],"Respiratory Syncytial Viruses",[12486],"lumicitabine",{"nctId":12488,"briefTitle":12489,"status":137,"phases":12490,"primaryCompletion":12491,"completion":12492,"start":4879,"enrollment":99,"conditions":12493,"interventions":12495},"NCT03502694","Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus",[88],"2019-04-30","2020-10-28",[12494],"Metapneumovirus",[12444],{"nctId":12497,"briefTitle":12498,"status":125,"phases":12499,"primaryCompletion":3246,"completion":3246,"start":12500,"enrollment":2948,"conditions":12501,"interventions":12502},"NCT03333317","A Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) Regimens in Hospitalized Infants and Children Aged 28 Days to 36 Months Infected With Respiratory Syncytial Virus",[88],"2017-11-24",[12484],[12444],{"trials":12504,"activeCount":99},[],{"trials":12506,"activeCount":99},[],{"trials":12508,"activeCount":99},[],{"intervention":12213,"totalTrials":641,"cells":12510},{"EARLY_PHASE1":12511,"PHASE1":12513,"PHASE2":12519,"PHASE3":12541,"PHASE4":12543,"NA":12545},{"trials":12512,"activeCount":99},[],{"trials":12514,"activeCount":99},[12515],{"nctId":10436,"briefTitle":10437,"status":125,"phases":12516,"primaryCompletion":10439,"completion":10440,"start":10441,"enrollment":656,"conditions":12517,"interventions":12518},[87],[15,2412],[10444,10429,7294,7295,10444],{"trials":12520,"activeCount":99},[12521,12525,12529,12533,12537],{"nctId":12204,"briefTitle":12205,"status":105,"phases":12522,"primaryCompletion":12207,"completion":12208,"start":1034,"enrollment":19,"conditions":12523,"interventions":12524},[88],[12210],[7292,12212,12174,12213],{"nctId":12215,"briefTitle":12216,"status":105,"phases":12526,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":12527,"interventions":12528},[88],[12222],[7292,12224,7295,12174,12213,12201],{"nctId":7284,"briefTitle":7285,"status":105,"phases":12530,"primaryCompletion":7287,"completion":7288,"start":7289,"enrollment":5539,"conditions":12531,"interventions":12532},[88],[2412],[7292,7271,7293,7294,7295],{"nctId":12230,"briefTitle":12231,"status":105,"phases":12534,"primaryCompletion":12233,"completion":12234,"start":1691,"enrollment":1972,"conditions":12535,"interventions":12536},[88],[2412],[7292,12174,12213,12212,12237],{"nctId":12239,"briefTitle":12240,"status":105,"phases":12538,"primaryCompletion":12242,"completion":12243,"start":1796,"enrollment":3312,"conditions":12539,"interventions":12540},[88],[2412],[7292,12201,12174,12213,12224],{"trials":12542,"activeCount":99},[],{"trials":12544,"activeCount":99},[],{"trials":12546,"activeCount":99},[],{"intervention":6788,"totalTrials":641,"cells":12548},{"EARLY_PHASE1":12549,"PHASE1":12551,"PHASE2":12574,"PHASE3":12591,"PHASE4":12593,"NA":12595},{"trials":12550,"activeCount":99},[],{"trials":12552,"activeCount":99},[12553,12559,12565],{"nctId":12554,"briefTitle":12555,"status":105,"phases":12556,"primaryCompletion":5618,"completion":5618,"start":2524,"enrollment":1132,"conditions":12557,"interventions":12558},"NCT01863784","A Study to Evaluate the Pharmacokinetics of JNJ-38518168 in Patients With Mild and Moderate Hepatic Impairment Compared With Patients With Normal Hepatic Function",[87],[505],[6788],{"nctId":12560,"briefTitle":12561,"status":105,"phases":12562,"primaryCompletion":3392,"completion":3392,"start":9543,"enrollment":641,"conditions":12563,"interventions":12564},"NCT01970020","A Study to Investigate the Absorption, Metabolism, and Excretion of JNJ-38518168 After a Single Oral Dose in Healthy Male Participants.",[87],[15],[6788],{"nctId":12566,"briefTitle":12567,"status":105,"phases":12568,"primaryCompletion":5899,"completion":5899,"start":5878,"enrollment":12569,"conditions":12570,"interventions":12572},"NCT01442532","A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam",[87],94,[12571],"Healthy Male Volunteer",[6788,6788,6788,12573],"Midazolam and JNJ-38518168",{"trials":12575,"activeCount":99},[12576,12580,12587],{"nctId":6782,"briefTitle":6783,"status":125,"phases":12577,"primaryCompletion":6033,"completion":6033,"start":3328,"enrollment":1419,"conditions":12578,"interventions":12579},[88],[6786],[6788,879],{"nctId":12581,"briefTitle":12582,"status":105,"phases":12583,"primaryCompletion":12281,"completion":12281,"start":6823,"enrollment":1676,"conditions":12584,"interventions":12586},"NCT01823016","A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma",[88],[12585],"Asthma",[6788],{"nctId":6801,"briefTitle":6802,"status":125,"phases":12588,"primaryCompletion":6804,"completion":6805,"start":6806,"enrollment":2985,"conditions":12589,"interventions":12590},[88],[6786],[6788,6788,6788,879],{"trials":12592,"activeCount":99},[],{"trials":12594,"activeCount":99},[],{"trials":12596,"activeCount":99},[],{"intervention":8357,"totalTrials":641,"cells":12598},{"EARLY_PHASE1":12599,"PHASE1":12601,"PHASE2":12639,"PHASE3":12650,"PHASE4":12652,"NA":12654},{"trials":12600,"activeCount":99},[],{"trials":12602,"activeCount":99},[12603,12612,12619,12623,12631],{"nctId":12604,"briefTitle":12605,"status":105,"phases":12606,"primaryCompletion":12607,"completion":12608,"start":12609,"enrollment":641,"conditions":12610,"interventions":12611},"NCT03002779","A Study to Characterize the Absorption, Metabolism, and Excretion of 14C-JNJ-53718678 After a Single Oral Dose in Healthy Male Participants",[87],"2017-03-10","2017-03-20","2017-01-26",[15],[8357],{"nctId":12613,"briefTitle":12614,"status":105,"phases":12615,"primaryCompletion":12616,"completion":12616,"start":5963,"enrollment":169,"conditions":12617,"interventions":12618},"NCT04090086","A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants",[87],"2019-12-10",[15],[8357,8349],{"nctId":8352,"briefTitle":8353,"status":105,"phases":12620,"primaryCompletion":3597,"completion":3597,"start":3632,"enrollment":2515,"conditions":12621,"interventions":12622},[87],[15],[8357,1799,3345],{"nctId":12624,"briefTitle":12625,"status":125,"phases":12626,"primaryCompletion":12627,"completion":12627,"start":12628,"enrollment":2472,"conditions":12629,"interventions":12630},"NCT04332523","A Study of JNJ-53718678 in Participants With Hepatic Impairment",[87],"2022-03-16","2020-08-17",[505],[8357],{"nctId":12632,"briefTitle":12633,"status":105,"phases":12634,"primaryCompletion":12635,"completion":12635,"start":12636,"enrollment":3380,"conditions":12637,"interventions":12638},"NCT02945007","A Study to Assess the Relative Oral Bioavailability of a Single Dose of JNJ-53718678 Administered as Oral Concept Formulation Compared to the Current Oral Solution and to Assess the Effect of Food on the Pharmacokinetics of Oral Concept Formulation",[87],"2020-01-16","2016-11-08",[15],[8357],{"trials":12640,"activeCount":99},[12641],{"nctId":12642,"briefTitle":12643,"status":125,"phases":12644,"primaryCompletion":12645,"completion":12645,"start":12646,"enrollment":12647,"conditions":12648,"interventions":12649},"NCT03656510","Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to \u003C=3 Years) With Respiratory Syncytial Virus Infection",[88],"2022-04-18","2018-11-29",246,[12475],[8357],{"trials":12651,"activeCount":99},[],{"trials":12653,"activeCount":99},[],{"trials":12655,"activeCount":99},[],{"intervention":12657,"totalTrials":641,"cells":12658},"JNJ-42165279",{"EARLY_PHASE1":12659,"PHASE1":12661,"PHASE2":12683,"PHASE3":12714,"PHASE4":12716,"NA":12718},{"trials":12660,"activeCount":99},[],{"trials":12662,"activeCount":99},[12663,12669,12676],{"nctId":12664,"briefTitle":12665,"status":105,"phases":12666,"primaryCompletion":5530,"completion":5530,"start":9488,"enrollment":678,"conditions":12667,"interventions":12668},"NCT01826786","The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers",[87],[15],[12657],{"nctId":12670,"briefTitle":12671,"status":105,"phases":12672,"primaryCompletion":4414,"completion":4414,"start":12673,"enrollment":544,"conditions":12674,"interventions":12675},"NCT03564379","A Single and Multiple Dose Study to Investigate Safety, Tolerability and Pharmacokinetics of JNJ-42165279 in Healthy Japanese Male Participants",[87],"2018-06-12",[15],[12657],{"nctId":12677,"briefTitle":12678,"status":105,"phases":12679,"primaryCompletion":6033,"completion":6033,"start":8396,"enrollment":1177,"conditions":12680,"interventions":12681},"NCT02169973","A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279",[87],[15],[12657,12682],"11C-MK-3168",{"trials":12684,"activeCount":99},[12685,12695,12704],{"nctId":12686,"briefTitle":12687,"status":105,"phases":12688,"primaryCompletion":12689,"completion":12689,"start":12690,"enrollment":12691,"conditions":12692,"interventions":12694},"NCT02432703","A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder",[88],"2018-08-09","2015-06-11",150,[12693],"Phobic Disorders",[12657],{"nctId":12696,"briefTitle":12697,"status":105,"phases":12698,"primaryCompletion":12188,"completion":12699,"start":12700,"enrollment":399,"conditions":12701,"interventions":12703},"NCT03664232","A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder",[88],"2022-10-28","2018-11-07",[12702],"Autism Spectrum Disorder",[12657],{"nctId":12705,"briefTitle":12706,"status":105,"phases":12707,"primaryCompletion":12708,"completion":12708,"start":12709,"enrollment":12710,"conditions":12711,"interventions":12713},"NCT02498392","An Efficacy, Safety and Tolerability Study of JNJ-42165279 in Participants With Major Depressive Disorder With Anxious Distress",[88],"2019-02-04","2015-10-07",161,[6036,12712],"Anxiety",[12657],{"trials":12715,"activeCount":99},[],{"trials":12717,"activeCount":99},[],{"trials":12719,"activeCount":99},[],{"intervention":1246,"totalTrials":641,"cells":12721},{"EARLY_PHASE1":12722,"PHASE1":12724,"PHASE2":12734,"PHASE3":12766,"PHASE4":12768,"NA":12770},{"trials":12723,"activeCount":99},[],{"trials":12725,"activeCount":99},[12726],{"nctId":12727,"briefTitle":12728,"status":105,"phases":12729,"primaryCompletion":3640,"completion":5572,"start":9617,"enrollment":22,"conditions":12730,"interventions":12733},"NCT01219010","A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma",[87],[12731,18,12732],"Monoclonal Gammopathy of Undetermined Significance","Plasma Cell Neoplasm",[1246],{"trials":12735,"activeCount":99},[12736,12744,12748,12752,12762],{"nctId":12737,"briefTitle":12738,"status":105,"phases":12739,"primaryCompletion":12740,"completion":12740,"start":12741,"enrollment":656,"conditions":12742,"interventions":12743},"NCT01400503","A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease",[88],"2017-03-01","2011-04-01",[4844],[1246],{"nctId":4836,"briefTitle":4837,"status":105,"phases":12745,"primaryCompletion":4839,"completion":4840,"start":4841,"enrollment":4842,"conditions":12746,"interventions":12747},[88],[4844],[1246,3155],{"nctId":1237,"briefTitle":1238,"status":105,"phases":12749,"primaryCompletion":1240,"completion":1241,"start":1242,"enrollment":1243,"conditions":12750,"interventions":12751},[88],[18],[1246,682,684],{"nctId":12753,"briefTitle":12754,"status":105,"phases":12755,"primaryCompletion":12756,"completion":12757,"start":12758,"enrollment":7367,"conditions":12759,"interventions":12761},"NCT01484275","A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma",[88],"2015-05-12","2019-08-21","2012-03-01",[12760],"High-risk Smoldering Multiple Myeloma",[1246],{"nctId":4847,"briefTitle":4848,"status":125,"phases":12763,"primaryCompletion":3310,"completion":3310,"start":4850,"enrollment":4851,"conditions":12764,"interventions":12765},[88],[4853],[1246,4855],{"trials":12767,"activeCount":99},[],{"trials":12769,"activeCount":99},[],{"trials":12771,"activeCount":99},[],{"intervention":12224,"totalTrials":1029,"cells":12773},{"EARLY_PHASE1":12774,"PHASE1":12776,"PHASE2":12801,"PHASE3":12811,"PHASE4":12813,"NA":12815},{"trials":12775,"activeCount":99},[],{"trials":12777,"activeCount":99},[12778,12787,12795],{"nctId":12779,"briefTitle":12780,"status":137,"phases":12781,"primaryCompletion":12782,"completion":12783,"start":4605,"enrollment":99,"conditions":12784,"interventions":12785},"NCT04853524","A Study of JNJ-56136379 in Healthy Participants",[87],"2021-06-15","2021-07-30",[15],[12224,12786],"Bictegravir",{"nctId":12788,"briefTitle":12789,"status":105,"phases":12790,"primaryCompletion":12791,"completion":12791,"start":12792,"enrollment":1507,"conditions":12793,"interventions":12794},"NCT02933580","A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult Participants",[87],"2017-02-04","2016-10-12",[15],[12224],{"nctId":12796,"briefTitle":12797,"status":125,"phases":12798,"primaryCompletion":159,"completion":159,"start":594,"enrollment":468,"conditions":12799,"interventions":12800},"NCT04474210","A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult Participants",[87],[8885],[12224],{"trials":12802,"activeCount":99},[12803,12807],{"nctId":12215,"briefTitle":12216,"status":105,"phases":12804,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":12805,"interventions":12806},[88],[12222],[7292,12224,7295,12174,12213,12201],{"nctId":12239,"briefTitle":12240,"status":105,"phases":12808,"primaryCompletion":12242,"completion":12243,"start":1796,"enrollment":3312,"conditions":12809,"interventions":12810},[88],[2412],[7292,12201,12174,12213,12224],{"trials":12812,"activeCount":99},[],{"trials":12814,"activeCount":99},[],{"trials":12816,"activeCount":99},[],{"intervention":12389,"totalTrials":1029,"cells":12818},{"EARLY_PHASE1":12819,"PHASE1":12821,"PHASE2":12843,"PHASE3":12849,"PHASE4":12851,"NA":12853},{"trials":12820,"activeCount":99},[],{"trials":12822,"activeCount":99},[12823,12831,12835,12839],{"nctId":12824,"briefTitle":12825,"status":105,"phases":12826,"primaryCompletion":12827,"completion":12305,"start":12828,"enrollment":3586,"conditions":12829,"interventions":12830},"NCT02894905","A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335",[87],"2017-08-08","2016-09-13",[8885],[12389],{"nctId":12383,"briefTitle":12384,"status":105,"phases":12832,"primaryCompletion":583,"completion":583,"start":9096,"enrollment":12386,"conditions":12833,"interventions":12834},[87],[15],[12389,12370,12390],{"nctId":12401,"briefTitle":12402,"status":105,"phases":12836,"primaryCompletion":12404,"completion":12405,"start":5831,"enrollment":3138,"conditions":12837,"interventions":12838},[87],[15],[12370,12389],{"nctId":12409,"briefTitle":12410,"status":105,"phases":12840,"primaryCompletion":12412,"completion":12412,"start":3596,"enrollment":3586,"conditions":12841,"interventions":12842},[87],[15],[12415,12389,12370,12390],{"trials":12844,"activeCount":99},[12845],{"nctId":12429,"briefTitle":12430,"status":105,"phases":12846,"primaryCompletion":12432,"completion":1584,"start":9531,"enrollment":12433,"conditions":12847,"interventions":12848},[88],[12435],[12389,12370,12390],{"trials":12850,"activeCount":99},[],{"trials":12852,"activeCount":99},[],{"trials":12854,"activeCount":99},[],{"intervention":12390,"totalTrials":1029,"cells":12856},{"EARLY_PHASE1":12857,"PHASE1":12859,"PHASE2":12873,"PHASE3":12890,"PHASE4":12892,"NA":12894},{"trials":12858,"activeCount":99},[],{"trials":12860,"activeCount":99},[12861,12865,12869],{"nctId":12383,"briefTitle":12384,"status":105,"phases":12862,"primaryCompletion":583,"completion":583,"start":9096,"enrollment":12386,"conditions":12863,"interventions":12864},[87],[15],[12389,12370,12390],{"nctId":12392,"briefTitle":12393,"status":105,"phases":12866,"primaryCompletion":8487,"completion":12395,"start":12396,"enrollment":1177,"conditions":12867,"interventions":12868},[87],[15],[12399,12370,12390],{"nctId":12409,"briefTitle":12410,"status":105,"phases":12870,"primaryCompletion":12412,"completion":12412,"start":3596,"enrollment":3586,"conditions":12871,"interventions":12872},[87],[15],[12415,12389,12370,12390],{"trials":12874,"activeCount":99},[12875,12886],{"nctId":12876,"briefTitle":12877,"status":105,"phases":12878,"primaryCompletion":12879,"completion":12880,"start":12881,"enrollment":3138,"conditions":12882,"interventions":12883},"NCT02262728","An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease",[88],"2015-08-13","2018-04-25","2014-09-30",[12435],[12390,12884,12885],"Daclatasvir","Sofosbuvir",{"nctId":12429,"briefTitle":12430,"status":105,"phases":12887,"primaryCompletion":12432,"completion":1584,"start":9531,"enrollment":12433,"conditions":12888,"interventions":12889},[88],[12435],[12389,12370,12390],{"trials":12891,"activeCount":99},[],{"trials":12893,"activeCount":99},[],{"trials":12895,"activeCount":99},[],{"intervention":6003,"totalTrials":352,"cells":12897},{"EARLY_PHASE1":12898,"PHASE1":12900,"PHASE2":12902,"PHASE3":12929,"PHASE4":12931,"NA":12933},{"trials":12899,"activeCount":99},[],{"trials":12901,"activeCount":99},[],{"trials":12903,"activeCount":99},[12904,12908,12914,12918],{"nctId":5995,"briefTitle":5996,"status":125,"phases":12905,"primaryCompletion":5998,"completion":5999,"start":512,"enrollment":2065,"conditions":12906,"interventions":12907},[88],[6001],[6003,5986],{"nctId":12909,"briefTitle":12910,"status":125,"phases":12911,"primaryCompletion":716,"completion":716,"start":4424,"enrollment":641,"conditions":12912,"interventions":12913},"NCT04990440","A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis",[88],[6001],[6003],{"nctId":9371,"briefTitle":9372,"status":125,"phases":12915,"primaryCompletion":9374,"completion":9375,"start":3865,"enrollment":1213,"conditions":12916,"interventions":12917},[88],[3916],[6003,3491],{"nctId":12919,"briefTitle":12920,"status":105,"phases":12921,"primaryCompletion":12922,"completion":12923,"start":5963,"enrollment":7420,"conditions":12924,"interventions":12927},"NCT04019041","A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa",[88],"2020-05-19","2020-11-17",[3916,12925,12926],"Acne Inversa","Suppurative Hidradenitis",[12928],"bermekimab",{"trials":12930,"activeCount":99},[],{"trials":12932,"activeCount":99},[],{"trials":12934,"activeCount":99},[],{"intervention":3490,"totalTrials":352,"cells":12936},{"EARLY_PHASE1":12937,"PHASE1":12939,"PHASE2":12950,"PHASE3":12969,"PHASE4":12971,"NA":12973},{"trials":12938,"activeCount":99},[],{"trials":12940,"activeCount":99},[12941],{"nctId":12942,"briefTitle":12943,"status":137,"phases":12944,"primaryCompletion":12945,"completion":12946,"start":12947,"enrollment":99,"conditions":12948,"interventions":12949},"NCT04712006","A Study of JNJ-64304500 Following Subcutaneous Injection in Healthy Chinese Adult Participants",[87],"2021-08-27","2021-10-30","2021-05-30",[15],[3490],{"trials":12951,"activeCount":99},[12952,12956,12965],{"nctId":3482,"briefTitle":3483,"status":137,"phases":12953,"primaryCompletion":3485,"completion":3486,"start":3487,"enrollment":99,"conditions":12954,"interventions":12955},[88],[311],[3490,3491,214],{"nctId":12957,"briefTitle":12958,"status":137,"phases":12959,"primaryCompletion":12960,"completion":2129,"start":12961,"enrollment":99,"conditions":12962,"interventions":12964},"NCT04740970","A Study of JNJ-64304500 in Participants With Alopecia Areata",[88],"2022-06-02","2021-03-24",[12963],"Alopecia Areata",[3490],{"nctId":3493,"briefTitle":3494,"status":105,"phases":12966,"primaryCompletion":230,"completion":3496,"start":3497,"enrollment":3498,"conditions":12967,"interventions":12968},[88],[311],[3490,214],{"trials":12970,"activeCount":99},[],{"trials":12972,"activeCount":99},[],{"trials":12974,"activeCount":99},[],{"intervention":12976,"totalTrials":352,"cells":12977},"JNJ-61393215",{"EARLY_PHASE1":12978,"PHASE1":12980,"PHASE2":13005,"PHASE3":13016,"PHASE4":13018,"NA":13020},{"trials":12979,"activeCount":99},[],{"trials":12981,"activeCount":99},[12982,12990,12998],{"nctId":12983,"briefTitle":12984,"status":105,"phases":12985,"primaryCompletion":12986,"completion":12986,"start":12987,"enrollment":832,"conditions":12988,"interventions":12989},"NCT03007693","A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ 61393215 in Healthy Participants",[87],"2017-10","2017-01",[15],[12976],{"nctId":12991,"briefTitle":12992,"status":105,"phases":12993,"primaryCompletion":12994,"completion":12994,"start":12995,"enrollment":860,"conditions":12996,"interventions":12997},"NCT03649997","A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants",[87],"2018-12-14","2018-08-28",[15],[12976,12976],{"nctId":12999,"briefTitle":13000,"status":105,"phases":13001,"primaryCompletion":3460,"completion":3460,"start":7350,"enrollment":544,"conditions":13002,"interventions":13003},"NCT03593954","A Study to Assess the Effect of Ritonavir on the Single-Dose Pharmacokinetics of JNJ-61393215 in Healthy Participants",[87],[15],[12976,13004],"Ritonavir",{"trials":13006,"activeCount":99},[13007],{"nctId":13008,"briefTitle":13009,"status":105,"phases":13010,"primaryCompletion":4424,"completion":4424,"start":13011,"enrollment":13012,"conditions":13013,"interventions":13015},"NCT04080752","A Study of JNJ-61393215 in the Treatment of Depression",[88],"2019-09-17",222,[13014],"Major Depressive Disorder With Anxious Distress",[12976],{"trials":13017,"activeCount":99},[],{"trials":13019,"activeCount":99},[],{"trials":13021,"activeCount":99},[],{"intervention":13023,"totalTrials":352,"cells":13024},"JNJ-63623872",{"EARLY_PHASE1":13025,"PHASE1":13027,"PHASE2":13053,"PHASE3":13065,"PHASE4":13067,"NA":13069},{"trials":13026,"activeCount":99},[],{"trials":13028,"activeCount":99},[13029,13036,13045],{"nctId":13030,"briefTitle":13031,"status":105,"phases":13032,"primaryCompletion":3633,"completion":3633,"start":3657,"enrollment":5557,"conditions":13033,"interventions":13034},"NCT02595268","A Study to Investigate the Effect of JNJ-63623872 on Pitavastatin in Healthy Participants",[87],[15],[13035,13023],"Pitavastatin",{"nctId":13037,"briefTitle":13038,"status":105,"phases":13039,"primaryCompletion":3597,"completion":3597,"start":13040,"enrollment":503,"conditions":13041,"interventions":13042},"NCT02652650","A Study to Investigate the Effect of JNJ-63623872 at Steady-state on the Steady-state Pharmacokinetics of Ethinylestradiol and Norethindrone",[87],"2015-12",[15],[13043,13044,13023],"Ethinylestradiol","Norethindrone",{"nctId":13046,"briefTitle":13047,"status":105,"phases":13048,"primaryCompletion":8190,"completion":8190,"start":3633,"enrollment":1436,"conditions":13049,"interventions":13050},"NCT02658825","A Study to Evaluate the Effect of JNJ-63623872 on Cardiac Repolarization Interval in Healthy Participants",[87],[15],[13051,13052,13023,3616],"JNJ-63623872 2400 milligram","JNJ-63623872 3000 mg",{"trials":13054,"activeCount":99},[13055],{"nctId":13056,"briefTitle":13057,"status":105,"phases":13058,"primaryCompletion":4840,"completion":13059,"start":13060,"enrollment":3360,"conditions":13061,"interventions":13063},"NCT02532283","A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection",[88],"2017-03-15","2015-12-11",[13062],"Influenza A Virus",[13023,13064],"Oseltamivir",{"trials":13066,"activeCount":99},[],{"trials":13068,"activeCount":99},[],{"trials":13070,"activeCount":99},[],{"intervention":4887,"totalTrials":571,"cells":13072},{"EARLY_PHASE1":13073,"PHASE1":13075,"PHASE2":13095,"PHASE3":13101,"PHASE4":13103,"NA":13105},{"trials":13074,"activeCount":99},[],{"trials":13076,"activeCount":99},[13077,13085],{"nctId":13078,"briefTitle":13079,"status":105,"phases":13080,"primaryCompletion":12432,"completion":12432,"start":13081,"enrollment":8144,"conditions":13082,"interventions":13083},"NCT02949206","A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Male Subjects",[87],"2016-11-14",[15],[4887,13084],"4 Factor Prothrombin Complex Concentrate",{"nctId":13086,"briefTitle":13087,"status":105,"phases":13088,"primaryCompletion":13089,"completion":13089,"start":13090,"enrollment":3138,"conditions":13091,"interventions":13092},"NCT03080987","A Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of JNJ-64179375 in Healthy Japanese Participants",[87],"2018-06-25","2017-06-27",[15],[4884,13093,13094,4887],"JNJ-64179375 1.0 mg\u002Fkg","JNJ-64179375 2.5 mg\u002Fkg",{"trials":13096,"activeCount":99},[13097],{"nctId":4876,"briefTitle":4877,"status":105,"phases":13098,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":13099,"interventions":13100},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":13102,"activeCount":99},[],{"trials":13104,"activeCount":99},[],{"trials":13106,"activeCount":99},[],{"intervention":12201,"totalTrials":571,"cells":13108},{"EARLY_PHASE1":13109,"PHASE1":13111,"PHASE2":13113,"PHASE3":13127,"PHASE4":13129,"NA":13131},{"trials":13110,"activeCount":99},[],{"trials":13112,"activeCount":99},[],{"trials":13114,"activeCount":99},[13115,13119,13123],{"nctId":12194,"briefTitle":12195,"status":125,"phases":13116,"primaryCompletion":12197,"completion":12197,"start":12198,"enrollment":468,"conditions":13117,"interventions":13118},[88],[2412],[7292,12201,12174,12175,12202],{"nctId":12215,"briefTitle":12216,"status":105,"phases":13120,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":13121,"interventions":13122},[88],[12222],[7292,12224,7295,12174,12213,12201],{"nctId":12239,"briefTitle":12240,"status":105,"phases":13124,"primaryCompletion":12242,"completion":12243,"start":1796,"enrollment":3312,"conditions":13125,"interventions":13126},[88],[2412],[7292,12201,12174,12213,12224],{"trials":13128,"activeCount":99},[],{"trials":13130,"activeCount":99},[],{"trials":13132,"activeCount":99},[],{"intervention":13134,"totalTrials":571,"cells":13135},"JNJ-42756493",{"EARLY_PHASE1":13136,"PHASE1":13138,"PHASE2":13153,"PHASE3":13164,"PHASE4":13166,"NA":13168},{"trials":13137,"activeCount":99},[],{"trials":13139,"activeCount":99},[13140,13147],{"nctId":13141,"briefTitle":13142,"status":105,"phases":13143,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":544,"conditions":13144,"interventions":13145},"NCT02231489","Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants",[87],[15],[13134,13134,13146],"JNJ-61818549",{"nctId":13148,"briefTitle":13149,"status":105,"phases":13150,"primaryCompletion":3596,"completion":3596,"start":3632,"enrollment":109,"conditions":13151,"interventions":13152},"NCT02692677","A Study to Assess the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ--42756493 to Healthy Male Participants",[87],[15],[13134],{"trials":13154,"activeCount":99},[13155],{"nctId":13156,"briefTitle":13157,"status":105,"phases":13158,"primaryCompletion":13159,"completion":13160,"start":13161,"enrollment":231,"conditions":13162,"interventions":13163},"NCT02421185","Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma",[87,88],"2019-05-13","2019-05-16","2015-05-25",[841],[13134],{"trials":13165,"activeCount":99},[],{"trials":13167,"activeCount":99},[],{"trials":13169,"activeCount":99},[],{"intervention":9538,"totalTrials":571,"cells":13171},{"EARLY_PHASE1":13172,"PHASE1":13174,"PHASE2":13184,"PHASE3":13190,"PHASE4":13192,"NA":13194},{"trials":13173,"activeCount":99},[],{"trials":13175,"activeCount":99},[13176,13180],{"nctId":9528,"briefTitle":9529,"status":105,"phases":13177,"primaryCompletion":9531,"completion":9531,"start":9532,"enrollment":1264,"conditions":13178,"interventions":13179},[87],[9534,9535],[9521,9537,9538],{"nctId":9540,"briefTitle":9541,"status":105,"phases":13181,"primaryCompletion":2487,"completion":9543,"start":2564,"enrollment":3471,"conditions":13182,"interventions":13183},[87],[15],[9521,9546,9547,9538,9537],{"trials":13185,"activeCount":99},[13186],{"nctId":9551,"briefTitle":9552,"status":125,"phases":13187,"primaryCompletion":3633,"completion":3633,"start":3613,"enrollment":2149,"conditions":13188,"interventions":13189},[88],[32,9555],[9521,9547,9537,9546,9538],{"trials":13191,"activeCount":99},[],{"trials":13193,"activeCount":99},[],{"trials":13195,"activeCount":99},[],{"intervention":13197,"totalTrials":571,"cells":13198},"JNJ-63733657",{"EARLY_PHASE1":13199,"PHASE1":13201,"PHASE2":13220,"PHASE3":13231,"PHASE4":13233,"NA":13235},{"trials":13200,"activeCount":99},[],{"trials":13202,"activeCount":99},[13203,13211],{"nctId":13204,"briefTitle":13205,"status":105,"phases":13206,"primaryCompletion":13207,"completion":13207,"start":13208,"enrollment":1380,"conditions":13209,"interventions":13210},"NCT03375697","A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-63733657 in Healthy Subjects and Subjects With Alzheimer's Disease",[87],"2019-12-16","2017-12-22",[4445],[13197],{"nctId":13212,"briefTitle":13213,"status":105,"phases":13214,"primaryCompletion":13215,"completion":13216,"start":13217,"enrollment":893,"conditions":13218,"interventions":13219},"NCT05407818","A Study of JNJ-63733657 in Healthy Chinese Participants",[87],"2022-08-02","2022-11-07","2022-06-27",[15],[13197],{"trials":13221,"activeCount":99},[13222],{"nctId":13223,"briefTitle":13224,"status":125,"phases":13225,"primaryCompletion":13226,"completion":849,"start":13227,"enrollment":3742,"conditions":13228,"interventions":13230},"NCT04619420","A Study of JNJ-63733657 in Participants With Early Alzheimer's Disease",[88],"2025-10-17","2021-01-06",[4445,13229,6845],"Cognitive Dysfunction",[13197],{"trials":13232,"activeCount":99},[],{"trials":13234,"activeCount":99},[],{"trials":13236,"activeCount":99},[],{"intervention":13238,"totalTrials":571,"cells":13239},"JNJ-64281802",{"EARLY_PHASE1":13240,"PHASE1":13242,"PHASE2":13252,"PHASE3":13271,"PHASE4":13273,"NA":13275},{"trials":13241,"activeCount":99},[],{"trials":13243,"activeCount":99},[13244],{"nctId":13245,"briefTitle":13246,"status":105,"phases":13247,"primaryCompletion":13248,"completion":13248,"start":13249,"enrollment":2515,"conditions":13250,"interventions":13251},"NCT05201937","A Study of JNJ-64281802 in Healthy Adult Participants",[87],"2022-12-11","2022-02-23",[15],[13238],{"trials":13253,"activeCount":99},[13254,13263],{"nctId":13255,"briefTitle":13256,"status":125,"phases":13257,"primaryCompletion":13258,"completion":13259,"start":3496,"enrollment":1029,"conditions":13260,"interventions":13262},"NCT04906980","A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever",[88],"2022-09-24","2023-03-21",[13261],"Dengue",[13238],{"nctId":13264,"briefTitle":13265,"status":125,"phases":13266,"primaryCompletion":7176,"completion":7176,"start":13267,"enrollment":13268,"conditions":13269,"interventions":13270},"NCT05201794","A Study of JNJ-64281802 for the Prevention of Dengue Infection",[88],"2023-02-22",1595,[13261],[13238],{"trials":13272,"activeCount":99},[],{"trials":13274,"activeCount":99},[],{"trials":13276,"activeCount":99},[],{"intervention":6038,"totalTrials":571,"cells":13278},{"EARLY_PHASE1":13279,"PHASE1":13281,"PHASE2":13283,"PHASE3":13302,"PHASE4":13304,"NA":13306},{"trials":13280,"activeCount":99},[],{"trials":13282,"activeCount":99},[],{"trials":13284,"activeCount":99},[13285,13289,13295],{"nctId":6030,"briefTitle":6031,"status":125,"phases":13286,"primaryCompletion":6033,"completion":6033,"start":6034,"enrollment":1857,"conditions":13287,"interventions":13288},[88],[6036],[1843,6038],{"nctId":13290,"briefTitle":13291,"status":125,"phases":13292,"primaryCompletion":8420,"completion":8420,"start":8396,"enrollment":479,"conditions":13293,"interventions":13294},"NCT01957410","A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive Disorder",[88],[5630],[6038],{"nctId":13296,"briefTitle":13297,"status":105,"phases":13298,"primaryCompletion":13299,"completion":13299,"start":9752,"enrollment":809,"conditions":13300,"interventions":13301},"NCT01627782","A Study of Ketamine in Patients With Treatment-resistant Depression",[88],"2013-09-12",[5630],[6038],{"trials":13303,"activeCount":99},[],{"trials":13305,"activeCount":99},[],{"trials":13307,"activeCount":99},[],{"intervention":4366,"totalTrials":571,"cells":13309},{"EARLY_PHASE1":13310,"PHASE1":13312,"PHASE2":13329,"PHASE3":13335,"PHASE4":13337,"NA":13339},{"trials":13311,"activeCount":99},[],{"trials":13313,"activeCount":99},[13314,13325],{"nctId":13315,"briefTitle":13316,"status":105,"phases":13317,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":13319,"interventions":13320},"NCT02737605","A Study to Evaluate the Effects of Esketamine on Cardiac Repolarization in Healthy Participants",[87],62,[15],[13321,13322,3616,13323,13324,4366],"Intranasal Esketamine","Intravenous Esketamine","Oral Placebo","Intravenous Placebo",{"nctId":8484,"briefTitle":8485,"status":105,"phases":13326,"primaryCompletion":8487,"completion":8487,"start":8488,"enrollment":8489,"conditions":13327,"interventions":13328},[87],[8491],[8493,8494,8495,8496,8477],{"trials":13330,"activeCount":99},[13331],{"nctId":4360,"briefTitle":4361,"status":105,"phases":13332,"primaryCompletion":1784,"completion":1784,"start":1602,"enrollment":4363,"conditions":13333,"interventions":13334},[88],[21],[4366,4367,173,4318,4318,4318],{"trials":13336,"activeCount":99},[],{"trials":13338,"activeCount":99},[],{"trials":13340,"activeCount":99},[],{"intervention":5848,"totalTrials":571,"cells":13342},{"EARLY_PHASE1":13343,"PHASE1":13345,"PHASE2":13355,"PHASE3":13361,"PHASE4":13363,"NA":13365},{"trials":13344,"activeCount":99},[],{"trials":13346,"activeCount":99},[13347,13351],{"nctId":8187,"briefTitle":8188,"status":105,"phases":13348,"primaryCompletion":8190,"completion":8190,"start":5572,"enrollment":33,"conditions":13349,"interventions":13350},[87],[24],[8193,5848,5861],{"nctId":9007,"briefTitle":9008,"status":105,"phases":13352,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":13353,"interventions":13354},[87],[15],[9013,5848,8193,9014],{"trials":13356,"activeCount":99},[13357],{"nctId":5842,"briefTitle":5843,"status":105,"phases":13358,"primaryCompletion":2487,"completion":2487,"start":5845,"enrollment":1663,"conditions":13359,"interventions":13360},[88],[24],[5848,5849,1779],{"trials":13362,"activeCount":99},[],{"trials":13364,"activeCount":99},[],{"trials":13366,"activeCount":99},[],{"intervention":13368,"totalTrials":571,"cells":13369},"JNJ-54452840",{"EARLY_PHASE1":13370,"PHASE1":13372,"PHASE2":13387,"PHASE3":13395,"PHASE4":13397,"NA":13399},{"trials":13371,"activeCount":99},[],{"trials":13373,"activeCount":99},[13374,13381],{"nctId":13375,"briefTitle":13376,"status":137,"phases":13377,"primaryCompletion":5556,"completion":2217,"start":3328,"enrollment":99,"conditions":13378,"interventions":13379},"NCT01902550","A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants",[87],[15],[13380,13368],"Metoprolol tartrate immediate-release",{"nctId":13382,"briefTitle":13383,"status":105,"phases":13384,"primaryCompletion":4348,"completion":4348,"start":3328,"enrollment":1507,"conditions":13385,"interventions":13386},"NCT01809353","To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants",[87],[15],[13368],{"trials":13388,"activeCount":99},[13389],{"nctId":13390,"briefTitle":13391,"status":137,"phases":13392,"primaryCompletion":13040,"completion":13040,"start":3358,"enrollment":99,"conditions":13393,"interventions":13394},"NCT01798745","A Study to Assess the Pharmacokinetics and Pharmacodynamics of JNJ-54452840 in Participants With Heart Failure and Anti-beta1-adrenergic Receptor Autoantibodies",[88],[8947],[13368],{"trials":13396,"activeCount":99},[],{"trials":13398,"activeCount":99},[],{"trials":13400,"activeCount":99},[],{"intervention":13402,"totalTrials":571,"cells":13403},"ExPEC4V",{"EARLY_PHASE1":13404,"PHASE1":13406,"PHASE2":13408,"PHASE3":13439,"PHASE4":13441,"NA":13443},{"trials":13405,"activeCount":99},[],{"trials":13407,"activeCount":99},[],{"trials":13409,"activeCount":99},[13410,13423,13432],{"nctId":13411,"briefTitle":13412,"status":105,"phases":13413,"primaryCompletion":13414,"completion":13415,"start":13416,"enrollment":13417,"conditions":13418,"interventions":13420},"NCT03819049","A Study of Three Different Doses of VAC52416 (ExPEC10V) in Adults Aged 60 to 85 Years in Stable Health",[87,88],"2021-06-08","2024-12-18","2019-06-06",836,[13419],"Extraintestinal Pathogenic Escherichia Coli Prevention",[13421,13402,13422],"ExPEC10V","Prevnar 13",{"nctId":13424,"briefTitle":13425,"status":105,"phases":13426,"primaryCompletion":12421,"completion":13427,"start":13428,"enrollment":13429,"conditions":13430,"interventions":13431},"NCT02546960","A Study in Healthy Adults to Evaluate the Safety and Immunogenicity of Different Doses of JNJ-63871860",[88],"2019-06-21","2015-11-12",848,[15],[13402,13402,13402,13402,13402],{"nctId":13433,"briefTitle":13434,"status":105,"phases":13435,"primaryCompletion":4879,"completion":608,"start":13436,"enrollment":1480,"conditions":13437,"interventions":13438},"NCT03500679","A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older",[88],"2018-05-09",[15],[13402],{"trials":13440,"activeCount":99},[],{"trials":13442,"activeCount":99},[],{"trials":13444,"activeCount":99},[],{"intervention":2015,"totalTrials":571,"cells":13446},{"EARLY_PHASE1":13447,"PHASE1":13449,"PHASE2":13451,"PHASE3":13465,"PHASE4":13467,"NA":13469},{"trials":13448,"activeCount":99},[],{"trials":13450,"activeCount":99},[],{"trials":13452,"activeCount":99},[13453,13457,13461],{"nctId":3890,"briefTitle":3891,"status":125,"phases":13454,"primaryCompletion":3893,"completion":3893,"start":3894,"enrollment":2515,"conditions":13455,"interventions":13456},[88],[2044],[412,413,2015],{"nctId":2006,"briefTitle":2007,"status":105,"phases":13458,"primaryCompletion":2009,"completion":2010,"start":2011,"enrollment":1045,"conditions":13459,"interventions":13460},[88],[2013],[1953,2015],{"nctId":2038,"briefTitle":2039,"status":137,"phases":13462,"primaryCompletion":2041,"completion":2041,"start":2042,"enrollment":99,"conditions":13463,"interventions":13464},[88],[2044],[1953,2015],{"trials":13466,"activeCount":99},[],{"trials":13468,"activeCount":99},[],{"trials":13470,"activeCount":99},[],{"intervention":3383,"totalTrials":571,"cells":13472},{"EARLY_PHASE1":13473,"PHASE1":13475,"PHASE2":13477,"PHASE3":13497,"PHASE4":13499,"NA":13501},{"trials":13474,"activeCount":99},[],{"trials":13476,"activeCount":99},[],{"trials":13478,"activeCount":99},[13479,13483,13491],{"nctId":3374,"briefTitle":3375,"status":105,"phases":13480,"primaryCompletion":3377,"completion":3378,"start":3379,"enrollment":3380,"conditions":13481,"interventions":13482},[88],[2568],[518,3383],{"nctId":13484,"briefTitle":13485,"status":105,"phases":13486,"primaryCompletion":13487,"completion":13487,"start":13488,"enrollment":1972,"conditions":13489,"interventions":13490},"NCT01756638","A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer",[88],"2014-10-17","2012-06-06",[2568],[2570,3383],{"nctId":13492,"briefTitle":13493,"status":105,"phases":13494,"primaryCompletion":3359,"completion":3359,"start":3640,"enrollment":12,"conditions":13495,"interventions":13496},"NCT01795703","A Phase 2 Study to Evaluate Safety and Efficacy of Abiraterone in Participants With Prostate Cancer Who Have Received Docetaxel",[88],[2568],[2570,3383],{"trials":13498,"activeCount":99},[],{"trials":13500,"activeCount":99},[],{"trials":13502,"activeCount":99},[],{"intervention":7295,"totalTrials":571,"cells":13504},{"EARLY_PHASE1":13505,"PHASE1":13507,"PHASE2":13513,"PHASE3":13523,"PHASE4":13525,"NA":13527},{"trials":13506,"activeCount":99},[],{"trials":13508,"activeCount":99},[13509],{"nctId":10436,"briefTitle":10437,"status":125,"phases":13510,"primaryCompletion":10439,"completion":10440,"start":10441,"enrollment":656,"conditions":13511,"interventions":13512},[87],[15,2412],[10444,10429,7294,7295,10444],{"trials":13514,"activeCount":99},[13515,13519],{"nctId":12215,"briefTitle":12216,"status":105,"phases":13516,"primaryCompletion":12218,"completion":12219,"start":12220,"enrollment":3586,"conditions":13517,"interventions":13518},[88],[12222],[7292,12224,7295,12174,12213,12201],{"nctId":7284,"briefTitle":7285,"status":105,"phases":13520,"primaryCompletion":7287,"completion":7288,"start":7289,"enrollment":5539,"conditions":13521,"interventions":13522},[88],[2412],[7292,7271,7293,7294,7295],{"trials":13524,"activeCount":99},[],{"trials":13526,"activeCount":99},[],{"trials":13528,"activeCount":99},[],{"intervention":13530,"totalTrials":571,"cells":13531},"JNJ-40411813",{"EARLY_PHASE1":13532,"PHASE1":13534,"PHASE2":13536,"PHASE3":13562,"PHASE4":13564,"NA":13566},{"trials":13533,"activeCount":99},[],{"trials":13535,"activeCount":99},[],{"trials":13537,"activeCount":99},[13538,13546,13555],{"nctId":13539,"briefTitle":13540,"status":105,"phases":13541,"primaryCompletion":5888,"completion":3392,"start":13542,"enrollment":1480,"conditions":13543,"interventions":13544},"NCT01323205","Investigation of the Safety, Tolerability and Potential Therapeutic Effects of JNJ-40411813 in Patients With Schizophrenia",[88],"2011-05",[32],[13530,13530,13545],"Antipsychotic medication",{"nctId":13547,"briefTitle":13548,"status":105,"phases":13549,"primaryCompletion":13550,"completion":13550,"start":13551,"enrollment":9507,"conditions":13552,"interventions":13554},"NCT04836559","A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy",[88],"2024-02-08","2021-05-18",[13553],"Focal Onset Seizures",[13530],{"nctId":13556,"briefTitle":13557,"status":105,"phases":13558,"primaryCompletion":5618,"completion":5618,"start":3310,"enrollment":13559,"conditions":13560,"interventions":13561},"NCT01582815","A Study of JNJ-40411813 as Supplementary Treatment to an Antidepressant in Adults With Depression and Anxiety Symptoms",[88],121,[5630],[13530],{"trials":13563,"activeCount":99},[],{"trials":13565,"activeCount":99},[],{"trials":13567,"activeCount":99},[],{"intervention":2570,"totalTrials":571,"cells":13569},{"EARLY_PHASE1":13570,"PHASE1":13572,"PHASE2":13574,"PHASE3":13588,"PHASE4":13590,"NA":13592},{"trials":13571,"activeCount":99},[],{"trials":13573,"activeCount":99},[],{"trials":13575,"activeCount":99},[13576,13580,13584],{"nctId":13484,"briefTitle":13485,"status":105,"phases":13577,"primaryCompletion":13487,"completion":13487,"start":13488,"enrollment":1972,"conditions":13578,"interventions":13579},[88],[2568],[2570,3383],{"nctId":2561,"briefTitle":2562,"status":105,"phases":13581,"primaryCompletion":2564,"completion":2565,"start":2512,"enrollment":2566,"conditions":13582,"interventions":13583},[88],[2568],[2570,2571,496],{"nctId":13492,"briefTitle":13493,"status":105,"phases":13585,"primaryCompletion":3359,"completion":3359,"start":3640,"enrollment":12,"conditions":13586,"interventions":13587},[88],[2568],[2570,3383],{"trials":13589,"activeCount":99},[],{"trials":13591,"activeCount":99},[],{"trials":13593,"activeCount":99},[],{"intervention":4884,"totalTrials":245,"cells":13595},{"EARLY_PHASE1":13596,"PHASE1":13598,"PHASE2":13604,"PHASE3":13610,"PHASE4":13612,"NA":13614},{"trials":13597,"activeCount":99},[],{"trials":13599,"activeCount":99},[13600],{"nctId":13086,"briefTitle":13087,"status":105,"phases":13601,"primaryCompletion":13089,"completion":13089,"start":13090,"enrollment":3138,"conditions":13602,"interventions":13603},[87],[15],[4884,13093,13094,4887],{"trials":13605,"activeCount":99},[13606],{"nctId":4876,"briefTitle":4877,"status":105,"phases":13607,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":13608,"interventions":13609},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":13611,"activeCount":99},[],{"trials":13613,"activeCount":99},[],{"trials":13615,"activeCount":99},[],{"intervention":12175,"totalTrials":245,"cells":13617},{"EARLY_PHASE1":13618,"PHASE1":13620,"PHASE2":13626,"PHASE3":13632,"PHASE4":13634,"NA":13636},{"trials":13619,"activeCount":99},[],{"trials":13621,"activeCount":99},[13622],{"nctId":12165,"briefTitle":12166,"status":105,"phases":13623,"primaryCompletion":12168,"completion":7176,"start":12169,"enrollment":3586,"conditions":13624,"interventions":13625},[87],[2412],[7292,12172,12173,12174,12175],{"trials":13627,"activeCount":99},[13628],{"nctId":12194,"briefTitle":12195,"status":125,"phases":13629,"primaryCompletion":12197,"completion":12197,"start":12198,"enrollment":468,"conditions":13630,"interventions":13631},[88],[2412],[7292,12201,12174,12175,12202],{"trials":13633,"activeCount":99},[],{"trials":13635,"activeCount":99},[],{"trials":13637,"activeCount":99},[],{"intervention":12212,"totalTrials":245,"cells":13639},{"EARLY_PHASE1":13640,"PHASE1":13642,"PHASE2":13644,"PHASE3":13654,"PHASE4":13656,"NA":13658},{"trials":13641,"activeCount":99},[],{"trials":13643,"activeCount":99},[],{"trials":13645,"activeCount":99},[13646,13650],{"nctId":12204,"briefTitle":12205,"status":105,"phases":13647,"primaryCompletion":12207,"completion":12208,"start":1034,"enrollment":19,"conditions":13648,"interventions":13649},[88],[12210],[7292,12212,12174,12213],{"nctId":12230,"briefTitle":12231,"status":105,"phases":13651,"primaryCompletion":12233,"completion":12234,"start":1691,"enrollment":1972,"conditions":13652,"interventions":13653},[88],[2412],[7292,12174,12213,12212,12237],{"trials":13655,"activeCount":99},[],{"trials":13657,"activeCount":99},[],{"trials":13659,"activeCount":99},[],{"intervention":13661,"totalTrials":245,"cells":13662},"JNJ-67953964",{"EARLY_PHASE1":13663,"PHASE1":13665,"PHASE2":13675,"PHASE3":13686,"PHASE4":13688,"NA":13690},{"trials":13664,"activeCount":99},[],{"trials":13666,"activeCount":99},[13667],{"nctId":13668,"briefTitle":13669,"status":105,"phases":13670,"primaryCompletion":13671,"completion":13672,"start":633,"enrollment":4851,"conditions":13673,"interventions":13674},"NCT04185051","A Study to Investigate the Effect of JNJ-67953964 on Gastric Mucosal Integrity in Healthy Male and Female Participants",[87],"2021-04-21","2021-05-05",[15],[13661],{"trials":13676,"activeCount":99},[13677],{"nctId":13678,"briefTitle":13679,"status":105,"phases":13680,"primaryCompletion":13681,"completion":13681,"start":13682,"enrollment":13683,"conditions":13684,"interventions":13685},"NCT03559192","A Study to Explore the Efficacy of JNJ-67953964 in the Treatment of Depression",[88],"2020-05-06","2018-07-16",181,[21],[13661],{"trials":13687,"activeCount":99},[],{"trials":13689,"activeCount":99},[],{"trials":13691,"activeCount":99},[],{"intervention":9547,"totalTrials":245,"cells":13693},{"EARLY_PHASE1":13694,"PHASE1":13696,"PHASE2":13702,"PHASE3":13708,"PHASE4":13710,"NA":13712},{"trials":13695,"activeCount":99},[],{"trials":13697,"activeCount":99},[13698],{"nctId":9540,"briefTitle":9541,"status":105,"phases":13699,"primaryCompletion":2487,"completion":9543,"start":2564,"enrollment":3471,"conditions":13700,"interventions":13701},[87],[15],[9521,9546,9547,9538,9537],{"trials":13703,"activeCount":99},[13704],{"nctId":9551,"briefTitle":9552,"status":125,"phases":13705,"primaryCompletion":3633,"completion":3633,"start":3613,"enrollment":2149,"conditions":13706,"interventions":13707},[88],[32,9555],[9521,9547,9537,9546,9538],{"trials":13709,"activeCount":99},[],{"trials":13711,"activeCount":99},[],{"trials":13713,"activeCount":99},[],{"intervention":9546,"totalTrials":245,"cells":13715},{"EARLY_PHASE1":13716,"PHASE1":13718,"PHASE2":13724,"PHASE3":13730,"PHASE4":13732,"NA":13734},{"trials":13717,"activeCount":99},[],{"trials":13719,"activeCount":99},[13720],{"nctId":9540,"briefTitle":9541,"status":105,"phases":13721,"primaryCompletion":2487,"completion":9543,"start":2564,"enrollment":3471,"conditions":13722,"interventions":13723},[87],[15],[9521,9546,9547,9538,9537],{"trials":13725,"activeCount":99},[13726],{"nctId":9551,"briefTitle":9552,"status":125,"phases":13727,"primaryCompletion":3633,"completion":3633,"start":3613,"enrollment":2149,"conditions":13728,"interventions":13729},[88],[32,9555],[9521,9547,9537,9546,9538],{"trials":13731,"activeCount":99},[],{"trials":13733,"activeCount":99},[],{"trials":13735,"activeCount":99},[],{"intervention":13737,"totalTrials":245,"cells":13738},"JNJ-54861911, 25 mg",{"EARLY_PHASE1":13739,"PHASE1":13741,"PHASE2":13751,"PHASE3":13762,"PHASE4":13764,"NA":13766},{"trials":13740,"activeCount":99},[],{"trials":13742,"activeCount":99},[13743],{"nctId":13744,"briefTitle":13745,"status":105,"phases":13746,"primaryCompletion":4348,"completion":4348,"start":6033,"enrollment":479,"conditions":13747,"interventions":13748},"NCT02197884","A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants",[87],[15],[13737,13749,13750],"Itraconazole 200 mg","Clarithromycin 500 mg",{"trials":13752,"activeCount":99},[13753],{"nctId":13754,"briefTitle":13755,"status":125,"phases":13756,"primaryCompletion":6090,"completion":6090,"start":13757,"enrollment":2766,"conditions":13758,"interventions":13759},"NCT02406027","An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum",[88],"2015-07-02",[4445],[13760,13737,13761],"JNJ-54861911, 10 mg","JNJ-54861911, 5 mg",{"trials":13763,"activeCount":99},[],{"trials":13765,"activeCount":99},[],{"trials":13767,"activeCount":99},[],{"intervention":4403,"totalTrials":245,"cells":13769},{"EARLY_PHASE1":13770,"PHASE1":13772,"PHASE2":13778,"PHASE3":13790,"PHASE4":13792,"NA":13794},{"trials":13771,"activeCount":99},[],{"trials":13773,"activeCount":99},[13774],{"nctId":4392,"briefTitle":4393,"status":105,"phases":13775,"primaryCompletion":4395,"completion":4395,"start":4396,"enrollment":4397,"conditions":13776,"interventions":13777},[87],[4399,4400],[4402,4403,4385],{"trials":13779,"activeCount":99},[13780],{"nctId":13781,"briefTitle":13782,"status":105,"phases":13783,"primaryCompletion":7312,"completion":7312,"start":1629,"enrollment":12433,"conditions":13784,"interventions":13786},"NCT03375203","A Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-42847922 in Participants With Insomnia Disorder",[88],[13785],"Insomnia Disorders",[13787,13788,13789,4403],"JNJ-42847922, 5 mg","JNJ-42847922, 10 mg","JNJ-42847922, 20 mg",{"trials":13791,"activeCount":99},[],{"trials":13793,"activeCount":99},[],{"trials":13795,"activeCount":99},[],{"intervention":3702,"totalTrials":245,"cells":13797},{"EARLY_PHASE1":13798,"PHASE1":13800,"PHASE2":13802,"PHASE3":13818,"PHASE4":13820,"NA":13822},{"trials":13799,"activeCount":99},[],{"trials":13801,"activeCount":99},[],{"trials":13803,"activeCount":99},[13804,13808],{"nctId":3693,"briefTitle":3694,"status":105,"phases":13805,"primaryCompletion":3696,"completion":3696,"start":3697,"enrollment":3698,"conditions":13806,"interventions":13807},[87,88],[3700],[46,3702],{"nctId":13809,"briefTitle":13810,"status":125,"phases":13811,"primaryCompletion":13812,"completion":13812,"start":13813,"enrollment":544,"conditions":13814,"interventions":13816},"NCT03371381","An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung",[87,88],"2018-10-09","2018-01-02",[13815],"Adenocarcinoma of Lung",[13817,3702],"JNJ-64041757",{"trials":13819,"activeCount":99},[],{"trials":13821,"activeCount":99},[],{"trials":13823,"activeCount":99},[],{"intervention":13825,"totalTrials":245,"cells":13826},"Bermekimab Monoclonal Antibody 400 mg",{"EARLY_PHASE1":13827,"PHASE1":13829,"PHASE2":13831,"PHASE3":13852,"PHASE4":13854,"NA":13856},{"trials":13828,"activeCount":99},[],{"trials":13830,"activeCount":99},[],{"trials":13832,"activeCount":99},[13833,13841],{"nctId":13834,"briefTitle":13835,"status":105,"phases":13836,"primaryCompletion":13837,"completion":13837,"start":13838,"enrollment":6909,"conditions":13839,"interventions":13840},"NCT03512275","A Study of Bermekimab in Patients With Hidradenitis Suppurativa",[88],"2019-01-14","2018-06-20",[3916],[13825],{"nctId":13842,"briefTitle":13843,"status":105,"phases":13844,"primaryCompletion":3674,"completion":13845,"start":13846,"enrollment":13847,"conditions":13848,"interventions":13850},"NCT03496974","A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis",[88],"2018-12-11","2018-05-21",38,[13849],"Atopic Dermatitis",[13851,13825],"Bermekimab Monoclonal Antibody 200 mg",{"trials":13853,"activeCount":99},[],{"trials":13855,"activeCount":99},[],{"trials":13857,"activeCount":99},[],{"intervention":13859,"totalTrials":245,"cells":13860},"Rilpivirine",{"EARLY_PHASE1":13861,"PHASE1":13863,"PHASE2":13874,"PHASE3":13886,"PHASE4":13888,"NA":13890},{"trials":13862,"activeCount":99},[],{"trials":13864,"activeCount":99},[13865],{"nctId":13866,"briefTitle":13867,"status":105,"phases":13868,"primaryCompletion":13869,"completion":13869,"start":13870,"enrollment":9507,"conditions":13871,"interventions":13872},"NCT03127189","A Study to Investigate the Effect of Different Particle Sizes on the Single-dose Pharmacokinetics of Rilpivirine After Intramuscular Injection of a Long-acting Nanosuspension in Healthy Participants",[87],"2018-04-10","2017-04-20",[15],[13859,13873],"Rilpivirine Long-acting Parenteral Formulation",{"trials":13875,"activeCount":99},[13876],{"nctId":13877,"briefTitle":13878,"status":105,"phases":13879,"primaryCompletion":13880,"completion":13881,"start":489,"enrollment":25,"conditions":13882,"interventions":13884},"NCT04012931","A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to \u003C12 Years) Who Are Virologically Suppressed",[88],"2023-02-17","2023-02-23",[13883],"HIV",[13859,13885],"ARV Background Regimen",{"trials":13887,"activeCount":99},[],{"trials":13889,"activeCount":99},[],{"trials":13891,"activeCount":99},[],{"intervention":13893,"totalTrials":245,"cells":13894},"JNJ-53718678 500 mg",{"EARLY_PHASE1":13895,"PHASE1":13897,"PHASE2":13912,"PHASE3":13923,"PHASE4":13925,"NA":13927},{"trials":13896,"activeCount":99},[],{"trials":13898,"activeCount":99},[13899],{"nctId":13900,"briefTitle":13901,"status":105,"phases":13902,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":13904,"interventions":13905},"NCT03696459","A Study to Evaluate the Effect of JNJ-53718678 on the Cardiac Repolarization Interval in Healthy Adult Participants",[87],"2018-10-02",[15],[13906,13907,13908,13893,13909,13910,13911],"JNJ-53718678, 2000 mg","JNJ-53718678, 3000 mg","JNJ-53718678, 4500 mg or Dose to be decided","JNJ-53718678 Placebo","Moxifloxacin 400 mg","Moxifloxacin Placebo",{"trials":13913,"activeCount":99},[13914],{"nctId":13915,"briefTitle":13916,"status":105,"phases":13917,"primaryCompletion":13918,"completion":13919,"start":397,"enrollment":1380,"conditions":13920,"interventions":13921},"NCT03379675","A Study to Explore the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of JNJ-53718678 at Two Dose Levels in Non-Hospitalized Adult Participants Infected With Respiratory Syncytial Virus",[88],"2019-11-27","2019-12-26",[12475],[13893,13922],"JNJ-53718678 80 mg",{"trials":13924,"activeCount":99},[],{"trials":13926,"activeCount":99},[],{"trials":13928,"activeCount":99},[],{"intervention":13930,"totalTrials":245,"cells":13931},"JNJ-64565111 Dose Level 1",{"EARLY_PHASE1":13932,"PHASE1":13934,"PHASE2":13936,"PHASE3":13959,"PHASE4":13961,"NA":13963},{"trials":13933,"activeCount":99},[],{"trials":13935,"activeCount":99},[],{"trials":13937,"activeCount":99},[13938,13951],{"nctId":13939,"briefTitle":13940,"status":105,"phases":13941,"primaryCompletion":13942,"completion":13942,"start":13943,"enrollment":13944,"conditions":13945,"interventions":13947},"NCT03486392","A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants",[88],"2019-03-08","2018-03-26",474,[13946],"Obesity",[13930,13948,13949,13950],"JNJ-64565111 Dose Level 2","JNJ-64565111 Dose Level 3","Liraglutide",{"nctId":13952,"briefTitle":13953,"status":105,"phases":13954,"primaryCompletion":2628,"completion":2628,"start":13955,"enrollment":423,"conditions":13956,"interventions":13958},"NCT03586830","A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes Mellitus",[88],"2018-06-26",[13957],"Obesity and Diabetes Mellitus, Type 2",[13930,13948,13949],{"trials":13960,"activeCount":99},[],{"trials":13962,"activeCount":99},[],{"trials":13964,"activeCount":99},[],{"intervention":13948,"totalTrials":245,"cells":13966},{"EARLY_PHASE1":13967,"PHASE1":13969,"PHASE2":13971,"PHASE3":13981,"PHASE4":13983,"NA":13985},{"trials":13968,"activeCount":99},[],{"trials":13970,"activeCount":99},[],{"trials":13972,"activeCount":99},[13973,13977],{"nctId":13939,"briefTitle":13940,"status":105,"phases":13974,"primaryCompletion":13942,"completion":13942,"start":13943,"enrollment":13944,"conditions":13975,"interventions":13976},[88],[13946],[13930,13948,13949,13950],{"nctId":13952,"briefTitle":13953,"status":105,"phases":13978,"primaryCompletion":2628,"completion":2628,"start":13955,"enrollment":423,"conditions":13979,"interventions":13980},[88],[13957],[13930,13948,13949],{"trials":13982,"activeCount":99},[],{"trials":13984,"activeCount":99},[],{"trials":13986,"activeCount":99},[],{"intervention":13949,"totalTrials":245,"cells":13988},{"EARLY_PHASE1":13989,"PHASE1":13991,"PHASE2":13993,"PHASE3":14003,"PHASE4":14005,"NA":14007},{"trials":13990,"activeCount":99},[],{"trials":13992,"activeCount":99},[],{"trials":13994,"activeCount":99},[13995,13999],{"nctId":13939,"briefTitle":13940,"status":105,"phases":13996,"primaryCompletion":13942,"completion":13942,"start":13943,"enrollment":13944,"conditions":13997,"interventions":13998},[88],[13946],[13930,13948,13949,13950],{"nctId":13952,"briefTitle":13953,"status":105,"phases":14000,"primaryCompletion":2628,"completion":2628,"start":13955,"enrollment":423,"conditions":14001,"interventions":14002},[88],[13957],[13930,13948,13949],{"trials":14004,"activeCount":99},[],{"trials":14006,"activeCount":99},[],{"trials":14008,"activeCount":99},[],{"intervention":1170,"totalTrials":245,"cells":14010},{"EARLY_PHASE1":14011,"PHASE1":14013,"PHASE2":14019,"PHASE3":14025,"PHASE4":14027,"NA":14029},{"trials":14012,"activeCount":99},[],{"trials":14014,"activeCount":99},[14015],{"nctId":1157,"briefTitle":1158,"status":105,"phases":14016,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":14017,"interventions":14018},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":14020,"activeCount":99},[14021],{"nctId":1485,"briefTitle":1486,"status":105,"phases":14022,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":14023,"interventions":14024},[88],[18],[1494,1495,1496,1170,1169,681],{"trials":14026,"activeCount":99},[],{"trials":14028,"activeCount":99},[],{"trials":14030,"activeCount":99},[],{"intervention":1169,"totalTrials":245,"cells":14032},{"EARLY_PHASE1":14033,"PHASE1":14035,"PHASE2":14041,"PHASE3":14047,"PHASE4":14049,"NA":14051},{"trials":14034,"activeCount":99},[],{"trials":14036,"activeCount":99},[14037],{"nctId":1157,"briefTitle":1158,"status":105,"phases":14038,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":14039,"interventions":14040},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":14042,"activeCount":99},[14043],{"nctId":1485,"briefTitle":1486,"status":105,"phases":14044,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":14045,"interventions":14046},[88],[18],[1494,1495,1496,1170,1169,681],{"trials":14048,"activeCount":99},[],{"trials":14050,"activeCount":99},[],{"trials":14052,"activeCount":99},[],{"intervention":14054,"totalTrials":245,"cells":14055},"NNC0142-0002",{"EARLY_PHASE1":14056,"PHASE1":14058,"PHASE2":14068,"PHASE3":14076,"PHASE4":14078,"NA":14080},{"trials":14057,"activeCount":99},[],{"trials":14059,"activeCount":99},[14060],{"nctId":14061,"briefTitle":14062,"status":105,"phases":14063,"primaryCompletion":5867,"completion":5867,"start":2525,"enrollment":14064,"conditions":14065,"interventions":14067},"NCT00927927","First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis",[87],65,[14066,6786],"Inflammation",[14054,14054,14054,14054,14054,14054,14054,14054,14054,14054,14054,14054,14054],{"trials":14069,"activeCount":99},[14070],{"nctId":14071,"briefTitle":14072,"status":105,"phases":14073,"primaryCompletion":2487,"completion":2487,"start":11934,"enrollment":8662,"conditions":14074,"interventions":14075},"NCT01181050","Efficacy of NNC0142-0002 in Subjects With Rheumatoid Arthritis (RA)",[88],[14066,6786],[14054],{"trials":14077,"activeCount":99},[],{"trials":14079,"activeCount":99},[],{"trials":14081,"activeCount":99},[],{"intervention":14083,"totalTrials":245,"cells":14084},"RA-18C3",{"EARLY_PHASE1":14085,"PHASE1":14087,"PHASE2":14089,"PHASE3":14109,"PHASE4":14111,"NA":14113},{"trials":14086,"activeCount":99},[],{"trials":14088,"activeCount":99},[],{"trials":14090,"activeCount":99},[14091,14100],{"nctId":14092,"briefTitle":14093,"status":105,"phases":14094,"primaryCompletion":14095,"completion":14096,"start":14097,"enrollment":109,"conditions":14098,"interventions":14099},"NCT01384630","Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis",[88],"2012-07-31","2012-08-31","2011-09-30",[171],[14083],{"nctId":14101,"briefTitle":14102,"status":105,"phases":14103,"primaryCompletion":6806,"completion":14104,"start":14105,"enrollment":129,"conditions":14106,"interventions":14108},"NCT01474798","Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris",[88],"2012-12-31","2012-02-29",[14107],"Acne Vulgaris",[14083],{"trials":14110,"activeCount":99},[],{"trials":14112,"activeCount":99},[],{"trials":14114,"activeCount":99},[],{"intervention":13817,"totalTrials":245,"cells":14116},{"EARLY_PHASE1":14117,"PHASE1":14119,"PHASE2":14129,"PHASE3":14135,"PHASE4":14137,"NA":14139},{"trials":14118,"activeCount":99},[],{"trials":14120,"activeCount":99},[14121],{"nctId":14122,"briefTitle":14123,"status":125,"phases":14124,"primaryCompletion":14125,"completion":14126,"start":12316,"enrollment":503,"conditions":14127,"interventions":14128},"NCT02592967","Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer",[87],"2018-08-14","2018-10-22",[35],[13817,13817],{"trials":14130,"activeCount":99},[14131],{"nctId":13809,"briefTitle":13810,"status":125,"phases":14132,"primaryCompletion":13812,"completion":13812,"start":13813,"enrollment":544,"conditions":14133,"interventions":14134},[87,88],[13815],[13817,3702],{"trials":14136,"activeCount":99},[],{"trials":14138,"activeCount":99},[],{"trials":14140,"activeCount":99},[],{"intervention":14142,"totalTrials":245,"cells":14143},"JNJ-38518168 30 mg",{"EARLY_PHASE1":14144,"PHASE1":14146,"PHASE2":14157,"PHASE3":14168,"PHASE4":14170,"NA":14172},{"trials":14145,"activeCount":99},[],{"trials":14147,"activeCount":99},[14148],{"nctId":14149,"briefTitle":14150,"status":105,"phases":14151,"primaryCompletion":3392,"completion":3392,"start":9543,"enrollment":2515,"conditions":14152,"interventions":14153},"NCT01690286","Effect of Ketoconazole on the Pharmacokinetics of JNJ-38518168 in Healthy Volunteers",[87],[15],[14154,14142,14155,14156],"JNJ-38518168 3 mg","JNJ-38518168 10 mg","Ketoconazole 200 mg",{"trials":14158,"activeCount":99},[14159],{"nctId":14160,"briefTitle":14161,"status":105,"phases":14162,"primaryCompletion":14163,"completion":14163,"start":14164,"enrollment":13318,"conditions":14165,"interventions":14166},"NCT02295865","A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type Psoriasis",[88],"2016-03-11","2014-11-17",[171],[14167,14142,14154],"JNJ-38518168 60 mg",{"trials":14169,"activeCount":99},[],{"trials":14171,"activeCount":99},[],{"trials":14173,"activeCount":99},[],{"intervention":14154,"totalTrials":245,"cells":14175},{"EARLY_PHASE1":14176,"PHASE1":14178,"PHASE2":14184,"PHASE3":14190,"PHASE4":14192,"NA":14194},{"trials":14177,"activeCount":99},[],{"trials":14179,"activeCount":99},[14180],{"nctId":14149,"briefTitle":14150,"status":105,"phases":14181,"primaryCompletion":3392,"completion":3392,"start":9543,"enrollment":2515,"conditions":14182,"interventions":14183},[87],[15],[14154,14142,14155,14156],{"trials":14185,"activeCount":99},[14186],{"nctId":14160,"briefTitle":14161,"status":105,"phases":14187,"primaryCompletion":14163,"completion":14163,"start":14164,"enrollment":13318,"conditions":14188,"interventions":14189},[88],[171],[14167,14142,14154],{"trials":14191,"activeCount":99},[],{"trials":14193,"activeCount":99},[],{"trials":14195,"activeCount":99},[],{"intervention":3643,"totalTrials":245,"cells":14197},{"EARLY_PHASE1":14198,"PHASE1":14200,"PHASE2":14206,"PHASE3":14215,"PHASE4":14217,"NA":14219},{"trials":14199,"activeCount":99},[],{"trials":14201,"activeCount":99},[14202],{"nctId":3637,"briefTitle":3638,"status":105,"phases":14203,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1419,"conditions":14204,"interventions":14205},[87],[15],[46,3643],{"trials":14207,"activeCount":99},[14208],{"nctId":14209,"briefTitle":14210,"status":105,"phases":14211,"primaryCompletion":5888,"completion":5888,"start":8883,"enrollment":544,"conditions":14212,"interventions":14213},"NCT01267084","A Study to Assess the Potential Effects of Ketoconazole on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies",[87,88],[1179],[1182,3643,14214],"Dexamethasone or equivalent steroid",{"trials":14216,"activeCount":99},[],{"trials":14218,"activeCount":99},[],{"trials":14220,"activeCount":99},[],{"intervention":4885,"totalTrials":468,"cells":14222},{"EARLY_PHASE1":14223,"PHASE1":14225,"PHASE2":14227,"PHASE3":14233,"PHASE4":14235,"NA":14237},{"trials":14224,"activeCount":99},[],{"trials":14226,"activeCount":99},[],{"trials":14228,"activeCount":99},[14229],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14230,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14231,"interventions":14232},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14234,"activeCount":99},[],{"trials":14236,"activeCount":99},[],{"trials":14238,"activeCount":99},[],{"intervention":4886,"totalTrials":468,"cells":14240},{"EARLY_PHASE1":14241,"PHASE1":14243,"PHASE2":14245,"PHASE3":14251,"PHASE4":14253,"NA":14255},{"trials":14242,"activeCount":99},[],{"trials":14244,"activeCount":99},[],{"trials":14246,"activeCount":99},[14247],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14248,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14249,"interventions":14250},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14252,"activeCount":99},[],{"trials":14254,"activeCount":99},[],{"trials":14256,"activeCount":99},[],{"intervention":4888,"totalTrials":468,"cells":14258},{"EARLY_PHASE1":14259,"PHASE1":14261,"PHASE2":14263,"PHASE3":14269,"PHASE4":14271,"NA":14273},{"trials":14260,"activeCount":99},[],{"trials":14262,"activeCount":99},[],{"trials":14264,"activeCount":99},[14265],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14266,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14267,"interventions":14268},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14270,"activeCount":99},[],{"trials":14272,"activeCount":99},[],{"trials":14274,"activeCount":99},[],{"intervention":4889,"totalTrials":468,"cells":14276},{"EARLY_PHASE1":14277,"PHASE1":14279,"PHASE2":14281,"PHASE3":14287,"PHASE4":14289,"NA":14291},{"trials":14278,"activeCount":99},[],{"trials":14280,"activeCount":99},[],{"trials":14282,"activeCount":99},[14283],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14284,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14285,"interventions":14286},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14288,"activeCount":99},[],{"trials":14290,"activeCount":99},[],{"trials":14292,"activeCount":99},[],{"intervention":4890,"totalTrials":468,"cells":14294},{"EARLY_PHASE1":14295,"PHASE1":14297,"PHASE2":14299,"PHASE3":14305,"PHASE4":14307,"NA":14309},{"trials":14296,"activeCount":99},[],{"trials":14298,"activeCount":99},[],{"trials":14300,"activeCount":99},[14301],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14302,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14303,"interventions":14304},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14306,"activeCount":99},[],{"trials":14308,"activeCount":99},[],{"trials":14310,"activeCount":99},[],{"intervention":4891,"totalTrials":468,"cells":14312},{"EARLY_PHASE1":14313,"PHASE1":14315,"PHASE2":14317,"PHASE3":14323,"PHASE4":14325,"NA":14327},{"trials":14314,"activeCount":99},[],{"trials":14316,"activeCount":99},[],{"trials":14318,"activeCount":99},[14319],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14320,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14321,"interventions":14322},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14324,"activeCount":99},[],{"trials":14326,"activeCount":99},[],{"trials":14328,"activeCount":99},[],{"intervention":4892,"totalTrials":468,"cells":14330},{"EARLY_PHASE1":14331,"PHASE1":14333,"PHASE2":14335,"PHASE3":14341,"PHASE4":14343,"NA":14345},{"trials":14332,"activeCount":99},[],{"trials":14334,"activeCount":99},[],{"trials":14336,"activeCount":99},[14337],{"nctId":4876,"briefTitle":4877,"status":105,"phases":14338,"primaryCompletion":4879,"completion":4879,"start":4880,"enrollment":957,"conditions":14339,"interventions":14340},[88],[4882],[4884,4885,4886,4887,4888,4889,4890,4891,4867,4892],{"trials":14342,"activeCount":99},[],{"trials":14344,"activeCount":99},[],{"trials":14346,"activeCount":99},[],{"intervention":12202,"totalTrials":468,"cells":14348},{"EARLY_PHASE1":14349,"PHASE1":14351,"PHASE2":14353,"PHASE3":14359,"PHASE4":14361,"NA":14363},{"trials":14350,"activeCount":99},[],{"trials":14352,"activeCount":99},[],{"trials":14354,"activeCount":99},[14355],{"nctId":12194,"briefTitle":12195,"status":125,"phases":14356,"primaryCompletion":12197,"completion":12197,"start":12198,"enrollment":468,"conditions":14357,"interventions":14358},[88],[2412],[7292,12201,12174,12175,12202],{"trials":14360,"activeCount":99},[],{"trials":14362,"activeCount":99},[],{"trials":14364,"activeCount":99},[],{"intervention":8508,"totalTrials":468,"cells":14366},{"EARLY_PHASE1":14367,"PHASE1":14369,"PHASE2":14371,"PHASE3":14377,"PHASE4":14379,"NA":14381},{"trials":14368,"activeCount":99},[],{"trials":14370,"activeCount":99},[],{"trials":14372,"activeCount":99},[14373],{"nctId":8500,"briefTitle":8501,"status":105,"phases":14374,"primaryCompletion":8503,"completion":108,"start":8504,"enrollment":595,"conditions":14375,"interventions":14376},[88],[8506],[8508,8509,8510,8477],{"trials":14378,"activeCount":99},[],{"trials":14380,"activeCount":99},[],{"trials":14382,"activeCount":99},[],{"intervention":8509,"totalTrials":468,"cells":14384},{"EARLY_PHASE1":14385,"PHASE1":14387,"PHASE2":14389,"PHASE3":14395,"PHASE4":14397,"NA":14399},{"trials":14386,"activeCount":99},[],{"trials":14388,"activeCount":99},[],{"trials":14390,"activeCount":99},[14391],{"nctId":8500,"briefTitle":8501,"status":105,"phases":14392,"primaryCompletion":8503,"completion":108,"start":8504,"enrollment":595,"conditions":14393,"interventions":14394},[88],[8506],[8508,8509,8510,8477],{"trials":14396,"activeCount":99},[],{"trials":14398,"activeCount":99},[],{"trials":14400,"activeCount":99},[],{"intervention":14402,"totalTrials":468,"cells":14403},"Exemestane",{"EARLY_PHASE1":14404,"PHASE1":14406,"PHASE2":14408,"PHASE3":14424,"PHASE4":14426,"NA":14428},{"trials":14405,"activeCount":99},[],{"trials":14407,"activeCount":99},[],{"trials":14409,"activeCount":99},[14410],{"nctId":14411,"briefTitle":14412,"status":105,"phases":14413,"primaryCompletion":14414,"completion":14415,"start":14416,"enrollment":14417,"conditions":14418,"interventions":14421},"NCT01381874","A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy",[88],"2014-07-28","2018-08-08","2011-08-24",297,[14419,14420],"Metastatic ER+ Her2- Breast Cancer","Postmenopausal",[14402,14422,14423],"Abiraterone acetate + Prednisone\u002F Prednisolone + Exemestane","Abiraterone acetate + Prednisone or Prednisolone",{"trials":14425,"activeCount":99},[],{"trials":14427,"activeCount":99},[],{"trials":14429,"activeCount":99},[],{"intervention":14422,"totalTrials":468,"cells":14431},{"EARLY_PHASE1":14432,"PHASE1":14434,"PHASE2":14436,"PHASE3":14442,"PHASE4":14444,"NA":14446},{"trials":14433,"activeCount":99},[],{"trials":14435,"activeCount":99},[],{"trials":14437,"activeCount":99},[14438],{"nctId":14411,"briefTitle":14412,"status":105,"phases":14439,"primaryCompletion":14414,"completion":14415,"start":14416,"enrollment":14417,"conditions":14440,"interventions":14441},[88],[14419,14420],[14402,14422,14423],{"trials":14443,"activeCount":99},[],{"trials":14445,"activeCount":99},[],{"trials":14447,"activeCount":99},[],{"intervention":14423,"totalTrials":468,"cells":14449},{"EARLY_PHASE1":14450,"PHASE1":14452,"PHASE2":14454,"PHASE3":14460,"PHASE4":14462,"NA":14464},{"trials":14451,"activeCount":99},[],{"trials":14453,"activeCount":99},[],{"trials":14455,"activeCount":99},[14456],{"nctId":14411,"briefTitle":14412,"status":105,"phases":14457,"primaryCompletion":14414,"completion":14415,"start":14416,"enrollment":14417,"conditions":14458,"interventions":14459},[88],[14419,14420],[14402,14422,14423],{"trials":14461,"activeCount":99},[],{"trials":14463,"activeCount":99},[],{"trials":14465,"activeCount":99},[],{"intervention":1469,"totalTrials":468,"cells":14467},{"EARLY_PHASE1":14468,"PHASE1":14470,"PHASE2":14472,"PHASE3":14478,"PHASE4":14480,"NA":14482},{"trials":14469,"activeCount":99},[],{"trials":14471,"activeCount":99},[],{"trials":14473,"activeCount":99},[14474],{"nctId":1460,"briefTitle":1461,"status":105,"phases":14475,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":492,"conditions":14476,"interventions":14477},[88],[1467],[1469,681],{"trials":14479,"activeCount":99},[],{"trials":14481,"activeCount":99},[],{"trials":14483,"activeCount":99},[],{"intervention":1195,"totalTrials":468,"cells":14485},{"EARLY_PHASE1":14486,"PHASE1":14488,"PHASE2":14490,"PHASE3":14496,"PHASE4":14498,"NA":14500},{"trials":14487,"activeCount":99},[],{"trials":14489,"activeCount":99},[],{"trials":14491,"activeCount":99},[14492],{"nctId":1186,"briefTitle":1187,"status":105,"phases":14493,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":14494,"interventions":14495},[87,88],[18],[1195,1196,683,684],{"trials":14497,"activeCount":99},[],{"trials":14499,"activeCount":99},[],{"trials":14501,"activeCount":99},[],{"intervention":1196,"totalTrials":468,"cells":14503},{"EARLY_PHASE1":14504,"PHASE1":14506,"PHASE2":14508,"PHASE3":14514,"PHASE4":14516,"NA":14518},{"trials":14505,"activeCount":99},[],{"trials":14507,"activeCount":99},[],{"trials":14509,"activeCount":99},[14510],{"nctId":1186,"briefTitle":1187,"status":105,"phases":14511,"primaryCompletion":1189,"completion":1190,"start":1191,"enrollment":1192,"conditions":14512,"interventions":14513},[87,88],[18],[1195,1196,683,684],{"trials":14515,"activeCount":99},[],{"trials":14517,"activeCount":99},[],{"trials":14519,"activeCount":99},[],{"intervention":587,"totalTrials":468,"cells":14521},{"EARLY_PHASE1":14522,"PHASE1":14524,"PHASE2":14526,"PHASE3":14532,"PHASE4":14534,"NA":14536},{"trials":14523,"activeCount":99},[],{"trials":14525,"activeCount":99},[],{"trials":14527,"activeCount":99},[14528],{"nctId":579,"briefTitle":580,"status":137,"phases":14529,"primaryCompletion":582,"completion":582,"start":583,"enrollment":99,"conditions":14530,"interventions":14531},[88],[585],[587,41],{"trials":14533,"activeCount":99},[],{"trials":14535,"activeCount":99},[],{"trials":14537,"activeCount":99},[],{"intervention":3856,"totalTrials":468,"cells":14539},{"EARLY_PHASE1":14540,"PHASE1":14542,"PHASE2":14544,"PHASE3":14550,"PHASE4":14552,"NA":14554},{"trials":14541,"activeCount":99},[],{"trials":14543,"activeCount":99},[],{"trials":14545,"activeCount":99},[14546],{"nctId":3847,"briefTitle":3848,"status":105,"phases":14547,"primaryCompletion":3850,"completion":3851,"start":3852,"enrollment":3853,"conditions":14548,"interventions":14549},[88],[2424],[75,3856,3856],{"trials":14551,"activeCount":99},[],{"trials":14553,"activeCount":99},[],{"trials":14555,"activeCount":99},[],{"intervention":14557,"totalTrials":468,"cells":14558},"Simeprevir 150 mg",{"EARLY_PHASE1":14559,"PHASE1":14561,"PHASE2":14563,"PHASE3":14574,"PHASE4":14576,"NA":14578},{"trials":14560,"activeCount":99},[],{"trials":14562,"activeCount":99},[],{"trials":14564,"activeCount":99},[14565],{"nctId":14566,"briefTitle":14567,"status":105,"phases":14568,"primaryCompletion":4314,"completion":9096,"start":5493,"enrollment":809,"conditions":14569,"interventions":14571},"NCT02349048","Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection",[88],[14570],"Hepatitis C Virus",[14557,14572,14573],"Daclatasvir 60 mg","Sofosbuvir 400 mg",{"trials":14575,"activeCount":99},[],{"trials":14577,"activeCount":99},[],{"trials":14579,"activeCount":99},[],{"intervention":14572,"totalTrials":468,"cells":14581},{"EARLY_PHASE1":14582,"PHASE1":14584,"PHASE2":14586,"PHASE3":14592,"PHASE4":14594,"NA":14596},{"trials":14583,"activeCount":99},[],{"trials":14585,"activeCount":99},[],{"trials":14587,"activeCount":99},[14588],{"nctId":14566,"briefTitle":14567,"status":105,"phases":14589,"primaryCompletion":4314,"completion":9096,"start":5493,"enrollment":809,"conditions":14590,"interventions":14591},[88],[14570],[14557,14572,14573],{"trials":14593,"activeCount":99},[],{"trials":14595,"activeCount":99},[],{"trials":14597,"activeCount":99},[],{"intervention":14573,"totalTrials":468,"cells":14599},{"EARLY_PHASE1":14600,"PHASE1":14602,"PHASE2":14604,"PHASE3":14610,"PHASE4":14612,"NA":14614},{"trials":14601,"activeCount":99},[],{"trials":14603,"activeCount":99},[],{"trials":14605,"activeCount":99},[14606],{"nctId":14566,"briefTitle":14567,"status":105,"phases":14607,"primaryCompletion":4314,"completion":9096,"start":5493,"enrollment":809,"conditions":14608,"interventions":14609},[88],[14570],[14557,14572,14573],{"trials":14611,"activeCount":99},[],{"trials":14613,"activeCount":99},[],{"trials":14615,"activeCount":99},[],{"intervention":1483,"totalTrials":468,"cells":14617},{"EARLY_PHASE1":14618,"PHASE1":14620,"PHASE2":14622,"PHASE3":14628,"PHASE4":14630,"NA":14632},{"trials":14619,"activeCount":99},[],{"trials":14621,"activeCount":99},[],{"trials":14623,"activeCount":99},[14624],{"nctId":1475,"briefTitle":1476,"status":105,"phases":14625,"primaryCompletion":1478,"completion":296,"start":1479,"enrollment":1480,"conditions":14626,"interventions":14627},[87,88],[35],[1483,681],{"trials":14629,"activeCount":99},[],{"trials":14631,"activeCount":99},[],{"trials":14633,"activeCount":99},[],{"intervention":13421,"totalTrials":468,"cells":14635},{"EARLY_PHASE1":14636,"PHASE1":14638,"PHASE2":14640,"PHASE3":14646,"PHASE4":14648,"NA":14650},{"trials":14637,"activeCount":99},[],{"trials":14639,"activeCount":99},[],{"trials":14641,"activeCount":99},[14642],{"nctId":13411,"briefTitle":13412,"status":105,"phases":14643,"primaryCompletion":13414,"completion":13415,"start":13416,"enrollment":13417,"conditions":14644,"interventions":14645},[87,88],[13419],[13421,13402,13422],{"trials":14647,"activeCount":99},[],{"trials":14649,"activeCount":99},[],{"trials":14651,"activeCount":99},[],{"intervention":13422,"totalTrials":468,"cells":14653},{"EARLY_PHASE1":14654,"PHASE1":14656,"PHASE2":14658,"PHASE3":14664,"PHASE4":14666,"NA":14668},{"trials":14655,"activeCount":99},[],{"trials":14657,"activeCount":99},[],{"trials":14659,"activeCount":99},[14660],{"nctId":13411,"briefTitle":13412,"status":105,"phases":14661,"primaryCompletion":13414,"completion":13415,"start":13416,"enrollment":13417,"conditions":14662,"interventions":14663},[87,88],[13419],[13421,13402,13422],{"trials":14665,"activeCount":99},[],{"trials":14667,"activeCount":99},[],{"trials":14669,"activeCount":99},[],{"intervention":13851,"totalTrials":468,"cells":14671},{"EARLY_PHASE1":14672,"PHASE1":14674,"PHASE2":14676,"PHASE3":14682,"PHASE4":14684,"NA":14686},{"trials":14673,"activeCount":99},[],{"trials":14675,"activeCount":99},[],{"trials":14677,"activeCount":99},[14678],{"nctId":13842,"briefTitle":13843,"status":105,"phases":14679,"primaryCompletion":3674,"completion":13845,"start":13846,"enrollment":13847,"conditions":14680,"interventions":14681},[88],[13849],[13851,13825],{"trials":14683,"activeCount":99},[],{"trials":14685,"activeCount":99},[],{"trials":14687,"activeCount":99},[],{"intervention":2529,"totalTrials":468,"cells":14689},{"EARLY_PHASE1":14690,"PHASE1":14692,"PHASE2":14694,"PHASE3":14700,"PHASE4":14702,"NA":14704},{"trials":14691,"activeCount":99},[],{"trials":14693,"activeCount":99},[],{"trials":14695,"activeCount":99},[14696],{"nctId":2521,"briefTitle":2522,"status":105,"phases":14697,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":2526,"conditions":14698,"interventions":14699},[88],[18],[2529,2530,1166,1166,1167,1167,496,496,1166,1167,496],{"trials":14701,"activeCount":99},[],{"trials":14703,"activeCount":99},[],{"trials":14705,"activeCount":99},[],{"intervention":2530,"totalTrials":468,"cells":14707},{"EARLY_PHASE1":14708,"PHASE1":14710,"PHASE2":14712,"PHASE3":14718,"PHASE4":14720,"NA":14722},{"trials":14709,"activeCount":99},[],{"trials":14711,"activeCount":99},[],{"trials":14713,"activeCount":99},[14714],{"nctId":2521,"briefTitle":2522,"status":105,"phases":14715,"primaryCompletion":2524,"completion":2524,"start":2525,"enrollment":2526,"conditions":14716,"interventions":14717},[88],[18],[2529,2530,1166,1166,1167,1167,496,496,1166,1167,496],{"trials":14719,"activeCount":99},[],{"trials":14721,"activeCount":99},[],{"trials":14723,"activeCount":99},[],{"intervention":9063,"totalTrials":468,"cells":14725},{"EARLY_PHASE1":14726,"PHASE1":14728,"PHASE2":14730,"PHASE3":14736,"PHASE4":14738,"NA":14740},{"trials":14727,"activeCount":99},[],{"trials":14729,"activeCount":99},[],{"trials":14731,"activeCount":99},[14732],{"nctId":9055,"briefTitle":9056,"status":105,"phases":14733,"primaryCompletion":6034,"completion":6034,"start":5878,"enrollment":745,"conditions":14734,"interventions":14735},[88],[9059],[9061,9062,9063],{"trials":14737,"activeCount":99},[],{"trials":14739,"activeCount":99},[],{"trials":14741,"activeCount":99},[],{"intervention":13885,"totalTrials":468,"cells":14743},{"EARLY_PHASE1":14744,"PHASE1":14746,"PHASE2":14748,"PHASE3":14754,"PHASE4":14756,"NA":14758},{"trials":14745,"activeCount":99},[],{"trials":14747,"activeCount":99},[],{"trials":14749,"activeCount":99},[14750],{"nctId":13877,"briefTitle":13878,"status":105,"phases":14751,"primaryCompletion":13880,"completion":13881,"start":489,"enrollment":25,"conditions":14752,"interventions":14753},[88],[13883],[13859,13885],{"trials":14755,"activeCount":99},[],{"trials":14757,"activeCount":99},[],{"trials":14759,"activeCount":99},[],{"intervention":13787,"totalTrials":468,"cells":14761},{"EARLY_PHASE1":14762,"PHASE1":14764,"PHASE2":14766,"PHASE3":14772,"PHASE4":14774,"NA":14776},{"trials":14763,"activeCount":99},[],{"trials":14765,"activeCount":99},[],{"trials":14767,"activeCount":99},[14768],{"nctId":13781,"briefTitle":13782,"status":105,"phases":14769,"primaryCompletion":7312,"completion":7312,"start":1629,"enrollment":12433,"conditions":14770,"interventions":14771},[88],[13785],[13787,13788,13789,4403],{"trials":14773,"activeCount":99},[],{"trials":14775,"activeCount":99},[],{"trials":14777,"activeCount":99},[],{"intervention":13788,"totalTrials":468,"cells":14779},{"EARLY_PHASE1":14780,"PHASE1":14782,"PHASE2":14784,"PHASE3":14790,"PHASE4":14792,"NA":14794},{"trials":14781,"activeCount":99},[],{"trials":14783,"activeCount":99},[],{"trials":14785,"activeCount":99},[14786],{"nctId":13781,"briefTitle":13782,"status":105,"phases":14787,"primaryCompletion":7312,"completion":7312,"start":1629,"enrollment":12433,"conditions":14788,"interventions":14789},[88],[13785],[13787,13788,13789,4403],{"trials":14791,"activeCount":99},[],{"trials":14793,"activeCount":99},[],{"trials":14795,"activeCount":99},[],{"intervention":13789,"totalTrials":468,"cells":14797},{"EARLY_PHASE1":14798,"PHASE1":14800,"PHASE2":14802,"PHASE3":14808,"PHASE4":14810,"NA":14812},{"trials":14799,"activeCount":99},[],{"trials":14801,"activeCount":99},[],{"trials":14803,"activeCount":99},[14804],{"nctId":13781,"briefTitle":13782,"status":105,"phases":14805,"primaryCompletion":7312,"completion":7312,"start":1629,"enrollment":12433,"conditions":14806,"interventions":14807},[88],[13785],[13787,13788,13789,4403],{"trials":14809,"activeCount":99},[],{"trials":14811,"activeCount":99},[],{"trials":14813,"activeCount":99},[],{"intervention":14815,"totalTrials":468,"cells":14816},"JNJ 49095397",{"EARLY_PHASE1":14817,"PHASE1":14819,"PHASE2":14821,"PHASE3":14832,"PHASE4":14834,"NA":14836},{"trials":14818,"activeCount":99},[],{"trials":14820,"activeCount":99},[],{"trials":14822,"activeCount":99},[14823],{"nctId":14824,"briefTitle":14825,"status":105,"phases":14826,"primaryCompletion":14827,"completion":14828,"start":3769,"enrollment":2938,"conditions":14829,"interventions":14831},"NCT01867762","An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",[88],"2014-08-06","2014-09-01",[14830],"Chronic Obstructive Pulmonary Disease",[14815],{"trials":14833,"activeCount":99},[],{"trials":14835,"activeCount":99},[],{"trials":14837,"activeCount":99},[],{"intervention":6796,"totalTrials":468,"cells":14839},{"EARLY_PHASE1":14840,"PHASE1":14842,"PHASE2":14844,"PHASE3":14850,"PHASE4":14852,"NA":14854},{"trials":14841,"activeCount":99},[],{"trials":14843,"activeCount":99},[],{"trials":14845,"activeCount":99},[14846],{"nctId":6790,"briefTitle":6791,"status":105,"phases":14847,"primaryCompletion":3444,"completion":3613,"start":6034,"enrollment":6793,"conditions":14848,"interventions":14849},[88],[6786],[6796,6796,6797,6798,6799,879],{"trials":14851,"activeCount":99},[],{"trials":14853,"activeCount":99},[],{"trials":14855,"activeCount":99},[],{"intervention":6797,"totalTrials":468,"cells":14857},{"EARLY_PHASE1":14858,"PHASE1":14860,"PHASE2":14862,"PHASE3":14868,"PHASE4":14870,"NA":14872},{"trials":14859,"activeCount":99},[],{"trials":14861,"activeCount":99},[],{"trials":14863,"activeCount":99},[14864],{"nctId":6790,"briefTitle":6791,"status":105,"phases":14865,"primaryCompletion":3444,"completion":3613,"start":6034,"enrollment":6793,"conditions":14866,"interventions":14867},[88],[6786],[6796,6796,6797,6798,6799,879],{"trials":14869,"activeCount":99},[],{"trials":14871,"activeCount":99},[],{"trials":14873,"activeCount":99},[],{"intervention":6798,"totalTrials":468,"cells":14875},{"EARLY_PHASE1":14876,"PHASE1":14878,"PHASE2":14880,"PHASE3":14886,"PHASE4":14888,"NA":14890},{"trials":14877,"activeCount":99},[],{"trials":14879,"activeCount":99},[],{"trials":14881,"activeCount":99},[14882],{"nctId":6790,"briefTitle":6791,"status":105,"phases":14883,"primaryCompletion":3444,"completion":3613,"start":6034,"enrollment":6793,"conditions":14884,"interventions":14885},[88],[6786],[6796,6796,6797,6798,6799,879],{"trials":14887,"activeCount":99},[],{"trials":14889,"activeCount":99},[],{"trials":14891,"activeCount":99},[],{"intervention":6799,"totalTrials":468,"cells":14893},{"EARLY_PHASE1":14894,"PHASE1":14896,"PHASE2":14898,"PHASE3":14904,"PHASE4":14906,"NA":14908},{"trials":14895,"activeCount":99},[],{"trials":14897,"activeCount":99},[],{"trials":14899,"activeCount":99},[14900],{"nctId":6790,"briefTitle":6791,"status":105,"phases":14901,"primaryCompletion":3444,"completion":3613,"start":6034,"enrollment":6793,"conditions":14902,"interventions":14903},[88],[6786],[6796,6796,6797,6798,6799,879],{"trials":14905,"activeCount":99},[],{"trials":14907,"activeCount":99},[],{"trials":14909,"activeCount":99},[],{"intervention":14911,"totalTrials":468,"cells":14912},"Bermekimab Monoclonal Antibody",{"EARLY_PHASE1":14913,"PHASE1":14915,"PHASE2":14917,"PHASE3":14929,"PHASE4":14931,"NA":14933},{"trials":14914,"activeCount":99},[],{"trials":14916,"activeCount":99},[],{"trials":14918,"activeCount":99},[14919],{"nctId":14920,"briefTitle":14921,"status":105,"phases":14922,"primaryCompletion":14923,"completion":14924,"start":1856,"enrollment":14925,"conditions":14926,"interventions":14928},"NCT04021862","A Study to Evaluate the Safety and Efficacy of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis",[88],"2020-06-30","2020-11-19",87,[13849,14927],"Eczema",[14911],{"trials":14930,"activeCount":99},[],{"trials":14932,"activeCount":99},[],{"trials":14934,"activeCount":99},[],{"intervention":14936,"totalTrials":468,"cells":14937},"JNJ-54781532 25 mg once daily",{"EARLY_PHASE1":14938,"PHASE1":14940,"PHASE2":14942,"PHASE3":14956,"PHASE4":14958,"NA":14960},{"trials":14939,"activeCount":99},[],{"trials":14941,"activeCount":99},[],{"trials":14943,"activeCount":99},[14944],{"nctId":14945,"briefTitle":14946,"status":105,"phases":14947,"primaryCompletion":1521,"completion":14948,"start":14949,"enrollment":14950,"conditions":14951,"interventions":14952},"NCT01959282","A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis",[88],"2015-12-05","2013-11-15",219,[27],[14936,14953,14954,14955],"JNJ-54781532 75 mg once daily","JNJ-54781532 150 mg once daily","JNJ-54781532 75 mg twice daily",{"trials":14957,"activeCount":99},[],{"trials":14959,"activeCount":99},[],{"trials":14961,"activeCount":99},[],{"intervention":14953,"totalTrials":468,"cells":14963},{"EARLY_PHASE1":14964,"PHASE1":14966,"PHASE2":14968,"PHASE3":14974,"PHASE4":14976,"NA":14978},{"trials":14965,"activeCount":99},[],{"trials":14967,"activeCount":99},[],{"trials":14969,"activeCount":99},[14970],{"nctId":14945,"briefTitle":14946,"status":105,"phases":14971,"primaryCompletion":1521,"completion":14948,"start":14949,"enrollment":14950,"conditions":14972,"interventions":14973},[88],[27],[14936,14953,14954,14955],{"trials":14975,"activeCount":99},[],{"trials":14977,"activeCount":99},[],{"trials":14979,"activeCount":99},[],{"intervention":14954,"totalTrials":468,"cells":14981},{"EARLY_PHASE1":14982,"PHASE1":14984,"PHASE2":14986,"PHASE3":14992,"PHASE4":14994,"NA":14996},{"trials":14983,"activeCount":99},[],{"trials":14985,"activeCount":99},[],{"trials":14987,"activeCount":99},[14988],{"nctId":14945,"briefTitle":14946,"status":105,"phases":14989,"primaryCompletion":1521,"completion":14948,"start":14949,"enrollment":14950,"conditions":14990,"interventions":14991},[88],[27],[14936,14953,14954,14955],{"trials":14993,"activeCount":99},[],{"trials":14995,"activeCount":99},[],{"trials":14997,"activeCount":99},[],{"intervention":14955,"totalTrials":468,"cells":14999},{"EARLY_PHASE1":15000,"PHASE1":15002,"PHASE2":15004,"PHASE3":15010,"PHASE4":15012,"NA":15014},{"trials":15001,"activeCount":99},[],{"trials":15003,"activeCount":99},[],{"trials":15005,"activeCount":99},[15006],{"nctId":14945,"briefTitle":14946,"status":105,"phases":15007,"primaryCompletion":1521,"completion":14948,"start":14949,"enrollment":14950,"conditions":15008,"interventions":15009},[88],[27],[14936,14953,14954,14955],{"trials":15011,"activeCount":99},[],{"trials":15013,"activeCount":99},[],{"trials":15015,"activeCount":99},[],{"intervention":13950,"totalTrials":468,"cells":15017},{"EARLY_PHASE1":15018,"PHASE1":15020,"PHASE2":15022,"PHASE3":15028,"PHASE4":15030,"NA":15032},{"trials":15019,"activeCount":99},[],{"trials":15021,"activeCount":99},[],{"trials":15023,"activeCount":99},[15024],{"nctId":13939,"briefTitle":13940,"status":105,"phases":15025,"primaryCompletion":13942,"completion":13942,"start":13943,"enrollment":13944,"conditions":15026,"interventions":15027},[88],[13946],[13930,13948,13949,13950],{"trials":15029,"activeCount":99},[],{"trials":15031,"activeCount":99},[],{"trials":15033,"activeCount":99},[],{"intervention":15035,"totalTrials":468,"cells":15036},"CNTO 2476 3.0 x 10^5 cells",{"EARLY_PHASE1":15037,"PHASE1":15039,"PHASE2":15041,"PHASE3":15051,"PHASE4":15053,"NA":15055},{"trials":15038,"activeCount":99},[],{"trials":15040,"activeCount":99},[],{"trials":15042,"activeCount":99},[15043],{"nctId":15044,"briefTitle":15045,"status":105,"phases":15046,"primaryCompletion":15047,"completion":15047,"start":5587,"enrollment":1419,"conditions":15048,"interventions":15050},"NCT02659098","A Study to Evaluate the Safety and Clinical Response of Subretinal Administration of CNTO 2476 in Participants With Geographic Atrophy",[88],"2019-06-05",[15049,2556,6066],"Visual Acuity",[15035],{"trials":15052,"activeCount":99},[],{"trials":15054,"activeCount":99},[],{"trials":15056,"activeCount":99},[],{"intervention":15058,"totalTrials":468,"cells":15059},"JNJ-42160443",{"EARLY_PHASE1":15060,"PHASE1":15062,"PHASE2":15064,"PHASE3":15077,"PHASE4":15079,"NA":15081},{"trials":15061,"activeCount":99},[],{"trials":15063,"activeCount":99},[],{"trials":15065,"activeCount":99},[15066],{"nctId":15067,"briefTitle":15068,"status":105,"phases":15069,"primaryCompletion":5493,"completion":5493,"start":8263,"enrollment":1480,"conditions":15070,"interventions":15076},"NCT00929188","A Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Cancer-related Pain",[88],[15071,15072,15073,15074,15075],"Pain, Burning","Pain, Crushing","Pain, Migratory","Pain, Radiating","Pain, Splitting",[15058],{"trials":15078,"activeCount":99},[],{"trials":15080,"activeCount":99},[],{"trials":15082,"activeCount":99},[],{"intervention":1494,"totalTrials":468,"cells":15084},{"EARLY_PHASE1":15085,"PHASE1":15087,"PHASE2":15089,"PHASE3":15095,"PHASE4":15097,"NA":15099},{"trials":15086,"activeCount":99},[],{"trials":15088,"activeCount":99},[],{"trials":15090,"activeCount":99},[15091],{"nctId":1485,"briefTitle":1486,"status":105,"phases":15092,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":15093,"interventions":15094},[88],[18],[1494,1495,1496,1170,1169,681],{"trials":15096,"activeCount":99},[],{"trials":15098,"activeCount":99},[],{"trials":15100,"activeCount":99},[],{"intervention":1495,"totalTrials":468,"cells":15102},{"EARLY_PHASE1":15103,"PHASE1":15105,"PHASE2":15107,"PHASE3":15113,"PHASE4":15115,"NA":15117},{"trials":15104,"activeCount":99},[],{"trials":15106,"activeCount":99},[],{"trials":15108,"activeCount":99},[15109],{"nctId":1485,"briefTitle":1486,"status":105,"phases":15110,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":15111,"interventions":15112},[88],[18],[1494,1495,1496,1170,1169,681],{"trials":15114,"activeCount":99},[],{"trials":15116,"activeCount":99},[],{"trials":15118,"activeCount":99},[],{"intervention":1496,"totalTrials":468,"cells":15120},{"EARLY_PHASE1":15121,"PHASE1":15123,"PHASE2":15125,"PHASE3":15131,"PHASE4":15133,"NA":15135},{"trials":15122,"activeCount":99},[],{"trials":15124,"activeCount":99},[],{"trials":15126,"activeCount":99},[15127],{"nctId":1485,"briefTitle":1486,"status":105,"phases":15128,"primaryCompletion":1488,"completion":1489,"start":1490,"enrollment":1491,"conditions":15129,"interventions":15130},[88],[18],[1494,1495,1496,1170,1169,681],{"trials":15132,"activeCount":99},[],{"trials":15134,"activeCount":99},[],{"trials":15136,"activeCount":99},[],{"intervention":13545,"totalTrials":468,"cells":15138},{"EARLY_PHASE1":15139,"PHASE1":15141,"PHASE2":15143,"PHASE3":15149,"PHASE4":15151,"NA":15153},{"trials":15140,"activeCount":99},[],{"trials":15142,"activeCount":99},[],{"trials":15144,"activeCount":99},[15145],{"nctId":13539,"briefTitle":13540,"status":105,"phases":15146,"primaryCompletion":5888,"completion":3392,"start":13542,"enrollment":1480,"conditions":15147,"interventions":15148},[88],[32],[13530,13530,13545],{"trials":15150,"activeCount":99},[],{"trials":15152,"activeCount":99},[],{"trials":15154,"activeCount":99},[],{"intervention":3396,"totalTrials":468,"cells":15156},{"EARLY_PHASE1":15157,"PHASE1":15159,"PHASE2":15161,"PHASE3":15167,"PHASE4":15169,"NA":15171},{"trials":15158,"activeCount":99},[],{"trials":15160,"activeCount":99},[],{"trials":15162,"activeCount":99},[15163],{"nctId":3389,"briefTitle":3390,"status":105,"phases":15164,"primaryCompletion":3392,"completion":3392,"start":3393,"enrollment":1436,"conditions":15165,"interventions":15166},[87,88],[2490],[518,518,3396],{"trials":15168,"activeCount":99},[],{"trials":15170,"activeCount":99},[],{"trials":15172,"activeCount":99},[],{"intervention":15174,"totalTrials":468,"cells":15175},"Bedaquiline 200 mg",{"EARLY_PHASE1":15176,"PHASE1":15178,"PHASE2":15180,"PHASE3":15191,"PHASE4":15193,"NA":15195},{"trials":15177,"activeCount":99},[],{"trials":15179,"activeCount":99},[],{"trials":15181,"activeCount":99},[15182],{"nctId":15183,"briefTitle":15184,"status":105,"phases":15185,"primaryCompletion":15186,"completion":12219,"start":15187,"enrollment":129,"conditions":15188,"interventions":15190},"NCT03384641","A Study to Evaluate the Efficacy and Safety of Bedaquiline (TMC207) in Participants With Multibacillary Leprosy",[88],"2023-01-13","2018-09-26",[15189],"Leprosy, Multibacillary",[15174],{"trials":15192,"activeCount":99},[],{"trials":15194,"activeCount":99},[],{"trials":15196,"activeCount":99},[],{"intervention":15198,"totalTrials":468,"cells":15199},"NNC 0142-0000-0002",{"EARLY_PHASE1":15200,"PHASE1":15202,"PHASE2":15204,"PHASE3":15212,"PHASE4":15214,"NA":15216},{"trials":15201,"activeCount":99},[],{"trials":15203,"activeCount":99},[],{"trials":15205,"activeCount":99},[15206],{"nctId":15207,"briefTitle":15208,"status":105,"phases":15209,"primaryCompletion":3329,"completion":3329,"start":8883,"enrollment":399,"conditions":15210,"interventions":15211},"NCT01203631","Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease",[88],[14066,199],[15198],{"trials":15213,"activeCount":99},[],{"trials":15215,"activeCount":99},[],{"trials":15217,"activeCount":99},[],{"intervention":15219,"totalTrials":468,"cells":15220},"CNTO 136",{"EARLY_PHASE1":15221,"PHASE1":15223,"PHASE2":15225,"PHASE3":15233,"PHASE4":15235,"NA":15237},{"trials":15222,"activeCount":99},[],{"trials":15224,"activeCount":99},[],{"trials":15226,"activeCount":99},[15227],{"nctId":15228,"briefTitle":15229,"status":105,"phases":15230,"primaryCompletion":6823,"completion":6823,"start":5889,"enrollment":2472,"conditions":15231,"interventions":15232},"NCT01273389","An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis",[88],[2044],[15219],{"trials":15234,"activeCount":99},[],{"trials":15236,"activeCount":99},[],{"trials":15238,"activeCount":99},[],{"intervention":2025,"totalTrials":468,"cells":15240},{"EARLY_PHASE1":15241,"PHASE1":15243,"PHASE2":15245,"PHASE3":15251,"PHASE4":15253,"NA":15255},{"trials":15242,"activeCount":99},[],{"trials":15244,"activeCount":99},[],{"trials":15246,"activeCount":99},[15247],{"nctId":2017,"briefTitle":2018,"status":105,"phases":15248,"primaryCompletion":2020,"completion":422,"start":2021,"enrollment":2022,"conditions":15249,"interventions":15250},[88],[2003],[1953,2025],{"trials":15252,"activeCount":99},[],{"trials":15254,"activeCount":99},[],{"trials":15256,"activeCount":99},[],{"intervention":15258,"totalTrials":468,"cells":15259},"VX-787 300 mg",{"EARLY_PHASE1":15260,"PHASE1":15262,"PHASE2":15264,"PHASE3":15277,"PHASE4":15279,"NA":15281},{"trials":15261,"activeCount":99},[],{"trials":15263,"activeCount":99},[],{"trials":15265,"activeCount":99},[15266],{"nctId":15267,"briefTitle":15268,"status":105,"phases":15269,"primaryCompletion":15270,"completion":15270,"start":15271,"enrollment":15272,"conditions":15273,"interventions":15274},"NCT02342249","Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects",[88],"2016-05-25","2014-12-11",292,[10502],[15258,15275,15276],"VX-787 600 mg","Oseltamivir 75 mg",{"trials":15278,"activeCount":99},[],{"trials":15280,"activeCount":99},[],{"trials":15282,"activeCount":99},[],{"intervention":15275,"totalTrials":468,"cells":15284},{"EARLY_PHASE1":15285,"PHASE1":15287,"PHASE2":15289,"PHASE3":15295,"PHASE4":15297,"NA":15299},{"trials":15286,"activeCount":99},[],{"trials":15288,"activeCount":99},[],{"trials":15290,"activeCount":99},[15291],{"nctId":15267,"briefTitle":15268,"status":105,"phases":15292,"primaryCompletion":15270,"completion":15270,"start":15271,"enrollment":15272,"conditions":15293,"interventions":15294},[88],[10502],[15258,15275,15276],{"trials":15296,"activeCount":99},[],{"trials":15298,"activeCount":99},[],{"trials":15300,"activeCount":99},[],{"intervention":15276,"totalTrials":468,"cells":15302},{"EARLY_PHASE1":15303,"PHASE1":15305,"PHASE2":15307,"PHASE3":15313,"PHASE4":15315,"NA":15317},{"trials":15304,"activeCount":99},[],{"trials":15306,"activeCount":99},[],{"trials":15308,"activeCount":99},[15309],{"nctId":15267,"briefTitle":15268,"status":105,"phases":15310,"primaryCompletion":15270,"completion":15270,"start":15271,"enrollment":15272,"conditions":15311,"interventions":15312},[88],[10502],[15258,15275,15276],{"trials":15314,"activeCount":99},[],{"trials":15316,"activeCount":99},[],{"trials":15318,"activeCount":99},[],{"intervention":15320,"totalTrials":468,"cells":15321},"EVT 101",{"EARLY_PHASE1":15322,"PHASE1":15324,"PHASE2":15326,"PHASE3":15335,"PHASE4":15337,"NA":15339},{"trials":15323,"activeCount":99},[],{"trials":15325,"activeCount":99},[],{"trials":15327,"activeCount":99},[15328],{"nctId":15329,"briefTitle":15330,"status":125,"phases":15331,"primaryCompletion":15332,"completion":15332,"start":2486,"enrollment":109,"conditions":15333,"interventions":15334},"NCT01128452","Safety and Efficacy of EVT 101 in Treatment-Resistant Depression",[88],"2011-03",[5565],[15320],{"trials":15336,"activeCount":99},[],{"trials":15338,"activeCount":99},[],{"trials":15340,"activeCount":99},[],{"intervention":15342,"totalTrials":468,"cells":15343},"JNJ-67864238",{"EARLY_PHASE1":15344,"PHASE1":15346,"PHASE2":15348,"PHASE3":15358,"PHASE4":15360,"NA":15362},{"trials":15345,"activeCount":99},[],{"trials":15347,"activeCount":99},[],{"trials":15349,"activeCount":99},[15350],{"nctId":15351,"briefTitle":15352,"status":125,"phases":15353,"primaryCompletion":928,"completion":15354,"start":15355,"enrollment":1972,"conditions":15356,"interventions":15357},"NCT04102111","A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease",[88],"2021-12-22","2019-09-23",[311],[15342],{"trials":15359,"activeCount":99},[],{"trials":15361,"activeCount":99},[],{"trials":15363,"activeCount":99},[],{"intervention":4994,"totalTrials":468,"cells":15365},{"EARLY_PHASE1":15366,"PHASE1":15368,"PHASE2":15370,"PHASE3":15376,"PHASE4":15378,"NA":15380},{"trials":15367,"activeCount":99},[],{"trials":15369,"activeCount":99},[],{"trials":15371,"activeCount":99},[15372],{"nctId":4986,"briefTitle":4987,"status":105,"phases":15373,"primaryCompletion":4989,"completion":4990,"start":4991,"enrollment":3853,"conditions":15374,"interventions":15375},[88],[21],[4325,4457,4482,4994],{"trials":15377,"activeCount":99},[],{"trials":15379,"activeCount":99},[],{"trials":15381,"activeCount":99},[],{"intervention":4609,"totalTrials":468,"cells":15383},{"EARLY_PHASE1":15384,"PHASE1":15386,"PHASE2":15388,"PHASE3":15394,"PHASE4":15396,"NA":15398},{"trials":15385,"activeCount":99},[],{"trials":15387,"activeCount":99},[],{"trials":15389,"activeCount":99},[15390],{"nctId":4601,"briefTitle":4602,"status":137,"phases":15391,"primaryCompletion":2410,"completion":4604,"start":4605,"enrollment":99,"conditions":15392,"interventions":15393},[88],[1467,4607],[2908,4609],{"trials":15395,"activeCount":99},[],{"trials":15397,"activeCount":99},[],{"trials":15399,"activeCount":99},[],{"intervention":15401,"totalTrials":468,"cells":15402},"Quisinostat, 12 mg",{"EARLY_PHASE1":15403,"PHASE1":15405,"PHASE2":15407,"PHASE3":15417,"PHASE4":15419,"NA":15421},{"trials":15404,"activeCount":99},[],{"trials":15406,"activeCount":99},[],{"trials":15408,"activeCount":99},[15409],{"nctId":15410,"briefTitle":15411,"status":105,"phases":15412,"primaryCompletion":3358,"completion":15413,"start":4850,"enrollment":25,"conditions":15414,"interventions":15416},"NCT01486277","A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma",[88],"2016-07",[15415],"Lymphoma, T-Cell, Cutaneous",[15401],{"trials":15418,"activeCount":99},[],{"trials":15420,"activeCount":99},[],{"trials":15422,"activeCount":99},[],{"intervention":13064,"totalTrials":468,"cells":15424},{"EARLY_PHASE1":15425,"PHASE1":15427,"PHASE2":15429,"PHASE3":15435,"PHASE4":15437,"NA":15439},{"trials":15426,"activeCount":99},[],{"trials":15428,"activeCount":99},[],{"trials":15430,"activeCount":99},[15431],{"nctId":13056,"briefTitle":13057,"status":105,"phases":15432,"primaryCompletion":4840,"completion":13059,"start":13060,"enrollment":3360,"conditions":15433,"interventions":15434},[88],[13062],[13023,13064],{"trials":15436,"activeCount":99},[],{"trials":15438,"activeCount":99},[],{"trials":15440,"activeCount":99},[],{"intervention":15442,"totalTrials":468,"cells":15443},"Tapentadol (OS) Oral Solution",{"EARLY_PHASE1":15444,"PHASE1":15446,"PHASE2":15448,"PHASE3":15459,"PHASE4":15461,"NA":15463},{"trials":15445,"activeCount":99},[],{"trials":15447,"activeCount":99},[],{"trials":15449,"activeCount":99},[15450],{"nctId":15451,"briefTitle":15452,"status":105,"phases":15453,"primaryCompletion":15454,"completion":15454,"start":8891,"enrollment":1192,"conditions":15455,"interventions":15458},"NCT01134536","Pharmacokinetics and Safety Study of Tapentadol for Postsurgical Pain in Children and Adolescents",[88],"2013-03",[15456,15457],"Pain, Postoperative","Postoperative Pain",[15442],{"trials":15460,"activeCount":99},[],{"trials":15462,"activeCount":99},[],{"trials":15464,"activeCount":99},[],{"intervention":2559,"totalTrials":468,"cells":15466},{"EARLY_PHASE1":15467,"PHASE1":15469,"PHASE2":15471,"PHASE3":15477,"PHASE4":15479,"NA":15481},{"trials":15468,"activeCount":99},[],{"trials":15470,"activeCount":99},[],{"trials":15472,"activeCount":99},[15473],{"nctId":2550,"briefTitle":2551,"status":105,"phases":15474,"primaryCompletion":2553,"completion":2553,"start":2554,"enrollment":1838,"conditions":15475,"interventions":15476},[88],[2556],[2558,496,2559],{"trials":15478,"activeCount":99},[],{"trials":15480,"activeCount":99},[],{"trials":15482,"activeCount":99},[],{"intervention":15484,"totalTrials":468,"cells":15485},"JNJ-40346527",{"EARLY_PHASE1":15486,"PHASE1":15488,"PHASE2":15490,"PHASE3":15499,"PHASE4":15501,"NA":15503},{"trials":15487,"activeCount":99},[],{"trials":15489,"activeCount":99},[],{"trials":15491,"activeCount":99},[15492],{"nctId":15493,"briefTitle":15494,"status":105,"phases":15495,"primaryCompletion":2524,"completion":2524,"start":5899,"enrollment":15496,"conditions":15497,"interventions":15498},"NCT01597739","A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy",[88],96,[2003],[15484],{"trials":15500,"activeCount":99},[],{"trials":15502,"activeCount":99},[],{"trials":15504,"activeCount":99},[],{"intervention":15506,"totalTrials":468,"cells":15507},"JNJ-70033093 25 mg",{"EARLY_PHASE1":15508,"PHASE1":15510,"PHASE2":15512,"PHASE3":15527,"PHASE4":15529,"NA":15531},{"trials":15509,"activeCount":99},[],{"trials":15511,"activeCount":99},[],{"trials":15513,"activeCount":99},[15514],{"nctId":15515,"briefTitle":15516,"status":105,"phases":15517,"primaryCompletion":3553,"completion":3553,"start":15518,"enrollment":15519,"conditions":15520,"interventions":15522},"NCT03891524","A Study of JNJ-70033093 (BMS-986177) Versus Subcutaneous Enoxaparin in Participants Undergoing Elective Total Knee Replacement Surgery",[88],"2019-06-17",1242,[15521],"Arthroplasty, Replacement, Knee",[15506,15523,15524,15525,15526],"JNJ-70033093 50 mg","JNJ-70033093 100 mg","JNJ-70033093 200 mg","Enoxaparin 40 mg",{"trials":15528,"activeCount":99},[],{"trials":15530,"activeCount":99},[],{"trials":15532,"activeCount":99},[],{"intervention":15523,"totalTrials":468,"cells":15534},{"EARLY_PHASE1":15535,"PHASE1":15537,"PHASE2":15539,"PHASE3":15545,"PHASE4":15547,"NA":15549},{"trials":15536,"activeCount":99},[],{"trials":15538,"activeCount":99},[],{"trials":15540,"activeCount":99},[15541],{"nctId":15515,"briefTitle":15516,"status":105,"phases":15542,"primaryCompletion":3553,"completion":3553,"start":15518,"enrollment":15519,"conditions":15543,"interventions":15544},[88],[15521],[15506,15523,15524,15525,15526],{"trials":15546,"activeCount":99},[],{"trials":15548,"activeCount":99},[],{"trials":15550,"activeCount":99},[],{"intervention":15524,"totalTrials":468,"cells":15552},{"EARLY_PHASE1":15553,"PHASE1":15555,"PHASE2":15557,"PHASE3":15563,"PHASE4":15565,"NA":15567},{"trials":15554,"activeCount":99},[],{"trials":15556,"activeCount":99},[],{"trials":15558,"activeCount":99},[15559],{"nctId":15515,"briefTitle":15516,"status":105,"phases":15560,"primaryCompletion":3553,"completion":3553,"start":15518,"enrollment":15519,"conditions":15561,"interventions":15562},[88],[15521],[15506,15523,15524,15525,15526],{"trials":15564,"activeCount":99},[],{"trials":15566,"activeCount":99},[],{"trials":15568,"activeCount":99},[],{"intervention":15525,"totalTrials":468,"cells":15570},{"EARLY_PHASE1":15571,"PHASE1":15573,"PHASE2":15575,"PHASE3":15581,"PHASE4":15583,"NA":15585},{"trials":15572,"activeCount":99},[],{"trials":15574,"activeCount":99},[],{"trials":15576,"activeCount":99},[15577],{"nctId":15515,"briefTitle":15516,"status":105,"phases":15578,"primaryCompletion":3553,"completion":3553,"start":15518,"enrollment":15519,"conditions":15579,"interventions":15580},[88],[15521],[15506,15523,15524,15525,15526],{"trials":15582,"activeCount":99},[],{"trials":15584,"activeCount":99},[],{"trials":15586,"activeCount":99},[],{"intervention":15526,"totalTrials":468,"cells":15588},{"EARLY_PHASE1":15589,"PHASE1":15591,"PHASE2":15593,"PHASE3":15599,"PHASE4":15601,"NA":15603},{"trials":15590,"activeCount":99},[],{"trials":15592,"activeCount":99},[],{"trials":15594,"activeCount":99},[15595],{"nctId":15515,"briefTitle":15516,"status":105,"phases":15596,"primaryCompletion":3553,"completion":3553,"start":15518,"enrollment":15519,"conditions":15597,"interventions":15598},[88],[15521],[15506,15523,15524,15525,15526],{"trials":15600,"activeCount":99},[],{"trials":15602,"activeCount":99},[],{"trials":15604,"activeCount":99},[],{"intervention":15606,"totalTrials":468,"cells":15607},"CNTO 2476",{"EARLY_PHASE1":15608,"PHASE1":15610,"PHASE2":15612,"PHASE3":15623,"PHASE4":15625,"NA":15627},{"trials":15609,"activeCount":99},[],{"trials":15611,"activeCount":99},[],{"trials":15613,"activeCount":99},[15614],{"nctId":15615,"briefTitle":15616,"status":105,"phases":15617,"primaryCompletion":15618,"completion":5751,"start":15619,"enrollment":2108,"conditions":15620,"interventions":15622},"NCT01226628","A Safety Study of CNTO 2476 in Patients With Age-Related Macular Degeneration",[87,88],"2015-03-31","2010-10-21",[15621],"Age-related Macular Degeneration",[15606],{"trials":15624,"activeCount":99},[],{"trials":15626,"activeCount":99},[],{"trials":15628,"activeCount":99},[],{"intervention":15630,"totalTrials":468,"cells":15631},"CV-18C3",{"EARLY_PHASE1":15632,"PHASE1":15634,"PHASE2":15636,"PHASE3":15648,"PHASE4":15650,"NA":15652},{"trials":15633,"activeCount":99},[],{"trials":15635,"activeCount":99},[],{"trials":15637,"activeCount":99},[15638],{"nctId":15639,"briefTitle":15640,"status":105,"phases":15641,"primaryCompletion":15642,"completion":15643,"start":15644,"enrollment":678,"conditions":15645,"interventions":15647},"NCT01270945","Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.",[88],"2013-09-30","2014-04-30","2011-06-30",[15646],"Patients Undergoing Repeat Peripheral Artery Revascularization",[15630],{"trials":15649,"activeCount":99},[],{"trials":15651,"activeCount":99},[],{"trials":15653,"activeCount":99},[],{"intervention":2571,"totalTrials":468,"cells":15655},{"EARLY_PHASE1":15656,"PHASE1":15658,"PHASE2":15660,"PHASE3":15666,"PHASE4":15668,"NA":15670},{"trials":15657,"activeCount":99},[],{"trials":15659,"activeCount":99},[],{"trials":15661,"activeCount":99},[15662],{"nctId":2561,"briefTitle":2562,"status":105,"phases":15663,"primaryCompletion":2564,"completion":2565,"start":2512,"enrollment":2566,"conditions":15664,"interventions":15665},[88],[2568],[2570,2571,496],{"trials":15667,"activeCount":99},[],{"trials":15669,"activeCount":99},[],{"trials":15671,"activeCount":99},[],{"intervention":14167,"totalTrials":468,"cells":15673},{"EARLY_PHASE1":15674,"PHASE1":15676,"PHASE2":15678,"PHASE3":15684,"PHASE4":15686,"NA":15688},{"trials":15675,"activeCount":99},[],{"trials":15677,"activeCount":99},[],{"trials":15679,"activeCount":99},[15680],{"nctId":14160,"briefTitle":14161,"status":105,"phases":15681,"primaryCompletion":14163,"completion":14163,"start":14164,"enrollment":13318,"conditions":15682,"interventions":15683},[88],[171],[14167,14142,14154],{"trials":15685,"activeCount":99},[],{"trials":15687,"activeCount":99},[],{"trials":15689,"activeCount":99},[],{"intervention":15691,"totalTrials":468,"cells":15692},"Carfilzomib 20 mg\u002Fm^2",{"EARLY_PHASE1":15693,"PHASE1":15695,"PHASE2":15697,"PHASE3":15712,"PHASE4":15714,"NA":15716},{"trials":15694,"activeCount":99},[],{"trials":15696,"activeCount":99},[],{"trials":15698,"activeCount":99},[15699],{"nctId":15700,"briefTitle":15701,"status":125,"phases":15702,"primaryCompletion":15703,"completion":15704,"start":15705,"enrollment":4443,"conditions":15706,"interventions":15707},"NCT03871829","Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab",[88],"2022-10-24","2023-01-10","2019-05-31",[18],[15691,15708,15709,15710,15711],"Carfilzomib 70 mg\u002Fm^2","Dexamethasone 40 mg","Dara-SC 1800 mg","Dexamethasone 20 mg",{"trials":15713,"activeCount":99},[],{"trials":15715,"activeCount":99},[],{"trials":15717,"activeCount":99},[],{"intervention":15708,"totalTrials":468,"cells":15719},{"EARLY_PHASE1":15720,"PHASE1":15722,"PHASE2":15724,"PHASE3":15730,"PHASE4":15732,"NA":15734},{"trials":15721,"activeCount":99},[],{"trials":15723,"activeCount":99},[],{"trials":15725,"activeCount":99},[15726],{"nctId":15700,"briefTitle":15701,"status":125,"phases":15727,"primaryCompletion":15703,"completion":15704,"start":15705,"enrollment":4443,"conditions":15728,"interventions":15729},[88],[18],[15691,15708,15709,15710,15711],{"trials":15731,"activeCount":99},[],{"trials":15733,"activeCount":99},[],{"trials":15735,"activeCount":99},[],{"intervention":15709,"totalTrials":468,"cells":15737},{"EARLY_PHASE1":15738,"PHASE1":15740,"PHASE2":15742,"PHASE3":15748,"PHASE4":15750,"NA":15752},{"trials":15739,"activeCount":99},[],{"trials":15741,"activeCount":99},[],{"trials":15743,"activeCount":99},[15744],{"nctId":15700,"briefTitle":15701,"status":125,"phases":15745,"primaryCompletion":15703,"completion":15704,"start":15705,"enrollment":4443,"conditions":15746,"interventions":15747},[88],[18],[15691,15708,15709,15710,15711],{"trials":15749,"activeCount":99},[],{"trials":15751,"activeCount":99},[],{"trials":15753,"activeCount":99},[],{"intervention":15710,"totalTrials":468,"cells":15755},{"EARLY_PHASE1":15756,"PHASE1":15758,"PHASE2":15760,"PHASE3":15766,"PHASE4":15768,"NA":15770},{"trials":15757,"activeCount":99},[],{"trials":15759,"activeCount":99},[],{"trials":15761,"activeCount":99},[15762],{"nctId":15700,"briefTitle":15701,"status":125,"phases":15763,"primaryCompletion":15703,"completion":15704,"start":15705,"enrollment":4443,"conditions":15764,"interventions":15765},[88],[18],[15691,15708,15709,15710,15711],{"trials":15767,"activeCount":99},[],{"trials":15769,"activeCount":99},[],{"trials":15771,"activeCount":99},[],{"intervention":15711,"totalTrials":468,"cells":15773},{"EARLY_PHASE1":15774,"PHASE1":15776,"PHASE2":15778,"PHASE3":15784,"PHASE4":15786,"NA":15788},{"trials":15775,"activeCount":99},[],{"trials":15777,"activeCount":99},[],{"trials":15779,"activeCount":99},[15780],{"nctId":15700,"briefTitle":15701,"status":125,"phases":15781,"primaryCompletion":15703,"completion":15704,"start":15705,"enrollment":4443,"conditions":15782,"interventions":15783},[88],[18],[15691,15708,15709,15710,15711],{"trials":15785,"activeCount":99},[],{"trials":15787,"activeCount":99},[],{"trials":15789,"activeCount":99},[],{"intervention":15791,"totalTrials":468,"cells":15792},"CNTO 6785",{"EARLY_PHASE1":15793,"PHASE1":15795,"PHASE2":15797,"PHASE3":15807,"PHASE4":15809,"NA":15811},{"trials":15794,"activeCount":99},[],{"trials":15796,"activeCount":99},[],{"trials":15798,"activeCount":99},[15799],{"nctId":15800,"briefTitle":15801,"status":105,"phases":15802,"primaryCompletion":8420,"completion":8420,"start":5618,"enrollment":15803,"conditions":15804,"interventions":15806},"NCT01966549","A Study to Evaluate the Effectiveness and Safety of CNTO6785 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease",[88],187,[15805],"Pulmonary Disease, Chronic Obstructive",[15791],{"trials":15808,"activeCount":99},[],{"trials":15810,"activeCount":99},[],{"trials":15812,"activeCount":99},[],{"intervention":15814,"totalTrials":468,"cells":15815},"Part 1: Daratumumab",{"EARLY_PHASE1":15816,"PHASE1":15818,"PHASE2":15820,"PHASE3":15832,"PHASE4":15834,"NA":15836},{"trials":15817,"activeCount":99},[],{"trials":15819,"activeCount":99},[],{"trials":15821,"activeCount":99},[15822],{"nctId":15823,"briefTitle":15824,"status":105,"phases":15825,"primaryCompletion":1488,"completion":15826,"start":15827,"enrollment":15828,"conditions":15829,"interventions":15830},"NCT00574288","Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma",[88],"2017-04-03","2008-03-26",104,[18],[15814,15831],"Part 2: Daratumumab",{"trials":15833,"activeCount":99},[],{"trials":15835,"activeCount":99},[],{"trials":15837,"activeCount":99},[],{"intervention":15831,"totalTrials":468,"cells":15839},{"EARLY_PHASE1":15840,"PHASE1":15842,"PHASE2":15844,"PHASE3":15850,"PHASE4":15852,"NA":15854},{"trials":15841,"activeCount":99},[],{"trials":15843,"activeCount":99},[],{"trials":15845,"activeCount":99},[15846],{"nctId":15823,"briefTitle":15824,"status":105,"phases":15847,"primaryCompletion":1488,"completion":15826,"start":15827,"enrollment":15828,"conditions":15848,"interventions":15849},[88],[18],[15814,15831],{"trials":15851,"activeCount":99},[],{"trials":15853,"activeCount":99},[],{"trials":15855,"activeCount":99},[],{"intervention":15857,"totalTrials":468,"cells":15858},"JNJ-39758979",{"EARLY_PHASE1":15859,"PHASE1":15861,"PHASE2":15863,"PHASE3":15872,"PHASE4":15874,"NA":15876},{"trials":15860,"activeCount":99},[],{"trials":15862,"activeCount":99},[],{"trials":15864,"activeCount":99},[15865],{"nctId":15866,"briefTitle":15867,"status":137,"phases":15868,"primaryCompletion":5572,"completion":5572,"start":5867,"enrollment":99,"conditions":15869,"interventions":15871},"NCT01480388","A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With Methotrexate",[88],[15870],"Active Rheumatoid Arthritis; Rheumatoid Arthritis",[15857,15857,15857,15857],{"trials":15873,"activeCount":99},[],{"trials":15875,"activeCount":99},[],{"trials":15877,"activeCount":99},[],{"intervention":15879,"totalTrials":468,"cells":15880},"JNJ-64281802 High dose",{"EARLY_PHASE1":15881,"PHASE1":15883,"PHASE2":15885,"PHASE3":15901,"PHASE4":15903,"NA":15905},{"trials":15882,"activeCount":99},[],{"trials":15884,"activeCount":99},[],{"trials":15886,"activeCount":99},[15887],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15890,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15894,"interventions":15895},"NCT04480736","A Study of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model in Healthy Adult Participants",[88],"2027-09-02","2027-12-09","2020-07-28",[15],[15879,15896,15897,15898,15899,15900],"JNJ-64281802 Medium dose","JNJ-64281802 Low dose","JNJ-64281802 Dosing Regimen X","JNJ-64281802 Dosing Regimen Y","JNJ-64281802 Dosing Regimen Z",{"trials":15902,"activeCount":99},[],{"trials":15904,"activeCount":99},[],{"trials":15906,"activeCount":99},[],{"intervention":15896,"totalTrials":468,"cells":15908},{"EARLY_PHASE1":15909,"PHASE1":15911,"PHASE2":15913,"PHASE3":15919,"PHASE4":15921,"NA":15923},{"trials":15910,"activeCount":99},[],{"trials":15912,"activeCount":99},[],{"trials":15914,"activeCount":99},[15915],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15916,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15917,"interventions":15918},[88],[15],[15879,15896,15897,15898,15899,15900],{"trials":15920,"activeCount":99},[],{"trials":15922,"activeCount":99},[],{"trials":15924,"activeCount":99},[],{"intervention":15897,"totalTrials":468,"cells":15926},{"EARLY_PHASE1":15927,"PHASE1":15929,"PHASE2":15931,"PHASE3":15937,"PHASE4":15939,"NA":15941},{"trials":15928,"activeCount":99},[],{"trials":15930,"activeCount":99},[],{"trials":15932,"activeCount":99},[15933],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15934,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15935,"interventions":15936},[88],[15],[15879,15896,15897,15898,15899,15900],{"trials":15938,"activeCount":99},[],{"trials":15940,"activeCount":99},[],{"trials":15942,"activeCount":99},[],{"intervention":15898,"totalTrials":468,"cells":15944},{"EARLY_PHASE1":15945,"PHASE1":15947,"PHASE2":15949,"PHASE3":15955,"PHASE4":15957,"NA":15959},{"trials":15946,"activeCount":99},[],{"trials":15948,"activeCount":99},[],{"trials":15950,"activeCount":99},[15951],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15952,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15953,"interventions":15954},[88],[15],[15879,15896,15897,15898,15899,15900],{"trials":15956,"activeCount":99},[],{"trials":15958,"activeCount":99},[],{"trials":15960,"activeCount":99},[],{"intervention":15899,"totalTrials":468,"cells":15962},{"EARLY_PHASE1":15963,"PHASE1":15965,"PHASE2":15967,"PHASE3":15973,"PHASE4":15975,"NA":15977},{"trials":15964,"activeCount":99},[],{"trials":15966,"activeCount":99},[],{"trials":15968,"activeCount":99},[15969],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15970,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15971,"interventions":15972},[88],[15],[15879,15896,15897,15898,15899,15900],{"trials":15974,"activeCount":99},[],{"trials":15976,"activeCount":99},[],{"trials":15978,"activeCount":99},[],{"intervention":15900,"totalTrials":468,"cells":15980},{"EARLY_PHASE1":15981,"PHASE1":15983,"PHASE2":15985,"PHASE3":15991,"PHASE4":15993,"NA":15995},{"trials":15982,"activeCount":99},[],{"trials":15984,"activeCount":99},[],{"trials":15986,"activeCount":99},[15987],{"nctId":15888,"briefTitle":15889,"status":137,"phases":15988,"primaryCompletion":15891,"completion":15892,"start":15893,"enrollment":99,"conditions":15989,"interventions":15990},[88],[15],[15879,15896,15897,15898,15899,15900],{"trials":15992,"activeCount":99},[],{"trials":15994,"activeCount":99},[],{"trials":15996,"activeCount":99},[],{"intervention":15998,"totalTrials":468,"cells":15999},"JNJ-31001074",{"EARLY_PHASE1":16000,"PHASE1":16002,"PHASE2":16004,"PHASE3":16013,"PHASE4":16015,"NA":16017},{"trials":16001,"activeCount":99},[],{"trials":16003,"activeCount":99},[],{"trials":16005,"activeCount":99},[16006],{"nctId":16007,"briefTitle":16008,"status":137,"phases":16009,"completion":2535,"start":5889,"enrollment":99,"conditions":16010,"interventions":16012},"NCT01362699","Effect of JNJ 31001074 on Urge to Drink in Alcohol-Dependent Adults",[88],[16011],"Alcoholism",[15998],{"trials":16014,"activeCount":99},[],{"trials":16016,"activeCount":99},[],{"trials":16018,"activeCount":99},[],{"intervention":16020,"totalTrials":468,"cells":16021},"Venlafaxine XR",{"EARLY_PHASE1":16022,"PHASE1":16024,"PHASE2":16026,"PHASE3":16035,"PHASE4":16037,"NA":16039},{"trials":16023,"activeCount":99},[],{"trials":16025,"activeCount":99},[],{"trials":16027,"activeCount":99},[16028],{"nctId":16029,"briefTitle":16030,"status":125,"phases":16031,"primaryCompletion":3342,"completion":2564,"start":15332,"enrollment":544,"conditions":16032,"interventions":16033},"NCT01114698","A Safety and Efficacy Study of JNJ26489112 in Patients With Treatment-Resistant Major Depressive Disorder",[88],[5565],[16020,16034],"JNJ26489112",{"trials":16036,"activeCount":99},[],{"trials":16038,"activeCount":99},[],{"trials":16040,"activeCount":99},[],{"intervention":16034,"totalTrials":468,"cells":16042},{"EARLY_PHASE1":16043,"PHASE1":16045,"PHASE2":16047,"PHASE3":16053,"PHASE4":16055,"NA":16057},{"trials":16044,"activeCount":99},[],{"trials":16046,"activeCount":99},[],{"trials":16048,"activeCount":99},[16049],{"nctId":16029,"briefTitle":16030,"status":125,"phases":16050,"primaryCompletion":3342,"completion":2564,"start":15332,"enrollment":544,"conditions":16051,"interventions":16052},[88],[5565],[16020,16034],{"trials":16054,"activeCount":99},[],{"trials":16056,"activeCount":99},[],{"trials":16058,"activeCount":99},[],{"intervention":598,"totalTrials":468,"cells":16060},{"EARLY_PHASE1":16061,"PHASE1":16063,"PHASE2":16065,"PHASE3":16071,"PHASE4":16073,"NA":16075},{"trials":16062,"activeCount":99},[],{"trials":16064,"activeCount":99},[],{"trials":16066,"activeCount":99},[16067],{"nctId":589,"briefTitle":590,"status":105,"phases":16068,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":16069,"interventions":16070},[88],[30],[41,598,599],{"trials":16072,"activeCount":99},[],{"trials":16074,"activeCount":99},[],{"trials":16076,"activeCount":99},[],{"intervention":599,"totalTrials":468,"cells":16078},{"EARLY_PHASE1":16079,"PHASE1":16081,"PHASE2":16083,"PHASE3":16089,"PHASE4":16091,"NA":16093},{"trials":16080,"activeCount":99},[],{"trials":16082,"activeCount":99},[],{"trials":16084,"activeCount":99},[16085],{"nctId":589,"briefTitle":590,"status":105,"phases":16086,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":16087,"interventions":16088},[88],[30],[41,598,599],{"trials":16090,"activeCount":99},[],{"trials":16092,"activeCount":99},[],{"trials":16094,"activeCount":99},[],{"intervention":13922,"totalTrials":468,"cells":16096},{"EARLY_PHASE1":16097,"PHASE1":16099,"PHASE2":16101,"PHASE3":16107,"PHASE4":16109,"NA":16111},{"trials":16098,"activeCount":99},[],{"trials":16100,"activeCount":99},[],{"trials":16102,"activeCount":99},[16103],{"nctId":13915,"briefTitle":13916,"status":105,"phases":16104,"primaryCompletion":13918,"completion":13919,"start":397,"enrollment":1380,"conditions":16105,"interventions":16106},[88],[12475],[13893,13922],{"trials":16108,"activeCount":99},[],{"trials":16110,"activeCount":99},[],{"trials":16112,"activeCount":99},[],{"intervention":16114,"totalTrials":468,"cells":16115},"Phentermine",{"EARLY_PHASE1":16116,"PHASE1":16118,"PHASE2":16120,"PHASE3":16129,"PHASE4":16131,"NA":16133},{"trials":16117,"activeCount":99},[],{"trials":16119,"activeCount":99},[],{"trials":16121,"activeCount":99},[16122],{"nctId":16123,"briefTitle":16124,"status":105,"phases":16125,"primaryCompletion":8200,"completion":8200,"start":4348,"enrollment":16126,"conditions":16127,"interventions":16128},"NCT02243202","Effects of Co-administration of Canagliflozin 300 mg and Phentermine 15 mg With Placebo in the Treatment of Non-Diabetic Overweight and Obese Participants",[88],335,[13946],[5826,16114],{"trials":16130,"activeCount":99},[],{"trials":16132,"activeCount":99},[],{"trials":16134,"activeCount":99},[],{"intervention":16136,"totalTrials":468,"cells":16137},"CERC-501",{"EARLY_PHASE1":16138,"PHASE1":16140,"PHASE2":16142,"PHASE3":16152,"PHASE4":16154,"NA":16156},{"trials":16139,"activeCount":99},[],{"trials":16141,"activeCount":99},[],{"trials":16143,"activeCount":99},[16144],{"nctId":16145,"briefTitle":16146,"status":105,"phases":16147,"primaryCompletion":12828,"completion":9782,"start":16148,"enrollment":832,"conditions":16149,"interventions":16151},"NCT02641028","A Study in a Human Laboratory Model of Smoking Behavior",[88],"2015-12-31",[16150],"Smoking",[16136],{"trials":16153,"activeCount":99},[],{"trials":16155,"activeCount":99},[],{"trials":16157,"activeCount":99},[],{"intervention":16159,"totalTrials":468,"cells":16160},"T2-18C3 therapeutic antibody",{"EARLY_PHASE1":16161,"PHASE1":16163,"PHASE2":16165,"PHASE3":16174,"PHASE4":16176,"NA":16178},{"trials":16162,"activeCount":99},[],{"trials":16164,"activeCount":99},[],{"trials":16166,"activeCount":99},[16167],{"nctId":16168,"briefTitle":16169,"status":105,"phases":16170,"primaryCompletion":6806,"start":15644,"enrollment":2948,"conditions":16171,"interventions":16173},"NCT01427699","A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes",[88],[16172],"Type 2 Diabetes",[16159],{"trials":16175,"activeCount":99},[],{"trials":16177,"activeCount":99},[],{"trials":16179,"activeCount":99},[],{"intervention":16181,"totalTrials":468,"cells":16182},"JNJ-53718678 2.5 mg\u002Fkg",{"EARLY_PHASE1":16183,"PHASE1":16185,"PHASE2":16187,"PHASE3":16199,"PHASE4":16201,"NA":16203},{"trials":16184,"activeCount":99},[],{"trials":16186,"activeCount":99},[],{"trials":16188,"activeCount":99},[16189],{"nctId":16190,"briefTitle":16191,"status":105,"phases":16192,"primaryCompletion":16193,"completion":16193,"start":16194,"enrollment":12386,"conditions":16195,"interventions":16196},"NCT04068792","A Two-Part Infant Study for Early Diagnosis of Respiratory Syncytial Virus (RSV) and Evaluation of JNJ-53718678 in RSV Acute Respiratory Tract Disease",[88],"2021-05-15","2019-10-10",[12484],[16181,16197,16198],"JNJ-53718678 3 mg\u002Fkg","JNJ-53718678 4.5 mg\u002Fkg",{"trials":16200,"activeCount":99},[],{"trials":16202,"activeCount":99},[],{"trials":16204,"activeCount":99},[],{"intervention":16197,"totalTrials":468,"cells":16206},{"EARLY_PHASE1":16207,"PHASE1":16209,"PHASE2":16211,"PHASE3":16217,"PHASE4":16219,"NA":16221},{"trials":16208,"activeCount":99},[],{"trials":16210,"activeCount":99},[],{"trials":16212,"activeCount":99},[16213],{"nctId":16190,"briefTitle":16191,"status":105,"phases":16214,"primaryCompletion":16193,"completion":16193,"start":16194,"enrollment":12386,"conditions":16215,"interventions":16216},[88],[12484],[16181,16197,16198],{"trials":16218,"activeCount":99},[],{"trials":16220,"activeCount":99},[],{"trials":16222,"activeCount":99},[],{"intervention":16198,"totalTrials":468,"cells":16224},{"EARLY_PHASE1":16225,"PHASE1":16227,"PHASE2":16229,"PHASE3":16235,"PHASE4":16237,"NA":16239},{"trials":16226,"activeCount":99},[],{"trials":16228,"activeCount":99},[],{"trials":16230,"activeCount":99},[16231],{"nctId":16190,"briefTitle":16191,"status":105,"phases":16232,"primaryCompletion":16193,"completion":16193,"start":16194,"enrollment":12386,"conditions":16233,"interventions":16234},[88],[12484],[16181,16197,16198],{"trials":16236,"activeCount":99},[],{"trials":16238,"activeCount":99},[],{"trials":16240,"activeCount":99},[],{"intervention":4367,"totalTrials":468,"cells":16242},{"EARLY_PHASE1":16243,"PHASE1":16245,"PHASE2":16247,"PHASE3":16253,"PHASE4":16255,"NA":16257},{"trials":16244,"activeCount":99},[],{"trials":16246,"activeCount":99},[],{"trials":16248,"activeCount":99},[16249],{"nctId":4360,"briefTitle":4361,"status":105,"phases":16250,"primaryCompletion":1784,"completion":1784,"start":1602,"enrollment":4363,"conditions":16251,"interventions":16252},[88],[21],[4366,4367,173,4318,4318,4318],{"trials":16254,"activeCount":99},[],{"trials":16256,"activeCount":99},[],{"trials":16258,"activeCount":99},[],{"intervention":12237,"totalTrials":468,"cells":16260},{"EARLY_PHASE1":16261,"PHASE1":16263,"PHASE2":16265,"PHASE3":16271,"PHASE4":16273,"NA":16275},{"trials":16262,"activeCount":99},[],{"trials":16264,"activeCount":99},[],{"trials":16266,"activeCount":99},[16267],{"nctId":12230,"briefTitle":12231,"status":105,"phases":16268,"primaryCompletion":12233,"completion":12234,"start":1691,"enrollment":1972,"conditions":16269,"interventions":16270},[88],[2412],[7292,12174,12213,12212,12237],{"trials":16272,"activeCount":99},[],{"trials":16274,"activeCount":99},[],{"trials":16276,"activeCount":99},[],{"intervention":12884,"totalTrials":468,"cells":16278},{"EARLY_PHASE1":16279,"PHASE1":16281,"PHASE2":16283,"PHASE3":16289,"PHASE4":16291,"NA":16293},{"trials":16280,"activeCount":99},[],{"trials":16282,"activeCount":99},[],{"trials":16284,"activeCount":99},[16285],{"nctId":12876,"briefTitle":12877,"status":105,"phases":16286,"primaryCompletion":12879,"completion":12880,"start":12881,"enrollment":3138,"conditions":16287,"interventions":16288},[88],[12435],[12390,12884,12885],{"trials":16290,"activeCount":99},[],{"trials":16292,"activeCount":99},[],{"trials":16294,"activeCount":99},[],{"intervention":12885,"totalTrials":468,"cells":16296},{"EARLY_PHASE1":16297,"PHASE1":16299,"PHASE2":16301,"PHASE3":16307,"PHASE4":16309,"NA":16311},{"trials":16298,"activeCount":99},[],{"trials":16300,"activeCount":99},[],{"trials":16302,"activeCount":99},[16303],{"nctId":12876,"briefTitle":12877,"status":105,"phases":16304,"primaryCompletion":12879,"completion":12880,"start":12881,"enrollment":3138,"conditions":16305,"interventions":16306},[88],[12435],[12390,12884,12885],{"trials":16308,"activeCount":99},[],{"trials":16310,"activeCount":99},[],{"trials":16312,"activeCount":99},[],{"intervention":13760,"totalTrials":468,"cells":16314},{"EARLY_PHASE1":16315,"PHASE1":16317,"PHASE2":16319,"PHASE3":16325,"PHASE4":16327,"NA":16329},{"trials":16316,"activeCount":99},[],{"trials":16318,"activeCount":99},[],{"trials":16320,"activeCount":99},[16321],{"nctId":13754,"briefTitle":13755,"status":125,"phases":16322,"primaryCompletion":6090,"completion":6090,"start":13757,"enrollment":2766,"conditions":16323,"interventions":16324},[88],[4445],[13760,13737,13761],{"trials":16326,"activeCount":99},[],{"trials":16328,"activeCount":99},[],{"trials":16330,"activeCount":99},[],{"intervention":13761,"totalTrials":468,"cells":16332},{"EARLY_PHASE1":16333,"PHASE1":16335,"PHASE2":16337,"PHASE3":16343,"PHASE4":16345,"NA":16347},{"trials":16334,"activeCount":99},[],{"trials":16336,"activeCount":99},[],{"trials":16338,"activeCount":99},[16339],{"nctId":13754,"briefTitle":13755,"status":125,"phases":16340,"primaryCompletion":6090,"completion":6090,"start":13757,"enrollment":2766,"conditions":16341,"interventions":16342},[88],[4445],[13760,13737,13761],{"trials":16344,"activeCount":99},[],{"trials":16346,"activeCount":99},[],{"trials":16348,"activeCount":99},[],{"intervention":16350,"totalTrials":468,"cells":16351},"Phase1 and Phase 2: decitabine",{"EARLY_PHASE1":16352,"PHASE1":16354,"PHASE2":16356,"PHASE3":16368,"PHASE4":16370,"NA":16372},{"trials":16353,"activeCount":99},[],{"trials":16355,"activeCount":99},[],{"trials":16357,"activeCount":99},[16358],{"nctId":16359,"briefTitle":16360,"status":125,"phases":16361,"primaryCompletion":16362,"completion":16362,"start":16363,"enrollment":33,"conditions":16364,"interventions":16365},"NCT01853228","A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia",[87,88],"2017-08-28","2013-10-22",[1147],[16350,16366,16367],"Phase 1: cytarabine","Phase 2: cytarabine",{"trials":16369,"activeCount":99},[],{"trials":16371,"activeCount":99},[],{"trials":16373,"activeCount":99},[],{"intervention":16366,"totalTrials":468,"cells":16375},{"EARLY_PHASE1":16376,"PHASE1":16378,"PHASE2":16380,"PHASE3":16386,"PHASE4":16388,"NA":16390},{"trials":16377,"activeCount":99},[],{"trials":16379,"activeCount":99},[],{"trials":16381,"activeCount":99},[16382],{"nctId":16359,"briefTitle":16360,"status":125,"phases":16383,"primaryCompletion":16362,"completion":16362,"start":16363,"enrollment":33,"conditions":16384,"interventions":16385},[87,88],[1147],[16350,16366,16367],{"trials":16387,"activeCount":99},[],{"trials":16389,"activeCount":99},[],{"trials":16391,"activeCount":99},[],{"intervention":16367,"totalTrials":468,"cells":16393},{"EARLY_PHASE1":16394,"PHASE1":16396,"PHASE2":16398,"PHASE3":16404,"PHASE4":16406,"NA":16408},{"trials":16395,"activeCount":99},[],{"trials":16397,"activeCount":99},[],{"trials":16399,"activeCount":99},[16400],{"nctId":16359,"briefTitle":16360,"status":125,"phases":16401,"primaryCompletion":16362,"completion":16362,"start":16363,"enrollment":33,"conditions":16402,"interventions":16403},[87,88],[1147],[16350,16366,16367],{"trials":16405,"activeCount":99},[],{"trials":16407,"activeCount":99},[],{"trials":16409,"activeCount":99},[],{"intervention":5849,"totalTrials":468,"cells":16411},{"EARLY_PHASE1":16412,"PHASE1":16414,"PHASE2":16416,"PHASE3":16422,"PHASE4":16424,"NA":16426},{"trials":16413,"activeCount":99},[],{"trials":16415,"activeCount":99},[],{"trials":16417,"activeCount":99},[16418],{"nctId":5842,"briefTitle":5843,"status":105,"phases":16419,"primaryCompletion":2487,"completion":2487,"start":5845,"enrollment":1663,"conditions":16420,"interventions":16421},[88],[24],[5848,5849,1779],{"trials":16423,"activeCount":99},[],{"trials":16425,"activeCount":99},[],{"trials":16427,"activeCount":99},[],{"intervention":14214,"totalTrials":468,"cells":16429},{"EARLY_PHASE1":16430,"PHASE1":16432,"PHASE2":16434,"PHASE3":16440,"PHASE4":16442,"NA":16444},{"trials":16431,"activeCount":99},[],{"trials":16433,"activeCount":99},[],{"trials":16435,"activeCount":99},[16436],{"nctId":14209,"briefTitle":14210,"status":105,"phases":16437,"primaryCompletion":5888,"completion":5888,"start":8883,"enrollment":544,"conditions":16438,"interventions":16439},[87,88],[1179],[1182,3643,14214],{"trials":16441,"activeCount":99},[],{"trials":16443,"activeCount":99},[],{"trials":16445,"activeCount":99},[],{"intervention":3906,"totalTrials":468,"cells":16447},{"EARLY_PHASE1":16448,"PHASE1":16450,"PHASE2":16452,"PHASE3":16458,"PHASE4":16460,"NA":16462},{"trials":16449,"activeCount":99},[],{"trials":16451,"activeCount":99},[],{"trials":16453,"activeCount":99},[16454],{"nctId":3898,"briefTitle":3899,"status":105,"phases":16455,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":2653,"conditions":16456,"interventions":16457},[88],[27],[412,413,3906,3907],{"trials":16459,"activeCount":99},[],{"trials":16461,"activeCount":99},[],{"trials":16463,"activeCount":99},[],{"intervention":3907,"totalTrials":468,"cells":16465},{"EARLY_PHASE1":16466,"PHASE1":16468,"PHASE2":16470,"PHASE3":16476,"PHASE4":16478,"NA":16480},{"trials":16467,"activeCount":99},[],{"trials":16469,"activeCount":99},[],{"trials":16471,"activeCount":99},[16472],{"nctId":3898,"briefTitle":3899,"status":105,"phases":16473,"primaryCompletion":3901,"completion":3902,"start":3903,"enrollment":2653,"conditions":16474,"interventions":16475},[88],[27],[412,413,3906,3907],{"trials":16477,"activeCount":99},[],{"trials":16479,"activeCount":99},[],{"trials":16481,"activeCount":99},[],{"intervention":16483,"totalTrials":468,"cells":16484},"Ustekinumab + MTX",{"EARLY_PHASE1":16485,"PHASE1":16487,"PHASE2":16489,"PHASE3":16498,"PHASE4":16500,"NA":16502},{"trials":16486,"activeCount":99},[],{"trials":16488,"activeCount":99},[],{"trials":16490,"activeCount":99},[16491],{"nctId":16492,"briefTitle":16493,"status":105,"phases":16494,"primaryCompletion":4223,"completion":2217,"start":2535,"enrollment":6064,"conditions":16495,"interventions":16496},"NCT01645280","A Study of the Effectiveness and Safety of Ustekinumab (STELARA) and CNTO 1959 Administered Under the Skin of Patients With Active Rheumatoid Arthritis, Despite Existing Methotrexate Therapy",[88],[2003],[16483,16483,16497,16497],"CNTO 1959 + MTX",{"trials":16499,"activeCount":99},[],{"trials":16501,"activeCount":99},[],{"trials":16503,"activeCount":99},[],{"intervention":16497,"totalTrials":468,"cells":16505},{"EARLY_PHASE1":16506,"PHASE1":16508,"PHASE2":16510,"PHASE3":16516,"PHASE4":16518,"NA":16520},{"trials":16507,"activeCount":99},[],{"trials":16509,"activeCount":99},[],{"trials":16511,"activeCount":99},[16512],{"nctId":16492,"briefTitle":16493,"status":105,"phases":16513,"primaryCompletion":4223,"completion":2217,"start":2535,"enrollment":6064,"conditions":16514,"interventions":16515},[88],[2003],[16483,16483,16497,16497],{"trials":16517,"activeCount":99},[],{"trials":16519,"activeCount":99},[],{"trials":16521,"activeCount":99},[],{"intervention":1557,"totalTrials":468,"cells":16523},{"EARLY_PHASE1":16524,"PHASE1":16526,"PHASE2":16528,"PHASE3":16534,"PHASE4":16536,"NA":16538},{"trials":16525,"activeCount":99},[],{"trials":16527,"activeCount":99},[],{"trials":16529,"activeCount":99},[16530],{"nctId":1547,"briefTitle":1548,"status":105,"phases":16531,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":16532,"interventions":16533},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":16535,"activeCount":99},[],{"trials":16537,"activeCount":99},[],{"trials":16539,"activeCount":99},[],{"intervention":1558,"totalTrials":468,"cells":16541},{"EARLY_PHASE1":16542,"PHASE1":16544,"PHASE2":16546,"PHASE3":16552,"PHASE4":16554,"NA":16556},{"trials":16543,"activeCount":99},[],{"trials":16545,"activeCount":99},[],{"trials":16547,"activeCount":99},[16548],{"nctId":1547,"briefTitle":1548,"status":105,"phases":16549,"primaryCompletion":1550,"completion":1551,"start":1552,"enrollment":12,"conditions":16550,"interventions":16551},[88],[1554],[681,1154,496,1556,1557,659,1152,1558,879],{"trials":16553,"activeCount":99},[],{"trials":16555,"activeCount":99},[],{"trials":16557,"activeCount":99},[],{"intervention":16559,"totalTrials":468,"cells":16560},"JNJ-54861911, 10 milligram",{"EARLY_PHASE1":16561,"PHASE1":16563,"PHASE2":16565,"PHASE3":16574,"PHASE4":16576,"NA":16578},{"trials":16562,"activeCount":99},[],{"trials":16564,"activeCount":99},[],{"trials":16566,"activeCount":99},[16567],{"nctId":16568,"briefTitle":16569,"status":105,"phases":16570,"primaryCompletion":3597,"completion":3597,"start":3358,"enrollment":7449,"conditions":16571,"interventions":16572},"NCT02260674","A Safety and Tolerability Study of JNJ-54861911 in Participants With Early Alzheimer's Disease",[88],[10873],[16559,16573],"JNJ-54861911, 50 mg",{"trials":16575,"activeCount":99},[],{"trials":16577,"activeCount":99},[],{"trials":16579,"activeCount":99},[],{"intervention":16573,"totalTrials":468,"cells":16581},{"EARLY_PHASE1":16582,"PHASE1":16584,"PHASE2":16586,"PHASE3":16592,"PHASE4":16594,"NA":16596},{"trials":16583,"activeCount":99},[],{"trials":16585,"activeCount":99},[],{"trials":16587,"activeCount":99},[16588],{"nctId":16568,"briefTitle":16569,"status":105,"phases":16589,"primaryCompletion":3597,"completion":3597,"start":3358,"enrollment":7449,"conditions":16590,"interventions":16591},[88],[10873],[16559,16573],{"trials":16593,"activeCount":99},[],{"trials":16595,"activeCount":99},[],{"trials":16597,"activeCount":99},[],{"intervention":8906,"totalTrials":468,"cells":16599},{"EARLY_PHASE1":16600,"PHASE1":16602,"PHASE2":16604,"PHASE3":16610,"PHASE4":16612,"NA":16614},{"trials":16601,"activeCount":99},[],{"trials":16603,"activeCount":99},[],{"trials":16605,"activeCount":99},[16606],{"nctId":8897,"briefTitle":8898,"status":105,"phases":16607,"primaryCompletion":8900,"completion":8900,"start":8901,"enrollment":8902,"conditions":16608,"interventions":16609},[88],[4545],[8905,8873,8906,8907],{"trials":16611,"activeCount":99},[],{"trials":16613,"activeCount":99},[],{"trials":16615,"activeCount":99},[],{"intervention":8907,"totalTrials":468,"cells":16617},{"EARLY_PHASE1":16618,"PHASE1":16620,"PHASE2":16622,"PHASE3":16628,"PHASE4":16630,"NA":16632},{"trials":16619,"activeCount":99},[],{"trials":16621,"activeCount":99},[],{"trials":16623,"activeCount":99},[16624],{"nctId":8897,"briefTitle":8898,"status":105,"phases":16625,"primaryCompletion":8900,"completion":8900,"start":8901,"enrollment":8902,"conditions":16626,"interventions":16627},[88],[4545],[8905,8873,8906,8907],{"trials":16629,"activeCount":99},[],{"trials":16631,"activeCount":99},[],{"trials":16633,"activeCount":99},[],{"intervention":3616,"totalTrials":2149,"cells":16635},{"EARLY_PHASE1":16636,"PHASE1":16638,"PHASE2":16705,"PHASE3":16707,"PHASE4":16709,"NA":16711},{"trials":16637,"activeCount":99},[],{"trials":16639,"activeCount":99},[16640,16650,16654,16663,16672,16676,16680,16690,16698],{"nctId":16641,"briefTitle":16642,"status":105,"phases":16643,"primaryCompletion":16644,"completion":16645,"start":16646,"enrollment":1436,"conditions":16647,"interventions":16648},"NCT04225078","A Study to Evaluate the Effects of Loperamide (JNJ-289679) on Electrocardiogram Intervals in Healthy Adult Participants",[87],"2021-12-21","2022-01-12","2020-01-17",[3667],[16649,3616],"Loperamide",{"nctId":13315,"briefTitle":13316,"status":105,"phases":16651,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":16652,"interventions":16653},[87],[15],[13321,13322,3616,13323,13324,4366],{"nctId":16655,"briefTitle":16656,"status":105,"phases":16657,"primaryCompletion":16658,"completion":4840,"start":16659,"enrollment":2022,"conditions":16660,"interventions":16661},"NCT02833831","Study to Evaluate the Effect of ALS-008176 on Cardiac Repolarization Interval in Healthy Participants",[87],"2017-02-17","2016-06-02",[15],[16662,3616],"ALS-008176",{"nctId":16664,"briefTitle":16665,"status":105,"phases":16666,"primaryCompletion":16667,"completion":16668,"start":7448,"enrollment":11,"conditions":16669,"interventions":16670},"NCT03606057","A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)",[87],"2019-02-08","2019-02-28",[15],[16671,3616],"JNJ-64565111",{"nctId":3609,"briefTitle":3610,"status":105,"phases":16673,"primaryCompletion":3612,"completion":3613,"start":3359,"enrollment":1132,"conditions":16674,"interventions":16675},[87],[15],[46,3616],{"nctId":13046,"briefTitle":13047,"status":105,"phases":16677,"primaryCompletion":8190,"completion":8190,"start":3633,"enrollment":1436,"conditions":16678,"interventions":16679},[87],[15],[13051,13052,13023,3616],{"nctId":16681,"briefTitle":16682,"status":105,"phases":16683,"primaryCompletion":3359,"completion":3359,"start":6033,"enrollment":1787,"conditions":16684,"interventions":16685},"NCT02152332","A Study to Evaluate the Effects of JNJ-54861911 on Electrocardiogram Intervals in Healthy Particiants",[87],[15],[16686,16687,16688,3616,16689],"JNJ-54861911-Therapeutic Dose","JNJ-54861911 - Supratherapeutic Dose","JNJ-54861911-Matched Placebo","Moxifloxacin Matched Placebo",{"nctId":16691,"briefTitle":16692,"status":105,"phases":16693,"primaryCompletion":2904,"completion":2904,"start":1964,"enrollment":656,"conditions":16694,"interventions":16695},"NCT05387759","A Thorough QT Study of Aticaprant (JNJ-67953964) in Healthy Adult Participants",[87],[15],[16696,16697,3616],"Aticaprant Supratherapeutic Dose","Aticaprant Therapeutic Dose",{"nctId":16699,"briefTitle":16700,"status":105,"phases":16701,"primaryCompletion":3596,"completion":3596,"start":9096,"enrollment":9010,"conditions":16702,"interventions":16703},"NCT02816853","Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Chinese Healthy Participants",[87],[15],[16704,3616],"Domperidone",{"trials":16706,"activeCount":99},[],{"trials":16708,"activeCount":99},[],{"trials":16710,"activeCount":99},[],{"trials":16712,"activeCount":99},[],{"intervention":8349,"totalTrials":641,"cells":16714},{"EARLY_PHASE1":16715,"PHASE1":16717,"PHASE2":16759,"PHASE3":16761,"PHASE4":16763,"NA":16765},{"trials":16716,"activeCount":99},[],{"trials":16718,"activeCount":99},[16719,16727,16734,16738,16742,16751],{"nctId":16720,"briefTitle":16721,"status":105,"phases":16722,"primaryCompletion":16723,"completion":16723,"start":16724,"enrollment":169,"conditions":16725,"interventions":16726},"NCT04258189","A Study of JNJ-64417184, Administered as an Oral Solution, in Healthy Participants",[87],"2020-08-05","2020-02-11",[15],[8349],{"nctId":16728,"briefTitle":16729,"status":105,"phases":16730,"primaryCompletion":2958,"completion":2958,"start":16731,"enrollment":745,"conditions":16732,"interventions":16733},"NCT04121052","A Study in Healthy Volunteers to Assess the Effect of Different Types of Food on a Single-dose of JNJ-64417184 Administered as Tablets",[87],"2019-10-08",[15],[8349],{"nctId":12613,"briefTitle":12614,"status":105,"phases":16735,"primaryCompletion":12616,"completion":12616,"start":5963,"enrollment":169,"conditions":16736,"interventions":16737},[87],[15],[8357,8349],{"nctId":8342,"briefTitle":8343,"status":105,"phases":16739,"primaryCompletion":8345,"completion":8345,"start":8346,"enrollment":1507,"conditions":16740,"interventions":16741},[87],[15],[8349,1799,8350],{"nctId":16743,"briefTitle":16744,"status":105,"phases":16745,"primaryCompletion":16746,"completion":16746,"start":16747,"enrollment":503,"conditions":16748,"interventions":16749},"NCT03952507","A Study to Assess the Relative Oral Bioavailability and Food Effect of Single-dose of JNJ-64417184 in Healthy Participants",[87],"2019-06-22","2019-05-15",[15],[16750,8349],"JNJ-64417184 600",{"nctId":16752,"briefTitle":16753,"status":105,"phases":16754,"primaryCompletion":1796,"completion":1796,"start":16755,"enrollment":5557,"conditions":16756,"interventions":16757},"NCT04453189","A Study to Assess the Effects of Acid-Reducing Agent(s) on JNJ-64417184 in Healthy Participants",[87],"2020-07-20",[3667],[8349,12456,16758],"Famotidine",{"trials":16760,"activeCount":99},[],{"trials":16762,"activeCount":99},[],{"trials":16764,"activeCount":99},[],{"trials":16766,"activeCount":99},[],{"intervention":16671,"totalTrials":1029,"cells":16768},{"EARLY_PHASE1":16769,"PHASE1":16771,"PHASE2":16810,"PHASE3":16812,"PHASE4":16814,"NA":16816},{"trials":16770,"activeCount":99},[],{"trials":16772,"activeCount":99},[16773,16782,16786,16795,16803],{"nctId":16774,"briefTitle":16775,"status":105,"phases":16776,"primaryCompletion":16777,"completion":16777,"start":16778,"enrollment":3138,"conditions":16779,"interventions":16781},"NCT03546205","A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal Function",[87],"2018-12-17","2018-06-06",[16780],"Kidney Failure, Chronic",[16671],{"nctId":16664,"briefTitle":16665,"status":105,"phases":16783,"primaryCompletion":16667,"completion":16668,"start":7448,"enrollment":11,"conditions":16784,"interventions":16785},[87],[15],[16671,3616],{"nctId":16787,"briefTitle":16788,"status":125,"phases":16789,"primaryCompletion":16790,"completion":16791,"start":16792,"enrollment":3586,"conditions":16793,"interventions":16794},"NCT02862431","Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)",[87],"2016-11-29","2016-12-05","2016-07-12",[24],[16671],{"nctId":16796,"briefTitle":16797,"status":105,"phases":16798,"primaryCompletion":16799,"completion":16799,"start":16800,"enrollment":2108,"conditions":16801,"interventions":16802},"NCT03235219","A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus",[87],"2018-02-19","2017-08-01",[24],[16671],{"nctId":16804,"briefTitle":16805,"status":105,"phases":16806,"primaryCompletion":16807,"completion":16807,"start":5595,"enrollment":19,"conditions":16808,"interventions":16809},"NCT03586843","A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight\u002FObese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple Dose",[87],"2019-03-17",[13946],[16671],{"trials":16811,"activeCount":99},[],{"trials":16813,"activeCount":99},[],{"trials":16815,"activeCount":99},[],{"trials":16817,"activeCount":99},[],{"intervention":16819,"totalTrials":352,"cells":16820},"JNJ-70033093",{"EARLY_PHASE1":16821,"PHASE1":16823,"PHASE2":16859,"PHASE3":16861,"PHASE4":16863,"NA":16865},{"trials":16822,"activeCount":99},[],{"trials":16824,"activeCount":99},[16825,16834,16843,16851],{"nctId":16826,"briefTitle":16827,"status":105,"phases":16828,"primaryCompletion":16829,"completion":16830,"start":16831,"enrollment":3138,"conditions":16832,"interventions":16833},"NCT04569695","A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants",[87],"2021-12-04","2021-12-16","2021-03-08",[15],[16819],{"nctId":16835,"briefTitle":16836,"status":105,"phases":16837,"primaryCompletion":16838,"completion":16838,"start":16839,"enrollment":22,"conditions":16840,"interventions":16841},"NCT04206488","A Study of JNJ-70033093 and Digoxin in Healthy Participants",[87],"2021-06-09","2020-01-09",[15],[16819,16842],"Digoxin",{"nctId":16844,"briefTitle":16845,"status":105,"phases":16846,"primaryCompletion":16847,"completion":16847,"start":16848,"enrollment":1436,"conditions":16849,"interventions":16850},"NCT04223349","A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants",[87],"2020-04-08","2020-01-10",[15],[16819],{"nctId":16852,"briefTitle":16853,"status":105,"phases":16854,"primaryCompletion":16855,"completion":16855,"start":16856,"enrollment":3586,"conditions":16857,"interventions":16858},"NCT04448964","A Study of JNJ-70033093 in Healthy Participants",[87],"2020-11-14","2020-06-26",[15],[16819],{"trials":16860,"activeCount":99},[],{"trials":16862,"activeCount":99},[],{"trials":16864,"activeCount":99},[],{"trials":16866,"activeCount":99},[],{"intervention":4351,"totalTrials":352,"cells":16868},{"EARLY_PHASE1":16869,"PHASE1":16871,"PHASE2":16893,"PHASE3":16895,"PHASE4":16897,"NA":16899},{"trials":16870,"activeCount":99},[],{"trials":16872,"activeCount":99},[16873,16879,16885,16889],{"nctId":16874,"briefTitle":16875,"status":105,"phases":16876,"primaryCompletion":3658,"completion":3658,"start":5493,"enrollment":544,"conditions":16877,"interventions":16878},"NCT02355561","A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants",[87],[15],[4351,4351,4351],{"nctId":16880,"briefTitle":16881,"status":105,"phases":16882,"primaryCompletion":5618,"completion":5618,"start":6823,"enrollment":544,"conditions":16883,"interventions":16884},"NCT02260700","A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants",[87],[15],[4351,4351,4351],{"nctId":5828,"briefTitle":5829,"status":105,"phases":16886,"primaryCompletion":5831,"completion":5831,"start":5832,"enrollment":1507,"conditions":16887,"interventions":16888},[87],[15],[1778,4351,1779],{"nctId":4345,"briefTitle":4346,"status":105,"phases":16890,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":169,"conditions":16891,"interventions":16892},[87],[15],[4351,177,173,4352],{"trials":16894,"activeCount":99},[],{"trials":16896,"activeCount":99},[],{"trials":16898,"activeCount":99},[],{"trials":16900,"activeCount":99},[],{"intervention":1800,"totalTrials":352,"cells":16902},{"EARLY_PHASE1":16903,"PHASE1":16905,"PHASE2":16923,"PHASE3":16925,"PHASE4":16927,"NA":16929},{"trials":16904,"activeCount":99},[],{"trials":16906,"activeCount":99},[16907,16911,16915,16919],{"nctId":12272,"briefTitle":12273,"status":105,"phases":16908,"primaryCompletion":4314,"completion":4314,"start":3633,"enrollment":5557,"conditions":16909,"interventions":16910},[87],[15],[4325,1800],{"nctId":1791,"briefTitle":1792,"status":105,"phases":16912,"primaryCompletion":1794,"completion":1795,"start":1796,"enrollment":1507,"conditions":16913,"interventions":16914},[87],[15],[759,1799,1800],{"nctId":5601,"briefTitle":5602,"status":105,"phases":16916,"primaryCompletion":5604,"completion":5604,"start":5605,"enrollment":1436,"conditions":16917,"interventions":16918},[87],[15],[4318,1800],{"nctId":9494,"briefTitle":9495,"status":105,"phases":16920,"primaryCompletion":5868,"completion":5868,"start":3392,"enrollment":503,"conditions":16921,"interventions":16922},[87],[3667],[2676,1800],{"trials":16924,"activeCount":99},[],{"trials":16926,"activeCount":99},[],{"trials":16928,"activeCount":99},[],{"trials":16930,"activeCount":99},[],{"intervention":16932,"totalTrials":352,"cells":16933},"Candin",{"EARLY_PHASE1":16934,"PHASE1":16946,"PHASE2":16971,"PHASE3":16973,"PHASE4":16975,"NA":16977},{"trials":16935,"activeCount":99},[16936],{"nctId":16937,"briefTitle":16938,"status":105,"phases":16939,"primaryCompletion":13919,"completion":13919,"start":16940,"enrollment":1972,"conditions":16941,"interventions":16942},"NCT03953196","A Study Exploring the Use of Vaccine and Antigen Challenges for Immune Monitoring in Healthy Participants",[86],"2019-04-08",[15],[16943,16944,16945,16932],"Imvanex","Shingrix","LPS",{"trials":16947,"activeCount":99},[16948,16957,16964],{"nctId":16949,"briefTitle":16950,"status":105,"phases":16951,"primaryCompletion":16952,"completion":16952,"start":16953,"enrollment":745,"conditions":16954,"interventions":16955},"NCT05522517","A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4",[87],"2022-11-02","2022-08-22",[15],[16956,16932],"Cosentyx",{"nctId":16958,"briefTitle":16959,"status":105,"phases":16960,"primaryCompletion":4605,"completion":4605,"start":16961,"enrollment":544,"conditions":16962,"interventions":16963},"NCT04589026","A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1",[87],"2020-10-21",[15],[16956,16932],{"nctId":16965,"briefTitle":16966,"status":105,"phases":16967,"primaryCompletion":4605,"completion":4605,"start":6841,"enrollment":479,"conditions":16968,"interventions":16969},"NCT04611971","A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 2",[87],[15],[16970,16932],"Benlysta",{"trials":16972,"activeCount":99},[],{"trials":16974,"activeCount":99},[],{"trials":16976,"activeCount":99},[],{"trials":16978,"activeCount":99},[],{"intervention":8399,"totalTrials":352,"cells":16980},{"EARLY_PHASE1":16981,"PHASE1":16983,"PHASE2":17001,"PHASE3":17003,"PHASE4":17005,"NA":17007},{"trials":16982,"activeCount":99},[],{"trials":16984,"activeCount":99},[16985,16989,16993,16997],{"nctId":8447,"briefTitle":8394,"status":105,"phases":16986,"primaryCompletion":2218,"completion":2218,"start":8396,"enrollment":19,"conditions":16987,"interventions":16988},[87],[3331],[8391,8399,8451,8452],{"nctId":8393,"briefTitle":8394,"status":105,"phases":16990,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":245,"conditions":16991,"interventions":16992},[87],[3331],[8377,8399,8400,8401],{"nctId":8454,"briefTitle":8404,"status":105,"phases":16994,"primaryCompletion":2217,"completion":2217,"start":8396,"enrollment":571,"conditions":16995,"interventions":16996},[87],[15],[8391,8399,8458,8459],{"nctId":8403,"briefTitle":8404,"status":105,"phases":16998,"primaryCompletion":6033,"completion":6033,"start":5572,"enrollment":12,"conditions":16999,"interventions":17000},[87],[15],[8377,8399,8408,8409],{"trials":17002,"activeCount":99},[],{"trials":17004,"activeCount":99},[],{"trials":17006,"activeCount":99},[],{"trials":17008,"activeCount":99},[],{"intervention":9013,"totalTrials":352,"cells":17010},{"EARLY_PHASE1":17011,"PHASE1":17013,"PHASE2":17038,"PHASE3":17040,"PHASE4":17042,"NA":17044},{"trials":17012,"activeCount":99},[],{"trials":17014,"activeCount":99},[17015,17019,17025,17031],{"nctId":9007,"briefTitle":9008,"status":105,"phases":17016,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17017,"interventions":17018},[87],[15],[9013,5848,8193,9014],{"nctId":17020,"briefTitle":17021,"status":105,"phases":17022,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17023,"interventions":17024},"NCT02851212","A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants",[87],[15],[9013,5826,5826,9014],{"nctId":17026,"briefTitle":17027,"status":105,"phases":17028,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17029,"interventions":17030},"NCT02865668","A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants",[87],[15],[9013,5826,9014],{"nctId":17032,"briefTitle":17033,"status":105,"phases":17034,"primaryCompletion":17035,"completion":17035,"start":3596,"enrollment":9010,"conditions":17036,"interventions":17037},"NCT02851095","A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants",[87],"2016-11",[15],[9013,5826,9014],{"trials":17039,"activeCount":99},[],{"trials":17041,"activeCount":99},[],{"trials":17043,"activeCount":99},[],{"trials":17045,"activeCount":99},[],{"intervention":9014,"totalTrials":352,"cells":17047},{"EARLY_PHASE1":17048,"PHASE1":17050,"PHASE2":17068,"PHASE3":17070,"PHASE4":17072,"NA":17074},{"trials":17049,"activeCount":99},[],{"trials":17051,"activeCount":99},[17052,17056,17060,17064],{"nctId":9007,"briefTitle":9008,"status":105,"phases":17053,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17054,"interventions":17055},[87],[15],[9013,5848,8193,9014],{"nctId":17020,"briefTitle":17021,"status":105,"phases":17057,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17058,"interventions":17059},[87],[15],[9013,5826,5826,9014],{"nctId":17026,"briefTitle":17027,"status":105,"phases":17061,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":17062,"interventions":17063},[87],[15],[9013,5826,9014],{"nctId":17032,"briefTitle":17033,"status":105,"phases":17065,"primaryCompletion":17035,"completion":17035,"start":3596,"enrollment":9010,"conditions":17066,"interventions":17067},[87],[15],[9013,5826,9014],{"trials":17069,"activeCount":99},[],{"trials":17071,"activeCount":99},[],{"trials":17073,"activeCount":99},[],{"trials":17075,"activeCount":99},[],{"intervention":17077,"totalTrials":571,"cells":17078},"Darunavir",{"EARLY_PHASE1":17079,"PHASE1":17081,"PHASE2":17111,"PHASE3":17113,"PHASE4":17115,"NA":17117},{"trials":17080,"activeCount":99},[],{"trials":17082,"activeCount":99},[17083,17092,17101],{"nctId":17084,"briefTitle":17085,"status":105,"phases":17086,"primaryCompletion":17087,"completion":17087,"start":4008,"enrollment":12386,"conditions":17088,"interventions":17089},"NCT04718805","A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed Conditions",[87],"2021-03-01",[15],[17077,17090,17091],"Cobicistat","Darunavir\u002FCobicistat FDC",{"nctId":17093,"briefTitle":17094,"status":105,"phases":17095,"primaryCompletion":17096,"completion":17096,"start":4212,"enrollment":5539,"conditions":17097,"interventions":17098},"NCT04661397","A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide) Compared With Co-administration of the Separate Agents",[87],"2021-07-02",[15],[17099,17077,17100,17090],"Darunavir\u002FCobicistat\u002FEmtricitabine\u002FTenofovir Alafenamide FDC","Emtricitabine\u002FTenofovir Alafenamide",{"nctId":17102,"briefTitle":17103,"status":105,"phases":17104,"primaryCompletion":17105,"completion":17106,"start":3791,"enrollment":1132,"conditions":17107,"interventions":17108},"NCT04208061","A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants",[87],"2021-03-25","2021-04-01",[15],[17109,17110,13004,17077],"Dabigatran Etexilate","DRV\u002FCOBI",{"trials":17112,"activeCount":99},[],{"trials":17114,"activeCount":99},[],{"trials":17116,"activeCount":99},[],{"trials":17118,"activeCount":99},[],{"intervention":17120,"totalTrials":571,"cells":17121},"JNJ-77474462",{"EARLY_PHASE1":17122,"PHASE1":17124,"PHASE2":17148,"PHASE3":17150,"PHASE4":17152,"NA":17154},{"trials":17123,"activeCount":99},[],{"trials":17125,"activeCount":99},[17126,17134,17141],{"nctId":17127,"briefTitle":17128,"status":137,"phases":17129,"primaryCompletion":17130,"completion":17130,"start":17131,"enrollment":99,"conditions":17132,"interventions":17133},"NCT05252520","A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants",[87],"2023-11-20","2023-05-01",[15],[17120],{"nctId":17135,"briefTitle":17136,"status":105,"phases":17137,"primaryCompletion":12262,"completion":12262,"start":17138,"enrollment":3586,"conditions":17139,"interventions":17140},"NCT04544826","A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses",[87],"2020-10-16",[15],[17120],{"nctId":17142,"briefTitle":17143,"status":105,"phases":17144,"primaryCompletion":12947,"completion":12947,"start":956,"enrollment":399,"conditions":17145,"interventions":17146},"NCT04544813","A Study of JNJ-77474462 in Healthy Participants",[87],[15],[17120,17147],"Anakinra",{"trials":17149,"activeCount":99},[],{"trials":17151,"activeCount":99},[],{"trials":17153,"activeCount":99},[],{"trials":17155,"activeCount":99},[],{"intervention":17157,"totalTrials":571,"cells":17158},"JNJ-64140284",{"EARLY_PHASE1":17159,"PHASE1":17161,"PHASE2":17193,"PHASE3":17195,"PHASE4":17197,"NA":17199},{"trials":17160,"activeCount":99},[],{"trials":17162,"activeCount":99},[17163,17171,17184],{"nctId":17164,"briefTitle":17165,"status":125,"phases":17166,"primaryCompletion":17167,"completion":17167,"start":17168,"enrollment":468,"conditions":17169,"interventions":17170},"NCT04033458","A Study of JNJ-64140284 Solid Dose Formulations in Healthy Male Participants",[87],"2019-08-01","2019-07-29",[15],[17157],{"nctId":17172,"briefTitle":17173,"status":125,"phases":17174,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":17176,"interventions":17177},"NCT03180762","A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants",[87],"2017-09-25",[15],[17178,17179,17180,17181,17182,17183,17157],"JNJ-64140284 0.1 mg","JNJ-64140284 0.5 mg","JNJ-64140284 2.5 mg","JNJ-64140284 10 mg","JNJ-64140284 50 mg","JNJ-64140284 150 mg",{"nctId":17185,"briefTitle":17186,"status":125,"phases":17187,"primaryCompletion":17188,"completion":9968,"start":17189,"enrollment":12386,"conditions":17190,"interventions":17191},"NCT03693391","A Study to Investigate Alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA Gamma 8) Receptor Occupancy of JNJ-64140284 With Newly Developed Transmembrane AMPA Receptor Regulatory Protein (TARP)-Gamma 8 Positron Emission Tomography (PET) [18F]JNJ-64511070 in Healthy Men",[87],"2019-03-02","2018-10-17",[15],[17157,17192],"Fluorine-18 Labeled [18F]-JNJ-64511070",{"trials":17194,"activeCount":99},[],{"trials":17196,"activeCount":99},[],{"trials":17198,"activeCount":99},[],{"trials":17200,"activeCount":99},[],{"intervention":9958,"totalTrials":571,"cells":17202},{"EARLY_PHASE1":17203,"PHASE1":17205,"PHASE2":17235,"PHASE3":17237,"PHASE4":17239,"NA":17241},{"trials":17204,"activeCount":99},[],{"trials":17206,"activeCount":99},[17207,17221,17225],{"nctId":17208,"briefTitle":17209,"status":125,"phases":17210,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":17213,"interventions":17214},"NCT03059303","Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)",[87],"2017-04-24","2017-02-20",[15],[17215,17216,17217,17218,17219,17220,9958],"Simeprevir 75 mg","Odalasvir 25 mg","Odalasvir 12.5 mg","Odalasvir 75 mg","AL-335 800 mg","Lansoprazole 30 mg",{"nctId":9948,"briefTitle":9949,"status":125,"phases":17222,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":17223,"interventions":17224},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"nctId":17226,"briefTitle":17227,"status":105,"phases":17228,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":17229,"interventions":17230},"NCT03058419","A Study to Evaluate the Effect of Oral Doses of JNJ-54175446 on the Inhibition of Cytochrome P450 CYP3A4, CYP2C9, CYP1A2 and CYP2D6 Activity and the Induction of CYP2B6 and CYP2C19 Activity Using a Multiple Probe Substrate Cocktail in Healthy Subjects",[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],"JNJ-54175446 150 mg","JNJ-54175446 600 mg","Caffeine 50 mg","Bupropion 150 mg",{"trials":17236,"activeCount":99},[],{"trials":17238,"activeCount":99},[],{"trials":17240,"activeCount":99},[],{"trials":17242,"activeCount":99},[],{"intervention":175,"totalTrials":571,"cells":17244},{"EARLY_PHASE1":17245,"PHASE1":17247,"PHASE2":17261,"PHASE3":17263,"PHASE4":17265,"NA":17267},{"trials":17246,"activeCount":99},[],{"trials":17248,"activeCount":99},[17249,17253,17257],{"nctId":3629,"briefTitle":3630,"status":105,"phases":17250,"primaryCompletion":3632,"completion":3632,"start":3633,"enrollment":745,"conditions":17251,"interventions":17252},[87],[15],[46,175],{"nctId":4327,"briefTitle":4328,"status":105,"phases":17254,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":17255,"interventions":17256},[87],[2003],[4334,173,174,4335,175,177],{"nctId":164,"briefTitle":165,"status":105,"phases":17258,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":17259,"interventions":17260},[87],[171],[94,173,174,175,176,177],{"trials":17262,"activeCount":99},[],{"trials":17264,"activeCount":99},[],{"trials":17266,"activeCount":99},[],{"trials":17268,"activeCount":99},[],{"intervention":17270,"totalTrials":571,"cells":17271},"Metformin IR",{"EARLY_PHASE1":17272,"PHASE1":17274,"PHASE2":17296,"PHASE3":17298,"PHASE4":17300,"NA":17302},{"trials":17273,"activeCount":99},[],{"trials":17275,"activeCount":99},[17276,17283,17289],{"nctId":17277,"briefTitle":17278,"status":105,"phases":17279,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":17280,"interventions":17281},"NCT01508195","A Study of Canagliflozin and Metformin Immediate Release (50 mg\u002F500 mg) FDC Tablets in Healthy Volunteers",[87],[15],[5826,17270,17282,17282,5826,17270],"Canagliflozin\u002Fmetformin IR FDC",{"nctId":17284,"briefTitle":17285,"status":105,"phases":17286,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":17287,"interventions":17288},"NCT01508182","A Study of Canagliflozin and Metformin Immediate Release (150 mg\u002F500 mg) FDC Tablets in Healthy Volunteers",[87],[15],[5826,17270,17282,5826,17270,17282],{"nctId":17290,"briefTitle":17291,"status":105,"phases":17292,"primaryCompletion":3359,"completion":3359,"start":5530,"enrollment":245,"conditions":17293,"interventions":17294},"NCT02220218","Bioequivalence Study of Metformin Component of Canagliflozin and Metformin Fixed Dose Combination Immediate Release (IR) Tablet Comparing With Metformin IR Tablet Co-administered With Canagliflozin Tablet in Healthy Fed and Fasted Participants",[87],[15],[17295,5826,17270],"Canagliflozin + Metformin Immediate Release",{"trials":17297,"activeCount":99},[],{"trials":17299,"activeCount":99},[],{"trials":17301,"activeCount":99},[],{"trials":17303,"activeCount":99},[],{"intervention":177,"totalTrials":571,"cells":17305},{"EARLY_PHASE1":17306,"PHASE1":17308,"PHASE2":17322,"PHASE3":17324,"PHASE4":17326,"NA":17328},{"trials":17307,"activeCount":99},[],{"trials":17309,"activeCount":99},[17310,17314,17318],{"nctId":4327,"briefTitle":4328,"status":105,"phases":17311,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":17312,"interventions":17313},[87],[2003],[4334,173,174,4335,175,177],{"nctId":164,"briefTitle":165,"status":105,"phases":17315,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":17316,"interventions":17317},[87],[171],[94,173,174,175,176,177],{"nctId":4345,"briefTitle":4346,"status":105,"phases":17319,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":169,"conditions":17320,"interventions":17321},[87],[15],[4351,177,173,4352],{"trials":17323,"activeCount":99},[],{"trials":17325,"activeCount":99},[],{"trials":17327,"activeCount":99},[],{"trials":17329,"activeCount":99},[],{"intervention":5496,"totalTrials":245,"cells":17331},{"EARLY_PHASE1":17332,"PHASE1":17334,"PHASE2":17344,"PHASE3":17346,"PHASE4":17348,"NA":17350},{"trials":17333,"activeCount":99},[],{"trials":17335,"activeCount":99},[17336,17340],{"nctId":5490,"briefTitle":5491,"status":105,"phases":17337,"primaryCompletion":3612,"completion":3612,"start":5493,"enrollment":503,"conditions":17338,"interventions":17339},[87],[15],[4318,5496],{"nctId":5952,"briefTitle":5953,"status":105,"phases":17341,"primaryCompletion":5955,"completion":5955,"start":5956,"enrollment":169,"conditions":17342,"interventions":17343},[87],[15],[5945,5496],{"trials":17345,"activeCount":99},[],{"trials":17347,"activeCount":99},[],{"trials":17349,"activeCount":99},[],{"trials":17351,"activeCount":99},[],{"intervention":3626,"totalTrials":245,"cells":17353},{"EARLY_PHASE1":17354,"PHASE1":17356,"PHASE2":17366,"PHASE3":17368,"PHASE4":17370,"NA":17372},{"trials":17355,"activeCount":99},[],{"trials":17357,"activeCount":99},[17358,17362],{"nctId":8880,"briefTitle":8881,"status":105,"phases":17359,"primaryCompletion":2565,"completion":2565,"start":8883,"enrollment":1857,"conditions":17360,"interventions":17361},[87],[15,8885],[8873,8873,3626,3626],{"nctId":3618,"briefTitle":3619,"status":105,"phases":17363,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":25,"conditions":17364,"interventions":17365},[87],[3624],[46,3626,3627],{"trials":17367,"activeCount":99},[],{"trials":17369,"activeCount":99},[],{"trials":17371,"activeCount":99},[],{"trials":17373,"activeCount":99},[],{"intervention":17090,"totalTrials":245,"cells":17375},{"EARLY_PHASE1":17376,"PHASE1":17378,"PHASE2":17388,"PHASE3":17390,"PHASE4":17392,"NA":17394},{"trials":17377,"activeCount":99},[],{"trials":17379,"activeCount":99},[17380,17384],{"nctId":17084,"briefTitle":17085,"status":105,"phases":17381,"primaryCompletion":17087,"completion":17087,"start":4008,"enrollment":12386,"conditions":17382,"interventions":17383},[87],[15],[17077,17090,17091],{"nctId":17093,"briefTitle":17094,"status":105,"phases":17385,"primaryCompletion":17096,"completion":17096,"start":4212,"enrollment":5539,"conditions":17386,"interventions":17387},[87],[15],[17099,17077,17100,17090],{"trials":17389,"activeCount":99},[],{"trials":17391,"activeCount":99},[],{"trials":17393,"activeCount":99},[],{"trials":17395,"activeCount":99},[],{"intervention":17397,"totalTrials":245,"cells":17398},"JNJ-64251330",{"EARLY_PHASE1":17399,"PHASE1":17401,"PHASE2":17419,"PHASE3":17421,"PHASE4":17423,"NA":17425},{"trials":17400,"activeCount":99},[],{"trials":17402,"activeCount":99},[17403,17412],{"nctId":17404,"briefTitle":17405,"status":105,"phases":17406,"primaryCompletion":17407,"completion":17407,"start":17408,"enrollment":1532,"conditions":17409,"interventions":17410},"NCT04552197","A Study of JNJ-64251330 in Healthy Participants",[87],"2020-12-29","2020-09-02",[15],[17397,17411],"Tofacitinib",{"nctId":17413,"briefTitle":17414,"status":105,"phases":17415,"primaryCompletion":4553,"completion":4553,"start":17416,"enrollment":6909,"conditions":17417,"interventions":17418},"NCT05014360","A Study of JNJ-64251330 in Participants With Familial Adenomatous Polyposis",[87],"2021-11-10",[152],[17397],{"trials":17420,"activeCount":99},[],{"trials":17422,"activeCount":99},[],{"trials":17424,"activeCount":99},[],{"trials":17426,"activeCount":99},[],{"intervention":17411,"totalTrials":245,"cells":17428},{"EARLY_PHASE1":17429,"PHASE1":17431,"PHASE2":17443,"PHASE3":17445,"PHASE4":17447,"NA":17449},{"trials":17430,"activeCount":99},[],{"trials":17432,"activeCount":99},[17433,17437],{"nctId":17404,"briefTitle":17405,"status":105,"phases":17434,"primaryCompletion":17407,"completion":17407,"start":17408,"enrollment":1532,"conditions":17435,"interventions":17436},[87],[15],[17397,17411],{"nctId":17438,"briefTitle":17439,"status":105,"phases":17440,"primaryCompletion":2031,"completion":2031,"start":12783,"enrollment":544,"conditions":17441,"interventions":17442},"NCT04985955","A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 3",[87],[15],[17411],{"trials":17444,"activeCount":99},[],{"trials":17446,"activeCount":99},[],{"trials":17448,"activeCount":99},[],{"trials":17450,"activeCount":99},[],{"intervention":3600,"totalTrials":245,"cells":17452},{"EARLY_PHASE1":17453,"PHASE1":17455,"PHASE2":17465,"PHASE3":17467,"PHASE4":17469,"NA":17471},{"trials":17454,"activeCount":99},[],{"trials":17456,"activeCount":99},[17457,17461],{"nctId":3593,"briefTitle":3594,"status":105,"phases":17458,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":3360,"conditions":17459,"interventions":17460},[87],[15],[3600,46],{"nctId":3602,"briefTitle":3603,"status":105,"phases":17462,"primaryCompletion":3605,"completion":3605,"start":1203,"enrollment":2022,"conditions":17463,"interventions":17464},[87],[15],[46,3600],{"trials":17466,"activeCount":99},[],{"trials":17468,"activeCount":99},[],{"trials":17470,"activeCount":99},[],{"trials":17472,"activeCount":99},[],{"intervention":17474,"totalTrials":245,"cells":17475},"TMC435",{"EARLY_PHASE1":17476,"PHASE1":17478,"PHASE2":17494,"PHASE3":17496,"PHASE4":17498,"NA":17500},{"trials":17477,"activeCount":99},[],{"trials":17479,"activeCount":99},[17480,17488],{"nctId":17481,"briefTitle":17482,"status":105,"phases":17483,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1532,"conditions":17484,"interventions":17485},"NCT01689623","A Pharmacokinetic Interaction Study Between TMC435, Atorvastatin and Simvastatin in Healthy Participants",[87],[3667],[17474,17486,17487],"Atorvastatin","Simvastatin",{"nctId":17489,"briefTitle":17490,"status":105,"phases":17491,"primaryCompletion":5899,"completion":5899,"start":2513,"enrollment":3586,"conditions":17492,"interventions":17493},"NCT01799603","A Pharmacokinetic Study to Assess the Effect of Food in Healthy Male Participants Receiving TMC435",[87],[15],[17474],{"trials":17495,"activeCount":99},[],{"trials":17497,"activeCount":99},[],{"trials":17499,"activeCount":99},[],{"trials":17501,"activeCount":99},[],{"intervention":13146,"totalTrials":245,"cells":17503},{"EARLY_PHASE1":17504,"PHASE1":17506,"PHASE2":17520,"PHASE3":17522,"PHASE4":17524,"NA":17526},{"trials":17505,"activeCount":99},[],{"trials":17507,"activeCount":99},[17508,17512],{"nctId":13141,"briefTitle":13142,"status":105,"phases":17509,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":544,"conditions":17510,"interventions":17511},[87],[15],[13134,13134,13146],{"nctId":17513,"briefTitle":17514,"status":105,"phases":17515,"primaryCompletion":3444,"completion":3444,"start":3359,"enrollment":109,"conditions":17516,"interventions":17517},"NCT02218073","Pharmacokinetic Study of JNJ-42756493 in Healthy Participants",[87],[15],[17518,17519,13146],"JNJ-42756493 10 mg","JNJ-42756493 10 mg Oral Solution",{"trials":17521,"activeCount":99},[],{"trials":17523,"activeCount":99},[],{"trials":17525,"activeCount":99},[],{"trials":17527,"activeCount":99},[],{"intervention":17529,"totalTrials":245,"cells":17530},"JNJ-39439335",{"EARLY_PHASE1":17531,"PHASE1":17533,"PHASE2":17549,"PHASE3":17551,"PHASE4":17553,"NA":17555},{"trials":17532,"activeCount":99},[],{"trials":17534,"activeCount":99},[17535,17543],{"nctId":17536,"briefTitle":17537,"status":105,"phases":17538,"completion":5867,"start":15332,"enrollment":678,"conditions":17539,"interventions":17541},"NCT01343303","A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-39439335 in Patients With Osteoarthritis",[87],[17540],"Osteoarthritis, Knee",[17529,17542,17529],"Naproxen",{"nctId":17544,"briefTitle":17545,"status":105,"phases":17546,"primaryCompletion":2487,"completion":2487,"start":5845,"enrollment":678,"conditions":17547,"interventions":17548},"NCT01454245","A Study to Evaluate the Bioavailability and Food Effect of JNJ-39439335 in Healthy Adult Male Volunteers",[87],[15],[17529,17529],{"trials":17550,"activeCount":99},[],{"trials":17552,"activeCount":99},[],{"trials":17554,"activeCount":99},[],{"trials":17556,"activeCount":99},[],{"intervention":4335,"totalTrials":245,"cells":17558},{"EARLY_PHASE1":17559,"PHASE1":17561,"PHASE2":17571,"PHASE3":17573,"PHASE4":17575,"NA":17577},{"trials":17560,"activeCount":99},[],{"trials":17562,"activeCount":99},[17563,17567],{"nctId":8888,"briefTitle":8889,"status":105,"phases":17564,"primaryCompletion":2513,"completion":2513,"start":8891,"enrollment":2545,"conditions":17565,"interventions":17566},[87],[15],[8873,174,4335,4335,174,174,174],{"nctId":4327,"briefTitle":4328,"status":105,"phases":17568,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":17569,"interventions":17570},[87],[2003],[4334,173,174,4335,175,177],{"trials":17572,"activeCount":99},[],{"trials":17574,"activeCount":99},[],{"trials":17576,"activeCount":99},[],{"trials":17578,"activeCount":99},[],{"intervention":17580,"totalTrials":245,"cells":17581},"DRV\u002FCOBI FDC",{"EARLY_PHASE1":17582,"PHASE1":17584,"PHASE2":17604,"PHASE3":17606,"PHASE4":17608,"NA":17610},{"trials":17583,"activeCount":99},[],{"trials":17585,"activeCount":99},[17586,17594],{"nctId":17587,"briefTitle":17588,"status":105,"phases":17589,"primaryCompletion":2097,"completion":2097,"start":17590,"enrollment":1177,"conditions":17591,"interventions":17593},"NCT05197075","A Study to Assess the Acceptability of the Darunavir\u002FCobicistat (DRV\u002FCOBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children",[87],"2022-08-03",[17592],"Human Immunodeficiency Virus (HIV)",[17580],{"nctId":17595,"briefTitle":17596,"status":105,"phases":17597,"primaryCompletion":17598,"completion":17598,"start":17599,"enrollment":1507,"conditions":17600,"interventions":17601},"NCT05378906","A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy Participants",[87],"2022-09-28","2022-06-07",[15],[17580,17602,17603],"COBI","DRV",{"trials":17605,"activeCount":99},[],{"trials":17607,"activeCount":99},[],{"trials":17609,"activeCount":99},[],{"trials":17611,"activeCount":99},[],{"intervention":12456,"totalTrials":245,"cells":17613},{"EARLY_PHASE1":17614,"PHASE1":17616,"PHASE2":17626,"PHASE3":17628,"PHASE4":17630,"NA":17632},{"trials":17615,"activeCount":99},[],{"trials":17617,"activeCount":99},[17618,17622],{"nctId":12451,"briefTitle":12452,"status":125,"phases":17619,"primaryCompletion":4257,"completion":4257,"start":3378,"enrollment":503,"conditions":17620,"interventions":17621},[87],[15],[12444,12456,12457],{"nctId":16752,"briefTitle":16753,"status":105,"phases":17623,"primaryCompletion":1796,"completion":1796,"start":16755,"enrollment":5557,"conditions":17624,"interventions":17625},[87],[3667],[8349,12456,16758],{"trials":17627,"activeCount":99},[],{"trials":17629,"activeCount":99},[],{"trials":17631,"activeCount":99},[],{"trials":17633,"activeCount":99},[],{"intervention":17635,"totalTrials":245,"cells":17636},"JNJ-54416076",{"EARLY_PHASE1":17637,"PHASE1":17639,"PHASE2":17655,"PHASE3":17657,"PHASE4":17659,"NA":17661},{"trials":17638,"activeCount":99},[],{"trials":17640,"activeCount":99},[17641,17648],{"nctId":17642,"briefTitle":17643,"status":137,"phases":17644,"primaryCompletion":16658,"completion":16658,"start":17645,"enrollment":99,"conditions":17646,"interventions":17647},"NCT02951845","Study to Investigate the Food Effect and Oral Bioavailability of Tablet Formulations Relative to Suspension Formulation of JNJ-54416076 in Healthy Participants",[87],"2016-11-22",[15],[17635,17635,17635],{"nctId":17649,"briefTitle":17650,"status":105,"phases":17651,"primaryCompletion":17652,"completion":17652,"start":8190,"enrollment":1787,"conditions":17653,"interventions":17654},"NCT02670395","A Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-54416076 in Healthy Participants",[87],"2016-09",[15],[17635],{"trials":17656,"activeCount":99},[],{"trials":17658,"activeCount":99},[],{"trials":17660,"activeCount":99},[],{"trials":17662,"activeCount":99},[],{"intervention":4304,"totalTrials":245,"cells":17664},{"EARLY_PHASE1":17665,"PHASE1":17667,"PHASE2":17677,"PHASE3":17679,"PHASE4":17681,"NA":17683},{"trials":17666,"activeCount":99},[],{"trials":17668,"activeCount":99},[17669,17673],{"nctId":4297,"briefTitle":4298,"status":137,"phases":17670,"primaryCompletion":4300,"completion":4301,"start":4193,"enrollment":99,"conditions":17671,"interventions":17672},[87],[15],[4304,173,4305],{"nctId":12409,"briefTitle":12410,"status":105,"phases":17674,"primaryCompletion":12412,"completion":12412,"start":3596,"enrollment":3586,"conditions":17675,"interventions":17676},[87],[15],[12415,12389,12370,12390],{"trials":17678,"activeCount":99},[],{"trials":17680,"activeCount":99},[],{"trials":17682,"activeCount":99},[],{"trials":17684,"activeCount":99},[],{"intervention":1778,"totalTrials":245,"cells":17686},{"EARLY_PHASE1":17687,"PHASE1":17689,"PHASE2":17699,"PHASE3":17701,"PHASE4":17703,"NA":17705},{"trials":17688,"activeCount":99},[],{"trials":17690,"activeCount":99},[17691,17695],{"nctId":1771,"briefTitle":1772,"status":105,"phases":17692,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":745,"conditions":17693,"interventions":17694},[87],[15],[759,173,1778,1779],{"nctId":5828,"briefTitle":5829,"status":105,"phases":17696,"primaryCompletion":5831,"completion":5831,"start":5832,"enrollment":1507,"conditions":17697,"interventions":17698},[87],[15],[1778,4351,1779],{"trials":17700,"activeCount":99},[],{"trials":17702,"activeCount":99},[],{"trials":17704,"activeCount":99},[],{"trials":17706,"activeCount":99},[],{"intervention":3679,"totalTrials":245,"cells":17708},{"EARLY_PHASE1":17709,"PHASE1":17711,"PHASE2":17721,"PHASE3":17723,"PHASE4":17725,"NA":17727},{"trials":17710,"activeCount":99},[],{"trials":17712,"activeCount":99},[17713,17717],{"nctId":4311,"briefTitle":4312,"status":105,"phases":17714,"primaryCompletion":4314,"completion":4314,"start":4315,"enrollment":832,"conditions":17715,"interventions":17716},[87],[15],[173,4318,3679],{"nctId":3670,"briefTitle":3671,"status":105,"phases":17718,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":2472,"conditions":17719,"interventions":17720},[87],[2920],[46,3678,3679,173],{"trials":17722,"activeCount":99},[],{"trials":17724,"activeCount":99},[],{"trials":17726,"activeCount":99},[],{"trials":17728,"activeCount":99},[],{"intervention":12172,"totalTrials":245,"cells":17730},{"EARLY_PHASE1":17731,"PHASE1":17733,"PHASE2":17746,"PHASE3":17748,"PHASE4":17750,"NA":17752},{"trials":17732,"activeCount":99},[],{"trials":17734,"activeCount":99},[17735,17739],{"nctId":12165,"briefTitle":12166,"status":105,"phases":17736,"primaryCompletion":12168,"completion":7176,"start":12169,"enrollment":3586,"conditions":17737,"interventions":17738},[87],[2412],[7292,12172,12173,12174,12175],{"nctId":17740,"briefTitle":17741,"status":105,"phases":17742,"primaryCompletion":182,"completion":182,"start":17743,"enrollment":5557,"conditions":17744,"interventions":17745},"NCT04736147","A Study of JNJ-64300535 in Healthy Participants",[87],"2021-02-03",[15],[12172],{"trials":17747,"activeCount":99},[],{"trials":17749,"activeCount":99},[],{"trials":17751,"activeCount":99},[],{"trials":17753,"activeCount":99},[],{"intervention":17219,"totalTrials":245,"cells":17755},{"EARLY_PHASE1":17756,"PHASE1":17758,"PHASE2":17773,"PHASE3":17775,"PHASE4":17777,"NA":17779},{"trials":17757,"activeCount":99},[],{"trials":17759,"activeCount":99},[17760,17764],{"nctId":17208,"briefTitle":17209,"status":125,"phases":17761,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":17762,"interventions":17763},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"nctId":17765,"briefTitle":17766,"status":137,"phases":17767,"primaryCompletion":13208,"completion":13208,"start":17768,"enrollment":99,"conditions":17769,"interventions":17770},"NCT03277755","A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function",[87],"2017-09-11",[505],[17219,17771,17772],"ODV 25 mg","SMV 75 mg",{"trials":17774,"activeCount":99},[],{"trials":17776,"activeCount":99},[],{"trials":17778,"activeCount":99},[],{"trials":17780,"activeCount":99},[],{"intervention":13324,"totalTrials":245,"cells":17782},{"EARLY_PHASE1":17783,"PHASE1":17785,"PHASE2":17795,"PHASE3":17797,"PHASE4":17799,"NA":17801},{"trials":17784,"activeCount":99},[],{"trials":17786,"activeCount":99},[17787,17791],{"nctId":13315,"briefTitle":13316,"status":105,"phases":17788,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":17789,"interventions":17790},[87],[15],[13321,13322,3616,13323,13324,4366],{"nctId":8484,"briefTitle":8485,"status":105,"phases":17792,"primaryCompletion":8487,"completion":8487,"start":8488,"enrollment":8489,"conditions":17793,"interventions":17794},[87],[8491],[8493,8494,8495,8496,8477],{"trials":17796,"activeCount":99},[],{"trials":17798,"activeCount":99},[],{"trials":17800,"activeCount":99},[],{"trials":17802,"activeCount":99},[],{"intervention":17804,"totalTrials":245,"cells":17805},"CANA\u002FMET XR FDC",{"EARLY_PHASE1":17806,"PHASE1":17808,"PHASE2":17822,"PHASE3":17824,"PHASE4":17826,"NA":17828},{"trials":17807,"activeCount":99},[],{"trials":17809,"activeCount":99},[17810,17816],{"nctId":17811,"briefTitle":17812,"status":105,"phases":17813,"primaryCompletion":5572,"completion":5572,"start":5555,"enrollment":3586,"conditions":17814,"interventions":17815},"NCT02039258","Pharmacokinetics of a Fixed Dose Combination of Canagliflozin\u002FMetformin Coadministered With Food",[87],[3331],[17804],{"nctId":17817,"briefTitle":17818,"status":105,"phases":17819,"primaryCompletion":8396,"completion":5572,"start":5555,"enrollment":544,"conditions":17820,"interventions":17821},"NCT02039245","Multiple Dose Pharmacokinetics of Canagliflozin\u002FMetformin 150\u002F1,000 mg Fixed Dose Combination",[87],[3331],[17804],{"trials":17823,"activeCount":99},[],{"trials":17825,"activeCount":99},[],{"trials":17827,"activeCount":99},[],{"trials":17829,"activeCount":99},[],{"intervention":17831,"totalTrials":245,"cells":17832},"MABp1",{"EARLY_PHASE1":17833,"PHASE1":17835,"PHASE2":17855,"PHASE3":17857,"PHASE4":17859,"NA":17861},{"trials":17834,"activeCount":99},[],{"trials":17836,"activeCount":99},[17837,17846],{"nctId":17838,"briefTitle":17839,"status":105,"phases":17840,"primaryCompletion":17841,"completion":17842,"start":17843,"enrollment":641,"conditions":17844,"interventions":17845},"NCT03047317","A Pharmacokinetic Study of MABp1 in Healthy Volunteers",[87],"2017-03-08","2017-03-31","2017-02-15",[15],[17831],{"nctId":17847,"briefTitle":17848,"status":105,"phases":17849,"primaryCompletion":6806,"completion":17850,"start":17851,"enrollment":19,"conditions":17852,"interventions":17854},"NCT01021072","A First in Man Study of MABp1 in Patients With Advanced Cancers",[87],"2013-08-31","2010-03-31",[17853],"Advanced Cancers",[17831],{"trials":17856,"activeCount":99},[],{"trials":17858,"activeCount":99},[],{"trials":17860,"activeCount":99},[],{"trials":17862,"activeCount":99},[],{"intervention":17864,"totalTrials":245,"cells":17865},"JNJ-54175446",{"EARLY_PHASE1":17866,"PHASE1":17868,"PHASE2":17882,"PHASE3":17884,"PHASE4":17886,"NA":17888},{"trials":17867,"activeCount":99},[],{"trials":17869,"activeCount":99},[17870,17876],{"nctId":17871,"briefTitle":17872,"status":105,"phases":17873,"primaryCompletion":17035,"completion":17035,"start":17652,"enrollment":2472,"conditions":17874,"interventions":17875},"NCT02933762","A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma",[87],[15],[17864],{"nctId":17877,"briefTitle":17878,"status":105,"phases":17879,"primaryCompletion":12412,"completion":12412,"start":583,"enrollment":1507,"conditions":17880,"interventions":17881},"NCT02930694","A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants",[87],[15],[17864,17864],{"trials":17883,"activeCount":99},[],{"trials":17885,"activeCount":99},[],{"trials":17887,"activeCount":99},[],{"trials":17889,"activeCount":99},[],{"intervention":13911,"totalTrials":245,"cells":17891},{"EARLY_PHASE1":17892,"PHASE1":17894,"PHASE2":17914,"PHASE3":17916,"PHASE4":17918,"NA":17920},{"trials":17893,"activeCount":99},[],{"trials":17895,"activeCount":99},[17896,17900],{"nctId":13900,"briefTitle":13901,"status":105,"phases":17897,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":17898,"interventions":17899},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"nctId":17901,"briefTitle":17902,"status":105,"phases":17903,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":17904,"interventions":17905},"NCT03155893","A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants",[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],"ODV Placebo","SMV Placebo","AL-335 Placebo","ODV 200 mg","ODV 125 mg","ODV 100 mg","SMV 150 mg","AL-335 1200 mg",{"trials":17915,"activeCount":99},[],{"trials":17917,"activeCount":99},[],{"trials":17919,"activeCount":99},[],{"trials":17921,"activeCount":99},[],{"intervention":16956,"totalTrials":245,"cells":17923},{"EARLY_PHASE1":17924,"PHASE1":17926,"PHASE2":17936,"PHASE3":17938,"PHASE4":17940,"NA":17942},{"trials":17925,"activeCount":99},[],{"trials":17927,"activeCount":99},[17928,17932],{"nctId":16949,"briefTitle":16950,"status":105,"phases":17929,"primaryCompletion":16952,"completion":16952,"start":16953,"enrollment":745,"conditions":17930,"interventions":17931},[87],[15],[16956,16932],{"nctId":16958,"briefTitle":16959,"status":105,"phases":17933,"primaryCompletion":4605,"completion":4605,"start":16961,"enrollment":544,"conditions":17934,"interventions":17935},[87],[15],[16956,16932],{"trials":17937,"activeCount":99},[],{"trials":17939,"activeCount":99},[],{"trials":17941,"activeCount":99},[],{"trials":17943,"activeCount":99},[],{"intervention":17945,"totalTrials":245,"cells":17946},"JNJ-55375515",{"EARLY_PHASE1":17947,"PHASE1":17949,"PHASE2":17970,"PHASE3":17972,"PHASE4":17974,"NA":17976},{"trials":17948,"activeCount":99},[],{"trials":17950,"activeCount":99},[17951,17958],{"nctId":17952,"briefTitle":17953,"status":105,"phases":17954,"primaryCompletion":17652,"completion":17652,"start":3657,"enrollment":17955,"conditions":17956,"interventions":17957},"NCT02623491","Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-55375515 in Healthy Participants",[87],175,[15],[17945],{"nctId":17959,"briefTitle":17960,"status":105,"phases":17961,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":17962,"interventions":17963},"NCT03405441","A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants",[87],[15],[17964,17965,17966,17967,17968,17969,17945],"JNJ-55375515 Dose Level 1","JNJ-55375515 Dose Level 2","JNJ-55375515 Dose Level 3","JNJ-55375515 Dose Level 4","JNJ-55375515 Dose Level 5","JNJ-55375515 Dose Level 6",{"trials":17971,"activeCount":99},[],{"trials":17973,"activeCount":99},[],{"trials":17975,"activeCount":99},[],{"trials":17977,"activeCount":99},[],{"intervention":17979,"totalTrials":245,"cells":17980},"JNJ-54861911 3 mg",{"EARLY_PHASE1":17981,"PHASE1":17983,"PHASE2":18008,"PHASE3":18010,"PHASE4":18012,"NA":18014},{"trials":17982,"activeCount":99},[],{"trials":17984,"activeCount":99},[17985,17995],{"nctId":17986,"briefTitle":17987,"status":105,"phases":17988,"primaryCompletion":4223,"completion":4223,"start":3329,"enrollment":6987,"conditions":17989,"interventions":17990},"NCT01887535","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants",[87],[15],[17979,17991,17992,17993,17994],"JNJ-54861911 10 mg","JNJ-54861911 30 mg","JNJ-54861911 80 mg","JNJ-54861911 25 mg",{"nctId":17996,"briefTitle":17997,"status":105,"phases":17998,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":18000,"interventions":18001},"NCT01827982","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo",[87],56,[15],[18002,17979,18003,18004,18005,18006,18007,18003],"JNJ-54861911 1mg","JNJ-54861911 9 mg","JNJ-54861911 27 mg","JNJ-54861911 81 mg","JNJ-54861911 160 mg","JNJ-54861911 tbd",{"trials":18009,"activeCount":99},[],{"trials":18011,"activeCount":99},[],{"trials":18013,"activeCount":99},[],{"trials":18015,"activeCount":99},[],{"intervention":17991,"totalTrials":245,"cells":18017},{"EARLY_PHASE1":18018,"PHASE1":18020,"PHASE2":18033,"PHASE3":18035,"PHASE4":18037,"NA":18039},{"trials":18019,"activeCount":99},[],{"trials":18021,"activeCount":99},[18022,18026],{"nctId":17986,"briefTitle":17987,"status":105,"phases":18023,"primaryCompletion":4223,"completion":4223,"start":3329,"enrollment":6987,"conditions":18024,"interventions":18025},[87],[15],[17979,17991,17992,17993,17994],{"nctId":18027,"briefTitle":18028,"status":105,"phases":18029,"primaryCompletion":3612,"completion":3612,"start":4223,"enrollment":1192,"conditions":18030,"interventions":18031},"NCT01978548","A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease",[87],[4445],[17991,18032],"JNJ-54861911 50 mg",{"trials":18034,"activeCount":99},[],{"trials":18036,"activeCount":99},[],{"trials":18038,"activeCount":99},[],{"trials":18040,"activeCount":99},[],{"intervention":3345,"totalTrials":245,"cells":18042},{"EARLY_PHASE1":18043,"PHASE1":18045,"PHASE2":18055,"PHASE3":18057,"PHASE4":18059,"NA":18061},{"trials":18044,"activeCount":99},[],{"trials":18046,"activeCount":99},[18047,18051],{"nctId":3339,"briefTitle":3340,"status":105,"phases":18048,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":28,"conditions":18049,"interventions":18050},[87],[15],[518,3345],{"nctId":8352,"briefTitle":8353,"status":105,"phases":18052,"primaryCompletion":3597,"completion":3597,"start":3632,"enrollment":2515,"conditions":18053,"interventions":18054},[87],[15],[8357,1799,3345],{"trials":18056,"activeCount":99},[],{"trials":18058,"activeCount":99},[],{"trials":18060,"activeCount":99},[],{"trials":18062,"activeCount":99},[],{"intervention":17282,"totalTrials":245,"cells":18064},{"EARLY_PHASE1":18065,"PHASE1":18067,"PHASE2":18077,"PHASE3":18079,"PHASE4":18081,"NA":18083},{"trials":18066,"activeCount":99},[],{"trials":18068,"activeCount":99},[18069,18073],{"nctId":17277,"briefTitle":17278,"status":105,"phases":18070,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":18071,"interventions":18072},[87],[15],[5826,17270,17282,17282,5826,17270],{"nctId":17284,"briefTitle":17285,"status":105,"phases":18074,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":18075,"interventions":18076},[87],[15],[5826,17270,17282,5826,17270,17282],{"trials":18078,"activeCount":99},[],{"trials":18080,"activeCount":99},[],{"trials":18082,"activeCount":99},[],{"trials":18084,"activeCount":99},[],{"intervention":17771,"totalTrials":245,"cells":18086},{"EARLY_PHASE1":18087,"PHASE1":18089,"PHASE2":18099,"PHASE3":18101,"PHASE4":18103,"NA":18105},{"trials":18088,"activeCount":99},[],{"trials":18090,"activeCount":99},[18091,18095],{"nctId":17765,"briefTitle":17766,"status":137,"phases":18092,"primaryCompletion":13208,"completion":13208,"start":17768,"enrollment":99,"conditions":18093,"interventions":18094},[87],[505],[17219,17771,17772],{"nctId":17901,"briefTitle":17902,"status":105,"phases":18096,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":18097,"interventions":18098},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":18100,"activeCount":99},[],{"trials":18102,"activeCount":99},[],{"trials":18104,"activeCount":99},[],{"trials":18106,"activeCount":99},[],{"intervention":18108,"totalTrials":245,"cells":18109},"A",{"EARLY_PHASE1":18110,"PHASE1":18112,"PHASE2":18128,"PHASE3":18130,"PHASE4":18132,"NA":18134},{"trials":18111,"activeCount":99},[],{"trials":18113,"activeCount":99},[18114,18122],{"nctId":18115,"briefTitle":18116,"status":105,"phases":18117,"primaryCompletion":3342,"completion":3342,"start":5878,"enrollment":18118,"conditions":18119,"interventions":18120},"NCT01463228","A Study to Assess the Bioequivalence of Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers",[87],83,[15],[18108,18121],"B",{"nctId":18123,"briefTitle":18124,"status":105,"phases":18125,"primaryCompletion":5867,"completion":5867,"start":8891,"enrollment":3586,"conditions":18126,"interventions":18127},"NCT01459094","Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers",[87],[15],[18108,18121],{"trials":18129,"activeCount":99},[],{"trials":18131,"activeCount":99},[],{"trials":18133,"activeCount":99},[],{"trials":18135,"activeCount":99},[],{"intervention":18121,"totalTrials":245,"cells":18137},{"EARLY_PHASE1":18138,"PHASE1":18140,"PHASE2":18150,"PHASE3":18152,"PHASE4":18154,"NA":18156},{"trials":18139,"activeCount":99},[],{"trials":18141,"activeCount":99},[18142,18146],{"nctId":18115,"briefTitle":18116,"status":105,"phases":18143,"primaryCompletion":3342,"completion":3342,"start":5878,"enrollment":18118,"conditions":18144,"interventions":18145},[87],[15],[18108,18121],{"nctId":18123,"briefTitle":18124,"status":105,"phases":18147,"primaryCompletion":5867,"completion":5867,"start":8891,"enrollment":3586,"conditions":18148,"interventions":18149},[87],[15],[18108,18121],{"trials":18151,"activeCount":99},[],{"trials":18153,"activeCount":99},[],{"trials":18155,"activeCount":99},[],{"trials":18157,"activeCount":99},[],{"intervention":13004,"totalTrials":245,"cells":18159},{"EARLY_PHASE1":18160,"PHASE1":18162,"PHASE2":18172,"PHASE3":18174,"PHASE4":18176,"NA":18178},{"trials":18161,"activeCount":99},[],{"trials":18163,"activeCount":99},[18164,18168],{"nctId":17102,"briefTitle":17103,"status":105,"phases":18165,"primaryCompletion":17105,"completion":17106,"start":3791,"enrollment":1132,"conditions":18166,"interventions":18167},[87],[15],[17109,17110,13004,17077],{"nctId":12999,"briefTitle":13000,"status":105,"phases":18169,"primaryCompletion":3460,"completion":3460,"start":7350,"enrollment":544,"conditions":18170,"interventions":18171},[87],[15],[12976,13004],{"trials":18173,"activeCount":99},[],{"trials":18175,"activeCount":99},[],{"trials":18177,"activeCount":99},[],{"trials":18179,"activeCount":99},[],{"intervention":18181,"totalTrials":245,"cells":18182},"Treatment A",{"EARLY_PHASE1":18183,"PHASE1":18185,"PHASE2":18203,"PHASE3":18205,"PHASE4":18207,"NA":18209},{"trials":18184,"activeCount":99},[],{"trials":18186,"activeCount":99},[18187,18196],{"nctId":18188,"briefTitle":18189,"status":105,"phases":18190,"primaryCompletion":5888,"completion":5888,"start":5899,"enrollment":9010,"conditions":18191,"interventions":18192},"NCT01643889","A Study to Evaluate the Effects of Domperidone on Cardiac Repolarization in Healthy Volunteers",[87],[15],[18181,18193,18194,18195],"Treatment B","Treatment C","Treatment D",{"nctId":18197,"briefTitle":18198,"status":105,"phases":18199,"primaryCompletion":6823,"completion":6823,"start":3328,"enrollment":1507,"conditions":18200,"interventions":18201},"NCT01897389","A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants",[87],[3331],[18181,18193,18194,18195,18202],"Treatment E",{"trials":18204,"activeCount":99},[],{"trials":18206,"activeCount":99},[],{"trials":18208,"activeCount":99},[],{"trials":18210,"activeCount":99},[],{"intervention":18193,"totalTrials":245,"cells":18212},{"EARLY_PHASE1":18213,"PHASE1":18215,"PHASE2":18225,"PHASE3":18227,"PHASE4":18229,"NA":18231},{"trials":18214,"activeCount":99},[],{"trials":18216,"activeCount":99},[18217,18221],{"nctId":18188,"briefTitle":18189,"status":105,"phases":18218,"primaryCompletion":5888,"completion":5888,"start":5899,"enrollment":9010,"conditions":18219,"interventions":18220},[87],[15],[18181,18193,18194,18195],{"nctId":18197,"briefTitle":18198,"status":105,"phases":18222,"primaryCompletion":6823,"completion":6823,"start":3328,"enrollment":1507,"conditions":18223,"interventions":18224},[87],[3331],[18181,18193,18194,18195,18202],{"trials":18226,"activeCount":99},[],{"trials":18228,"activeCount":99},[],{"trials":18230,"activeCount":99},[],{"trials":18232,"activeCount":99},[],{"intervention":18194,"totalTrials":245,"cells":18234},{"EARLY_PHASE1":18235,"PHASE1":18237,"PHASE2":18247,"PHASE3":18249,"PHASE4":18251,"NA":18253},{"trials":18236,"activeCount":99},[],{"trials":18238,"activeCount":99},[18239,18243],{"nctId":18188,"briefTitle":18189,"status":105,"phases":18240,"primaryCompletion":5888,"completion":5888,"start":5899,"enrollment":9010,"conditions":18241,"interventions":18242},[87],[15],[18181,18193,18194,18195],{"nctId":18197,"briefTitle":18198,"status":105,"phases":18244,"primaryCompletion":6823,"completion":6823,"start":3328,"enrollment":1507,"conditions":18245,"interventions":18246},[87],[3331],[18181,18193,18194,18195,18202],{"trials":18248,"activeCount":99},[],{"trials":18250,"activeCount":99},[],{"trials":18252,"activeCount":99},[],{"trials":18254,"activeCount":99},[],{"intervention":18195,"totalTrials":245,"cells":18256},{"EARLY_PHASE1":18257,"PHASE1":18259,"PHASE2":18269,"PHASE3":18271,"PHASE4":18273,"NA":18275},{"trials":18258,"activeCount":99},[],{"trials":18260,"activeCount":99},[18261,18265],{"nctId":18188,"briefTitle":18189,"status":105,"phases":18262,"primaryCompletion":5888,"completion":5888,"start":5899,"enrollment":9010,"conditions":18263,"interventions":18264},[87],[15],[18181,18193,18194,18195],{"nctId":18197,"briefTitle":18198,"status":105,"phases":18266,"primaryCompletion":6823,"completion":6823,"start":3328,"enrollment":1507,"conditions":18267,"interventions":18268},[87],[3331],[18181,18193,18194,18195,18202],{"trials":18270,"activeCount":99},[],{"trials":18272,"activeCount":99},[],{"trials":18274,"activeCount":99},[],{"trials":18276,"activeCount":99},[],{"intervention":18278,"totalTrials":245,"cells":18279},"Seltorexant 40 mg",{"EARLY_PHASE1":18280,"PHASE1":18282,"PHASE2":18302,"PHASE3":18304,"PHASE4":18306,"NA":18308},{"trials":18281,"activeCount":99},[],{"trials":18283,"activeCount":99},[18284,18292],{"nctId":18285,"briefTitle":18286,"status":105,"phases":18287,"primaryCompletion":18288,"completion":18288,"start":12462,"enrollment":12482,"conditions":18289,"interventions":18290},"NCT03438461","A Study to Evaluate the Relative Oral Bioavailability of Seltorexant (JNJ-42847922) After Administration of 3 Different Formulations in Healthy Participants Under Fasted and Semi-fasted Conditions",[87],"2018-05-30",[15],[18278,18291],"Seltorexant 20 mg",{"nctId":18293,"briefTitle":18294,"status":105,"phases":18295,"primaryCompletion":18296,"completion":18297,"start":18298,"enrollment":492,"conditions":18299,"interventions":18301},"NCT03796026","A Study to Assess the Effect of Seltorexant Compared to Placebo on Respiration During Sleep in Adult Participants With Obstructive Sleep Apnea",[87],"2019-06-07","2019-06-14","2019-01-04",[18300],"Sleep Apnea, Obstructive",[18278],{"trials":18303,"activeCount":99},[],{"trials":18305,"activeCount":99},[],{"trials":18307,"activeCount":99},[],{"trials":18309,"activeCount":99},[],{"intervention":9955,"totalTrials":245,"cells":18311},{"EARLY_PHASE1":18312,"PHASE1":18314,"PHASE2":18324,"PHASE3":18326,"PHASE4":18328,"NA":18330},{"trials":18313,"activeCount":99},[],{"trials":18315,"activeCount":99},[18316,18320],{"nctId":9948,"briefTitle":9949,"status":125,"phases":18317,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":18318,"interventions":18319},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"nctId":17226,"briefTitle":17227,"status":105,"phases":18321,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":18322,"interventions":18323},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":18325,"activeCount":99},[],{"trials":18327,"activeCount":99},[],{"trials":18329,"activeCount":99},[],{"trials":18331,"activeCount":99},[],{"intervention":9956,"totalTrials":245,"cells":18333},{"EARLY_PHASE1":18334,"PHASE1":18336,"PHASE2":18346,"PHASE3":18348,"PHASE4":18350,"NA":18352},{"trials":18335,"activeCount":99},[],{"trials":18337,"activeCount":99},[18338,18342],{"nctId":9948,"briefTitle":9949,"status":125,"phases":18339,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":18340,"interventions":18341},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"nctId":17226,"briefTitle":17227,"status":105,"phases":18343,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":18344,"interventions":18345},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":18347,"activeCount":99},[],{"trials":18349,"activeCount":99},[],{"trials":18351,"activeCount":99},[],{"trials":18353,"activeCount":99},[],{"intervention":9959,"totalTrials":245,"cells":18355},{"EARLY_PHASE1":18356,"PHASE1":18358,"PHASE2":18368,"PHASE3":18370,"PHASE4":18372,"NA":18374},{"trials":18357,"activeCount":99},[],{"trials":18359,"activeCount":99},[18360,18364],{"nctId":9948,"briefTitle":9949,"status":125,"phases":18361,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":18362,"interventions":18363},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"nctId":17226,"briefTitle":17227,"status":105,"phases":18365,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":18366,"interventions":18367},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":18369,"activeCount":99},[],{"trials":18371,"activeCount":99},[],{"trials":18373,"activeCount":99},[],{"trials":18375,"activeCount":99},[],{"intervention":18377,"totalTrials":468,"cells":18378},"JNJ-72537634",{"EARLY_PHASE1":18379,"PHASE1":18381,"PHASE2":18390,"PHASE3":18392,"PHASE4":18394,"NA":18396},{"trials":18380,"activeCount":99},[],{"trials":18382,"activeCount":99},[18383],{"nctId":18384,"briefTitle":18385,"status":105,"phases":18386,"primaryCompletion":18387,"completion":18387,"start":12491,"enrollment":3471,"conditions":18388,"interventions":18389},"NCT03931447","A Safety and Tolerability Study of JNJ-72537634 in Healthy Participants",[87],"2020-02-10",[15],[18377],{"trials":18391,"activeCount":99},[],{"trials":18393,"activeCount":99},[],{"trials":18395,"activeCount":99},[],{"trials":18397,"activeCount":99},[],{"intervention":18399,"totalTrials":468,"cells":18400},"Guselkumab (SC): Dose 1",{"EARLY_PHASE1":18401,"PHASE1":18403,"PHASE2":18417,"PHASE3":18419,"PHASE4":18421,"NA":18423},{"trials":18402,"activeCount":99},[],{"trials":18404,"activeCount":99},[18405],{"nctId":18406,"briefTitle":18407,"status":105,"phases":18408,"primaryCompletion":18409,"completion":18409,"start":18410,"enrollment":656,"conditions":18411,"interventions":18412},"NCT04030533","Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants",[87],"2020-12-31","2019-11-29",[15],[18399,18413,18414,18415,18416],"Guselkumab (SC): Dose 2","Guselkumab (IV): Dose 1","Guselkumab (IV): Dose 2","Ustekinumab 6 mg\u002FmL",{"trials":18418,"activeCount":99},[],{"trials":18420,"activeCount":99},[],{"trials":18422,"activeCount":99},[],{"trials":18424,"activeCount":99},[],{"intervention":18413,"totalTrials":468,"cells":18426},{"EARLY_PHASE1":18427,"PHASE1":18429,"PHASE2":18435,"PHASE3":18437,"PHASE4":18439,"NA":18441},{"trials":18428,"activeCount":99},[],{"trials":18430,"activeCount":99},[18431],{"nctId":18406,"briefTitle":18407,"status":105,"phases":18432,"primaryCompletion":18409,"completion":18409,"start":18410,"enrollment":656,"conditions":18433,"interventions":18434},[87],[15],[18399,18413,18414,18415,18416],{"trials":18436,"activeCount":99},[],{"trials":18438,"activeCount":99},[],{"trials":18440,"activeCount":99},[],{"trials":18442,"activeCount":99},[],{"intervention":18414,"totalTrials":468,"cells":18444},{"EARLY_PHASE1":18445,"PHASE1":18447,"PHASE2":18453,"PHASE3":18455,"PHASE4":18457,"NA":18459},{"trials":18446,"activeCount":99},[],{"trials":18448,"activeCount":99},[18449],{"nctId":18406,"briefTitle":18407,"status":105,"phases":18450,"primaryCompletion":18409,"completion":18409,"start":18410,"enrollment":656,"conditions":18451,"interventions":18452},[87],[15],[18399,18413,18414,18415,18416],{"trials":18454,"activeCount":99},[],{"trials":18456,"activeCount":99},[],{"trials":18458,"activeCount":99},[],{"trials":18460,"activeCount":99},[],{"intervention":18415,"totalTrials":468,"cells":18462},{"EARLY_PHASE1":18463,"PHASE1":18465,"PHASE2":18471,"PHASE3":18473,"PHASE4":18475,"NA":18477},{"trials":18464,"activeCount":99},[],{"trials":18466,"activeCount":99},[18467],{"nctId":18406,"briefTitle":18407,"status":105,"phases":18468,"primaryCompletion":18409,"completion":18409,"start":18410,"enrollment":656,"conditions":18469,"interventions":18470},[87],[15],[18399,18413,18414,18415,18416],{"trials":18472,"activeCount":99},[],{"trials":18474,"activeCount":99},[],{"trials":18476,"activeCount":99},[],{"trials":18478,"activeCount":99},[],{"intervention":18416,"totalTrials":468,"cells":18480},{"EARLY_PHASE1":18481,"PHASE1":18483,"PHASE2":18489,"PHASE3":18491,"PHASE4":18493,"NA":18495},{"trials":18482,"activeCount":99},[],{"trials":18484,"activeCount":99},[18485],{"nctId":18406,"briefTitle":18407,"status":105,"phases":18486,"primaryCompletion":18409,"completion":18409,"start":18410,"enrollment":656,"conditions":18487,"interventions":18488},[87],[15],[18399,18413,18414,18415,18416],{"trials":18490,"activeCount":99},[],{"trials":18492,"activeCount":99},[],{"trials":18494,"activeCount":99},[],{"trials":18496,"activeCount":99},[],{"intervention":17091,"totalTrials":468,"cells":18498},{"EARLY_PHASE1":18499,"PHASE1":18501,"PHASE2":18507,"PHASE3":18509,"PHASE4":18511,"NA":18513},{"trials":18500,"activeCount":99},[],{"trials":18502,"activeCount":99},[18503],{"nctId":17084,"briefTitle":17085,"status":105,"phases":18504,"primaryCompletion":17087,"completion":17087,"start":4008,"enrollment":12386,"conditions":18505,"interventions":18506},[87],[15],[17077,17090,17091],{"trials":18508,"activeCount":99},[],{"trials":18510,"activeCount":99},[],{"trials":18512,"activeCount":99},[],{"trials":18514,"activeCount":99},[],{"intervention":3315,"totalTrials":468,"cells":18516},{"EARLY_PHASE1":18517,"PHASE1":18519,"PHASE2":18525,"PHASE3":18527,"PHASE4":18529,"NA":18531},{"trials":18518,"activeCount":99},[],{"trials":18520,"activeCount":99},[18521],{"nctId":3306,"briefTitle":3307,"status":105,"phases":18522,"primaryCompletion":3309,"completion":3310,"start":3311,"enrollment":3312,"conditions":18523,"interventions":18524},[87],[2490],[518,3315],{"trials":18526,"activeCount":99},[],{"trials":18528,"activeCount":99},[],{"trials":18530,"activeCount":99},[],{"trials":18532,"activeCount":99},[],{"intervention":2492,"totalTrials":468,"cells":18534},{"EARLY_PHASE1":18535,"PHASE1":18537,"PHASE2":18543,"PHASE3":18545,"PHASE4":18547,"NA":18549},{"trials":18536,"activeCount":99},[],{"trials":18538,"activeCount":99},[18539],{"nctId":2483,"briefTitle":2484,"status":105,"phases":18540,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":492,"conditions":18541,"interventions":18542},[87],[2490],[518,496,2492,2493],{"trials":18544,"activeCount":99},[],{"trials":18546,"activeCount":99},[],{"trials":18548,"activeCount":99},[],{"trials":18550,"activeCount":99},[],{"intervention":2493,"totalTrials":468,"cells":18552},{"EARLY_PHASE1":18553,"PHASE1":18555,"PHASE2":18561,"PHASE3":18563,"PHASE4":18565,"NA":18567},{"trials":18554,"activeCount":99},[],{"trials":18556,"activeCount":99},[18557],{"nctId":2483,"briefTitle":2484,"status":105,"phases":18558,"primaryCompletion":2486,"completion":2487,"start":2488,"enrollment":492,"conditions":18559,"interventions":18560},[87],[2490],[518,496,2492,2493],{"trials":18562,"activeCount":99},[],{"trials":18564,"activeCount":99},[],{"trials":18566,"activeCount":99},[],{"trials":18568,"activeCount":99},[],{"intervention":4295,"totalTrials":468,"cells":18570},{"EARLY_PHASE1":18571,"PHASE1":18573,"PHASE2":18579,"PHASE3":18581,"PHASE4":18583,"NA":18585},{"trials":18572,"activeCount":99},[],{"trials":18574,"activeCount":99},[18575],{"nctId":4289,"briefTitle":4290,"status":125,"phases":18576,"primaryCompletion":2364,"completion":2364,"start":4292,"enrollment":12,"conditions":18577,"interventions":18578},[87],[15],[4295,173],{"trials":18580,"activeCount":99},[],{"trials":18582,"activeCount":99},[],{"trials":18584,"activeCount":99},[],{"trials":18586,"activeCount":99},[],{"intervention":12786,"totalTrials":468,"cells":18588},{"EARLY_PHASE1":18589,"PHASE1":18591,"PHASE2":18597,"PHASE3":18599,"PHASE4":18601,"NA":18603},{"trials":18590,"activeCount":99},[],{"trials":18592,"activeCount":99},[18593],{"nctId":12779,"briefTitle":12780,"status":137,"phases":18594,"primaryCompletion":12782,"completion":12783,"start":4605,"enrollment":99,"conditions":18595,"interventions":18596},[87],[15],[12224,12786],{"trials":18598,"activeCount":99},[],{"trials":18600,"activeCount":99},[],{"trials":18602,"activeCount":99},[],{"trials":18604,"activeCount":99},[],{"intervention":17486,"totalTrials":468,"cells":18606},{"EARLY_PHASE1":18607,"PHASE1":18609,"PHASE2":18615,"PHASE3":18617,"PHASE4":18619,"NA":18621},{"trials":18608,"activeCount":99},[],{"trials":18610,"activeCount":99},[18611],{"nctId":17481,"briefTitle":17482,"status":105,"phases":18612,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1532,"conditions":18613,"interventions":18614},[87],[3667],[17474,17486,17487],{"trials":18616,"activeCount":99},[],{"trials":18618,"activeCount":99},[],{"trials":18620,"activeCount":99},[],{"trials":18622,"activeCount":99},[],{"intervention":17487,"totalTrials":468,"cells":18624},{"EARLY_PHASE1":18625,"PHASE1":18627,"PHASE2":18633,"PHASE3":18635,"PHASE4":18637,"NA":18639},{"trials":18626,"activeCount":99},[],{"trials":18628,"activeCount":99},[18629],{"nctId":17481,"briefTitle":17482,"status":105,"phases":18630,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1532,"conditions":18631,"interventions":18632},[87],[3667],[17474,17486,17487],{"trials":18634,"activeCount":99},[],{"trials":18636,"activeCount":99},[],{"trials":18638,"activeCount":99},[],{"trials":18640,"activeCount":99},[],{"intervention":17542,"totalTrials":468,"cells":18642},{"EARLY_PHASE1":18643,"PHASE1":18645,"PHASE2":18651,"PHASE3":18653,"PHASE4":18655,"NA":18657},{"trials":18644,"activeCount":99},[],{"trials":18646,"activeCount":99},[18647],{"nctId":17536,"briefTitle":17537,"status":105,"phases":18648,"completion":5867,"start":15332,"enrollment":678,"conditions":18649,"interventions":18650},[87],[17540],[17529,17542,17529],{"trials":18652,"activeCount":99},[],{"trials":18654,"activeCount":99},[],{"trials":18656,"activeCount":99},[],{"trials":18658,"activeCount":99},[],{"intervention":18660,"totalTrials":468,"cells":18661},"JNJ-64041575",{"EARLY_PHASE1":18662,"PHASE1":18664,"PHASE2":18674,"PHASE3":18676,"PHASE4":18678,"NA":18680},{"trials":18663,"activeCount":99},[],{"trials":18665,"activeCount":99},[18666],{"nctId":18667,"briefTitle":18668,"status":105,"phases":18669,"primaryCompletion":18670,"completion":18670,"start":18671,"enrollment":1972,"conditions":18672,"interventions":18673},"NCT03010059","A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations",[87],"2017-05-29","2017-02-06",[15],[18660,18660],{"trials":18675,"activeCount":99},[],{"trials":18677,"activeCount":99},[],{"trials":18679,"activeCount":99},[],{"trials":18681,"activeCount":99},[],{"intervention":17099,"totalTrials":468,"cells":18683},{"EARLY_PHASE1":18684,"PHASE1":18686,"PHASE2":18692,"PHASE3":18694,"PHASE4":18696,"NA":18698},{"trials":18685,"activeCount":99},[],{"trials":18687,"activeCount":99},[18688],{"nctId":17093,"briefTitle":17094,"status":105,"phases":18689,"primaryCompletion":17096,"completion":17096,"start":4212,"enrollment":5539,"conditions":18690,"interventions":18691},[87],[15],[17099,17077,17100,17090],{"trials":18693,"activeCount":99},[],{"trials":18695,"activeCount":99},[],{"trials":18697,"activeCount":99},[],{"trials":18699,"activeCount":99},[],{"intervention":17100,"totalTrials":468,"cells":18701},{"EARLY_PHASE1":18702,"PHASE1":18704,"PHASE2":18710,"PHASE3":18712,"PHASE4":18714,"NA":18716},{"trials":18703,"activeCount":99},[],{"trials":18705,"activeCount":99},[18706],{"nctId":17093,"briefTitle":17094,"status":105,"phases":18707,"primaryCompletion":17096,"completion":17096,"start":4212,"enrollment":5539,"conditions":18708,"interventions":18709},[87],[15],[17099,17077,17100,17090],{"trials":18711,"activeCount":99},[],{"trials":18713,"activeCount":99},[],{"trials":18715,"activeCount":99},[],{"trials":18717,"activeCount":99},[],{"intervention":3810,"totalTrials":468,"cells":18719},{"EARLY_PHASE1":18720,"PHASE1":18722,"PHASE2":18728,"PHASE3":18730,"PHASE4":18732,"NA":18734},{"trials":18721,"activeCount":99},[],{"trials":18723,"activeCount":99},[18724],{"nctId":3803,"briefTitle":3804,"status":105,"phases":18725,"primaryCompletion":3806,"completion":3806,"start":3807,"enrollment":3312,"conditions":18726,"interventions":18727},[87],[15],[75,3810,1799],{"trials":18729,"activeCount":99},[],{"trials":18731,"activeCount":99},[],{"trials":18733,"activeCount":99},[],{"trials":18735,"activeCount":99},[],{"intervention":13084,"totalTrials":468,"cells":18737},{"EARLY_PHASE1":18738,"PHASE1":18740,"PHASE2":18746,"PHASE3":18748,"PHASE4":18750,"NA":18752},{"trials":18739,"activeCount":99},[],{"trials":18741,"activeCount":99},[18742],{"nctId":13078,"briefTitle":13079,"status":105,"phases":18743,"primaryCompletion":12432,"completion":12432,"start":13081,"enrollment":8144,"conditions":18744,"interventions":18745},[87],[15],[4887,13084],{"trials":18747,"activeCount":99},[],{"trials":18749,"activeCount":99},[],{"trials":18751,"activeCount":99},[],{"trials":18753,"activeCount":99},[],{"intervention":13093,"totalTrials":468,"cells":18755},{"EARLY_PHASE1":18756,"PHASE1":18758,"PHASE2":18764,"PHASE3":18766,"PHASE4":18768,"NA":18770},{"trials":18757,"activeCount":99},[],{"trials":18759,"activeCount":99},[18760],{"nctId":13086,"briefTitle":13087,"status":105,"phases":18761,"primaryCompletion":13089,"completion":13089,"start":13090,"enrollment":3138,"conditions":18762,"interventions":18763},[87],[15],[4884,13093,13094,4887],{"trials":18765,"activeCount":99},[],{"trials":18767,"activeCount":99},[],{"trials":18769,"activeCount":99},[],{"trials":18771,"activeCount":99},[],{"intervention":13094,"totalTrials":468,"cells":18773},{"EARLY_PHASE1":18774,"PHASE1":18776,"PHASE2":18782,"PHASE3":18784,"PHASE4":18786,"NA":18788},{"trials":18775,"activeCount":99},[],{"trials":18777,"activeCount":99},[18778],{"nctId":13086,"briefTitle":13087,"status":105,"phases":18779,"primaryCompletion":13089,"completion":13089,"start":13090,"enrollment":3138,"conditions":18780,"interventions":18781},[87],[15],[4884,13093,13094,4887],{"trials":18783,"activeCount":99},[],{"trials":18785,"activeCount":99},[],{"trials":18787,"activeCount":99},[],{"trials":18789,"activeCount":99},[],{"intervention":18791,"totalTrials":468,"cells":18792},"JNJ-26528398",{"EARLY_PHASE1":18793,"PHASE1":18795,"PHASE2":18803,"PHASE3":18805,"PHASE4":18807,"NA":18809},{"trials":18794,"activeCount":99},[],{"trials":18796,"activeCount":99},[18797],{"nctId":18798,"briefTitle":18799,"status":105,"phases":18800,"primaryCompletion":2487,"completion":2487,"start":4850,"enrollment":28,"conditions":18801,"interventions":18802},"NCT01520142","Safety, Tolerability and Pharmacodynamic Activity of JNJ-26528398 in Healthy Male Participants",[87],[3667],[18791],{"trials":18804,"activeCount":99},[],{"trials":18806,"activeCount":99},[],{"trials":18808,"activeCount":99},[],{"trials":18810,"activeCount":99},[],{"intervention":12457,"totalTrials":468,"cells":18812},{"EARLY_PHASE1":18813,"PHASE1":18815,"PHASE2":18821,"PHASE3":18823,"PHASE4":18825,"NA":18827},{"trials":18814,"activeCount":99},[],{"trials":18816,"activeCount":99},[18817],{"nctId":12451,"briefTitle":12452,"status":125,"phases":18818,"primaryCompletion":4257,"completion":4257,"start":3378,"enrollment":503,"conditions":18819,"interventions":18820},[87],[15],[12444,12456,12457],{"trials":18822,"activeCount":99},[],{"trials":18824,"activeCount":99},[],{"trials":18826,"activeCount":99},[],{"trials":18828,"activeCount":99},[],{"intervention":4512,"totalTrials":468,"cells":18830},{"EARLY_PHASE1":18831,"PHASE1":18833,"PHASE2":18839,"PHASE3":18841,"PHASE4":18843,"NA":18845},{"trials":18832,"activeCount":99},[],{"trials":18834,"activeCount":99},[18835],{"nctId":4504,"briefTitle":4505,"status":105,"phases":18836,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":19,"conditions":18837,"interventions":18838},[87],[15],[4497,4512,4513],{"trials":18840,"activeCount":99},[],{"trials":18842,"activeCount":99},[],{"trials":18844,"activeCount":99},[],{"trials":18846,"activeCount":99},[],{"intervention":4513,"totalTrials":468,"cells":18848},{"EARLY_PHASE1":18849,"PHASE1":18851,"PHASE2":18857,"PHASE3":18859,"PHASE4":18861,"NA":18863},{"trials":18850,"activeCount":99},[],{"trials":18852,"activeCount":99},[18853],{"nctId":4504,"briefTitle":4505,"status":105,"phases":18854,"primaryCompletion":4507,"completion":4508,"start":4509,"enrollment":19,"conditions":18855,"interventions":18856},[87],[15],[4497,4512,4513],{"trials":18858,"activeCount":99},[],{"trials":18860,"activeCount":99},[],{"trials":18862,"activeCount":99},[],{"trials":18864,"activeCount":99},[],{"intervention":18866,"totalTrials":468,"cells":18867},"Mebendazole - fasted state",{"EARLY_PHASE1":18868,"PHASE1":18870,"PHASE2":18879,"PHASE3":18881,"PHASE4":18883,"NA":18885},{"trials":18869,"activeCount":99},[],{"trials":18871,"activeCount":99},[18872],{"nctId":18873,"briefTitle":18874,"status":105,"phases":18875,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":468,"conditions":18876,"interventions":18877},"NCT02051738","A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants",[87],[15],[18866,18878],"Mebendazole - fed state",{"trials":18880,"activeCount":99},[],{"trials":18882,"activeCount":99},[],{"trials":18884,"activeCount":99},[],{"trials":18886,"activeCount":99},[],{"intervention":18878,"totalTrials":468,"cells":18888},{"EARLY_PHASE1":18889,"PHASE1":18891,"PHASE2":18897,"PHASE3":18899,"PHASE4":18901,"NA":18903},{"trials":18890,"activeCount":99},[],{"trials":18892,"activeCount":99},[18893],{"nctId":18873,"briefTitle":18874,"status":105,"phases":18894,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":468,"conditions":18895,"interventions":18896},[87],[15],[18866,18878],{"trials":18898,"activeCount":99},[],{"trials":18900,"activeCount":99},[],{"trials":18902,"activeCount":99},[],{"trials":18904,"activeCount":99},[],{"intervention":18906,"totalTrials":468,"cells":18907},"Treatment A: Canagliflozin",{"EARLY_PHASE1":18908,"PHASE1":18910,"PHASE2":18920,"PHASE3":18922,"PHASE4":18924,"NA":18926},{"trials":18909,"activeCount":99},[],{"trials":18911,"activeCount":99},[18912],{"nctId":18913,"briefTitle":18914,"status":105,"phases":18915,"primaryCompletion":5867,"completion":5867,"start":5878,"enrollment":1015,"conditions":18916,"interventions":18917},"NCT01463774","A Study to Assess the Bioequivalence of 2 Fixed Dose Combination Tablets of Canagliflozin and Metformin Immediate Release (IR) With Respect to the Individual Components of Canagliflozin and Metformin IR Tablets in Healthy Volunteers",[87],[15],[18906,18918,18919],"Treatment A: Metformin IR","Treatment B: Canagliflozin\u002Fmetformin fixed dose combination",{"trials":18921,"activeCount":99},[],{"trials":18923,"activeCount":99},[],{"trials":18925,"activeCount":99},[],{"trials":18927,"activeCount":99},[],{"intervention":18918,"totalTrials":468,"cells":18929},{"EARLY_PHASE1":18930,"PHASE1":18932,"PHASE2":18938,"PHASE3":18940,"PHASE4":18942,"NA":18944},{"trials":18931,"activeCount":99},[],{"trials":18933,"activeCount":99},[18934],{"nctId":18913,"briefTitle":18914,"status":105,"phases":18935,"primaryCompletion":5867,"completion":5867,"start":5878,"enrollment":1015,"conditions":18936,"interventions":18937},[87],[15],[18906,18918,18919],{"trials":18939,"activeCount":99},[],{"trials":18941,"activeCount":99},[],{"trials":18943,"activeCount":99},[],{"trials":18945,"activeCount":99},[],{"intervention":18919,"totalTrials":468,"cells":18947},{"EARLY_PHASE1":18948,"PHASE1":18950,"PHASE2":18956,"PHASE3":18958,"PHASE4":18960,"NA":18962},{"trials":18949,"activeCount":99},[],{"trials":18951,"activeCount":99},[18952],{"nctId":18913,"briefTitle":18914,"status":105,"phases":18953,"primaryCompletion":5867,"completion":5867,"start":5878,"enrollment":1015,"conditions":18954,"interventions":18955},[87],[15],[18906,18918,18919],{"trials":18957,"activeCount":99},[],{"trials":18959,"activeCount":99},[],{"trials":18961,"activeCount":99},[],{"trials":18963,"activeCount":99},[],{"intervention":5504,"totalTrials":468,"cells":18965},{"EARLY_PHASE1":18966,"PHASE1":18968,"PHASE2":18974,"PHASE3":18976,"PHASE4":18978,"NA":18980},{"trials":18967,"activeCount":99},[],{"trials":18969,"activeCount":99},[18970],{"nctId":5498,"briefTitle":5499,"status":105,"phases":18971,"primaryCompletion":3359,"completion":3359,"start":2218,"enrollment":12,"conditions":18972,"interventions":18973},[87],[5502],[4318,5504,5505],{"trials":18975,"activeCount":99},[],{"trials":18977,"activeCount":99},[],{"trials":18979,"activeCount":99},[],{"trials":18981,"activeCount":99},[],{"intervention":5505,"totalTrials":468,"cells":18983},{"EARLY_PHASE1":18984,"PHASE1":18986,"PHASE2":18992,"PHASE3":18994,"PHASE4":18996,"NA":18998},{"trials":18985,"activeCount":99},[],{"trials":18987,"activeCount":99},[18988],{"nctId":5498,"briefTitle":5499,"status":105,"phases":18989,"primaryCompletion":3359,"completion":3359,"start":2218,"enrollment":12,"conditions":18990,"interventions":18991},[87],[5502],[4318,5504,5505],{"trials":18993,"activeCount":99},[],{"trials":18995,"activeCount":99},[],{"trials":18997,"activeCount":99},[],{"trials":18999,"activeCount":99},[],{"intervention":4305,"totalTrials":468,"cells":19001},{"EARLY_PHASE1":19002,"PHASE1":19004,"PHASE2":19010,"PHASE3":19012,"PHASE4":19014,"NA":19016},{"trials":19003,"activeCount":99},[],{"trials":19005,"activeCount":99},[19006],{"nctId":4297,"briefTitle":4298,"status":137,"phases":19007,"primaryCompletion":4300,"completion":4301,"start":4193,"enrollment":99,"conditions":19008,"interventions":19009},[87],[15],[4304,173,4305],{"trials":19011,"activeCount":99},[],{"trials":19013,"activeCount":99},[],{"trials":19015,"activeCount":99},[],{"trials":19017,"activeCount":99},[],{"intervention":13749,"totalTrials":468,"cells":19019},{"EARLY_PHASE1":19020,"PHASE1":19022,"PHASE2":19028,"PHASE3":19030,"PHASE4":19032,"NA":19034},{"trials":19021,"activeCount":99},[],{"trials":19023,"activeCount":99},[19024],{"nctId":13744,"briefTitle":13745,"status":105,"phases":19025,"primaryCompletion":4348,"completion":4348,"start":6033,"enrollment":479,"conditions":19026,"interventions":19027},[87],[15],[13737,13749,13750],{"trials":19029,"activeCount":99},[],{"trials":19031,"activeCount":99},[],{"trials":19033,"activeCount":99},[],{"trials":19035,"activeCount":99},[],{"intervention":13750,"totalTrials":468,"cells":19037},{"EARLY_PHASE1":19038,"PHASE1":19040,"PHASE2":19046,"PHASE3":19048,"PHASE4":19050,"NA":19052},{"trials":19039,"activeCount":99},[],{"trials":19041,"activeCount":99},[19042],{"nctId":13744,"briefTitle":13745,"status":105,"phases":19043,"primaryCompletion":4348,"completion":4348,"start":6033,"enrollment":479,"conditions":19044,"interventions":19045},[87],[15],[13737,13749,13750],{"trials":19047,"activeCount":99},[],{"trials":19049,"activeCount":99},[],{"trials":19051,"activeCount":99},[],{"trials":19053,"activeCount":99},[],{"intervention":19055,"totalTrials":468,"cells":19056},"Daratumumab Subcutaneous (SC) Administration",{"EARLY_PHASE1":19057,"PHASE1":19059,"PHASE2":19070,"PHASE3":19072,"PHASE4":19074,"NA":19076},{"trials":19058,"activeCount":99},[],{"trials":19060,"activeCount":99},[19061],{"nctId":19062,"briefTitle":19063,"status":105,"phases":19064,"primaryCompletion":19065,"completion":1785,"start":19066,"enrollment":371,"conditions":19067,"interventions":19068},"NCT02519452","A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma",[87],"2017-12-13","2015-10-22",[18],[19055,19069],"Recombinant Human Hyaluronidase [rHuPH20]) SC Administration",{"trials":19071,"activeCount":99},[],{"trials":19073,"activeCount":99},[],{"trials":19075,"activeCount":99},[],{"trials":19077,"activeCount":99},[],{"intervention":19069,"totalTrials":468,"cells":19079},{"EARLY_PHASE1":19080,"PHASE1":19082,"PHASE2":19088,"PHASE3":19090,"PHASE4":19092,"NA":19094},{"trials":19081,"activeCount":99},[],{"trials":19083,"activeCount":99},[19084],{"nctId":19062,"briefTitle":19063,"status":105,"phases":19085,"primaryCompletion":19065,"completion":1785,"start":19066,"enrollment":371,"conditions":19086,"interventions":19087},[87],[18],[19055,19069],{"trials":19089,"activeCount":99},[],{"trials":19091,"activeCount":99},[],{"trials":19093,"activeCount":99},[],{"trials":19095,"activeCount":99},[],{"intervention":16649,"totalTrials":468,"cells":19097},{"EARLY_PHASE1":19098,"PHASE1":19100,"PHASE2":19106,"PHASE3":19108,"PHASE4":19110,"NA":19112},{"trials":19099,"activeCount":99},[],{"trials":19101,"activeCount":99},[19102],{"nctId":16641,"briefTitle":16642,"status":105,"phases":19103,"primaryCompletion":16644,"completion":16645,"start":16646,"enrollment":1436,"conditions":19104,"interventions":19105},[87],[3667],[16649,3616],{"trials":19107,"activeCount":99},[],{"trials":19109,"activeCount":99},[],{"trials":19111,"activeCount":99},[],{"trials":19113,"activeCount":99},[],{"intervention":19115,"totalTrials":468,"cells":19116},"18F-JNJ-64326067",{"EARLY_PHASE1":19117,"PHASE1":19119,"PHASE2":19128,"PHASE3":19130,"PHASE4":19132,"NA":19134},{"trials":19118,"activeCount":99},[],{"trials":19120,"activeCount":99},[19121],{"nctId":19122,"briefTitle":19123,"status":105,"phases":19124,"primaryCompletion":19125,"completion":19125,"start":443,"enrollment":641,"conditions":19126,"interventions":19127},"NCT03581916","A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants",[87],"2018-11-02",[15],[19115],{"trials":19129,"activeCount":99},[],{"trials":19131,"activeCount":99},[],{"trials":19133,"activeCount":99},[],{"trials":19135,"activeCount":99},[],{"intervention":19137,"totalTrials":468,"cells":19138},"14C-aticaprant",{"EARLY_PHASE1":19139,"PHASE1":19141,"PHASE2":19151,"PHASE3":19153,"PHASE4":19155,"NA":19157},{"trials":19140,"activeCount":99},[],{"trials":19142,"activeCount":99},[19143],{"nctId":19144,"briefTitle":19145,"status":105,"phases":19146,"primaryCompletion":19147,"completion":19147,"start":19148,"enrollment":109,"conditions":19149,"interventions":19150},"NCT05197062","A Study of 14C JNJ-67953964 in Healthy Adult Male Participants",[87],"2022-03-02","2022-01-14",[15],[19137],{"trials":19152,"activeCount":99},[],{"trials":19154,"activeCount":99},[],{"trials":19156,"activeCount":99},[],{"trials":19158,"activeCount":99},[],{"intervention":12173,"totalTrials":468,"cells":19160},{"EARLY_PHASE1":19161,"PHASE1":19163,"PHASE2":19169,"PHASE3":19171,"PHASE4":19173,"NA":19175},{"trials":19162,"activeCount":99},[],{"trials":19164,"activeCount":99},[19165],{"nctId":12165,"briefTitle":12166,"status":105,"phases":19166,"primaryCompletion":12168,"completion":7176,"start":12169,"enrollment":3586,"conditions":19167,"interventions":19168},[87],[2412],[7292,12172,12173,12174,12175],{"trials":19170,"activeCount":99},[],{"trials":19172,"activeCount":99},[],{"trials":19174,"activeCount":99},[],{"trials":19176,"activeCount":99},[],{"intervention":17215,"totalTrials":468,"cells":19178},{"EARLY_PHASE1":19179,"PHASE1":19181,"PHASE2":19187,"PHASE3":19189,"PHASE4":19191,"NA":19193},{"trials":19180,"activeCount":99},[],{"trials":19182,"activeCount":99},[19183],{"nctId":17208,"briefTitle":17209,"status":125,"phases":19184,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":19185,"interventions":19186},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"trials":19188,"activeCount":99},[],{"trials":19190,"activeCount":99},[],{"trials":19192,"activeCount":99},[],{"trials":19194,"activeCount":99},[],{"intervention":17216,"totalTrials":468,"cells":19196},{"EARLY_PHASE1":19197,"PHASE1":19199,"PHASE2":19205,"PHASE3":19207,"PHASE4":19209,"NA":19211},{"trials":19198,"activeCount":99},[],{"trials":19200,"activeCount":99},[19201],{"nctId":17208,"briefTitle":17209,"status":125,"phases":19202,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":19203,"interventions":19204},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"trials":19206,"activeCount":99},[],{"trials":19208,"activeCount":99},[],{"trials":19210,"activeCount":99},[],{"trials":19212,"activeCount":99},[],{"intervention":17217,"totalTrials":468,"cells":19214},{"EARLY_PHASE1":19215,"PHASE1":19217,"PHASE2":19223,"PHASE3":19225,"PHASE4":19227,"NA":19229},{"trials":19216,"activeCount":99},[],{"trials":19218,"activeCount":99},[19219],{"nctId":17208,"briefTitle":17209,"status":125,"phases":19220,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":19221,"interventions":19222},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"trials":19224,"activeCount":99},[],{"trials":19226,"activeCount":99},[],{"trials":19228,"activeCount":99},[],{"trials":19230,"activeCount":99},[],{"intervention":17218,"totalTrials":468,"cells":19232},{"EARLY_PHASE1":19233,"PHASE1":19235,"PHASE2":19241,"PHASE3":19243,"PHASE4":19245,"NA":19247},{"trials":19234,"activeCount":99},[],{"trials":19236,"activeCount":99},[19237],{"nctId":17208,"briefTitle":17209,"status":125,"phases":19238,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":19239,"interventions":19240},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"trials":19242,"activeCount":99},[],{"trials":19244,"activeCount":99},[],{"trials":19246,"activeCount":99},[],{"trials":19248,"activeCount":99},[],{"intervention":17220,"totalTrials":468,"cells":19250},{"EARLY_PHASE1":19251,"PHASE1":19253,"PHASE2":19259,"PHASE3":19261,"PHASE4":19263,"NA":19265},{"trials":19252,"activeCount":99},[],{"trials":19254,"activeCount":99},[19255],{"nctId":17208,"briefTitle":17209,"status":125,"phases":19256,"primaryCompletion":17211,"completion":17211,"start":17212,"enrollment":1380,"conditions":19257,"interventions":19258},[87],[15],[17215,17216,17217,17218,17219,17220,9958],{"trials":19260,"activeCount":99},[],{"trials":19262,"activeCount":99},[],{"trials":19264,"activeCount":99},[],{"trials":19266,"activeCount":99},[],{"intervention":19268,"totalTrials":468,"cells":19269},"JNJ-70075200",{"EARLY_PHASE1":19270,"PHASE1":19272,"PHASE2":19281,"PHASE3":19283,"PHASE4":19285,"NA":19287},{"trials":19271,"activeCount":99},[],{"trials":19273,"activeCount":99},[19274],{"nctId":19275,"briefTitle":19276,"status":137,"phases":19277,"primaryCompletion":19278,"completion":2097,"start":1212,"enrollment":99,"conditions":19279,"interventions":19280},"NCT04782661","A Study of JNJ-70075200 in Healthy Participants",[87],"2022-05-09",[15],[19268],{"trials":19282,"activeCount":99},[],{"trials":19284,"activeCount":99},[],{"trials":19286,"activeCount":99},[],{"trials":19288,"activeCount":99},[],{"intervention":19290,"totalTrials":468,"cells":19291},"Treatment A: abiraterone acetate",{"EARLY_PHASE1":19292,"PHASE1":19294,"PHASE2":19304,"PHASE3":19306,"PHASE4":19308,"NA":19310},{"trials":19293,"activeCount":99},[],{"trials":19295,"activeCount":99},[19296],{"nctId":19297,"briefTitle":19298,"status":105,"phases":19299,"primaryCompletion":3310,"completion":3310,"start":5899,"enrollment":1177,"conditions":19300,"interventions":19301},"NCT01678573","A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants",[87],[15],[19290,19302,19303],"Treatment B: abiraterone acetate","Treatment C: abiraterone acetate",{"trials":19305,"activeCount":99},[],{"trials":19307,"activeCount":99},[],{"trials":19309,"activeCount":99},[],{"trials":19311,"activeCount":99},[],{"intervention":19302,"totalTrials":468,"cells":19313},{"EARLY_PHASE1":19314,"PHASE1":19316,"PHASE2":19322,"PHASE3":19324,"PHASE4":19326,"NA":19328},{"trials":19315,"activeCount":99},[],{"trials":19317,"activeCount":99},[19318],{"nctId":19297,"briefTitle":19298,"status":105,"phases":19319,"primaryCompletion":3310,"completion":3310,"start":5899,"enrollment":1177,"conditions":19320,"interventions":19321},[87],[15],[19290,19302,19303],{"trials":19323,"activeCount":99},[],{"trials":19325,"activeCount":99},[],{"trials":19327,"activeCount":99},[],{"trials":19329,"activeCount":99},[],{"intervention":19303,"totalTrials":468,"cells":19331},{"EARLY_PHASE1":19332,"PHASE1":19334,"PHASE2":19340,"PHASE3":19342,"PHASE4":19344,"NA":19346},{"trials":19333,"activeCount":99},[],{"trials":19335,"activeCount":99},[19336],{"nctId":19297,"briefTitle":19298,"status":105,"phases":19337,"primaryCompletion":3310,"completion":3310,"start":5899,"enrollment":1177,"conditions":19338,"interventions":19339},[87],[15],[19290,19302,19303],{"trials":19341,"activeCount":99},[],{"trials":19343,"activeCount":99},[],{"trials":19345,"activeCount":99},[],{"trials":19347,"activeCount":99},[],{"intervention":19349,"totalTrials":468,"cells":19350},"Rabeprazole sodium",{"EARLY_PHASE1":19351,"PHASE1":19353,"PHASE2":19363,"PHASE3":19365,"PHASE4":19367,"NA":19369},{"trials":19352,"activeCount":99},[],{"trials":19354,"activeCount":99},[19355],{"nctId":19356,"briefTitle":19357,"status":105,"phases":19358,"primaryCompletion":5867,"completion":5867,"start":19359,"enrollment":4432,"conditions":19360,"interventions":19362},"NCT00855361","A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD)",[87],"2009-07",[19361],"Gastroesophageal Reflux",[19349],{"trials":19364,"activeCount":99},[],{"trials":19366,"activeCount":99},[],{"trials":19368,"activeCount":99},[],{"trials":19370,"activeCount":99},[],{"intervention":19372,"totalTrials":468,"cells":19373},"Cohort 1",{"EARLY_PHASE1":19374,"PHASE1":19376,"PHASE2":19385,"PHASE3":19387,"PHASE4":19389,"NA":19391},{"trials":19375,"activeCount":99},[],{"trials":19377,"activeCount":99},[19378],{"nctId":19379,"briefTitle":19380,"status":105,"phases":19381,"primaryCompletion":3310,"completion":3310,"start":3342,"enrollment":169,"conditions":19382,"interventions":19383},"NCT01516047","A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function",[87],[505],[19372,19384],"Cohort 2",{"trials":19386,"activeCount":99},[],{"trials":19388,"activeCount":99},[],{"trials":19390,"activeCount":99},[],{"trials":19392,"activeCount":99},[],{"intervention":19384,"totalTrials":468,"cells":19394},{"EARLY_PHASE1":19395,"PHASE1":19397,"PHASE2":19403,"PHASE3":19405,"PHASE4":19407,"NA":19409},{"trials":19396,"activeCount":99},[],{"trials":19398,"activeCount":99},[19399],{"nctId":19379,"briefTitle":19380,"status":105,"phases":19400,"primaryCompletion":3310,"completion":3310,"start":3342,"enrollment":169,"conditions":19401,"interventions":19402},[87],[505],[19372,19384],{"trials":19404,"activeCount":99},[],{"trials":19406,"activeCount":99},[],{"trials":19408,"activeCount":99},[],{"trials":19410,"activeCount":99},[],{"intervention":19412,"totalTrials":468,"cells":19413},"Esketamine 50 mg",{"EARLY_PHASE1":19414,"PHASE1":19416,"PHASE2":19425,"PHASE3":19427,"PHASE4":19429,"NA":19431},{"trials":19415,"activeCount":99},[],{"trials":19417,"activeCount":99},[19418],{"nctId":19419,"briefTitle":19420,"status":105,"phases":19421,"primaryCompletion":3596,"completion":3596,"start":3632,"enrollment":109,"conditions":19422,"interventions":19423},"NCT02674295","A Mass Balance Study With a Microtracer Dose of 14C-esketamine in Healthy Male Participants",[87],[15],[19412,19424],"Esketamine 20 mg",{"trials":19426,"activeCount":99},[],{"trials":19428,"activeCount":99},[],{"trials":19430,"activeCount":99},[],{"trials":19432,"activeCount":99},[],{"intervention":19424,"totalTrials":468,"cells":19434},{"EARLY_PHASE1":19435,"PHASE1":19437,"PHASE2":19443,"PHASE3":19445,"PHASE4":19447,"NA":19449},{"trials":19436,"activeCount":99},[],{"trials":19438,"activeCount":99},[19439],{"nctId":19419,"briefTitle":19420,"status":105,"phases":19440,"primaryCompletion":3596,"completion":3596,"start":3632,"enrollment":109,"conditions":19441,"interventions":19442},[87],[15],[19412,19424],{"trials":19444,"activeCount":99},[],{"trials":19446,"activeCount":99},[],{"trials":19448,"activeCount":99},[],{"trials":19450,"activeCount":99},[],{"intervention":4402,"totalTrials":468,"cells":19452},{"EARLY_PHASE1":19453,"PHASE1":19455,"PHASE2":19461,"PHASE3":19463,"PHASE4":19465,"NA":19467},{"trials":19454,"activeCount":99},[],{"trials":19456,"activeCount":99},[19457],{"nctId":4392,"briefTitle":4393,"status":105,"phases":19458,"primaryCompletion":4395,"completion":4395,"start":4396,"enrollment":4397,"conditions":19459,"interventions":19460},[87],[4399,4400],[4402,4403,4385],{"trials":19462,"activeCount":99},[],{"trials":19464,"activeCount":99},[],{"trials":19466,"activeCount":99},[],{"trials":19468,"activeCount":99},[],{"intervention":19470,"totalTrials":468,"cells":19471},"JNJ-39439335 10 mg",{"EARLY_PHASE1":19472,"PHASE1":19474,"PHASE2":19485,"PHASE3":19487,"PHASE4":19489,"NA":19491},{"trials":19473,"activeCount":99},[],{"trials":19475,"activeCount":99},[19476],{"nctId":19477,"briefTitle":19478,"status":105,"phases":19479,"primaryCompletion":15454,"completion":15454,"start":5899,"enrollment":19480,"conditions":19481,"interventions":19482},"NCT01631487","A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants",[87],86,[15],[19470,19483,19484],"JNJ-39439335 25 mg","JNJ-39439335 50 mg",{"trials":19486,"activeCount":99},[],{"trials":19488,"activeCount":99},[],{"trials":19490,"activeCount":99},[],{"trials":19492,"activeCount":99},[],{"intervention":19483,"totalTrials":468,"cells":19494},{"EARLY_PHASE1":19495,"PHASE1":19497,"PHASE2":19503,"PHASE3":19505,"PHASE4":19507,"NA":19509},{"trials":19496,"activeCount":99},[],{"trials":19498,"activeCount":99},[19499],{"nctId":19477,"briefTitle":19478,"status":105,"phases":19500,"primaryCompletion":15454,"completion":15454,"start":5899,"enrollment":19480,"conditions":19501,"interventions":19502},[87],[15],[19470,19483,19484],{"trials":19504,"activeCount":99},[],{"trials":19506,"activeCount":99},[],{"trials":19508,"activeCount":99},[],{"trials":19510,"activeCount":99},[],{"intervention":19484,"totalTrials":468,"cells":19512},{"EARLY_PHASE1":19513,"PHASE1":19515,"PHASE2":19521,"PHASE3":19523,"PHASE4":19525,"NA":19527},{"trials":19514,"activeCount":99},[],{"trials":19516,"activeCount":99},[19517],{"nctId":19477,"briefTitle":19478,"status":105,"phases":19518,"primaryCompletion":15454,"completion":15454,"start":5899,"enrollment":19480,"conditions":19519,"interventions":19520},[87],[15],[19470,19483,19484],{"trials":19522,"activeCount":99},[],{"trials":19524,"activeCount":99},[],{"trials":19526,"activeCount":99},[],{"trials":19528,"activeCount":99},[],{"intervention":17602,"totalTrials":468,"cells":19530},{"EARLY_PHASE1":19531,"PHASE1":19533,"PHASE2":19539,"PHASE3":19541,"PHASE4":19543,"NA":19545},{"trials":19532,"activeCount":99},[],{"trials":19534,"activeCount":99},[19535],{"nctId":17595,"briefTitle":17596,"status":105,"phases":19536,"primaryCompletion":17598,"completion":17598,"start":17599,"enrollment":1507,"conditions":19537,"interventions":19538},[87],[15],[17580,17602,17603],{"trials":19540,"activeCount":99},[],{"trials":19542,"activeCount":99},[],{"trials":19544,"activeCount":99},[],{"trials":19546,"activeCount":99},[],{"intervention":17603,"totalTrials":468,"cells":19548},{"EARLY_PHASE1":19549,"PHASE1":19551,"PHASE2":19557,"PHASE3":19559,"PHASE4":19561,"NA":19563},{"trials":19550,"activeCount":99},[],{"trials":19552,"activeCount":99},[19553],{"nctId":17595,"briefTitle":17596,"status":105,"phases":19554,"primaryCompletion":17598,"completion":17598,"start":17599,"enrollment":1507,"conditions":19555,"interventions":19556},[87],[15],[17580,17602,17603],{"trials":19558,"activeCount":99},[],{"trials":19560,"activeCount":99},[],{"trials":19562,"activeCount":99},[],{"trials":19564,"activeCount":99},[],{"intervention":13321,"totalTrials":468,"cells":19566},{"EARLY_PHASE1":19567,"PHASE1":19569,"PHASE2":19575,"PHASE3":19577,"PHASE4":19579,"NA":19581},{"trials":19568,"activeCount":99},[],{"trials":19570,"activeCount":99},[19571],{"nctId":13315,"briefTitle":13316,"status":105,"phases":19572,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":19573,"interventions":19574},[87],[15],[13321,13322,3616,13323,13324,4366],{"trials":19576,"activeCount":99},[],{"trials":19578,"activeCount":99},[],{"trials":19580,"activeCount":99},[],{"trials":19582,"activeCount":99},[],{"intervention":13322,"totalTrials":468,"cells":19584},{"EARLY_PHASE1":19585,"PHASE1":19587,"PHASE2":19593,"PHASE3":19595,"PHASE4":19597,"NA":19599},{"trials":19586,"activeCount":99},[],{"trials":19588,"activeCount":99},[19589],{"nctId":13315,"briefTitle":13316,"status":105,"phases":19590,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":19591,"interventions":19592},[87],[15],[13321,13322,3616,13323,13324,4366],{"trials":19594,"activeCount":99},[],{"trials":19596,"activeCount":99},[],{"trials":19598,"activeCount":99},[],{"trials":19600,"activeCount":99},[],{"intervention":13323,"totalTrials":468,"cells":19602},{"EARLY_PHASE1":19603,"PHASE1":19605,"PHASE2":19611,"PHASE3":19613,"PHASE4":19615,"NA":19617},{"trials":19604,"activeCount":99},[],{"trials":19606,"activeCount":99},[19607],{"nctId":13315,"briefTitle":13316,"status":105,"phases":19608,"primaryCompletion":8428,"completion":8428,"start":1379,"enrollment":13318,"conditions":19609,"interventions":19610},[87],[15],[13321,13322,3616,13323,13324,4366],{"trials":19612,"activeCount":99},[],{"trials":19614,"activeCount":99},[],{"trials":19616,"activeCount":99},[],{"trials":19618,"activeCount":99},[],{"intervention":19620,"totalTrials":468,"cells":19621},"Period 1: Abiraterone",{"EARLY_PHASE1":19622,"PHASE1":19624,"PHASE2":19633,"PHASE3":19635,"PHASE4":19637,"NA":19639},{"trials":19623,"activeCount":99},[],{"trials":19625,"activeCount":99},[19626],{"nctId":19627,"briefTitle":19628,"status":105,"phases":19629,"primaryCompletion":2564,"completion":2564,"start":3342,"enrollment":745,"conditions":19630,"interventions":19631},"NCT01588782","A Study to Assess the Effect of Ketoconazole on the Pharmacokinetics of Abiraterone Following Administration of Abiraterone Acetate Tablets in Healthy Adult Men",[87],[3331],[19620,19632,19632],"Period 2: Abiraterone\u002FKetoconazole",{"trials":19634,"activeCount":99},[],{"trials":19636,"activeCount":99},[],{"trials":19638,"activeCount":99},[],{"trials":19640,"activeCount":99},[],{"intervention":19632,"totalTrials":468,"cells":19642},{"EARLY_PHASE1":19643,"PHASE1":19645,"PHASE2":19651,"PHASE3":19653,"PHASE4":19655,"NA":19657},{"trials":19644,"activeCount":99},[],{"trials":19646,"activeCount":99},[19647],{"nctId":19627,"briefTitle":19628,"status":105,"phases":19648,"primaryCompletion":2564,"completion":2564,"start":3342,"enrollment":745,"conditions":19649,"interventions":19650},[87],[3331],[19620,19632,19632],{"trials":19652,"activeCount":99},[],{"trials":19654,"activeCount":99},[],{"trials":19656,"activeCount":99},[],{"trials":19658,"activeCount":99},[],{"intervention":19660,"totalTrials":468,"cells":19661},"Paliperidone IR",{"EARLY_PHASE1":19662,"PHASE1":19664,"PHASE2":19678,"PHASE3":19680,"PHASE4":19682,"NA":19684},{"trials":19663,"activeCount":99},[],{"trials":19665,"activeCount":99},[19666],{"nctId":19667,"briefTitle":19668,"status":105,"phases":19669,"primaryCompletion":19670,"completion":19671,"start":19672,"enrollment":19673,"conditions":19674,"interventions":19675},"NCT01559272","A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia",[87],"2014-04-09","2014-05-24","2008-02-21",328,[32],[19660,19676,19676,19676,19676,19676,19676,19676,19677,19676,19676,19676,19676],"Paliperidone palmitate F015","Paliperidone palmitate F016",{"trials":19679,"activeCount":99},[],{"trials":19681,"activeCount":99},[],{"trials":19683,"activeCount":99},[],{"trials":19685,"activeCount":99},[],{"intervention":19676,"totalTrials":468,"cells":19687},{"EARLY_PHASE1":19688,"PHASE1":19690,"PHASE2":19696,"PHASE3":19698,"PHASE4":19700,"NA":19702},{"trials":19689,"activeCount":99},[],{"trials":19691,"activeCount":99},[19692],{"nctId":19667,"briefTitle":19668,"status":105,"phases":19693,"primaryCompletion":19670,"completion":19671,"start":19672,"enrollment":19673,"conditions":19694,"interventions":19695},[87],[32],[19660,19676,19676,19676,19676,19676,19676,19676,19677,19676,19676,19676,19676],{"trials":19697,"activeCount":99},[],{"trials":19699,"activeCount":99},[],{"trials":19701,"activeCount":99},[],{"trials":19703,"activeCount":99},[],{"intervention":19677,"totalTrials":468,"cells":19705},{"EARLY_PHASE1":19706,"PHASE1":19708,"PHASE2":19714,"PHASE3":19716,"PHASE4":19718,"NA":19720},{"trials":19707,"activeCount":99},[],{"trials":19709,"activeCount":99},[19710],{"nctId":19667,"briefTitle":19668,"status":105,"phases":19711,"primaryCompletion":19670,"completion":19671,"start":19672,"enrollment":19673,"conditions":19712,"interventions":19713},[87],[32],[19660,19676,19676,19676,19676,19676,19676,19676,19677,19676,19676,19676,19676],{"trials":19715,"activeCount":99},[],{"trials":19717,"activeCount":99},[],{"trials":19719,"activeCount":99},[],{"trials":19721,"activeCount":99},[],{"intervention":19723,"totalTrials":468,"cells":19724},"FDC of macitentan\u002Ftadalafil",{"EARLY_PHASE1":19725,"PHASE1":19727,"PHASE2":19739,"PHASE3":19741,"PHASE4":19743,"NA":19745},{"trials":19726,"activeCount":99},[],{"trials":19728,"activeCount":99},[19729],{"nctId":19730,"briefTitle":19731,"status":105,"phases":19732,"primaryCompletion":19733,"completion":464,"start":19734,"enrollment":503,"conditions":19735,"interventions":19736},"NCT04540744","A Study of Macitentan\u002FTadalafil Combination Administered a Fixed-dose Combination Formulation Compared to the Reference Free Combination of Macitentan and Tadalafil",[87],"2021-08-08","2021-04-30",[15],[19723,19737,19738],"Macitentan 10 mg","Tadalafil 20 mg",{"trials":19740,"activeCount":99},[],{"trials":19742,"activeCount":99},[],{"trials":19744,"activeCount":99},[],{"trials":19746,"activeCount":99},[],{"intervention":19737,"totalTrials":468,"cells":19748},{"EARLY_PHASE1":19749,"PHASE1":19751,"PHASE2":19757,"PHASE3":19759,"PHASE4":19761,"NA":19763},{"trials":19750,"activeCount":99},[],{"trials":19752,"activeCount":99},[19753],{"nctId":19730,"briefTitle":19731,"status":105,"phases":19754,"primaryCompletion":19733,"completion":464,"start":19734,"enrollment":503,"conditions":19755,"interventions":19756},[87],[15],[19723,19737,19738],{"trials":19758,"activeCount":99},[],{"trials":19760,"activeCount":99},[],{"trials":19762,"activeCount":99},[],{"trials":19764,"activeCount":99},[],{"intervention":19738,"totalTrials":468,"cells":19766},{"EARLY_PHASE1":19767,"PHASE1":19769,"PHASE2":19775,"PHASE3":19777,"PHASE4":19779,"NA":19781},{"trials":19768,"activeCount":99},[],{"trials":19770,"activeCount":99},[19771],{"nctId":19730,"briefTitle":19731,"status":105,"phases":19772,"primaryCompletion":19733,"completion":464,"start":19734,"enrollment":503,"conditions":19773,"interventions":19774},[87],[15],[19723,19737,19738],{"trials":19776,"activeCount":99},[],{"trials":19778,"activeCount":99},[],{"trials":19780,"activeCount":99},[],{"trials":19782,"activeCount":99},[],{"intervention":19784,"totalTrials":468,"cells":19785},"JNJ-63898081",{"EARLY_PHASE1":19786,"PHASE1":19788,"PHASE2":19798,"PHASE3":19800,"PHASE4":19802,"NA":19804},{"trials":19787,"activeCount":99},[],{"trials":19789,"activeCount":99},[19790],{"nctId":19791,"briefTitle":19792,"status":105,"phases":19793,"primaryCompletion":19794,"completion":4424,"start":19795,"enrollment":3138,"conditions":19796,"interventions":19797},"NCT03926013","A Study of JNJ-63898081 in Participants With Advanced Stage Solid Tumors",[87],"2021-08-23","2019-05-01",[5932],[19784],{"trials":19799,"activeCount":99},[],{"trials":19801,"activeCount":99},[],{"trials":19803,"activeCount":99},[],{"trials":19805,"activeCount":99},[],{"intervention":8628,"totalTrials":468,"cells":19807},{"EARLY_PHASE1":19808,"PHASE1":19810,"PHASE2":19816,"PHASE3":19818,"PHASE4":19820,"NA":19822},{"trials":19809,"activeCount":99},[],{"trials":19811,"activeCount":99},[19812],{"nctId":8622,"briefTitle":8623,"status":105,"phases":19813,"primaryCompletion":1426,"completion":1426,"start":8625,"enrollment":809,"conditions":19814,"interventions":19815},[87],[15],[8615,8628],{"trials":19817,"activeCount":99},[],{"trials":19819,"activeCount":99},[],{"trials":19821,"activeCount":99},[],{"trials":19823,"activeCount":99},[],{"intervention":19825,"totalTrials":468,"cells":19826},"14C-JNJ-56136379",{"EARLY_PHASE1":19827,"PHASE1":19829,"PHASE2":19838,"PHASE3":19840,"PHASE4":19842,"NA":19844},{"trials":19828,"activeCount":99},[],{"trials":19830,"activeCount":99},[19831],{"nctId":19832,"briefTitle":19833,"status":105,"phases":19834,"primaryCompletion":18297,"completion":18297,"start":19835,"enrollment":641,"conditions":19836,"interventions":19837},"NCT03864601","A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants",[87],"2019-04-09",[15],[19825],{"trials":19839,"activeCount":99},[],{"trials":19841,"activeCount":99},[],{"trials":19843,"activeCount":99},[],{"trials":19845,"activeCount":99},[],{"intervention":19847,"totalTrials":468,"cells":19848},"JNJ-54175446, 600 mg",{"EARLY_PHASE1":19849,"PHASE1":19851,"PHASE2":19863,"PHASE3":19865,"PHASE4":19867,"NA":19869},{"trials":19850,"activeCount":99},[],{"trials":19852,"activeCount":99},[19853],{"nctId":19854,"briefTitle":19855,"status":105,"phases":19856,"primaryCompletion":19857,"completion":19858,"start":19859,"enrollment":6987,"conditions":19860,"interventions":19861},"NCT02902601","A Study to Investigate the Safety, Tolerability, and Pharmacodynamics of JNJ-54175446 in Participants With Major Depressive Disorder",[87],"2017-06-02","2017-06-07","2016-10-17",[21],[19847,19862],"JNJ-54175446, 150 mg",{"trials":19864,"activeCount":99},[],{"trials":19866,"activeCount":99},[],{"trials":19868,"activeCount":99},[],{"trials":19870,"activeCount":99},[],{"intervention":19862,"totalTrials":468,"cells":19872},{"EARLY_PHASE1":19873,"PHASE1":19875,"PHASE2":19881,"PHASE3":19883,"PHASE4":19885,"NA":19887},{"trials":19874,"activeCount":99},[],{"trials":19876,"activeCount":99},[19877],{"nctId":19854,"briefTitle":19855,"status":105,"phases":19878,"primaryCompletion":19857,"completion":19858,"start":19859,"enrollment":6987,"conditions":19879,"interventions":19880},[87],[21],[19847,19862],{"trials":19882,"activeCount":99},[],{"trials":19884,"activeCount":99},[],{"trials":19886,"activeCount":99},[],{"trials":19888,"activeCount":99},[],{"intervention":19890,"totalTrials":468,"cells":19891},"Treatment A: PCI-32765",{"EARLY_PHASE1":19892,"PHASE1":19894,"PHASE2":19903,"PHASE3":19905,"PHASE4":19907,"NA":19909},{"trials":19893,"activeCount":99},[],{"trials":19895,"activeCount":99},[19896],{"nctId":19897,"briefTitle":19898,"status":105,"phases":19899,"primaryCompletion":5618,"completion":5618,"start":5556,"enrollment":109,"conditions":19900,"interventions":19901},"NCT01969266","A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food",[87],[9490],[19890,19902],"Treatment B: PCI-32765",{"trials":19904,"activeCount":99},[],{"trials":19906,"activeCount":99},[],{"trials":19908,"activeCount":99},[],{"trials":19910,"activeCount":99},[],{"intervention":19902,"totalTrials":468,"cells":19912},{"EARLY_PHASE1":19913,"PHASE1":19915,"PHASE2":19921,"PHASE3":19923,"PHASE4":19925,"NA":19927},{"trials":19914,"activeCount":99},[],{"trials":19916,"activeCount":99},[19917],{"nctId":19897,"briefTitle":19898,"status":105,"phases":19918,"primaryCompletion":5618,"completion":5618,"start":5556,"enrollment":109,"conditions":19919,"interventions":19920},[87],[9490],[19890,19902],{"trials":19922,"activeCount":99},[],{"trials":19924,"activeCount":99},[],{"trials":19926,"activeCount":99},[],{"trials":19928,"activeCount":99},[],{"intervention":5516,"totalTrials":468,"cells":19930},{"EARLY_PHASE1":19931,"PHASE1":19933,"PHASE2":19939,"PHASE3":19941,"PHASE4":19943,"NA":19945},{"trials":19932,"activeCount":99},[],{"trials":19934,"activeCount":99},[19935],{"nctId":5511,"briefTitle":5512,"status":105,"phases":19936,"primaryCompletion":3329,"completion":3329,"start":3392,"enrollment":2566,"conditions":19937,"interventions":19938},[87],[15],[4318,5516],{"trials":19940,"activeCount":99},[],{"trials":19942,"activeCount":99},[],{"trials":19944,"activeCount":99},[],{"trials":19946,"activeCount":99},[],{"intervention":8495,"totalTrials":468,"cells":19948},{"EARLY_PHASE1":19949,"PHASE1":19951,"PHASE2":19957,"PHASE3":19959,"PHASE4":19961,"NA":19963},{"trials":19950,"activeCount":99},[],{"trials":19952,"activeCount":99},[19953],{"nctId":8484,"briefTitle":8485,"status":105,"phases":19954,"primaryCompletion":8487,"completion":8487,"start":8488,"enrollment":8489,"conditions":19955,"interventions":19956},[87],[8491],[8493,8494,8495,8496,8477],{"trials":19958,"activeCount":99},[],{"trials":19960,"activeCount":99},[],{"trials":19962,"activeCount":99},[],{"trials":19964,"activeCount":99},[],{"intervention":8496,"totalTrials":468,"cells":19966},{"EARLY_PHASE1":19967,"PHASE1":19969,"PHASE2":19975,"PHASE3":19977,"PHASE4":19979,"NA":19981},{"trials":19968,"activeCount":99},[],{"trials":19970,"activeCount":99},[19971],{"nctId":8484,"briefTitle":8485,"status":105,"phases":19972,"primaryCompletion":8487,"completion":8487,"start":8488,"enrollment":8489,"conditions":19973,"interventions":19974},[87],[8491],[8493,8494,8495,8496,8477],{"trials":19976,"activeCount":99},[],{"trials":19978,"activeCount":99},[],{"trials":19980,"activeCount":99},[],{"trials":19982,"activeCount":99},[],{"intervention":19984,"totalTrials":468,"cells":19985},"TMC435 100 mg",{"EARLY_PHASE1":19986,"PHASE1":19988,"PHASE2":19997,"PHASE3":19999,"PHASE4":20001,"NA":20003},{"trials":19987,"activeCount":99},[],{"trials":19989,"activeCount":99},[19990],{"nctId":19991,"briefTitle":19992,"status":105,"phases":19993,"primaryCompletion":2218,"completion":2218,"start":1175,"enrollment":1507,"conditions":19994,"interventions":19995},"NCT02071355","A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants",[87],[15],[19984,19996],"TMC435 150 mg",{"trials":19998,"activeCount":99},[],{"trials":20000,"activeCount":99},[],{"trials":20002,"activeCount":99},[],{"trials":20004,"activeCount":99},[],{"intervention":19996,"totalTrials":468,"cells":20006},{"EARLY_PHASE1":20007,"PHASE1":20009,"PHASE2":20015,"PHASE3":20017,"PHASE4":20019,"NA":20021},{"trials":20008,"activeCount":99},[],{"trials":20010,"activeCount":99},[20011],{"nctId":19991,"briefTitle":19992,"status":105,"phases":20012,"primaryCompletion":2218,"completion":2218,"start":1175,"enrollment":1507,"conditions":20013,"interventions":20014},[87],[15],[19984,19996],{"trials":20016,"activeCount":99},[],{"trials":20018,"activeCount":99},[],{"trials":20020,"activeCount":99},[],{"trials":20022,"activeCount":99},[],{"intervention":20024,"totalTrials":468,"cells":20025},"JNJ-61610588",{"EARLY_PHASE1":20026,"PHASE1":20028,"PHASE2":20038,"PHASE3":20040,"PHASE4":20042,"NA":20044},{"trials":20027,"activeCount":99},[],{"trials":20029,"activeCount":99},[20030],{"nctId":20031,"briefTitle":20032,"status":125,"phases":20033,"primaryCompletion":12987,"completion":20034,"start":3633,"enrollment":544,"conditions":20035,"interventions":20037},"NCT02671955","A Study of Safety, Pharmacokinetics, Pharmacodynamics of JNJ-61610588 in Participants With Advanced Cancer",[87],"2017-07",[20036],"Advanced Cancer",[20024],{"trials":20039,"activeCount":99},[],{"trials":20041,"activeCount":99},[],{"trials":20043,"activeCount":99},[],{"trials":20045,"activeCount":99},[],{"intervention":20047,"totalTrials":468,"cells":20048},"RPV LA",{"EARLY_PHASE1":20049,"PHASE1":20051,"PHASE2":20062,"PHASE3":20064,"PHASE4":20066,"NA":20068},{"trials":20050,"activeCount":99},[],{"trials":20052,"activeCount":99},[20053],{"nctId":20054,"briefTitle":20055,"status":105,"phases":20056,"primaryCompletion":20057,"completion":20057,"start":20058,"enrollment":6865,"conditions":20059,"interventions":20060},"NCT05112939","A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants",[87],"2024-05-23","2021-11-16",[15],[20047,20061],"CAB LA",{"trials":20063,"activeCount":99},[],{"trials":20065,"activeCount":99},[],{"trials":20067,"activeCount":99},[],{"trials":20069,"activeCount":99},[],{"intervention":20061,"totalTrials":468,"cells":20071},{"EARLY_PHASE1":20072,"PHASE1":20074,"PHASE2":20080,"PHASE3":20082,"PHASE4":20084,"NA":20086},{"trials":20073,"activeCount":99},[],{"trials":20075,"activeCount":99},[20076],{"nctId":20054,"briefTitle":20055,"status":105,"phases":20077,"primaryCompletion":20057,"completion":20057,"start":20058,"enrollment":6865,"conditions":20078,"interventions":20079},[87],[15],[20047,20061],{"trials":20081,"activeCount":99},[],{"trials":20083,"activeCount":99},[],{"trials":20085,"activeCount":99},[],{"trials":20087,"activeCount":99},[],{"intervention":20089,"totalTrials":468,"cells":20090},"CNTO 0007 or placebo",{"EARLY_PHASE1":20091,"PHASE1":20093,"PHASE2":20104,"PHASE3":20106,"PHASE4":20108,"NA":20110},{"trials":20092,"activeCount":99},[],{"trials":20094,"activeCount":99},[20095],{"nctId":20096,"briefTitle":20097,"status":105,"phases":20098,"completion":3328,"start":1176,"enrollment":479,"conditions":20099,"interventions":20103},"NCT01273467","A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)",[87],[20100,20101,20102],"Stroke","Ischemia","Infarction",[20089,20089],{"trials":20105,"activeCount":99},[],{"trials":20107,"activeCount":99},[],{"trials":20109,"activeCount":99},[],{"trials":20111,"activeCount":99},[],{"intervention":16662,"totalTrials":468,"cells":20113},{"EARLY_PHASE1":20114,"PHASE1":20116,"PHASE2":20122,"PHASE3":20124,"PHASE4":20126,"NA":20128},{"trials":20115,"activeCount":99},[],{"trials":20117,"activeCount":99},[20118],{"nctId":16655,"briefTitle":16656,"status":105,"phases":20119,"primaryCompletion":16658,"completion":4840,"start":16659,"enrollment":2022,"conditions":20120,"interventions":20121},[87],[15],[16662,3616],{"trials":20123,"activeCount":99},[],{"trials":20125,"activeCount":99},[],{"trials":20127,"activeCount":99},[],{"trials":20129,"activeCount":99},[],{"intervention":20131,"totalTrials":468,"cells":20132},"Treatment A: DUROGESIC",{"EARLY_PHASE1":20133,"PHASE1":20135,"PHASE2":20147,"PHASE3":20149,"PHASE4":20151,"NA":20153},{"trials":20134,"activeCount":99},[],{"trials":20136,"activeCount":99},[20137],{"nctId":20138,"briefTitle":20139,"status":105,"phases":20140,"primaryCompletion":5888,"completion":5888,"start":2535,"enrollment":1507,"conditions":20141,"interventions":20142},"NCT01717157","A Study to Assess the Relative Bioavailability of 4 Formulations of Fentanyl Transdermal System Compared Against DUROGESIC Fentanyl Transdermal Patch After Single Application in Healthy Volunteers",[87],[15],[20131,20143,20144,20145,20146],"Treatment B: Transdermal System-Concept 1","Treatment C: Transdermal System-Concept 2","Treatment D: Transdermal System-Concept 3","Treatment E: Transdermal System-Concept 4",{"trials":20148,"activeCount":99},[],{"trials":20150,"activeCount":99},[],{"trials":20152,"activeCount":99},[],{"trials":20154,"activeCount":99},[],{"intervention":20143,"totalTrials":468,"cells":20156},{"EARLY_PHASE1":20157,"PHASE1":20159,"PHASE2":20165,"PHASE3":20167,"PHASE4":20169,"NA":20171},{"trials":20158,"activeCount":99},[],{"trials":20160,"activeCount":99},[20161],{"nctId":20138,"briefTitle":20139,"status":105,"phases":20162,"primaryCompletion":5888,"completion":5888,"start":2535,"enrollment":1507,"conditions":20163,"interventions":20164},[87],[15],[20131,20143,20144,20145,20146],{"trials":20166,"activeCount":99},[],{"trials":20168,"activeCount":99},[],{"trials":20170,"activeCount":99},[],{"trials":20172,"activeCount":99},[],{"intervention":20144,"totalTrials":468,"cells":20174},{"EARLY_PHASE1":20175,"PHASE1":20177,"PHASE2":20183,"PHASE3":20185,"PHASE4":20187,"NA":20189},{"trials":20176,"activeCount":99},[],{"trials":20178,"activeCount":99},[20179],{"nctId":20138,"briefTitle":20139,"status":105,"phases":20180,"primaryCompletion":5888,"completion":5888,"start":2535,"enrollment":1507,"conditions":20181,"interventions":20182},[87],[15],[20131,20143,20144,20145,20146],{"trials":20184,"activeCount":99},[],{"trials":20186,"activeCount":99},[],{"trials":20188,"activeCount":99},[],{"trials":20190,"activeCount":99},[],{"intervention":20145,"totalTrials":468,"cells":20192},{"EARLY_PHASE1":20193,"PHASE1":20195,"PHASE2":20201,"PHASE3":20203,"PHASE4":20205,"NA":20207},{"trials":20194,"activeCount":99},[],{"trials":20196,"activeCount":99},[20197],{"nctId":20138,"briefTitle":20139,"status":105,"phases":20198,"primaryCompletion":5888,"completion":5888,"start":2535,"enrollment":1507,"conditions":20199,"interventions":20200},[87],[15],[20131,20143,20144,20145,20146],{"trials":20202,"activeCount":99},[],{"trials":20204,"activeCount":99},[],{"trials":20206,"activeCount":99},[],{"trials":20208,"activeCount":99},[],{"intervention":20146,"totalTrials":468,"cells":20210},{"EARLY_PHASE1":20211,"PHASE1":20213,"PHASE2":20219,"PHASE3":20221,"PHASE4":20223,"NA":20225},{"trials":20212,"activeCount":99},[],{"trials":20214,"activeCount":99},[20215],{"nctId":20138,"briefTitle":20139,"status":105,"phases":20216,"primaryCompletion":5888,"completion":5888,"start":2535,"enrollment":1507,"conditions":20217,"interventions":20218},[87],[15],[20131,20143,20144,20145,20146],{"trials":20220,"activeCount":99},[],{"trials":20222,"activeCount":99},[],{"trials":20224,"activeCount":99},[],{"trials":20226,"activeCount":99},[],{"intervention":3333,"totalTrials":468,"cells":20228},{"EARLY_PHASE1":20229,"PHASE1":20231,"PHASE2":20237,"PHASE3":20239,"PHASE4":20241,"NA":20243},{"trials":20230,"activeCount":99},[],{"trials":20232,"activeCount":99},[20233],{"nctId":3325,"briefTitle":3326,"status":105,"phases":20234,"primaryCompletion":3328,"completion":3328,"start":3329,"enrollment":169,"conditions":20235,"interventions":20236},[87],[3331],[3333,518],{"trials":20238,"activeCount":99},[],{"trials":20240,"activeCount":99},[],{"trials":20242,"activeCount":99},[],{"trials":20244,"activeCount":99},[],{"intervention":20246,"totalTrials":468,"cells":20247},"JNJ-43260295",{"EARLY_PHASE1":20248,"PHASE1":20250,"PHASE2":20259,"PHASE3":20261,"PHASE4":20263,"NA":20265},{"trials":20249,"activeCount":99},[],{"trials":20251,"activeCount":99},[20252],{"nctId":20253,"briefTitle":20254,"status":125,"phases":20255,"primaryCompletion":3444,"completion":3444,"start":3359,"enrollment":33,"conditions":20256,"interventions":20257},"NCT02243189","Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma",[87],[15,12585],[20246,20258],"Nasal Allergen Challenge",{"trials":20260,"activeCount":99},[],{"trials":20262,"activeCount":99},[],{"trials":20264,"activeCount":99},[],{"trials":20266,"activeCount":99},[],{"intervention":20258,"totalTrials":468,"cells":20268},{"EARLY_PHASE1":20269,"PHASE1":20271,"PHASE2":20277,"PHASE3":20279,"PHASE4":20281,"NA":20283},{"trials":20270,"activeCount":99},[],{"trials":20272,"activeCount":99},[20273],{"nctId":20253,"briefTitle":20254,"status":125,"phases":20274,"primaryCompletion":3444,"completion":3444,"start":3359,"enrollment":33,"conditions":20275,"interventions":20276},[87],[15,12585],[20246,20258],{"trials":20278,"activeCount":99},[],{"trials":20280,"activeCount":99},[],{"trials":20282,"activeCount":99},[],{"trials":20284,"activeCount":99},[],{"intervention":12284,"totalTrials":468,"cells":20286},{"EARLY_PHASE1":20287,"PHASE1":20289,"PHASE2":20295,"PHASE3":20297,"PHASE4":20299,"NA":20301},{"trials":20288,"activeCount":99},[],{"trials":20290,"activeCount":99},[20291],{"nctId":12278,"briefTitle":12279,"status":105,"phases":20292,"primaryCompletion":12281,"completion":12281,"start":8200,"enrollment":169,"conditions":20293,"interventions":20294},[87],[15],[4325,12284],{"trials":20296,"activeCount":99},[],{"trials":20298,"activeCount":99},[],{"trials":20300,"activeCount":99},[],{"trials":20302,"activeCount":99},[],{"intervention":13906,"totalTrials":468,"cells":20304},{"EARLY_PHASE1":20305,"PHASE1":20307,"PHASE2":20313,"PHASE3":20315,"PHASE4":20317,"NA":20319},{"trials":20306,"activeCount":99},[],{"trials":20308,"activeCount":99},[20309],{"nctId":13900,"briefTitle":13901,"status":105,"phases":20310,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":20311,"interventions":20312},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"trials":20314,"activeCount":99},[],{"trials":20316,"activeCount":99},[],{"trials":20318,"activeCount":99},[],{"trials":20320,"activeCount":99},[],{"intervention":13907,"totalTrials":468,"cells":20322},{"EARLY_PHASE1":20323,"PHASE1":20325,"PHASE2":20331,"PHASE3":20333,"PHASE4":20335,"NA":20337},{"trials":20324,"activeCount":99},[],{"trials":20326,"activeCount":99},[20327],{"nctId":13900,"briefTitle":13901,"status":105,"phases":20328,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":20329,"interventions":20330},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"trials":20332,"activeCount":99},[],{"trials":20334,"activeCount":99},[],{"trials":20336,"activeCount":99},[],{"trials":20338,"activeCount":99},[],{"intervention":13908,"totalTrials":468,"cells":20340},{"EARLY_PHASE1":20341,"PHASE1":20343,"PHASE2":20349,"PHASE3":20351,"PHASE4":20353,"NA":20355},{"trials":20342,"activeCount":99},[],{"trials":20344,"activeCount":99},[20345],{"nctId":13900,"briefTitle":13901,"status":105,"phases":20346,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":20347,"interventions":20348},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"trials":20350,"activeCount":99},[],{"trials":20352,"activeCount":99},[],{"trials":20354,"activeCount":99},[],{"trials":20356,"activeCount":99},[],{"intervention":13909,"totalTrials":468,"cells":20358},{"EARLY_PHASE1":20359,"PHASE1":20361,"PHASE2":20367,"PHASE3":20369,"PHASE4":20371,"NA":20373},{"trials":20360,"activeCount":99},[],{"trials":20362,"activeCount":99},[20363],{"nctId":13900,"briefTitle":13901,"status":105,"phases":20364,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":20365,"interventions":20366},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"trials":20368,"activeCount":99},[],{"trials":20370,"activeCount":99},[],{"trials":20372,"activeCount":99},[],{"trials":20374,"activeCount":99},[],{"intervention":13910,"totalTrials":468,"cells":20376},{"EARLY_PHASE1":20377,"PHASE1":20379,"PHASE2":20385,"PHASE3":20387,"PHASE4":20389,"NA":20391},{"trials":20378,"activeCount":99},[],{"trials":20380,"activeCount":99},[20381],{"nctId":13900,"briefTitle":13901,"status":105,"phases":20382,"primaryCompletion":1426,"completion":1426,"start":13903,"enrollment":19,"conditions":20383,"interventions":20384},[87],[15],[13906,13907,13908,13893,13909,13910,13911],{"trials":20386,"activeCount":99},[],{"trials":20388,"activeCount":99},[],{"trials":20390,"activeCount":99},[],{"trials":20392,"activeCount":99},[],{"intervention":17178,"totalTrials":468,"cells":20394},{"EARLY_PHASE1":20395,"PHASE1":20397,"PHASE2":20403,"PHASE3":20405,"PHASE4":20407,"NA":20409},{"trials":20396,"activeCount":99},[],{"trials":20398,"activeCount":99},[20399],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20400,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20401,"interventions":20402},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20404,"activeCount":99},[],{"trials":20406,"activeCount":99},[],{"trials":20408,"activeCount":99},[],{"trials":20410,"activeCount":99},[],{"intervention":17179,"totalTrials":468,"cells":20412},{"EARLY_PHASE1":20413,"PHASE1":20415,"PHASE2":20421,"PHASE3":20423,"PHASE4":20425,"NA":20427},{"trials":20414,"activeCount":99},[],{"trials":20416,"activeCount":99},[20417],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20418,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20419,"interventions":20420},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20422,"activeCount":99},[],{"trials":20424,"activeCount":99},[],{"trials":20426,"activeCount":99},[],{"trials":20428,"activeCount":99},[],{"intervention":17180,"totalTrials":468,"cells":20430},{"EARLY_PHASE1":20431,"PHASE1":20433,"PHASE2":20439,"PHASE3":20441,"PHASE4":20443,"NA":20445},{"trials":20432,"activeCount":99},[],{"trials":20434,"activeCount":99},[20435],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20436,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20437,"interventions":20438},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20440,"activeCount":99},[],{"trials":20442,"activeCount":99},[],{"trials":20444,"activeCount":99},[],{"trials":20446,"activeCount":99},[],{"intervention":17181,"totalTrials":468,"cells":20448},{"EARLY_PHASE1":20449,"PHASE1":20451,"PHASE2":20457,"PHASE3":20459,"PHASE4":20461,"NA":20463},{"trials":20450,"activeCount":99},[],{"trials":20452,"activeCount":99},[20453],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20454,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20455,"interventions":20456},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20458,"activeCount":99},[],{"trials":20460,"activeCount":99},[],{"trials":20462,"activeCount":99},[],{"trials":20464,"activeCount":99},[],{"intervention":17182,"totalTrials":468,"cells":20466},{"EARLY_PHASE1":20467,"PHASE1":20469,"PHASE2":20475,"PHASE3":20477,"PHASE4":20479,"NA":20481},{"trials":20468,"activeCount":99},[],{"trials":20470,"activeCount":99},[20471],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20472,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20473,"interventions":20474},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20476,"activeCount":99},[],{"trials":20478,"activeCount":99},[],{"trials":20480,"activeCount":99},[],{"trials":20482,"activeCount":99},[],{"intervention":17183,"totalTrials":468,"cells":20484},{"EARLY_PHASE1":20485,"PHASE1":20487,"PHASE2":20493,"PHASE3":20495,"PHASE4":20497,"NA":20499},{"trials":20486,"activeCount":99},[],{"trials":20488,"activeCount":99},[20489],{"nctId":17172,"briefTitle":17173,"status":125,"phases":20490,"primaryCompletion":17175,"completion":17175,"start":1489,"enrollment":1532,"conditions":20491,"interventions":20492},[87],[15],[17178,17179,17180,17181,17182,17183,17157],{"trials":20494,"activeCount":99},[],{"trials":20496,"activeCount":99},[],{"trials":20498,"activeCount":99},[],{"trials":20500,"activeCount":99},[],{"intervention":20502,"totalTrials":468,"cells":20503},"Part 1 (Dose Escalation): Duvortuxizumab",{"EARLY_PHASE1":20504,"PHASE1":20506,"PHASE2":20517,"PHASE3":20519,"PHASE4":20521,"NA":20523},{"trials":20505,"activeCount":99},[],{"trials":20507,"activeCount":99},[20508],{"nctId":20509,"briefTitle":20510,"status":125,"phases":20511,"primaryCompletion":20512,"completion":20512,"start":20513,"enrollment":8388,"conditions":20514,"interventions":20515},"NCT02454270","A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies",[87],"2018-07-26","2015-06-15",[2920,1535,1536,1534,1554],[20502,20516],"Part 2 (Dose Expansion): Duvortuxizumab",{"trials":20518,"activeCount":99},[],{"trials":20520,"activeCount":99},[],{"trials":20522,"activeCount":99},[],{"trials":20524,"activeCount":99},[],{"intervention":20516,"totalTrials":468,"cells":20526},{"EARLY_PHASE1":20527,"PHASE1":20529,"PHASE2":20535,"PHASE3":20537,"PHASE4":20539,"NA":20541},{"trials":20528,"activeCount":99},[],{"trials":20530,"activeCount":99},[20531],{"nctId":20509,"briefTitle":20510,"status":125,"phases":20532,"primaryCompletion":20512,"completion":20512,"start":20513,"enrollment":8388,"conditions":20533,"interventions":20534},[87],[2920,1535,1536,1534,1554],[20502,20516],{"trials":20536,"activeCount":99},[],{"trials":20538,"activeCount":99},[],{"trials":20540,"activeCount":99},[],{"trials":20542,"activeCount":99},[],{"intervention":20544,"totalTrials":468,"cells":20545},"FDC of Macitentan and Tadalafil",{"EARLY_PHASE1":20546,"PHASE1":20548,"PHASE2":20559,"PHASE3":20561,"PHASE4":20563,"NA":20565},{"trials":20547,"activeCount":99},[],{"trials":20549,"activeCount":99},[20550],{"nctId":20551,"briefTitle":20552,"status":105,"phases":20553,"primaryCompletion":20554,"completion":20554,"start":16646,"enrollment":13318,"conditions":20555,"interventions":20556},"NCT04235270","A Study of Macitentan and Tadalafil as a Fixed Dose Combination and the Free Combination in Healthy Adult Participants",[87],"2020-07-17",[15],[20544,20557,20558],"Macitentan","Tadalafil",{"trials":20560,"activeCount":99},[],{"trials":20562,"activeCount":99},[],{"trials":20564,"activeCount":99},[],{"trials":20566,"activeCount":99},[],{"intervention":20557,"totalTrials":468,"cells":20568},{"EARLY_PHASE1":20569,"PHASE1":20571,"PHASE2":20577,"PHASE3":20579,"PHASE4":20581,"NA":20583},{"trials":20570,"activeCount":99},[],{"trials":20572,"activeCount":99},[20573],{"nctId":20551,"briefTitle":20552,"status":105,"phases":20574,"primaryCompletion":20554,"completion":20554,"start":16646,"enrollment":13318,"conditions":20575,"interventions":20576},[87],[15],[20544,20557,20558],{"trials":20578,"activeCount":99},[],{"trials":20580,"activeCount":99},[],{"trials":20582,"activeCount":99},[],{"trials":20584,"activeCount":99},[],{"intervention":20558,"totalTrials":468,"cells":20586},{"EARLY_PHASE1":20587,"PHASE1":20589,"PHASE2":20595,"PHASE3":20597,"PHASE4":20599,"NA":20601},{"trials":20588,"activeCount":99},[],{"trials":20590,"activeCount":99},[20591],{"nctId":20551,"briefTitle":20552,"status":105,"phases":20592,"primaryCompletion":20554,"completion":20554,"start":16646,"enrollment":13318,"conditions":20593,"interventions":20594},[87],[15],[20544,20557,20558],{"trials":20596,"activeCount":99},[],{"trials":20598,"activeCount":99},[],{"trials":20600,"activeCount":99},[],{"trials":20602,"activeCount":99},[],{"intervention":20604,"totalTrials":468,"cells":20605},"Duragesic",{"EARLY_PHASE1":20606,"PHASE1":20608,"PHASE2":20622,"PHASE3":20624,"PHASE4":20626,"NA":20628},{"trials":20607,"activeCount":99},[],{"trials":20609,"activeCount":99},[20610],{"nctId":20611,"briefTitle":20612,"status":105,"phases":20613,"primaryCompletion":20614,"completion":20614,"start":20615,"enrollment":19,"conditions":20616,"interventions":20617},"NCT02608320","A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants",[87],"2016-04-13","2015-11-17",[15],[20604,20618,20619,20604,20620,20621],"New JNJ-35685-AAA-G016","Aged JNJ-35685-AAA-G016","New JNJ-35685-AAA-G021","Aged JNJ-35685-AAA-G021",{"trials":20623,"activeCount":99},[],{"trials":20625,"activeCount":99},[],{"trials":20627,"activeCount":99},[],{"trials":20629,"activeCount":99},[],{"intervention":20618,"totalTrials":468,"cells":20631},{"EARLY_PHASE1":20632,"PHASE1":20634,"PHASE2":20640,"PHASE3":20642,"PHASE4":20644,"NA":20646},{"trials":20633,"activeCount":99},[],{"trials":20635,"activeCount":99},[20636],{"nctId":20611,"briefTitle":20612,"status":105,"phases":20637,"primaryCompletion":20614,"completion":20614,"start":20615,"enrollment":19,"conditions":20638,"interventions":20639},[87],[15],[20604,20618,20619,20604,20620,20621],{"trials":20641,"activeCount":99},[],{"trials":20643,"activeCount":99},[],{"trials":20645,"activeCount":99},[],{"trials":20647,"activeCount":99},[],{"intervention":20619,"totalTrials":468,"cells":20649},{"EARLY_PHASE1":20650,"PHASE1":20652,"PHASE2":20658,"PHASE3":20660,"PHASE4":20662,"NA":20664},{"trials":20651,"activeCount":99},[],{"trials":20653,"activeCount":99},[20654],{"nctId":20611,"briefTitle":20612,"status":105,"phases":20655,"primaryCompletion":20614,"completion":20614,"start":20615,"enrollment":19,"conditions":20656,"interventions":20657},[87],[15],[20604,20618,20619,20604,20620,20621],{"trials":20659,"activeCount":99},[],{"trials":20661,"activeCount":99},[],{"trials":20663,"activeCount":99},[],{"trials":20665,"activeCount":99},[],{"intervention":20620,"totalTrials":468,"cells":20667},{"EARLY_PHASE1":20668,"PHASE1":20670,"PHASE2":20676,"PHASE3":20678,"PHASE4":20680,"NA":20682},{"trials":20669,"activeCount":99},[],{"trials":20671,"activeCount":99},[20672],{"nctId":20611,"briefTitle":20612,"status":105,"phases":20673,"primaryCompletion":20614,"completion":20614,"start":20615,"enrollment":19,"conditions":20674,"interventions":20675},[87],[15],[20604,20618,20619,20604,20620,20621],{"trials":20677,"activeCount":99},[],{"trials":20679,"activeCount":99},[],{"trials":20681,"activeCount":99},[],{"trials":20683,"activeCount":99},[],{"intervention":20621,"totalTrials":468,"cells":20685},{"EARLY_PHASE1":20686,"PHASE1":20688,"PHASE2":20694,"PHASE3":20696,"PHASE4":20698,"NA":20700},{"trials":20687,"activeCount":99},[],{"trials":20689,"activeCount":99},[20690],{"nctId":20611,"briefTitle":20612,"status":105,"phases":20691,"primaryCompletion":20614,"completion":20614,"start":20615,"enrollment":19,"conditions":20692,"interventions":20693},[87],[15],[20604,20618,20619,20604,20620,20621],{"trials":20695,"activeCount":99},[],{"trials":20697,"activeCount":99},[],{"trials":20699,"activeCount":99},[],{"trials":20701,"activeCount":99},[],{"intervention":20703,"totalTrials":468,"cells":20704},"JNJ-75220795",{"EARLY_PHASE1":20705,"PHASE1":20707,"PHASE2":20717,"PHASE3":20719,"PHASE4":20721,"NA":20723},{"trials":20706,"activeCount":99},[],{"trials":20708,"activeCount":99},[20709],{"nctId":20710,"briefTitle":20711,"status":105,"phases":20712,"primaryCompletion":1784,"completion":1784,"start":20713,"enrollment":8489,"conditions":20714,"interventions":20716},"NCT04844450","A Single and Multiple Ascending Dose Study of Subcutaneously Administered JNJ-75220795",[87],"2021-04-29",[20715],"Fatty Liver Disease",[20703],{"trials":20718,"activeCount":99},[],{"trials":20720,"activeCount":99},[],{"trials":20722,"activeCount":99},[],{"trials":20724,"activeCount":99},[],{"intervention":7424,"totalTrials":468,"cells":20726},{"EARLY_PHASE1":20727,"PHASE1":20729,"PHASE2":20735,"PHASE3":20737,"PHASE4":20739,"NA":20741},{"trials":20728,"activeCount":99},[],{"trials":20730,"activeCount":99},[20731],{"nctId":7415,"briefTitle":7416,"status":105,"phases":20732,"primaryCompletion":7418,"completion":7418,"start":7419,"enrollment":7420,"conditions":20733,"interventions":20734},[87],[1147,1467,7422],[6960,7424,7425],{"trials":20736,"activeCount":99},[],{"trials":20738,"activeCount":99},[],{"trials":20740,"activeCount":99},[],{"trials":20742,"activeCount":99},[],{"intervention":7425,"totalTrials":468,"cells":20744},{"EARLY_PHASE1":20745,"PHASE1":20747,"PHASE2":20753,"PHASE3":20755,"PHASE4":20757,"NA":20759},{"trials":20746,"activeCount":99},[],{"trials":20748,"activeCount":99},[20749],{"nctId":7415,"briefTitle":7416,"status":105,"phases":20750,"primaryCompletion":7418,"completion":7418,"start":7419,"enrollment":7420,"conditions":20751,"interventions":20752},[87],[1147,1467,7422],[6960,7424,7425],{"trials":20754,"activeCount":99},[],{"trials":20756,"activeCount":99},[],{"trials":20758,"activeCount":99},[],{"trials":20760,"activeCount":99},[],{"intervention":20762,"totalTrials":468,"cells":20763},"JNJ-64232025 IV",{"EARLY_PHASE1":20764,"PHASE1":20766,"PHASE2":20777,"PHASE3":20779,"PHASE4":20781,"NA":20783},{"trials":20765,"activeCount":99},[],{"trials":20767,"activeCount":99},[20768],{"nctId":20769,"briefTitle":20770,"status":105,"phases":20771,"primaryCompletion":20772,"completion":20772,"start":20773,"enrollment":1972,"conditions":20774,"interventions":20775},"NCT03550950","A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-64232025 in Healthy Participants",[87],"2019-02-05","2018-06-01",[15],[20762,20776],"JNJ-64232025 SC",{"trials":20778,"activeCount":99},[],{"trials":20780,"activeCount":99},[],{"trials":20782,"activeCount":99},[],{"trials":20784,"activeCount":99},[],{"intervention":20776,"totalTrials":468,"cells":20786},{"EARLY_PHASE1":20787,"PHASE1":20789,"PHASE2":20795,"PHASE3":20797,"PHASE4":20799,"NA":20801},{"trials":20788,"activeCount":99},[],{"trials":20790,"activeCount":99},[20791],{"nctId":20769,"briefTitle":20770,"status":105,"phases":20792,"primaryCompletion":20772,"completion":20772,"start":20773,"enrollment":1972,"conditions":20793,"interventions":20794},[87],[15],[20762,20776],{"trials":20796,"activeCount":99},[],{"trials":20798,"activeCount":99},[],{"trials":20800,"activeCount":99},[],{"trials":20802,"activeCount":99},[],{"intervention":20804,"totalTrials":468,"cells":20805},"[18F]-JNJ-70099731",{"EARLY_PHASE1":20806,"PHASE1":20808,"PHASE2":20818,"PHASE3":20820,"PHASE4":20822,"NA":20824},{"trials":20807,"activeCount":99},[],{"trials":20809,"activeCount":99},[20810],{"nctId":20811,"briefTitle":20812,"status":105,"phases":20813,"primaryCompletion":20814,"completion":20814,"start":20815,"enrollment":479,"conditions":20816,"interventions":20817},"NCT04911543","A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]-JNJ-70099731 in Healthy Male Participants",[87],"2022-02-01","2021-06-23",[15],[20804],{"trials":20819,"activeCount":99},[],{"trials":20821,"activeCount":99},[],{"trials":20823,"activeCount":99},[],{"trials":20825,"activeCount":99},[],{"intervention":20827,"totalTrials":468,"cells":20828},"JNJ-42756493 Current Clinical Formulation",{"EARLY_PHASE1":20829,"PHASE1":20831,"PHASE2":20842,"PHASE3":20844,"PHASE4":20846,"NA":20848},{"trials":20830,"activeCount":99},[],{"trials":20832,"activeCount":99},[20833],{"nctId":20834,"briefTitle":20835,"status":105,"phases":20836,"primaryCompletion":20837,"completion":20837,"start":8200,"enrollment":544,"conditions":20838,"interventions":20839},"NCT02466815","A Study to Assess the Relative Bioavailability of JNJ-42756493 Tablets",[87],"2015-08",[15],[20827,20840,20841],"JNJ-42756493 Prototype Formulation I","JNJ-42756493 Prototype Formulation II",{"trials":20843,"activeCount":99},[],{"trials":20845,"activeCount":99},[],{"trials":20847,"activeCount":99},[],{"trials":20849,"activeCount":99},[],{"intervention":20840,"totalTrials":468,"cells":20851},{"EARLY_PHASE1":20852,"PHASE1":20854,"PHASE2":20860,"PHASE3":20862,"PHASE4":20864,"NA":20866},{"trials":20853,"activeCount":99},[],{"trials":20855,"activeCount":99},[20856],{"nctId":20834,"briefTitle":20835,"status":105,"phases":20857,"primaryCompletion":20837,"completion":20837,"start":8200,"enrollment":544,"conditions":20858,"interventions":20859},[87],[15],[20827,20840,20841],{"trials":20861,"activeCount":99},[],{"trials":20863,"activeCount":99},[],{"trials":20865,"activeCount":99},[],{"trials":20867,"activeCount":99},[],{"intervention":20841,"totalTrials":468,"cells":20869},{"EARLY_PHASE1":20870,"PHASE1":20872,"PHASE2":20878,"PHASE3":20880,"PHASE4":20882,"NA":20884},{"trials":20871,"activeCount":99},[],{"trials":20873,"activeCount":99},[20874],{"nctId":20834,"briefTitle":20835,"status":105,"phases":20875,"primaryCompletion":20837,"completion":20837,"start":8200,"enrollment":544,"conditions":20876,"interventions":20877},[87],[15],[20827,20840,20841],{"trials":20879,"activeCount":99},[],{"trials":20881,"activeCount":99},[],{"trials":20883,"activeCount":99},[],{"trials":20885,"activeCount":99},[],{"intervention":20887,"totalTrials":468,"cells":20888},"JNJ-66525433",{"EARLY_PHASE1":20889,"PHASE1":20891,"PHASE2":20900,"PHASE3":20902,"PHASE4":20904,"NA":20906},{"trials":20890,"activeCount":99},[],{"trials":20892,"activeCount":99},[20893],{"nctId":20894,"briefTitle":20895,"status":125,"phases":20896,"primaryCompletion":20897,"completion":20897,"start":9395,"enrollment":3380,"conditions":20898,"interventions":20899},"NCT04457960","A Study of JNJ-66525433 in Healthy Participants and Participants With Ulcerative Colitis",[87],"2021-10-13",[15,27],[20887],{"trials":20901,"activeCount":99},[],{"trials":20903,"activeCount":99},[],{"trials":20905,"activeCount":99},[],{"trials":20907,"activeCount":99},[],{"intervention":20909,"totalTrials":468,"cells":20910},"Seltorexant Dose 1",{"EARLY_PHASE1":20911,"PHASE1":20913,"PHASE2":20924,"PHASE3":20926,"PHASE4":20928,"NA":20930},{"trials":20912,"activeCount":99},[],{"trials":20914,"activeCount":99},[20915],{"nctId":20916,"briefTitle":20917,"status":105,"phases":20918,"primaryCompletion":20919,"completion":20919,"start":8914,"enrollment":8662,"conditions":20920,"interventions":20921},"NCT04451187","A Study of Oral Seltorexant as an add-on Medication to an Antidepressant on On-road Driving Performance in Participants With Major Depressive Disorder",[87],"2023-03-16",[21],[20909,20922,20923],"Seltorexant Dose 2","Zopiclone",{"trials":20925,"activeCount":99},[],{"trials":20927,"activeCount":99},[],{"trials":20929,"activeCount":99},[],{"trials":20931,"activeCount":99},[],{"intervention":20922,"totalTrials":468,"cells":20933},{"EARLY_PHASE1":20934,"PHASE1":20936,"PHASE2":20942,"PHASE3":20944,"PHASE4":20946,"NA":20948},{"trials":20935,"activeCount":99},[],{"trials":20937,"activeCount":99},[20938],{"nctId":20916,"briefTitle":20917,"status":105,"phases":20939,"primaryCompletion":20919,"completion":20919,"start":8914,"enrollment":8662,"conditions":20940,"interventions":20941},[87],[21],[20909,20922,20923],{"trials":20943,"activeCount":99},[],{"trials":20945,"activeCount":99},[],{"trials":20947,"activeCount":99},[],{"trials":20949,"activeCount":99},[],{"intervention":20923,"totalTrials":468,"cells":20951},{"EARLY_PHASE1":20952,"PHASE1":20954,"PHASE2":20960,"PHASE3":20962,"PHASE4":20964,"NA":20966},{"trials":20953,"activeCount":99},[],{"trials":20955,"activeCount":99},[20956],{"nctId":20916,"briefTitle":20917,"status":105,"phases":20957,"primaryCompletion":20919,"completion":20919,"start":8914,"enrollment":8662,"conditions":20958,"interventions":20959},[87],[21],[20909,20922,20923],{"trials":20961,"activeCount":99},[],{"trials":20963,"activeCount":99},[],{"trials":20965,"activeCount":99},[],{"trials":20967,"activeCount":99},[],{"intervention":4418,"totalTrials":468,"cells":20969},{"EARLY_PHASE1":20970,"PHASE1":20972,"PHASE2":20978,"PHASE3":20980,"PHASE4":20982,"NA":20984},{"trials":20971,"activeCount":99},[],{"trials":20973,"activeCount":99},[20974],{"nctId":4411,"briefTitle":4412,"status":105,"phases":20975,"primaryCompletion":4414,"completion":4414,"start":4415,"enrollment":19,"conditions":20976,"interventions":20977},[87],[15],[4385,4418],{"trials":20979,"activeCount":99},[],{"trials":20981,"activeCount":99},[],{"trials":20983,"activeCount":99},[],{"trials":20985,"activeCount":99},[],{"intervention":5550,"totalTrials":468,"cells":20987},{"EARLY_PHASE1":20988,"PHASE1":20990,"PHASE2":20996,"PHASE3":20998,"PHASE4":21000,"NA":21002},{"trials":20989,"activeCount":99},[],{"trials":20991,"activeCount":99},[20992],{"nctId":5543,"briefTitle":5544,"status":105,"phases":20993,"primaryCompletion":5546,"completion":5546,"start":5547,"enrollment":169,"conditions":20994,"interventions":20995},[87],[15],[4318,5550],{"trials":20997,"activeCount":99},[],{"trials":20999,"activeCount":99},[],{"trials":21001,"activeCount":99},[],{"trials":21003,"activeCount":99},[],{"intervention":8451,"totalTrials":468,"cells":21005},{"EARLY_PHASE1":21006,"PHASE1":21008,"PHASE2":21014,"PHASE3":21016,"PHASE4":21018,"NA":21020},{"trials":21007,"activeCount":99},[],{"trials":21009,"activeCount":99},[21010],{"nctId":8447,"briefTitle":8394,"status":105,"phases":21011,"primaryCompletion":2218,"completion":2218,"start":8396,"enrollment":19,"conditions":21012,"interventions":21013},[87],[3331],[8391,8399,8451,8452],{"trials":21015,"activeCount":99},[],{"trials":21017,"activeCount":99},[],{"trials":21019,"activeCount":99},[],{"trials":21021,"activeCount":99},[],{"intervention":8452,"totalTrials":468,"cells":21023},{"EARLY_PHASE1":21024,"PHASE1":21026,"PHASE2":21032,"PHASE3":21034,"PHASE4":21036,"NA":21038},{"trials":21025,"activeCount":99},[],{"trials":21027,"activeCount":99},[21028],{"nctId":8447,"briefTitle":8394,"status":105,"phases":21029,"primaryCompletion":2218,"completion":2218,"start":8396,"enrollment":19,"conditions":21030,"interventions":21031},[87],[3331],[8391,8399,8451,8452],{"trials":21033,"activeCount":99},[],{"trials":21035,"activeCount":99},[],{"trials":21037,"activeCount":99},[],{"trials":21039,"activeCount":99},[],{"intervention":21041,"totalTrials":468,"cells":21042},"Formulation 2",{"EARLY_PHASE1":21043,"PHASE1":21045,"PHASE2":21054,"PHASE3":21056,"PHASE4":21058,"NA":21060},{"trials":21044,"activeCount":99},[],{"trials":21046,"activeCount":99},[21047],{"nctId":21048,"briefTitle":21049,"status":105,"phases":21050,"primaryCompletion":2218,"completion":2218,"start":1175,"enrollment":745,"conditions":21051,"interventions":21052},"NCT02117505","A Crossover Study to Evaluate Relative Bioavailability of Two JNJ-54781532 Tablet Formulations in Healthy Adult Participants",[87],[15],[21041,21053],"Formulation 1",{"trials":21055,"activeCount":99},[],{"trials":21057,"activeCount":99},[],{"trials":21059,"activeCount":99},[],{"trials":21061,"activeCount":99},[],{"intervention":21053,"totalTrials":468,"cells":21063},{"EARLY_PHASE1":21064,"PHASE1":21066,"PHASE2":21072,"PHASE3":21074,"PHASE4":21076,"NA":21078},{"trials":21065,"activeCount":99},[],{"trials":21067,"activeCount":99},[21068],{"nctId":21048,"briefTitle":21049,"status":105,"phases":21069,"primaryCompletion":2218,"completion":2218,"start":1175,"enrollment":745,"conditions":21070,"interventions":21071},[87],[15],[21041,21053],{"trials":21073,"activeCount":99},[],{"trials":21075,"activeCount":99},[],{"trials":21077,"activeCount":99},[],{"trials":21079,"activeCount":99},[],{"intervention":21081,"totalTrials":468,"cells":21082},"11C-JNJ-63779586",{"EARLY_PHASE1":21083,"PHASE1":21085,"PHASE2":21093,"PHASE3":21095,"PHASE4":21097,"NA":21099},{"trials":21084,"activeCount":99},[],{"trials":21086,"activeCount":99},[21087],{"nctId":21088,"briefTitle":21089,"status":105,"phases":21090,"primaryCompletion":8934,"completion":8934,"start":4292,"enrollment":129,"conditions":21091,"interventions":21092},"NCT03089918","A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain",[87],[4445],[21081],{"trials":21094,"activeCount":99},[],{"trials":21096,"activeCount":99},[],{"trials":21098,"activeCount":99},[],{"trials":21100,"activeCount":99},[],{"intervention":17992,"totalTrials":468,"cells":21102},{"EARLY_PHASE1":21103,"PHASE1":21105,"PHASE2":21111,"PHASE3":21113,"PHASE4":21115,"NA":21117},{"trials":21104,"activeCount":99},[],{"trials":21106,"activeCount":99},[21107],{"nctId":17986,"briefTitle":17987,"status":105,"phases":21108,"primaryCompletion":4223,"completion":4223,"start":3329,"enrollment":6987,"conditions":21109,"interventions":21110},[87],[15],[17979,17991,17992,17993,17994],{"trials":21112,"activeCount":99},[],{"trials":21114,"activeCount":99},[],{"trials":21116,"activeCount":99},[],{"trials":21118,"activeCount":99},[],{"intervention":17993,"totalTrials":468,"cells":21120},{"EARLY_PHASE1":21121,"PHASE1":21123,"PHASE2":21129,"PHASE3":21131,"PHASE4":21133,"NA":21135},{"trials":21122,"activeCount":99},[],{"trials":21124,"activeCount":99},[21125],{"nctId":17986,"briefTitle":17987,"status":105,"phases":21126,"primaryCompletion":4223,"completion":4223,"start":3329,"enrollment":6987,"conditions":21127,"interventions":21128},[87],[15],[17979,17991,17992,17993,17994],{"trials":21130,"activeCount":99},[],{"trials":21132,"activeCount":99},[],{"trials":21134,"activeCount":99},[],{"trials":21136,"activeCount":99},[],{"intervention":17994,"totalTrials":468,"cells":21138},{"EARLY_PHASE1":21139,"PHASE1":21141,"PHASE2":21147,"PHASE3":21149,"PHASE4":21151,"NA":21153},{"trials":21140,"activeCount":99},[],{"trials":21142,"activeCount":99},[21143],{"nctId":17986,"briefTitle":17987,"status":105,"phases":21144,"primaryCompletion":4223,"completion":4223,"start":3329,"enrollment":6987,"conditions":21145,"interventions":21146},[87],[15],[17979,17991,17992,17993,17994],{"trials":21148,"activeCount":99},[],{"trials":21150,"activeCount":99},[],{"trials":21152,"activeCount":99},[],{"trials":21154,"activeCount":99},[],{"intervention":18032,"totalTrials":468,"cells":21156},{"EARLY_PHASE1":21157,"PHASE1":21159,"PHASE2":21165,"PHASE3":21167,"PHASE4":21169,"NA":21171},{"trials":21158,"activeCount":99},[],{"trials":21160,"activeCount":99},[21161],{"nctId":18027,"briefTitle":18028,"status":105,"phases":21162,"primaryCompletion":3612,"completion":3612,"start":4223,"enrollment":1192,"conditions":21163,"interventions":21164},[87],[4445],[17991,18032],{"trials":21166,"activeCount":99},[],{"trials":21168,"activeCount":99},[],{"trials":21170,"activeCount":99},[],{"trials":21172,"activeCount":99},[],{"intervention":21174,"totalTrials":468,"cells":21175},"JNJ-78306358",{"EARLY_PHASE1":21176,"PHASE1":21178,"PHASE2":21188,"PHASE3":21190,"PHASE4":21192,"NA":21194},{"trials":21177,"activeCount":99},[],{"trials":21179,"activeCount":99},[21180],{"nctId":21181,"briefTitle":21182,"status":105,"phases":21183,"primaryCompletion":21184,"completion":21184,"start":21185,"enrollment":2108,"conditions":21186,"interventions":21187},"NCT04991740","A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors",[87],"2023-02-09","2021-10-24",[5932],[21174],{"trials":21189,"activeCount":99},[],{"trials":21191,"activeCount":99},[],{"trials":21193,"activeCount":99},[],{"trials":21195,"activeCount":99},[],{"intervention":12399,"totalTrials":468,"cells":21197},{"EARLY_PHASE1":21198,"PHASE1":21200,"PHASE2":21206,"PHASE3":21208,"PHASE4":21210,"NA":21212},{"trials":21199,"activeCount":99},[],{"trials":21201,"activeCount":99},[21202],{"nctId":12392,"briefTitle":12393,"status":105,"phases":21203,"primaryCompletion":8487,"completion":12395,"start":12396,"enrollment":1177,"conditions":21204,"interventions":21205},[87],[15],[12399,12370,12390],{"trials":21207,"activeCount":99},[],{"trials":21209,"activeCount":99},[],{"trials":21211,"activeCount":99},[],{"trials":21213,"activeCount":99},[],{"intervention":21215,"totalTrials":468,"cells":21216},"[18F]JNJ-64511070",{"EARLY_PHASE1":21217,"PHASE1":21219,"PHASE2":21228,"PHASE3":21230,"PHASE4":21232,"NA":21234},{"trials":21218,"activeCount":99},[],{"trials":21220,"activeCount":99},[21221],{"nctId":21222,"briefTitle":21223,"status":105,"phases":21224,"primaryCompletion":397,"completion":397,"start":21225,"enrollment":109,"conditions":21226,"interventions":21227},"NCT03270579","A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070",[87],"2017-09-12",[15],[21215],{"trials":21229,"activeCount":99},[],{"trials":21231,"activeCount":99},[],{"trials":21233,"activeCount":99},[],{"trials":21235,"activeCount":99},[],{"intervention":21237,"totalTrials":468,"cells":21238},"Tramodol Extended-Release",{"EARLY_PHASE1":21239,"PHASE1":21241,"PHASE2":21249,"PHASE3":21251,"PHASE4":21253,"NA":21255},{"trials":21240,"activeCount":99},[],{"trials":21242,"activeCount":99},[21243],{"nctId":21244,"briefTitle":21245,"status":105,"phases":21246,"primaryCompletion":5878,"completion":5878,"start":5845,"enrollment":22,"conditions":21247,"interventions":21248},"NCT01800682","A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants",[87],[15],[21237],{"trials":21250,"activeCount":99},[],{"trials":21252,"activeCount":99},[],{"trials":21254,"activeCount":99},[],{"trials":21256,"activeCount":99},[],{"intervention":10444,"totalTrials":468,"cells":21258},{"EARLY_PHASE1":21259,"PHASE1":21261,"PHASE2":21267,"PHASE3":21269,"PHASE4":21271,"NA":21273},{"trials":21260,"activeCount":99},[],{"trials":21262,"activeCount":99},[21263],{"nctId":10436,"briefTitle":10437,"status":125,"phases":21264,"primaryCompletion":10439,"completion":10440,"start":10441,"enrollment":656,"conditions":21265,"interventions":21266},[87],[15,2412],[10444,10429,7294,7295,10444],{"trials":21268,"activeCount":99},[],{"trials":21270,"activeCount":99},[],{"trials":21272,"activeCount":99},[],{"trials":21274,"activeCount":99},[],{"intervention":21276,"totalTrials":468,"cells":21277},"Treatment A: Canagliflozin 100 mg",{"EARLY_PHASE1":21278,"PHASE1":21280,"PHASE2":21289,"PHASE3":21291,"PHASE4":21293,"NA":21295},{"trials":21279,"activeCount":99},[],{"trials":21281,"activeCount":99},[21282],{"nctId":21283,"briefTitle":21284,"status":105,"phases":21285,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1177,"conditions":21286,"interventions":21287},"NCT01707316","A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers",[87],[15],[21276,21288],"Treatment B: Canagliflozin 300 mg",{"trials":21290,"activeCount":99},[],{"trials":21292,"activeCount":99},[],{"trials":21294,"activeCount":99},[],{"trials":21296,"activeCount":99},[],{"intervention":21288,"totalTrials":468,"cells":21298},{"EARLY_PHASE1":21299,"PHASE1":21301,"PHASE2":21307,"PHASE3":21309,"PHASE4":21311,"NA":21313},{"trials":21300,"activeCount":99},[],{"trials":21302,"activeCount":99},[21303],{"nctId":21283,"briefTitle":21284,"status":105,"phases":21304,"primaryCompletion":2535,"completion":2535,"start":3640,"enrollment":1177,"conditions":21305,"interventions":21306},[87],[15],[21276,21288],{"trials":21308,"activeCount":99},[],{"trials":21310,"activeCount":99},[],{"trials":21312,"activeCount":99},[],{"trials":21314,"activeCount":99},[],{"intervention":21316,"totalTrials":468,"cells":21317},"Part 1: JNJ-42756493",{"EARLY_PHASE1":21318,"PHASE1":21320,"PHASE2":21332,"PHASE3":21334,"PHASE4":21336,"NA":21338},{"trials":21319,"activeCount":99},[],{"trials":21321,"activeCount":99},[21322],{"nctId":21323,"briefTitle":21324,"status":105,"phases":21325,"primaryCompletion":21326,"completion":21326,"start":21327,"enrollment":28,"conditions":21328,"interventions":21330},"NCT01962532","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma",[87],"2016-01-28","2013-08-21",[5932,1509,7033,21329],"Esophagogastric Junction",[21316,21331],"Part 2: JNJ-42756493",{"trials":21333,"activeCount":99},[],{"trials":21335,"activeCount":99},[],{"trials":21337,"activeCount":99},[],{"trials":21339,"activeCount":99},[],{"intervention":21331,"totalTrials":468,"cells":21341},{"EARLY_PHASE1":21342,"PHASE1":21344,"PHASE2":21350,"PHASE3":21352,"PHASE4":21354,"NA":21356},{"trials":21343,"activeCount":99},[],{"trials":21345,"activeCount":99},[21346],{"nctId":21323,"briefTitle":21324,"status":105,"phases":21347,"primaryCompletion":21326,"completion":21326,"start":21327,"enrollment":28,"conditions":21348,"interventions":21349},[87],[5932,1509,7033,21329],[21316,21331],{"trials":21351,"activeCount":99},[],{"trials":21353,"activeCount":99},[],{"trials":21355,"activeCount":99},[],{"trials":21357,"activeCount":99},[],{"intervention":12682,"totalTrials":468,"cells":21359},{"EARLY_PHASE1":21360,"PHASE1":21362,"PHASE2":21368,"PHASE3":21370,"PHASE4":21372,"NA":21374},{"trials":21361,"activeCount":99},[],{"trials":21363,"activeCount":99},[21364],{"nctId":12677,"briefTitle":12678,"status":105,"phases":21365,"primaryCompletion":6033,"completion":6033,"start":8396,"enrollment":1177,"conditions":21366,"interventions":21367},[87],[15],[12657,12682],{"trials":21369,"activeCount":99},[],{"trials":21371,"activeCount":99},[],{"trials":21373,"activeCount":99},[],{"trials":21375,"activeCount":99},[],{"intervention":21377,"totalTrials":468,"cells":21378},"VAC85135",{"EARLY_PHASE1":21379,"PHASE1":21381,"PHASE2":21393,"PHASE3":21395,"PHASE4":21397,"NA":21399},{"trials":21380,"activeCount":99},[],{"trials":21382,"activeCount":99},[21383],{"nctId":21384,"briefTitle":21385,"status":105,"phases":21386,"primaryCompletion":21387,"completion":21387,"start":21388,"enrollment":5557,"conditions":21389,"interventions":21391},"NCT05444530","A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms",[87],"2025-06-24","2022-07-21",[21390],"Myeloproliferative Neoplasms",[21377,21392],"Ipilimumab",{"trials":21394,"activeCount":99},[],{"trials":21396,"activeCount":99},[],{"trials":21398,"activeCount":99},[],{"trials":21400,"activeCount":99},[],{"intervention":21392,"totalTrials":468,"cells":21402},{"EARLY_PHASE1":21403,"PHASE1":21405,"PHASE2":21411,"PHASE3":21413,"PHASE4":21415,"NA":21417},{"trials":21404,"activeCount":99},[],{"trials":21406,"activeCount":99},[21407],{"nctId":21384,"briefTitle":21385,"status":105,"phases":21408,"primaryCompletion":21387,"completion":21387,"start":21388,"enrollment":5557,"conditions":21409,"interventions":21410},[87],[21390],[21377,21392],{"trials":21412,"activeCount":99},[],{"trials":21414,"activeCount":99},[],{"trials":21416,"activeCount":99},[],{"trials":21418,"activeCount":99},[],{"intervention":21420,"totalTrials":468,"cells":21421},"Aripiprazole, oral formulation",{"EARLY_PHASE1":21422,"PHASE1":21424,"PHASE2":21439,"PHASE3":21441,"PHASE4":21443,"NA":21445},{"trials":21423,"activeCount":99},[],{"trials":21425,"activeCount":99},[21426],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21429,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21430,"interventions":21432},"NCT02087579","Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants",[87],[11912,32,21431,6036],"Bipolar Disorder",[21420,21433,21434,21435,21436,21437,21438],"Olanzapine, oral formulation","Paliperidone, oral formulation","Paliperidone, LAI","Quetiapine, oral formulation","Risperidone, oral formulation","Risperidone, LAI",{"trials":21440,"activeCount":99},[],{"trials":21442,"activeCount":99},[],{"trials":21444,"activeCount":99},[],{"trials":21446,"activeCount":99},[],{"intervention":21433,"totalTrials":468,"cells":21448},{"EARLY_PHASE1":21449,"PHASE1":21451,"PHASE2":21457,"PHASE3":21459,"PHASE4":21461,"NA":21463},{"trials":21450,"activeCount":99},[],{"trials":21452,"activeCount":99},[21453],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21454,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21455,"interventions":21456},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21458,"activeCount":99},[],{"trials":21460,"activeCount":99},[],{"trials":21462,"activeCount":99},[],{"trials":21464,"activeCount":99},[],{"intervention":21434,"totalTrials":468,"cells":21466},{"EARLY_PHASE1":21467,"PHASE1":21469,"PHASE2":21475,"PHASE3":21477,"PHASE4":21479,"NA":21481},{"trials":21468,"activeCount":99},[],{"trials":21470,"activeCount":99},[21471],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21472,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21473,"interventions":21474},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21476,"activeCount":99},[],{"trials":21478,"activeCount":99},[],{"trials":21480,"activeCount":99},[],{"trials":21482,"activeCount":99},[],{"intervention":21435,"totalTrials":468,"cells":21484},{"EARLY_PHASE1":21485,"PHASE1":21487,"PHASE2":21493,"PHASE3":21495,"PHASE4":21497,"NA":21499},{"trials":21486,"activeCount":99},[],{"trials":21488,"activeCount":99},[21489],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21490,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21491,"interventions":21492},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21494,"activeCount":99},[],{"trials":21496,"activeCount":99},[],{"trials":21498,"activeCount":99},[],{"trials":21500,"activeCount":99},[],{"intervention":21436,"totalTrials":468,"cells":21502},{"EARLY_PHASE1":21503,"PHASE1":21505,"PHASE2":21511,"PHASE3":21513,"PHASE4":21515,"NA":21517},{"trials":21504,"activeCount":99},[],{"trials":21506,"activeCount":99},[21507],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21508,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21509,"interventions":21510},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21512,"activeCount":99},[],{"trials":21514,"activeCount":99},[],{"trials":21516,"activeCount":99},[],{"trials":21518,"activeCount":99},[],{"intervention":21437,"totalTrials":468,"cells":21520},{"EARLY_PHASE1":21521,"PHASE1":21523,"PHASE2":21529,"PHASE3":21531,"PHASE4":21533,"NA":21535},{"trials":21522,"activeCount":99},[],{"trials":21524,"activeCount":99},[21525],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21526,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21527,"interventions":21528},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21530,"activeCount":99},[],{"trials":21532,"activeCount":99},[],{"trials":21534,"activeCount":99},[],{"trials":21536,"activeCount":99},[],{"intervention":21438,"totalTrials":468,"cells":21538},{"EARLY_PHASE1":21539,"PHASE1":21541,"PHASE2":21547,"PHASE3":21549,"PHASE4":21551,"NA":21553},{"trials":21540,"activeCount":99},[],{"trials":21542,"activeCount":99},[21543],{"nctId":21427,"briefTitle":21428,"status":105,"phases":21544,"primaryCompletion":3359,"completion":3444,"start":8396,"enrollment":1838,"conditions":21545,"interventions":21546},[87],[11912,32,21431,6036],[21420,21433,21434,21435,21436,21437,21438],{"trials":21548,"activeCount":99},[],{"trials":21550,"activeCount":99},[],{"trials":21552,"activeCount":99},[],{"trials":21554,"activeCount":99},[],{"intervention":21556,"totalTrials":468,"cells":21557},"JNJ-54135419",{"EARLY_PHASE1":21558,"PHASE1":21560,"PHASE2":21570,"PHASE3":21572,"PHASE4":21574,"NA":21576},{"trials":21559,"activeCount":99},[],{"trials":21561,"activeCount":99},[21562],{"nctId":21563,"briefTitle":21564,"status":105,"phases":21565,"primaryCompletion":21566,"completion":12628,"start":21567,"enrollment":33,"conditions":21568,"interventions":21569},"NCT04282746","A Study of Sublingually Administered (S)-Ketamine Oral Solution in Healthy Participants",[87],"2020-08-11","2020-02-18",[15],[21556],{"trials":21571,"activeCount":99},[],{"trials":21573,"activeCount":99},[],{"trials":21575,"activeCount":99},[],{"trials":21577,"activeCount":99},[],{"intervention":12465,"totalTrials":468,"cells":21579},{"EARLY_PHASE1":21580,"PHASE1":21582,"PHASE2":21588,"PHASE3":21590,"PHASE4":21592,"NA":21594},{"trials":21581,"activeCount":99},[],{"trials":21583,"activeCount":99},[21584],{"nctId":12459,"briefTitle":12460,"status":105,"phases":21585,"primaryCompletion":10982,"completion":10982,"start":12462,"enrollment":503,"conditions":21586,"interventions":21587},[87],[15],[12444,12465],{"trials":21589,"activeCount":99},[],{"trials":21591,"activeCount":99},[],{"trials":21593,"activeCount":99},[],{"trials":21595,"activeCount":99},[],{"intervention":21597,"totalTrials":468,"cells":21598},"JNJ-56022473",{"EARLY_PHASE1":21599,"PHASE1":21601,"PHASE2":21610,"PHASE3":21612,"PHASE4":21614,"NA":21616},{"trials":21600,"activeCount":99},[],{"trials":21602,"activeCount":99},[21603],{"nctId":21604,"briefTitle":21605,"status":137,"phases":21606,"primaryCompletion":21607,"completion":296,"start":9803,"enrollment":99,"conditions":21608,"interventions":21609},"NCT02920424","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus",[87],"2019-02-01",[2121],[21597],{"trials":21611,"activeCount":99},[],{"trials":21613,"activeCount":99},[],{"trials":21615,"activeCount":99},[],{"trials":21617,"activeCount":99},[],{"intervention":8350,"totalTrials":468,"cells":21619},{"EARLY_PHASE1":21620,"PHASE1":21622,"PHASE2":21628,"PHASE3":21630,"PHASE4":21632,"NA":21634},{"trials":21621,"activeCount":99},[],{"trials":21623,"activeCount":99},[21624],{"nctId":8342,"briefTitle":8343,"status":105,"phases":21625,"primaryCompletion":8345,"completion":8345,"start":8346,"enrollment":1507,"conditions":21626,"interventions":21627},[87],[15],[8349,1799,8350],{"trials":21629,"activeCount":99},[],{"trials":21631,"activeCount":99},[],{"trials":21633,"activeCount":99},[],{"trials":21635,"activeCount":99},[],{"intervention":5567,"totalTrials":468,"cells":21637},{"EARLY_PHASE1":21638,"PHASE1":21640,"PHASE2":21646,"PHASE3":21648,"PHASE4":21650,"NA":21652},{"trials":21639,"activeCount":99},[],{"trials":21641,"activeCount":99},[21642],{"nctId":5561,"briefTitle":5562,"status":137,"phases":21643,"primaryCompletion":4507,"completion":4507,"start":4184,"enrollment":99,"conditions":21644,"interventions":21645},[87],[5565],[4318,5567],{"trials":21647,"activeCount":99},[],{"trials":21649,"activeCount":99},[],{"trials":21651,"activeCount":99},[],{"trials":21653,"activeCount":99},[],{"intervention":21655,"totalTrials":468,"cells":21656},"JNJ-63623872 300 milligram",{"EARLY_PHASE1":21657,"PHASE1":21659,"PHASE2":21668,"PHASE3":21670,"PHASE4":21672,"NA":21674},{"trials":21658,"activeCount":99},[],{"trials":21660,"activeCount":99},[21661],{"nctId":21662,"briefTitle":21663,"status":105,"phases":21664,"primaryCompletion":8190,"completion":8190,"start":13040,"enrollment":2766,"conditions":21665,"interventions":21666},"NCT02659735","A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation",[87],[13062],[21655,21667,21667,21667],"JNJ-63623872 600 mg",{"trials":21669,"activeCount":99},[],{"trials":21671,"activeCount":99},[],{"trials":21673,"activeCount":99},[],{"trials":21675,"activeCount":99},[],{"intervention":21667,"totalTrials":468,"cells":21677},{"EARLY_PHASE1":21678,"PHASE1":21680,"PHASE2":21686,"PHASE3":21688,"PHASE4":21690,"NA":21692},{"trials":21679,"activeCount":99},[],{"trials":21681,"activeCount":99},[21682],{"nctId":21662,"briefTitle":21663,"status":105,"phases":21683,"primaryCompletion":8190,"completion":8190,"start":13040,"enrollment":2766,"conditions":21684,"interventions":21685},[87],[13062],[21655,21667,21667,21667],{"trials":21687,"activeCount":99},[],{"trials":21689,"activeCount":99},[],{"trials":21691,"activeCount":99},[],{"trials":21693,"activeCount":99},[],{"intervention":17147,"totalTrials":468,"cells":21695},{"EARLY_PHASE1":21696,"PHASE1":21698,"PHASE2":21704,"PHASE3":21706,"PHASE4":21708,"NA":21710},{"trials":21697,"activeCount":99},[],{"trials":21699,"activeCount":99},[21700],{"nctId":17142,"briefTitle":17143,"status":105,"phases":21701,"primaryCompletion":12947,"completion":12947,"start":956,"enrollment":399,"conditions":21702,"interventions":21703},[87],[15],[17120,17147],{"trials":21705,"activeCount":99},[],{"trials":21707,"activeCount":99},[],{"trials":21709,"activeCount":99},[],{"trials":21711,"activeCount":99},[],{"intervention":18002,"totalTrials":468,"cells":21713},{"EARLY_PHASE1":21714,"PHASE1":21716,"PHASE2":21722,"PHASE3":21724,"PHASE4":21726,"NA":21728},{"trials":21715,"activeCount":99},[],{"trials":21717,"activeCount":99},[21718],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21719,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21720,"interventions":21721},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21723,"activeCount":99},[],{"trials":21725,"activeCount":99},[],{"trials":21727,"activeCount":99},[],{"trials":21729,"activeCount":99},[],{"intervention":18003,"totalTrials":468,"cells":21731},{"EARLY_PHASE1":21732,"PHASE1":21734,"PHASE2":21740,"PHASE3":21742,"PHASE4":21744,"NA":21746},{"trials":21733,"activeCount":99},[],{"trials":21735,"activeCount":99},[21736],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21737,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21738,"interventions":21739},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21741,"activeCount":99},[],{"trials":21743,"activeCount":99},[],{"trials":21745,"activeCount":99},[],{"trials":21747,"activeCount":99},[],{"intervention":18004,"totalTrials":468,"cells":21749},{"EARLY_PHASE1":21750,"PHASE1":21752,"PHASE2":21758,"PHASE3":21760,"PHASE4":21762,"NA":21764},{"trials":21751,"activeCount":99},[],{"trials":21753,"activeCount":99},[21754],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21755,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21756,"interventions":21757},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21759,"activeCount":99},[],{"trials":21761,"activeCount":99},[],{"trials":21763,"activeCount":99},[],{"trials":21765,"activeCount":99},[],{"intervention":18005,"totalTrials":468,"cells":21767},{"EARLY_PHASE1":21768,"PHASE1":21770,"PHASE2":21776,"PHASE3":21778,"PHASE4":21780,"NA":21782},{"trials":21769,"activeCount":99},[],{"trials":21771,"activeCount":99},[21772],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21773,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21774,"interventions":21775},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21777,"activeCount":99},[],{"trials":21779,"activeCount":99},[],{"trials":21781,"activeCount":99},[],{"trials":21783,"activeCount":99},[],{"intervention":18006,"totalTrials":468,"cells":21785},{"EARLY_PHASE1":21786,"PHASE1":21788,"PHASE2":21794,"PHASE3":21796,"PHASE4":21798,"NA":21800},{"trials":21787,"activeCount":99},[],{"trials":21789,"activeCount":99},[21790],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21791,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21792,"interventions":21793},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21795,"activeCount":99},[],{"trials":21797,"activeCount":99},[],{"trials":21799,"activeCount":99},[],{"trials":21801,"activeCount":99},[],{"intervention":18007,"totalTrials":468,"cells":21803},{"EARLY_PHASE1":21804,"PHASE1":21806,"PHASE2":21812,"PHASE3":21814,"PHASE4":21816,"NA":21818},{"trials":21805,"activeCount":99},[],{"trials":21807,"activeCount":99},[21808],{"nctId":17996,"briefTitle":17997,"status":105,"phases":21809,"primaryCompletion":3328,"completion":3328,"start":15454,"enrollment":17999,"conditions":21810,"interventions":21811},[87],[15],[18002,17979,18003,18004,18005,18006,18007,18003],{"trials":21813,"activeCount":99},[],{"trials":21815,"activeCount":99},[],{"trials":21817,"activeCount":99},[],{"trials":21819,"activeCount":99},[],{"intervention":6094,"totalTrials":468,"cells":21821},{"EARLY_PHASE1":21822,"PHASE1":21824,"PHASE2":21830,"PHASE3":21832,"PHASE4":21834,"NA":21836},{"trials":21823,"activeCount":99},[],{"trials":21825,"activeCount":99},[21826],{"nctId":6086,"briefTitle":6087,"status":105,"phases":21827,"primaryCompletion":6089,"completion":6089,"start":6090,"enrollment":2515,"conditions":21828,"interventions":21829},[87],[6092],[6079,6094],{"trials":21831,"activeCount":99},[],{"trials":21833,"activeCount":99},[],{"trials":21835,"activeCount":99},[],{"trials":21837,"activeCount":99},[],{"intervention":21839,"totalTrials":468,"cells":21840},"Formulation A",{"EARLY_PHASE1":21841,"PHASE1":21843,"PHASE2":21862,"PHASE3":21864,"PHASE4":21866,"NA":21868},{"trials":21842,"activeCount":99},[],{"trials":21844,"activeCount":99},[21845],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21848,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21849,"interventions":21850},"NCT02813460","Study to Assess the Taste Profile of Different ALS-008176 Oral Liquid Formulations in Healthy Adult Participants",[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],"Formulation B","Formulation C","Formulation D","Formulation E","Formulation F","Formulation G1","Formulation G2","Formulation G3","Formulation H1","Formulation H2","Formulation H3",{"trials":21863,"activeCount":99},[],{"trials":21865,"activeCount":99},[],{"trials":21867,"activeCount":99},[],{"trials":21869,"activeCount":99},[],{"intervention":21851,"totalTrials":468,"cells":21871},{"EARLY_PHASE1":21872,"PHASE1":21874,"PHASE2":21880,"PHASE3":21882,"PHASE4":21884,"NA":21886},{"trials":21873,"activeCount":99},[],{"trials":21875,"activeCount":99},[21876],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21877,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21878,"interventions":21879},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21881,"activeCount":99},[],{"trials":21883,"activeCount":99},[],{"trials":21885,"activeCount":99},[],{"trials":21887,"activeCount":99},[],{"intervention":21852,"totalTrials":468,"cells":21889},{"EARLY_PHASE1":21890,"PHASE1":21892,"PHASE2":21898,"PHASE3":21900,"PHASE4":21902,"NA":21904},{"trials":21891,"activeCount":99},[],{"trials":21893,"activeCount":99},[21894],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21895,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21896,"interventions":21897},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21899,"activeCount":99},[],{"trials":21901,"activeCount":99},[],{"trials":21903,"activeCount":99},[],{"trials":21905,"activeCount":99},[],{"intervention":21853,"totalTrials":468,"cells":21907},{"EARLY_PHASE1":21908,"PHASE1":21910,"PHASE2":21916,"PHASE3":21918,"PHASE4":21920,"NA":21922},{"trials":21909,"activeCount":99},[],{"trials":21911,"activeCount":99},[21912],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21913,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21914,"interventions":21915},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21917,"activeCount":99},[],{"trials":21919,"activeCount":99},[],{"trials":21921,"activeCount":99},[],{"trials":21923,"activeCount":99},[],{"intervention":21854,"totalTrials":468,"cells":21925},{"EARLY_PHASE1":21926,"PHASE1":21928,"PHASE2":21934,"PHASE3":21936,"PHASE4":21938,"NA":21940},{"trials":21927,"activeCount":99},[],{"trials":21929,"activeCount":99},[21930],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21931,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21932,"interventions":21933},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21935,"activeCount":99},[],{"trials":21937,"activeCount":99},[],{"trials":21939,"activeCount":99},[],{"trials":21941,"activeCount":99},[],{"intervention":21855,"totalTrials":468,"cells":21943},{"EARLY_PHASE1":21944,"PHASE1":21946,"PHASE2":21952,"PHASE3":21954,"PHASE4":21956,"NA":21958},{"trials":21945,"activeCount":99},[],{"trials":21947,"activeCount":99},[21948],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21949,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21950,"interventions":21951},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21953,"activeCount":99},[],{"trials":21955,"activeCount":99},[],{"trials":21957,"activeCount":99},[],{"trials":21959,"activeCount":99},[],{"intervention":21856,"totalTrials":468,"cells":21961},{"EARLY_PHASE1":21962,"PHASE1":21964,"PHASE2":21970,"PHASE3":21972,"PHASE4":21974,"NA":21976},{"trials":21963,"activeCount":99},[],{"trials":21965,"activeCount":99},[21966],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21967,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21968,"interventions":21969},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21971,"activeCount":99},[],{"trials":21973,"activeCount":99},[],{"trials":21975,"activeCount":99},[],{"trials":21977,"activeCount":99},[],{"intervention":21857,"totalTrials":468,"cells":21979},{"EARLY_PHASE1":21980,"PHASE1":21982,"PHASE2":21988,"PHASE3":21990,"PHASE4":21992,"NA":21994},{"trials":21981,"activeCount":99},[],{"trials":21983,"activeCount":99},[21984],{"nctId":21846,"briefTitle":21847,"status":105,"phases":21985,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":21986,"interventions":21987},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":21989,"activeCount":99},[],{"trials":21991,"activeCount":99},[],{"trials":21993,"activeCount":99},[],{"trials":21995,"activeCount":99},[],{"intervention":21858,"totalTrials":468,"cells":21997},{"EARLY_PHASE1":21998,"PHASE1":22000,"PHASE2":22006,"PHASE3":22008,"PHASE4":22010,"NA":22012},{"trials":21999,"activeCount":99},[],{"trials":22001,"activeCount":99},[22002],{"nctId":21846,"briefTitle":21847,"status":105,"phases":22003,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":22004,"interventions":22005},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":22007,"activeCount":99},[],{"trials":22009,"activeCount":99},[],{"trials":22011,"activeCount":99},[],{"trials":22013,"activeCount":99},[],{"intervention":21859,"totalTrials":468,"cells":22015},{"EARLY_PHASE1":22016,"PHASE1":22018,"PHASE2":22024,"PHASE3":22026,"PHASE4":22028,"NA":22030},{"trials":22017,"activeCount":99},[],{"trials":22019,"activeCount":99},[22020],{"nctId":21846,"briefTitle":21847,"status":105,"phases":22021,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":22022,"interventions":22023},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":22025,"activeCount":99},[],{"trials":22027,"activeCount":99},[],{"trials":22029,"activeCount":99},[],{"trials":22031,"activeCount":99},[],{"intervention":21860,"totalTrials":468,"cells":22033},{"EARLY_PHASE1":22034,"PHASE1":22036,"PHASE2":22042,"PHASE3":22044,"PHASE4":22046,"NA":22048},{"trials":22035,"activeCount":99},[],{"trials":22037,"activeCount":99},[22038],{"nctId":21846,"briefTitle":21847,"status":105,"phases":22039,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":22040,"interventions":22041},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":22043,"activeCount":99},[],{"trials":22045,"activeCount":99},[],{"trials":22047,"activeCount":99},[],{"trials":22049,"activeCount":99},[],{"intervention":21861,"totalTrials":468,"cells":22051},{"EARLY_PHASE1":22052,"PHASE1":22054,"PHASE2":22060,"PHASE3":22062,"PHASE4":22064,"NA":22066},{"trials":22053,"activeCount":99},[],{"trials":22055,"activeCount":99},[22056],{"nctId":21846,"briefTitle":21847,"status":105,"phases":22057,"primaryCompletion":3596,"completion":3596,"start":3597,"enrollment":129,"conditions":22058,"interventions":22059},[87],[15],[21839,21851,21852,21853,21854,21855,21856,21857,21858,21859,21860,21861],{"trials":22061,"activeCount":99},[],{"trials":22063,"activeCount":99},[],{"trials":22065,"activeCount":99},[],{"trials":22067,"activeCount":99},[],{"intervention":22069,"totalTrials":468,"cells":22070},"JNJ-69095897",{"EARLY_PHASE1":22071,"PHASE1":22073,"PHASE2":22084,"PHASE3":22086,"PHASE4":22088,"NA":22090},{"trials":22072,"activeCount":99},[],{"trials":22074,"activeCount":99},[22075],{"nctId":22076,"briefTitle":22077,"status":125,"phases":22078,"primaryCompletion":22079,"completion":22080,"start":22081,"enrollment":1972,"conditions":22082,"interventions":22083},"NCT04920578","A Study of JNJ-69095897 in Healthy Participants",[87],"2023-01-27","2023-02-27","2021-06-16",[15],[22069],{"trials":22085,"activeCount":99},[],{"trials":22087,"activeCount":99},[],{"trials":22089,"activeCount":99},[],{"trials":22091,"activeCount":99},[],{"intervention":22093,"totalTrials":468,"cells":22094},"JNJ-88260237",{"EARLY_PHASE1":22095,"PHASE1":22097,"PHASE2":22106,"PHASE3":22108,"PHASE4":22110,"NA":22112},{"trials":22096,"activeCount":99},[],{"trials":22098,"activeCount":99},[22099],{"nctId":22100,"briefTitle":22101,"status":105,"phases":22102,"primaryCompletion":2409,"completion":2409,"start":22103,"enrollment":3138,"conditions":22104,"interventions":22105},"NCT05541315","A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants",[87],"2022-09-14",[15],[22093],{"trials":22107,"activeCount":99},[],{"trials":22109,"activeCount":99},[],{"trials":22111,"activeCount":99},[],{"trials":22113,"activeCount":99},[],{"intervention":17192,"totalTrials":468,"cells":22115},{"EARLY_PHASE1":22116,"PHASE1":22118,"PHASE2":22124,"PHASE3":22126,"PHASE4":22128,"NA":22130},{"trials":22117,"activeCount":99},[],{"trials":22119,"activeCount":99},[22120],{"nctId":17185,"briefTitle":17186,"status":125,"phases":22121,"primaryCompletion":17188,"completion":9968,"start":17189,"enrollment":12386,"conditions":22122,"interventions":22123},[87],[15],[17157,17192],{"trials":22125,"activeCount":99},[],{"trials":22127,"activeCount":99},[],{"trials":22129,"activeCount":99},[],{"trials":22131,"activeCount":99},[],{"intervention":22133,"totalTrials":468,"cells":22134},"JNJ-42756493: Part 1",{"EARLY_PHASE1":22135,"PHASE1":22137,"PHASE2":22151,"PHASE3":22153,"PHASE4":22155,"NA":22157},{"trials":22136,"activeCount":99},[],{"trials":22138,"activeCount":99},[22139],{"nctId":22140,"briefTitle":22141,"status":105,"phases":22142,"primaryCompletion":22143,"completion":22143,"start":22144,"enrollment":11,"conditions":22145,"interventions":22147},"NCT01703481","A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Adult Participants With Advanced or Refractory Solid Tumors or Lymphoma",[87],"2017-07-05","2012-06-15",[22146],"Tumor or Lymphoma",[22133,22148,22149,22150],"JNJ-42756493: Part 2","JNJ-42756493: Part 3","JNJ-42756493: Part 4",{"trials":22152,"activeCount":99},[],{"trials":22154,"activeCount":99},[],{"trials":22156,"activeCount":99},[],{"trials":22158,"activeCount":99},[],{"intervention":22148,"totalTrials":468,"cells":22160},{"EARLY_PHASE1":22161,"PHASE1":22163,"PHASE2":22169,"PHASE3":22171,"PHASE4":22173,"NA":22175},{"trials":22162,"activeCount":99},[],{"trials":22164,"activeCount":99},[22165],{"nctId":22140,"briefTitle":22141,"status":105,"phases":22166,"primaryCompletion":22143,"completion":22143,"start":22144,"enrollment":11,"conditions":22167,"interventions":22168},[87],[22146],[22133,22148,22149,22150],{"trials":22170,"activeCount":99},[],{"trials":22172,"activeCount":99},[],{"trials":22174,"activeCount":99},[],{"trials":22176,"activeCount":99},[],{"intervention":22149,"totalTrials":468,"cells":22178},{"EARLY_PHASE1":22179,"PHASE1":22181,"PHASE2":22187,"PHASE3":22189,"PHASE4":22191,"NA":22193},{"trials":22180,"activeCount":99},[],{"trials":22182,"activeCount":99},[22183],{"nctId":22140,"briefTitle":22141,"status":105,"phases":22184,"primaryCompletion":22143,"completion":22143,"start":22144,"enrollment":11,"conditions":22185,"interventions":22186},[87],[22146],[22133,22148,22149,22150],{"trials":22188,"activeCount":99},[],{"trials":22190,"activeCount":99},[],{"trials":22192,"activeCount":99},[],{"trials":22194,"activeCount":99},[],{"intervention":22150,"totalTrials":468,"cells":22196},{"EARLY_PHASE1":22197,"PHASE1":22199,"PHASE2":22205,"PHASE3":22207,"PHASE4":22209,"NA":22211},{"trials":22198,"activeCount":99},[],{"trials":22200,"activeCount":99},[22201],{"nctId":22140,"briefTitle":22141,"status":105,"phases":22202,"primaryCompletion":22143,"completion":22143,"start":22144,"enrollment":11,"conditions":22203,"interventions":22204},[87],[22146],[22133,22148,22149,22150],{"trials":22206,"activeCount":99},[],{"trials":22208,"activeCount":99},[],{"trials":22210,"activeCount":99},[],{"trials":22212,"activeCount":99},[],{"intervention":5581,"totalTrials":468,"cells":22214},{"EARLY_PHASE1":22215,"PHASE1":22217,"PHASE2":22223,"PHASE3":22225,"PHASE4":22227,"NA":22229},{"trials":22216,"activeCount":99},[],{"trials":22218,"activeCount":99},[22219],{"nctId":5576,"briefTitle":5577,"status":105,"phases":22220,"primaryCompletion":3444,"completion":3444,"start":4348,"enrollment":25,"conditions":22221,"interventions":22222},[87],[15],[4318,5581],{"trials":22224,"activeCount":99},[],{"trials":22226,"activeCount":99},[],{"trials":22228,"activeCount":99},[],{"trials":22230,"activeCount":99},[],{"intervention":3627,"totalTrials":468,"cells":22232},{"EARLY_PHASE1":22233,"PHASE1":22235,"PHASE2":22241,"PHASE3":22243,"PHASE4":22245,"NA":22247},{"trials":22234,"activeCount":99},[],{"trials":22236,"activeCount":99},[22237],{"nctId":3618,"briefTitle":3619,"status":105,"phases":22238,"primaryCompletion":3621,"completion":3621,"start":3622,"enrollment":25,"conditions":22239,"interventions":22240},[87],[3624],[46,3626,3627],{"trials":22242,"activeCount":99},[],{"trials":22244,"activeCount":99},[],{"trials":22246,"activeCount":99},[],{"trials":22248,"activeCount":99},[],{"intervention":5825,"totalTrials":468,"cells":22250},{"EARLY_PHASE1":22251,"PHASE1":22253,"PHASE2":22259,"PHASE3":22261,"PHASE4":22263,"NA":22265},{"trials":22252,"activeCount":99},[],{"trials":22254,"activeCount":99},[22255],{"nctId":5819,"briefTitle":5820,"status":105,"phases":22256,"primaryCompletion":3358,"completion":3358,"start":5530,"enrollment":245,"conditions":22257,"interventions":22258},[87],[5823],[5825,5826,1779],{"trials":22260,"activeCount":99},[],{"trials":22262,"activeCount":99},[],{"trials":22264,"activeCount":99},[],{"trials":22266,"activeCount":99},[],{"intervention":22268,"totalTrials":468,"cells":22269},"JNJ-55920839",{"EARLY_PHASE1":22270,"PHASE1":22272,"PHASE2":22280,"PHASE3":22282,"PHASE4":22284,"NA":22286},{"trials":22271,"activeCount":99},[],{"trials":22273,"activeCount":99},[22274],{"nctId":22275,"briefTitle":22276,"status":105,"phases":22277,"primaryCompletion":582,"completion":582,"start":13040,"enrollment":1380,"conditions":22278,"interventions":22279},"NCT02609789","A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus",[87],[2013,15],[22268],{"trials":22281,"activeCount":99},[],{"trials":22283,"activeCount":99},[],{"trials":22285,"activeCount":99},[],{"trials":22287,"activeCount":99},[],{"intervention":22289,"totalTrials":468,"cells":22290},"Treatment sequence 2",{"EARLY_PHASE1":22291,"PHASE1":22293,"PHASE2":22304,"PHASE3":22306,"PHASE4":22308,"NA":22310},{"trials":22292,"activeCount":99},[],{"trials":22294,"activeCount":99},[22295],{"nctId":22296,"briefTitle":22297,"status":105,"phases":22298,"primaryCompletion":2487,"completion":2487,"start":22299,"enrollment":3586,"conditions":22300,"interventions":22302},"NCT01366664","A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin",[87],"2011-04",[22301],"Ejaculation",[22289,22303],"Treatment sequence 1",{"trials":22305,"activeCount":99},[],{"trials":22307,"activeCount":99},[],{"trials":22309,"activeCount":99},[],{"trials":22311,"activeCount":99},[],{"intervention":22303,"totalTrials":468,"cells":22313},{"EARLY_PHASE1":22314,"PHASE1":22316,"PHASE2":22322,"PHASE3":22324,"PHASE4":22326,"NA":22328},{"trials":22315,"activeCount":99},[],{"trials":22317,"activeCount":99},[22318],{"nctId":22296,"briefTitle":22297,"status":105,"phases":22319,"primaryCompletion":2487,"completion":2487,"start":22299,"enrollment":3586,"conditions":22320,"interventions":22321},[87],[22301],[22289,22303],{"trials":22323,"activeCount":99},[],{"trials":22325,"activeCount":99},[],{"trials":22327,"activeCount":99},[],{"trials":22329,"activeCount":99},[],{"intervention":22331,"totalTrials":468,"cells":22332},"14C-lazertinib",{"EARLY_PHASE1":22333,"PHASE1":22335,"PHASE2":22344,"PHASE3":22346,"PHASE4":22348,"NA":22350},{"trials":22334,"activeCount":99},[],{"trials":22336,"activeCount":99},[22337],{"nctId":22338,"briefTitle":22339,"status":105,"phases":22340,"primaryCompletion":22341,"completion":22341,"start":3526,"enrollment":109,"conditions":22342,"interventions":22343},"NCT04410081","A Study of (14C)-JNJ-73841937 (Lazertinib) in Healthy Male Participants",[87],"2021-03-02",[15],[22331],{"trials":22345,"activeCount":99},[],{"trials":22347,"activeCount":99},[],{"trials":22349,"activeCount":99},[],{"trials":22351,"activeCount":99},[],{"intervention":22353,"totalTrials":468,"cells":22354},"JNJ 64304500",{"EARLY_PHASE1":22355,"PHASE1":22357,"PHASE2":22366,"PHASE3":22368,"PHASE4":22370,"NA":22372},{"trials":22356,"activeCount":99},[],{"trials":22358,"activeCount":99},[22359],{"nctId":22360,"briefTitle":22361,"status":105,"phases":22362,"primaryCompletion":12782,"completion":12782,"start":22363,"enrollment":678,"conditions":22364,"interventions":22365},"NCT04667052","A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants",[87],"2021-01-13",[15],[22353,22353],{"trials":22367,"activeCount":99},[],{"trials":22369,"activeCount":99},[],{"trials":22371,"activeCount":99},[],{"trials":22373,"activeCount":99},[],{"intervention":17772,"totalTrials":468,"cells":22375},{"EARLY_PHASE1":22376,"PHASE1":22378,"PHASE2":22384,"PHASE3":22386,"PHASE4":22388,"NA":22390},{"trials":22377,"activeCount":99},[],{"trials":22379,"activeCount":99},[22380],{"nctId":17765,"briefTitle":17766,"status":137,"phases":22381,"primaryCompletion":13208,"completion":13208,"start":17768,"enrollment":99,"conditions":22382,"interventions":22383},[87],[505],[17219,17771,17772],{"trials":22385,"activeCount":99},[],{"trials":22387,"activeCount":99},[],{"trials":22389,"activeCount":99},[],{"trials":22391,"activeCount":99},[],{"intervention":22393,"totalTrials":468,"cells":22394},"Abiraterone: Treatment A",{"EARLY_PHASE1":22395,"PHASE1":22397,"PHASE2":22410,"PHASE3":22412,"PHASE4":22414,"NA":22416},{"trials":22396,"activeCount":99},[],{"trials":22398,"activeCount":99},[22399],{"nctId":22400,"briefTitle":22401,"status":105,"phases":22402,"primaryCompletion":2513,"completion":2513,"start":3342,"enrollment":22403,"conditions":22404,"interventions":22406},"NCT01575587","A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men",[87],51,[22405],"Pharmacology",[22393,22407,22408,22409],"Abiraterone: Treatment B","Abiraterone: Treatment C","Abiraterone: Treatment D",{"trials":22411,"activeCount":99},[],{"trials":22413,"activeCount":99},[],{"trials":22415,"activeCount":99},[],{"trials":22417,"activeCount":99},[],{"intervention":22407,"totalTrials":468,"cells":22419},{"EARLY_PHASE1":22420,"PHASE1":22422,"PHASE2":22428,"PHASE3":22430,"PHASE4":22432,"NA":22434},{"trials":22421,"activeCount":99},[],{"trials":22423,"activeCount":99},[22424],{"nctId":22400,"briefTitle":22401,"status":105,"phases":22425,"primaryCompletion":2513,"completion":2513,"start":3342,"enrollment":22403,"conditions":22426,"interventions":22427},[87],[22405],[22393,22407,22408,22409],{"trials":22429,"activeCount":99},[],{"trials":22431,"activeCount":99},[],{"trials":22433,"activeCount":99},[],{"trials":22435,"activeCount":99},[],{"intervention":22408,"totalTrials":468,"cells":22437},{"EARLY_PHASE1":22438,"PHASE1":22440,"PHASE2":22446,"PHASE3":22448,"PHASE4":22450,"NA":22452},{"trials":22439,"activeCount":99},[],{"trials":22441,"activeCount":99},[22442],{"nctId":22400,"briefTitle":22401,"status":105,"phases":22443,"primaryCompletion":2513,"completion":2513,"start":3342,"enrollment":22403,"conditions":22444,"interventions":22445},[87],[22405],[22393,22407,22408,22409],{"trials":22447,"activeCount":99},[],{"trials":22449,"activeCount":99},[],{"trials":22451,"activeCount":99},[],{"trials":22453,"activeCount":99},[],{"intervention":22409,"totalTrials":468,"cells":22455},{"EARLY_PHASE1":22456,"PHASE1":22458,"PHASE2":22464,"PHASE3":22466,"PHASE4":22468,"NA":22470},{"trials":22457,"activeCount":99},[],{"trials":22459,"activeCount":99},[22460],{"nctId":22400,"briefTitle":22401,"status":105,"phases":22461,"primaryCompletion":2513,"completion":2513,"start":3342,"enrollment":22403,"conditions":22462,"interventions":22463},[87],[22405],[22393,22407,22408,22409],{"trials":22465,"activeCount":99},[],{"trials":22467,"activeCount":99},[],{"trials":22469,"activeCount":99},[],{"trials":22471,"activeCount":99},[],{"intervention":22473,"totalTrials":468,"cells":22474},"14C-JNJ-42847922 40 mg",{"EARLY_PHASE1":22475,"PHASE1":22477,"PHASE2":22485,"PHASE3":22487,"PHASE4":22489,"NA":22491},{"trials":22476,"activeCount":99},[],{"trials":22478,"activeCount":99},[22479],{"nctId":22480,"briefTitle":22481,"status":105,"phases":22482,"primaryCompletion":5521,"completion":5521,"start":208,"enrollment":109,"conditions":22483,"interventions":22484},"NCT03025022","A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects",[87],[15],[22473],{"trials":22486,"activeCount":99},[],{"trials":22488,"activeCount":99},[],{"trials":22490,"activeCount":99},[],{"trials":22492,"activeCount":99},[],{"intervention":17964,"totalTrials":468,"cells":22494},{"EARLY_PHASE1":22495,"PHASE1":22497,"PHASE2":22503,"PHASE3":22505,"PHASE4":22507,"NA":22509},{"trials":22496,"activeCount":99},[],{"trials":22498,"activeCount":99},[22499],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22500,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22501,"interventions":22502},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22504,"activeCount":99},[],{"trials":22506,"activeCount":99},[],{"trials":22508,"activeCount":99},[],{"trials":22510,"activeCount":99},[],{"intervention":17965,"totalTrials":468,"cells":22512},{"EARLY_PHASE1":22513,"PHASE1":22515,"PHASE2":22521,"PHASE3":22523,"PHASE4":22525,"NA":22527},{"trials":22514,"activeCount":99},[],{"trials":22516,"activeCount":99},[22517],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22518,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22519,"interventions":22520},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22522,"activeCount":99},[],{"trials":22524,"activeCount":99},[],{"trials":22526,"activeCount":99},[],{"trials":22528,"activeCount":99},[],{"intervention":17966,"totalTrials":468,"cells":22530},{"EARLY_PHASE1":22531,"PHASE1":22533,"PHASE2":22539,"PHASE3":22541,"PHASE4":22543,"NA":22545},{"trials":22532,"activeCount":99},[],{"trials":22534,"activeCount":99},[22535],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22536,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22537,"interventions":22538},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22540,"activeCount":99},[],{"trials":22542,"activeCount":99},[],{"trials":22544,"activeCount":99},[],{"trials":22546,"activeCount":99},[],{"intervention":17967,"totalTrials":468,"cells":22548},{"EARLY_PHASE1":22549,"PHASE1":22551,"PHASE2":22557,"PHASE3":22559,"PHASE4":22561,"NA":22563},{"trials":22550,"activeCount":99},[],{"trials":22552,"activeCount":99},[22553],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22554,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22555,"interventions":22556},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22558,"activeCount":99},[],{"trials":22560,"activeCount":99},[],{"trials":22562,"activeCount":99},[],{"trials":22564,"activeCount":99},[],{"intervention":17968,"totalTrials":468,"cells":22566},{"EARLY_PHASE1":22567,"PHASE1":22569,"PHASE2":22575,"PHASE3":22577,"PHASE4":22579,"NA":22581},{"trials":22568,"activeCount":99},[],{"trials":22570,"activeCount":99},[22571],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22572,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22573,"interventions":22574},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22576,"activeCount":99},[],{"trials":22578,"activeCount":99},[],{"trials":22580,"activeCount":99},[],{"trials":22582,"activeCount":99},[],{"intervention":17969,"totalTrials":468,"cells":22584},{"EARLY_PHASE1":22585,"PHASE1":22587,"PHASE2":22593,"PHASE3":22595,"PHASE4":22597,"NA":22599},{"trials":22586,"activeCount":99},[],{"trials":22588,"activeCount":99},[22589],{"nctId":17959,"briefTitle":17960,"status":105,"phases":22590,"primaryCompletion":3913,"completion":3913,"start":13813,"enrollment":6909,"conditions":22591,"interventions":22592},[87],[15],[17964,17965,17966,17967,17968,17969,17945],{"trials":22594,"activeCount":99},[],{"trials":22596,"activeCount":99},[],{"trials":22598,"activeCount":99},[],{"trials":22600,"activeCount":99},[],{"intervention":17518,"totalTrials":468,"cells":22602},{"EARLY_PHASE1":22603,"PHASE1":22605,"PHASE2":22611,"PHASE3":22613,"PHASE4":22615,"NA":22617},{"trials":22604,"activeCount":99},[],{"trials":22606,"activeCount":99},[22607],{"nctId":17513,"briefTitle":17514,"status":105,"phases":22608,"primaryCompletion":3444,"completion":3444,"start":3359,"enrollment":109,"conditions":22609,"interventions":22610},[87],[15],[17518,17519,13146],{"trials":22612,"activeCount":99},[],{"trials":22614,"activeCount":99},[],{"trials":22616,"activeCount":99},[],{"trials":22618,"activeCount":99},[],{"intervention":17519,"totalTrials":468,"cells":22620},{"EARLY_PHASE1":22621,"PHASE1":22623,"PHASE2":22629,"PHASE3":22631,"PHASE4":22633,"NA":22635},{"trials":22622,"activeCount":99},[],{"trials":22624,"activeCount":99},[22625],{"nctId":17513,"briefTitle":17514,"status":105,"phases":22626,"primaryCompletion":3444,"completion":3444,"start":3359,"enrollment":109,"conditions":22627,"interventions":22628},[87],[15],[17518,17519,13146],{"trials":22630,"activeCount":99},[],{"trials":22632,"activeCount":99},[],{"trials":22634,"activeCount":99},[],{"trials":22636,"activeCount":99},[],{"intervention":8400,"totalTrials":468,"cells":22638},{"EARLY_PHASE1":22639,"PHASE1":22641,"PHASE2":22647,"PHASE3":22649,"PHASE4":22651,"NA":22653},{"trials":22640,"activeCount":99},[],{"trials":22642,"activeCount":99},[22643],{"nctId":8393,"briefTitle":8394,"status":105,"phases":22644,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":245,"conditions":22645,"interventions":22646},[87],[3331],[8377,8399,8400,8401],{"trials":22648,"activeCount":99},[],{"trials":22650,"activeCount":99},[],{"trials":22652,"activeCount":99},[],{"trials":22654,"activeCount":99},[],{"intervention":8401,"totalTrials":468,"cells":22656},{"EARLY_PHASE1":22657,"PHASE1":22659,"PHASE2":22665,"PHASE3":22667,"PHASE4":22669,"NA":22671},{"trials":22658,"activeCount":99},[],{"trials":22660,"activeCount":99},[22661],{"nctId":8393,"briefTitle":8394,"status":105,"phases":22662,"primaryCompletion":1175,"completion":1175,"start":8396,"enrollment":245,"conditions":22663,"interventions":22664},[87],[3331],[8377,8399,8400,8401],{"trials":22666,"activeCount":99},[],{"trials":22668,"activeCount":99},[],{"trials":22670,"activeCount":99},[],{"trials":22672,"activeCount":99},[],{"intervention":8458,"totalTrials":468,"cells":22674},{"EARLY_PHASE1":22675,"PHASE1":22677,"PHASE2":22683,"PHASE3":22685,"PHASE4":22687,"NA":22689},{"trials":22676,"activeCount":99},[],{"trials":22678,"activeCount":99},[22679],{"nctId":8454,"briefTitle":8404,"status":105,"phases":22680,"primaryCompletion":2217,"completion":2217,"start":8396,"enrollment":571,"conditions":22681,"interventions":22682},[87],[15],[8391,8399,8458,8459],{"trials":22684,"activeCount":99},[],{"trials":22686,"activeCount":99},[],{"trials":22688,"activeCount":99},[],{"trials":22690,"activeCount":99},[],{"intervention":8459,"totalTrials":468,"cells":22692},{"EARLY_PHASE1":22693,"PHASE1":22695,"PHASE2":22701,"PHASE3":22703,"PHASE4":22705,"NA":22707},{"trials":22694,"activeCount":99},[],{"trials":22696,"activeCount":99},[22697],{"nctId":8454,"briefTitle":8404,"status":105,"phases":22698,"primaryCompletion":2217,"completion":2217,"start":8396,"enrollment":571,"conditions":22699,"interventions":22700},[87],[15],[8391,8399,8458,8459],{"trials":22702,"activeCount":99},[],{"trials":22704,"activeCount":99},[],{"trials":22706,"activeCount":99},[],{"trials":22708,"activeCount":99},[],{"intervention":1975,"totalTrials":468,"cells":22710},{"EARLY_PHASE1":22711,"PHASE1":22713,"PHASE2":22719,"PHASE3":22721,"PHASE4":22723,"NA":22725},{"trials":22712,"activeCount":99},[],{"trials":22714,"activeCount":99},[22715],{"nctId":1968,"briefTitle":1969,"status":105,"phases":22716,"primaryCompletion":1971,"completion":1971,"start":50,"enrollment":1972,"conditions":22717,"interventions":22718},[87],[15],[1953,446,1975],{"trials":22720,"activeCount":99},[],{"trials":22722,"activeCount":99},[],{"trials":22724,"activeCount":99},[],{"trials":22726,"activeCount":99},[],{"intervention":22728,"totalTrials":468,"cells":22729},"JNJ-64041809",{"EARLY_PHASE1":22730,"PHASE1":22732,"PHASE2":22742,"PHASE3":22744,"PHASE4":22746,"NA":22748},{"trials":22731,"activeCount":99},[],{"trials":22733,"activeCount":99},[22734],{"nctId":22735,"briefTitle":22736,"status":105,"phases":22737,"primaryCompletion":22738,"completion":22738,"start":22739,"enrollment":25,"conditions":22740,"interventions":22741},"NCT02625857","Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",[87],"2018-07-03","2015-12-10",[585],[22728,22728],{"trials":22743,"activeCount":99},[],{"trials":22745,"activeCount":99},[],{"trials":22747,"activeCount":99},[],{"trials":22749,"activeCount":99},[],{"intervention":22751,"totalTrials":468,"cells":22752},"Intravitreal anti-VEGF",{"EARLY_PHASE1":22753,"PHASE1":22755,"PHASE2":22769,"PHASE3":22771,"PHASE4":22773,"NA":22775},{"trials":22754,"activeCount":99},[],{"trials":22756,"activeCount":99},[22757],{"nctId":22758,"briefTitle":22759,"status":105,"phases":22760,"primaryCompletion":22761,"completion":22762,"start":22763,"enrollment":2472,"conditions":22764,"interventions":22766},"NCT03585556","AAVCAGsCD59 for the Treatment of Wet AMD",[87],"2020-01-29","2022-01-18","2018-09-13",[22765],"Wet Age-related Macular Degeneration",[22751,22767,22768],"Intravitreal AAVCAGsCD59","Oral prednisolone",{"trials":22770,"activeCount":99},[],{"trials":22772,"activeCount":99},[],{"trials":22774,"activeCount":99},[],{"trials":22776,"activeCount":99},[],{"intervention":22767,"totalTrials":468,"cells":22778},{"EARLY_PHASE1":22779,"PHASE1":22781,"PHASE2":22787,"PHASE3":22789,"PHASE4":22791,"NA":22793},{"trials":22780,"activeCount":99},[],{"trials":22782,"activeCount":99},[22783],{"nctId":22758,"briefTitle":22759,"status":105,"phases":22784,"primaryCompletion":22761,"completion":22762,"start":22763,"enrollment":2472,"conditions":22785,"interventions":22786},[87],[22765],[22751,22767,22768],{"trials":22788,"activeCount":99},[],{"trials":22790,"activeCount":99},[],{"trials":22792,"activeCount":99},[],{"trials":22794,"activeCount":99},[],{"intervention":22768,"totalTrials":468,"cells":22796},{"EARLY_PHASE1":22797,"PHASE1":22799,"PHASE2":22805,"PHASE3":22807,"PHASE4":22809,"NA":22811},{"trials":22798,"activeCount":99},[],{"trials":22800,"activeCount":99},[22801],{"nctId":22758,"briefTitle":22759,"status":105,"phases":22802,"primaryCompletion":22761,"completion":22762,"start":22763,"enrollment":2472,"conditions":22803,"interventions":22804},[87],[22765],[22751,22767,22768],{"trials":22806,"activeCount":99},[],{"trials":22808,"activeCount":99},[],{"trials":22810,"activeCount":99},[],{"trials":22812,"activeCount":99},[],{"intervention":1439,"totalTrials":468,"cells":22814},{"EARLY_PHASE1":22815,"PHASE1":22817,"PHASE2":22823,"PHASE3":22825,"PHASE4":22827,"NA":22829},{"trials":22816,"activeCount":99},[],{"trials":22818,"activeCount":99},[22819],{"nctId":1431,"briefTitle":1432,"status":105,"phases":22820,"primaryCompletion":1434,"completion":1434,"start":1435,"enrollment":1436,"conditions":22821,"interventions":22822},[87],[15],[681,1439],{"trials":22824,"activeCount":99},[],{"trials":22826,"activeCount":99},[],{"trials":22828,"activeCount":99},[],{"trials":22830,"activeCount":99},[],{"intervention":22832,"totalTrials":468,"cells":22833},"JNJ-74699157",{"EARLY_PHASE1":22834,"PHASE1":22836,"PHASE2":22848,"PHASE3":22850,"PHASE4":22852,"NA":22854},{"trials":22835,"activeCount":99},[],{"trials":22837,"activeCount":99},[22838],{"nctId":22839,"briefTitle":22840,"status":105,"phases":22841,"primaryCompletion":22842,"completion":22842,"start":22843,"enrollment":893,"conditions":22844,"interventions":22847},"NCT04006301","First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation",[87],"2020-07-13","2019-07-26",[5932,7476,22845,22846],"Non-small Cell Lung Cancer","Colorectal Cancer",[22832],{"trials":22849,"activeCount":99},[],{"trials":22851,"activeCount":99},[],{"trials":22853,"activeCount":99},[],{"trials":22855,"activeCount":99},[],{"intervention":17109,"totalTrials":468,"cells":22857},{"EARLY_PHASE1":22858,"PHASE1":22860,"PHASE2":22866,"PHASE3":22868,"PHASE4":22870,"NA":22872},{"trials":22859,"activeCount":99},[],{"trials":22861,"activeCount":99},[22862],{"nctId":17102,"briefTitle":17103,"status":105,"phases":22863,"primaryCompletion":17105,"completion":17106,"start":3791,"enrollment":1132,"conditions":22864,"interventions":22865},[87],[15],[17109,17110,13004,17077],{"trials":22867,"activeCount":99},[],{"trials":22869,"activeCount":99},[],{"trials":22871,"activeCount":99},[],{"trials":22873,"activeCount":99},[],{"intervention":17110,"totalTrials":468,"cells":22875},{"EARLY_PHASE1":22876,"PHASE1":22878,"PHASE2":22884,"PHASE3":22886,"PHASE4":22888,"NA":22890},{"trials":22877,"activeCount":99},[],{"trials":22879,"activeCount":99},[22880],{"nctId":17102,"briefTitle":17103,"status":105,"phases":22881,"primaryCompletion":17105,"completion":17106,"start":3791,"enrollment":1132,"conditions":22882,"interventions":22883},[87],[15],[17109,17110,13004,17077],{"trials":22885,"activeCount":99},[],{"trials":22887,"activeCount":99},[],{"trials":22889,"activeCount":99},[],{"trials":22891,"activeCount":99},[],{"intervention":22893,"totalTrials":468,"cells":22894},"100 mg CNTO 3157",{"EARLY_PHASE1":22895,"PHASE1":22897,"PHASE2":22907,"PHASE3":22909,"PHASE4":22911,"NA":22913},{"trials":22896,"activeCount":99},[],{"trials":22898,"activeCount":99},[22899],{"nctId":22900,"briefTitle":22901,"status":105,"phases":22902,"primaryCompletion":5530,"completion":5530,"start":4223,"enrollment":3138,"conditions":22903,"interventions":22904},"NCT02008279","A Safety and Pharmacokinetics Study of CNTO 3157 in Healthy Japanese and Caucasian Participants",[87],[15],[22893,22905,22906,22905],"300 mg CNTO 3157","600 mg CNTO 3157",{"trials":22908,"activeCount":99},[],{"trials":22910,"activeCount":99},[],{"trials":22912,"activeCount":99},[],{"trials":22914,"activeCount":99},[],{"intervention":22905,"totalTrials":468,"cells":22916},{"EARLY_PHASE1":22917,"PHASE1":22919,"PHASE2":22925,"PHASE3":22927,"PHASE4":22929,"NA":22931},{"trials":22918,"activeCount":99},[],{"trials":22920,"activeCount":99},[22921],{"nctId":22900,"briefTitle":22901,"status":105,"phases":22922,"primaryCompletion":5530,"completion":5530,"start":4223,"enrollment":3138,"conditions":22923,"interventions":22924},[87],[15],[22893,22905,22906,22905],{"trials":22926,"activeCount":99},[],{"trials":22928,"activeCount":99},[],{"trials":22930,"activeCount":99},[],{"trials":22932,"activeCount":99},[],{"intervention":22906,"totalTrials":468,"cells":22934},{"EARLY_PHASE1":22935,"PHASE1":22937,"PHASE2":22943,"PHASE3":22945,"PHASE4":22947,"NA":22949},{"trials":22936,"activeCount":99},[],{"trials":22938,"activeCount":99},[22939],{"nctId":22900,"briefTitle":22901,"status":105,"phases":22940,"primaryCompletion":5530,"completion":5530,"start":4223,"enrollment":3138,"conditions":22941,"interventions":22942},[87],[15],[22893,22905,22906,22905],{"trials":22944,"activeCount":99},[],{"trials":22946,"activeCount":99},[],{"trials":22948,"activeCount":99},[],{"trials":22950,"activeCount":99},[],{"intervention":22952,"totalTrials":468,"cells":22953},"JNJ-67670187",{"EARLY_PHASE1":22954,"PHASE1":22956,"PHASE2":22965,"PHASE3":22967,"PHASE4":22969,"NA":22971},{"trials":22955,"activeCount":99},[],{"trials":22957,"activeCount":99},[22958],{"nctId":22959,"briefTitle":22960,"status":105,"phases":22961,"primaryCompletion":13207,"completion":13207,"start":22962,"enrollment":1015,"conditions":22963,"interventions":22964},"NCT03723746","A Study to Evaluate the Safety and Tolerability of JNJ-67670187 in Healthy Participants",[87],"2018-10-25",[15],[22952],{"trials":22966,"activeCount":99},[],{"trials":22968,"activeCount":99},[],{"trials":22970,"activeCount":99},[],{"trials":22972,"activeCount":99},[],{"intervention":13035,"totalTrials":468,"cells":22974},{"EARLY_PHASE1":22975,"PHASE1":22977,"PHASE2":22983,"PHASE3":22985,"PHASE4":22987,"NA":22989},{"trials":22976,"activeCount":99},[],{"trials":22978,"activeCount":99},[22979],{"nctId":13030,"briefTitle":13031,"status":105,"phases":22980,"primaryCompletion":3633,"completion":3633,"start":3657,"enrollment":5557,"conditions":22981,"interventions":22982},[87],[15],[13035,13023],{"trials":22984,"activeCount":99},[],{"trials":22986,"activeCount":99},[],{"trials":22988,"activeCount":99},[],{"trials":22990,"activeCount":99},[],{"intervention":22992,"totalTrials":468,"cells":22993},"Hydromorphone 16 mg",{"EARLY_PHASE1":22994,"PHASE1":22996,"PHASE2":23004,"PHASE3":23006,"PHASE4":23008,"NA":23010},{"trials":22995,"activeCount":99},[],{"trials":22997,"activeCount":99},[22998],{"nctId":22999,"briefTitle":23000,"status":105,"phases":23001,"primaryCompletion":3342,"completion":3342,"start":8891,"enrollment":1857,"conditions":23002,"interventions":23003},"NCT01487564","Pharmacokinetic Profile of OROS Hydromorphone in Healthy Taiwanese Participants With Different Genotypes for the UGT2B7 Gene",[87],[3331],[22992],{"trials":23005,"activeCount":99},[],{"trials":23007,"activeCount":99},[],{"trials":23009,"activeCount":99},[],{"trials":23011,"activeCount":99},[],{"intervention":18291,"totalTrials":468,"cells":23013},{"EARLY_PHASE1":23014,"PHASE1":23016,"PHASE2":23022,"PHASE3":23024,"PHASE4":23026,"NA":23028},{"trials":23015,"activeCount":99},[],{"trials":23017,"activeCount":99},[23018],{"nctId":18285,"briefTitle":18286,"status":105,"phases":23019,"primaryCompletion":18288,"completion":18288,"start":12462,"enrollment":12482,"conditions":23020,"interventions":23021},[87],[15],[18278,18291],{"trials":23023,"activeCount":99},[],{"trials":23025,"activeCount":99},[],{"trials":23027,"activeCount":99},[],{"trials":23029,"activeCount":99},[],{"intervention":23031,"totalTrials":468,"cells":23032},"JNJ-64991524 Dose Level 1",{"EARLY_PHASE1":23033,"PHASE1":23035,"PHASE2":23052,"PHASE3":23054,"PHASE4":23056,"NA":23058},{"trials":23034,"activeCount":99},[],{"trials":23036,"activeCount":99},[23037],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23040,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23042,"interventions":23043},"NCT03346122","A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants",[87],"2017-11-15",[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],"JNJ-64991524 Dose Level 2","JNJ-64991524 Dose Level 3","JNJ-64991524 Dose Level 4","JNJ-64991524 Dose Level 5","JNJ-64991524 Dose Level 6","JNJ-64991524 Dose Level 7","JNJ-64991524 Dose Level 8","JNJ-64991524 Dose Level 9",{"trials":23053,"activeCount":99},[],{"trials":23055,"activeCount":99},[],{"trials":23057,"activeCount":99},[],{"trials":23059,"activeCount":99},[],{"intervention":23044,"totalTrials":468,"cells":23061},{"EARLY_PHASE1":23062,"PHASE1":23064,"PHASE2":23070,"PHASE3":23072,"PHASE4":23074,"NA":23076},{"trials":23063,"activeCount":99},[],{"trials":23065,"activeCount":99},[23066],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23067,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23068,"interventions":23069},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23071,"activeCount":99},[],{"trials":23073,"activeCount":99},[],{"trials":23075,"activeCount":99},[],{"trials":23077,"activeCount":99},[],{"intervention":23045,"totalTrials":468,"cells":23079},{"EARLY_PHASE1":23080,"PHASE1":23082,"PHASE2":23088,"PHASE3":23090,"PHASE4":23092,"NA":23094},{"trials":23081,"activeCount":99},[],{"trials":23083,"activeCount":99},[23084],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23085,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23086,"interventions":23087},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23089,"activeCount":99},[],{"trials":23091,"activeCount":99},[],{"trials":23093,"activeCount":99},[],{"trials":23095,"activeCount":99},[],{"intervention":23046,"totalTrials":468,"cells":23097},{"EARLY_PHASE1":23098,"PHASE1":23100,"PHASE2":23106,"PHASE3":23108,"PHASE4":23110,"NA":23112},{"trials":23099,"activeCount":99},[],{"trials":23101,"activeCount":99},[23102],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23103,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23104,"interventions":23105},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23107,"activeCount":99},[],{"trials":23109,"activeCount":99},[],{"trials":23111,"activeCount":99},[],{"trials":23113,"activeCount":99},[],{"intervention":23047,"totalTrials":468,"cells":23115},{"EARLY_PHASE1":23116,"PHASE1":23118,"PHASE2":23124,"PHASE3":23126,"PHASE4":23128,"NA":23130},{"trials":23117,"activeCount":99},[],{"trials":23119,"activeCount":99},[23120],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23121,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23122,"interventions":23123},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23125,"activeCount":99},[],{"trials":23127,"activeCount":99},[],{"trials":23129,"activeCount":99},[],{"trials":23131,"activeCount":99},[],{"intervention":23048,"totalTrials":468,"cells":23133},{"EARLY_PHASE1":23134,"PHASE1":23136,"PHASE2":23142,"PHASE3":23144,"PHASE4":23146,"NA":23148},{"trials":23135,"activeCount":99},[],{"trials":23137,"activeCount":99},[23138],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23139,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23140,"interventions":23141},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23143,"activeCount":99},[],{"trials":23145,"activeCount":99},[],{"trials":23147,"activeCount":99},[],{"trials":23149,"activeCount":99},[],{"intervention":23049,"totalTrials":468,"cells":23151},{"EARLY_PHASE1":23152,"PHASE1":23154,"PHASE2":23160,"PHASE3":23162,"PHASE4":23164,"NA":23166},{"trials":23153,"activeCount":99},[],{"trials":23155,"activeCount":99},[23156],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23157,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23158,"interventions":23159},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23161,"activeCount":99},[],{"trials":23163,"activeCount":99},[],{"trials":23165,"activeCount":99},[],{"trials":23167,"activeCount":99},[],{"intervention":23050,"totalTrials":468,"cells":23169},{"EARLY_PHASE1":23170,"PHASE1":23172,"PHASE2":23178,"PHASE3":23180,"PHASE4":23182,"NA":23184},{"trials":23171,"activeCount":99},[],{"trials":23173,"activeCount":99},[23174],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23175,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23176,"interventions":23177},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23179,"activeCount":99},[],{"trials":23181,"activeCount":99},[],{"trials":23183,"activeCount":99},[],{"trials":23185,"activeCount":99},[],{"intervention":23051,"totalTrials":468,"cells":23187},{"EARLY_PHASE1":23188,"PHASE1":23190,"PHASE2":23196,"PHASE3":23198,"PHASE4":23200,"NA":23202},{"trials":23189,"activeCount":99},[],{"trials":23191,"activeCount":99},[23192],{"nctId":23038,"briefTitle":23039,"status":105,"phases":23193,"primaryCompletion":3903,"completion":3903,"start":23041,"enrollment":19480,"conditions":23194,"interventions":23195},[87],[15],[23031,23044,23045,23046,23047,23048,23049,23050,23051],{"trials":23197,"activeCount":99},[],{"trials":23199,"activeCount":99},[],{"trials":23201,"activeCount":99},[],{"trials":23203,"activeCount":99},[],{"intervention":23205,"totalTrials":468,"cells":23206},"CA-18C3",{"EARLY_PHASE1":23207,"PHASE1":23209,"PHASE2":23221,"PHASE3":23223,"PHASE4":23225,"NA":23227},{"trials":23208,"activeCount":99},[],{"trials":23210,"activeCount":99},[23211],{"nctId":23212,"briefTitle":23213,"status":105,"phases":23214,"primaryCompletion":23215,"completion":23216,"start":23217,"enrollment":5557,"conditions":23218,"interventions":23220},"NCT01260545","Study of CA-18C3 in Subjects With Advanced Hematologic Malignancies",[87],"2012-06-30","2012-09-30","2011-04-30",[23219],"Hematologic Malignancies",[23205],{"trials":23222,"activeCount":99},[],{"trials":23224,"activeCount":99},[],{"trials":23226,"activeCount":99},[],{"trials":23228,"activeCount":99},[],{"intervention":1151,"totalTrials":468,"cells":23230},{"EARLY_PHASE1":23231,"PHASE1":23233,"PHASE2":23239,"PHASE3":23241,"PHASE4":23243,"NA":23245},{"trials":23232,"activeCount":99},[],{"trials":23234,"activeCount":99},[23235],{"nctId":1139,"briefTitle":1140,"status":137,"phases":23236,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":23237,"interventions":23238},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"trials":23240,"activeCount":99},[],{"trials":23242,"activeCount":99},[],{"trials":23244,"activeCount":99},[],{"trials":23246,"activeCount":99},[],{"intervention":1153,"totalTrials":468,"cells":23248},{"EARLY_PHASE1":23249,"PHASE1":23251,"PHASE2":23257,"PHASE3":23259,"PHASE4":23261,"NA":23263},{"trials":23250,"activeCount":99},[],{"trials":23252,"activeCount":99},[23253],{"nctId":1139,"briefTitle":1140,"status":137,"phases":23254,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":23255,"interventions":23256},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"trials":23258,"activeCount":99},[],{"trials":23260,"activeCount":99},[],{"trials":23262,"activeCount":99},[],{"trials":23264,"activeCount":99},[],{"intervention":1155,"totalTrials":468,"cells":23266},{"EARLY_PHASE1":23267,"PHASE1":23269,"PHASE2":23275,"PHASE3":23277,"PHASE4":23279,"NA":23281},{"trials":23268,"activeCount":99},[],{"trials":23270,"activeCount":99},[23271],{"nctId":1139,"briefTitle":1140,"status":137,"phases":23272,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":99,"conditions":23273,"interventions":23274},[87],[1146,1147,1148,1149],[1151,661,1152,1153,684,1154,1155],{"trials":23276,"activeCount":99},[],{"trials":23278,"activeCount":99},[],{"trials":23280,"activeCount":99},[],{"trials":23282,"activeCount":99},[],{"intervention":13043,"totalTrials":468,"cells":23284},{"EARLY_PHASE1":23285,"PHASE1":23287,"PHASE2":23293,"PHASE3":23295,"PHASE4":23297,"NA":23299},{"trials":23286,"activeCount":99},[],{"trials":23288,"activeCount":99},[23289],{"nctId":13037,"briefTitle":13038,"status":105,"phases":23290,"primaryCompletion":3597,"completion":3597,"start":13040,"enrollment":503,"conditions":23291,"interventions":23292},[87],[15],[13043,13044,13023],{"trials":23294,"activeCount":99},[],{"trials":23296,"activeCount":99},[],{"trials":23298,"activeCount":99},[],{"trials":23300,"activeCount":99},[],{"intervention":13044,"totalTrials":468,"cells":23302},{"EARLY_PHASE1":23303,"PHASE1":23305,"PHASE2":23311,"PHASE3":23313,"PHASE4":23315,"NA":23317},{"trials":23304,"activeCount":99},[],{"trials":23306,"activeCount":99},[23307],{"nctId":13037,"briefTitle":13038,"status":105,"phases":23308,"primaryCompletion":3597,"completion":3597,"start":13040,"enrollment":503,"conditions":23309,"interventions":23310},[87],[15],[13043,13044,13023],{"trials":23312,"activeCount":99},[],{"trials":23314,"activeCount":99},[],{"trials":23316,"activeCount":99},[],{"trials":23318,"activeCount":99},[],{"intervention":23320,"totalTrials":468,"cells":23321},"Rabeprazole sodium 5 mg",{"EARLY_PHASE1":23322,"PHASE1":23324,"PHASE2":23335,"PHASE3":23337,"PHASE4":23339,"NA":23341},{"trials":23323,"activeCount":99},[],{"trials":23325,"activeCount":99},[23326],{"nctId":23327,"briefTitle":23328,"status":105,"phases":23329,"primaryCompletion":2564,"completion":2564,"start":23330,"enrollment":22403,"conditions":23331,"interventions":23333},"NCT00747526","A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive",[87],"2007-12",[23332],"Gastroesophageal Reflux Disease (GERD)",[23320,23334],"Rabeprazole sodium 10 mg",{"trials":23336,"activeCount":99},[],{"trials":23338,"activeCount":99},[],{"trials":23340,"activeCount":99},[],{"trials":23342,"activeCount":99},[],{"intervention":23334,"totalTrials":468,"cells":23344},{"EARLY_PHASE1":23345,"PHASE1":23347,"PHASE2":23353,"PHASE3":23355,"PHASE4":23357,"NA":23359},{"trials":23346,"activeCount":99},[],{"trials":23348,"activeCount":99},[23349],{"nctId":23327,"briefTitle":23328,"status":105,"phases":23350,"primaryCompletion":2564,"completion":2564,"start":23330,"enrollment":22403,"conditions":23351,"interventions":23352},[87],[23332],[23320,23334],{"trials":23354,"activeCount":99},[],{"trials":23356,"activeCount":99},[],{"trials":23358,"activeCount":99},[],{"trials":23360,"activeCount":99},[],{"intervention":12573,"totalTrials":468,"cells":23362},{"EARLY_PHASE1":23363,"PHASE1":23365,"PHASE2":23371,"PHASE3":23373,"PHASE4":23375,"NA":23377},{"trials":23364,"activeCount":99},[],{"trials":23366,"activeCount":99},[23367],{"nctId":12566,"briefTitle":12567,"status":105,"phases":23368,"primaryCompletion":5899,"completion":5899,"start":5878,"enrollment":12569,"conditions":23369,"interventions":23370},[87],[12571],[6788,6788,6788,12573],{"trials":23372,"activeCount":99},[],{"trials":23374,"activeCount":99},[],{"trials":23376,"activeCount":99},[],{"trials":23378,"activeCount":99},[],{"intervention":23380,"totalTrials":468,"cells":23381},"Sequence 1",{"EARLY_PHASE1":23382,"PHASE1":23384,"PHASE2":23393,"PHASE3":23395,"PHASE4":23397,"NA":23399},{"trials":23383,"activeCount":99},[],{"trials":23385,"activeCount":99},[23386],{"nctId":23387,"briefTitle":23388,"status":105,"phases":23389,"primaryCompletion":9543,"completion":9543,"start":1176,"enrollment":544,"conditions":23390,"interventions":23391},"NCT01273480","A Study to Assess the Potential Effects of Rifampin on the Pharmacokinetics of Trabectedin in Patients With Advanced Malignancies",[87],[1179],[23380,23392,23380,23392],"Sequence 2",{"trials":23394,"activeCount":99},[],{"trials":23396,"activeCount":99},[],{"trials":23398,"activeCount":99},[],{"trials":23400,"activeCount":99},[],{"intervention":23392,"totalTrials":468,"cells":23402},{"EARLY_PHASE1":23403,"PHASE1":23405,"PHASE2":23411,"PHASE3":23413,"PHASE4":23415,"NA":23417},{"trials":23404,"activeCount":99},[],{"trials":23406,"activeCount":99},[23407],{"nctId":23387,"briefTitle":23388,"status":105,"phases":23408,"primaryCompletion":9543,"completion":9543,"start":1176,"enrollment":544,"conditions":23409,"interventions":23410},[87],[1179],[23380,23392,23380,23392],{"trials":23412,"activeCount":99},[],{"trials":23414,"activeCount":99},[],{"trials":23416,"activeCount":99},[],{"trials":23418,"activeCount":99},[],{"intervention":23420,"totalTrials":468,"cells":23421},"Rivaroxaban 15 mg",{"EARLY_PHASE1":23422,"PHASE1":23424,"PHASE2":23433,"PHASE3":23435,"PHASE4":23437,"NA":23439},{"trials":23423,"activeCount":99},[],{"trials":23425,"activeCount":99},[23426],{"nctId":23427,"briefTitle":23428,"status":105,"phases":23429,"primaryCompletion":3658,"completion":3658,"start":5493,"enrollment":169,"conditions":23430,"interventions":23432},"NCT02289703","A Pharmacokinetics, Pharmacodynamics and Safety Study of Single Dose of Rivaroxaban in Participants With End-Stage Renal Disease (ESRD) on Maintenance Hemodialysis",[87],[23431],"End-Stage Renal Disease",[23420],{"trials":23434,"activeCount":99},[],{"trials":23436,"activeCount":99},[],{"trials":23438,"activeCount":99},[],{"trials":23440,"activeCount":99},[],{"intervention":14155,"totalTrials":468,"cells":23442},{"EARLY_PHASE1":23443,"PHASE1":23445,"PHASE2":23451,"PHASE3":23453,"PHASE4":23455,"NA":23457},{"trials":23444,"activeCount":99},[],{"trials":23446,"activeCount":99},[23447],{"nctId":14149,"briefTitle":14150,"status":105,"phases":23448,"primaryCompletion":3392,"completion":3392,"start":9543,"enrollment":2515,"conditions":23449,"interventions":23450},[87],[15],[14154,14142,14155,14156],{"trials":23452,"activeCount":99},[],{"trials":23454,"activeCount":99},[],{"trials":23456,"activeCount":99},[],{"trials":23458,"activeCount":99},[],{"intervention":14156,"totalTrials":468,"cells":23460},{"EARLY_PHASE1":23461,"PHASE1":23463,"PHASE2":23469,"PHASE3":23471,"PHASE4":23473,"NA":23475},{"trials":23462,"activeCount":99},[],{"trials":23464,"activeCount":99},[23465],{"nctId":14149,"briefTitle":14150,"status":105,"phases":23466,"primaryCompletion":3392,"completion":3392,"start":9543,"enrollment":2515,"conditions":23467,"interventions":23468},[87],[15],[14154,14142,14155,14156],{"trials":23470,"activeCount":99},[],{"trials":23472,"activeCount":99},[],{"trials":23474,"activeCount":99},[],{"trials":23476,"activeCount":99},[],{"intervention":23478,"totalTrials":468,"cells":23479},"JNJ-75229414",{"EARLY_PHASE1":23480,"PHASE1":23482,"PHASE2":23492,"PHASE3":23494,"PHASE4":23496,"NA":23498},{"trials":23481,"activeCount":99},[],{"trials":23483,"activeCount":99},[23484],{"nctId":23485,"briefTitle":23486,"status":105,"phases":23487,"primaryCompletion":23488,"completion":23488,"start":286,"enrollment":1177,"conditions":23489,"interventions":23490},"NCT05022849","A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants",[87],"2026-03-11",[30],[23478,23491],"Bridging Therapy",{"trials":23493,"activeCount":99},[],{"trials":23495,"activeCount":99},[],{"trials":23497,"activeCount":99},[],{"trials":23499,"activeCount":99},[],{"intervention":23491,"totalTrials":468,"cells":23501},{"EARLY_PHASE1":23502,"PHASE1":23504,"PHASE2":23510,"PHASE3":23512,"PHASE4":23514,"NA":23516},{"trials":23503,"activeCount":99},[],{"trials":23505,"activeCount":99},[23506],{"nctId":23485,"briefTitle":23486,"status":105,"phases":23507,"primaryCompletion":23488,"completion":23488,"start":286,"enrollment":1177,"conditions":23508,"interventions":23509},[87],[30],[23478,23491],{"trials":23511,"activeCount":99},[],{"trials":23513,"activeCount":99},[],{"trials":23515,"activeCount":99},[],{"trials":23517,"activeCount":99},[],{"intervention":13380,"totalTrials":468,"cells":23519},{"EARLY_PHASE1":23520,"PHASE1":23522,"PHASE2":23528,"PHASE3":23530,"PHASE4":23532,"NA":23534},{"trials":23521,"activeCount":99},[],{"trials":23523,"activeCount":99},[23524],{"nctId":13375,"briefTitle":13376,"status":137,"phases":23525,"primaryCompletion":5556,"completion":2217,"start":3328,"enrollment":99,"conditions":23526,"interventions":23527},[87],[15],[13380,13368],{"trials":23529,"activeCount":99},[],{"trials":23531,"activeCount":99},[],{"trials":23533,"activeCount":99},[],{"trials":23535,"activeCount":99},[],{"intervention":176,"totalTrials":468,"cells":23537},{"EARLY_PHASE1":23538,"PHASE1":23540,"PHASE2":23546,"PHASE3":23548,"PHASE4":23550,"NA":23552},{"trials":23539,"activeCount":99},[],{"trials":23541,"activeCount":99},[23542],{"nctId":164,"briefTitle":165,"status":105,"phases":23543,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":23544,"interventions":23545},[87],[171],[94,173,174,175,176,177],{"trials":23547,"activeCount":99},[],{"trials":23549,"activeCount":99},[],{"trials":23551,"activeCount":99},[],{"trials":23553,"activeCount":99},[],{"intervention":10170,"totalTrials":468,"cells":23555},{"EARLY_PHASE1":23556,"PHASE1":23558,"PHASE2":23564,"PHASE3":23566,"PHASE4":23568,"NA":23570},{"trials":23557,"activeCount":99},[],{"trials":23559,"activeCount":99},[23560],{"nctId":10164,"briefTitle":10165,"status":105,"phases":23561,"primaryCompletion":10167,"completion":10167,"start":3564,"enrollment":503,"conditions":23562,"interventions":23563},[87],[15],[10157,10170],{"trials":23565,"activeCount":99},[],{"trials":23567,"activeCount":99},[],{"trials":23569,"activeCount":99},[],{"trials":23571,"activeCount":99},[],{"intervention":23573,"totalTrials":468,"cells":23574},"JNJ-67835989",{"EARLY_PHASE1":23575,"PHASE1":23577,"PHASE2":23587,"PHASE3":23589,"PHASE4":23591,"NA":23593},{"trials":23576,"activeCount":99},[],{"trials":23578,"activeCount":99},[23579],{"nctId":23580,"briefTitle":23581,"status":105,"phases":23582,"primaryCompletion":23583,"completion":23583,"start":1416,"enrollment":23584,"conditions":23585,"interventions":23586},"NCT04844411","A Study of JNJ-67835989 in Healthy Participants",[87],"2022-05-18",109,[15],[23573],{"trials":23588,"activeCount":99},[],{"trials":23590,"activeCount":99},[],{"trials":23592,"activeCount":99},[],{"trials":23594,"activeCount":99},[],{"intervention":16842,"totalTrials":468,"cells":23596},{"EARLY_PHASE1":23597,"PHASE1":23599,"PHASE2":23605,"PHASE3":23607,"PHASE4":23609,"NA":23611},{"trials":23598,"activeCount":99},[],{"trials":23600,"activeCount":99},[23601],{"nctId":16835,"briefTitle":16836,"status":105,"phases":23602,"primaryCompletion":16838,"completion":16838,"start":16839,"enrollment":22,"conditions":23603,"interventions":23604},[87],[15],[16819,16842],{"trials":23606,"activeCount":99},[],{"trials":23608,"activeCount":99},[],{"trials":23610,"activeCount":99},[],{"trials":23612,"activeCount":99},[],{"intervention":13873,"totalTrials":468,"cells":23614},{"EARLY_PHASE1":23615,"PHASE1":23617,"PHASE2":23623,"PHASE3":23625,"PHASE4":23627,"NA":23629},{"trials":23616,"activeCount":99},[],{"trials":23618,"activeCount":99},[23619],{"nctId":13866,"briefTitle":13867,"status":105,"phases":23620,"primaryCompletion":13869,"completion":13869,"start":13870,"enrollment":9507,"conditions":23621,"interventions":23622},[87],[15],[13859,13873],{"trials":23624,"activeCount":99},[],{"trials":23626,"activeCount":99},[],{"trials":23628,"activeCount":99},[],{"trials":23630,"activeCount":99},[],{"intervention":13051,"totalTrials":468,"cells":23632},{"EARLY_PHASE1":23633,"PHASE1":23635,"PHASE2":23641,"PHASE3":23643,"PHASE4":23645,"NA":23647},{"trials":23634,"activeCount":99},[],{"trials":23636,"activeCount":99},[23637],{"nctId":13046,"briefTitle":13047,"status":105,"phases":23638,"primaryCompletion":8190,"completion":8190,"start":3633,"enrollment":1436,"conditions":23639,"interventions":23640},[87],[15],[13051,13052,13023,3616],{"trials":23642,"activeCount":99},[],{"trials":23644,"activeCount":99},[],{"trials":23646,"activeCount":99},[],{"trials":23648,"activeCount":99},[],{"intervention":13052,"totalTrials":468,"cells":23650},{"EARLY_PHASE1":23651,"PHASE1":23653,"PHASE2":23659,"PHASE3":23661,"PHASE4":23663,"NA":23665},{"trials":23652,"activeCount":99},[],{"trials":23654,"activeCount":99},[23655],{"nctId":13046,"briefTitle":13047,"status":105,"phases":23656,"primaryCompletion":8190,"completion":8190,"start":3633,"enrollment":1436,"conditions":23657,"interventions":23658},[87],[15],[13051,13052,13023,3616],{"trials":23660,"activeCount":99},[],{"trials":23662,"activeCount":99},[],{"trials":23664,"activeCount":99},[],{"trials":23666,"activeCount":99},[],{"intervention":16686,"totalTrials":468,"cells":23668},{"EARLY_PHASE1":23669,"PHASE1":23671,"PHASE2":23677,"PHASE3":23679,"PHASE4":23681,"NA":23683},{"trials":23670,"activeCount":99},[],{"trials":23672,"activeCount":99},[23673],{"nctId":16681,"briefTitle":16682,"status":105,"phases":23674,"primaryCompletion":3359,"completion":3359,"start":6033,"enrollment":1787,"conditions":23675,"interventions":23676},[87],[15],[16686,16687,16688,3616,16689],{"trials":23678,"activeCount":99},[],{"trials":23680,"activeCount":99},[],{"trials":23682,"activeCount":99},[],{"trials":23684,"activeCount":99},[],{"intervention":16687,"totalTrials":468,"cells":23686},{"EARLY_PHASE1":23687,"PHASE1":23689,"PHASE2":23695,"PHASE3":23697,"PHASE4":23699,"NA":23701},{"trials":23688,"activeCount":99},[],{"trials":23690,"activeCount":99},[23691],{"nctId":16681,"briefTitle":16682,"status":105,"phases":23692,"primaryCompletion":3359,"completion":3359,"start":6033,"enrollment":1787,"conditions":23693,"interventions":23694},[87],[15],[16686,16687,16688,3616,16689],{"trials":23696,"activeCount":99},[],{"trials":23698,"activeCount":99},[],{"trials":23700,"activeCount":99},[],{"trials":23702,"activeCount":99},[],{"intervention":16688,"totalTrials":468,"cells":23704},{"EARLY_PHASE1":23705,"PHASE1":23707,"PHASE2":23713,"PHASE3":23715,"PHASE4":23717,"NA":23719},{"trials":23706,"activeCount":99},[],{"trials":23708,"activeCount":99},[23709],{"nctId":16681,"briefTitle":16682,"status":105,"phases":23710,"primaryCompletion":3359,"completion":3359,"start":6033,"enrollment":1787,"conditions":23711,"interventions":23712},[87],[15],[16686,16687,16688,3616,16689],{"trials":23714,"activeCount":99},[],{"trials":23716,"activeCount":99},[],{"trials":23718,"activeCount":99},[],{"trials":23720,"activeCount":99},[],{"intervention":16689,"totalTrials":468,"cells":23722},{"EARLY_PHASE1":23723,"PHASE1":23725,"PHASE2":23731,"PHASE3":23733,"PHASE4":23735,"NA":23737},{"trials":23724,"activeCount":99},[],{"trials":23726,"activeCount":99},[23727],{"nctId":16681,"briefTitle":16682,"status":105,"phases":23728,"primaryCompletion":3359,"completion":3359,"start":6033,"enrollment":1787,"conditions":23729,"interventions":23730},[87],[15],[16686,16687,16688,3616,16689],{"trials":23732,"activeCount":99},[],{"trials":23734,"activeCount":99},[],{"trials":23736,"activeCount":99},[],{"trials":23738,"activeCount":99},[],{"intervention":16970,"totalTrials":468,"cells":23740},{"EARLY_PHASE1":23741,"PHASE1":23743,"PHASE2":23749,"PHASE3":23751,"PHASE4":23753,"NA":23755},{"trials":23742,"activeCount":99},[],{"trials":23744,"activeCount":99},[23745],{"nctId":16965,"briefTitle":16966,"status":105,"phases":23746,"primaryCompletion":4605,"completion":4605,"start":6841,"enrollment":479,"conditions":23747,"interventions":23748},[87],[15],[16970,16932],{"trials":23750,"activeCount":99},[],{"trials":23752,"activeCount":99},[],{"trials":23754,"activeCount":99},[],{"trials":23756,"activeCount":99},[],{"intervention":23758,"totalTrials":468,"cells":23759},"Part 1: CNTO 7160",{"EARLY_PHASE1":23760,"PHASE1":23762,"PHASE2":23775,"PHASE3":23777,"PHASE4":23779,"NA":23781},{"trials":23761,"activeCount":99},[],{"trials":23763,"activeCount":99},[23764],{"nctId":23765,"briefTitle":23766,"status":105,"phases":23767,"primaryCompletion":23768,"completion":23768,"start":23769,"enrollment":595,"conditions":23770,"interventions":23771},"NCT02345928","A Single Ascending Dose Study in Healthy Participants and Multiple Ascending Dose Study of CNTO 7160 in Participants With Asthma and Participants With Atopic Dermatitis",[87],"2017-03-16","2014-08-05",[12585,13849,15],[23758,23772,23773,23774],"Part 2 (Asthma): CNTO 7160","Part 2 (Atopic Dermatitis): CNTO 7160","Part 1 and Part 2: Placebo",{"trials":23776,"activeCount":99},[],{"trials":23778,"activeCount":99},[],{"trials":23780,"activeCount":99},[],{"trials":23782,"activeCount":99},[],{"intervention":23772,"totalTrials":468,"cells":23784},{"EARLY_PHASE1":23785,"PHASE1":23787,"PHASE2":23793,"PHASE3":23795,"PHASE4":23797,"NA":23799},{"trials":23786,"activeCount":99},[],{"trials":23788,"activeCount":99},[23789],{"nctId":23765,"briefTitle":23766,"status":105,"phases":23790,"primaryCompletion":23768,"completion":23768,"start":23769,"enrollment":595,"conditions":23791,"interventions":23792},[87],[12585,13849,15],[23758,23772,23773,23774],{"trials":23794,"activeCount":99},[],{"trials":23796,"activeCount":99},[],{"trials":23798,"activeCount":99},[],{"trials":23800,"activeCount":99},[],{"intervention":23773,"totalTrials":468,"cells":23802},{"EARLY_PHASE1":23803,"PHASE1":23805,"PHASE2":23811,"PHASE3":23813,"PHASE4":23815,"NA":23817},{"trials":23804,"activeCount":99},[],{"trials":23806,"activeCount":99},[23807],{"nctId":23765,"briefTitle":23766,"status":105,"phases":23808,"primaryCompletion":23768,"completion":23768,"start":23769,"enrollment":595,"conditions":23809,"interventions":23810},[87],[12585,13849,15],[23758,23772,23773,23774],{"trials":23812,"activeCount":99},[],{"trials":23814,"activeCount":99},[],{"trials":23816,"activeCount":99},[],{"trials":23818,"activeCount":99},[],{"intervention":23774,"totalTrials":468,"cells":23820},{"EARLY_PHASE1":23821,"PHASE1":23823,"PHASE2":23829,"PHASE3":23831,"PHASE4":23833,"NA":23835},{"trials":23822,"activeCount":99},[],{"trials":23824,"activeCount":99},[23825],{"nctId":23765,"briefTitle":23766,"status":105,"phases":23826,"primaryCompletion":23768,"completion":23768,"start":23769,"enrollment":595,"conditions":23827,"interventions":23828},[87],[12585,13849,15],[23758,23772,23773,23774],{"trials":23830,"activeCount":99},[],{"trials":23832,"activeCount":99},[],{"trials":23834,"activeCount":99},[],{"trials":23836,"activeCount":99},[],{"intervention":23838,"totalTrials":468,"cells":23839},"Rivaroxaban 20 mg twice daily",{"EARLY_PHASE1":23840,"PHASE1":23842,"PHASE2":23853,"PHASE3":23855,"PHASE4":23857,"NA":23859},{"trials":23841,"activeCount":99},[],{"trials":23843,"activeCount":99},[23844],{"nctId":23845,"briefTitle":23846,"status":105,"phases":23847,"primaryCompletion":2535,"completion":2535,"start":5899,"enrollment":95,"conditions":23848,"interventions":23849},"NCT01656330","A Study to Assess the Effects of 2 Different Prothrombin Complex Concentrates on the Pharmacodynamics of Rivaroxaban in Healthy Adult Volunteers",[87],[15],[23838,23850,23851,23852],"Rivaroxaban 20 mg once daily","Profilnine SD","Beriplex P\u002FN",{"trials":23854,"activeCount":99},[],{"trials":23856,"activeCount":99},[],{"trials":23858,"activeCount":99},[],{"trials":23860,"activeCount":99},[],{"intervention":23850,"totalTrials":468,"cells":23862},{"EARLY_PHASE1":23863,"PHASE1":23865,"PHASE2":23871,"PHASE3":23873,"PHASE4":23875,"NA":23877},{"trials":23864,"activeCount":99},[],{"trials":23866,"activeCount":99},[23867],{"nctId":23845,"briefTitle":23846,"status":105,"phases":23868,"primaryCompletion":2535,"completion":2535,"start":5899,"enrollment":95,"conditions":23869,"interventions":23870},[87],[15],[23838,23850,23851,23852],{"trials":23872,"activeCount":99},[],{"trials":23874,"activeCount":99},[],{"trials":23876,"activeCount":99},[],{"trials":23878,"activeCount":99},[],{"intervention":23851,"totalTrials":468,"cells":23880},{"EARLY_PHASE1":23881,"PHASE1":23883,"PHASE2":23889,"PHASE3":23891,"PHASE4":23893,"NA":23895},{"trials":23882,"activeCount":99},[],{"trials":23884,"activeCount":99},[23885],{"nctId":23845,"briefTitle":23846,"status":105,"phases":23886,"primaryCompletion":2535,"completion":2535,"start":5899,"enrollment":95,"conditions":23887,"interventions":23888},[87],[15],[23838,23850,23851,23852],{"trials":23890,"activeCount":99},[],{"trials":23892,"activeCount":99},[],{"trials":23894,"activeCount":99},[],{"trials":23896,"activeCount":99},[],{"intervention":23852,"totalTrials":468,"cells":23898},{"EARLY_PHASE1":23899,"PHASE1":23901,"PHASE2":23907,"PHASE3":23909,"PHASE4":23911,"NA":23913},{"trials":23900,"activeCount":99},[],{"trials":23902,"activeCount":99},[23903],{"nctId":23845,"briefTitle":23846,"status":105,"phases":23904,"primaryCompletion":2535,"completion":2535,"start":5899,"enrollment":95,"conditions":23905,"interventions":23906},[87],[15],[23838,23850,23851,23852],{"trials":23908,"activeCount":99},[],{"trials":23910,"activeCount":99},[],{"trials":23912,"activeCount":99},[],{"trials":23914,"activeCount":99},[],{"intervention":1168,"totalTrials":468,"cells":23916},{"EARLY_PHASE1":23917,"PHASE1":23919,"PHASE2":23925,"PHASE3":23927,"PHASE4":23929,"NA":23931},{"trials":23918,"activeCount":99},[],{"trials":23920,"activeCount":99},[23921],{"nctId":1157,"briefTitle":1158,"status":105,"phases":23922,"primaryCompletion":1160,"completion":1161,"start":1162,"enrollment":1163,"conditions":23923,"interventions":23924},[87],[18],[681,1166,707,684,1167,496,1168,1169,1170,1096,683,878],{"trials":23926,"activeCount":99},[],{"trials":23928,"activeCount":99},[],{"trials":23930,"activeCount":99},[],{"trials":23932,"activeCount":99},[],{"intervention":9957,"totalTrials":468,"cells":23934},{"EARLY_PHASE1":23935,"PHASE1":23937,"PHASE2":23943,"PHASE3":23945,"PHASE4":23947,"NA":23949},{"trials":23936,"activeCount":99},[],{"trials":23938,"activeCount":99},[23939],{"nctId":9948,"briefTitle":9949,"status":125,"phases":23940,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":23941,"interventions":23942},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"trials":23944,"activeCount":99},[],{"trials":23946,"activeCount":99},[],{"trials":23948,"activeCount":99},[],{"trials":23950,"activeCount":99},[],{"intervention":9960,"totalTrials":468,"cells":23952},{"EARLY_PHASE1":23953,"PHASE1":23955,"PHASE2":23961,"PHASE3":23963,"PHASE4":23965,"NA":23967},{"trials":23954,"activeCount":99},[],{"trials":23956,"activeCount":99},[23957],{"nctId":9948,"briefTitle":9949,"status":125,"phases":23958,"primaryCompletion":9951,"completion":9951,"start":5586,"enrollment":1132,"conditions":23959,"interventions":23960},[87],[311,299],[9941,9954,9955,9956,9957,9958,9959,9960],{"trials":23962,"activeCount":99},[],{"trials":23964,"activeCount":99},[],{"trials":23966,"activeCount":99},[],{"trials":23968,"activeCount":99},[],{"intervention":16750,"totalTrials":468,"cells":23970},{"EARLY_PHASE1":23971,"PHASE1":23973,"PHASE2":23979,"PHASE3":23981,"PHASE4":23983,"NA":23985},{"trials":23972,"activeCount":99},[],{"trials":23974,"activeCount":99},[23975],{"nctId":16743,"briefTitle":16744,"status":105,"phases":23976,"primaryCompletion":16746,"completion":16746,"start":16747,"enrollment":503,"conditions":23977,"interventions":23978},[87],[15],[16750,8349],{"trials":23980,"activeCount":99},[],{"trials":23982,"activeCount":99},[],{"trials":23984,"activeCount":99},[],{"trials":23986,"activeCount":99},[],{"intervention":23988,"totalTrials":468,"cells":23989},"Sequence 1: PCI-32765",{"EARLY_PHASE1":23990,"PHASE1":23992,"PHASE2":24004,"PHASE3":24006,"PHASE4":24008,"NA":24010},{"trials":23991,"activeCount":99},[],{"trials":23993,"activeCount":99},[23994],{"nctId":23995,"briefTitle":23996,"status":105,"phases":23997,"primaryCompletion":6034,"completion":6034,"start":15454,"enrollment":19,"conditions":23998,"interventions":23999},"NCT01820936","A Study to Determine the Effect of Food on the Pharmacokinetics of PCI-32765",[87],[3331],[23988,24000,24001,24002,24003],"Sequence 2: PCI-32765","Sequence 3: PCI-32765","Sequence 4: PCI-32765","Sequence 5: PCI-32765",{"trials":24005,"activeCount":99},[],{"trials":24007,"activeCount":99},[],{"trials":24009,"activeCount":99},[],{"trials":24011,"activeCount":99},[],{"intervention":24000,"totalTrials":468,"cells":24013},{"EARLY_PHASE1":24014,"PHASE1":24016,"PHASE2":24022,"PHASE3":24024,"PHASE4":24026,"NA":24028},{"trials":24015,"activeCount":99},[],{"trials":24017,"activeCount":99},[24018],{"nctId":23995,"briefTitle":23996,"status":105,"phases":24019,"primaryCompletion":6034,"completion":6034,"start":15454,"enrollment":19,"conditions":24020,"interventions":24021},[87],[3331],[23988,24000,24001,24002,24003],{"trials":24023,"activeCount":99},[],{"trials":24025,"activeCount":99},[],{"trials":24027,"activeCount":99},[],{"trials":24029,"activeCount":99},[],{"intervention":24001,"totalTrials":468,"cells":24031},{"EARLY_PHASE1":24032,"PHASE1":24034,"PHASE2":24040,"PHASE3":24042,"PHASE4":24044,"NA":24046},{"trials":24033,"activeCount":99},[],{"trials":24035,"activeCount":99},[24036],{"nctId":23995,"briefTitle":23996,"status":105,"phases":24037,"primaryCompletion":6034,"completion":6034,"start":15454,"enrollment":19,"conditions":24038,"interventions":24039},[87],[3331],[23988,24000,24001,24002,24003],{"trials":24041,"activeCount":99},[],{"trials":24043,"activeCount":99},[],{"trials":24045,"activeCount":99},[],{"trials":24047,"activeCount":99},[],{"intervention":24002,"totalTrials":468,"cells":24049},{"EARLY_PHASE1":24050,"PHASE1":24052,"PHASE2":24058,"PHASE3":24060,"PHASE4":24062,"NA":24064},{"trials":24051,"activeCount":99},[],{"trials":24053,"activeCount":99},[24054],{"nctId":23995,"briefTitle":23996,"status":105,"phases":24055,"primaryCompletion":6034,"completion":6034,"start":15454,"enrollment":19,"conditions":24056,"interventions":24057},[87],[3331],[23988,24000,24001,24002,24003],{"trials":24059,"activeCount":99},[],{"trials":24061,"activeCount":99},[],{"trials":24063,"activeCount":99},[],{"trials":24065,"activeCount":99},[],{"intervention":24003,"totalTrials":468,"cells":24067},{"EARLY_PHASE1":24068,"PHASE1":24070,"PHASE2":24076,"PHASE3":24078,"PHASE4":24080,"NA":24082},{"trials":24069,"activeCount":99},[],{"trials":24071,"activeCount":99},[24072],{"nctId":23995,"briefTitle":23996,"status":105,"phases":24073,"primaryCompletion":6034,"completion":6034,"start":15454,"enrollment":19,"conditions":24074,"interventions":24075},[87],[3331],[23988,24000,24001,24002,24003],{"trials":24077,"activeCount":99},[],{"trials":24079,"activeCount":99},[],{"trials":24081,"activeCount":99},[],{"trials":24083,"activeCount":99},[],{"intervention":9492,"totalTrials":468,"cells":24085},{"EARLY_PHASE1":24086,"PHASE1":24088,"PHASE2":24094,"PHASE3":24096,"PHASE4":24098,"NA":24100},{"trials":24087,"activeCount":99},[],{"trials":24089,"activeCount":99},[24090],{"nctId":9485,"briefTitle":9486,"status":105,"phases":24091,"primaryCompletion":9488,"completion":9488,"start":6034,"enrollment":109,"conditions":24092,"interventions":24093},[87],[9490],[2676,2676,2676,9492],{"trials":24095,"activeCount":99},[],{"trials":24097,"activeCount":99},[],{"trials":24099,"activeCount":99},[],{"trials":24101,"activeCount":99},[],{"intervention":24103,"totalTrials":468,"cells":24104},"AAVCAGsCD59",{"EARLY_PHASE1":24105,"PHASE1":24107,"PHASE2":24119,"PHASE3":24121,"PHASE4":24123,"NA":24125},{"trials":24106,"activeCount":99},[],{"trials":24108,"activeCount":99},[24109],{"nctId":24110,"briefTitle":24111,"status":105,"phases":24112,"primaryCompletion":24113,"completion":24114,"start":24115,"enrollment":33,"conditions":24116,"interventions":24118},"NCT03144999","Treatment of Advanced Dry Age Related Macular Degeneration With AAVCAGsCD59",[87],"2017-12-06","2019-12-09","2017-03-29",[24117],"Dry Age-related Macular Degeneration",[24103],{"trials":24120,"activeCount":99},[],{"trials":24122,"activeCount":99},[],{"trials":24124,"activeCount":99},[],{"trials":24126,"activeCount":99},[],{"intervention":3661,"totalTrials":468,"cells":24128},{"EARLY_PHASE1":24129,"PHASE1":24131,"PHASE2":24137,"PHASE3":24139,"PHASE4":24141,"NA":24143},{"trials":24130,"activeCount":99},[],{"trials":24132,"activeCount":99},[24133],{"nctId":3654,"briefTitle":3655,"status":105,"phases":24134,"primaryCompletion":3657,"completion":3657,"start":3658,"enrollment":3138,"conditions":24135,"interventions":24136},[87],[15],[3661,46,46,46,46,46],{"trials":24138,"activeCount":99},[],{"trials":24140,"activeCount":99},[],{"trials":24142,"activeCount":99},[],{"trials":24144,"activeCount":99},[],{"intervention":24146,"totalTrials":468,"cells":24147},"JNJ-42847922 20mg",{"EARLY_PHASE1":24148,"PHASE1":24150,"PHASE2":24160,"PHASE3":24162,"PHASE4":24164,"NA":24166},{"trials":24149,"activeCount":99},[],{"trials":24151,"activeCount":99},[24152],{"nctId":24153,"briefTitle":24154,"status":105,"phases":24155,"primaryCompletion":24156,"completion":24156,"start":12473,"enrollment":160,"conditions":24157,"interventions":24158},"NCT03374475","A Study to Investigate the Antidepressant Mechanism-of-action of JNJ-42847922 in Participants With Major Depressive Disorder",[87],"2019-04-29",[21],[24146,24159],"JNJ-42847922 40mg",{"trials":24161,"activeCount":99},[],{"trials":24163,"activeCount":99},[],{"trials":24165,"activeCount":99},[],{"trials":24167,"activeCount":99},[],{"intervention":24159,"totalTrials":468,"cells":24169},{"EARLY_PHASE1":24170,"PHASE1":24172,"PHASE2":24178,"PHASE3":24180,"PHASE4":24182,"NA":24184},{"trials":24171,"activeCount":99},[],{"trials":24173,"activeCount":99},[24174],{"nctId":24153,"briefTitle":24154,"status":105,"phases":24175,"primaryCompletion":24156,"completion":24156,"start":12473,"enrollment":160,"conditions":24176,"interventions":24177},[87],[21],[24146,24159],{"trials":24179,"activeCount":99},[],{"trials":24181,"activeCount":99},[],{"trials":24183,"activeCount":99},[],{"trials":24185,"activeCount":99},[],{"intervention":574,"totalTrials":468,"cells":24187},{"EARLY_PHASE1":24188,"PHASE1":24190,"PHASE2":24196,"PHASE3":24198,"PHASE4":24200,"NA":24202},{"trials":24189,"activeCount":99},[],{"trials":24191,"activeCount":99},[24192],{"nctId":568,"briefTitle":569,"status":125,"phases":24193,"primaryCompletion":79,"completion":79,"start":148,"enrollment":571,"conditions":24194,"interventions":24195},[87],[30],[574,495,575,41],{"trials":24197,"activeCount":99},[],{"trials":24199,"activeCount":99},[],{"trials":24201,"activeCount":99},[],{"trials":24203,"activeCount":99},[],{"intervention":24205,"totalTrials":468,"cells":24206},"JNJ-63709178",{"EARLY_PHASE1":24207,"PHASE1":24209,"PHASE2":24219,"PHASE3":24221,"PHASE4":24223,"NA":24225},{"trials":24208,"activeCount":99},[],{"trials":24210,"activeCount":99},[24211],{"nctId":24212,"briefTitle":24213,"status":105,"phases":24214,"primaryCompletion":24215,"completion":24215,"start":24216,"enrollment":13318,"conditions":24217,"interventions":24218},"NCT02715011","Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)",[87],"2021-03-26","2016-06-01",[2894],[24205],{"trials":24220,"activeCount":99},[],{"trials":24222,"activeCount":99},[],{"trials":24224,"activeCount":99},[],{"trials":24226,"activeCount":99},[],{"intervention":24228,"totalTrials":468,"cells":24229},"Seltorexant High Dose",{"EARLY_PHASE1":24230,"PHASE1":24232,"PHASE2":24242,"PHASE3":24244,"PHASE4":24246,"NA":24248},{"trials":24231,"activeCount":99},[],{"trials":24233,"activeCount":99},[24234],{"nctId":24235,"briefTitle":24236,"status":105,"phases":24237,"primaryCompletion":24238,"completion":24238,"start":5911,"enrollment":1213,"conditions":24239,"interventions":24240},"NCT03682380","A Study of Seltorexant (JNJ-42847922) After Single-Dose Administration in Healthy Participants",[87],"2019-08-23",[15],[24228,24241],"Seltorexant Low Dose",{"trials":24243,"activeCount":99},[],{"trials":24245,"activeCount":99},[],{"trials":24247,"activeCount":99},[],{"trials":24249,"activeCount":99},[],{"intervention":24241,"totalTrials":468,"cells":24251},{"EARLY_PHASE1":24252,"PHASE1":24254,"PHASE2":24260,"PHASE3":24262,"PHASE4":24264,"NA":24266},{"trials":24253,"activeCount":99},[],{"trials":24255,"activeCount":99},[24256],{"nctId":24235,"briefTitle":24236,"status":105,"phases":24257,"primaryCompletion":24238,"completion":24238,"start":5911,"enrollment":1213,"conditions":24258,"interventions":24259},[87],[15],[24228,24241],{"trials":24261,"activeCount":99},[],{"trials":24263,"activeCount":99},[],{"trials":24265,"activeCount":99},[],{"trials":24267,"activeCount":99},[],{"intervention":24269,"totalTrials":468,"cells":24270},"DOXIL\u002FCAELYX (doxorubicin) Treatment Sequence AB",{"EARLY_PHASE1":24271,"PHASE1":24273,"PHASE2":24285,"PHASE3":24287,"PHASE4":24289,"NA":24291},{"trials":24272,"activeCount":99},[],{"trials":24274,"activeCount":99},[24275],{"nctId":24276,"briefTitle":24277,"status":105,"phases":24278,"primaryCompletion":3444,"completion":3444,"start":3329,"enrollment":3312,"conditions":24279,"interventions":24283},"NCT01815294","A Pivotal Bioequivalence Study of DOXIL\u002FCAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer",[87],[5932,24280,24281,24282],"Neoplasms, Ovarian","Neoplasms, Breast","Advanced or Refractory Solid Malignancies",[24269,24284],"DOXIL\u002FCAELYX (doxorubicin) Treatment Sequence BA",{"trials":24286,"activeCount":99},[],{"trials":24288,"activeCount":99},[],{"trials":24290,"activeCount":99},[],{"trials":24292,"activeCount":99},[],{"intervention":24284,"totalTrials":468,"cells":24294},{"EARLY_PHASE1":24295,"PHASE1":24297,"PHASE2":24303,"PHASE3":24305,"PHASE4":24307,"NA":24309},{"trials":24296,"activeCount":99},[],{"trials":24298,"activeCount":99},[24299],{"nctId":24276,"briefTitle":24277,"status":105,"phases":24300,"primaryCompletion":3444,"completion":3444,"start":3329,"enrollment":3312,"conditions":24301,"interventions":24302},[87],[5932,24280,24281,24282],[24269,24284],{"trials":24304,"activeCount":99},[],{"trials":24306,"activeCount":99},[],{"trials":24308,"activeCount":99},[],{"trials":24310,"activeCount":99},[],{"intervention":24312,"totalTrials":468,"cells":24313},"JNJ-80038114",{"EARLY_PHASE1":24314,"PHASE1":24316,"PHASE2":24326,"PHASE3":24328,"PHASE4":24330,"NA":24332},{"trials":24315,"activeCount":99},[],{"trials":24317,"activeCount":99},[24318],{"nctId":24319,"briefTitle":24320,"status":105,"phases":24321,"primaryCompletion":24322,"completion":24323,"start":1730,"enrollment":2108,"conditions":24324,"interventions":24325},"NCT05441501","A Study of JNJ-80038114 in Participants With Advanced Stage Prostate Cancer",[87],"2024-03-26","2024-03-31",[30],[24312],{"trials":24327,"activeCount":99},[],{"trials":24329,"activeCount":99},[],{"trials":24331,"activeCount":99},[],{"trials":24333,"activeCount":99},[],{"intervention":24335,"totalTrials":468,"cells":24336},"JNJ-64457107",{"EARLY_PHASE1":24337,"PHASE1":24339,"PHASE2":24352,"PHASE3":24354,"PHASE4":24356,"NA":24358},{"trials":24338,"activeCount":99},[],{"trials":24340,"activeCount":99},[24341],{"nctId":24342,"briefTitle":24343,"status":105,"phases":24344,"primaryCompletion":24345,"completion":24346,"start":24347,"enrollment":24348,"conditions":24349,"interventions":24351},"NCT02829099","A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors",[87],"2021-07-01","2021-07-29","2016-09-21",95,[24350],"Advanced Solid Neoplasms",[24335],{"trials":24353,"activeCount":99},[],{"trials":24355,"activeCount":99},[],{"trials":24357,"activeCount":99},[],{"trials":24359,"activeCount":99},[],{"intervention":17231,"totalTrials":468,"cells":24361},{"EARLY_PHASE1":24362,"PHASE1":24364,"PHASE2":24370,"PHASE3":24372,"PHASE4":24374,"NA":24376},{"trials":24363,"activeCount":99},[],{"trials":24365,"activeCount":99},[24366],{"nctId":17226,"briefTitle":17227,"status":105,"phases":24367,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":24368,"interventions":24369},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":24371,"activeCount":99},[],{"trials":24373,"activeCount":99},[],{"trials":24375,"activeCount":99},[],{"trials":24377,"activeCount":99},[],{"intervention":17232,"totalTrials":468,"cells":24379},{"EARLY_PHASE1":24380,"PHASE1":24382,"PHASE2":24388,"PHASE3":24390,"PHASE4":24392,"NA":24394},{"trials":24381,"activeCount":99},[],{"trials":24383,"activeCount":99},[24384],{"nctId":17226,"briefTitle":17227,"status":105,"phases":24385,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":24386,"interventions":24387},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":24389,"activeCount":99},[],{"trials":24391,"activeCount":99},[],{"trials":24393,"activeCount":99},[],{"trials":24395,"activeCount":99},[],{"intervention":17233,"totalTrials":468,"cells":24397},{"EARLY_PHASE1":24398,"PHASE1":24400,"PHASE2":24406,"PHASE3":24408,"PHASE4":24410,"NA":24412},{"trials":24399,"activeCount":99},[],{"trials":24401,"activeCount":99},[24402],{"nctId":17226,"briefTitle":17227,"status":105,"phases":24403,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":24404,"interventions":24405},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":24407,"activeCount":99},[],{"trials":24409,"activeCount":99},[],{"trials":24411,"activeCount":99},[],{"trials":24413,"activeCount":99},[],{"intervention":17234,"totalTrials":468,"cells":24415},{"EARLY_PHASE1":24416,"PHASE1":24418,"PHASE2":24424,"PHASE3":24426,"PHASE4":24428,"NA":24430},{"trials":24417,"activeCount":99},[],{"trials":24419,"activeCount":99},[24420],{"nctId":17226,"briefTitle":17227,"status":105,"phases":24421,"primaryCompletion":9967,"completion":9967,"start":3816,"enrollment":169,"conditions":24422,"interventions":24423},[87],[15],[17231,17232,9955,9956,17233,9959,17234,9958],{"trials":24425,"activeCount":99},[],{"trials":24427,"activeCount":99},[],{"trials":24429,"activeCount":99},[],{"trials":24431,"activeCount":99},[],{"intervention":24433,"totalTrials":468,"cells":24434},"DOXIL\u002FCAELYX reference product",{"EARLY_PHASE1":24435,"PHASE1":24437,"PHASE2":24446,"PHASE3":24448,"PHASE4":24450,"NA":24452},{"trials":24436,"activeCount":99},[],{"trials":24438,"activeCount":99},[24439],{"nctId":24440,"briefTitle":24441,"status":105,"phases":24442,"primaryCompletion":3657,"completion":3657,"start":5530,"enrollment":95,"conditions":24443,"interventions":24444},"NCT02081495","A Study of DOXIL\u002FCAELYX in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer",[87],[5932],[24433,24445],"DOXIL\u002FCAELYX test product",{"trials":24447,"activeCount":99},[],{"trials":24449,"activeCount":99},[],{"trials":24451,"activeCount":99},[],{"trials":24453,"activeCount":99},[],{"intervention":24445,"totalTrials":468,"cells":24455},{"EARLY_PHASE1":24456,"PHASE1":24458,"PHASE2":24464,"PHASE3":24466,"PHASE4":24468,"NA":24470},{"trials":24457,"activeCount":99},[],{"trials":24459,"activeCount":99},[24460],{"nctId":24440,"briefTitle":24441,"status":105,"phases":24461,"primaryCompletion":3657,"completion":3657,"start":5530,"enrollment":95,"conditions":24462,"interventions":24463},[87],[5932],[24433,24445],{"trials":24465,"activeCount":99},[],{"trials":24467,"activeCount":99},[],{"trials":24469,"activeCount":99},[],{"trials":24471,"activeCount":99},[],{"intervention":24473,"totalTrials":468,"cells":24474},"JNJ-79032421",{"EARLY_PHASE1":24475,"PHASE1":24477,"PHASE2":24488,"PHASE3":24490,"PHASE4":24492,"NA":24494},{"trials":24476,"activeCount":99},[],{"trials":24478,"activeCount":99},[24479],{"nctId":24480,"briefTitle":24481,"status":105,"phases":24482,"primaryCompletion":24483,"completion":24483,"start":24484,"enrollment":95,"conditions":24485,"interventions":24487},"NCT06255665","A Study of JNJ-79032421 Targeting Mesothelin for Advanced Stage Solid Tumors",[87],"2025-06-23","2024-02-09",[24486],"Advanced Stage Solid Tumors",[24473,24473],{"trials":24489,"activeCount":99},[],{"trials":24491,"activeCount":99},[],{"trials":24493,"activeCount":99},[],{"trials":24495,"activeCount":99},[],{"intervention":17295,"totalTrials":468,"cells":24497},{"EARLY_PHASE1":24498,"PHASE1":24500,"PHASE2":24506,"PHASE3":24508,"PHASE4":24510,"NA":24512},{"trials":24499,"activeCount":99},[],{"trials":24501,"activeCount":99},[24502],{"nctId":17290,"briefTitle":17291,"status":105,"phases":24503,"primaryCompletion":3359,"completion":3359,"start":5530,"enrollment":245,"conditions":24504,"interventions":24505},[87],[15],[17295,5826,17270],{"trials":24507,"activeCount":99},[],{"trials":24509,"activeCount":99},[],{"trials":24511,"activeCount":99},[],{"trials":24513,"activeCount":99},[],{"intervention":3678,"totalTrials":468,"cells":24515},{"EARLY_PHASE1":24516,"PHASE1":24518,"PHASE2":24524,"PHASE3":24526,"PHASE4":24528,"NA":24530},{"trials":24517,"activeCount":99},[],{"trials":24519,"activeCount":99},[24520],{"nctId":3670,"briefTitle":3671,"status":105,"phases":24521,"primaryCompletion":3673,"completion":3674,"start":3675,"enrollment":2472,"conditions":24522,"interventions":24523},[87],[2920],[46,3678,3679,173],{"trials":24525,"activeCount":99},[],{"trials":24527,"activeCount":99},[],{"trials":24529,"activeCount":99},[],{"trials":24531,"activeCount":99},[],{"intervention":24533,"totalTrials":468,"cells":24534},"JNJ-67571244",{"EARLY_PHASE1":24535,"PHASE1":24537,"PHASE2":24548,"PHASE3":24550,"PHASE4":24552,"NA":24554},{"trials":24536,"activeCount":99},[],{"trials":24538,"activeCount":99},[24539],{"nctId":24540,"briefTitle":24541,"status":105,"phases":24542,"primaryCompletion":24543,"completion":24544,"start":24545,"enrollment":809,"conditions":24546,"interventions":24547},"NCT03915379","A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",[87],"2022-03-26","2022-03-28","2019-03-28",[2894,1467],[24533],{"trials":24549,"activeCount":99},[],{"trials":24551,"activeCount":99},[],{"trials":24553,"activeCount":99},[],{"trials":24555,"activeCount":99},[],{"intervention":16758,"totalTrials":468,"cells":24557},{"EARLY_PHASE1":24558,"PHASE1":24560,"PHASE2":24566,"PHASE3":24568,"PHASE4":24570,"NA":24572},{"trials":24559,"activeCount":99},[],{"trials":24561,"activeCount":99},[24562],{"nctId":16752,"briefTitle":16753,"status":105,"phases":24563,"primaryCompletion":1796,"completion":1796,"start":16755,"enrollment":5557,"conditions":24564,"interventions":24565},[87],[3667],[8349,12456,16758],{"trials":24567,"activeCount":99},[],{"trials":24569,"activeCount":99},[],{"trials":24571,"activeCount":99},[],{"trials":24573,"activeCount":99},[],{"intervention":24575,"totalTrials":468,"cells":24576},"Norgestimate \u002FEthinyl estradiol",{"EARLY_PHASE1":24577,"PHASE1":24579,"PHASE2":24587,"PHASE3":24589,"PHASE4":24591,"NA":24593},{"trials":24578,"activeCount":99},[],{"trials":24580,"activeCount":99},[24581],{"nctId":24582,"briefTitle":24583,"status":105,"phases":24584,"primaryCompletion":4348,"completion":4348,"start":6034,"enrollment":3554,"conditions":24585,"interventions":24586},"NCT02127593","A Bioequivalence Study of Norgestimate \u002FEthinyl Estradiol (NGM\u002FEE) Tablets Manufactured at 2 Different Facilities",[87],[15],[24575,24575],{"trials":24588,"activeCount":99},[],{"trials":24590,"activeCount":99},[],{"trials":24592,"activeCount":99},[],{"trials":24594,"activeCount":99},[],{"intervention":24596,"totalTrials":468,"cells":24597},"JNJ-67484703",{"EARLY_PHASE1":24598,"PHASE1":24600,"PHASE2":24608,"PHASE3":24610,"PHASE4":24612,"NA":24614},{"trials":24599,"activeCount":99},[],{"trials":24601,"activeCount":99},[24602],{"nctId":24603,"briefTitle":24604,"status":105,"phases":24605,"primaryCompletion":831,"completion":831,"start":3539,"enrollment":9010,"conditions":24606,"interventions":24607},"NCT04985812","A Study of JNJ-67484703 in Participants With Active Rheumatoid Arthritis",[87],[6786],[24596],{"trials":24609,"activeCount":99},[],{"trials":24611,"activeCount":99},[],{"trials":24613,"activeCount":99},[],{"trials":24615,"activeCount":99},[],{"intervention":24617,"totalTrials":468,"cells":24618},"OTF 1",{"EARLY_PHASE1":24619,"PHASE1":24621,"PHASE2":24634,"PHASE3":24636,"PHASE4":24638,"NA":24640},{"trials":24620,"activeCount":99},[],{"trials":24622,"activeCount":99},[24623],{"nctId":24624,"briefTitle":24625,"status":105,"phases":24626,"primaryCompletion":24627,"completion":24627,"start":24628,"enrollment":169,"conditions":24629,"interventions":24630},"NCT04300621","A Study of Different Oral Thin Film (S)-Ketamine Formulations for Sublingual Administration in Healthy Participants",[87],"2020-08-10","2020-06-19",[15],[24617,24631,24632,24633],"OTF 2","OTF 3","OTF 4",{"trials":24635,"activeCount":99},[],{"trials":24637,"activeCount":99},[],{"trials":24639,"activeCount":99},[],{"trials":24641,"activeCount":99},[],{"intervention":24631,"totalTrials":468,"cells":24643},{"EARLY_PHASE1":24644,"PHASE1":24646,"PHASE2":24652,"PHASE3":24654,"PHASE4":24656,"NA":24658},{"trials":24645,"activeCount":99},[],{"trials":24647,"activeCount":99},[24648],{"nctId":24624,"briefTitle":24625,"status":105,"phases":24649,"primaryCompletion":24627,"completion":24627,"start":24628,"enrollment":169,"conditions":24650,"interventions":24651},[87],[15],[24617,24631,24632,24633],{"trials":24653,"activeCount":99},[],{"trials":24655,"activeCount":99},[],{"trials":24657,"activeCount":99},[],{"trials":24659,"activeCount":99},[],{"intervention":24632,"totalTrials":468,"cells":24661},{"EARLY_PHASE1":24662,"PHASE1":24664,"PHASE2":24670,"PHASE3":24672,"PHASE4":24674,"NA":24676},{"trials":24663,"activeCount":99},[],{"trials":24665,"activeCount":99},[24666],{"nctId":24624,"briefTitle":24625,"status":105,"phases":24667,"primaryCompletion":24627,"completion":24627,"start":24628,"enrollment":169,"conditions":24668,"interventions":24669},[87],[15],[24617,24631,24632,24633],{"trials":24671,"activeCount":99},[],{"trials":24673,"activeCount":99},[],{"trials":24675,"activeCount":99},[],{"trials":24677,"activeCount":99},[],{"intervention":24633,"totalTrials":468,"cells":24679},{"EARLY_PHASE1":24680,"PHASE1":24682,"PHASE2":24688,"PHASE3":24690,"PHASE4":24692,"NA":24694},{"trials":24681,"activeCount":99},[],{"trials":24683,"activeCount":99},[24684],{"nctId":24624,"briefTitle":24625,"status":105,"phases":24685,"primaryCompletion":24627,"completion":24627,"start":24628,"enrollment":169,"conditions":24686,"interventions":24687},[87],[15],[24617,24631,24632,24633],{"trials":24689,"activeCount":99},[],{"trials":24691,"activeCount":99},[],{"trials":24693,"activeCount":99},[],{"trials":24695,"activeCount":99},[],{"intervention":24697,"totalTrials":468,"cells":24698},"JNJ-68179280",{"EARLY_PHASE1":24699,"PHASE1":24701,"PHASE2":24712,"PHASE3":24714,"PHASE4":24716,"NA":24718},{"trials":24700,"activeCount":99},[],{"trials":24702,"activeCount":99},[24703],{"nctId":24704,"briefTitle":24705,"status":105,"phases":24706,"primaryCompletion":24707,"completion":24708,"start":24709,"enrollment":12569,"conditions":24710,"interventions":24711},"NCT04844463","A Study of JNJ-68179280 in Healthy Participants",[87],"2023-03-07","2023-03-13","2021-05-26",[15],[24697],{"trials":24713,"activeCount":99},[],{"trials":24715,"activeCount":99},[],{"trials":24717,"activeCount":99},[],{"trials":24719,"activeCount":99},[],{"intervention":24721,"totalTrials":468,"cells":24722},"Fentanyl",{"EARLY_PHASE1":24723,"PHASE1":24725,"PHASE2":24733,"PHASE3":24735,"PHASE4":24737,"NA":24739},{"trials":24724,"activeCount":99},[],{"trials":24726,"activeCount":99},[24727],{"nctId":24728,"briefTitle":24729,"status":105,"phases":24730,"primaryCompletion":3597,"completion":3597,"start":3657,"enrollment":17999,"conditions":24731,"interventions":24732},"NCT02617758","Bioequivalence Study of Fentanyl Transdermal System (JNJ-35685-AAA-G021) Compared With DURAGESIC Fentanyl Transdermal Patch in Healthy Participants",[87],[15],[24721,24721],{"trials":24734,"activeCount":99},[],{"trials":24736,"activeCount":99},[],{"trials":24738,"activeCount":99},[],{"trials":24740,"activeCount":99},[],{"intervention":24742,"totalTrials":468,"cells":24743},"Part 1, Cohort 1",{"EARLY_PHASE1":24744,"PHASE1":24746,"PHASE2":24761,"PHASE3":24763,"PHASE4":24765,"NA":24767},{"trials":24745,"activeCount":99},[],{"trials":24747,"activeCount":99},[24748],{"nctId":24749,"briefTitle":24750,"status":105,"phases":24751,"primaryCompletion":24752,"completion":24752,"start":24753,"enrollment":2515,"conditions":24754,"interventions":24756},"NCT01569750","A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma",[87],"2014-09-04","2012-06-14",[24755],"CD20-positive B-cell Non-Hodgkin Lymphoma",[24742,24757,24758,24759,24760],"Part 1, Cohort 2","Part 1, Cohort 3","Part 2, Cohort 1","Part 2, Cohort 2",{"trials":24762,"activeCount":99},[],{"trials":24764,"activeCount":99},[],{"trials":24766,"activeCount":99},[],{"trials":24768,"activeCount":99},[],{"intervention":24757,"totalTrials":468,"cells":24770},{"EARLY_PHASE1":24771,"PHASE1":24773,"PHASE2":24779,"PHASE3":24781,"PHASE4":24783,"NA":24785},{"trials":24772,"activeCount":99},[],{"trials":24774,"activeCount":99},[24775],{"nctId":24749,"briefTitle":24750,"status":105,"phases":24776,"primaryCompletion":24752,"completion":24752,"start":24753,"enrollment":2515,"conditions":24777,"interventions":24778},[87],[24755],[24742,24757,24758,24759,24760],{"trials":24780,"activeCount":99},[],{"trials":24782,"activeCount":99},[],{"trials":24784,"activeCount":99},[],{"trials":24786,"activeCount":99},[],{"intervention":24758,"totalTrials":468,"cells":24788},{"EARLY_PHASE1":24789,"PHASE1":24791,"PHASE2":24797,"PHASE3":24799,"PHASE4":24801,"NA":24803},{"trials":24790,"activeCount":99},[],{"trials":24792,"activeCount":99},[24793],{"nctId":24749,"briefTitle":24750,"status":105,"phases":24794,"primaryCompletion":24752,"completion":24752,"start":24753,"enrollment":2515,"conditions":24795,"interventions":24796},[87],[24755],[24742,24757,24758,24759,24760],{"trials":24798,"activeCount":99},[],{"trials":24800,"activeCount":99},[],{"trials":24802,"activeCount":99},[],{"trials":24804,"activeCount":99},[],{"intervention":24759,"totalTrials":468,"cells":24806},{"EARLY_PHASE1":24807,"PHASE1":24809,"PHASE2":24815,"PHASE3":24817,"PHASE4":24819,"NA":24821},{"trials":24808,"activeCount":99},[],{"trials":24810,"activeCount":99},[24811],{"nctId":24749,"briefTitle":24750,"status":105,"phases":24812,"primaryCompletion":24752,"completion":24752,"start":24753,"enrollment":2515,"conditions":24813,"interventions":24814},[87],[24755],[24742,24757,24758,24759,24760],{"trials":24816,"activeCount":99},[],{"trials":24818,"activeCount":99},[],{"trials":24820,"activeCount":99},[],{"trials":24822,"activeCount":99},[],{"intervention":24760,"totalTrials":468,"cells":24824},{"EARLY_PHASE1":24825,"PHASE1":24827,"PHASE2":24833,"PHASE3":24835,"PHASE4":24837,"NA":24839},{"trials":24826,"activeCount":99},[],{"trials":24828,"activeCount":99},[24829],{"nctId":24749,"briefTitle":24750,"status":105,"phases":24830,"primaryCompletion":24752,"completion":24752,"start":24753,"enrollment":2515,"conditions":24831,"interventions":24832},[87],[24755],[24742,24757,24758,24759,24760],{"trials":24834,"activeCount":99},[],{"trials":24836,"activeCount":99},[],{"trials":24838,"activeCount":99},[],{"trials":24840,"activeCount":99},[],{"intervention":3689,"totalTrials":468,"cells":24842},{"EARLY_PHASE1":24843,"PHASE1":24845,"PHASE2":24851,"PHASE3":24853,"PHASE4":24855,"NA":24857},{"trials":24844,"activeCount":99},[],{"trials":24846,"activeCount":99},[24847],{"nctId":3681,"briefTitle":3682,"status":137,"phases":24848,"primaryCompletion":3684,"completion":3685,"start":3686,"enrollment":99,"conditions":24849,"interventions":24850},[87],[2920,1535,1536,1534],[3689,46],{"trials":24852,"activeCount":99},[],{"trials":24854,"activeCount":99},[],{"trials":24856,"activeCount":99},[],{"trials":24858,"activeCount":99},[],{"intervention":24860,"totalTrials":468,"cells":24861},"JNJ-42165279 50 mg",{"EARLY_PHASE1":24862,"PHASE1":24864,"PHASE2":24874,"PHASE3":24876,"PHASE4":24878,"NA":24880},{"trials":24863,"activeCount":99},[],{"trials":24865,"activeCount":99},[24866],{"nctId":24867,"briefTitle":24868,"status":105,"phases":24869,"primaryCompletion":3359,"completion":3359,"start":5556,"enrollment":3138,"conditions":24870,"interventions":24871},"NCT01964651","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42165279 in Healthy Young and Elderly Participants",[87],[15],[24860,24872,24873],"JNJ-42165279 100 mg","JNJ-42165279 30 mg",{"trials":24875,"activeCount":99},[],{"trials":24877,"activeCount":99},[],{"trials":24879,"activeCount":99},[],{"trials":24881,"activeCount":99},[],{"intervention":24872,"totalTrials":468,"cells":24883},{"EARLY_PHASE1":24884,"PHASE1":24886,"PHASE2":24892,"PHASE3":24894,"PHASE4":24896,"NA":24898},{"trials":24885,"activeCount":99},[],{"trials":24887,"activeCount":99},[24888],{"nctId":24867,"briefTitle":24868,"status":105,"phases":24889,"primaryCompletion":3359,"completion":3359,"start":5556,"enrollment":3138,"conditions":24890,"interventions":24891},[87],[15],[24860,24872,24873],{"trials":24893,"activeCount":99},[],{"trials":24895,"activeCount":99},[],{"trials":24897,"activeCount":99},[],{"trials":24899,"activeCount":99},[],{"intervention":24873,"totalTrials":468,"cells":24901},{"EARLY_PHASE1":24902,"PHASE1":24904,"PHASE2":24910,"PHASE3":24912,"PHASE4":24914,"NA":24916},{"trials":24903,"activeCount":99},[],{"trials":24905,"activeCount":99},[24906],{"nctId":24867,"briefTitle":24868,"status":105,"phases":24907,"primaryCompletion":3359,"completion":3359,"start":5556,"enrollment":3138,"conditions":24908,"interventions":24909},[87],[15],[24860,24872,24873],{"trials":24911,"activeCount":99},[],{"trials":24913,"activeCount":99},[],{"trials":24915,"activeCount":99},[],{"trials":24917,"activeCount":99},[],{"intervention":8408,"totalTrials":468,"cells":24919},{"EARLY_PHASE1":24920,"PHASE1":24922,"PHASE2":24928,"PHASE3":24930,"PHASE4":24932,"NA":24934},{"trials":24921,"activeCount":99},[],{"trials":24923,"activeCount":99},[24924],{"nctId":8403,"briefTitle":8404,"status":105,"phases":24925,"primaryCompletion":6033,"completion":6033,"start":5572,"enrollment":12,"conditions":24926,"interventions":24927},[87],[15],[8377,8399,8408,8409],{"trials":24929,"activeCount":99},[],{"trials":24931,"activeCount":99},[],{"trials":24933,"activeCount":99},[],{"trials":24935,"activeCount":99},[],{"intervention":8409,"totalTrials":468,"cells":24937},{"EARLY_PHASE1":24938,"PHASE1":24940,"PHASE2":24946,"PHASE3":24948,"PHASE4":24950,"NA":24952},{"trials":24939,"activeCount":99},[],{"trials":24941,"activeCount":99},[24942],{"nctId":8403,"briefTitle":8404,"status":105,"phases":24943,"primaryCompletion":6033,"completion":6033,"start":5572,"enrollment":12,"conditions":24944,"interventions":24945},[87],[15],[8377,8399,8408,8409],{"trials":24947,"activeCount":99},[],{"trials":24949,"activeCount":99},[],{"trials":24951,"activeCount":99},[],{"trials":24953,"activeCount":99},[],{"intervention":9363,"totalTrials":468,"cells":24955},{"EARLY_PHASE1":24956,"PHASE1":24958,"PHASE2":24964,"PHASE3":24966,"PHASE4":24968,"NA":24970},{"trials":24957,"activeCount":99},[],{"trials":24959,"activeCount":99},[24960],{"nctId":9356,"briefTitle":9357,"status":105,"phases":24961,"primaryCompletion":9359,"completion":9360,"start":3580,"enrollment":745,"conditions":24962,"interventions":24963},[87],[15],[3491,9363],{"trials":24965,"activeCount":99},[],{"trials":24967,"activeCount":99},[],{"trials":24969,"activeCount":99},[],{"trials":24971,"activeCount":99},[],{"intervention":4352,"totalTrials":468,"cells":24973},{"EARLY_PHASE1":24974,"PHASE1":24976,"PHASE2":24982,"PHASE3":24984,"PHASE4":24986,"NA":24988},{"trials":24975,"activeCount":99},[],{"trials":24977,"activeCount":99},[24978],{"nctId":4345,"briefTitle":4346,"status":105,"phases":24979,"primaryCompletion":3358,"completion":3358,"start":4348,"enrollment":169,"conditions":24980,"interventions":24981},[87],[15],[4351,177,173,4352],{"trials":24983,"activeCount":99},[],{"trials":24985,"activeCount":99},[],{"trials":24987,"activeCount":99},[],{"trials":24989,"activeCount":99},[],{"intervention":24991,"totalTrials":468,"cells":24992},"(S)-ketamine Oral Thin Film",{"EARLY_PHASE1":24993,"PHASE1":24995,"PHASE2":25004,"PHASE3":25006,"PHASE4":25008,"NA":25010},{"trials":24994,"activeCount":99},[],{"trials":24996,"activeCount":99},[24997],{"nctId":24998,"briefTitle":24999,"status":105,"phases":25000,"primaryCompletion":768,"completion":768,"start":12111,"enrollment":15496,"conditions":25001,"interventions":25002},"NCT03808259","A Study to Investigate the Different Modes of (S) Ketamine Administration in Healthy Participants",[87],[15],[24991,25003],"(S)-ketamine IV",{"trials":25005,"activeCount":99},[],{"trials":25007,"activeCount":99},[],{"trials":25009,"activeCount":99},[],{"trials":25011,"activeCount":99},[],{"intervention":25003,"totalTrials":468,"cells":25013},{"EARLY_PHASE1":25014,"PHASE1":25016,"PHASE2":25022,"PHASE3":25024,"PHASE4":25026,"NA":25028},{"trials":25015,"activeCount":99},[],{"trials":25017,"activeCount":99},[25018],{"nctId":24998,"briefTitle":24999,"status":105,"phases":25019,"primaryCompletion":768,"completion":768,"start":12111,"enrollment":15496,"conditions":25020,"interventions":25021},[87],[15],[24991,25003],{"trials":25023,"activeCount":99},[],{"trials":25025,"activeCount":99},[],{"trials":25027,"activeCount":99},[],{"trials":25029,"activeCount":99},[],{"intervention":16696,"totalTrials":468,"cells":25031},{"EARLY_PHASE1":25032,"PHASE1":25034,"PHASE2":25040,"PHASE3":25042,"PHASE4":25044,"NA":25046},{"trials":25033,"activeCount":99},[],{"trials":25035,"activeCount":99},[25036],{"nctId":16691,"briefTitle":16692,"status":105,"phases":25037,"primaryCompletion":2904,"completion":2904,"start":1964,"enrollment":656,"conditions":25038,"interventions":25039},[87],[15],[16696,16697,3616],{"trials":25041,"activeCount":99},[],{"trials":25043,"activeCount":99},[],{"trials":25045,"activeCount":99},[],{"trials":25047,"activeCount":99},[],{"intervention":16697,"totalTrials":468,"cells":25049},{"EARLY_PHASE1":25050,"PHASE1":25052,"PHASE2":25058,"PHASE3":25060,"PHASE4":25062,"NA":25064},{"trials":25051,"activeCount":99},[],{"trials":25053,"activeCount":99},[25054],{"nctId":16691,"briefTitle":16692,"status":105,"phases":25055,"primaryCompletion":2904,"completion":2904,"start":1964,"enrollment":656,"conditions":25056,"interventions":25057},[87],[15],[16696,16697,3616],{"trials":25059,"activeCount":99},[],{"trials":25061,"activeCount":99},[],{"trials":25063,"activeCount":99},[],{"trials":25065,"activeCount":99},[],{"intervention":18202,"totalTrials":468,"cells":25067},{"EARLY_PHASE1":25068,"PHASE1":25070,"PHASE2":25076,"PHASE3":25078,"PHASE4":25080,"NA":25082},{"trials":25069,"activeCount":99},[],{"trials":25071,"activeCount":99},[25072],{"nctId":18197,"briefTitle":18198,"status":105,"phases":25073,"primaryCompletion":6823,"completion":6823,"start":3328,"enrollment":1507,"conditions":25074,"interventions":25075},[87],[3331],[18181,18193,18194,18195,18202],{"trials":25077,"activeCount":99},[],{"trials":25079,"activeCount":99},[],{"trials":25081,"activeCount":99},[],{"trials":25083,"activeCount":99},[],{"intervention":25085,"totalTrials":468,"cells":25086},"TMC278, Long acting",{"EARLY_PHASE1":25087,"PHASE1":25089,"PHASE2":25097,"PHASE3":25099,"PHASE4":25101,"NA":25103},{"trials":25088,"activeCount":99},[],{"trials":25090,"activeCount":99},[25091],{"nctId":25092,"briefTitle":25093,"status":105,"phases":25094,"primaryCompletion":3633,"completion":3633,"start":5888,"enrollment":352,"conditions":25095,"interventions":25096},"NCT01656018","A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants",[87],[15],[25085],{"trials":25098,"activeCount":99},[],{"trials":25100,"activeCount":99},[],{"trials":25102,"activeCount":99},[],{"trials":25104,"activeCount":99},[],{"intervention":25106,"totalTrials":468,"cells":25107},"JNJ-49122944, 5 milligram",{"EARLY_PHASE1":25108,"PHASE1":25110,"PHASE2":25118,"PHASE3":25120,"PHASE4":25122,"NA":25124},{"trials":25109,"activeCount":99},[],{"trials":25111,"activeCount":99},[25112],{"nctId":25113,"briefTitle":25114,"status":105,"phases":25115,"primaryCompletion":3444,"completion":3444,"start":3358,"enrollment":544,"conditions":25116,"interventions":25117},"NCT02280018","A Safety, Tolerability and Pharmacokinetics Study of a Single Intravenous Dose of JNJ-49122944 in Healthy Male Participants",[87],[15],[25106],{"trials":25119,"activeCount":99},[],{"trials":25121,"activeCount":99},[],{"trials":25123,"activeCount":99},[],{"trials":25125,"activeCount":99},[],{"intervention":25127,"totalTrials":468,"cells":25128},"Phase 1, Cohort 1",{"EARLY_PHASE1":25129,"PHASE1":25131,"PHASE2":25146,"PHASE3":25148,"PHASE4":25150,"NA":25152},{"trials":25130,"activeCount":99},[],{"trials":25132,"activeCount":99},[25133],{"nctId":25134,"briefTitle":25135,"status":105,"phases":25136,"primaryCompletion":25137,"completion":25137,"start":25138,"enrollment":1419,"conditions":25139,"interventions":25141},"NCT01572519","A Study of JNJ-40346527 in Patients With Relapsed or Refractory Hodgkin Lymphoma",[87],"2013-08-13","2012-07-17",[25140],"Relapsed or Refractory Hodgkin Lymphoma",[25127,25142,25143,25144,25145],"Phase 1, Cohort 2","Phase 1, Cohort 3","Phase 1, Cohort 4","Phase 2",{"trials":25147,"activeCount":99},[],{"trials":25149,"activeCount":99},[],{"trials":25151,"activeCount":99},[],{"trials":25153,"activeCount":99},[],{"intervention":25142,"totalTrials":468,"cells":25155},{"EARLY_PHASE1":25156,"PHASE1":25158,"PHASE2":25164,"PHASE3":25166,"PHASE4":25168,"NA":25170},{"trials":25157,"activeCount":99},[],{"trials":25159,"activeCount":99},[25160],{"nctId":25134,"briefTitle":25135,"status":105,"phases":25161,"primaryCompletion":25137,"completion":25137,"start":25138,"enrollment":1419,"conditions":25162,"interventions":25163},[87],[25140],[25127,25142,25143,25144,25145],{"trials":25165,"activeCount":99},[],{"trials":25167,"activeCount":99},[],{"trials":25169,"activeCount":99},[],{"trials":25171,"activeCount":99},[],{"intervention":25143,"totalTrials":468,"cells":25173},{"EARLY_PHASE1":25174,"PHASE1":25176,"PHASE2":25182,"PHASE3":25184,"PHASE4":25186,"NA":25188},{"trials":25175,"activeCount":99},[],{"trials":25177,"activeCount":99},[25178],{"nctId":25134,"briefTitle":25135,"status":105,"phases":25179,"primaryCompletion":25137,"completion":25137,"start":25138,"enrollment":1419,"conditions":25180,"interventions":25181},[87],[25140],[25127,25142,25143,25144,25145],{"trials":25183,"activeCount":99},[],{"trials":25185,"activeCount":99},[],{"trials":25187,"activeCount":99},[],{"trials":25189,"activeCount":99},[],{"intervention":25144,"totalTrials":468,"cells":25191},{"EARLY_PHASE1":25192,"PHASE1":25194,"PHASE2":25200,"PHASE3":25202,"PHASE4":25204,"NA":25206},{"trials":25193,"activeCount":99},[],{"trials":25195,"activeCount":99},[25196],{"nctId":25134,"briefTitle":25135,"status":105,"phases":25197,"primaryCompletion":25137,"completion":25137,"start":25138,"enrollment":1419,"conditions":25198,"interventions":25199},[87],[25140],[25127,25142,25143,25144,25145],{"trials":25201,"activeCount":99},[],{"trials":25203,"activeCount":99},[],{"trials":25205,"activeCount":99},[],{"trials":25207,"activeCount":99},[],{"intervention":25145,"totalTrials":468,"cells":25209},{"EARLY_PHASE1":25210,"PHASE1":25212,"PHASE2":25218,"PHASE3":25220,"PHASE4":25222,"NA":25224},{"trials":25211,"activeCount":99},[],{"trials":25213,"activeCount":99},[25214],{"nctId":25134,"briefTitle":25135,"status":105,"phases":25215,"primaryCompletion":25137,"completion":25137,"start":25138,"enrollment":1419,"conditions":25216,"interventions":25217},[87],[25140],[25127,25142,25143,25144,25145],{"trials":25219,"activeCount":99},[],{"trials":25221,"activeCount":99},[],{"trials":25223,"activeCount":99},[],{"trials":25225,"activeCount":99},[],{"intervention":25227,"totalTrials":468,"cells":25228},"JNJ-64155806 150 mg",{"EARLY_PHASE1":25229,"PHASE1":25231,"PHASE2":25243,"PHASE3":25245,"PHASE4":25247,"NA":25249},{"trials":25230,"activeCount":99},[],{"trials":25232,"activeCount":99},[25233],{"nctId":25234,"briefTitle":25235,"status":125,"phases":25236,"primaryCompletion":25237,"completion":25237,"start":25238,"enrollment":503,"conditions":25239,"interventions":25240},"NCT03126097","A Study to Investigate the Interaction Between JNJ-64155806 and Ethinylestradiol\u002FDrospirenone in Healthy Females",[87],"2017-05-26","2017-04-13",[15],[25227,25241,25242],"Ethinylestradiol\u002Fdrospirenone 0.02 mg\u002F3 mg","COCP Placebo",{"trials":25244,"activeCount":99},[],{"trials":25246,"activeCount":99},[],{"trials":25248,"activeCount":99},[],{"trials":25250,"activeCount":99},[],{"intervention":25241,"totalTrials":468,"cells":25252},{"EARLY_PHASE1":25253,"PHASE1":25255,"PHASE2":25261,"PHASE3":25263,"PHASE4":25265,"NA":25267},{"trials":25254,"activeCount":99},[],{"trials":25256,"activeCount":99},[25257],{"nctId":25234,"briefTitle":25235,"status":125,"phases":25258,"primaryCompletion":25237,"completion":25237,"start":25238,"enrollment":503,"conditions":25259,"interventions":25260},[87],[15],[25227,25241,25242],{"trials":25262,"activeCount":99},[],{"trials":25264,"activeCount":99},[],{"trials":25266,"activeCount":99},[],{"trials":25268,"activeCount":99},[],{"intervention":25242,"totalTrials":468,"cells":25270},{"EARLY_PHASE1":25271,"PHASE1":25273,"PHASE2":25279,"PHASE3":25281,"PHASE4":25283,"NA":25285},{"trials":25272,"activeCount":99},[],{"trials":25274,"activeCount":99},[25275],{"nctId":25234,"briefTitle":25235,"status":125,"phases":25276,"primaryCompletion":25237,"completion":25237,"start":25238,"enrollment":503,"conditions":25277,"interventions":25278},[87],[15],[25227,25241,25242],{"trials":25280,"activeCount":99},[],{"trials":25282,"activeCount":99},[],{"trials":25284,"activeCount":99},[],{"trials":25286,"activeCount":99},[],{"intervention":25288,"totalTrials":468,"cells":25289},"CNTO 3157",{"EARLY_PHASE1":25290,"PHASE1":25292,"PHASE2":25301,"PHASE3":25303,"PHASE4":25305,"NA":25307},{"trials":25291,"activeCount":99},[],{"trials":25293,"activeCount":99},[25294],{"nctId":25295,"briefTitle":25296,"status":105,"phases":25297,"primaryCompletion":3358,"completion":3358,"start":9543,"enrollment":4851,"conditions":25298,"interventions":25300},"NCT01704040","A Study of CNTO 3157 in Healthy Normal and Asthmatic Participants Inoculated With Human Rhinovirus Type 16",[87],[25299],"Healthy Volunteers and Asthma",[25288,25288],{"trials":25302,"activeCount":99},[],{"trials":25304,"activeCount":99},[],{"trials":25306,"activeCount":99},[],{"trials":25308,"activeCount":99},[],{"intervention":1993,"totalTrials":468,"cells":25310},{"EARLY_PHASE1":25311,"PHASE1":25313,"PHASE2":25319,"PHASE3":25321,"PHASE4":25323,"NA":25325},{"trials":25312,"activeCount":99},[],{"trials":25314,"activeCount":99},[25315],{"nctId":1986,"briefTitle":1987,"status":105,"phases":25316,"primaryCompletion":1989,"completion":1989,"start":1990,"enrollment":1507,"conditions":25317,"interventions":25318},[87],[15],[1953,1993,1994],{"trials":25320,"activeCount":99},[],{"trials":25322,"activeCount":99},[],{"trials":25324,"activeCount":99},[],{"trials":25326,"activeCount":99},[],{"intervention":1994,"totalTrials":468,"cells":25328},{"EARLY_PHASE1":25329,"PHASE1":25331,"PHASE2":25337,"PHASE3":25339,"PHASE4":25341,"NA":25343},{"trials":25330,"activeCount":99},[],{"trials":25332,"activeCount":99},[25333],{"nctId":1986,"briefTitle":1987,"status":105,"phases":25334,"primaryCompletion":1989,"completion":1989,"start":1990,"enrollment":1507,"conditions":25335,"interventions":25336},[87],[15],[1953,1993,1994],{"trials":25338,"activeCount":99},[],{"trials":25340,"activeCount":99},[],{"trials":25342,"activeCount":99},[],{"trials":25344,"activeCount":99},[],{"intervention":25346,"totalTrials":468,"cells":25347},"JNJ-61178104 Intravenous",{"EARLY_PHASE1":25348,"PHASE1":25350,"PHASE2":25359,"PHASE3":25361,"PHASE4":25363,"NA":25365},{"trials":25349,"activeCount":99},[],{"trials":25351,"activeCount":99},[25352],{"nctId":25353,"briefTitle":25354,"status":105,"phases":25355,"primaryCompletion":12987,"completion":12987,"start":8190,"enrollment":3312,"conditions":25356,"interventions":25357},"NCT02758392","A Study to Evaluate Safety and Tolerability of JNJ-61178104 in Healthy Participants",[87],[15],[25346,25358],"JNJ-61178104 Subcutaneous",{"trials":25360,"activeCount":99},[],{"trials":25362,"activeCount":99},[],{"trials":25364,"activeCount":99},[],{"trials":25366,"activeCount":99},[],{"intervention":25358,"totalTrials":468,"cells":25368},{"EARLY_PHASE1":25369,"PHASE1":25371,"PHASE2":25377,"PHASE3":25379,"PHASE4":25381,"NA":25383},{"trials":25370,"activeCount":99},[],{"trials":25372,"activeCount":99},[25373],{"nctId":25353,"briefTitle":25354,"status":105,"phases":25374,"primaryCompletion":12987,"completion":12987,"start":8190,"enrollment":3312,"conditions":25375,"interventions":25376},[87],[15],[25346,25358],{"trials":25378,"activeCount":99},[],{"trials":25380,"activeCount":99},[],{"trials":25382,"activeCount":99},[],{"trials":25384,"activeCount":99},[],{"intervention":25386,"totalTrials":468,"cells":25387},"JNJ-42721458",{"EARLY_PHASE1":25388,"PHASE1":25390,"PHASE2":25398,"PHASE3":25400,"PHASE4":25402,"NA":25404},{"trials":25389,"activeCount":99},[],{"trials":25391,"activeCount":99},[25392],{"nctId":25393,"briefTitle":25394,"status":105,"phases":25395,"primaryCompletion":1175,"completion":1175,"start":2524,"enrollment":595,"conditions":25396,"interventions":25397},"NCT01840501","A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants",[87],[15],[25386,25386],{"trials":25399,"activeCount":99},[],{"trials":25401,"activeCount":99},[],{"trials":25403,"activeCount":99},[],{"trials":25405,"activeCount":99},[],{"intervention":25407,"totalTrials":468,"cells":25408},"JNJ-26366821",{"EARLY_PHASE1":25409,"PHASE1":25411,"PHASE2":25421,"PHASE3":25423,"PHASE4":25425,"NA":25427},{"trials":25410,"activeCount":99},[],{"trials":25412,"activeCount":99},[25413],{"nctId":25414,"briefTitle":25415,"status":105,"phases":25416,"primaryCompletion":25417,"completion":25417,"start":25418,"enrollment":2515,"conditions":25419,"interventions":25420},"NCT03990519","A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants",[87],"2020-02-19","2019-06-24",[15],[25407],{"trials":25422,"activeCount":99},[],{"trials":25424,"activeCount":99},[],{"trials":25426,"activeCount":99},[],{"trials":25428,"activeCount":99},[],{"intervention":25430,"totalTrials":468,"cells":25431},"JNJ-42847922 10 milligram",{"EARLY_PHASE1":25432,"PHASE1":25434,"PHASE2":25447,"PHASE3":25449,"PHASE4":25451,"NA":25453},{"trials":25433,"activeCount":99},[],{"trials":25435,"activeCount":99},[25436],{"nctId":25437,"briefTitle":25438,"status":105,"phases":25439,"primaryCompletion":25440,"completion":17768,"start":25441,"enrollment":160,"conditions":25442,"interventions":25443},"NCT02837692","A Study to Assess the Effects of Age and Gender on the Pharmacokinetics of JNJ-42847922 in Healthy Adults",[87],"2017-09-07","2016-06-08",[15],[25430,25444,25445,25446],"JNJ-42847922 20 mg","JNJ-42847922 40 mg","JNJ-42847922 60 or 80 mg",{"trials":25448,"activeCount":99},[],{"trials":25450,"activeCount":99},[],{"trials":25452,"activeCount":99},[],{"trials":25454,"activeCount":99},[],{"intervention":25444,"totalTrials":468,"cells":25456},{"EARLY_PHASE1":25457,"PHASE1":25459,"PHASE2":25465,"PHASE3":25467,"PHASE4":25469,"NA":25471},{"trials":25458,"activeCount":99},[],{"trials":25460,"activeCount":99},[25461],{"nctId":25437,"briefTitle":25438,"status":105,"phases":25462,"primaryCompletion":25440,"completion":17768,"start":25441,"enrollment":160,"conditions":25463,"interventions":25464},[87],[15],[25430,25444,25445,25446],{"trials":25466,"activeCount":99},[],{"trials":25468,"activeCount":99},[],{"trials":25470,"activeCount":99},[],{"trials":25472,"activeCount":99},[],{"intervention":25445,"totalTrials":468,"cells":25474},{"EARLY_PHASE1":25475,"PHASE1":25477,"PHASE2":25483,"PHASE3":25485,"PHASE4":25487,"NA":25489},{"trials":25476,"activeCount":99},[],{"trials":25478,"activeCount":99},[25479],{"nctId":25437,"briefTitle":25438,"status":105,"phases":25480,"primaryCompletion":25440,"completion":17768,"start":25441,"enrollment":160,"conditions":25481,"interventions":25482},[87],[15],[25430,25444,25445,25446],{"trials":25484,"activeCount":99},[],{"trials":25486,"activeCount":99},[],{"trials":25488,"activeCount":99},[],{"trials":25490,"activeCount":99},[],{"intervention":25446,"totalTrials":468,"cells":25492},{"EARLY_PHASE1":25493,"PHASE1":25495,"PHASE2":25501,"PHASE3":25503,"PHASE4":25505,"NA":25507},{"trials":25494,"activeCount":99},[],{"trials":25496,"activeCount":99},[25497],{"nctId":25437,"briefTitle":25438,"status":105,"phases":25498,"primaryCompletion":25440,"completion":17768,"start":25441,"enrollment":160,"conditions":25499,"interventions":25500},[87],[15],[25430,25444,25445,25446],{"trials":25502,"activeCount":99},[],{"trials":25504,"activeCount":99},[],{"trials":25506,"activeCount":99},[],{"trials":25508,"activeCount":99},[],{"intervention":17906,"totalTrials":468,"cells":25510},{"EARLY_PHASE1":25511,"PHASE1":25513,"PHASE2":25519,"PHASE3":25521,"PHASE4":25523,"NA":25525},{"trials":25512,"activeCount":99},[],{"trials":25514,"activeCount":99},[25515],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25516,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25517,"interventions":25518},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25520,"activeCount":99},[],{"trials":25522,"activeCount":99},[],{"trials":25524,"activeCount":99},[],{"trials":25526,"activeCount":99},[],{"intervention":17907,"totalTrials":468,"cells":25528},{"EARLY_PHASE1":25529,"PHASE1":25531,"PHASE2":25537,"PHASE3":25539,"PHASE4":25541,"NA":25543},{"trials":25530,"activeCount":99},[],{"trials":25532,"activeCount":99},[25533],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25534,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25535,"interventions":25536},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25538,"activeCount":99},[],{"trials":25540,"activeCount":99},[],{"trials":25542,"activeCount":99},[],{"trials":25544,"activeCount":99},[],{"intervention":17908,"totalTrials":468,"cells":25546},{"EARLY_PHASE1":25547,"PHASE1":25549,"PHASE2":25555,"PHASE3":25557,"PHASE4":25559,"NA":25561},{"trials":25548,"activeCount":99},[],{"trials":25550,"activeCount":99},[25551],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25552,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25553,"interventions":25554},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25556,"activeCount":99},[],{"trials":25558,"activeCount":99},[],{"trials":25560,"activeCount":99},[],{"trials":25562,"activeCount":99},[],{"intervention":17909,"totalTrials":468,"cells":25564},{"EARLY_PHASE1":25565,"PHASE1":25567,"PHASE2":25573,"PHASE3":25575,"PHASE4":25577,"NA":25579},{"trials":25566,"activeCount":99},[],{"trials":25568,"activeCount":99},[25569],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25570,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25571,"interventions":25572},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25574,"activeCount":99},[],{"trials":25576,"activeCount":99},[],{"trials":25578,"activeCount":99},[],{"trials":25580,"activeCount":99},[],{"intervention":17910,"totalTrials":468,"cells":25582},{"EARLY_PHASE1":25583,"PHASE1":25585,"PHASE2":25591,"PHASE3":25593,"PHASE4":25595,"NA":25597},{"trials":25584,"activeCount":99},[],{"trials":25586,"activeCount":99},[25587],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25588,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25589,"interventions":25590},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25592,"activeCount":99},[],{"trials":25594,"activeCount":99},[],{"trials":25596,"activeCount":99},[],{"trials":25598,"activeCount":99},[],{"intervention":17911,"totalTrials":468,"cells":25600},{"EARLY_PHASE1":25601,"PHASE1":25603,"PHASE2":25609,"PHASE3":25611,"PHASE4":25613,"NA":25615},{"trials":25602,"activeCount":99},[],{"trials":25604,"activeCount":99},[25605],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25606,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25607,"interventions":25608},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25610,"activeCount":99},[],{"trials":25612,"activeCount":99},[],{"trials":25614,"activeCount":99},[],{"trials":25616,"activeCount":99},[],{"intervention":17912,"totalTrials":468,"cells":25618},{"EARLY_PHASE1":25619,"PHASE1":25621,"PHASE2":25627,"PHASE3":25629,"PHASE4":25631,"NA":25633},{"trials":25620,"activeCount":99},[],{"trials":25622,"activeCount":99},[25623],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25624,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25625,"interventions":25626},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25628,"activeCount":99},[],{"trials":25630,"activeCount":99},[],{"trials":25632,"activeCount":99},[],{"trials":25634,"activeCount":99},[],{"intervention":17913,"totalTrials":468,"cells":25636},{"EARLY_PHASE1":25637,"PHASE1":25639,"PHASE2":25645,"PHASE3":25647,"PHASE4":25649,"NA":25651},{"trials":25638,"activeCount":99},[],{"trials":25640,"activeCount":99},[25641],{"nctId":17901,"briefTitle":17902,"status":105,"phases":25642,"primaryCompletion":5912,"completion":5912,"start":3815,"enrollment":8388,"conditions":25643,"interventions":25644},[87],[15],[17906,17906,17906,17906,17907,17908,13911,17771,17909,17910,17911,17912,17913],{"trials":25646,"activeCount":99},[],{"trials":25648,"activeCount":99},[],{"trials":25650,"activeCount":99},[],{"trials":25652,"activeCount":99},[],{"intervention":12424,"totalTrials":468,"cells":25654},{"EARLY_PHASE1":25655,"PHASE1":25657,"PHASE2":25663,"PHASE3":25665,"PHASE4":25667,"NA":25669},{"trials":25656,"activeCount":99},[],{"trials":25658,"activeCount":99},[25659],{"nctId":12417,"briefTitle":12418,"status":105,"phases":25660,"primaryCompletion":12420,"completion":12420,"start":12421,"enrollment":656,"conditions":25661,"interventions":25662},[87],[15],[12424,12425,12370],{"trials":25664,"activeCount":99},[],{"trials":25666,"activeCount":99},[],{"trials":25668,"activeCount":99},[],{"trials":25670,"activeCount":99},[],{"intervention":12425,"totalTrials":468,"cells":25672},{"EARLY_PHASE1":25673,"PHASE1":25675,"PHASE2":25681,"PHASE3":25683,"PHASE4":25685,"NA":25687},{"trials":25674,"activeCount":99},[],{"trials":25676,"activeCount":99},[25677],{"nctId":12417,"briefTitle":12418,"status":105,"phases":25678,"primaryCompletion":12420,"completion":12420,"start":12421,"enrollment":656,"conditions":25679,"interventions":25680},[87],[15],[12424,12425,12370],{"trials":25682,"activeCount":99},[],{"trials":25684,"activeCount":99},[],{"trials":25686,"activeCount":99},[],{"trials":25688,"activeCount":99},[],{"intervention":25690,"totalTrials":468,"cells":25691},"Abiraterone acetate, 250 mg",{"EARLY_PHASE1":25692,"PHASE1":25694,"PHASE2":25703,"PHASE3":25705,"PHASE4":25707,"NA":25709},{"trials":25693,"activeCount":99},[],{"trials":25695,"activeCount":99},[25696],{"nctId":25697,"briefTitle":25698,"status":105,"phases":25699,"primaryCompletion":5899,"completion":5899,"start":2513,"enrollment":1507,"conditions":25700,"interventions":25701},"NCT01640093","A Comparative Study of Bioavailability of 3 New Abiraterone Acetate Tablets With Current Commercial Tablet",[87],[3667],[25690,25702,25690,25702],"Abiraterone acetate, 500 mg",{"trials":25704,"activeCount":99},[],{"trials":25706,"activeCount":99},[],{"trials":25708,"activeCount":99},[],{"trials":25710,"activeCount":99},[],{"intervention":25702,"totalTrials":468,"cells":25712},{"EARLY_PHASE1":25713,"PHASE1":25715,"PHASE2":25721,"PHASE3":25723,"PHASE4":25725,"NA":25727},{"trials":25714,"activeCount":99},[],{"trials":25716,"activeCount":99},[25717],{"nctId":25697,"briefTitle":25698,"status":105,"phases":25718,"primaryCompletion":5899,"completion":5899,"start":2513,"enrollment":1507,"conditions":25719,"interventions":25720},[87],[3667],[25690,25702,25690,25702],{"trials":25722,"activeCount":99},[],{"trials":25724,"activeCount":99},[],{"trials":25726,"activeCount":99},[],{"trials":25728,"activeCount":99},[],{"intervention":25730,"totalTrials":468,"cells":25731},"DRV\u002FCOBI FDC placebo",{"EARLY_PHASE1":25732,"PHASE1":25734,"PHASE2":25745,"PHASE3":25747,"PHASE4":25749,"NA":25751},{"trials":25733,"activeCount":99},[],{"trials":25735,"activeCount":99},[25736],{"nctId":25737,"briefTitle":25738,"status":105,"phases":25739,"primaryCompletion":2606,"completion":2606,"start":25740,"enrollment":5597,"conditions":25741,"interventions":25743},"NCT02993237","Study to Assess the Acceptability\u002FSwallowability of DRV-Containing FDC Tablets in HIV-1 Infected Adolescents, Using Matching Placebo Tablets",[87],"2017-01-23",[25742],"HIV-1",[25730,25744],"D\u002FC\u002FF\u002FTAF FDC placebo",{"trials":25746,"activeCount":99},[],{"trials":25748,"activeCount":99},[],{"trials":25750,"activeCount":99},[],{"trials":25752,"activeCount":99},[],{"intervention":25744,"totalTrials":468,"cells":25754},{"EARLY_PHASE1":25755,"PHASE1":25757,"PHASE2":25763,"PHASE3":25765,"PHASE4":25767,"NA":25769},{"trials":25756,"activeCount":99},[],{"trials":25758,"activeCount":99},[25759],{"nctId":25737,"briefTitle":25738,"status":105,"phases":25760,"primaryCompletion":2606,"completion":2606,"start":25740,"enrollment":5597,"conditions":25761,"interventions":25762},[87],[25742],[25730,25744],{"trials":25764,"activeCount":99},[],{"trials":25766,"activeCount":99},[],{"trials":25768,"activeCount":99},[],{"trials":25770,"activeCount":99},[],{"intervention":25772,"totalTrials":468,"cells":25773},"JNJ-2641585 \u002F VELCADE \u002F Dexamethasone",{"EARLY_PHASE1":25774,"PHASE1":25776,"PHASE2":25786,"PHASE3":25788,"PHASE4":25790,"NA":25792},{"trials":25775,"activeCount":99},[],{"trials":25777,"activeCount":99},[25778],{"nctId":25779,"briefTitle":25780,"status":105,"phases":25781,"primaryCompletion":25782,"completion":25782,"start":25783,"enrollment":503,"conditions":25784,"interventions":25785},"NCT01464112","A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma",[87],"2013-11-19","2011-09-16",[18],[25772],{"trials":25787,"activeCount":99},[],{"trials":25789,"activeCount":99},[],{"trials":25791,"activeCount":99},[],{"trials":25793,"activeCount":99},[],{"intervention":16704,"totalTrials":468,"cells":25795},{"EARLY_PHASE1":25796,"PHASE1":25798,"PHASE2":25804,"PHASE3":25806,"PHASE4":25808,"NA":25810},{"trials":25797,"activeCount":99},[],{"trials":25799,"activeCount":99},[25800],{"nctId":16699,"briefTitle":16700,"status":105,"phases":25801,"primaryCompletion":3596,"completion":3596,"start":9096,"enrollment":9010,"conditions":25802,"interventions":25803},[87],[15],[16704,3616],{"trials":25805,"activeCount":99},[],{"trials":25807,"activeCount":99},[],{"trials":25809,"activeCount":99},[],{"trials":25811,"activeCount":99},[],{"intervention":25813,"totalTrials":468,"cells":25814},"[18F]MNI-1020",{"EARLY_PHASE1":25815,"PHASE1":25823,"PHASE2":25825,"PHASE3":25827,"PHASE4":25829,"NA":25831},{"trials":25816,"activeCount":99},[25817],{"nctId":25818,"briefTitle":25819,"status":105,"phases":25820,"primaryCompletion":10063,"completion":10063,"start":9082,"enrollment":1177,"conditions":25821,"interventions":25822},"NCT03239561","Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants",[86],[4445],[25813],{"trials":25824,"activeCount":99},[],{"trials":25826,"activeCount":99},[],{"trials":25828,"activeCount":99},[],{"trials":25830,"activeCount":99},[],{"trials":25832,"activeCount":99},[],{"intervention":25834,"totalTrials":468,"cells":25835},"Indomethacin",{"EARLY_PHASE1":25836,"PHASE1":25846,"PHASE2":25848,"PHASE3":25850,"PHASE4":25852,"NA":25854},{"trials":25837,"activeCount":99},[25838],{"nctId":25839,"briefTitle":25840,"status":105,"phases":25841,"primaryCompletion":25842,"completion":25842,"start":25843,"enrollment":893,"conditions":25844,"interventions":25845},"NCT04821323","A Study Exploring the Use of Challenge Agents in Healthy Volunteers - Intervention Specific Appendix",[86],"2021-05-07","2021-03-10",[15],[25834],{"trials":25847,"activeCount":99},[],{"trials":25849,"activeCount":99},[],{"trials":25851,"activeCount":99},[],{"trials":25853,"activeCount":99},[],{"trials":25855,"activeCount":99},[],{"intervention":16943,"totalTrials":468,"cells":25857},{"EARLY_PHASE1":25858,"PHASE1":25864,"PHASE2":25866,"PHASE3":25868,"PHASE4":25870,"NA":25872},{"trials":25859,"activeCount":99},[25860],{"nctId":16937,"briefTitle":16938,"status":105,"phases":25861,"primaryCompletion":13919,"completion":13919,"start":16940,"enrollment":1972,"conditions":25862,"interventions":25863},[86],[15],[16943,16944,16945,16932],{"trials":25865,"activeCount":99},[],{"trials":25867,"activeCount":99},[],{"trials":25869,"activeCount":99},[],{"trials":25871,"activeCount":99},[],{"trials":25873,"activeCount":99},[],{"intervention":16944,"totalTrials":468,"cells":25875},{"EARLY_PHASE1":25876,"PHASE1":25882,"PHASE2":25884,"PHASE3":25886,"PHASE4":25888,"NA":25890},{"trials":25877,"activeCount":99},[25878],{"nctId":16937,"briefTitle":16938,"status":105,"phases":25879,"primaryCompletion":13919,"completion":13919,"start":16940,"enrollment":1972,"conditions":25880,"interventions":25881},[86],[15],[16943,16944,16945,16932],{"trials":25883,"activeCount":99},[],{"trials":25885,"activeCount":99},[],{"trials":25887,"activeCount":99},[],{"trials":25889,"activeCount":99},[],{"trials":25891,"activeCount":99},[],{"intervention":16945,"totalTrials":468,"cells":25893},{"EARLY_PHASE1":25894,"PHASE1":25900,"PHASE2":25902,"PHASE3":25904,"PHASE4":25906,"NA":25908},{"trials":25895,"activeCount":99},[25896],{"nctId":16937,"briefTitle":16938,"status":105,"phases":25897,"primaryCompletion":13919,"completion":13919,"start":16940,"enrollment":1972,"conditions":25898,"interventions":25899},[86],[15],[16943,16944,16945,16932],{"trials":25901,"activeCount":99},[],{"trials":25903,"activeCount":99},[],{"trials":25905,"activeCount":99},[],{"trials":25907,"activeCount":99},[],{"trials":25909,"activeCount":99},[],{"intervention":25911,"totalTrials":468,"cells":25912},"JNJ-35684-AAA-023: Size 1; small patch",{"EARLY_PHASE1":25913,"PHASE1":25922,"PHASE2":25924,"PHASE3":25926,"PHASE4":25928,"NA":25930},{"trials":25914,"activeCount":99},[25915],{"nctId":25916,"briefTitle":25917,"status":105,"phases":25918,"primaryCompletion":5530,"completion":5530,"start":5530,"enrollment":169,"conditions":25919,"interventions":25920},"NCT02221726","Study to Assess Adhesion Quality and Wear of Placebo JNJ-35685-AAA-G-023 Transdermal System in Healthy Adults",[86],[15],[25911,25921],"JNJ-35684-AAA-023: Size 2; large patch",{"trials":25923,"activeCount":99},[],{"trials":25925,"activeCount":99},[],{"trials":25927,"activeCount":99},[],{"trials":25929,"activeCount":99},[],{"trials":25931,"activeCount":99},[],{"intervention":25921,"totalTrials":468,"cells":25933},{"EARLY_PHASE1":25934,"PHASE1":25940,"PHASE2":25942,"PHASE3":25944,"PHASE4":25946,"NA":25948},{"trials":25935,"activeCount":99},[25936],{"nctId":25916,"briefTitle":25917,"status":105,"phases":25937,"primaryCompletion":5530,"completion":5530,"start":5530,"enrollment":169,"conditions":25938,"interventions":25939},[86],[15],[25911,25921],{"trials":25941,"activeCount":99},[],{"trials":25943,"activeCount":99},[],{"trials":25945,"activeCount":99},[],{"trials":25947,"activeCount":99},[],{"trials":25949,"activeCount":99},[],{"intervention":25951,"totalTrials":468,"cells":25952},"Atabecestat",{"EARLY_PHASE1":25953,"PHASE1":25962,"PHASE2":25964,"PHASE3":25966,"PHASE4":25968,"NA":25970},{"trials":25954,"activeCount":99},[25955],{"nctId":25956,"briefTitle":25957,"status":105,"phases":25958,"primaryCompletion":25959,"completion":25959,"start":18288,"enrollment":2149,"conditions":25960,"interventions":25961},"NCT03587376","Characterization of T-Cell Response in Participants Previously Treated With JNJ-54861911 (Atabecestat)",[86],"2018-08-23",[4445],[25951],{"trials":25963,"activeCount":99},[],{"trials":25965,"activeCount":99},[],{"trials":25967,"activeCount":99},[],{"trials":25969,"activeCount":99},[],{"trials":25971,"activeCount":99},[],{"intervention":5826,"totalTrials":503,"cells":25973},{"EARLY_PHASE1":25974,"PHASE1":25976,"PHASE2":26013,"PHASE3":26019,"PHASE4":26057,"NA":26059},{"trials":25975,"activeCount":99},[],{"trials":25977,"activeCount":99},[25978,25985,25989,25993,25997,26001,26005,26009],{"nctId":25979,"briefTitle":25980,"status":105,"phases":25981,"primaryCompletion":2535,"completion":2535,"start":5867,"enrollment":1532,"conditions":25982,"interventions":25984},"NCT01483781","A Study of the Effects of Canagliflozin on Plasma Volume in Patients With Type 2 Diabetes Mellitus",[87],[24,25983],"Plasma Volume",[5826],{"nctId":5819,"briefTitle":5820,"status":105,"phases":25986,"primaryCompletion":3358,"completion":3358,"start":5530,"enrollment":245,"conditions":25987,"interventions":25988},[87],[5823],[5825,5826,1779],{"nctId":17277,"briefTitle":17278,"status":105,"phases":25990,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":25991,"interventions":25992},[87],[15],[5826,17270,17282,17282,5826,17270],{"nctId":17284,"briefTitle":17285,"status":105,"phases":25994,"primaryCompletion":2565,"completion":2565,"start":3342,"enrollment":1787,"conditions":25995,"interventions":25996},[87],[15],[5826,17270,17282,5826,17270,17282],{"nctId":17020,"briefTitle":17021,"status":105,"phases":25998,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":25999,"interventions":26000},[87],[15],[9013,5826,5826,9014],{"nctId":17290,"briefTitle":17291,"status":105,"phases":26002,"primaryCompletion":3359,"completion":3359,"start":5530,"enrollment":245,"conditions":26003,"interventions":26004},[87],[15],[17295,5826,17270],{"nctId":17026,"briefTitle":17027,"status":105,"phases":26006,"primaryCompletion":583,"completion":583,"start":3596,"enrollment":9010,"conditions":26007,"interventions":26008},[87],[15],[9013,5826,9014],{"nctId":17032,"briefTitle":17033,"status":105,"phases":26010,"primaryCompletion":17035,"completion":17035,"start":3596,"enrollment":9010,"conditions":26011,"interventions":26012},[87],[15],[9013,5826,9014],{"trials":26014,"activeCount":99},[26015],{"nctId":16123,"briefTitle":16124,"status":105,"phases":26016,"primaryCompletion":8200,"completion":8200,"start":4348,"enrollment":16126,"conditions":26017,"interventions":26018},[88],[13946],[5826,16114],{"trials":26020,"activeCount":99},[26021,26025,26029,26033,26039,26043,26047],{"nctId":9824,"briefTitle":9825,"status":105,"phases":26022,"primaryCompletion":5889,"completion":2565,"start":9074,"enrollment":5890,"conditions":26023,"interventions":26024},[89],[24],[5826,5903],{"nctId":5864,"briefTitle":5865,"status":105,"phases":26026,"primaryCompletion":5867,"completion":5868,"start":5869,"enrollment":5870,"conditions":26027,"interventions":26028},[89],[24],[5873,5826,1779],{"nctId":9830,"briefTitle":9831,"status":105,"phases":26030,"primaryCompletion":8891,"completion":2513,"start":5879,"enrollment":8926,"conditions":26031,"interventions":26032},[89],[24],[5826,5903,9835],{"nctId":26034,"briefTitle":26035,"status":105,"phases":26036,"primaryCompletion":5867,"completion":2535,"start":2486,"enrollment":2985,"conditions":26037,"interventions":26038},"NCT01064414","An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment",[89],[24,8885],[5826],{"nctId":5875,"briefTitle":5876,"status":105,"phases":26040,"primaryCompletion":5878,"completion":2487,"start":5879,"enrollment":5880,"conditions":26041,"interventions":26042},[89],[24],[5826,1779,5883],{"nctId":5896,"briefTitle":5897,"status":105,"phases":26044,"primaryCompletion":4850,"completion":5899,"start":2486,"enrollment":5900,"conditions":26045,"interventions":26046},[89],[24],[5826,5903,1779,5904],{"nctId":26048,"briefTitle":26049,"status":105,"phases":26050,"primaryCompletion":26051,"completion":26051,"start":26052,"enrollment":26053,"conditions":26054,"interventions":26056},"NCT02065791","Evaluation of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Participants With Diabetic Nephropathy",[89],"2018-10-30","2014-02-17",4401,[24,26055],"Diabetic Nephropathy",[5826],{"trials":26058,"activeCount":99},[],{"trials":26060,"activeCount":99},[26061,26077],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26064,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26068,"interventions":26069},"NCT03249506","Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)",[],"2017-11-01","2016-05-12",25358,[24],[5826,26070,26071,26072,26073,26074,26075,26076],"Empagliflozin","Dapagliflozin","Dipeptidyl Peptidase-4 Inhibitor","Glucagon-Like Peptide-1 Agonist","Thiazolidinedione","Sulfonylureas","Insulin",{"nctId":26078,"briefTitle":26079,"status":105,"phases":26080,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26084,"interventions":26085},"NCT03492580","A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease",[],"2018-04-06","2018-02-22",714582,[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],"Dipeptidyl Peptidase-4 (DPP-4) Inhibitors","Glucagon-like Peptide-1 (GLP-1) Agonist","Anti-hyperglycemic Agents","Thiazolidinediones",{"intervention":26091,"totalTrials":641,"cells":26092},"No Intervention",{"EARLY_PHASE1":26093,"PHASE1":26095,"PHASE2":26097,"PHASE3":26099,"PHASE4":26101,"NA":26103},{"trials":26094,"activeCount":99},[],{"trials":26096,"activeCount":99},[],{"trials":26098,"activeCount":99},[],{"trials":26100,"activeCount":99},[],{"trials":26102,"activeCount":99},[],{"trials":26104,"activeCount":99},[26105,26112,26121,26129,26139,26147],{"nctId":26106,"briefTitle":26107,"status":105,"phases":26108,"primaryCompletion":4348,"completion":4348,"start":5572,"enrollment":26109,"conditions":26110,"interventions":26111},"NCT02155192","An Exploratory Genetic Study in Participants With Psoriasis",[],712,[171],[26091],{"nctId":26113,"briefTitle":26114,"status":105,"phases":26115,"primaryCompletion":26116,"completion":26116,"start":26117,"enrollment":8,"conditions":26118,"interventions":26119},"NCT01677598","A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific Countries",[],"2013-11-30","2011-12-02",[332],[26120],"No intervention",{"nctId":26122,"briefTitle":26123,"status":105,"phases":26124,"primaryCompletion":3903,"completion":3903,"start":26125,"enrollment":1029,"conditions":26126,"interventions":26128},"NCT02274389","A Prospective Patient Registry of Patients Exposed to Bedaquiline",[],"2013-12-24",[26127],"Pulmonary Multi-drug Resistant Tuberculosis",[26091],{"nctId":26130,"briefTitle":26131,"status":105,"phases":26132,"primaryCompletion":26133,"completion":26133,"start":26134,"enrollment":26135,"conditions":26136,"interventions":26138},"NCT01880294","A Study to Assess Different Diagnostic Criteria of Chronic Constipation in Asia",[],"2013-12-14","2013-03-18",461,[26137],"Constipation",[26120],{"nctId":26140,"briefTitle":26141,"status":105,"phases":26142,"primaryCompletion":26143,"completion":26143,"start":9113,"enrollment":26144,"conditions":26145,"interventions":26146},"NCT02636192","Study on Incidence of Diabetic Ketoacidosis Among Participants With Type 2 Diabetes Mellitus Treated With Sodium-glucose Co-transporter 2 (SGLT2) Inhibitors or Other Antihyperglycemic Agents",[],"2017-04-07",200000,[24],[26091],{"nctId":26148,"briefTitle":26149,"status":105,"phases":26150,"primaryCompletion":4223,"completion":4223,"start":5867,"enrollment":26151,"conditions":26152,"interventions":26154},"NCT01907633","An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide",[],15000,[26153],"Death, Sudden, Cardiac",[26120],{"intervention":174,"totalTrials":1029,"cells":26156},{"EARLY_PHASE1":26157,"PHASE1":26159,"PHASE2":26177,"PHASE3":26179,"PHASE4":26181,"NA":26183},{"trials":26158,"activeCount":99},[],{"trials":26160,"activeCount":99},[26161,26165,26169,26173],{"nctId":8888,"briefTitle":8889,"status":105,"phases":26162,"primaryCompletion":2513,"completion":2513,"start":8891,"enrollment":2545,"conditions":26163,"interventions":26164},[87],[15],[8873,174,4335,4335,174,174,174],{"nctId":4320,"briefTitle":4321,"status":105,"phases":26166,"primaryCompletion":4314,"completion":4314,"start":3657,"enrollment":503,"conditions":26167,"interventions":26168},[87],[15],[4325,173,174],{"nctId":4327,"briefTitle":4328,"status":105,"phases":26170,"primaryCompletion":4330,"completion":4330,"start":4331,"enrollment":544,"conditions":26171,"interventions":26172},[87],[2003],[4334,173,174,4335,175,177],{"nctId":164,"briefTitle":165,"status":105,"phases":26174,"primaryCompletion":167,"completion":167,"start":168,"enrollment":169,"conditions":26175,"interventions":26176},[87],[171],[94,173,174,175,176,177],{"trials":26178,"activeCount":99},[],{"trials":26180,"activeCount":99},[],{"trials":26182,"activeCount":99},[],{"trials":26184,"activeCount":99},[26185],{"nctId":6932,"briefTitle":6933,"status":105,"phases":26186,"primaryCompletion":6935,"completion":6935,"start":6936,"enrollment":6937,"conditions":26187,"interventions":26188},[],[6939],[6913,174],{"intervention":1182,"totalTrials":1029,"cells":26190},{"EARLY_PHASE1":26191,"PHASE1":26193,"PHASE2":26199,"PHASE3":26205,"PHASE4":26215,"NA":26217},{"trials":26192,"activeCount":99},[],{"trials":26194,"activeCount":99},[26195],{"nctId":1172,"briefTitle":1173,"status":105,"phases":26196,"primaryCompletion":1175,"completion":1175,"start":1176,"enrollment":1177,"conditions":26197,"interventions":26198},[87],[1179,1180],[1182,684],{"trials":26200,"activeCount":99},[26201],{"nctId":14209,"briefTitle":14210,"status":105,"phases":26202,"primaryCompletion":5888,"completion":5888,"start":8883,"enrollment":544,"conditions":26203,"interventions":26204},[87,88],[1179],[1182,3643,14214],{"trials":26206,"activeCount":99},[26207,26211],{"nctId":10779,"briefTitle":10780,"status":105,"phases":26208,"primaryCompletion":5493,"completion":8190,"start":9596,"enrollment":10782,"conditions":26209,"interventions":26210},[89],[10784],[1182,10768],{"nctId":1316,"briefTitle":1317,"status":105,"phases":26212,"primaryCompletion":1319,"completion":1320,"start":1321,"enrollment":1322,"conditions":26213,"interventions":26214},[89],[1324,1325,1326],[1182,1328,684,1328],{"trials":26216,"activeCount":99},[],{"trials":26218,"activeCount":99},[26219],{"nctId":26220,"briefTitle":26221,"status":474,"phases":26222,"conditions":26223,"interventions":26225},"NCT00210665","A Study to Provide Access to Trabectedin in Participants With Locally Advanced or Metastatic Soft Tissue Sarcoma Who Have Persistent or Recurrent Disease and Who Are Not Expected to Benefit From Currently Available Standard of Care Treatment",[],[26224],"Sarcoma",[1182],{"intervention":26227,"totalTrials":245,"cells":26228},"Atomoxetine",{"EARLY_PHASE1":26229,"PHASE1":26231,"PHASE2":26233,"PHASE3":26235,"PHASE4":26237,"NA":26239},{"trials":26230,"activeCount":99},[],{"trials":26232,"activeCount":99},[],{"trials":26234,"activeCount":99},[],{"trials":26236,"activeCount":99},[],{"trials":26238,"activeCount":99},[],{"trials":26240,"activeCount":99},[26241,26255],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26244,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26248,"interventions":26250},"NCT04132557","A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine\u002FDextroamphetamine or Lisdexamfetamine",[],"2019-10-25","2019-10-09",430000,[26249],"Attention Deficit Disorder With Hyperactivity",[26251,26252,26227,26253,26254],"Methylphenidate","Lisdexamfetamine","Amphetamine","Dextroamphetamine",{"nctId":26256,"briefTitle":26257,"status":105,"phases":26258,"primaryCompletion":16848,"completion":16848,"start":11281,"enrollment":26259,"conditions":26260,"interventions":26261},"NCT04113551","A Study of Label Compliance for Attention Deficit\u002FHyperactivity Disorder (ADHD) Medications in Japan",[],17418,[26249],[26262,26262,26227,26263],"MPH","Guanfacine",{"intervention":26070,"totalTrials":245,"cells":26265},{"EARLY_PHASE1":26266,"PHASE1":26268,"PHASE2":26270,"PHASE3":26272,"PHASE4":26274,"NA":26276},{"trials":26267,"activeCount":99},[],{"trials":26269,"activeCount":99},[],{"trials":26271,"activeCount":99},[],{"trials":26273,"activeCount":99},[],{"trials":26275,"activeCount":99},[],{"trials":26277,"activeCount":99},[26278,26282],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26279,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26280,"interventions":26281},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26283,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26284,"interventions":26285},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26071,"totalTrials":245,"cells":26287},{"EARLY_PHASE1":26288,"PHASE1":26290,"PHASE2":26292,"PHASE3":26294,"PHASE4":26296,"NA":26298},{"trials":26289,"activeCount":99},[],{"trials":26291,"activeCount":99},[],{"trials":26293,"activeCount":99},[],{"trials":26295,"activeCount":99},[],{"trials":26297,"activeCount":99},[],{"trials":26299,"activeCount":99},[26300,26304],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26301,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26302,"interventions":26303},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26305,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26306,"interventions":26307},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26075,"totalTrials":245,"cells":26309},{"EARLY_PHASE1":26310,"PHASE1":26312,"PHASE2":26314,"PHASE3":26316,"PHASE4":26318,"NA":26320},{"trials":26311,"activeCount":99},[],{"trials":26313,"activeCount":99},[],{"trials":26315,"activeCount":99},[],{"trials":26317,"activeCount":99},[],{"trials":26319,"activeCount":99},[],{"trials":26321,"activeCount":99},[26322,26326],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26323,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26324,"interventions":26325},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26327,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26328,"interventions":26329},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26076,"totalTrials":245,"cells":26331},{"EARLY_PHASE1":26332,"PHASE1":26334,"PHASE2":26336,"PHASE3":26338,"PHASE4":26340,"NA":26342},{"trials":26333,"activeCount":99},[],{"trials":26335,"activeCount":99},[],{"trials":26337,"activeCount":99},[],{"trials":26339,"activeCount":99},[],{"trials":26341,"activeCount":99},[],{"trials":26343,"activeCount":99},[26344,26348],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26345,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26346,"interventions":26347},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26349,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26350,"interventions":26351},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":3433,"totalTrials":245,"cells":26353},{"EARLY_PHASE1":26354,"PHASE1":26356,"PHASE2":26362,"PHASE3":26364,"PHASE4":26366,"NA":26368},{"trials":26355,"activeCount":99},[],{"trials":26357,"activeCount":99},[26358],{"nctId":568,"briefTitle":569,"status":125,"phases":26359,"primaryCompletion":79,"completion":79,"start":148,"enrollment":571,"conditions":26360,"interventions":26361},[87],[30],[574,495,575,41],{"trials":26363,"activeCount":99},[],{"trials":26365,"activeCount":99},[],{"trials":26367,"activeCount":99},[],{"trials":26369,"activeCount":99},[26370],{"nctId":3428,"briefTitle":3429,"status":474,"phases":26371,"conditions":26372,"interventions":26373},[],[2490],[518,3433],{"intervention":26375,"totalTrials":468,"cells":26376},"Fluoroquinolone",{"EARLY_PHASE1":26377,"PHASE1":26379,"PHASE2":26381,"PHASE3":26383,"PHASE4":26385,"NA":26387},{"trials":26378,"activeCount":99},[],{"trials":26380,"activeCount":99},[],{"trials":26382,"activeCount":99},[],{"trials":26384,"activeCount":99},[],{"trials":26386,"activeCount":99},[],{"trials":26388,"activeCount":99},[26389],{"nctId":26390,"briefTitle":26391,"status":105,"phases":26392,"primaryCompletion":26393,"completion":26393,"start":1478,"enrollment":26394,"conditions":26395,"interventions":26398},"NCT03535558","Fluoroquinolone Associated Disability",[],"2018-12-31",239306,[26396,26397,8322],"Bronchitis","Sinusitis",[26375,26399,26400],"Azithromycin","Sulfamethoxazole\u002FTrimethoprim (ST) Fixed Dose Combination",{"intervention":26399,"totalTrials":468,"cells":26402},{"EARLY_PHASE1":26403,"PHASE1":26405,"PHASE2":26407,"PHASE3":26409,"PHASE4":26411,"NA":26413},{"trials":26404,"activeCount":99},[],{"trials":26406,"activeCount":99},[],{"trials":26408,"activeCount":99},[],{"trials":26410,"activeCount":99},[],{"trials":26412,"activeCount":99},[],{"trials":26414,"activeCount":99},[26415],{"nctId":26390,"briefTitle":26391,"status":105,"phases":26416,"primaryCompletion":26393,"completion":26393,"start":1478,"enrollment":26394,"conditions":26417,"interventions":26418},[],[26396,26397,8322],[26375,26399,26400],{"intervention":26400,"totalTrials":468,"cells":26420},{"EARLY_PHASE1":26421,"PHASE1":26423,"PHASE2":26425,"PHASE3":26427,"PHASE4":26429,"NA":26431},{"trials":26422,"activeCount":99},[],{"trials":26424,"activeCount":99},[],{"trials":26426,"activeCount":99},[],{"trials":26428,"activeCount":99},[],{"trials":26430,"activeCount":99},[],{"trials":26432,"activeCount":99},[26433],{"nctId":26390,"briefTitle":26391,"status":105,"phases":26434,"primaryCompletion":26393,"completion":26393,"start":1478,"enrollment":26394,"conditions":26435,"interventions":26436},[],[26396,26397,8322],[26375,26399,26400],{"intervention":26438,"totalTrials":468,"cells":26439},"Haloperidol",{"EARLY_PHASE1":26440,"PHASE1":26442,"PHASE2":26444,"PHASE3":26446,"PHASE4":26448,"NA":26450},{"trials":26441,"activeCount":99},[],{"trials":26443,"activeCount":99},[],{"trials":26445,"activeCount":99},[],{"trials":26447,"activeCount":99},[],{"trials":26449,"activeCount":99},[],{"trials":26451,"activeCount":99},[26452],{"nctId":26453,"briefTitle":26454,"status":105,"phases":26455,"primaryCompletion":15705,"completion":15705,"start":26456,"enrollment":26457,"conditions":26458,"interventions":26459},"NCT04002700","A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group",[],"2019-05-06",1234412,[20100],[26438,26460,26461],"Typical Antipsychotics","Atypical Antipsychotics",{"intervention":26460,"totalTrials":468,"cells":26463},{"EARLY_PHASE1":26464,"PHASE1":26466,"PHASE2":26468,"PHASE3":26470,"PHASE4":26472,"NA":26474},{"trials":26465,"activeCount":99},[],{"trials":26467,"activeCount":99},[],{"trials":26469,"activeCount":99},[],{"trials":26471,"activeCount":99},[],{"trials":26473,"activeCount":99},[],{"trials":26475,"activeCount":99},[26476],{"nctId":26453,"briefTitle":26454,"status":105,"phases":26477,"primaryCompletion":15705,"completion":15705,"start":26456,"enrollment":26457,"conditions":26478,"interventions":26479},[],[20100],[26438,26460,26461],{"intervention":26461,"totalTrials":468,"cells":26481},{"EARLY_PHASE1":26482,"PHASE1":26484,"PHASE2":26486,"PHASE3":26488,"PHASE4":26490,"NA":26492},{"trials":26483,"activeCount":99},[],{"trials":26485,"activeCount":99},[],{"trials":26487,"activeCount":99},[],{"trials":26489,"activeCount":99},[],{"trials":26491,"activeCount":99},[],{"trials":26493,"activeCount":99},[26494],{"nctId":26453,"briefTitle":26454,"status":105,"phases":26495,"primaryCompletion":15705,"completion":15705,"start":26456,"enrollment":26457,"conditions":26496,"interventions":26497},[],[20100],[26438,26460,26461],{"intervention":26251,"totalTrials":468,"cells":26499},{"EARLY_PHASE1":26500,"PHASE1":26502,"PHASE2":26504,"PHASE3":26506,"PHASE4":26508,"NA":26510},{"trials":26501,"activeCount":99},[],{"trials":26503,"activeCount":99},[],{"trials":26505,"activeCount":99},[],{"trials":26507,"activeCount":99},[],{"trials":26509,"activeCount":99},[],{"trials":26511,"activeCount":99},[26512],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26513,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26514,"interventions":26515},[],[26249],[26251,26252,26227,26253,26254],{"intervention":26252,"totalTrials":468,"cells":26517},{"EARLY_PHASE1":26518,"PHASE1":26520,"PHASE2":26522,"PHASE3":26524,"PHASE4":26526,"NA":26528},{"trials":26519,"activeCount":99},[],{"trials":26521,"activeCount":99},[],{"trials":26523,"activeCount":99},[],{"trials":26525,"activeCount":99},[],{"trials":26527,"activeCount":99},[],{"trials":26529,"activeCount":99},[26530],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26531,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26532,"interventions":26533},[],[26249],[26251,26252,26227,26253,26254],{"intervention":26253,"totalTrials":468,"cells":26535},{"EARLY_PHASE1":26536,"PHASE1":26538,"PHASE2":26540,"PHASE3":26542,"PHASE4":26544,"NA":26546},{"trials":26537,"activeCount":99},[],{"trials":26539,"activeCount":99},[],{"trials":26541,"activeCount":99},[],{"trials":26543,"activeCount":99},[],{"trials":26545,"activeCount":99},[],{"trials":26547,"activeCount":99},[26548],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26549,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26550,"interventions":26551},[],[26249],[26251,26252,26227,26253,26254],{"intervention":26254,"totalTrials":468,"cells":26553},{"EARLY_PHASE1":26554,"PHASE1":26556,"PHASE2":26558,"PHASE3":26560,"PHASE4":26562,"NA":26564},{"trials":26555,"activeCount":99},[],{"trials":26557,"activeCount":99},[],{"trials":26559,"activeCount":99},[],{"trials":26561,"activeCount":99},[],{"trials":26563,"activeCount":99},[],{"trials":26565,"activeCount":99},[26566],{"nctId":26242,"briefTitle":26243,"status":105,"phases":26567,"primaryCompletion":26245,"completion":26245,"start":26246,"enrollment":26247,"conditions":26568,"interventions":26569},[],[26249],[26251,26252,26227,26253,26254],{"intervention":26571,"totalTrials":468,"cells":26572},"Oral Fluoroquinolones",{"EARLY_PHASE1":26573,"PHASE1":26575,"PHASE2":26577,"PHASE3":26579,"PHASE4":26581,"NA":26583},{"trials":26574,"activeCount":99},[],{"trials":26576,"activeCount":99},[],{"trials":26578,"activeCount":99},[],{"trials":26580,"activeCount":99},[],{"trials":26582,"activeCount":99},[],{"trials":26584,"activeCount":99},[26585],{"nctId":26586,"briefTitle":26587,"status":105,"phases":26588,"primaryCompletion":13846,"completion":26589,"start":2959,"enrollment":26590,"conditions":26591,"interventions":26595},"NCT03479736","A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events",[],"2018-06-04",117911,[26592,26593,26594],"Retinal Detachment","Achilles Tendon","Aneurysm, Dissecting",[26571,26596],"Other Antibiotics",{"intervention":26596,"totalTrials":468,"cells":26598},{"EARLY_PHASE1":26599,"PHASE1":26601,"PHASE2":26603,"PHASE3":26605,"PHASE4":26607,"NA":26609},{"trials":26600,"activeCount":99},[],{"trials":26602,"activeCount":99},[],{"trials":26604,"activeCount":99},[],{"trials":26606,"activeCount":99},[],{"trials":26608,"activeCount":99},[],{"trials":26610,"activeCount":99},[26611],{"nctId":26586,"briefTitle":26587,"status":105,"phases":26612,"primaryCompletion":13846,"completion":26589,"start":2959,"enrollment":26590,"conditions":26613,"interventions":26614},[],[26592,26593,26594],[26571,26596],{"intervention":26616,"totalTrials":468,"cells":26617},"Pimodivir",{"EARLY_PHASE1":26618,"PHASE1":26620,"PHASE2":26622,"PHASE3":26624,"PHASE4":26626,"NA":26628},{"trials":26619,"activeCount":99},[],{"trials":26621,"activeCount":99},[],{"trials":26623,"activeCount":99},[],{"trials":26625,"activeCount":99},[],{"trials":26627,"activeCount":99},[],{"trials":26629,"activeCount":99},[26630],{"nctId":26631,"briefTitle":26632,"status":474,"phases":26633,"conditions":26634,"interventions":26636},"NCT03834376","Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A Infection",[],[26635],"H7N9 Subtype of Influenza A Virus",[26616],{"intervention":5756,"totalTrials":468,"cells":26638},{"EARLY_PHASE1":26639,"PHASE1":26641,"PHASE2":26643,"PHASE3":26645,"PHASE4":26647,"NA":26649},{"trials":26640,"activeCount":99},[],{"trials":26642,"activeCount":99},[],{"trials":26644,"activeCount":99},[],{"trials":26646,"activeCount":99},[],{"trials":26648,"activeCount":99},[],{"trials":26650,"activeCount":99},[26651],{"nctId":5748,"briefTitle":5749,"status":125,"phases":26652,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":4851,"conditions":26653,"interventions":26654},[],[5754],[4241,5756,5757],{"intervention":5757,"totalTrials":468,"cells":26656},{"EARLY_PHASE1":26657,"PHASE1":26659,"PHASE2":26661,"PHASE3":26663,"PHASE4":26665,"NA":26667},{"trials":26658,"activeCount":99},[],{"trials":26660,"activeCount":99},[],{"trials":26662,"activeCount":99},[],{"trials":26664,"activeCount":99},[],{"trials":26666,"activeCount":99},[],{"trials":26668,"activeCount":99},[26669],{"nctId":5748,"briefTitle":5749,"status":125,"phases":26670,"primaryCompletion":5751,"completion":5751,"start":5752,"enrollment":4851,"conditions":26671,"interventions":26672},[],[5754],[4241,5756,5757],{"intervention":26674,"totalTrials":468,"cells":26675},"Ad26.COV2.S",{"EARLY_PHASE1":26676,"PHASE1":26678,"PHASE2":26680,"PHASE3":26682,"PHASE4":26684,"NA":26686},{"trials":26677,"activeCount":99},[],{"trials":26679,"activeCount":99},[],{"trials":26681,"activeCount":99},[],{"trials":26683,"activeCount":99},[],{"trials":26685,"activeCount":99},[],{"trials":26687,"activeCount":99},[26688],{"nctId":26689,"briefTitle":26690,"status":474,"phases":26691,"conditions":26692,"interventions":26693},"NCT04817657","Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use",[],[15],[26674],{"intervention":26072,"totalTrials":468,"cells":26695},{"EARLY_PHASE1":26696,"PHASE1":26698,"PHASE2":26700,"PHASE3":26702,"PHASE4":26704,"NA":26706},{"trials":26697,"activeCount":99},[],{"trials":26699,"activeCount":99},[],{"trials":26701,"activeCount":99},[],{"trials":26703,"activeCount":99},[],{"trials":26705,"activeCount":99},[],{"trials":26707,"activeCount":99},[26708],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26709,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26710,"interventions":26711},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"intervention":26073,"totalTrials":468,"cells":26713},{"EARLY_PHASE1":26714,"PHASE1":26716,"PHASE2":26718,"PHASE3":26720,"PHASE4":26722,"NA":26724},{"trials":26715,"activeCount":99},[],{"trials":26717,"activeCount":99},[],{"trials":26719,"activeCount":99},[],{"trials":26721,"activeCount":99},[],{"trials":26723,"activeCount":99},[],{"trials":26725,"activeCount":99},[26726],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26727,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26728,"interventions":26729},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"intervention":26074,"totalTrials":468,"cells":26731},{"EARLY_PHASE1":26732,"PHASE1":26734,"PHASE2":26736,"PHASE3":26738,"PHASE4":26740,"NA":26742},{"trials":26733,"activeCount":99},[],{"trials":26735,"activeCount":99},[],{"trials":26737,"activeCount":99},[],{"trials":26739,"activeCount":99},[],{"trials":26741,"activeCount":99},[],{"trials":26743,"activeCount":99},[26744],{"nctId":26062,"briefTitle":26063,"status":105,"phases":26745,"primaryCompletion":26065,"completion":26065,"start":26066,"enrollment":26067,"conditions":26746,"interventions":26747},[],[24],[5826,26070,26071,26072,26073,26074,26075,26076],{"intervention":26086,"totalTrials":468,"cells":26749},{"EARLY_PHASE1":26750,"PHASE1":26752,"PHASE2":26754,"PHASE3":26756,"PHASE4":26758,"NA":26760},{"trials":26751,"activeCount":99},[],{"trials":26753,"activeCount":99},[],{"trials":26755,"activeCount":99},[],{"trials":26757,"activeCount":99},[],{"trials":26759,"activeCount":99},[],{"trials":26761,"activeCount":99},[26762],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26763,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26764,"interventions":26765},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26087,"totalTrials":468,"cells":26767},{"EARLY_PHASE1":26768,"PHASE1":26770,"PHASE2":26772,"PHASE3":26774,"PHASE4":26776,"NA":26778},{"trials":26769,"activeCount":99},[],{"trials":26771,"activeCount":99},[],{"trials":26773,"activeCount":99},[],{"trials":26775,"activeCount":99},[],{"trials":26777,"activeCount":99},[],{"trials":26779,"activeCount":99},[26780],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26781,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26782,"interventions":26783},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26088,"totalTrials":468,"cells":26785},{"EARLY_PHASE1":26786,"PHASE1":26788,"PHASE2":26790,"PHASE3":26792,"PHASE4":26794,"NA":26796},{"trials":26787,"activeCount":99},[],{"trials":26789,"activeCount":99},[],{"trials":26791,"activeCount":99},[],{"trials":26793,"activeCount":99},[],{"trials":26795,"activeCount":99},[],{"trials":26797,"activeCount":99},[26798],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26799,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26800,"interventions":26801},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26089,"totalTrials":468,"cells":26803},{"EARLY_PHASE1":26804,"PHASE1":26806,"PHASE2":26808,"PHASE3":26810,"PHASE4":26812,"NA":26814},{"trials":26805,"activeCount":99},[],{"trials":26807,"activeCount":99},[],{"trials":26809,"activeCount":99},[],{"trials":26811,"activeCount":99},[],{"trials":26813,"activeCount":99},[],{"trials":26815,"activeCount":99},[26816],{"nctId":26078,"briefTitle":26079,"status":105,"phases":26817,"primaryCompletion":26081,"completion":13089,"start":26082,"enrollment":26083,"conditions":26818,"interventions":26819},[],[24,11980],[5826,26070,26071,26086,26087,26088,26089,26075,26076],{"intervention":26821,"totalTrials":468,"cells":26822},"Infliximab 5 mg\u002Fkg",{"EARLY_PHASE1":26823,"PHASE1":26825,"PHASE2":26827,"PHASE3":26829,"PHASE4":26831,"NA":26833},{"trials":26824,"activeCount":99},[],{"trials":26826,"activeCount":99},[],{"trials":26828,"activeCount":99},[],{"trials":26830,"activeCount":99},[],{"trials":26832,"activeCount":99},[],{"trials":26834,"activeCount":99},[26835],{"nctId":26836,"briefTitle":26837,"status":105,"phases":26838,"primaryCompletion":26839,"completion":26839,"start":26840,"enrollment":26841,"conditions":26842,"interventions":26843},"NCT00207688","A Long Term Safety Study of Infliximab (Remicade) in in Ulcerative Colitis Patients",[],"2015-09-09","2004-08-31",505,[299],[26821,26844],"Infliximab 10 mg\u002Fkg",{"intervention":26844,"totalTrials":468,"cells":26846},{"EARLY_PHASE1":26847,"PHASE1":26849,"PHASE2":26851,"PHASE3":26853,"PHASE4":26855,"NA":26857},{"trials":26848,"activeCount":99},[],{"trials":26850,"activeCount":99},[],{"trials":26852,"activeCount":99},[],{"trials":26854,"activeCount":99},[],{"trials":26856,"activeCount":99},[],{"trials":26858,"activeCount":99},[26859],{"nctId":26836,"briefTitle":26837,"status":105,"phases":26860,"primaryCompletion":26839,"completion":26839,"start":26840,"enrollment":26841,"conditions":26861,"interventions":26862},[],[299],[26821,26844],{"intervention":26864,"totalTrials":468,"cells":26865},"PRILIGY",{"EARLY_PHASE1":26866,"PHASE1":26868,"PHASE2":26870,"PHASE3":26872,"PHASE4":26874,"NA":26876},{"trials":26867,"activeCount":99},[],{"trials":26869,"activeCount":99},[],{"trials":26871,"activeCount":99},[],{"trials":26873,"activeCount":99},[],{"trials":26875,"activeCount":99},[],{"trials":26877,"activeCount":99},[26878],{"nctId":26879,"briefTitle":26880,"status":105,"phases":26881,"completion":3392,"start":2488,"enrollment":26882,"conditions":26883,"interventions":26884},"NCT01273545","PRILIGY Usage Patterns in Selected Populations",[],3000,[10849],[26864],{"intervention":26886,"totalTrials":468,"cells":26887},"Niraparib plus Abiraterone Acetate (Nira\u002FAA) combination",{"EARLY_PHASE1":26888,"PHASE1":26890,"PHASE2":26892,"PHASE3":26894,"PHASE4":26896,"NA":26898},{"trials":26889,"activeCount":99},[],{"trials":26891,"activeCount":99},[],{"trials":26893,"activeCount":99},[],{"trials":26895,"activeCount":99},[],{"trials":26897,"activeCount":99},[],{"trials":26899,"activeCount":99},[26900],{"nctId":26901,"briefTitle":26902,"status":967,"phases":26903,"conditions":26904,"interventions":26905},"NCT05401214","Pre-approval Access Single Patient Request for Niraparib \u002F Abiraterone Acetate Combination (Nira\u002FAA Combination)",[],[2663],[26886,26906],"Prednisone\u002FPrednisolone",{"intervention":26906,"totalTrials":468,"cells":26908},{"EARLY_PHASE1":26909,"PHASE1":26911,"PHASE2":26913,"PHASE3":26915,"PHASE4":26917,"NA":26919},{"trials":26910,"activeCount":99},[],{"trials":26912,"activeCount":99},[],{"trials":26914,"activeCount":99},[],{"trials":26916,"activeCount":99},[],{"trials":26918,"activeCount":99},[],{"trials":26920,"activeCount":99},[26921],{"nctId":26901,"briefTitle":26902,"status":967,"phases":26922,"conditions":26923,"interventions":26924},[],[2663],[26886,26906],{"intervention":26926,"totalTrials":468,"cells":26927},"Oral Antipsychotics",{"EARLY_PHASE1":26928,"PHASE1":26930,"PHASE2":26932,"PHASE3":26934,"PHASE4":26936,"NA":26938},{"trials":26929,"activeCount":99},[],{"trials":26931,"activeCount":99},[],{"trials":26933,"activeCount":99},[],{"trials":26935,"activeCount":99},[],{"trials":26937,"activeCount":99},[],{"trials":26939,"activeCount":99},[26940],{"nctId":26941,"briefTitle":26942,"status":105,"phases":26943,"primaryCompletion":26944,"completion":26944,"start":12646,"enrollment":26945,"conditions":26946,"interventions":26947},"NCT03629951","A Study for Schizophrenia Relapse Prediction",[],"2021-12-31",333,[32],[26926],{"intervention":6847,"totalTrials":468,"cells":26949},{"EARLY_PHASE1":26950,"PHASE1":26952,"PHASE2":26954,"PHASE3":26956,"PHASE4":26958,"NA":26960},{"trials":26951,"activeCount":99},[],{"trials":26953,"activeCount":99},[],{"trials":26955,"activeCount":99},[],{"trials":26957,"activeCount":99},[],{"trials":26959,"activeCount":99},[],{"trials":26961,"activeCount":99},[26962],{"nctId":6838,"briefTitle":6839,"status":105,"phases":26963,"primaryCompletion":6841,"completion":6841,"start":6842,"enrollment":6843,"conditions":26964,"interventions":26965},[],[6845,4445],[879,6847],{"intervention":26967,"totalTrials":468,"cells":26968},"Dapoxetine hydrochloride",{"EARLY_PHASE1":26969,"PHASE1":26971,"PHASE2":26973,"PHASE3":26975,"PHASE4":26977,"NA":26979},{"trials":26970,"activeCount":99},[],{"trials":26972,"activeCount":99},[],{"trials":26974,"activeCount":99},[],{"trials":26976,"activeCount":99},[],{"trials":26978,"activeCount":99},[],{"trials":26980,"activeCount":99},[26981],{"nctId":26982,"briefTitle":26983,"status":105,"phases":26984,"completion":3310,"start":5869,"enrollment":26985,"conditions":26986,"interventions":26987},"NCT01021670","An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride",[],10027,[10849,22301],[26967],{"intervention":26262,"totalTrials":468,"cells":26989},{"EARLY_PHASE1":26990,"PHASE1":26992,"PHASE2":26994,"PHASE3":26996,"PHASE4":26998,"NA":27000},{"trials":26991,"activeCount":99},[],{"trials":26993,"activeCount":99},[],{"trials":26995,"activeCount":99},[],{"trials":26997,"activeCount":99},[],{"trials":26999,"activeCount":99},[],{"trials":27001,"activeCount":99},[27002],{"nctId":26256,"briefTitle":26257,"status":105,"phases":27003,"primaryCompletion":16848,"completion":16848,"start":11281,"enrollment":26259,"conditions":27004,"interventions":27005},[],[26249],[26262,26262,26227,26263],{"intervention":26263,"totalTrials":468,"cells":27007},{"EARLY_PHASE1":27008,"PHASE1":27010,"PHASE2":27012,"PHASE3":27014,"PHASE4":27016,"NA":27018},{"trials":27009,"activeCount":99},[],{"trials":27011,"activeCount":99},[],{"trials":27013,"activeCount":99},[],{"trials":27015,"activeCount":99},[],{"trials":27017,"activeCount":99},[],{"trials":27019,"activeCount":99},[27020],{"nctId":26256,"briefTitle":26257,"status":105,"phases":27021,"primaryCompletion":16848,"completion":16848,"start":11281,"enrollment":26259,"conditions":27022,"interventions":27023},[],[26249],[26262,26262,26227,26263],{"intervention":27025,"totalTrials":468,"cells":27026},"Concerta",{"EARLY_PHASE1":27027,"PHASE1":27029,"PHASE2":27031,"PHASE3":27033,"PHASE4":27035,"NA":27037},{"trials":27028,"activeCount":99},[],{"trials":27030,"activeCount":99},[],{"trials":27032,"activeCount":99},[],{"trials":27034,"activeCount":99},[],{"trials":27036,"activeCount":99},[],{"trials":27038,"activeCount":99},[27039],{"nctId":27040,"briefTitle":27041,"status":105,"phases":27042,"primaryCompletion":583,"completion":583,"start":8420,"enrollment":27043,"conditions":27044,"interventions":27045},"NCT02730572","Concerta (Methylphenidate) -To-Generic Switch Study",[],1464,[26249],[27025,27046,27047],"Concerta AG formulation","Concerta EG formulation",{"intervention":27046,"totalTrials":468,"cells":27049},{"EARLY_PHASE1":27050,"PHASE1":27052,"PHASE2":27054,"PHASE3":27056,"PHASE4":27058,"NA":27060},{"trials":27051,"activeCount":99},[],{"trials":27053,"activeCount":99},[],{"trials":27055,"activeCount":99},[],{"trials":27057,"activeCount":99},[],{"trials":27059,"activeCount":99},[],{"trials":27061,"activeCount":99},[27062],{"nctId":27040,"briefTitle":27041,"status":105,"phases":27063,"primaryCompletion":583,"completion":583,"start":8420,"enrollment":27043,"conditions":27064,"interventions":27065},[],[26249],[27025,27046,27047],{"intervention":27047,"totalTrials":468,"cells":27067},{"EARLY_PHASE1":27068,"PHASE1":27070,"PHASE2":27072,"PHASE3":27074,"PHASE4":27076,"NA":27078},{"trials":27069,"activeCount":99},[],{"trials":27071,"activeCount":99},[],{"trials":27073,"activeCount":99},[],{"trials":27075,"activeCount":99},[],{"trials":27077,"activeCount":99},[],{"trials":27079,"activeCount":99},[27080],{"nctId":27040,"briefTitle":27041,"status":105,"phases":27081,"primaryCompletion":583,"completion":583,"start":8420,"enrollment":27043,"conditions":27082,"interventions":27083},[],[26249],[27025,27046,27047]]